Clustering O 0 2.476656683556011e-12
of O 0 1.2475037554254169e-17
missense O 0 3.762694366152286e-13
mutations O 0 4.6817459170523865e-14
in O 0 5.660846123860209e-16
the O 0 1.194311094465661e-09
ataxia B-Disease 1 1.0
- I-Disease 1 0.999996542930603
telangiectasia I-Disease 1 0.9999996423721313
gene O 0 3.521768432435124e-10
in O 0 6.305883021366938e-17
a O 0 2.3115894744400605e-17
sporadic B-Disease 0 4.090843219728413e-10
T I-Disease 0 0.06689594686031342
- I-Disease 0 8.617212188255507e-06
cell I-Disease 0 3.985111561632948e-06
leukaemia I-Disease 1 0.9960945248603821
. O 0 5.703014883257085e-12

Ataxia B-Disease 1 0.9999902248382568
- I-Disease 1 0.99996018409729
telangiectasia I-Disease 1 0.9999994039535522
( O 0 8.603975402365904e-06
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999977350234985
T I-Disease 1 0.9999996423721313
) O 0 3.764091994867453e-18
is O 0 2.0609904965371541e-22
a O 0 5.430608843446747e-22
recessive B-Disease 0 8.94629856307283e-12
multi I-Disease 0 9.061322089110035e-06
- I-Disease 1 0.9962544441223145
system I-Disease 0 0.25872668623924255
disorder I-Disease 1 0.999987006187439
caused O 0 1.1153068746327932e-10
by O 0 1.8669740428899743e-19
mutations O 0 1.2525781610675724e-16
in O 0 3.611321112596634e-21
the O 0 3.48462515396964e-21
ATM O 0 8.932376458501215e-14
gene O 0 1.7275953549124833e-14
at O 0 5.629271869608474e-14
11q22 O 0 1.894046117861814e-12
- O 0 1.379796832345903e-10
q23 O 0 2.8315130188444337e-12
( O 0 8.363818388148225e-18
ref O 0 2.793918221777325e-11
. O 0 1.6723218970080927e-16
3 O 0 1.624027175319866e-15
) O 0 4.516698900301926e-16
. O 0 3.550676056342586e-14

The O 0 2.6156613767286396e-12
risk O 0 2.6962978516564817e-09
of O 0 2.3449138350801883e-16
cancer B-Disease 0 9.758058250319834e-11
, O 0 3.1374137635748964e-14
especially O 0 5.1489584487361337e-14
lymphoid B-Disease 0 1.688641726449447e-10
neoplasias I-Disease 0 5.387270074486139e-10
, O 0 2.0575776525253885e-18
is O 0 1.7908537809955476e-20
substantially O 0 1.7129524131266564e-17
elevated O 0 1.9961957705306316e-13
in O 0 7.045235705591124e-13
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.20805035261651e-09
and O 0 5.816508333192447e-15
has O 0 4.016497886981884e-17
long O 0 6.9104798362757256e-18
been O 0 6.41256632476525e-18
associated O 0 7.372071185344508e-17
with O 0 7.633362664833873e-14
chromosomal O 1 0.9999997615814209
instability O 1 0.999998927116394
. O 0 5.70306468716808e-10

By O 0 2.91339814474534e-16
analysing O 0 2.7871093020298554e-12
tumour B-Disease 1 0.999919056892395
DNA O 0 3.3858679748810516e-11
from O 0 6.092155432950997e-17
patients O 0 2.803399054774385e-18
with O 0 1.1466957970108564e-19
sporadic B-Disease 0 2.0201481112924746e-11
T I-Disease 0 0.00016166969726327807
- I-Disease 0 3.8702054894201865e-07
cell I-Disease 0 2.840945683146856e-07
prolymphocytic I-Disease 0 0.00015020232240203768
leukaemia I-Disease 0 0.11083976179361343
( O 0 5.198651584762586e-15
T B-Disease 0 2.3657669157017835e-09
- I-Disease 0 1.169144750630402e-12
PLL I-Disease 0 2.9547037559696232e-12
) O 0 2.3004329689860704e-19
, O 0 1.1279003218572846e-22
a O 0 4.9086891915482806e-23
rare O 0 1.910058908317535e-20
clonal B-Disease 0 9.58701204983326e-17
malignancy I-Disease 0 1.007641886596744e-10
with O 0 1.2906726572333343e-18
similarities O 0 3.6112180988835676e-17
to O 0 1.9189553650525137e-19
a O 0 3.8746095285591315e-18
mature B-Disease 0 2.247477160974287e-12
T I-Disease 0 3.99172570553219e-08
- I-Disease 0 1.1776881553293705e-11
cell I-Disease 0 5.030570578157256e-12
leukaemia I-Disease 0 4.034978246636456e-06
seen O 0 2.2754719983253402e-11
in O 0 1.2786536203625428e-15
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999967813491821
T I-Disease 1 0.9999998807907104
, O 0 6.388694123897541e-16
we O 0 6.345256983960585e-19
demonstrate O 0 6.338763692892432e-22
a O 0 3.4090592464689816e-23
high O 0 9.587179688324152e-20
frequency O 0 1.1317913951380072e-16
of O 0 2.0014573576845296e-20
ATM O 0 4.0324455580220686e-11
mutations O 0 1.1128747662986216e-12
in O 0 1.246046180732735e-13
T B-Disease 0 3.5909040889237076e-05
- I-Disease 0 1.121840753626202e-08
PLL I-Disease 0 2.8705075649781975e-08
. O 0 6.785321002983347e-13

In O 0 5.866263789667994e-16
marked O 0 6.947994743529884e-16
contrast O 0 5.214908473052278e-19
to O 0 2.9723939635429607e-21
the O 0 4.0554084533028553e-22
ATM O 0 1.2262601687112323e-13
mutation O 0 4.4766483238195456e-15
pattern O 0 7.095981580107491e-10
in O 0 7.264980717708314e-13
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
, O 0 2.618176457682878e-16
the O 0 1.2161318266424857e-22
most O 0 1.5729854895670767e-24
frequent O 0 1.2633866143491417e-21
nucleotide O 0 9.916142955587955e-20
changes O 0 1.478633489435127e-20
in O 0 9.824193106332163e-21
this O 0 4.560061842137936e-18
leukaemia B-Disease 0 2.895891881848911e-08
were O 0 7.13346743040779e-16
missense O 0 2.2626159572238652e-13
mutations O 0 7.8090073470094e-13
. O 0 1.1213935596082747e-12

These O 0 1.90373513631601e-15
clustered O 0 2.6315180503416746e-13
in O 0 3.193470755079638e-18
the O 0 1.8372809679158267e-17
region O 0 6.6685836675817525e-15
corresponding O 0 2.276072820478871e-17
to O 0 2.0414885346618952e-17
the O 0 1.3927411872026373e-19
kinase O 0 1.2726069113441763e-12
domain O 0 1.1128917882727296e-12
, O 0 8.455963264361978e-16
which O 0 5.715302699219801e-18
is O 0 5.135870088199259e-23
highly O 0 4.928651080096627e-24
conserved O 0 1.0685147971816e-21
in O 0 5.522676105497495e-22
ATM O 0 1.6695964001525038e-13
- O 0 9.83697308722456e-15
related O 0 1.8613367036178488e-17
proteins O 0 5.2014605842436976e-18
in O 0 2.5507985037973656e-20
mouse O 0 1.2267877685934181e-11
, O 0 4.235311974420536e-18
yeast O 0 4.160170980220448e-15
and O 0 5.1113567927350313e-17
Drosophila O 0 5.7668209569900365e-15
. O 0 1.1312782519906487e-15

The O 0 8.378292990076719e-16
resulting O 0 2.6082689779966407e-15
amino O 0 6.719652131004662e-16
- O 0 1.2790799235745665e-12
acid O 0 1.969207818523452e-15
substitutions O 0 2.146787799459283e-16
are O 0 1.4058302605711291e-18
predicted O 0 1.5418137074731103e-17
to O 0 9.375499775174828e-19
interfere O 0 3.676008607754466e-13
with O 0 4.005313412483432e-17
ATP O 0 1.6580874289201454e-15
binding O 0 1.0596337446811682e-13
or O 0 1.8591255108741517e-14
substrate O 0 3.205332874123279e-11
recognition O 0 3.4634336956544665e-14
. O 0 2.213569090395509e-13

Two O 0 7.508820551862876e-16
of O 0 2.8230702369215085e-18
seventeen O 0 6.730562423585065e-14
mutated O 0 4.9832798477977835e-12
T B-Disease 0 3.0446037158071704e-07
- I-Disease 0 8.391464190182774e-10
PLL I-Disease 0 3.544005089395341e-10
samples O 0 4.639417647799016e-13
had O 0 2.791886768599178e-16
a O 0 2.7869010537792884e-20
previously O 0 1.7834400465425461e-16
reported O 0 3.1935161182161664e-09
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999978542327881
T I-Disease 1 0.9999995231628418
allele O 0 3.8802724589004356e-07
. O 0 1.4328732428001145e-12

In O 0 6.257270397625695e-15
contrast O 0 6.57660224225704e-15
, O 0 6.862672188310672e-17
no O 0 5.720453552894168e-17
mutations O 0 1.2578890311770773e-15
were O 0 3.9849888119154395e-14
detected O 0 1.350379985783079e-12
in O 0 1.0341296212852195e-18
the O 0 6.234667071965308e-20
p53 O 0 7.789451777944347e-19
gene O 0 6.474930945304195e-17
, O 0 4.628373312254709e-19
suggesting O 0 4.613409614973625e-18
that O 0 5.815099351787333e-19
this O 0 5.5851230823677366e-18
tumour B-Disease 1 0.9999997615814209
suppressor O 0 2.600117454676365e-08
is O 0 3.154099973822627e-14
not O 0 7.172924342673263e-16
frequently O 0 3.122406846967074e-13
altered O 0 3.284161354324966e-12
in O 0 7.268258430282327e-15
this O 0 1.3195911377494873e-13
leukaemia B-Disease 0 0.0005338490009307861
. O 0 2.1415493076798464e-12

Occasional O 0 6.950567410513031e-08
missense O 0 4.657998292634247e-11
mutations O 0 7.962369235085462e-14
in O 0 1.21536042672028e-17
ATM O 0 5.586282825209565e-11
were O 0 4.592298763483882e-13
also O 0 1.8116296206645245e-15
found O 0 8.071106962634291e-16
in O 0 7.484733019338108e-18
tumour B-Disease 1 0.9999997615814209
DNA O 0 3.7742722835965026e-10
from O 0 1.449157071157983e-17
patients O 0 1.6775522675547452e-19
with O 0 7.267435670950148e-20
B B-Disease 0 3.0700437747555043e-09
- I-Disease 0 4.2377719111641454e-09
cell I-Disease 0 1.0541097253735643e-05
non I-Disease 0 8.449179404124152e-06
- I-Disease 1 0.9999302625656128
Hodgkins I-Disease 1 0.9999600648880005
lymphomas I-Disease 1 0.9751646518707275
( O 0 1.3784577761199752e-14
B B-Disease 0 5.202850927865654e-10
- I-Disease 0 8.693700056724984e-13
NHL I-Disease 0 8.365307144903023e-13
) O 0 1.091900907882658e-17
and O 0 4.2113253910177234e-17
a O 0 1.1845510921890075e-17
B B-Disease 0 3.5712679341548537e-11
- I-Disease 0 8.093811536789841e-13
NHL I-Disease 0 6.030432772065331e-13
cell O 0 6.872408458286072e-12
line O 0 1.3802153864261868e-10
. O 0 1.0790251071118862e-14

The O 0 1.5102291723589775e-16
evidence O 0 1.1005781979444617e-17
of O 0 2.056099382219941e-21
a O 0 7.541872549327648e-21
significant O 0 2.1513425816143663e-19
proportion O 0 2.4967857837317003e-16
of O 0 3.5940395427943114e-17
loss O 0 2.04656102720073e-13
- O 0 1.0033239430246033e-12
of O 0 3.496509323746144e-17
- O 0 2.3328780313774944e-12
function O 0 7.142534918108147e-16
mutations O 0 8.767593991316006e-15
and O 0 1.2395121219908032e-15
a O 0 9.712863940438508e-18
complete O 0 4.87191857799637e-16
absence O 0 4.148125218798426e-16
of O 0 5.1250523439426545e-21
the O 0 4.6246691974716965e-18
normal O 0 7.863316214910765e-18
copy O 0 1.4209232858866249e-15
of O 0 8.6028100409029e-21
ATM O 0 2.1511605159934416e-13
in O 0 3.018999545533269e-18
the O 0 1.2595064935294186e-16
majority O 0 5.457123053342525e-16
of O 0 2.108800687880643e-17
mutated O 0 7.066327611937595e-08
tumours B-Disease 1 0.9999990463256836
establishes O 0 2.883727111269163e-12
somatic O 0 3.806813398581424e-14
inactivation O 0 4.4212655758713026e-10
of O 0 1.6136123694271325e-19
this O 0 3.711288797680508e-21
gene O 0 1.6231754820370405e-19
in O 0 3.5690573531740025e-21
the O 0 1.3622381912564055e-20
pathogenesis O 0 6.2992057282948346e-15
of O 0 1.2370208955225324e-18
sporadic B-Disease 0 2.977621038624534e-09
T I-Disease 0 5.166748815099709e-05
- I-Disease 0 4.634706485262541e-08
PLL I-Disease 0 5.393856028490518e-08
and O 0 1.5504130368871466e-13
suggests O 0 3.6254906040448026e-17
that O 0 9.718001371814967e-21
ATM O 0 1.409973923911529e-14
acts O 0 9.589289642019088e-15
as O 0 1.1456082561306235e-17
a O 0 1.1105781167185133e-16
tumour B-Disease 1 0.9999977350234985
suppressor O 0 1.5497731510549784e-05
. O 0 1.8960893619079933e-11

As O 0 1.373978231790509e-16
constitutional O 0 6.997728779336288e-18
DNA O 0 8.044246489085673e-15
was O 0 1.3833771740710387e-15
not O 0 2.211427301099599e-19
available O 0 6.753737042729754e-21
, O 0 1.2822453023785528e-20
a O 0 1.7144606787459491e-19
putative O 0 4.919141483039624e-11
hereditary O 0 1.0920247405010741e-05
predisposition O 0 3.360891241754871e-06
to O 0 5.580907402880086e-10
T B-Disease 0 1.3017104720347561e-05
- I-Disease 0 2.1830652563448183e-10
PLL I-Disease 0 6.045894340722668e-11
will O 0 2.6265082178592063e-17
require O 0 6.239943276622014e-22
further O 0 2.3493936763519848e-21
investigation O 0 1.8025559258008506e-17
. O 0 1.032332902276693e-17
. O 0 1.8143466906010795e-16

Myotonic B-Disease 1 0.9999009370803833
dystrophy I-Disease 1 0.9999271631240845
protein O 0 1.924564951849561e-10
kinase O 0 3.5598038405915133e-10
is O 0 8.25692266476861e-18
involved O 0 2.290229865766878e-21
in O 0 4.331388711535694e-24
the O 0 3.92143663175406e-24
modulation O 0 2.678543689332595e-19
of O 0 1.4871738313858592e-22
the O 0 3.543585495895517e-18
Ca2 O 0 7.367486620779573e-10
+ O 0 2.159435963378087e-09
homeostasis O 0 2.4139990273397416e-07
in O 0 6.141774236542372e-14
skeletal O 0 4.810126483789645e-05
muscle O 0 9.577418857986686e-09
cells O 0 1.3939838053398518e-13
. O 0 8.346047716324169e-15

Myotonic B-Disease 1 0.9998846054077148
dystrophy I-Disease 1 0.9999809265136719
( O 0 2.0096001251967976e-10
DM B-Disease 1 0.9999966621398926
) O 0 4.021377008516305e-15
, O 0 1.8480681837552213e-20
the O 0 1.8632935980740605e-21
most O 0 1.5999883273372297e-17
prevalent O 0 4.118813734521609e-08
muscular B-Disease 0 1.4242054930946324e-06
disorder I-Disease 0 5.531253464141628e-07
in O 0 3.3271432992325236e-15
adults O 0 5.525957469387777e-09
, O 0 2.469299246955943e-15
is O 0 1.5215068178346496e-14
caused O 0 1.2709325508241526e-13
by O 0 6.4399240827545224e-18
( O 0 9.462595689822067e-19
CTG O 0 2.0152020243496827e-12
) O 0 5.607734643438302e-17
n O 0 1.945311316545184e-12
- O 0 8.735762807576819e-11
repeat O 0 4.898917035922601e-11
expansion O 0 2.0191433257485715e-18
in O 0 2.088772031917376e-22
a O 0 6.697692564868734e-24
gene O 0 5.1357944837701025e-22
encoding O 0 6.281861199423796e-21
a O 0 2.3160067604365266e-21
protein O 0 1.8289456343192523e-17
kinase O 0 9.79730511128929e-13
( O 0 6.314133279437512e-19
DM B-Disease 1 0.999966025352478
protein O 0 4.3439486482917795e-16
kinase O 0 6.180898349562869e-13
; O 0 2.9014170622297748e-18
DMPK O 0 1.9404742840779116e-13
) O 0 1.2506419138795554e-20
and O 0 4.731263885269479e-21
involves O 0 6.64659534297783e-21
changes O 0 2.8979061070444905e-21
in O 0 4.356516332659579e-21
cytoarchitecture O 0 4.657798127229162e-13
and O 0 8.189608195444147e-17
ion O 0 2.6528175489648476e-11
homeostasis O 0 6.292479071134949e-08
. O 0 1.210302040879907e-12

To O 0 1.5109256253475227e-17
obtain O 0 1.9956337153664722e-19
clues O 0 1.0451250697935798e-14
to O 0 2.6267085610035667e-17
the O 0 5.285831352362881e-18
normal O 0 6.251823790486393e-17
biological O 0 8.726481235517768e-16
role O 0 1.2708524171398287e-17
of O 0 2.2084344582458055e-19
DMPK O 0 3.788911025204289e-12
in O 0 2.9474532563841365e-20
cellular O 0 7.757700139938769e-17
ion O 0 4.77554714523043e-12
homeostasis O 0 2.7123963075581514e-09
, O 0 2.6904381619021226e-15
we O 0 2.919084329859817e-15
have O 0 3.630636742789679e-18
compared O 0 3.6865997505295304e-19
the O 0 6.713003001984849e-20
resting O 0 1.8219876996017348e-11
[ O 0 8.267827386783897e-18
Ca2 O 0 2.1267872445801528e-14
+ O 0 2.667652557186706e-12
] O 0 1.1259156584494945e-12
i O 0 7.58752124172847e-14
, O 0 5.125186639623159e-22
the O 0 1.1701672367235368e-22
amplitude O 0 7.438678911553605e-18
and O 0 2.9424279226114352e-15
shape O 0 3.3771688109874784e-14
of O 0 7.249825124955865e-20
depolarization O 0 6.353359932744591e-15
- O 0 2.303410413795337e-11
induced O 0 4.595006597440943e-09
Ca2 O 0 1.626253125219801e-11
+ O 0 1.284204253354515e-11
transients O 0 1.8149761693564415e-09
, O 0 2.1236292652086666e-18
and O 0 2.1755470495604043e-20
the O 0 2.497910385898057e-23
content O 0 1.9747705401072656e-19
of O 0 3.798180034098626e-23
ATP O 0 2.1625163699732798e-19
- O 0 4.468884843341486e-15
driven O 0 1.5290591329989583e-14
ion O 0 1.1046097711650202e-13
pumps O 0 4.602312454748958e-13
in O 0 8.968986257532646e-20
cultured O 0 4.956999437658038e-13
skeletal O 0 7.179646388522087e-08
muscle O 0 3.1887027740484797e-12
cells O 0 8.105996117382797e-18
of O 0 6.623562321106706e-21
wild O 0 1.7408586414928884e-15
- O 0 2.6977637901381968e-09
type O 0 4.6117701671399836e-12
and O 0 5.527886633681367e-13
DMPK O 0 1.3487905237141717e-10
[ O 0 1.8584642693099217e-16
- O 0 1.066455192384741e-12
/ O 0 5.740012631871849e-11
- O 0 5.766582766852935e-10
] O 0 3.220033614748097e-11
knockout O 0 5.549921633374311e-10
mice O 0 4.0442479920521635e-10
. O 0 5.1932830052395934e-14

In O 0 2.1198930740158606e-15
vitro O 0 2.0786874825595714e-12
- O 0 2.8311391009339104e-09
differentiated O 0 6.581007266914796e-11
DMPK O 0 1.4542148107921093e-07
[ O 0 1.8421596713336097e-12
- O 0 1.231662688505608e-10
/ O 0 6.041643851872891e-10
- O 0 2.0509290099557376e-10
] O 0 2.058006814010388e-13
myotubes O 0 8.082021786840962e-14
exhibit O 0 4.580372848488869e-18
a O 0 4.017411055604051e-20
higher O 0 6.268244142486425e-20
resting O 0 2.0626101416171836e-15
[ O 0 6.804455444273858e-19
Ca2 O 0 2.1356080762862696e-14
+ O 0 1.4195277982589904e-12
] O 0 5.248112599880173e-13
i O 0 5.904819141240233e-14
than O 0 2.0219315318736376e-20
do O 0 4.072655592358415e-18
wild O 0 1.1052360519737478e-16
- O 0 6.004380104229767e-09
type O 0 3.5087607819228595e-10
myotubes O 0 2.5208132115039916e-07
because O 0 1.9767048647879523e-14
of O 0 3.006535207188653e-22
an O 0 1.5359460593080238e-21
altered O 0 1.471155113691707e-14
open O 0 1.3515427112979067e-15
probability O 0 8.7769843507705e-18
of O 0 2.296906723884151e-20
voltage O 0 3.4485757213200893e-14
- O 0 1.535573231070675e-11
dependent O 0 6.052615006413298e-13
l O 0 1.3868348743700798e-12
- O 0 3.4117140333017083e-15
type O 0 7.938795122317249e-16
Ca2 O 0 8.583046383001114e-13
+ O 0 4.3378803153693024e-12
and O 0 2.9805625740945974e-14
Na O 0 3.847880347684907e-12
+ O 0 1.917240780198448e-14
channels O 0 1.1571631673701344e-11
. O 0 2.2000913731893418e-13

The O 0 3.5279025485282056e-16
mutant O 0 3.2028118221796853e-13
myotubes O 0 1.9846706743320564e-12
exhibit O 0 2.0990024357399318e-16
smaller O 0 4.146507104627762e-18
and O 0 7.41250906764202e-17
slower O 0 4.461543608787633e-15
Ca2 O 0 3.4570352223234346e-12
+ O 0 1.5047699197801023e-11
responses O 0 1.2872279231293613e-15
upon O 0 4.319241441682923e-18
triggering O 0 1.4234786784093727e-15
by O 0 1.3394933739740968e-19
acetylcholine O 0 1.3329584831744956e-12
or O 0 6.268990188074142e-11
high O 0 5.608625543163104e-12
external O 0 5.887492271483552e-09
K O 0 4.3636614321940215e-09
+ O 0 6.677579929975641e-12
. O 0 4.151374543063212e-14

In O 0 9.84992273868042e-16
addition O 0 6.662293392465928e-18
, O 0 7.009827846758524e-19
we O 0 9.938258404746385e-20
observed O 0 9.558614209482047e-22
that O 0 5.177598103782162e-21
these O 0 3.0853630053074794e-18
Ca2 O 0 8.302576681717966e-11
+ O 0 1.1299064794911828e-08
transients O 0 1.0128388794328202e-06
partially O 0 1.8261495093874203e-10
result O 0 2.0062532875450964e-17
from O 0 8.915183409344257e-22
an O 0 2.2462647037656404e-23
influx O 0 4.811310169302107e-21
of O 0 4.069958708709731e-23
extracellular O 0 1.7313806075109088e-16
Ca2 O 0 2.2204280243891955e-13
+ O 0 2.107842844495042e-14
through O 0 7.523723004691407e-18
the O 0 5.047049786681689e-17
l O 0 5.112963614235973e-14
- O 0 3.8207906598209816e-16
type O 0 2.456314284814094e-16
Ca2 O 0 5.412991561058733e-13
+ O 0 9.787051811344094e-13
channel O 0 2.9912943233512124e-09
. O 0 2.0723605665719236e-13

Neither O 0 4.600226449769096e-12
the O 0 1.152877486266515e-16
content O 0 3.0067768885594023e-14
nor O 0 9.798318315160136e-16
the O 0 1.7980001691236083e-20
activity O 0 5.867290023023152e-17
of O 0 2.660376735129399e-19
Na O 0 9.024689849590484e-12
+ O 0 3.068318168986117e-12
/ O 0 3.5297270748607668e-12
K O 0 3.540513693854608e-13
+ O 0 7.482343360722891e-16
ATPase O 0 8.584875432066097e-14
and O 0 9.094030536550683e-16
sarcoplasmic O 0 8.739445278571623e-11
reticulum O 0 9.26445448135027e-11
Ca2 O 0 1.6987400375256811e-10
+ O 0 6.050739770335767e-11
- O 0 2.580817937830604e-12
ATPase O 0 7.94175055579549e-12
are O 0 3.3321826158730946e-17
affected O 0 8.584464680643683e-18
by O 0 3.714918795788166e-19
DMPK O 0 8.016574071234572e-10
absence O 0 3.932489709844618e-14
. O 0 5.950784442914172e-16

In O 0 2.307178199642654e-15
conclusion O 0 3.0266708019904733e-16
, O 0 1.1941793421702267e-16
our O 0 2.2321795731521533e-15
data O 0 7.727868036583167e-17
suggest O 0 2.227618830126781e-16
that O 0 2.0338399264098624e-17
DMPK O 0 1.2230561615561575e-12
is O 0 2.255971623320433e-20
involved O 0 3.2939703221441453e-21
in O 0 3.2040069079514114e-22
modulating O 0 1.247456788110236e-16
the O 0 9.286721194215896e-20
initial O 0 1.1159182643429622e-20
events O 0 6.108179524078586e-20
of O 0 1.4592503010426976e-21
excitation O 0 4.716827650035407e-14
- O 0 3.886447608181243e-09
contraction O 0 1.7900833593209597e-11
coupling O 0 2.125143984399447e-11
in O 0 2.4680750725889237e-15
skeletal O 0 1.2354339560260996e-05
muscle O 0 1.8719193306537818e-08
. O 0 1.5870120472830898e-15
. O 0 3.1775932796476725e-15

Constitutional O 0 6.308356614859179e-11
RB1 O 0 8.829953003441915e-06
- O 0 1.81955943645562e-08
gene O 0 2.4188571284833316e-11
mutations O 0 1.0457448275380532e-11
in O 0 2.711557439516806e-17
patients O 0 1.4992420300674562e-17
with O 0 9.192338206112976e-19
isolated O 0 1.3172134390171397e-11
unilateral B-Disease 0 5.179446649350439e-09
retinoblastoma I-Disease 0 4.358188562036958e-06
. O 0 5.798830512993014e-11

In O 0 3.594752572482332e-17
most O 0 3.0554707659213444e-19
patients O 0 9.036370199688806e-19
with O 0 1.701261461109017e-19
isolated O 0 1.961256894736363e-12
unilateral B-Disease 0 1.2753181843905281e-09
retinoblastoma I-Disease 0 1.9551079333268717e-07
, O 0 4.5990611018402634e-15
tumor B-Disease 0 1.7777438050294025e-13
development O 0 9.31769975439086e-20
is O 0 1.4390071962034146e-21
initiated O 0 7.641755416086993e-21
by O 0 9.059066589746776e-22
somatic O 0 3.1320753834234515e-17
inactivation O 0 4.610345525485338e-12
of O 0 6.552041894276413e-21
both O 0 1.2682842384727623e-19
alleles O 0 4.619485670163133e-18
of O 0 4.972284120928258e-20
the O 0 1.056250720500823e-15
RB1 O 0 1.6984039730161271e-09
gene O 0 9.968516897357338e-13
. O 0 2.77143271439767e-13

However O 0 1.8378385564701144e-13
, O 0 1.639575040784425e-17
some O 0 1.5385321094384066e-21
of O 0 2.7302440588730665e-22
these O 0 1.7571226997841305e-17
patients O 0 1.995496713577518e-19
can O 0 1.8665396438214132e-19
transmit O 0 6.535817893837947e-13
retinoblastoma B-Disease 0 2.4526129391300167e-11
predisposition O 0 4.1522860150244867e-10
to O 0 7.207849226330276e-14
their O 0 1.3136807613944868e-11
offspring O 0 1.7182331946141716e-10
. O 0 5.0655551801781495e-14

To O 0 4.180324646892706e-16
determine O 0 8.854600362007575e-18
the O 0 1.0571757908044389e-19
frequency O 0 2.4566180795333736e-13
and O 0 2.2416354254588267e-14
nature O 0 3.5083220584634423e-16
of O 0 2.6561772748687866e-20
constitutional O 0 1.8688375906473695e-15
RB1 O 0 1.3667639242598284e-09
- O 0 5.008812781854763e-14
gene O 0 3.3258869376135087e-15
mutations O 0 8.098868255722314e-15
in O 0 8.518111043639246e-19
patients O 0 1.9000903221111113e-18
with O 0 3.314833570104773e-20
isolated O 0 1.0691837362295994e-13
unilateral B-Disease 0 1.0256820349649476e-12
retinoblastoma I-Disease 0 1.9873318268803786e-10
, O 0 7.31765990639526e-17
we O 0 1.358010845961862e-18
analyzed O 0 5.367040946373617e-19
DNA O 0 1.796313206688105e-13
from O 0 1.5603340828648256e-16
peripheral O 0 1.430205820440733e-08
blood O 0 2.1436273982544662e-06
and O 0 3.4885046240606954e-12
from O 0 9.502654053382734e-16
tumor B-Disease 0 6.503722893569375e-09
tissue O 0 3.193048669913878e-08
. O 0 6.441971088511078e-12

The O 0 1.6495130202742085e-16
analysis O 0 7.049583322421473e-15
of O 0 1.436549752038222e-14
tumors B-Disease 1 0.9999994039535522
from O 0 1.2839188533956408e-13
54 O 0 1.7299497676926713e-14
( O 0 3.4986290567838725e-18
71 O 0 1.0925364345854005e-13
% O 0 1.921081312284594e-17
) O 0 2.594352729599065e-18
of O 0 8.935718733506383e-21
76 O 0 1.7244914172356487e-17
informative O 0 5.912587043230277e-13
patients O 0 1.3394196342331188e-11
showed O 0 1.7511018413074453e-08
loss O 0 7.206203407432443e-13
of O 0 4.986953626254609e-18
constitutional O 0 1.0350061085961926e-10
heterozygosity O 0 3.1420859158970416e-07
( O 0 2.7250329271734375e-13
LOH O 0 2.6366642487118952e-05
) O 0 2.999206514652658e-13
at O 0 1.6395793143303417e-12
intragenic O 0 2.464761283960115e-09
loci O 0 9.817157503588803e-12
. O 0 6.916721427378814e-13

Three O 0 6.383696739623024e-13
of O 0 4.6215325285888954e-17
13 O 0 5.209014185839295e-15
uninformative O 0 1.6346918263465682e-09
patients O 0 3.149883867327669e-15
had O 0 3.012410737625651e-16
constitutional O 0 1.4886718397442208e-15
deletions O 0 5.691092930248942e-09
. O 0 1.8088307240926582e-10

For O 0 2.0349963249062115e-17
39 O 0 4.3866279915259635e-16
randomly O 0 1.6494455540999597e-14
selected O 0 5.028210920549059e-12
tumors B-Disease 1 0.9999992847442627
, O 0 5.801979990199824e-12
SSCP O 0 4.074549906363245e-07
, O 0 4.853649983148226e-15
hetero O 0 1.3673152887694329e-11
- O 0 3.356594787274486e-13
duplex O 0 4.327548248136276e-13
analysis O 0 1.0356376749394802e-18
, O 0 7.36047109378572e-23
sequencing O 0 4.904841112906483e-20
, O 0 1.5951723163748235e-19
and O 0 7.016898359159959e-17
Southern O 0 1.2634807489568786e-17
blot O 0 4.8650461437205195e-09
analysis O 0 3.397489186978646e-17
were O 0 7.395410205234905e-20
used O 0 2.5196482067100684e-20
to O 0 4.015329597764229e-19
identify O 0 3.645827671878987e-14
mutations O 0 3.690916929727228e-13
. O 0 6.955152599685821e-13

Mutations O 0 2.777270817835853e-12
were O 0 1.3703678491440441e-14
detected O 0 4.646641483586379e-14
in O 0 5.854367476621603e-17
21 O 0 4.3771693863622115e-15
( O 0 4.0734790506582116e-18
91 O 0 8.554962294127222e-14
% O 0 8.716400484654258e-16
) O 0 9.902408076465849e-15
of O 0 4.577797017325802e-14
23 O 0 3.587850869735121e-07
tumors B-Disease 1 0.9999998807907104
with O 0 5.784089207594434e-09
LOH O 0 0.010076045989990234
. O 0 2.9688068670097323e-10

In O 0 4.169417191872676e-15
6 O 0 1.9677220803823205e-14
( O 0 1.2438306599153752e-17
38 O 0 2.4382851355922268e-14
% O 0 9.233183888452477e-17
) O 0 7.99160392080941e-16
of O 0 7.4947169238955e-15
16 O 0 3.610173848755949e-08
tumors B-Disease 1 1.0
without O 0 3.864987441204448e-09
LOH O 0 3.3657940434750344e-07
, O 0 3.324794370990669e-16
one O 0 1.2565353269435771e-17
mutation O 0 1.2788960868524168e-17
was O 0 3.978199334623428e-14
detected O 0 9.735735031742368e-14
, O 0 2.4957180589970168e-17
and O 0 4.568476436180805e-16
in O 0 2.702664792982524e-18
9 O 0 6.911703299267418e-15
( O 0 1.8149047035403804e-19
56 O 0 4.481962608530619e-15
% O 0 4.944371609091298e-18
) O 0 6.654575383760502e-17
of O 0 1.692854769742925e-16
the O 0 5.711256534368658e-08
tumors B-Disease 1 1.0
without O 0 1.1079997364049632e-07
LOH O 0 2.563143880252028e-06
, O 0 9.336112552875962e-16
both O 0 4.893541277731853e-17
mutations O 0 3.6082217807131486e-14
were O 0 4.6880370001582336e-14
found O 0 2.3503486483444913e-13
. O 0 1.7987063119333235e-13

Thus O 0 1.3141557612082744e-13
, O 0 8.667422789712748e-17
a O 0 4.832599242410376e-18
total O 0 1.6934536774577349e-18
of O 0 9.094259400882564e-19
45 O 0 1.180356128430506e-17
mutations O 0 6.004252603616212e-17
were O 0 5.260832167541406e-16
identified O 0 3.9530219917739695e-13
in O 0 1.3707613603225477e-12
tumors B-Disease 1 0.9999998807907104
of O 0 3.776475388916206e-14
36 O 0 1.3793369116159304e-13
patients O 0 2.8481590848126624e-15
. O 0 2.39431446945413e-14

Thirty O 0 7.518115574534079e-10
- O 0 2.6086615534381963e-08
nine O 0 1.140252822717791e-12
of O 0 5.679955875778126e-20
the O 0 1.9960372244090332e-19
mutations O 0 3.227506548949204e-17
- O 0 1.6706356350398854e-12
including O 0 1.9277260210580078e-16
34 O 0 4.21899335529609e-18
small O 0 1.2715347997861543e-19
mutations O 0 1.0164143374749796e-15
, O 0 2.5573301106146615e-17
2 O 0 3.53943759871387e-18
large O 0 1.1807743716277282e-18
structural O 0 4.487409575870682e-12
alterations O 0 7.70806554977084e-14
, O 0 4.651229966940774e-16
and O 0 4.651782550059739e-15
hypermethylation O 0 1.4450323750081484e-11
in O 0 2.5022600517906864e-15
3 O 0 2.485568868781929e-11
tumors O 1 0.9999998807907104
- O 0 4.916541485044945e-08
were O 0 1.9527938023133212e-13
not O 0 8.27919384101711e-17
detected O 0 6.87698373639682e-16
in O 0 6.155610637974777e-22
the O 0 2.9533607315185716e-21
corresponding O 0 3.3166586278040976e-18
peripheral O 0 1.6292770951831237e-11
blood O 0 9.196413075507337e-10
DNA O 0 2.1925095072816703e-09
. O 0 2.650634974097482e-13

In O 0 1.434769797002862e-14
6 O 0 8.865501513249593e-14
( O 0 9.059366110230994e-17
17 O 0 1.1153817263244784e-13
% O 0 5.978400727932092e-18
) O 0 4.32822850054437e-19
of O 0 2.8511288010665467e-21
the O 0 8.072580667613615e-17
36 O 0 5.958072764378601e-17
patients O 0 1.7744863323655667e-19
, O 0 2.4446141605913074e-21
a O 0 1.1787614534564745e-20
mutation O 0 1.4820070602604238e-17
was O 0 1.4015401252759352e-12
detected O 0 1.396698512054484e-13
in O 0 1.7723551790655063e-19
constitutional O 0 3.0286775587001392e-18
DNA O 0 6.823380055420714e-11
, O 0 5.396409213990995e-15
and O 0 3.338356533146513e-15
1 O 0 1.6602938678568622e-18
of O 0 1.0364869050852366e-19
these O 0 1.8518342512641867e-15
mutations O 0 4.2754256019179277e-17
is O 0 4.2636759717755853e-20
known O 0 9.555305446642157e-20
to O 0 9.274272927328191e-17
be O 0 1.1762355844573548e-15
associated O 0 3.0612052352225376e-15
with O 0 1.8695906029374786e-14
reduced O 0 3.1314740297355703e-12
expressivity O 0 3.889344952767715e-06
. O 0 3.912906023501028e-12

The O 0 5.147794561939135e-16
presence O 0 1.0869601911711032e-16
of O 0 3.4647975377515155e-20
a O 0 1.3384163848165528e-18
constitutional O 0 1.0691006338271443e-16
mutation O 0 7.779401309335882e-15
was O 0 3.1825477583152795e-12
not O 0 1.113858490034772e-15
associated O 0 1.2119382978080869e-18
with O 0 1.6541852876671744e-20
an O 0 3.6329901750299687e-19
early O 0 3.4257013892258215e-11
age O 0 1.2393355786066707e-10
at O 0 6.003935230958787e-16
treatment O 0 3.288667886394681e-16
. O 0 5.1547874144887605e-17

In O 0 8.435601651101169e-16
1 O 0 8.514253424814059e-17
patient O 0 5.0073966274702484e-15
, O 0 9.387780305343943e-18
somatic O 0 5.290136225263734e-15
mosaicism O 0 5.128090313499811e-11
was O 0 3.626380811849565e-14
demonstrated O 0 6.625236941794471e-19
by O 0 6.162585809207613e-23
molecular O 0 1.1950934884164805e-19
analysis O 0 4.628705929333835e-20
of O 0 2.672567661301972e-23
DNA O 0 1.808053447561217e-15
and O 0 9.705425270625941e-17
RNA O 0 1.3850638301213247e-12
from O 0 4.461405118900757e-16
peripheral O 0 1.6740129282766247e-09
blood O 0 1.1591313153758165e-07
. O 0 4.556335777422538e-13

In O 0 7.413756985401342e-16
2 O 0 3.4135755999615365e-15
patients O 0 1.0540640123032574e-17
without O 0 5.04974366578259e-18
a O 0 8.383879172363861e-18
detectable O 0 8.696130621155262e-11
mutation O 0 4.957351369683227e-12
in O 0 1.7061288362998916e-12
peripheral O 0 0.0017141076968982816
blood O 0 0.05171765759587288
, O 0 9.85278956404205e-14
mosaicism O 0 3.031131118672037e-12
was O 0 5.704420463282286e-15
suggested O 0 2.127270638342217e-17
because O 0 1.2826667121265574e-19
1 O 0 6.422076492161399e-22
of O 0 1.3797621518777317e-22
the O 0 9.945934982042879e-17
patients O 0 1.2513853851531167e-14
showed O 0 3.9839007093256384e-11
multifocal O 0 0.003594650886952877
tumors B-Disease 1 1.0
and O 0 3.5129548159318347e-09
the O 0 7.231357836981887e-17
other O 0 6.026970953703858e-17
later O 0 1.6396832029213224e-15
developed O 0 6.135816010915016e-17
bilateral B-Disease 0 1.3185838969905894e-14
retinoblastoma I-Disease 0 9.857578642247233e-11
. O 0 2.2890152298030327e-14

In O 0 4.084439881988809e-15
conclusion O 0 7.978931778522894e-16
, O 0 2.544408887702093e-16
our O 0 9.65499229367171e-15
results O 0 1.9881408807334196e-20
emphasize O 0 1.685455564717383e-18
that O 0 2.094023714990615e-20
the O 0 5.7883801093762914e-21
manifestation O 0 5.952214869803848e-16
and O 0 3.0017315050453466e-16
transmissibility O 0 1.0077743896547489e-14
of O 0 2.5516316557714268e-23
retinoblastoma B-Disease 0 2.0330951329863197e-17
depend O 0 1.9793182240187173e-19
on O 0 3.0961187686380574e-16
the O 0 7.55484071215504e-18
nature O 0 8.310269891665095e-16
of O 0 7.989236704638188e-21
the O 0 9.730771780314822e-19
first O 0 2.118741661764244e-18
mutation O 0 9.222442617326231e-18
, O 0 7.994370575260604e-18
its O 0 4.678201845174291e-18
time O 0 1.1277574007267086e-16
in O 0 5.454115535270689e-20
development O 0 5.022458441193281e-20
, O 0 3.4795277503800097e-19
and O 0 9.68537341996092e-18
the O 0 2.6289312056492543e-19
number O 0 1.2004268388134927e-17
and O 0 7.1156262305971385e-12
types O 0 4.553761271601335e-14
of O 0 2.9804910439199605e-20
cells O 0 2.6292934590587642e-18
that O 0 1.131954275272425e-18
are O 0 2.918967094792371e-19
affected O 0 1.1334319300391744e-18
. O 0 9.32883644886918e-19
. O 0 1.033398237452023e-14

Hereditary B-Disease 1 0.9998456239700317
deficiency I-Disease 1 0.9999676942825317
of I-Disease 0 4.1103684604767694e-16
the I-Disease 0 1.2791652017929048e-16
fifth I-Disease 0 8.32763322005086e-15
component I-Disease 0 2.384768058737483e-16
of I-Disease 0 3.0976954281353354e-20
complement I-Disease 0 2.6880159123707714e-16
in O 0 5.032438799213797e-17
man O 0 4.091782024318036e-09
. O 0 1.7124896336054296e-12

I O 0 3.3017151963576907e-06
. O 0 1.9957027350137047e-11

Clinical O 0 3.4225840477714042e-12
, O 0 7.284222460239229e-14
immunochemical O 0 7.063265972107047e-09
, O 0 1.062154497791538e-14
and O 0 7.326413510155144e-14
family O 0 2.714577521101269e-11
studies O 0 1.4186060366769976e-14
. O 0 7.867045608333297e-16

The O 0 6.634246593026398e-17
first O 0 7.605700842696052e-19
recognized O 0 6.82114705981602e-17
human O 0 8.318318906949673e-14
kindred O 0 1.4932022622815566e-06
with O 0 1.0568414199330078e-11
hereditary B-Disease 1 0.9999440908432007
deficiency I-Disease 1 0.9999827146530151
of I-Disease 0 3.678706689726973e-18
the I-Disease 0 1.4362788616372673e-17
fifth I-Disease 0 4.969717637361062e-15
component I-Disease 0 3.539751745366905e-16
of I-Disease 0 1.2809986345666846e-20
complement I-Disease 0 5.180021518604201e-16
( O 0 9.646684347404831e-20
C5 O 0 1.3095043938093909e-09
) O 0 7.754475459038792e-17
is O 0 2.2643902178155397e-17
described O 0 9.500204442569604e-13
. O 0 3.6427574823770514e-13

The O 0 8.36782069823334e-15
proband O 0 5.705955499757387e-11
, O 0 1.245563086310791e-18
a O 0 2.795483052634526e-20
20 O 0 1.1888504719902072e-19
- O 0 1.3971247390335423e-13
year O 0 3.2955011129384183e-15
- O 0 1.62815955162543e-10
old O 0 1.9876627010972925e-09
black O 0 4.7658862967203675e-11
female O 0 1.6993281781729763e-12
with O 0 3.6374112814645254e-13
systemic B-Disease 1 0.9999957084655762
lupus I-Disease 1 0.9742340445518494
erythematosus I-Disease 1 0.9999948740005493
since O 0 1.2735899002080942e-09
age O 0 5.1005817625071614e-11
11 O 0 5.2861767829866834e-17
, O 0 1.3192340082503113e-20
lacked O 0 2.8643362097302476e-17
serum O 0 2.2266781788630313e-14
hemolytic O 0 7.394642352869657e-14
complement O 0 1.3402556209085644e-18
activity O 0 1.0928192927678066e-14
, O 0 2.2158458000788852e-17
even O 0 1.4218234701513194e-15
during O 0 1.8498935293754376e-14
remission O 0 9.71992208942396e-11
. O 0 6.195188134196228e-14

C5 O 0 9.145169315161183e-05
was O 0 2.4926452013573908e-09
undetectable O 0 1.626332402082653e-09
in O 0 6.102695566839495e-16
her O 0 1.7371009145006333e-11
serum O 0 2.6650217948252786e-13
by O 0 4.401086310404099e-19
both O 0 5.245379573431078e-17
immunodiffusion O 0 4.4496935025506446e-09
and O 0 8.273780423805055e-13
hemolytic O 0 2.5792554203540874e-10
assays O 0 1.5845221185487035e-12
. O 0 8.836397461181936e-14

Other O 0 5.201120923204668e-19
complement O 0 3.861169580684431e-17
components O 0 2.2284859801065325e-16
were O 0 6.968612848955034e-18
normal O 0 4.730999956492938e-18
during O 0 1.213809542481082e-15
remission O 0 7.98974515020534e-12
of O 0 1.19136610917874e-18
lupus O 0 4.836964704636737e-13
, O 0 1.016726878570446e-18
but O 0 1.148522496146709e-17
C1 O 0 6.246365729344061e-13
, O 0 7.416853570145635e-20
C4 O 0 7.577517172757675e-13
, O 0 3.330441566119793e-17
C2 O 0 8.248923766274174e-11
, O 0 4.3223922553541985e-17
and O 0 9.004116761001865e-14
C3 O 0 6.0548227338586e-06
levels O 0 4.933420859332127e-12
fell O 0 2.726078252024422e-09
during O 0 3.1963537041766396e-14
exacerbations O 0 1.2977569951999612e-07
. O 0 3.378921491561937e-14

A O 0 2.9508630781938106e-12
younger O 0 2.231601986535381e-10
half O 0 1.5077332828419832e-13
- O 0 1.5584836754456433e-09
sister O 0 2.674770449573316e-08
, O 0 3.2932266177168037e-15
who O 0 2.1291899382383343e-14
had O 0 1.2000275773083047e-11
no O 0 1.5695157846995489e-12
underlying O 0 1.264638282982844e-09
disease O 0 1.387927217599838e-09
, O 0 5.545344711172613e-16
was O 0 1.2766889325235842e-12
also O 0 5.744908214644568e-15
found O 0 3.356593364259135e-14
to O 0 1.6193643648243494e-13
lack O 0 3.7307076915585324e-13
immunochemically O 0 3.794979264171161e-08
detectable O 0 4.281824672602852e-09
C5 O 0 3.098347178820404e-07
. O 0 2.668110524184364e-12

By O 0 1.7415968095305968e-14
hemolytic O 0 6.435232208223951e-11
assay O 0 1.3055172177686702e-12
, O 0 1.4204742525454617e-14
she O 0 1.7324790080731726e-14
exhibited O 0 2.4918650517037448e-17
1 O 0 3.325777234232335e-20
- O 0 4.0611782057935197e-13
2 O 0 8.27961322820512e-15
% O 0 1.384884522347032e-19
of O 0 9.603998923526787e-24
the O 0 6.302888469868192e-21
normal O 0 3.048707944028264e-18
serum O 0 1.2694734349285534e-14
C5 O 0 9.160759824322628e-12
level O 0 4.849187390065617e-16
and O 0 2.408042406545663e-16
normal O 0 3.6190909557996636e-18
concentrations O 0 4.824328677055765e-18
of O 0 4.8351663296625055e-24
other O 0 6.924693222580087e-21
complement O 0 1.002832932616546e-18
components O 0 3.5894514035470513e-16
. O 0 2.942851531729291e-17

C5 O 0 8.939833787735552e-05
levels O 0 1.1603336069754278e-09
of O 0 3.9101835681753167e-19
other O 0 4.0308627054994796e-18
family O 0 1.89348688468718e-15
members O 0 7.084608883854182e-21
were O 0 1.5372723876824965e-19
either O 0 7.094753963261461e-20
normal O 0 1.4446974096034645e-17
or O 0 2.997418995613079e-15
approximately O 0 1.1029737957164766e-17
half O 0 1.8131482236840094e-14
- O 0 2.2630035345638788e-10
normal O 0 5.231761746916919e-13
, O 0 1.3004141978712488e-17
consistent O 0 8.058400939029884e-16
with O 0 1.3139173423447482e-17
autosomal O 0 1.2999655796264165e-09
codominant O 0 7.914859878610514e-09
inheritance O 0 4.970973719459204e-13
of O 0 7.716133331881002e-20
the O 0 1.9776879027301636e-19
gene O 0 1.8021118926010542e-14
determining O 0 2.7322285059416807e-11
C5 B-Disease 1 0.9999939203262329
deficiency I-Disease 1 0.9999958276748657
. O 0 2.396473427687673e-12

Normal O 0 3.888842581289964e-09
hemolytic O 0 1.4977674709371058e-06
titers O 0 3.704818896110851e-09
were O 0 4.895616442278177e-16
restored O 0 3.316231926685112e-16
to O 0 1.5068160266282367e-17
both O 0 5.509751857333395e-16
homozygous O 0 1.2295954832097777e-07
C5 B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999979734420776
deficient I-Disease 1 0.9999998807907104
( O 0 5.00626068378196e-11
C5D B-Disease 1 0.9999991655349731
) O 0 3.207780517448279e-14
sera O 0 3.161310460370742e-13
by O 0 9.514599759451452e-21
addition O 0 3.2024691214354353e-21
of O 0 1.535213062376667e-22
highly O 0 3.3100355994345386e-18
purified O 0 1.8143269970850558e-15
human O 0 1.3969774738853327e-14
C5 O 0 1.0647321602164084e-07
. O 0 9.382608351284766e-14

In O 0 7.632651607144433e-17
specific O 0 1.9858708624200753e-16
C5 O 0 1.586978370937686e-08
titrations O 0 3.457684971674979e-10
, O 0 5.636951747934639e-15
however O 0 1.2375891454422991e-15
, O 0 2.144618733369822e-16
it O 0 2.7037619901624328e-15
was O 0 6.402756471714233e-13
noted O 0 5.519512853259317e-16
that O 0 7.470418327965633e-17
when O 0 2.0403451394447754e-16
limited O 0 1.675043870619953e-21
amounts O 0 9.348700973175378e-22
of O 0 4.672861622069611e-21
C5 O 0 2.242536711882792e-11
were O 0 9.599774288632096e-19
assayed O 0 1.4513604619341425e-15
in O 0 9.95483513653369e-21
the O 0 4.687772441183803e-20
presence O 0 3.092398838161733e-17
of O 0 4.80665503269038e-19
low O 0 3.8649185035103534e-14
dilutions O 0 2.5708726597226117e-13
of O 0 7.385518288331507e-19
either O 0 4.257033771716892e-14
C5D B-Disease 1 0.999991774559021
serum O 0 7.681575375784178e-10
, O 0 2.79236167366836e-19
curving O 0 3.0379391459855933e-15
rather O 0 2.6191044550684892e-17
than O 0 2.513791864908421e-20
linear O 0 1.9123867755070183e-18
dose O 0 6.880684211585137e-16
- O 0 1.241397284447443e-12
response O 0 1.6746592050167022e-15
plots O 0 2.504374312095603e-12
were O 0 5.723449058442354e-15
consistently O 0 8.919598924140236e-16
obtained O 0 4.218616681155823e-21
, O 0 1.065771025357271e-21
suggesting O 0 1.675806140980434e-19
some O 0 2.7088832201726195e-22
inhibitory O 0 2.091354628198732e-15
effect O 0 7.719630598819471e-14
. O 0 6.649916077863804e-14

Further O 0 4.9641280669421306e-15
studies O 0 1.164328842317801e-16
suggested O 0 4.7278093554341984e-17
that O 0 7.330396006286739e-18
low O 0 2.3639386821194645e-14
dilutions O 0 6.332563640132349e-11
of O 0 3.904929460026626e-15
C5D B-Disease 1 0.9999973773956299
serum O 0 4.3239701597030944e-08
contain O 0 4.183261945395547e-15
a O 0 8.73732683066287e-19
factor O 0 4.0240278775340764e-17
( O 0 2.6153077994544474e-19
or O 0 5.478845458914416e-13
factors O 0 1.9024329502145484e-14
) O 0 1.0516456877439127e-18
interfering O 0 2.5642404595082463e-14
at O 0 2.3325037436117287e-16
some O 0 4.22609038723721e-21
step O 0 1.557330292275625e-17
in O 0 2.6383523404618358e-21
the O 0 8.841124814347262e-20
hemolytic O 0 2.8974506848704687e-15
assay O 0 4.5330083211779604e-17
of O 0 2.521965604894924e-20
C5 O 0 2.0919983800826714e-10
, O 0 1.017328238875772e-18
rather O 0 1.7748788554156173e-19
than O 0 4.369046422573267e-22
a O 0 2.6212679104177047e-21
true O 0 2.153916243454918e-16
C5 O 0 2.5956141749827744e-11
inhibitor O 0 3.8479842820156665e-15
or O 0 1.3700993735810824e-13
inactivator O 0 6.849730027624901e-08
. O 0 5.798857487943065e-13

Of O 0 2.7619734824295373e-15
clinical O 0 1.1648981543374744e-15
interest O 0 9.745767289969648e-14
are O 0 1.5763085154451109e-15
( O 0 3.050624327637093e-20
a O 0 1.6115770656805517e-18
) O 0 2.3435341970801233e-18
the O 0 6.611956557059932e-19
documentation O 0 5.3674231536128894e-14
of O 0 5.442484802001644e-17
membranous O 0 0.0027095037512481213
glomerulonephritis B-Disease 1 0.9999994039535522
, O 0 1.3926313435774773e-09
vasculitis B-Disease 1 0.9999973773956299
, O 0 1.01075588870847e-11
and O 0 2.1288984441980574e-07
arthritis B-Disease 1 1.0
in O 0 1.1583122614143354e-17
an O 0 2.4757375113007984e-18
individual O 0 5.047298570846209e-14
lacking O 0 6.086421731194003e-12
C5 O 0 1.6907511835029254e-08
( O 0 1.5028714711206704e-18
and O 0 1.0904439946697683e-17
its O 0 2.6278670184041592e-20
biologic O 0 2.2138424099943124e-18
functions O 0 9.340256905071696e-21
) O 0 1.2686374704437166e-19
, O 0 2.017603322243151e-18
and O 0 1.2908083313974052e-14
( O 0 7.81397509816713e-19
b O 0 1.5129929508686177e-14
) O 0 5.173170271697367e-23
a O 0 7.276935772632608e-24
remarkable O 0 1.1574045022625685e-21
propensity O 0 8.421587808626202e-15
to O 0 8.473166694103126e-14
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 8.479090969591165e-16
the O 0 2.1438652049190107e-17
proband O 0 2.6067327116297e-11
, O 0 3.5054539172228943e-19
even O 0 1.7221044221420044e-18
during O 0 6.78150004490217e-18
periods O 0 1.3514550433878659e-15
of O 0 6.17841297419802e-20
low O 0 1.1927601172912784e-14
- O 0 9.678191679064058e-14
dose O 0 1.1145080848959772e-16
or O 0 3.653879845918171e-19
alternate O 0 1.5235778491248888e-17
- O 0 2.9937867912803104e-14
day O 0 2.215407394354232e-16
corticosteroid O 0 5.418827821353223e-13
therapy O 0 6.840257933639002e-14
. O 0 1.4461149986500334e-16

Other O 0 1.4052258066103121e-16
observations O 0 1.1087506272529444e-14
indicate O 0 3.863160571331622e-16
that O 0 4.0295404572903136e-18
the O 0 1.3638788197323795e-16
C5D B-Disease 1 0.9999982118606567
state O 0 1.6440404926032312e-17
is O 0 6.929188593780144e-20
compatible O 0 8.363831173051773e-15
with O 0 3.924295968393089e-16
normal O 0 6.214377919726158e-16
coagulation O 0 1.805444032124126e-12
function O 0 2.9608710062467136e-15
and O 0 1.3189103434884612e-15
the O 0 1.222748462739601e-19
capacity O 0 7.767100743870053e-21
to O 0 1.7430270703947838e-20
mount O 0 6.945905219128126e-15
a O 0 2.1096487187385882e-14
neutrophilic O 0 6.508946535177529e-05
leukocytosis O 0 3.826223110081628e-05
during O 0 1.8574881910371488e-10
pyogenic B-Disease 0 0.0004531753365881741
infection I-Disease 0 0.0017907385481521487
. O 0 7.266820337744478e-14
. O 0 3.6150572010722193e-13

Susceptibility O 0 2.47989966339901e-08
to O 0 2.6756481474876637e-08
ankylosing B-Disease 1 0.9999945163726807
spondylitis I-Disease 1 1.0
in O 0 4.2563524926819696e-10
twins O 0 1.9820407537451956e-09
: O 0 2.6355698987516635e-18
the O 0 5.785595745925223e-22
role O 0 4.37170382107045e-19
of O 0 2.9797263057501324e-22
genes O 0 7.973290601132726e-19
, O 0 2.327629375057107e-19
HLA O 0 2.7068491287936432e-14
, O 0 6.165378784263171e-17
and O 0 6.818630895506642e-15
the O 0 8.755457703247746e-16
environment O 0 8.624441438787045e-11
. O 0 1.2418988363724348e-13

OBJECTIVE O 0 3.379477145175336e-13
To O 0 4.51428558432119e-17
determine O 0 5.578120915764414e-17
the O 0 2.13274603632992e-18
relative O 0 2.5645828302255265e-14
effects O 0 1.9526586158549394e-14
of O 0 8.520864230297598e-21
genetic O 0 6.39298794566541e-15
and O 0 7.84100583030123e-17
environmental O 0 5.241771163444938e-20
factors O 0 1.0379062872396536e-21
in O 0 4.91114286450788e-23
susceptibility O 0 2.9263622232898745e-13
to O 0 2.4722324187820277e-10
ankylosing B-Disease 1 0.9999992847442627
spondylitis I-Disease 1 1.0
( O 0 6.094827420533022e-10
AS B-Disease 1 0.9999920129776001
) O 0 9.135097023174176e-15
. O 0 5.629752391399451e-15

METHODS O 0 2.131425732524589e-13
Twins O 0 6.74706332470798e-11
with O 0 9.91627612339477e-16
AS B-Disease 1 0.9999908208847046
were O 0 2.891113396117349e-15
identified O 0 1.942237548329046e-16
from O 0 6.5086814032214614e-18
the O 0 2.7077345746850555e-16
Royal O 0 6.16120381709967e-14
National O 0 1.3331597670018834e-15
Hospital O 0 1.861261389153948e-14
for O 0 1.79818113297718e-17
Rheumatic B-Disease 0 0.003179385093972087
Diseases I-Disease 0 6.2972067560451706e-09
database O 0 7.938440215512349e-14
. O 0 5.87180261010789e-13

Clinical O 0 4.5141912126747674e-13
and O 0 3.9108724125911515e-14
radiographic O 0 2.6352486859337887e-10
examinations O 0 2.818558103925839e-13
were O 0 1.7083787660837282e-16
performed O 0 1.200298625818547e-17
to O 0 2.9112146676186445e-20
establish O 0 3.146637732671325e-17
diagnoses O 0 1.2173831387407574e-10
, O 0 2.526700340450762e-15
and O 0 1.514017210213492e-11
disease O 0 8.02788169274038e-10
severity O 0 1.1651209240026023e-14
was O 0 2.0899636346632178e-18
assessed O 0 2.926513631541754e-20
using O 0 6.486318032523813e-20
a O 0 6.002780945908903e-19
combination O 0 6.787866440486684e-18
of O 0 3.972849285042171e-20
validated O 0 1.9291256688879627e-14
scoring O 0 6.023696081866592e-13
systems O 0 5.033719101266154e-12
. O 0 2.2852461025943405e-14

HLA O 0 2.5563455796628887e-09
typing O 0 7.114137057229186e-11
for O 0 2.1693431949662566e-17
HLA O 0 1.0534442242138287e-11
- O 0 2.4277128918281932e-11
B27 O 0 4.0319185707141103e-13
, O 0 6.2472195377608e-18
HLA O 0 7.57031969663563e-14
- O 0 7.304242253354173e-14
B60 O 0 5.621146960171821e-15
, O 0 1.9648517398339598e-19
and O 0 1.2420946146047795e-18
HLA O 0 1.797870121007794e-12
- O 0 3.4578828689291186e-10
DR1 O 0 3.4962486097356305e-05
was O 0 1.2672671682108401e-14
performed O 0 7.416461047095584e-19
by O 0 5.282330319406954e-23
polymerase O 0 1.1344930331930544e-16
chain O 0 7.670479569173218e-17
reaction O 0 8.919810046998942e-22
with O 0 2.6106063842861612e-24
sequence O 0 3.501747954208201e-21
- O 0 1.4645329680479389e-19
specific O 0 1.1687764787341645e-20
primers O 0 5.92762228190935e-11
, O 0 7.614558189297693e-18
and O 0 7.048393426419038e-17
zygosity O 0 1.5502734119761212e-14
was O 0 3.764247711617766e-19
assessed O 0 4.231674098710013e-20
using O 0 1.1931171471379382e-18
microsatellite O 0 5.643810752076206e-09
markers O 0 7.25371336329772e-08
. O 0 3.869525359856407e-12

Genetic O 0 8.442769400263117e-11
and O 0 2.0636187460991266e-14
environmental O 0 9.835382624047412e-18
variance O 0 9.516787393677713e-19
components O 0 4.354968229298203e-15
were O 0 6.045365961601935e-18
assessed O 0 1.1651097421750818e-18
with O 0 3.279955176459048e-19
the O 0 1.8377217311052256e-18
program O 0 4.920257689504989e-15
Mx O 0 6.462356555913748e-14
, O 0 5.551565627573536e-24
using O 0 1.7462655716026568e-23
data O 0 6.552948594087696e-19
from O 0 1.0712912402167441e-19
this O 0 1.517914422644195e-19
and O 0 1.7304834408010889e-15
previous O 0 2.333092325630952e-15
studies O 0 4.301056703096557e-18
of O 0 4.81823215237727e-22
twins O 0 5.845176904446098e-16
with O 0 5.785207112401198e-19
AS B-Disease 1 0.999839186668396
. O 0 5.539644264140886e-13

RESULTS O 0 2.7457851964340918e-11
Six O 0 4.3646972497303656e-15
of O 0 1.0551376306998053e-18
8 O 0 1.9569800085452414e-14
monozygotic O 0 3.027406103583985e-11
( O 0 1.3571372315656234e-16
MZ O 0 0.0503021739423275
) O 0 2.730768302455777e-12
twin O 0 1.6491790120198857e-06
pairs O 0 1.5845487144616754e-09
were O 0 4.713291909541617e-11
disease O 0 2.8877188834597334e-11
concordant O 0 8.844963335970929e-14
, O 0 1.9614323737050126e-16
compared O 0 6.083330408431791e-17
with O 0 1.328456716651108e-18
4 O 0 5.418705344624214e-16
of O 0 2.868117872695687e-18
15 O 0 9.47738494298377e-16
B27 O 0 1.2594699588808211e-13
- O 0 2.8001372921748757e-12
positive O 0 3.656020358146477e-15
dizygotic O 0 1.6227324388731756e-12
( O 0 1.219064975773114e-18
DZ O 0 2.4535712128681553e-08
) O 0 2.072073828978619e-15
twin O 0 2.5145732163167622e-09
pairs O 0 1.781332460010221e-12
( O 0 7.902771075768319e-18
27 O 0 1.9310840090620146e-14
% O 0 2.760861601966575e-19
) O 0 9.751204433914588e-20
and O 0 2.574931984654198e-16
4 O 0 4.460058932084664e-17
of O 0 1.2945779837003503e-18
32 O 0 1.4801816049974173e-14
DZ O 0 7.192707016656641e-06
twin O 0 2.0232668873632065e-08
pairs O 0 3.2368159259658913e-13
overall O 0 6.202820155160873e-16
( O 0 3.846127218527093e-19
12 O 0 2.088235488927472e-17
. O 0 6.250107225279223e-17
5 O 0 1.3911305748570257e-14
% O 0 1.434384287162276e-17
) O 0 1.8338718588264752e-16
. O 0 2.696769097908138e-14

Nonsignificant O 0 7.558132786300575e-09
increases O 0 4.901879615648412e-15
in O 0 6.975198091972705e-21
similarity O 0 5.35054153658654e-20
with O 0 5.095069066221525e-22
regard O 0 2.0664098735159235e-19
to O 0 5.314020013277463e-16
age O 0 2.0051718532115848e-12
at O 0 1.7885423231420866e-13
disease O 0 3.018451807945688e-11
onset O 0 3.558438943897582e-14
and O 0 4.083487605197858e-16
all O 0 2.7753282153983034e-19
of O 0 4.522118456748192e-21
the O 0 9.622079346198486e-16
disease O 0 6.46245557067715e-10
severity O 0 4.2807134247903333e-13
scores O 0 4.2197037380061505e-17
assessed O 0 3.213512100550879e-18
were O 0 3.0290818432245245e-18
noted O 0 8.424695572509678e-17
in O 0 1.9582922637508633e-16
disease O 0 1.8019014191850147e-07
- O 0 6.623143917749985e-07
concordant O 0 2.0836174371652305e-05
MZ O 1 0.7113606333732605
twins O 0 5.479533493613076e-10
compared O 0 6.055250075090229e-16
with O 0 5.430352709393451e-17
concordant O 0 3.527849656848048e-08
DZ O 0 0.003063805866986513
twins O 0 3.50626265799292e-08
. O 0 8.363329018039323e-13

HLA O 0 7.517764544218153e-08
- O 0 6.764454951735388e-08
B27 O 0 4.435918993239696e-11
and O 0 7.699951312949323e-15
B60 O 0 9.33163153682675e-15
were O 0 6.547229674127658e-18
associated O 0 1.1980381479995927e-18
with O 0 1.4232212159621737e-18
the O 0 5.730546876902989e-16
disease O 0 5.308562964212449e-11
in O 0 1.0187417871450486e-18
probands O 0 5.476678138771618e-11
, O 0 3.045335476972097e-19
and O 0 1.212817073811348e-18
the O 0 9.603248317957848e-20
rate O 0 1.0332168876980158e-14
of O 0 5.170021646359059e-20
disease O 0 1.1317665453089171e-14
concordance O 0 2.6689879954988058e-18
was O 0 6.461261951117879e-17
significantly O 0 5.046915121677965e-17
increased O 0 2.0289646479565667e-18
among O 0 1.1909362647734268e-15
DZ O 0 0.11280088871717453
twin O 0 0.00015537846775259823
pairs O 0 1.8696194592493498e-10
in O 0 7.667412118764075e-16
which O 0 4.178779870555151e-15
the O 0 2.1420024603539903e-16
co O 0 5.198885322243996e-09
- O 0 4.2324103333157836e-08
twin O 0 9.827835611986302e-08
was O 0 1.0047342190004638e-14
positive O 0 5.2993903515610085e-21
for O 0 4.241606953076771e-23
both O 0 2.063700081527988e-19
B27 O 0 3.5331583985538303e-14
and O 0 1.363568038050076e-14
DR1 O 0 3.365836892044172e-05
. O 0 3.211080218997603e-14

Additive O 0 8.853808392819337e-14
genetic O 0 5.944123231821363e-13
effects O 0 7.118116588777229e-14
were O 0 3.1982131883265576e-18
estimated O 0 1.1477324061835759e-20
to O 0 7.55238388233818e-20
contribute O 0 4.1071218096597233e-17
97 O 0 1.4201112142242685e-14
% O 0 8.239051427634402e-18
of O 0 2.2347203113302444e-21
the O 0 1.0889766589811605e-17
population O 0 2.86628964844558e-19
variance O 0 1.2202009222288178e-17
. O 0 5.310208110904935e-13

CONCLUSION O 0 1.381205296890984e-14
Susceptibility O 0 2.996200293078899e-12
to O 0 2.9029760366394708e-12
AS B-Disease 1 0.9999986886978149
is O 0 1.1829582732014753e-15
largely O 0 2.401372319871056e-17
genetically O 0 3.591830805122672e-18
determined O 0 9.992378222057306e-15
, O 0 4.01908795491591e-17
and O 0 6.656685289892553e-16
the O 0 1.4624409300510945e-17
environmental O 0 6.570884769863073e-15
trigger O 0 2.8705111746775425e-13
for O 0 1.576611934392782e-19
the O 0 2.9680292816839596e-15
disease O 0 3.908067272573312e-11
is O 0 3.4267885860197645e-17
probably O 0 3.5059290845083305e-15
ubiquitous O 0 6.074129046962362e-12
. O 0 2.318916001060878e-13

HLA O 0 1.400575655452485e-08
- O 0 1.4173971718545175e-10
B27 O 0 9.02929464595241e-14
accounts O 0 3.692852884408671e-17
for O 0 2.1136054388469607e-20
a O 0 5.303400254983201e-19
minority O 0 2.6288948655369933e-16
of O 0 2.6046902193755386e-22
the O 0 1.4963828143642116e-20
overall O 0 6.844073001218144e-20
genetic O 0 2.769396554924474e-18
susceptibility O 0 1.3937272814117758e-15
to O 0 3.801383917389524e-15
AS B-Disease 1 0.9999969005584717
. O 0 1.3152904980440194e-11

Cell O 0 3.600965570171866e-08
cycle O 0 3.1872079375716567e-07
- O 0 2.211460525813891e-08
dependent O 0 1.1314186566802054e-11
colocalization O 0 1.6364793964385171e-09
of O 0 3.2973069441685726e-18
BARD1 O 0 1.3724128604397645e-11
and O 0 4.19607114654648e-19
BRCA1 O 0 1.4689314234070072e-18
proteins O 0 2.3330777811074464e-20
in O 0 5.441432772372849e-22
discrete O 0 1.9238919793618204e-15
nuclear O 0 1.6904021515884438e-09
domains O 0 4.6396525510417064e-11
. O 0 2.0758468728676593e-12

Germ O 0 6.545284122694284e-05
- O 0 1.451540447305888e-05
line O 0 1.265848048603857e-08
mutations O 0 1.390481425746909e-13
of O 0 1.3309814269769848e-20
the O 0 1.0200513433016908e-20
BRCA1 O 0 2.1392493716648423e-17
gene O 0 4.356473668234547e-18
predispose O 0 2.4646846114593016e-14
women O 0 4.936493540937343e-18
to O 0 6.941252506026347e-20
early O 0 2.2160447305311082e-13
- O 0 6.337371451081708e-05
onset O 0 0.0016846746439114213
breast B-Disease 1 0.9999884366989136
and I-Disease 1 0.9999828338623047
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999963045120239
by O 0 3.1697312918848255e-18
compromising O 0 7.092895335739785e-14
the O 0 2.6495690388150256e-20
genes O 0 5.743784016635104e-17
presumptive O 0 2.7180267585247275e-12
function O 0 5.7471346771423726e-18
as O 0 1.5314493205134587e-18
a O 0 1.9895776572682724e-17
tumor B-Disease 0 1.9105905746386043e-09
suppressor O 0 1.9628646441560704e-06
. O 0 5.836170990924927e-10

Although O 0 3.988730325850051e-14
the O 0 8.556544026247568e-18
biochemical O 0 1.0572591555761766e-14
properties O 0 2.1392914255271845e-16
of O 0 4.937919613238081e-20
BRCA1 O 0 3.8307915460654776e-14
polypeptides O 0 5.600025516005677e-14
are O 0 4.706591097387417e-18
not O 0 4.473005632160099e-18
understood O 0 4.922974680032205e-17
, O 0 9.353958958048181e-19
their O 0 3.3015896387028414e-16
expression O 0 6.748554589230873e-15
pattern O 0 5.3681888795287236e-11
and O 0 1.0336269363477816e-14
subcellular O 0 7.00431263011593e-14
localization O 0 3.424335459490508e-15
suggest O 0 4.100309894597288e-18
a O 0 6.496117335894761e-22
role O 0 6.2789477045164965e-18
in O 0 1.7548644967118608e-18
cell O 0 3.5770733042284064e-09
- O 0 1.6249522332145716e-06
cycle O 0 1.5605851899636036e-07
regulation O 0 6.30443544591408e-11
. O 0 3.0103016975847885e-13

When O 0 2.7137672534496837e-13
resting O 0 2.4614221251495483e-12
cells O 0 9.834936608261124e-17
are O 0 1.1200049275410606e-18
induced O 0 1.200040094422386e-13
to O 0 4.197390507895308e-16
proliferate O 0 3.220078093058021e-10
, O 0 2.1816920088949382e-17
the O 0 2.058637477685222e-18
steady O 0 1.9315640395738826e-13
- O 0 2.0295481163452433e-15
state O 0 1.3988324676852954e-19
levels O 0 2.239860342186402e-19
of O 0 5.296287872061301e-25
BRCA1 O 0 1.9270980534543032e-19
increase O 0 9.97215084166257e-24
in O 0 2.601490110450201e-24
late O 0 1.0448518465778615e-18
G1 O 0 3.7631227615356894e-14
and O 0 7.757337524637741e-19
reach O 0 2.6747846381246816e-20
a O 0 1.685440274800748e-21
maximum O 0 4.115348917012903e-20
during O 0 2.8128370062308582e-14
S O 0 1.4771084124731715e-06
phase O 0 2.2445446448194663e-14
. O 0 1.605689526110697e-14

Moreover O 0 6.116584018792115e-13
, O 0 9.459067723150498e-17
in O 0 1.4776538361712257e-18
S O 0 9.913914307546623e-12
phase O 0 1.1410716667791376e-18
cells O 0 5.8025379938002555e-18
, O 0 1.931808717795822e-19
BRCA1 O 0 3.691687221489461e-15
polypeptides O 0 1.8780550031793908e-13
are O 0 3.4248040804685763e-16
hyperphosphorylated O 0 9.895089192468731e-10
and O 0 7.253305080038089e-14
accumulate O 0 1.6813372254783493e-13
into O 0 3.921389073740843e-18
discrete O 0 1.2238349439766538e-13
subnuclear O 0 1.0933375982347115e-08
foci O 0 7.50933037974022e-10
termed O 0 1.3344083867397605e-12
" O 0 5.130220467192137e-12
BRCA1 O 0 1.6281936909834371e-10
nuclear O 0 3.969371942247335e-09
dots O 0 2.4764621464612446e-09
. O 0 4.00364290331634e-12

" O 0 4.07055014695068e-11
BRCA1 O 0 8.8572291861988e-12
associates O 0 8.583934778261249e-12
in O 0 4.399745967619034e-18
vivo O 0 1.9237840758346697e-13
with O 0 7.034909058945444e-17
a O 0 4.061564671987243e-17
structurally O 0 2.3606892482486153e-11
related O 0 5.632587834190385e-15
protein O 0 5.702226478542308e-14
termed O 0 3.830810235000426e-12
BARD1 O 0 1.1077837598350015e-06
. O 0 4.809990296686384e-13

Here O 0 1.294404253920911e-12
we O 0 5.052660797622097e-15
show O 0 4.315034183373541e-14
that O 0 2.0590616145443087e-18
the O 0 2.962153160597999e-19
steady O 0 1.053358721320001e-13
- O 0 1.2292390141801363e-13
state O 0 7.639439120378798e-17
levels O 0 2.2928768953612124e-15
of O 0 2.751039543050847e-21
BARD1 O 0 3.862636122412e-13
, O 0 3.5502095097732276e-21
unlike O 0 1.8563913655516093e-20
those O 0 6.21787142812136e-21
of O 0 4.952362108983126e-23
BRCA1 O 0 3.337847466345213e-15
, O 0 5.3465301965842675e-17
remain O 0 8.046298955795988e-16
relatively O 0 4.632771328174077e-19
constant O 0 1.9354414853558696e-15
during O 0 2.3229241186156378e-15
cell O 0 1.647538816484939e-08
cycle O 0 2.237968743656893e-07
progression O 0 3.0790882732389946e-08
. O 0 8.608988522063044e-12

However O 0 6.055692752804376e-11
, O 0 3.201051687715291e-14
immunostaining O 0 1.5171116585221966e-09
revealed O 0 1.0017888428526245e-11
that O 0 6.547286220194332e-16
BARD1 O 0 1.2123409220965442e-10
resides O 0 1.4312486175136548e-15
within O 0 2.981343750809229e-20
BRCA1 O 0 4.482013854023928e-15
nuclear O 0 1.6396129245976887e-13
dots O 0 4.759483890445955e-14
during O 0 9.053640405735572e-15
S O 0 1.2644110758408544e-10
phase O 0 1.0296937825323426e-17
of O 0 1.7547019492591456e-20
the O 0 5.3050040754728804e-17
cell O 0 1.6486184639674661e-10
cycle O 0 9.453150484617368e-10
, O 0 6.274518152336275e-18
but O 0 1.2250787856215277e-18
not O 0 1.238114893581422e-20
during O 0 2.9482293844432586e-20
the O 0 1.2290147436206023e-19
G1 O 0 6.536456705757976e-12
phase O 0 7.002596075496672e-16
. O 0 9.938093574533673e-15

Nevertheless O 0 7.780870392437578e-11
, O 0 2.4163897574221768e-15
BARD1 O 0 3.794837777348903e-10
polypeptides O 0 2.9762124839280424e-13
are O 0 3.1184946907675252e-18
found O 0 5.372407797585438e-19
exclusively O 0 1.1133177719945134e-17
in O 0 2.693266987248156e-19
the O 0 1.7413475383221317e-18
nuclear O 0 8.690541945203124e-15
fractions O 0 3.14091270708439e-20
of O 0 3.213614539579407e-23
both O 0 4.6593339071007445e-21
G1 O 0 1.7161673557947177e-13
- O 0 7.461718417624275e-13
and O 0 2.4927591458015486e-13
S O 0 2.961692002756422e-10
- O 0 5.151821674207737e-16
phase O 0 2.4085543155395478e-18
cells O 0 6.810512825861038e-17
. O 0 2.448503052853633e-16

Therefore O 0 2.009189764161281e-14
, O 0 4.906102180769593e-17
progression O 0 7.986862581889353e-13
to O 0 5.821284074355657e-14
S O 0 4.7846469897194766e-08
phase O 0 8.128484445085705e-16
is O 0 6.21584168199452e-18
accompanied O 0 9.46112508677004e-17
by O 0 4.311462858153499e-22
the O 0 3.6549775081286805e-21
aggregation O 0 9.290212896255435e-16
of O 0 3.3786179712019227e-18
nuclear O 0 2.0858523241962246e-12
BARD1 O 0 6.22748380640914e-14
polypeptides O 0 6.179459383522294e-17
into O 0 1.403665942498384e-17
BRCA1 O 0 5.154820147124095e-12
nuclear O 0 4.0537757178826794e-11
dots O 0 4.164156866548474e-11
. O 0 6.256632039715326e-13

This O 0 5.2636602649685e-17
cell O 0 9.072803272558438e-13
cycle O 0 4.4967896073444535e-09
- O 0 8.760629444104495e-10
dependent O 0 1.1276135190516068e-12
colocalization O 0 6.632322469002361e-10
of O 0 5.371916142108851e-19
BARD1 O 0 1.188987519551432e-10
and O 0 8.611397515952287e-17
BRCA1 O 0 2.4397678667663954e-15
indicates O 0 3.0299008037297403e-19
a O 0 5.47954901670019e-23
role O 0 4.5754432527036624e-20
for O 0 1.7763207669326164e-20
BARD1 O 0 1.8772009988121674e-11
in O 0 9.83432186830939e-20
BRCA1 O 0 1.2000590408553502e-12
- O 0 2.7560206720955716e-12
mediated O 0 3.053455752133338e-11
tumor B-Disease 0 7.374339929810958e-07
suppression O 0 6.939295360552933e-08
. O 0 2.4940681030843903e-12

Ethnic O 0 1.1257552756660516e-07
differences O 0 1.375816238713412e-09
in O 0 2.6357735671620863e-16
the O 0 2.6837652363436533e-15
HFE O 0 1.1798505283877603e-06
codon O 0 1.860448878288068e-10
282 O 0 4.090373179055362e-11
( O 0 6.364642835118492e-14
Cys O 0 3.741582258953713e-05
/ O 0 1.1336322991439829e-08
Tyr O 0 2.815198907324401e-10
) O 0 3.0202005290646346e-16
polymorphism O 0 3.215716972218563e-12
. O 0 4.5284032058022505e-13

Recent O 0 9.777040424008634e-15
studies O 0 9.772295874833708e-17
have O 0 7.060795510779168e-18
shown O 0 4.637627697774878e-14
that O 0 3.884036980927874e-10
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 1.4594351118238369e-12
HH B-Disease 0 7.218332757474855e-05
) O 0 3.212202384127993e-17
is O 0 2.7582209312585762e-18
likely O 0 2.411203361451249e-17
to O 0 4.9299823887456315e-18
be O 0 9.097261755486221e-15
caused O 0 3.136540303199688e-14
by O 0 1.5557553507290817e-19
homozygosity O 0 1.1073151943985504e-11
for O 0 3.58019957296032e-20
a O 0 7.926078543888226e-18
Cys282Tyr O 0 1.842572761034944e-10
mutation O 0 3.684835571979121e-15
in O 0 1.3567991297620484e-18
the O 0 2.9237046166544035e-18
HFE O 0 3.311896113258883e-12
gene O 0 3.4150864949812013e-15
located O 0 1.3908380520286914e-15
4 O 0 6.917720790731302e-14
. O 0 1.8867509822290823e-13

5 O 0 2.2748461100952078e-12
Mb O 0 1.7371523108877795e-09
telomeric O 0 1.7538027918817534e-08
to O 0 1.4144830191029426e-14
HLA O 0 3.347829347077891e-09
- O 0 3.183074470669567e-09
A O 0 1.3961799381553841e-12
. O 0 2.9893261802547977e-13

Population O 0 3.2815549865124194e-13
studies O 0 1.356961816336203e-15
of O 0 2.558661687547056e-21
this O 0 5.370330277739255e-22
polymorphism O 0 7.829460436222005e-19
are O 0 7.220640765169864e-23
facilitated O 0 6.1750405976147325e-21
by O 0 8.53469511019214e-20
the O 0 1.0424313093103782e-18
fact O 0 1.6857136864275302e-17
that O 0 1.3771513917460328e-18
the O 0 9.843188727488075e-18
Cys282Tyr O 0 2.86227652690485e-10
mutation O 0 4.131151631447515e-15
creates O 0 7.0966127092354e-15
a O 0 1.6502046425279764e-17
Rsal O 0 1.7381748818046105e-11
restriction O 0 9.50138964495072e-15
site O 0 1.224167555519129e-11
. O 0 7.777183302741519e-13

We O 0 3.200125169196266e-13
have O 0 5.559742286042466e-18
studied O 0 4.5023990816368644e-18
the O 0 2.069954466517805e-17
codon O 0 2.1147058442468752e-13
282 O 0 1.0754176954334838e-13
( O 0 3.226127804304201e-17
Cys O 0 7.107934862915499e-08
/ O 0 8.987654370740117e-12
Tyr O 0 5.933000401733834e-13
) O 0 4.260800355924227e-19
polymorphism O 0 1.0035840911949023e-16
in O 0 7.992406486594885e-21
different O 0 3.020103624855874e-19
ethnic O 0 1.749233827989631e-14
groups O 0 2.2107483690371986e-15
. O 0 9.406183141679337e-15

In O 0 1.9859163904409902e-16
agreement O 0 2.3635293031551227e-17
with O 0 3.10368381510461e-18
previous O 0 1.643715344448049e-16
observations O 0 5.6238066436261995e-15
the O 0 3.129340724318351e-17
Tyr O 0 7.477276176698355e-13
allele O 0 9.935446427166914e-14
appeared O 0 3.6665410833337797e-13
to O 0 4.72391308659489e-18
be O 0 5.432152571688305e-18
rare O 0 2.0407566452559083e-17
or O 0 5.230484556757731e-13
absent O 0 1.3708222924846414e-11
in O 0 4.790499124128326e-16
Asiatic O 0 1.01426400611615e-09
( O 0 2.372650747846837e-19
Indian O 0 8.376334457996765e-18
, O 0 1.484562888086969e-19
Chinese O 0 2.8832985497912015e-19
) O 0 4.8169162081891e-19
populations O 0 6.000085598562415e-17
. O 0 4.57238178746324e-16

The O 0 1.2046477429560038e-16
highest O 0 4.735175696574004e-16
allele O 0 8.226721102846772e-15
frequency O 0 2.0582265004755879e-13
( O 0 1.408273173074182e-17
7 O 0 8.317469671716756e-16
. O 0 1.2812944308640653e-16
5 O 0 3.739594981469691e-15
% O 0 8.814458320856142e-19
) O 0 9.919627453918335e-19
was O 0 1.27755797477494e-13
found O 0 4.0190940853168655e-14
in O 0 5.845310841530883e-16
Swedes O 0 3.323172137470465e-08
. O 0 2.7061022151407543e-13

Saamis O 0 4.2644664688396006e-08
( O 0 3.9444711602901195e-14
2 O 0 3.739969759667533e-13
% O 0 1.1203398802680435e-15
) O 0 3.709994382806485e-17
and O 0 4.459963214714646e-14
Mordvinians O 0 2.8067140625531728e-12
( O 0 9.551032057114298e-22
1 O 0 1.9736087148537337e-21
. O 0 1.970068974752485e-18
8 O 0 7.479688971224433e-16
% O 0 9.925826461751081e-21
) O 0 3.867412272054573e-21
had O 0 3.959314560363848e-17
significantly O 0 3.2824478852349763e-18
lower O 0 6.036464257439945e-20
frequencies O 0 1.2785804578917238e-15
of O 0 1.2909034923230249e-19
the O 0 2.2399235718724257e-16
Tyr O 0 1.5060333188876562e-11
allele O 0 6.662284656247519e-13
. O 0 5.013190248126173e-14

Comparisons O 0 7.065598915509039e-16
with O 0 8.324440144894909e-19
allele O 0 2.0327162842657704e-16
frequencies O 0 1.4132141213963082e-16
based O 0 7.575239916638786e-19
on O 0 1.435528670760966e-13
prevalence O 0 1.7082195213902196e-08
estimates O 0 2.1879086338342547e-14
of O 0 1.4361418805278286e-17
HH B-Disease 1 0.8823972344398499
showed O 0 2.037722351966309e-10
some O 0 2.6036496903845354e-20
disagreements O 0 1.2841723576512598e-15
with O 0 1.2544309503846738e-20
the O 0 1.6692209108874596e-20
RFLP O 0 1.6128280233286248e-15
data O 0 5.500007802066418e-16
, O 0 2.8514594891346347e-18
particularly O 0 2.801433425484775e-17
in O 0 7.275431508943815e-18
Finns O 0 4.2377373832280796e-10
. O 0 1.2008941746837615e-13

The O 0 6.517934199231365e-15
newly O 0 7.872153111126122e-15
described O 0 6.234207384537855e-15
HFE O 0 1.9053510939143203e-12
marker O 0 8.150663304007377e-14
provides O 0 1.3366809598914165e-19
a O 0 3.545878524564045e-21
new O 0 8.84425792247602e-21
approach O 0 8.324031827865037e-18
to O 0 4.374253863802586e-20
the O 0 7.811280488659285e-22
screening O 0 2.067625208630917e-18
of O 0 1.0609971067404924e-20
HH B-Disease 0 3.5025111699837908e-09
as O 0 9.263303064839666e-19
well O 0 1.3989397426709859e-18
as O 0 1.787252133210915e-18
studies O 0 1.850490545989931e-17
of O 0 2.930890135918434e-22
the O 0 2.0797658354165858e-20
relationship O 0 6.84283110326573e-17
between O 0 3.678520005402477e-20
the O 0 1.820499643343764e-20
HFE O 0 6.703276714085937e-13
Tyr O 0 2.0385267502894336e-14
allele O 0 2.1714341479420196e-13
and O 0 1.006514174035824e-14
different O 0 8.431395094902691e-14
disorders O 0 8.807045759340326e-08
including O 0 2.6682095186189754e-14
cancer B-Disease 0 5.43615124115604e-06

Autosomal B-Disease 1 0.999579131603241
dominant I-Disease 1 0.9989088773727417
neurohypophyseal I-Disease 1 0.9994044303894043
diabetes I-Disease 1 0.9996787309646606
insipidus I-Disease 1 0.7833388447761536
associated O 0 4.060725367072138e-11
with O 0 5.217739498698741e-17
a O 0 1.441371729950695e-18
missense O 0 2.773978903907446e-15
mutation O 0 1.0733375687299267e-17
encoding O 0 2.7145097794719058e-15
Gly23 O 0 4.518509655326852e-08
- O 0 2.860456760345187e-08
- O 0 1.574631269818383e-08
> O 0 1.069331147067476e-12
Val O 0 1.3063859993778237e-09
in O 0 5.634218584372086e-16
neurophysin O 0 1.5710194034568303e-08
II O 0 6.745667135987787e-09
. O 0 3.3115705137939586e-14

Autosomal B-Disease 1 0.9991482496261597
dominant I-Disease 1 0.9989122152328491
neurohypophyseal I-Disease 1 0.999377965927124
diabetes I-Disease 1 0.9994039535522461
insipidus I-Disease 1 0.9773442149162292
( O 0 1.2660144200343781e-12
ADNDI B-Disease 0 1.0041434350682721e-08
) O 0 3.1232600865482494e-16
is O 0 2.9755877007794446e-17
an O 0 2.003970313258982e-13
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 2.928442199845449e-07
by O 0 7.512541673479283e-17
progressive O 0 5.100622701981194e-10
degeneration O 0 5.553649202738598e-07
of O 0 4.3143155811351695e-19
the O 0 1.3824261777556763e-17
magnocellular O 0 4.093321168130437e-12
neurons O 0 8.66478706140891e-15
of O 0 2.7541595649238203e-20
the O 0 1.6945133992199919e-18
hypothalamus O 0 6.035216814151423e-14
leading O 0 2.887565810376011e-14
to O 0 2.395428995406127e-14
decreased O 0 2.588151589745513e-13
ability O 0 2.0622169065714208e-15
to O 0 1.796379851240395e-15
produce O 0 7.650524928773785e-16
the O 0 1.1517076378134057e-17
hormone O 0 2.6296989115621745e-15
arginine O 0 4.84085152707345e-16
vasopressin O 0 3.0964493761852826e-16
( O 0 1.2468746070213879e-19
AVP O 0 6.047825543316343e-13
) O 0 2.5179142265075707e-16
. O 0 5.313434713510911e-15

Affected O 0 1.3662631952442855e-13
individuals O 0 8.322027362445668e-19
are O 0 4.706191426979886e-20
not O 0 1.7140692930692408e-18
symptomatic O 0 3.16575890588555e-16
at O 0 2.392395855125304e-15
birth O 0 3.9619213942562737e-13
, O 0 1.9001863329648103e-16
but O 0 1.8695194521699092e-14
usually O 0 8.37703861898513e-14
develop O 0 9.005500338499228e-12
diabetes B-Disease 0 2.289563738600009e-08
insipidus I-Disease 0 1.764338577459057e-07
at O 0 8.115221819190999e-13
1 O 0 5.390031479414643e-15
- O 0 4.033083200738474e-07
6 O 0 1.3203432791542014e-10
yr O 0 6.430323264794424e-05
of O 0 8.984687053389625e-16
age O 0 1.8235520732323707e-11
. O 0 8.353341517032976e-15

The O 0 1.4258691906749815e-16
genetic O 0 3.050307944597874e-14
locus O 0 3.2644095759870595e-11
of O 0 2.9961029711108418e-16
the O 0 6.272066199741744e-14
disease O 0 2.530361163655126e-11
is O 0 1.9961983695321162e-18
the O 0 4.7216812705841606e-17
AVP O 0 1.8996070494381456e-08
- O 0 2.4989500957417476e-07
neurophysin O 0 1.5988402424227388e-07
II O 0 2.6485647453000638e-08
( O 0 6.077645030645592e-18
NPII O 0 3.883307304192174e-12
) O 0 5.720816013098831e-20
gene O 0 6.153439590173826e-18
, O 0 3.4067015801787106e-18
and O 0 6.427533496204907e-17
mutations O 0 7.22157129771865e-17
that O 0 1.8997595871780718e-15
cause O 0 3.805724453024434e-14
ADNDI B-Disease 0 2.920160779851244e-10
have O 0 2.62593977934226e-15
been O 0 8.889371918142756e-15
found O 0 2.926442928589089e-15
in O 0 6.54173073251177e-20
both O 0 2.3370148053940293e-20
the O 0 2.634521621808663e-20
signal O 0 2.3334753962813478e-15
peptide O 0 7.389721399819042e-18
of O 0 4.5347239996297423e-23
the O 0 4.617263242652356e-19
prepro O 0 7.787934359904103e-12
- O 0 1.8976466719614754e-13
AVP O 0 2.061309872791739e-10
- O 0 4.444326417302191e-12
NPII O 0 3.091075659322762e-11
precursor O 0 2.4917439259922874e-15
and O 0 8.023866029341787e-15
within O 0 5.912808614079087e-18
NPII O 0 2.243411900693104e-09
itself O 0 1.3819077175972194e-12
. O 0 1.058756455717038e-14

An O 0 1.4216715336164056e-15
affected O 0 3.0074207013619514e-13
girl O 0 6.84499923409021e-09
who O 0 7.757437956771814e-16
presented O 0 2.0051360974097823e-17
at O 0 8.618035474931902e-17
9 O 0 1.2097177645409128e-16
months O 0 2.3151746141812082e-15
of O 0 6.992468427628333e-19
age O 0 4.186365663849667e-12
and O 0 1.371273293483341e-13
her O 0 5.368557681739716e-11
similarly O 0 9.571309673647721e-15
affected O 0 1.6931840538011701e-16
younger O 0 1.2607672067802e-14
brother O 0 1.9512421192691143e-12
and O 0 4.042062823637676e-15
father O 0 2.2640936434698e-12
were O 0 7.45797124498018e-18
all O 0 5.027996350770838e-21
found O 0 2.1772334640342467e-19
to O 0 5.521778521636615e-19
have O 0 2.0659222505448235e-18
a O 0 1.2363833719148013e-19
novel O 0 5.191180754167803e-15
missense O 0 2.158319909514178e-13
mutation O 0 5.14987900414321e-15
( O 0 2.3922919446967553e-18
G1758 O 0 1.9734802103577552e-14
- O 0 2.3444635122160662e-11
- O 0 2.1154231144571156e-10
> O 0 5.926185547334723e-15
T O 0 1.9935008505056473e-14
) O 0 8.501634754923539e-23
encoding O 0 1.881003992401928e-22
the O 0 9.362435357079638e-23
amino O 0 5.189501749784683e-21
acid O 0 8.188338330870652e-22
substitution O 0 5.037419868574442e-22
Gly23 O 0 2.3434808035641998e-14
- O 0 2.2709540845045062e-11
- O 0 1.044545783202011e-09
> O 0 1.02987273385962e-13
Val O 0 1.9035657772281667e-10
within O 0 2.539745918387899e-15
NPII O 0 1.0505888781153772e-07
. O 0 6.038671353323505e-14

The O 0 4.082352792806774e-15
mutation O 0 5.95696503057205e-15
was O 0 5.864076856477302e-14
confirmed O 0 2.2912393424461534e-17
by O 0 3.392135537052414e-20
restriction O 0 3.4663625608855265e-17
endonuclease O 0 1.9251531480080075e-09
analysis O 0 1.467133532717657e-11
. O 0 1.4433285567150983e-13

A O 0 4.096860773127346e-15
T1 O 0 5.650739424989393e-12
- O 0 5.902068401744025e-15
weighted O 0 1.3287970807936583e-17
magnetic O 0 1.2169986744670536e-16
resonance O 0 1.1289982722307006e-14
imaging O 0 6.20075041660173e-12
of O 0 3.186524050936387e-17
the O 0 5.014041008018395e-14
fathers O 0 1.3350366367959055e-09
pituitary O 0 1.6468765587362988e-11
gland O 0 3.9657619094017604e-13
demonstrates O 0 5.468375886046799e-16
an O 0 8.598946752013108e-19
attenuated O 0 9.280964832214522e-07
posterior O 0 3.86388774131774e-06
pituitary O 0 0.002434944733977318
bright O 0 6.77249090585974e-07
spot O 0 4.782316409546183e-07
. O 0 1.978073260744395e-11

This O 0 3.437434400503322e-16
mutation O 0 1.3046184095089986e-16
may O 0 1.892011249068306e-18
be O 0 1.4771760646528823e-24
valuable O 0 1.5479320560781625e-23
for O 0 1.6920100851242713e-22
developing O 0 1.5357684068587768e-16
models O 0 6.174402623296965e-14
of O 0 3.38023089067834e-17
dominantly B-Disease 0 9.091946751027535e-09
inherited I-Disease 0 1.4563050854121684e-06
neurodegeneration I-Disease 1 0.9999990463256836
, O 0 7.4292358176807e-18
as O 0 2.1063201102253853e-21
the O 0 5.045249609670461e-21
early O 0 9.08269787099113e-15
age O 0 2.8796596183988665e-12
of O 0 8.150486647014421e-19
onset O 0 9.3258456512757e-12
of O 0 3.023313110447998e-16
symptoms O 0 4.450909259212654e-12
suggests O 0 1.5787786306097881e-19
that O 0 2.8431040989931453e-20
this O 0 1.0059508219145027e-20
mutation O 0 3.581666906063988e-17
may O 0 1.1073304071102831e-14
be O 0 4.136288198058343e-17
particularly O 0 6.634095053538179e-17
deleterious O 0 3.503497676433237e-14
to O 0 1.4217366492742258e-15
the O 0 4.8953150838374116e-17
magnocellular O 0 1.5374010658292248e-12
neuron O 0 9.323932007336208e-14
. O 0 2.138321334574562e-15
. O 0 1.8850783293274803e-13

Frequent O 0 1.609414962411293e-10
inactivation O 0 8.224921854704803e-10
of O 0 1.955604787027903e-16
PTEN O 0 2.414259459015966e-09
/ O 0 2.4055584191273738e-09
MMAC1 O 0 4.643404594162348e-08
in O 0 2.8896359588991005e-15
primary O 0 3.284430860617249e-08
prostate B-Disease 1 0.9999934434890747
cancer I-Disease 1 0.9999927282333374
. O 0 1.6037345895725252e-09

Sporadic B-Disease 0 2.5534009182592854e-05
prostate I-Disease 0 0.003219235921278596
carcinoma I-Disease 1 0.9999990463256836
is O 0 2.699252496865534e-12
the O 0 1.777089350846058e-17
most O 0 9.103466086536402e-17
common O 0 4.3145592350593565e-13
male B-Disease 0 3.048253316428884e-11
cancer I-Disease 0 4.440406918028439e-14
in O 0 2.5751455957755836e-18
the O 0 1.4644074162998189e-15
Western O 0 1.1530760721245592e-11
world O 0 2.1411103445778679e-10
, O 0 1.588731524166016e-16
yet O 0 1.1834581384456411e-17
many O 0 2.4031359804125314e-21
of O 0 1.735851503248472e-23
the O 0 4.163204213408517e-22
major O 0 8.534848954476964e-22
genetic O 0 1.4972637035554437e-18
events O 0 3.2179879748454034e-19
involved O 0 4.063137018254614e-21
in O 0 3.127804963990979e-22
the O 0 1.144004358092762e-19
progression O 0 5.996505375582828e-13
of O 0 1.7711318564877227e-19
this O 0 1.5492380836046923e-15
often O 0 2.9532378764685063e-09
fatal O 0 2.9239203058750718e-08
cancer B-Disease 0 3.978103180202197e-09
remain O 0 9.821904709906085e-14
to O 0 2.2496587928504603e-17
be O 0 2.440641528311929e-16
elucidated O 0 8.556905739531828e-10
. O 0 3.188208432067935e-13

Numerous O 0 5.351129289026327e-14
cytogenetic O 0 3.39333396937036e-08
and O 0 2.8139183691489045e-12
allelotype O 0 1.239813807174528e-09
studies O 0 1.803879311548795e-14
have O 0 6.13919104016313e-16
reported O 0 3.0051316117626556e-14
frequent O 0 1.995404031894174e-13
loss O 0 1.6657085866872423e-14
of O 0 1.2904997247865224e-19
heterozygosity O 0 1.0421760026149696e-12
on O 0 3.993410116476248e-11
chromosomal O 1 0.9898170232772827
arm O 0 0.15152953565120697
10q O 0 5.819663639883288e-10
in O 0 5.053293742991933e-16
sporadic B-Disease 0 1.9531978523446014e-07
prostate I-Disease 1 0.9999948740005493
cancer I-Disease 1 0.9999935626983643
. O 0 8.755149938366458e-10

Deletion O 0 2.4529777514770146e-11
mapping O 0 2.6671857430993207e-11
studies O 0 2.347002529389658e-13
have O 0 8.641935700678764e-17
unambiguously O 0 3.0413178486038417e-12
identified O 0 2.5994472357301055e-16
a O 0 2.4659458435177632e-17
region O 0 2.407686747999023e-14
of O 0 1.6603571471737225e-18
chromosome O 0 1.9844682841441141e-10
10q23 O 0 1.7414971984559997e-14
to O 0 4.7134724129032456e-18
be O 0 1.5349518875703438e-19
the O 0 1.0618925297535811e-19
minimal O 0 3.644573978413756e-15
area O 0 2.662708547846327e-14
of O 0 1.2831055831816641e-14
loss O 0 1.5765380667609463e-10
. O 0 1.3949360058978372e-13

A O 0 3.3785842453939877e-15
new O 0 1.7411822676357436e-17
tumor B-Disease 0 3.953283691073353e-14
suppressor O 0 1.0710254298024191e-12
gene O 0 1.283208972023206e-13
, O 0 7.176865692855956e-16
PTEN O 0 2.847116466198063e-11
/ O 0 9.84161530048766e-10
MMAC1 O 0 6.501095981548133e-07
, O 0 1.5684517554637352e-14
was O 0 2.1093107525926337e-14
isolated O 0 1.6417188517924702e-13
recently O 0 3.5841888810193845e-13
at O 0 3.7360730184750075e-15
this O 0 5.280769627399516e-19
region O 0 1.0286975857595878e-15
of O 0 3.653435494832865e-18
chromosome O 0 2.9201414619706156e-08
10q23 O 0 1.0971902206224904e-11
and O 0 2.2434906393715504e-15
found O 0 4.273105701511719e-19
to O 0 2.7555858052456208e-22
be O 0 6.042675796170399e-23
inactivated O 0 7.988121225732766e-18
by O 0 1.6092209632786262e-22
mutation O 0 3.0925981473303276e-18
in O 0 1.5629246801944437e-17
three O 0 5.7598960323534953e-11
prostate B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999992847442627
cell O 0 7.958748682312944e-08
lines O 0 1.3679531951638069e-09
. O 0 8.591825710092815e-13

We O 0 4.209635764973463e-11
screened O 0 4.882168891384708e-09
80 O 0 3.5321244627045667e-12
prostate B-Disease 0 6.592478166567162e-05
tumors I-Disease 1 0.9999992847442627
by O 0 1.7130978778004576e-15
microsatellite O 0 1.3944972954149648e-09
analysis O 0 1.9039914230748606e-13
and O 0 1.306152862632509e-15
found O 0 6.66967043732286e-17
chromosome O 0 1.5849150334160123e-12
10q23 O 0 5.0121548350514494e-15
to O 0 4.942749507910081e-18
be O 0 8.543237171733427e-18
deleted O 0 3.109943400893267e-13
in O 0 8.047737455968442e-17
23 O 0 4.857574075034618e-16
cases O 0 4.655044262181379e-17
. O 0 4.899598555921456e-15

We O 0 2.1840863807191108e-13
then O 0 1.0737067063500846e-16
proceeded O 0 8.523510568485263e-18
with O 0 3.26796239851435e-21
sequence O 0 4.1331944598493335e-18
analysis O 0 2.1258663751753163e-18
of O 0 9.301921647713517e-22
the O 0 1.5603615835182657e-19
entire O 0 3.966238062090917e-17
PTEN O 0 4.956904569967946e-13
/ O 0 2.352262671754743e-14
MMAC1 O 0 1.3172838687902644e-11
coding O 0 2.3213344441108674e-11
region O 0 3.704003927575486e-14
and O 0 2.1390874758753535e-16
tested O 0 6.668856491600107e-17
for O 0 4.922978617985454e-23
homozygous O 0 4.533907631939928e-17
deletion O 0 1.5181838440550999e-15
with O 0 2.376067872316324e-17
new O 0 1.3823952246571546e-16
intragenic O 0 1.2008564281851264e-11
markers O 0 1.429815575833271e-12
in O 0 4.565784303464972e-20
these O 0 2.425574021931921e-19
23 O 0 5.383133745190836e-20
cases O 0 8.682065898930271e-21
with O 0 7.462012849453114e-18
10q23 O 0 1.3601673606866704e-11
loss O 0 1.3926976705127408e-13
of O 0 8.824993913523077e-18
heterozygosity O 0 5.654227086537844e-10
. O 0 4.133411928702868e-12

The O 0 5.3138930410534365e-18
identification O 0 4.610245483694487e-17
of O 0 5.1318433836806155e-20
the O 0 2.1587836140615577e-18
second O 0 3.8155784955196115e-15
mutational O 0 1.6136443570236025e-10
event O 0 4.698906736801123e-13
in O 0 3.7621699579961246e-17
10 O 0 2.0072275276356716e-15
( O 0 1.997592168864268e-18
43 O 0 4.219856885798179e-13
% O 0 3.070315709844968e-15
) O 0 2.2157839799086254e-12
tumors B-Disease 1 0.9999977350234985
establishes O 0 1.426258937342606e-11
PTEN O 0 3.0618205193455594e-10
/ O 0 1.0278916606765165e-11
MMAC1 O 0 2.2674527186405946e-11
as O 0 2.825751336081946e-19
a O 0 1.5782299125956328e-20
main O 0 2.703202419021653e-17
inactivation O 0 4.18315642541911e-12
target O 0 1.01696225767757e-13
of O 0 7.7897485289891e-19
10q O 0 1.0814249669366394e-11
loss O 0 7.721471032007265e-14
in O 0 1.0841766953226378e-17
sporadic B-Disease 0 1.0421621254863567e-06
prostate I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999994039535522
. O 0 7.814926657190302e-12
. O 0 1.299886169840378e-13

Risk O 0 2.4346488367021912e-12
reversals O 0 1.0532094910553538e-14
in O 0 5.622440973811548e-20
predictive O 0 2.0173139959715758e-15
testing O 0 1.1471711947074522e-14
for O 0 2.5907766888446553e-15
Huntington B-Disease 1 0.9999839067459106
disease I-Disease 1 0.9999974966049194
. O 0 8.283290720001446e-12

The O 0 5.664725671243435e-19
first O 0 2.84841259519769e-20
predictive O 0 7.148940604771758e-16
testing O 0 4.2295082502497375e-14
for O 0 1.450515055290147e-13
Huntington B-Disease 1 0.9999980926513672
disease I-Disease 1 0.9999998807907104
( O 0 1.2567085054766212e-16
HD B-Disease 0 3.314013241606517e-08
) O 0 1.151664852723402e-15
was O 0 2.407335398732502e-16
based O 0 8.947823318158682e-22
on O 0 3.8008998777648375e-18
analysis O 0 9.483948840347241e-20
of O 0 1.2553378270901264e-24
linked O 0 7.132395334023569e-19
polymorphic O 0 2.927174018938604e-19
DNA O 0 9.707794315900293e-17
markers O 0 8.6717310375105e-15
to O 0 1.6928336021910498e-18
estimate O 0 2.4920242839716613e-19
the O 0 1.2651765435296205e-20
likelihood O 0 1.8924010579319715e-18
of O 0 1.4259805353892858e-20
inheriting O 0 1.1449764476378216e-14
the O 0 2.83815335840353e-19
mutation O 0 1.4964185317645677e-18
for O 0 2.3624013596718453e-18
HD B-Disease 0 1.5368815411420655e-06
. O 0 1.5659522289990235e-11

Limits O 0 9.49211632824418e-15
to O 0 5.109541379444661e-18
accuracy O 0 2.062529362467284e-17
included O 0 1.6357601373964336e-22
recombination O 0 5.203184221845105e-19
between O 0 2.0036050222850985e-19
the O 0 1.7502631236087756e-20
DNA O 0 1.0966110357561905e-14
markers O 0 1.647184298680937e-11
and O 0 3.287064241267292e-15
the O 0 2.007423624034767e-18
mutation O 0 4.836273843389133e-16
, O 0 1.6285000386769607e-15
pedigree O 0 1.0846589182378352e-09
structure O 0 1.1949181666584693e-15
, O 0 1.9159855281595069e-19
and O 0 1.3868662015254648e-20
whether O 0 1.688380189000551e-22
DNA O 0 8.873540978237692e-17
samples O 0 1.622813482985569e-15
were O 0 5.293738785428582e-19
available O 0 2.075889880323664e-20
from O 0 2.092020806997243e-19
family O 0 5.758843515989501e-14
members O 0 1.2118782238161002e-18
. O 0 2.3514246729432667e-17

With O 0 2.4663597646962848e-17
direct O 0 5.3435533389958116e-17
tests O 0 3.115240008026731e-16
for O 0 6.379030182720789e-22
the O 0 4.187753393122862e-20
HD B-Disease 0 1.1210440215014827e-10
mutation O 0 9.224000330768567e-16
, O 0 2.261101347700029e-17
we O 0 6.356016535778368e-18
have O 0 4.275367814304853e-21
assessed O 0 1.5138599128612353e-20
the O 0 2.822314917624671e-19
accuracy O 0 1.0429720455340519e-11
of O 0 8.943882928604099e-18
results O 0 2.7868919418678533e-19
obtained O 0 5.220652693106834e-22
by O 0 1.8953303375294658e-22
linkage O 0 4.625821096105513e-16
approaches O 0 3.661657521229132e-16
when O 0 1.7310163833435894e-17
requested O 0 1.8191467183660996e-19
to O 0 1.0046412941921941e-16
do O 0 7.282992039004223e-16
so O 0 1.9640498916276662e-19
by O 0 1.8068344822994816e-21
the O 0 6.0775759610644435e-18
test O 0 6.419110865275206e-15
individuals O 0 1.940109345995821e-19
. O 0 2.680775898254115e-16

For O 0 1.7730555284883268e-15
six O 0 9.664121164790963e-17
such O 0 1.639447578714379e-20
individuals O 0 1.1746419647589897e-18
, O 0 1.7435343970665688e-18
there O 0 2.7066033036092702e-20
was O 0 8.618852233068737e-18
significant O 0 1.7289218638049074e-20
disparity O 0 5.42472126378319e-17
between O 0 5.667995081935035e-17
the O 0 1.3839900871116719e-14
tests O 0 3.1740001252278383e-12
. O 0 6.554108541188873e-16

Three O 0 1.1261298967987776e-13
went O 0 3.1291935188859643e-12
from O 0 8.2050824285993e-18
a O 0 1.634055429992981e-17
decreased O 0 2.7012582031219964e-14
risk O 0 1.162735361585779e-16
to O 0 3.146538698472487e-19
an O 0 2.905282477232235e-18
increased O 0 9.790887718630348e-15
risk O 0 4.46715364352257e-12
, O 0 2.428225348794161e-16
while O 0 3.7897122268928333e-16
in O 0 6.95235207431233e-21
another O 0 4.107900931078687e-19
three O 0 1.1914661980328589e-18
the O 0 2.3208152183352114e-16
risk O 0 1.2302622028753651e-12
was O 0 3.166234635587628e-13
decreased O 0 2.354984154732953e-13
. O 0 5.310678468300545e-15

Knowledge O 0 1.5811520658309125e-13
of O 0 4.849792605032597e-18
the O 0 5.463134518133902e-19
potential O 0 7.844139273179642e-19
reasons O 0 1.0193905681639287e-19
for O 0 6.997897999971659e-23
these O 0 3.1412139817731184e-19
changes O 0 2.2526276164472167e-19
in O 0 5.055217119895854e-18
results O 0 2.657236587952122e-16
and O 0 2.575445350147705e-14
impact O 0 8.766314548049178e-17
of O 0 1.2997867012435055e-21
these O 0 1.3837874688897548e-17
risk O 0 3.981136742975854e-18
reversals O 0 1.3514072356571828e-17
on O 0 1.3042450532677166e-16
both O 0 2.2534796641769346e-18
patients O 0 2.413832968618555e-19
and O 0 1.817724613947362e-19
the O 0 4.4772346188911703e-20
counseling O 0 8.7595996943598195e-16
team O 0 2.9097160489932457e-20
can O 0 5.573065763332627e-22
assist O 0 2.266348377922712e-20
in O 0 8.706907974494571e-21
the O 0 4.368450674817644e-20
development O 0 3.268646296742966e-22
of O 0 5.17513905158005e-25
strategies O 0 1.879922553715469e-20
for O 0 3.155279439208148e-25
the O 0 3.5678436938267636e-22
prevention O 0 2.111860792925946e-16
and O 0 2.630576261092469e-19
, O 0 5.118423955963753e-23
where O 0 6.665355641750787e-22
necessary O 0 2.7408894149337747e-21
, O 0 4.886033093728559e-21
management O 0 8.328851214758318e-20
of O 0 1.3780729482441638e-23
a O 0 1.5165897445919795e-18
risk O 0 1.713913994045137e-16
reversal O 0 7.194370807443339e-19
in O 0 4.763330525708636e-23
any O 0 2.4783500433276864e-22
predictive O 0 8.425109162815954e-18
testing O 0 2.273982501983725e-16
program O 0 1.7733259437567378e-15
. O 0 1.2465178853822244e-19
. O 0 1.6303071437652583e-17

A O 0 1.1147090805204048e-14
novel O 0 2.7830427917177776e-14
common O 0 8.524922440059438e-15
missense O 0 2.2520945611864684e-12
mutation O 0 6.838352448320859e-14
G301C O 0 1.1362494061958883e-12
in O 0 3.734001645724611e-18
the O 0 4.5317635797921906e-17
N O 0 4.0657646693809113e-10
- O 0 5.480560449910854e-09
acetylgalactosamine O 0 6.268293191169505e-07
- O 0 2.7871863150785714e-10
6 O 0 2.6000648709794197e-14
- O 0 8.905311384144188e-14
sulfate O 0 7.96410057042965e-14
sulfatase O 0 4.795845795144138e-13
gene O 0 1.622398860357888e-15
in O 0 1.883069054415332e-17
mucopolysaccharidosis B-Disease 0 1.017783191059607e-09
IVA I-Disease 0 3.89036536319054e-08
. O 0 7.099733669892194e-13

Mucopolysaccharidosis B-Disease 0 3.1636365747544914e-05
IVA I-Disease 0 0.0008536193636246026
( O 0 8.76544337113927e-10
MPS B-Disease 1 0.9999853372573853
IVA I-Disease 1 0.9999890327453613
) O 0 4.3937024699937377e-13
is O 0 5.162979215705445e-15
an O 0 1.0182899310004143e-13
autosomal B-Disease 1 0.9999895095825195
recessive I-Disease 1 0.9999892711639404
lysosomal I-Disease 1 0.9999909400939941
storage I-Disease 1 0.9999098777770996
disorder I-Disease 1 0.9999834299087524
caused O 0 2.459378534158674e-10
by O 0 4.575168641664992e-18
a O 0 7.011998945892495e-14
genetic B-Disease 1 0.9999996423721313
defect I-Disease 1 0.9999991655349731
in O 0 1.8175410636034122e-15
N O 0 4.5945639653988124e-11
- O 0 1.4188099584089287e-09
acetylgalactosamine O 0 1.318490831181407e-06
- O 0 2.1093976343422582e-08
6 O 0 2.1745103547660127e-12
- O 0 2.7005746527919428e-09
sulfate O 0 2.6660798013722342e-09
sulfatase O 0 2.55771261947757e-08
( O 0 1.3757300018045493e-16
GALNS O 0 2.3239404844943579e-10
) O 0 1.605032540887027e-16
. O 0 7.269696268710291e-16

In O 0 9.889125922226544e-14
previous O 0 9.687702164995829e-14
studies O 0 8.785405400130869e-15
, O 0 4.064199738546592e-17
we O 0 1.0153298388409625e-14
have O 0 8.577819938783044e-18
found O 0 6.302994258513719e-18
two O 0 2.2624895222040153e-18
common O 0 4.31015568983464e-18
mutations O 0 2.758115879320782e-18
in O 0 7.494300810688355e-19
Caucasians O 0 1.8643418785765226e-14
and O 0 1.4083505005648214e-14
Japanese O 0 1.0621151310882815e-12
, O 0 7.748142895141332e-18
respectively O 0 1.3185323815055285e-16
. O 0 2.300946578249704e-15

To O 0 3.222060391796155e-15
characterize O 0 2.1517350076195874e-13
the O 0 5.46184777665253e-17
mutational O 0 6.741811102439765e-12
spectrum O 0 5.581106442205689e-15
in O 0 2.989201320393629e-20
various O 0 5.584307947572854e-20
ethnic O 0 1.3926749488539308e-15
groups O 0 5.4130007762478037e-17
, O 0 6.558149492189123e-19
mutations O 0 8.407317955406011e-19
in O 0 1.156667976283066e-20
the O 0 1.0552418037581987e-19
GALNS O 0 1.480281012784107e-13
gene O 0 1.0456697834470693e-17
in O 0 8.530044674938972e-19
Colombian O 0 2.6293342503258543e-10
MPS B-Disease 1 0.9999979734420776
IVA I-Disease 1 0.9999960660934448
patients O 0 6.841069594490379e-13
were O 0 1.1078695468899329e-17
investigated O 0 1.2064734960040308e-16
, O 0 4.804020813991159e-17
and O 0 8.564390893148817e-16
genetic O 0 4.234868274739963e-14
backgrounds O 0 7.772938109135152e-14
were O 0 1.507359921145445e-20
extensively O 0 2.712268618388206e-19
analyzed O 0 5.2396002279272926e-17
to O 0 2.633901268660991e-18
identify O 0 7.995476449565138e-16
racial O 0 5.722030701772176e-15
origin O 0 7.249587574193576e-17
, O 0 7.624080892842208e-21
based O 0 2.1518143875835287e-23
on O 0 1.7366441893591552e-18
mitochondrial O 0 4.162189120920576e-14
DNA O 0 1.061742382381381e-12
( O 0 5.015301002449224e-19
mtDNA O 0 5.716442190144429e-16
) O 0 1.981337284006019e-17
lineages O 0 3.3156278016113067e-14
. O 0 4.792567049189929e-15

Three O 0 4.41455379196487e-12
novel O 0 7.18874890170973e-11
missense O 0 1.0838007158398e-09
mutations O 0 9.598861289150662e-11
never O 0 3.543180748799557e-10
identified O 0 5.009498116212386e-15
previously O 0 4.3102261490792176e-16
in O 0 3.715046491795229e-19
other O 0 1.5295417882541716e-16
populations O 0 1.33659576462275e-13
and O 0 1.082758362136449e-11
found O 0 6.576433191421427e-13
in O 0 3.08010792687593e-17
16 O 0 4.817233204479346e-17
out O 0 5.536509628137158e-16
of O 0 5.3863384238296256e-20
19 O 0 2.586992675031915e-16
Colombian O 0 6.689626717154562e-12
MPS B-Disease 1 0.9999914169311523
IVA I-Disease 1 0.9999845027923584
unrelated O 0 1.2988818354209286e-10
alleles O 0 3.312715499050739e-13
account O 0 1.8092064711606667e-14
for O 0 5.552580887171227e-17
84 O 0 2.5354409327257854e-13
. O 0 1.0645604271155781e-13

2 O 0 7.834929927064138e-11
% O 0 5.97859189929782e-15
of O 0 1.3865805657201926e-20
the O 0 7.415159788594462e-19
alleles O 0 1.0905604617000158e-17
in O 0 5.52321109505998e-19
this O 0 5.060851047047952e-18
study O 0 7.306948248334943e-17
. O 0 2.2915005938768662e-14

The O 0 2.7401099103466567e-14
G301C O 0 7.305768837118087e-12
and O 0 8.85349922579359e-15
S162F O 0 4.4042382723675014e-14
mutations O 0 1.612010001259814e-15
account O 0 2.8186088581400384e-15
for O 0 1.5437507659443625e-16
68 O 0 1.683918521115657e-12
. O 0 1.5996162998788838e-13

4 O 0 1.8411121516237472e-09
% O 0 2.852576302340287e-13
and O 0 4.583574188601891e-13
10 O 0 2.136316873456532e-14
. O 0 3.483986103086645e-14

5 O 0 7.661068827935491e-12
% O 0 5.771527389682337e-16
of O 0 1.2158129248883847e-20
mutations O 0 1.6691097892534268e-16
, O 0 1.779037910436547e-15
respectively O 0 1.0886543470628625e-14
, O 0 1.549084453003884e-15
whereas O 0 7.2668167802061e-15
the O 0 1.547176828927549e-15
remaining O 0 5.738652174985814e-12
F69V O 0 1.0539035200096691e-09
is O 0 4.28476041784865e-19
limited O 0 5.565969801717983e-22
to O 0 1.820583686186469e-19
a O 0 7.844677974553567e-19
single O 0 5.684612936623923e-14
allele O 0 1.0387309679060763e-08
. O 0 2.7409099989661456e-10

The O 0 2.1655422206422366e-15
skewed O 0 1.9276425941572306e-11
prevalence O 0 3.631285494520853e-08
of O 0 1.563645464700707e-18
G301C O 0 1.4021208485234739e-15
in O 0 2.411299542200091e-21
only O 0 2.039079373712774e-21
Colombian O 0 1.3149560495835433e-16
patients O 0 7.4922181767011e-18
and O 0 1.4150520836301766e-18
haplotype O 0 3.6437955551352295e-15
analysis O 0 3.712890652323763e-20
by O 0 6.633142348913906e-22
restriction O 0 2.0891587879272037e-18
fragment O 0 3.85581594864598e-15
length O 0 2.836781500037126e-17
polymorphisms O 0 1.289317129893764e-14
in O 0 2.0850663118465976e-18
the O 0 2.8937348290858417e-18
GALNS O 0 7.0798050581799554e-12
gene O 0 1.9310379198817721e-16
suggest O 0 4.913069357633005e-17
that O 0 1.4693621518616e-19
G301C O 0 1.5676605208118813e-16
originated O 0 1.6362707189350716e-16
from O 0 5.805875383228571e-20
a O 0 6.007683025014046e-19
common O 0 4.1204470937579115e-16
ancestor O 0 3.283879244919685e-12
. O 0 9.636283437863824e-11

Investigation O 0 2.7068477311892802e-15
of O 0 4.3131309034016287e-19
the O 0 2.229171359214627e-19
genetic O 0 3.5602412076631907e-16
background O 0 3.2265498781748397e-15
by O 0 1.3892974016680318e-19
means O 0 2.5318403746027175e-17
of O 0 6.996440316285266e-20
mtDNA O 0 5.006864267262899e-14
lineages O 0 4.1525962356236956e-13
indicate O 0 1.3511162132683052e-13
that O 0 6.787018778882164e-16
all O 0 1.8424324833346844e-17
our O 0 5.545241373153048e-15
patients O 0 3.999671101080343e-21
are O 0 9.903387572048446e-23
probably O 0 9.81461377322743e-19
of O 0 6.67301665496551e-21
native O 0 8.24192449721704e-15
American O 0 2.70438915705995e-09
descent O 0 0.0002657200675457716

Low O 0 7.911633154167319e-12
frequency O 0 1.1926742959130626e-13
of O 0 2.075353557094e-18
BRCA1 O 0 5.177085973459561e-13
germline O 0 4.249708291975858e-14
mutations O 0 1.6540713026688691e-13
in O 0 1.5093258911300696e-15
45 O 0 4.0408491440088734e-13
German O 0 0.0005922477575950325
breast B-Disease 1 0.9999806880950928
/ I-Disease 1 0.9999889135360718
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999988079071045
families O 0 1.2185040532131097e-08
. O 0 1.160038556912487e-14

In O 0 1.7517694846447079e-16
this O 0 6.979433353644205e-20
study O 0 4.50775629102467e-20
we O 0 3.563606989032057e-18
investigated O 0 1.0636541060971808e-15
45 O 0 1.1384826695476965e-14
German O 0 2.197268031522981e-06
breast B-Disease 1 0.9999477863311768
/ I-Disease 1 0.9999312162399292
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999986886978149
families O 0 9.944204747841523e-14
for O 0 1.2674462818940262e-21
germline O 0 8.086110695457022e-17
mutations O 0 4.9219420277554936e-17
in O 0 6.01708367418177e-20
the O 0 1.9378544257966072e-18
BRCA1 O 0 7.961340462749045e-13
gene O 0 5.472498322556252e-12
. O 0 1.977898747562712e-12

We O 0 1.647145012615217e-13
identified O 0 4.159454813863544e-16
four O 0 1.949325063427972e-17
germline O 0 3.4103088056422134e-15
mutations O 0 1.893993622147875e-14
in O 0 8.300349812363767e-17
three O 0 1.9090523432907514e-14
breast B-Disease 0 2.2839398639007413e-07
cancer I-Disease 0 1.5112783913195926e-08
families O 0 3.4211270426819096e-13
and O 0 1.971851838485751e-17
in O 0 4.784337182775817e-19
one O 0 5.6600831660480466e-11
breast B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.002903091799737e-10
. O 0 1.1525327194551544e-19
among O 0 9.176168257961404e-23
these O 0 6.956566737247872e-22
were O 0 8.697517212720107e-20
one O 0 1.483996786355253e-19
frameshift O 0 5.724279150730663e-15
mutation O 0 5.940529256203087e-17
, O 0 2.9446513840979778e-15
one O 0 4.716830225015567e-13
nonsense O 0 3.2451882958639544e-08
mutation O 0 1.9619855328063818e-13
, O 0 1.1710606578419283e-14
one O 0 2.360836466301793e-16
novel O 0 1.6796047127583648e-15
splice O 0 2.8168990695576213e-08
site O 0 1.1729586746334064e-10
mutation O 0 4.482054918181211e-12
, O 0 5.9694079445672156e-15
and O 0 8.65494284449592e-15
one O 0 3.922786185104167e-15
missense O 0 1.4296580412576088e-11
mutation O 0 1.4184296098784799e-11
. O 0 7.470611629312174e-11

The O 0 1.576982901901891e-14
missense O 0 9.932349213925828e-12
mutation O 0 3.284497782259088e-13
was O 0 4.844540393844632e-11
also O 0 1.38019221160475e-13
found O 0 2.6629421595331798e-14
in O 0 7.429267746852345e-17
2 O 0 1.6269681457105334e-13
. O 0 3.4331676499084474e-13

8 O 0 4.468939107660219e-10
% O 0 1.513887756474097e-14
of O 0 2.841715986527705e-20
the O 0 3.453345416041175e-19
general O 0 7.212671661508192e-19
population O 0 6.295040916924022e-18
, O 0 5.007773596836446e-17
suggesting O 0 3.6520913111173434e-14
that O 0 6.648006907952341e-16
it O 0 5.134245317035737e-15
is O 0 2.4588282256619853e-15
not O 0 4.2091818312078866e-13
disease O 0 4.744049597604771e-10
associated O 0 5.086916131380459e-13
. O 0 1.8993894998486915e-12

The O 0 2.763195962730662e-15
average O 0 1.4497440791252925e-12
age O 0 3.3749809587660384e-13
of O 0 4.912319601125787e-17
disease O 0 4.5512223323385115e-08
onset O 0 4.0691783276258775e-10
in O 0 3.2848813844226583e-16
those O 0 4.5838688883049e-14
families O 0 2.249523843296606e-15
harbouring O 0 1.9986369503843804e-10
causative O 0 2.763841672887013e-13
mutations O 0 1.5066925842816686e-13
was O 0 1.7255826975648425e-11
between O 0 6.226702638743864e-13
32 O 0 7.20628981834559e-12
. O 0 2.056253821727805e-12

3 O 0 6.536272911805696e-11
and O 0 4.070897698799092e-12
37 O 0 6.561573116445341e-13
. O 0 8.801746359749299e-14

4 O 0 2.866662289491284e-11
years O 0 3.679817681036951e-13
, O 0 2.1161833079349032e-16
whereas O 0 5.680333307951876e-17
the O 0 3.6045669567129395e-19
family O 0 9.128726827191055e-14
harbouring O 0 9.222335395353554e-11
the O 0 2.679606357925784e-19
missense O 0 2.9608003584049566e-17
mutation O 0 2.4831041750410426e-19
had O 0 1.7126126073310196e-17
an O 0 2.837936740480618e-19
average O 0 1.2010992894717631e-11
age O 0 1.1855340320554575e-10
of O 0 3.854492459665895e-15
onset O 0 2.486729755446504e-08
of O 0 6.772823777235603e-15
51 O 0 1.1838996796798007e-11
. O 0 3.495163143282798e-13

2 O 0 5.978718214949552e-11
years O 0 4.769937157929338e-13
. O 0 1.6490437216697823e-13

These O 0 1.2078002672367863e-15
findings O 0 1.7048307568259168e-16
show O 0 2.7434947217665206e-13
that O 0 8.65839725661306e-18
BRCA1 O 0 3.880398962357668e-15
is O 0 5.214272060968495e-19
implicated O 0 2.501008507671559e-16
in O 0 1.3426491164786006e-20
a O 0 5.9659295003200405e-21
small O 0 2.3798559756583138e-20
fraction O 0 1.674977874693327e-16
of O 0 8.446783989488407e-14
breast B-Disease 1 0.9999945163726807
/ I-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 5.0020418362883845e-11
suggesting O 0 2.524482967013528e-16
the O 0 1.750869736187874e-21
involvement O 0 2.241117863512636e-18
of O 0 1.4895193357381347e-21
another O 0 4.816971008904682e-19
susceptibility O 0 1.777654832688623e-14
gene O 0 1.123813628961523e-11
( O 0 9.42718464598015e-14
s O 0 6.924691206222633e-06
) O 0 2.7347607685357378e-12

Paternal O 0 5.65317168366164e-06
transmission O 0 0.0009073827532120049
of O 0 3.810846083140973e-10
congenital B-Disease 1 0.9998661279678345
myotonic I-Disease 1 0.9999727010726929
dystrophy I-Disease 1 0.999972939491272
. O 0 1.3765282247391042e-08

We O 0 2.093805684388883e-11
report O 0 1.4300574708141335e-17
a O 0 7.476845974982037e-21
rare O 0 2.4814565346584135e-19
case O 0 8.493849195208091e-17
of O 0 9.402125006829042e-16
paternally O 0 0.00357729266397655
transmitted O 1 0.9999356269836426
congenital B-Disease 1 0.9999951124191284
myotonic I-Disease 1 0.9999978542327881
dystrophy I-Disease 1 0.9999971389770508
( O 0 1.9843037435407496e-08
DM B-Disease 1 0.9999885559082031
) O 0 1.6719244044782755e-11
. O 0 5.0961903967639e-13

The O 0 5.515937421309838e-15
proband O 0 3.823614688758248e-11
is O 0 2.1143586798525092e-17
a O 0 4.0764014797623614e-18
23 O 0 7.664312507572716e-16
year O 0 4.008110275570596e-17
old O 0 3.037297913177639e-10
, O 0 3.505183610811452e-13
mentally B-Disease 1 0.9999990463256836
retarded I-Disease 1 0.9999984502792358
male O 0 5.306538241711678e-06
who O 0 9.973976311528077e-09
suffers O 1 0.6159957647323608
severe O 0 2.3328362658503465e-05
muscular B-Disease 0 0.003138740547001362
weakness I-Disease 0 0.008684996515512466
. O 0 2.1965643193233575e-10

He O 0 1.7973619012394415e-13
presented O 0 5.317043920899161e-15
with O 0 1.1085022873572048e-12
respiratory O 0 7.464749160135398e-06
and O 0 3.8119053052954044e-11
feeding O 0 5.290707576932618e-06
difficulties O 0 5.928710855584995e-10
at O 0 2.7385842346020622e-14
birth O 0 3.8956073609985875e-12
. O 0 1.504647778984361e-13

His O 0 1.689279549577094e-10
two O 0 1.0506174402680202e-10
sibs O 1 0.8636197447776794
suffer O 0 1.123480956266576e-06
from O 0 2.999616749649672e-14
childhood O 0 0.006098608020693064
onset O 0 0.01400383748114109
DM B-Disease 1 0.9999889135360718
. O 0 1.0442071651795004e-09

Their O 0 8.554216363032552e-13
late O 0 1.2632809295171077e-13
father O 0 6.635589430356581e-13
had O 0 5.253306610677296e-18
the O 0 1.1983243961123887e-21
adult O 0 3.353556698203669e-16
type O 0 4.197468461396235e-17
of O 0 6.987112743354782e-18
DM B-Disease 1 0.9999997615814209
, O 0 2.3995433308924728e-15
with O 0 2.186510097735043e-15
onset O 0 6.865572693692812e-11
around O 0 3.5004421236606298e-12
30 O 0 9.491319270240814e-15
years O 0 1.9047677118303602e-14
. O 0 9.23378779647409e-16

Only O 0 1.2431292438431547e-16
six O 0 4.0446592250868574e-20
other O 0 1.464117257283549e-22
cases O 0 6.025829008896244e-22
of O 0 3.881228722736525e-22
paternal O 0 2.681404653870345e-09
transmission O 0 8.369599527213722e-06
of O 0 1.771110385087593e-13
congenital B-Disease 1 0.999983549118042
DM I-Disease 1 0.9999998807907104
have O 0 1.2396185640473067e-11
been O 0 1.2271352553896997e-13
reported O 0 3.2888798563897315e-13
recently O 0 4.23745619756305e-13
. O 0 3.465614297273878e-14

We O 0 5.999565282104784e-15
review O 0 2.3414153739410688e-19
the O 0 6.223231542334832e-22
sex O 0 9.088684699862324e-17
related O 0 5.513257217158823e-18
effects O 0 2.7644265229320103e-17
on O 0 4.601076616738255e-16
transmission O 0 8.203180357213569e-09
of O 0 2.040400514223702e-15
congenital B-Disease 1 0.9995496869087219
DM I-Disease 1 0.9999940395355225
. O 0 3.199255443897542e-11

Decreased O 0 9.582393038776171e-12
fertility O 0 2.9082335498142875e-13
of O 0 2.807045163516942e-20
males O 0 1.9184596460511683e-17
with O 0 4.539668531316054e-18
adult O 0 2.529687792574009e-09
onset O 0 2.2697097392665455e-06
DM B-Disease 1 0.9999997615814209
and O 0 2.81581247207896e-09
contraction O 0 9.833376924143697e-14
of O 0 9.886520842370607e-22
the O 0 3.4723147354385473e-19
repeat O 0 2.6230591049919427e-13
upon O 0 4.422025829263966e-17
male O 0 2.0610786298155825e-13
transmission O 0 5.918225301103017e-14
contribute O 0 3.617556794257319e-19
to O 0 3.997417518587276e-19
the O 0 7.63427476298093e-19
almost O 0 4.4120847726623034e-17
absent O 0 5.680531698949991e-16
occurrence O 0 7.723536257151349e-17
of O 0 2.7200293819915435e-19
paternal O 0 5.3612183137374814e-08
transmission O 0 5.209343726164661e-06
of O 0 2.643033361615643e-12
congenital B-Disease 1 0.9999508857727051
DM I-Disease 1 0.9999967813491821
. O 0 1.2977434682426292e-09

Also O 0 1.7741533340099452e-13
the O 0 2.316693079557839e-16
fathers O 0 3.8503614359364224e-12
of O 0 4.5257791348555226e-20
the O 0 1.0584282172150872e-16
reported O 0 1.5344225889890595e-11
congenitally O 0 1.009248080663383e-06
affected O 0 4.401589336067158e-12
children O 0 4.0725613853487275e-11
showed O 0 1.7750332995981888e-13
, O 0 1.2274399015942265e-20
on O 0 9.857289807739165e-16
average O 0 1.1446746074470675e-15
, O 0 5.652055332210654e-19
shorter O 0 1.8254527324955937e-14
CTG O 0 5.6063400449835044e-11
repeat O 0 8.71326483187218e-11
lengths O 0 4.20344176133014e-11
and O 0 3.858687051523993e-14
hence O 0 8.893403371455213e-16
less O 0 5.706873894214008e-17
severe O 0 1.5979535742034236e-14
clinical O 0 3.8475878705963515e-15
symptoms O 0 5.366161681674697e-11
than O 0 5.882321735230103e-19
the O 0 3.2563729023960388e-16
mothers O 0 7.634684551227622e-11
of O 0 5.785560215125181e-19
children O 0 6.035084324645945e-12
with O 0 3.7758218860567405e-13
congenital B-Disease 1 0.9997857213020325
DM I-Disease 1 0.9999979734420776
. O 0 1.6890476517428255e-10

We O 0 1.9557027252124293e-15
conclude O 0 2.1374385078678413e-17
that O 0 1.164594201858308e-18
paternal O 0 1.4900797262740184e-09
transmission O 0 5.548251010623062e-06
of O 0 4.599556954927586e-13
congenital B-Disease 1 0.9999268054962158
DM I-Disease 1 0.9999997615814209
is O 0 1.6183739715507723e-16
rare O 0 1.2652110040031864e-19
and O 0 1.3715305960861584e-19
preferentially O 0 9.46437875207868e-16
occurs O 0 2.063898842689427e-17
with O 0 3.3874967211019138e-18
onset O 0 6.864705418690997e-12
of O 0 1.1650359030705216e-15
DM B-Disease 1 0.9999997615814209
past O 0 2.397638310114303e-09
30 O 0 2.5815918870811033e-15
years O 0 4.4326176453971357e-16
in O 0 5.6250341527201595e-21
the O 0 2.7232683110775715e-19
father O 0 2.302043104751572e-12
. O 0 3.1197083715212937e-18
. O 0 1.1100402507970068e-16

The O 0 2.5176944743973174e-15
RB1 O 0 1.1378120667870917e-10
gene O 0 1.1047272207534865e-14
mutation O 0 7.278274594883609e-15
in O 0 9.831518036225564e-18
a O 0 1.3415160646639023e-15
child O 0 5.05620278090646e-07
with O 0 1.8315005068103574e-10
ectopic B-Disease 1 0.9995993971824646
intracranial I-Disease 1 0.9995833039283752
retinoblastoma I-Disease 1 0.984718918800354
. O 0 9.012235580030392e-08

The O 0 1.2393757285104716e-14
RB1 O 0 2.8661059636725383e-10
gene O 0 3.3533665922465695e-15
mutation O 0 4.292093622133116e-17
was O 0 7.69873936762048e-17
investigated O 0 5.763054016185139e-17
in O 0 7.776536386655097e-19
a O 0 7.887332788573866e-15
child O 0 7.4870717980957124e-06
with O 0 7.444269506384771e-11
ectopic B-Disease 0 0.004933243151754141
intracranial I-Disease 0 4.768576218339149e-06
retinoblastoma I-Disease 0 5.6816940041670705e-11
using O 0 3.7264761219477264e-17
DNA O 0 1.646108515338321e-13
obtained O 0 3.4833961949314634e-17
from O 0 2.372650747846837e-19
both O 0 1.2790260026762017e-20
the O 0 1.2541875298712102e-19
pineal B-Disease 0 6.649646805412246e-11
and I-Disease 0 1.0852973034158886e-11
retinal I-Disease 0 3.1781112852513616e-07
tumours I-Disease 1 0.9999997615814209
of O 0 4.412844190639076e-16
the O 0 9.843461994875238e-16
patient O 0 6.892124891633156e-12
. O 0 4.02103616245833e-13

A O 0 3.4039825537283963e-13
nonsense O 0 7.14634115772661e-11
mutation O 0 3.1104326725345894e-15
in O 0 2.3929149275032935e-16
exon O 0 4.073757997602456e-11
17 O 0 1.3794750931828137e-11
( O 0 5.4361770535225594e-17
codon O 0 3.0936899228376294e-14
556 O 0 3.095367657936915e-13
) O 0 1.5207690944892384e-15
of O 0 1.7128404128717167e-18
the O 0 1.253936563686952e-15
RB1 O 0 3.1647964804371043e-10
gene O 0 2.691896117362584e-15
was O 0 4.419166042216732e-14
found O 0 1.698889680968765e-17
to O 0 6.452831305635223e-19
be O 0 1.3096739058023511e-17
present O 0 1.8145672500396106e-17
homozygously O 0 1.0554151302910597e-11
in O 0 1.0062122885362518e-19
both O 0 3.1406388327534526e-19
the O 0 8.630894328426284e-18
retinal B-Disease 0 2.79025283780876e-12
and I-Disease 0 4.570734415954014e-12
the I-Disease 0 3.9499089762862205e-13
pineal I-Disease 0 0.0013467648532241583
tumours I-Disease 1 0.9999953508377075
. O 0 2.2702449642419964e-10

The O 0 8.866976472896471e-17
same O 0 9.357211018626433e-18
mutation O 0 3.684227375853213e-17
was O 0 4.5517639679117095e-14
present O 0 9.227022385505692e-17
heterozygously O 0 3.658563252698088e-13
in O 0 2.8231841923599976e-21
the O 0 7.351751870998297e-21
DNA O 0 1.6617870274293622e-13
from O 0 8.03264339502282e-18
the O 0 1.3305709385980053e-19
constitutional O 0 3.562644068080984e-17
cells O 0 3.4958195345246136e-15
of O 0 3.5541428020535312e-19
the O 0 1.7357716792490343e-16
patient O 0 1.4144128847749099e-14
, O 0 3.464074000284776e-18
proving O 0 2.070619896924657e-15
it O 0 2.6097279492348943e-18
to O 0 1.0230256521398842e-18
be O 0 1.786816829413559e-17
of O 0 7.044838266184831e-19
germline O 0 5.996253840678811e-13
origin O 0 6.709109721773909e-13
. O 0 3.713954491169069e-12

The O 0 7.760723915211569e-16
initial O 0 5.5343107835456454e-17
mutation O 0 4.223810193439109e-17
was O 0 3.404693400718391e-15
shown O 0 2.1215433059553488e-15
to O 0 1.2225584696926552e-17
have O 0 1.9974495381112455e-16
occurred O 0 1.4022003108018382e-16
in O 0 2.7881544262777623e-21
the O 0 2.361878788319865e-18
paternally O 0 2.0235148626146504e-11
derived O 0 6.396009312188266e-16
RB1 O 0 7.86902454308347e-09
allele O 0 2.1208043654574738e-10
. O 0 4.11769012984009e-12

The O 0 3.267673327764036e-15
mutation O 0 7.918505295098719e-15
is O 0 1.3393063939325323e-16
in O 0 3.949729263803887e-20
an O 0 1.1265738789780739e-18
area O 0 1.3567665328902134e-13
of O 0 1.122426916510519e-16
the O 0 1.7519766106700911e-16
gene O 0 9.86059958898056e-16
that O 0 4.355127431787617e-18
encodes O 0 3.2188614775722594e-18
the O 0 7.244241009586278e-20
protein O 0 4.964409281880619e-16
- O 0 1.9224625689116814e-14
binding O 0 1.7592506913930946e-15
region O 0 4.742243657123249e-16
known O 0 5.733383626639291e-18
as O 0 1.4113984268645298e-16
the O 0 2.9812830179678845e-15
pocket O 0 0.015435409732162952
region O 0 1.928412984852912e-09
and O 0 4.4990181025106324e-10
has O 0 1.2944462125449863e-12
been O 0 3.5014647973598267e-15
detected O 0 1.5154296105479841e-15
in O 0 4.602888523816804e-22
other O 0 5.1078766332254585e-21
cases O 0 2.7194039235885283e-21
of O 0 8.8909634862878e-23
retinoblastoma B-Disease 0 7.336837923461179e-16
. O 0 1.0775549490830283e-17
. O 0 1.5059391992970628e-14

Low O 0 2.86130585891442e-07
levels O 0 5.215066659763901e-12
of O 0 2.7657104313197845e-19
beta O 0 2.829757611670918e-16
hexosaminidase O 0 4.148703516143604e-12
A O 0 2.1549681524962895e-16
in O 0 5.548531610598111e-19
healthy O 0 1.5334275783694803e-15
individuals O 0 8.088566879039028e-20
with O 0 8.088143078222065e-18
apparent O 0 4.878992210244348e-10
deficiency O 0 3.083825461658307e-08
of O 0 5.547630868264384e-23
this O 0 2.8376647402307556e-20
enzyme O 0 8.361849433592553e-16
. O 0 6.2565542312687916e-15

Appreciable O 0 7.039172023048934e-11
beta O 0 4.842055575937643e-11
hexosaminidase O 0 8.931278472346094e-08
A O 0 4.096304892509117e-12
( O 0 1.232683607067835e-16
hex O 0 1.087714224246028e-10
A O 0 9.96139333333027e-16
) O 0 1.357332454461992e-18
activity O 0 2.364764780118032e-17
has O 0 5.988440736014531e-19
been O 0 1.494506633025622e-19
detected O 0 8.064363124536268e-17
in O 0 1.2481063306522676e-20
cultured O 0 2.0727320413412714e-13
skin O 0 2.397987941549218e-07
fibroblasts O 0 7.258301737422812e-10
and O 0 8.162226450281196e-09
melanoma B-Disease 0 0.08337727189064026
tissue O 0 6.251869422158052e-07
from O 0 6.704015733391758e-14
healthy O 0 1.807792264951931e-14
individuals O 0 1.2437718719307471e-20
previously O 0 1.4268036317975643e-18
reported O 0 1.865618018414856e-15
as O 0 1.9977991708125595e-17
having O 0 1.5992152047061836e-11
deficiency B-Disease 0 6.2445519688481e-07
of I-Disease 0 9.648147019216501e-22
hex I-Disease 0 1.324696428939287e-11
A I-Disease 0 1.2045782101537126e-17
activity O 0 1.987038709096102e-15
indistinguishable O 0 1.6319461922228648e-14
from O 0 6.119607541228889e-20
that O 0 6.595028822811917e-19
of O 0 8.941349377785425e-20
patients O 0 4.647898056963631e-15
with O 0 1.3865679271418685e-08
Tay B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
Sachs I-Disease 1 0.9999995231628418
disease I-Disease 0 0.061346981674432755
( O 0 1.9772685810962178e-16
TSD B-Disease 0 7.49287368262408e-11
) O 0 1.6967143283066485e-16
. O 0 1.0380559233982086e-15

Identification O 0 2.269856394856995e-13
and O 0 5.216175256485267e-14
quantitation O 0 3.797406139538495e-11
of O 0 5.217196661421753e-19
hex O 0 7.087587461374056e-12
A O 0 7.03485545764175e-17
, O 0 7.393947258773422e-19
amounting O 0 3.1429326914460265e-16
to O 0 3.114242097335747e-16
3 O 0 1.6665770326274032e-13
. O 0 2.6744589615851355e-12

5 O 0 2.489061734500808e-10
% O 0 2.8910942108210935e-13
- O 0 1.8144895364002878e-07
6 O 0 9.877679230108072e-11
. O 0 3.5834252232191943e-12

9 O 0 4.1696984753869515e-10
% O 0 1.7951819772463878e-14
of O 0 7.0432257809782355e-19
total O 0 1.0517144057733005e-17
beta O 0 1.5292274596214015e-15
hexosaminidase O 0 3.728209685416317e-10
activity O 0 2.3308366955271387e-12
, O 0 2.51694301720676e-17
has O 0 5.295576677352098e-19
been O 0 3.8399533492301504e-20
obtained O 0 3.746792688099443e-22
by O 0 5.476775356513884e-21
cellulose O 0 6.1732077782927774e-12
acetate O 0 4.185692320090445e-13
gel O 0 1.4996783329057628e-11
electrophoresis O 0 4.988281489259894e-12
, O 0 2.7621392031021786e-17
DEAE O 0 7.461878337444716e-12
- O 0 3.4797224780433456e-14
cellulose O 0 1.031458165406951e-11
ion O 0 9.695268676432334e-13
- O 0 6.371614932713932e-14
exchange O 0 5.067148786641625e-18
chromatography O 0 3.647968039433404e-15
, O 0 8.959006064948253e-19
radial O 0 3.6201337744569753e-14
immunodiffusion O 0 1.5541162801113728e-10
, O 0 7.059156700549578e-17
and O 0 3.888548689859675e-15
radioimmunoassay O 0 2.4398032483219367e-09
. O 0 1.9658088023610625e-14

Previous O 0 2.1796077442903794e-10
family O 0 3.768947307025705e-11
studies O 0 3.988924052873e-16
suggested O 0 1.6971220952614126e-16
that O 0 3.767309727450284e-18
these O 0 6.668392505315011e-19
individuals O 0 4.5939821150650804e-20
may O 0 3.336467121932905e-18
be O 0 4.224284968615085e-21
compound O 0 2.516383460541641e-19
heterozygotes O 0 1.1420241329427498e-20
for O 0 1.3559627547926293e-23
the O 0 6.289369559849205e-20
common O 0 1.0374699883569454e-15
mutant O 0 8.946703512584253e-13
TSD B-Disease 0 4.371683950173816e-13
gene O 0 4.36264742999801e-16
and O 0 2.243155796659589e-16
a O 0 3.5435427409976056e-19
rare O 0 1.2768488148363481e-17
( O 0 4.0159424868993426e-19
allelic O 0 1.4927230458650076e-12
) O 0 2.6138769713821746e-15
mutant O 0 9.929715903689296e-12
gene O 0 1.0163258429285449e-10
. O 0 1.5579404086252246e-12

Thus O 0 1.998001238198363e-13
, O 0 9.075237555516294e-18
the O 0 7.820650833451345e-20
postulated O 0 1.4001967073046673e-15
rate O 0 1.0276945716950966e-13
mutant O 0 1.4291216119039808e-14
gene O 0 2.155372107802791e-15
appears O 0 9.537672978872716e-14
to O 0 1.0922622720730094e-19
code O 0 1.0809958136360958e-19
for O 0 2.066344829977913e-21
the O 0 1.097383626418782e-17
expression O 0 1.509661129829934e-13
of O 0 4.1542357012450286e-17
low O 0 6.440984356113899e-13
amounts O 0 7.726294728718333e-20
of O 0 2.412442788201583e-19
hex O 0 2.0257719945959707e-09
A O 0 1.7852601721154299e-13
. O 0 1.190206245192671e-13

Heterozygotes O 0 8.667271409043206e-14
for O 0 8.423943380989532e-20
the O 0 4.308014791312988e-20
rare O 0 1.5769865851717226e-17
mutant O 0 1.0354878759999409e-10
may O 0 2.0378525256159463e-12
be O 0 1.9691992687846405e-16
indistinguishable O 0 1.8098702061781352e-13
from O 0 1.0398616727374822e-18
heterozygotes O 0 1.4343735338143127e-17
for O 0 6.530852964144432e-22
the O 0 6.62089114165127e-19
common O 0 7.483917253818008e-15
TSD B-Disease 0 1.2297098062052925e-10
mutant O 0 4.5124480541058887e-11
. O 0 2.0314866867703063e-13

However O 0 4.9587859757275855e-17
, O 0 5.2650748769403455e-21
direct O 0 1.057046188404558e-20
visualization O 0 1.737404030323006e-13
and O 0 1.3323940475234997e-12
quantitation O 0 1.0765445201954549e-09
of O 0 3.767352327251831e-18
hex O 0 8.965635525659543e-12
A O 0 5.283429530056757e-19
by O 0 3.1339199612927626e-22
the O 0 1.8574175057197012e-21
methods O 0 2.1553710225418273e-16
described O 0 4.551147666739287e-14
may O 0 4.940169448861467e-17
prevent O 0 1.0859897097892315e-17
false O 0 6.605084572141413e-16
- O 0 2.5904292465176034e-16
positive O 0 2.520457066564523e-19
prenatal O 0 4.0470001786872215e-15
diagnosis O 0 3.59154886888269e-15
of O 0 4.310198661221228e-21
TSD B-Disease 0 2.142463317216306e-13
in O 0 6.049768940604978e-19
fetuses O 0 9.615484813539285e-14
having O 0 1.337640489401978e-18
the O 0 7.345952559422476e-20
incomplete O 0 2.699817366197399e-13
hex B-Disease 0 6.727578494292175e-08
A I-Disease 0 4.426680549896034e-11
deficiency I-Disease 0 0.00044489384163171053
of O 0 9.271682404444828e-19
the O 0 3.3139083247283804e-14
type O 0 9.82180222569573e-12
described O 0 1.3993291768377158e-11
in O 0 7.231302912189214e-17
the O 0 1.7585672840354262e-14
four O 0 5.808410393284835e-13
healthy O 0 2.3935966056432e-11
individuals O 0 8.872500715899345e-15

The O 0 3.428151978192599e-15
tumor B-Disease 0 9.82791192177812e-12
suppressor O 0 2.8891858350199584e-10
gene O 0 1.6279637360394617e-10
Smad4 O 0 1.8638857568475942e-07
/ O 0 3.307385754158787e-10
Dpc4 O 0 1.7899945414789897e-11
is O 0 1.6429731452697023e-19
required O 0 9.569517655587395e-23
for O 0 2.5668307177184105e-24
gastrulation O 0 3.6854259539433575e-15
and O 0 2.8990414656849715e-16
later O 0 2.7297314909296576e-16
for O 0 2.5137343500064544e-20
anterior O 0 1.1890167398841828e-14
development O 0 2.5018922901854775e-19
of O 0 3.2890482339923497e-21
the O 0 3.182368130102798e-18
mouse O 0 3.148246108253261e-10
embryo O 0 1.7354624681775732e-10
. O 0 7.855875672202473e-12

Mutations O 0 2.1414105298017683e-12
in O 0 4.554347397225011e-16
the O 0 1.4713058643804947e-15
SMAD4 O 0 1.5143997416089405e-06
/ O 0 4.06422406840079e-09
DPC4 O 0 1.3875089965864618e-09
tumor B-Disease 0 1.2237607845480558e-12
suppressor O 0 5.292745408613797e-13
gene O 0 2.8337669362476278e-15
, O 0 1.022619920049427e-18
a O 0 5.500518832827137e-21
key O 0 4.223812377195926e-16
signal O 0 2.8850747745695626e-12
transducer O 0 2.3277990646164426e-11
in O 0 5.094537894776113e-17
most O 0 3.810047171850694e-17
TGFbeta O 0 2.2408448707711415e-10
- O 0 5.674519014398083e-13
related O 0 1.241693761225575e-15
pathways O 0 3.2353852788476493e-16
, O 0 1.3524726940462348e-20
are O 0 1.999362442256318e-24
involved O 0 6.298699656326792e-23
in O 0 4.848952945625022e-21
50 O 0 2.948932500371638e-16
% O 0 8.828932947600055e-18
of O 0 1.0635522371503836e-16
pancreatic B-Disease 0 7.622616976732388e-05
cancers I-Disease 0 5.475637590279803e-05
. O 0 8.944393142806817e-11

Homozygous O 0 2.732950310502247e-09
Smad4 O 0 2.5548297344357707e-06
mutant O 0 1.5882988009252585e-05
mice O 0 0.0003511786926537752
die O 0 0.0001612829219084233
before O 0 1.7136921222349333e-12
day O 0 2.945267944462482e-12
7 O 0 4.181684431234581e-14
. O 0 4.350852157394315e-14

5 O 0 3.9862758276568155e-13
of O 0 4.6538723126895136e-17
embryogenesis O 0 2.119874276118594e-10
. O 0 9.967343790606709e-12

Mutant O 0 2.1530006510256383e-12
embryos O 0 7.155495813926382e-14
have O 0 5.947931085376404e-14
reduced O 0 4.163060209603532e-15
size O 0 1.6565419175273988e-11
, O 0 8.358198681779339e-12
fail O 0 4.2232795038898985e-09
to O 0 6.402753219107715e-14
gastrulate O 0 3.718938330621313e-07
or O 0 7.74937926328878e-12
express O 0 5.286136085700546e-17
a O 0 5.725069288566874e-21
mesodermal O 0 2.5767230146453435e-14
marker O 0 2.5249144441907845e-10
, O 0 1.017411295253898e-15
and O 0 2.35963660178036e-14
show O 0 1.9488943792111968e-09
abnormal O 0 2.0295910785339544e-11
visceral O 0 1.344622872247181e-12
endoderm O 0 1.3849495994477934e-09
development O 0 6.341809367959358e-15
. O 0 1.298339962017142e-13

Growth B-Disease 1 0.9999746084213257
retardation I-Disease 1 0.9999833106994629
of O 0 4.569537278772792e-17
the O 0 2.1008287181835508e-16
Smad4 O 0 2.0426663027706127e-08
- O 0 1.6109153122556563e-08
deficient O 0 3.103675894067237e-08
embryos O 0 8.502817373801097e-12
results O 0 2.032982072616707e-14
from O 0 2.5634737464602154e-17
reduced O 0 1.1623717991629496e-16
cell O 0 1.2046541878179412e-13
proliferation O 0 5.165509079502195e-12
rather O 0 2.4024809073279997e-17
than O 0 2.4705274108150566e-20
increased O 0 4.4623153179445254e-20
apoptosis O 0 1.8454732455885437e-15
. O 0 7.509200509667191e-14

Aggregation O 0 5.790225612346822e-13
of O 0 5.16823823151671e-16
mutant O 0 6.654976569819837e-11
Smad4 O 0 6.169906252573298e-10
ES O 0 4.390181591201227e-14
cells O 0 3.961125176006665e-18
with O 0 6.881437938559295e-18
wild O 0 1.2146126118772749e-12
- O 0 6.237080924620386e-06
type O 0 1.1997799198582015e-08
tetraploid O 0 5.134479152957283e-08
morulae O 0 1.4215049759513931e-07
rescues O 0 3.333681941608546e-10
the O 0 4.6839002924141686e-17
gastrulation B-Disease 0 1.575910513196277e-09
defect I-Disease 0 3.2968692220691764e-09
. O 0 4.405019575558049e-14

These O 0 1.5078317283992448e-12
results O 0 7.175524733821334e-16
indicate O 0 1.7007976888569042e-15
that O 0 3.1298777299720206e-17
Smad4 O 0 7.243575856318019e-13
is O 0 6.654923936991116e-19
initially O 0 1.909456281391896e-18
required O 0 4.054170762097e-22
for O 0 3.756279213801269e-23
the O 0 2.4297865038248326e-20
differentiation O 0 4.452033294909429e-18
of O 0 3.649782264582222e-20
the O 0 1.1499560001482634e-17
visceral O 0 1.0532899591853429e-14
endoderm O 0 5.066951198895442e-12
and O 0 2.2748761217430784e-16
that O 0 6.564178992619781e-20
the O 0 4.3506065149238e-20
gastrulation B-Disease 0 5.0821668921841034e-12
defect I-Disease 0 1.0366784470791646e-12
in O 0 4.820479353301158e-20
the O 0 5.445597151774436e-18
epiblast O 0 3.782432145271741e-09
is O 0 3.490768888818373e-15
secondary O 0 4.2117337720713743e-14
and O 0 3.463952432183892e-12
non O 0 1.1911016877669267e-12
- O 0 3.245126833917311e-07
cell O 0 6.932626206435089e-07
autonomous O 0 5.840692374192713e-10
. O 0 2.0597051841875214e-11

Rescued O 0 4.16572554229333e-09
embryos O 0 1.9959627006738145e-10
show O 0 1.7064085113815963e-05
severe O 0 8.810470717435237e-07
anterior O 0 2.3476894739360432e-07
truncations O 0 7.341189434129092e-09
, O 0 1.5983635855837397e-12
indicating O 0 4.077918490624603e-14
a O 0 1.2767890768864853e-19
second O 0 6.971051041358716e-20
important O 0 9.739600964001545e-21
role O 0 1.4883530906582571e-16
for O 0 4.737049955493151e-18
Smad4 O 0 1.3297507539533626e-09
in O 0 8.701408994104592e-18
anterior O 0 1.845646031839454e-11
patterning O 0 2.6841318057080343e-09
during O 0 4.574072782863314e-13
embryogenesis O 0 3.6811940162806422e-09
. O 0 1.6936073854098566e-12

Prevalence O 0 9.834845968725858e-07
of O 0 1.4669729202783745e-16
p16 O 0 9.89303582631107e-13
and O 0 1.778919961098642e-14
CDK4 O 0 7.405663582371602e-11
germline O 0 9.854249171216758e-15
mutations O 0 1.0372920055589036e-15
in O 0 3.0299371479779044e-18
48 O 0 1.611407443196961e-15
melanoma B-Disease 0 0.0005207601352594793
- O 1 0.9982300400733948
prone O 1 0.9999959468841553
families O 0 2.5370493403897854e-06
in O 0 1.4656998488168926e-13
France O 0 6.059011625758615e-10
. O 0 2.1946316292043022e-12

The O 0 1.680522854121541e-13
French O 0 1.4506279510939635e-10
Familial B-Disease 0 2.9136435841792263e-05
Melanoma I-Disease 0 0.08839883655309677
Study O 0 1.0609325917787515e-12
Group O 0 2.0713261834892638e-12
. O 0 3.902177111167818e-14

Germline O 0 1.0106060432946151e-10
mutations O 0 4.064006347160448e-13
in O 0 7.675246776479483e-18
the O 0 6.083231498310045e-19
p16 O 0 5.633404373951538e-15
and O 0 1.9872737607389652e-15
CDK4 O 0 2.10949812305683e-12
genes O 0 1.3605537654281532e-15
have O 0 3.6016860003767516e-16
been O 0 6.396984988264384e-16
reported O 0 9.92035723401376e-17
in O 0 3.0555577375206006e-23
a O 0 2.2694182762048565e-21
subset O 0 6.760136141029033e-19
of O 0 6.135441463533652e-17
melanoma B-Disease 0 7.052592536638258e-06
pedigrees O 0 4.039580048242897e-08
, O 0 5.268911188968141e-14
but O 0 7.347040456486681e-14
their O 0 3.7994186789791495e-12
prevalence O 0 9.503625664208926e-10
is O 0 1.825404804989158e-17
not O 0 2.3030078064570678e-17
well O 0 3.103377510123782e-17
known O 0 7.541833660982113e-16
. O 0 4.2922989381549703e-13

We O 0 1.3109898442778046e-15
searched O 0 3.259776188133878e-17
for O 0 1.2660062888867486e-21
such O 0 1.0894778076477455e-20
germline O 0 1.2406806039415405e-15
mutations O 0 4.184490990202013e-15
in O 0 1.0346199739523409e-16
48 O 0 5.6072907717041615e-15
French O 0 2.666839839238211e-11
melanoma B-Disease 1 0.998297393321991
- O 1 0.6977877616882324
prone O 1 0.9998997449874878
families O 0 1.3351517157492165e-12
selected O 0 6.681705848027081e-20
according O 0 7.988718908961775e-21
to O 0 2.0968304745183268e-19
two O 0 1.1459173425062616e-19
major O 0 1.3894671029405759e-19
criteria O 0 7.87350497570994e-15
families O 0 1.8739407523963398e-16
with O 0 3.063486986162293e-20
at O 0 4.6805604679729245e-17
least O 0 6.988785018210029e-20
three O 0 1.421880873177108e-18
affected O 0 9.545952127715108e-18
members O 0 1.2473020105976592e-20
( O 0 1.916254159910195e-21
n O 0 4.532807709365337e-14
= O 0 5.570222018011495e-13
20 O 0 4.825730665475981e-17
) O 0 6.7281096722649345e-18
or O 0 1.769509967155733e-13
families O 0 1.5683970159595189e-15
with O 0 2.116235614700938e-20
two O 0 1.7750220610591655e-18
affected O 0 8.95333367389767e-19
members O 0 1.7687257353061836e-22
, O 0 2.2850538779995714e-22
one O 0 2.2372281064588292e-21
of O 0 5.468877937463084e-23
them O 0 1.7176046423277772e-17
affected O 0 1.3634242260831388e-19
before O 0 6.10201056616653e-19
the O 0 1.640269376190602e-17
age O 0 1.2009284625774663e-13
of O 0 2.61495718473465e-20
50 O 0 1.78175763769082e-19
( O 0 1.698354874452302e-21
n O 0 2.7035071772409103e-13
= O 0 1.9806519271914347e-11
28 O 0 1.2025353857223614e-13
) O 0 4.3945337205996023e-16
, O 0 1.2392744663833718e-17
and O 0 3.267545399319221e-17
one O 0 2.2444959140379376e-19
additional O 0 1.04651813406719e-20
minor O 0 8.077294273616187e-17
criterion O 0 2.6045929735901696e-13
. O 0 5.054160215345327e-13

Sixteen O 0 7.103278604420407e-14
different O 0 1.314769751965984e-17
p16 O 0 1.756830527680376e-14
germline O 0 2.4337084471716224e-14
mutations O 0 2.3571400568716226e-14
were O 0 8.093032198715731e-15
found O 0 5.182057044655572e-16
in O 0 7.458280196938968e-19
21 O 0 1.5722308988370287e-15
families O 0 2.218131319963704e-15
, O 0 2.06781362486482e-19
while O 0 4.809445629884404e-18
one O 0 1.4459535867612029e-18
germline O 0 1.5183634150399178e-15
mutation O 0 5.2047040586871915e-15
, O 0 6.035766199721012e-15
Arg24His O 0 8.142971852365122e-10
, O 0 1.428280852294492e-16
was O 0 8.039368426342435e-15
detected O 0 1.8843089523608303e-13
in O 0 8.26690869931608e-19
the O 0 9.750660800476261e-17
CDK4 O 0 1.4159827976811812e-08
gene O 0 6.0138955447486264e-12
. O 0 8.043011786099119e-13

The O 0 2.317549310753505e-17
frequency O 0 2.5503283245144207e-15
of O 0 2.9974686028751846e-20
p16 O 0 2.7545316230085285e-17
gene O 0 2.4845565801195938e-17
mutation O 0 2.5386776841099583e-17
in O 0 1.4329890816230827e-18
our O 0 4.431791152998852e-15
sample O 0 8.600010216767637e-16
( O 0 7.870545463271749e-19
44 O 0 2.1465841409750277e-15
% O 0 1.5708975639261126e-18
) O 0 6.542130105651268e-20
is O 0 6.409285933251018e-19
among O 0 5.897754469767899e-20
the O 0 2.5208827130282275e-17
highest O 0 1.5415736178900352e-12
rates O 0 5.741121467117694e-10
yet O 0 3.3909168333477735e-14
reported O 0 4.0609361576585123e-14
and O 0 5.573484072122687e-17
the O 0 2.170938619572718e-19
CDK4 O 0 6.9710530750666244e-12
mutation O 0 5.770839191956305e-18
is O 0 6.804585208232453e-19
the O 0 2.7837774776146204e-20
second O 0 4.457456291005327e-17
mutation O 0 7.727776054099051e-18
detected O 0 1.0728316869048574e-14
in O 0 4.280526868699512e-20
this O 0 3.3011799201188196e-20
gene O 0 2.4217605815824795e-15
worldwide O 0 1.8689819928242174e-13
. O 0 1.46772812003107e-13

In O 0 4.59178635937277e-15
summary O 0 7.392059186983602e-11
, O 0 3.418894331595583e-14
our O 0 1.929090784683063e-12
results O 0 9.583314221622903e-18
show O 0 1.349447355074307e-13
frequent O 0 2.2185534600087918e-16
involvement O 0 2.591704560498813e-16
of O 0 8.020260824370328e-21
the O 0 1.338241390880558e-20
p16 O 0 5.4194648618626606e-18
gene O 0 3.940492809987755e-18
in O 0 7.656056108720071e-20
familial B-Disease 0 1.4764316158544233e-10
melanoma I-Disease 0 1.6298006357828854e-06
and O 0 5.048215534833589e-13
confirm O 0 9.631407296530124e-16
the O 0 9.762779146376649e-20
role O 0 2.312340389000136e-16
of O 0 5.984829446405883e-20
the O 0 1.2799357701643347e-17
CDK4 O 0 3.206431864813397e-12
gene O 0 6.30337848390825e-18
as O 0 1.2408112438844035e-18
a O 0 2.5542979973612872e-17
melanoma B-Disease 0 1.3152779843039752e-07
- O 0 6.887851178305482e-09
predisposing O 0 1.433388546745462e-10
gene O 0 1.4657797545170048e-11
. O 0 3.225837565817846e-14
. O 0 3.1405748905340494e-14

Progression O 0 1.966270479769605e-10
of O 0 1.4977385465860798e-17
somatic O 0 4.918554712823875e-13
CTG O 0 5.7392957053536975e-09
repeat O 0 8.552484276336259e-10
length O 0 5.0556130462564575e-14
heterogeneity O 0 2.780985348688897e-13
in O 0 5.1565178763302214e-17
the O 0 3.787053072834047e-16
blood O 0 6.397284924020141e-10
cells O 0 2.0558422585831293e-12
of O 0 2.934427603250994e-13
myotonic B-Disease 1 0.9999914169311523
dystrophy I-Disease 1 0.9999905824661255
patients O 0 5.078991394125154e-11
. O 0 7.482122560409366e-14

The O 0 6.026465380913466e-17
genetic O 0 9.064560354491574e-15
basis O 0 2.7960341595462904e-15
of O 0 2.590245726241669e-13
myotonic B-Disease 1 0.9999901056289673
dystrophy I-Disease 1 0.9999947547912598
( O 0 4.902298619130496e-12
DM B-Disease 1 0.999997615814209
) O 0 6.575322375473739e-15
is O 0 1.7827978173111054e-19
the O 0 5.449846447243574e-22
expansion O 0 3.799941072037312e-19
of O 0 1.3716509250158908e-19
an O 0 4.958428699877412e-16
unstable O 0 9.319701348431408e-05
CTG O 0 6.517755224422217e-09
repeat O 0 9.087087748937961e-10
in O 0 4.573668136033821e-18
the O 0 7.415644413035841e-18
34 O 0 5.956774504407199e-18
UTR O 0 3.7462078523922e-14
of O 0 4.425982944345911e-21
the O 0 2.5287708727856557e-17
DM B-Disease 1 0.9999938011169434
protein O 0 1.9301689170174484e-16
kinase O 0 1.908818181032483e-15
gene O 0 1.171783393998129e-16
on O 0 4.464448762390126e-14
chromosome O 0 2.672241095069694e-08
19 O 0 1.4844032849691685e-13
. O 0 6.033441094280799e-15

One O 0 4.5397144160172487e-13
of O 0 3.9923122632441755e-19
the O 0 7.942691122322858e-19
principal O 0 1.0306335589698763e-16
features O 0 4.660839026331782e-16
of O 0 5.040752832909598e-19
the O 0 2.983184649286118e-14
DM B-Disease 1 0.9999994039535522
mutation O 0 8.010676455803617e-17
is O 0 1.5654641892984668e-20
an O 0 6.706571289020305e-22
extraordinarily O 0 1.987496755714857e-12
high O 0 3.768283862032318e-12
level O 0 1.3560517217860255e-14
of O 0 1.767325403953301e-19
somatic O 0 1.2760619113021815e-14
mosaicism O 0 9.746562584789231e-11
, O 0 3.456960495171004e-17
due O 0 4.3211015640854014e-19
to O 0 3.3402971620394815e-20
an O 0 1.1410835381133975e-20
extremely O 0 3.731191787828547e-13
high O 0 4.610219541192895e-13
degree O 0 1.6421548185916308e-16
of O 0 8.399784924965067e-19
somatic O 0 1.1271366652521042e-11
instability O 0 1.1599640004078537e-07
both O 0 9.242386239679905e-16
within O 0 1.7722490207736427e-17
and O 0 1.4006600512674744e-13
between O 0 2.5793474615291162e-15
different O 0 3.421567144060644e-15
tissues O 0 1.7498413829031279e-10
. O 0 5.761415108017365e-14

This O 0 1.100944205592591e-12
instability O 0 7.981148519853321e-10
appears O 0 2.060106778093221e-14
to O 0 3.41793381401778e-19
be O 0 1.443147441156602e-20
biased O 0 9.34370196808336e-16
towards O 0 9.26691763732137e-17
further O 0 3.9421597857172025e-19
expansion O 0 8.2675399415210345e-19
and O 0 1.3965684681448832e-16
continuous O 0 2.5521941461913198e-17
throughout O 0 4.7023401335014457e-17
the O 0 5.532624393887221e-16
life O 0 1.1255157640307004e-13
of O 0 4.173619701712331e-22
an O 0 2.9191103650594045e-20
individual O 0 1.2707069987881419e-17
, O 0 3.756419398377656e-17
features O 0 2.9559536242340645e-13
that O 0 8.203132183942641e-13
could O 0 3.7496408430461037e-13
be O 0 8.895672360962671e-17
associated O 0 1.1696442387596178e-16
with O 0 2.3395782885186497e-17
the O 0 6.587571107165746e-16
progressive O 0 3.1621098101064504e-11
nature O 0 2.736190397520377e-12
of O 0 9.431355352832624e-18
the O 0 2.0725332596492098e-14
disease O 0 3.16375842190908e-10
. O 0 1.9513740056871336e-14

Although O 0 1.0838186359669877e-14
increasing O 0 1.824243211798562e-16
measured O 0 3.681844529235777e-14
allele O 0 1.224311776092113e-12
size O 0 4.4685655458016893e-13
between O 0 1.2113914201177661e-13
patients O 0 1.9052309435613017e-16
clearly O 0 6.174579017908231e-18
correlates O 0 2.0642275384154613e-19
with O 0 2.479275282506202e-23
an O 0 1.0535187533217403e-22
increased O 0 2.089279390860514e-17
severity O 0 2.2228455187622842e-11
of O 0 1.1643154750791022e-16
symptoms O 0 8.617892857665232e-12
and O 0 5.273200924794656e-19
an O 0 3.599069307566759e-20
earlier O 0 8.730232509135405e-11
age O 0 1.3588722369561879e-09
of O 0 2.883774623252999e-17
onset O 0 1.3465471142629082e-13
, O 0 1.1880519680492808e-20
this O 0 1.3543749750056457e-24
correlation O 0 1.2904399642184397e-20
is O 0 1.132899716863179e-19
not O 0 1.172502048514315e-18
precise O 0 3.007455124780928e-13
and O 0 9.698594150009399e-10
measured O 0 5.740037334334147e-10
allele O 0 1.0567492020330249e-10
length O 0 1.3619949786047858e-11
cannot O 0 1.652448143596441e-12
be O 0 9.421750545149964e-19
used O 0 4.803209308451214e-19
as O 0 1.830841501263951e-20
an O 0 1.5158420767158082e-20
accurate O 0 4.4240448977828084e-12
predictor O 0 3.3556399325895825e-10
of O 0 9.124648871769794e-15
age O 0 2.067351800860706e-08
of O 0 3.1286875030973405e-15
onset O 0 5.330654251345379e-10
. O 0 3.05430295855294e-13

In O 0 1.4313563098119643e-17
order O 0 1.5343079791622595e-19
to O 0 1.1666918866553028e-20
further O 0 1.0262257942100016e-20
characterize O 0 6.554508234860859e-16
the O 0 3.375217018113411e-18
dynamics O 0 6.791117825423812e-14
of O 0 2.1486967999641575e-16
DM B-Disease 1 0.9999890327453613
CTG O 0 2.346344896153596e-09
repeat O 0 1.8081950867165908e-11
somatic O 0 4.994200582600361e-13
instability O 0 8.158152553505715e-08
, O 0 2.625788107505142e-16
we O 0 1.67586620049676e-16
have O 0 1.2581360248264438e-19
studied O 0 8.84537936612914e-19
repeat O 0 1.416805854494857e-13
length O 0 1.1321799715025601e-16
changes O 0 3.754266743551548e-19
over O 0 4.9223152516478775e-18
time O 0 2.7900223034984836e-17
in O 0 1.4214903405304065e-18
111 O 0 7.1258671706375676e-12
myotonic B-Disease 1 0.9999911785125732
dystrophy I-Disease 1 0.9999971389770508
patients O 0 1.7784805362874742e-16
with O 0 3.266043484896069e-21
varying O 0 1.8176353042906004e-18
clinical O 0 2.2760479388860455e-16
severity O 0 4.4748905969616004e-11
and O 0 7.891218467516101e-14
CTG O 0 8.811905372052564e-11
repeat O 0 4.6996108393759783e-11
size O 0 1.7531149329539503e-14
over O 0 1.5685226944730677e-15
time O 0 9.284512788036887e-15
intervals O 0 5.084624941139454e-14
of O 0 1.3997985887913632e-19
1 O 0 9.996213832087935e-18
- O 0 1.9808672063748034e-11
7 O 0 3.354788506455125e-14
years O 0 1.462733234503747e-14
. O 0 4.601568425243255e-16

We O 0 9.51012163984133e-13
have O 0 5.169691885637986e-18
found O 0 8.21149367288265e-20
a O 0 2.5112316843670197e-21
direct O 0 3.0974861643650566e-18
progression O 0 4.29877156093994e-09
of O 0 1.7583432874960138e-17
the O 0 1.063588699271785e-16
size O 0 1.1828629819949092e-16
heterogeneity O 0 1.0258594695209143e-17
over O 0 3.70164978478705e-19
time O 0 1.7315762088424077e-19
related O 0 2.927977935096429e-19
to O 0 1.156558245604932e-19
initial O 0 6.624984134719759e-19
CTG O 0 2.0525763163789512e-14
repeat O 0 5.508309737153883e-13
size O 0 1.477183447177316e-14
and O 0 1.7537302176868358e-14
the O 0 5.471458953625906e-18
time O 0 6.672222521123157e-15
interval O 0 2.051382508143091e-14
and O 0 2.037203176606054e-16
always O 0 1.6783028098835452e-17
biased O 0 8.067563320890113e-17
towards O 0 2.35284229507706e-17
further O 0 4.353333690629296e-18
expansion O 0 2.0105676961840505e-16
. O 0 7.286108802612764e-15

Attempts O 0 5.443925814156182e-14
to O 0 1.3489812803566873e-17
mathematically O 0 5.716289724213923e-16
model O 0 2.834134548546736e-15
the O 0 1.7780540816683113e-15
dynamics O 0 1.5625725713341865e-10
have O 0 2.6701518600347196e-12
proved O 0 5.817996084900301e-11
only O 0 2.1791729130574692e-16
partially O 0 6.766145369679899e-12
successful O 0 7.455195213609562e-15
suggesting O 0 6.005773948904863e-14
that O 0 2.1604456719437697e-20
individual O 0 2.1727652710487504e-23
specific O 0 7.400458591910892e-21
genetic O 0 1.2044200001486843e-13
and O 0 4.3998073413764605e-13
/ O 0 2.716575662337073e-12
or O 0 1.4532345053892837e-13
environmental O 0 1.90241397667653e-15
factors O 0 2.0308096660410602e-16
also O 0 1.625370529869542e-17
play O 0 6.4631318756106164e-18
a O 0 2.921035862195256e-21
role O 0 5.909899419864738e-18
in O 0 1.4043983592320116e-19
somatic O 0 9.575357008827939e-16
mosaicism O 0 7.611097516124765e-12
. O 0 3.443629387721303e-16
. O 0 1.1414963280707326e-14

Aspartylglucosaminuria B-Disease 1 0.9999204874038696
among O 0 1.2365959818627648e-11
Palestinian O 0 7.0329790879952725e-09
Arabs O 0 1.035062346943505e-08
. O 0 9.055691960191403e-12

Aspartylglucosaminuria B-Disease 1 0.9999738931655884
( O 0 1.313686520676427e-10
AGU B-Disease 1 0.9999244213104248
) O 0 3.544197080153214e-16
is O 0 8.866387427242514e-20
a O 0 5.975889304194804e-19
rare O 0 7.375528546195095e-14
disorder B-Disease 0 2.003207100642612e-06
of I-Disease 0 2.995197009816749e-18
glycoprotein I-Disease 0 9.813722057216978e-10
metabolism I-Disease 0 2.871335027521127e-07
caused O 0 1.9533583084374584e-11
by O 0 9.158636386415728e-18
the O 0 7.848263597169669e-13
deficiency B-Disease 0 9.71566350926878e-06
of I-Disease 0 4.093630417613271e-21
the I-Disease 0 4.244304668449906e-18
lysosomal I-Disease 0 2.994796424737878e-11
enzyme I-Disease 0 1.2975287077415798e-12
aspartylglucosaminidase I-Disease 0 1.6323292717501658e-10
( O 0 6.7631577284091125e-18
AGA O 0 1.292110190544149e-12
) O 0 1.327947020365362e-15
. O 0 5.176054016279262e-15

AGU B-Disease 1 0.9998365640640259
is O 0 7.797235079820553e-13
inherited O 0 4.493662386639841e-12
as O 0 8.595775052031365e-17
an O 0 8.768893763373567e-16
autosomal O 0 0.0009681340889073908
recessive O 0 3.9126098272390664e-05
trait O 0 2.4231881980085745e-05
and O 0 2.4496840111964957e-09
occurs O 0 2.467897407428237e-14
with O 0 7.288035053142132e-20
a O 0 1.8435626343562215e-19
high O 0 4.047988242620194e-15
frequency O 0 2.8607319291218403e-10
in O 0 3.8184798205331827e-13
Finland O 0 4.4166728230266017e-07
because O 0 4.6401787577241e-13
of O 0 4.675217713566323e-20
a O 0 1.6559041237436199e-18
founder O 0 7.614636460435975e-13
effect O 0 1.503795731602059e-13
. O 0 5.5601671948265e-14

While O 0 1.9843631945959395e-13
very O 0 3.3925824177594307e-16
few O 0 1.793263775846124e-16
patients O 0 3.1808142713221172e-18
with O 0 1.566082524900926e-16
AGU B-Disease 1 0.9999978542327881
have O 0 1.5553727197251815e-15
been O 0 4.575193407452532e-15
reported O 0 3.3302069326994477e-13
from O 0 2.5836382591246656e-17
non O 0 4.928090626684723e-15
- O 0 1.8485921127187055e-10
Finnish O 0 1.8562379411335428e-10
origin O 0 2.1528104006494214e-13
, O 0 4.6123612131780505e-15
we O 0 1.3646303867725224e-13
diagnosed O 0 2.6134422317219963e-12
the O 0 2.4352660454704164e-16
disorder O 0 8.101762594137085e-10
in O 0 1.4532300619652846e-19
8 O 0 3.3046497437481446e-17
patients O 0 5.838969716314082e-20
originating O 0 2.611061002490812e-19
from O 0 6.634746416911534e-19
3 O 0 1.0531431948453634e-18
unrelated O 0 3.8957349173841804e-15
families O 0 6.162422612807474e-15
, O 0 5.649788986579229e-20
all O 0 3.7826007814587863e-19
Palestinian O 0 1.0967132584027706e-11
Arabs O 0 1.0452023795071153e-11
from O 0 1.275360568021855e-15
the O 0 2.6617437773194044e-14
region O 0 1.2505141019913957e-11
of O 0 6.851371577654218e-17
Jerusalem O 0 6.284065490191892e-10
. O 0 1.4600985351331808e-11

The O 0 3.2619553789140366e-16
clinical O 0 9.515390252535887e-15
diagnosis O 0 6.730023760503911e-10
of O 0 1.0040680445281072e-13
AGU B-Disease 1 0.9999985694885254
is O 0 1.6010914382497132e-12
often O 0 5.029032745795803e-13
difficult O 0 7.769691601254916e-14
, O 0 9.235922352588395e-19
in O 0 4.274568906467143e-21
particular O 0 4.264103236411363e-18
early O 0 8.416701169674373e-16
in O 0 5.480103611412545e-19
the O 0 2.59622513563364e-17
course O 0 8.788079313738761e-13
of O 0 2.715954483498954e-19
the O 0 1.4377091707364238e-14
disease O 0 1.2156731177270785e-10
, O 0 1.2382390223720933e-18
and O 0 7.850822148066519e-17
most O 0 1.0394168692877789e-19
of O 0 1.7950865385069896e-21
the O 0 3.605682771660485e-18
patients O 0 2.5968975507535843e-18
are O 0 1.5777913130005237e-19
diagnosed O 0 9.746988542072999e-15
after O 0 3.1089380828991592e-15
the O 0 3.258389380794008e-14
age O 0 2.2848410663467433e-10
of O 0 8.936004860450144e-18
5 O 0 8.173789061060785e-16
years O 0 5.535118482400412e-15
. O 0 3.4835722851402637e-15

However O 0 1.3530399944981092e-13
, O 0 1.9840752518335697e-17
since O 0 6.994659939263716e-18
these O 0 2.8139313387188695e-18
patients O 0 1.907510481172533e-20
excrete O 0 1.5114774065148838e-19
early O 0 1.442260483820095e-21
large O 0 7.936167393593103e-22
amounts O 0 9.906123730418407e-20
of O 0 4.1419700189679086e-18
aspartylglucosamine O 0 2.063163639931531e-09
in O 0 9.244038483322643e-17
urine O 0 5.5804810777807315e-14
, O 0 3.7300235499819106e-21
biochemical O 0 1.4025245366506375e-19
screening O 0 3.56544105524524e-19
is O 0 2.3498978526288586e-19
easy O 0 7.112110553433957e-16
by O 0 8.173784561198253e-17
urine O 0 3.1866172027494866e-12
chromatography O 0 2.9662795657248164e-12
. O 0 8.356109726583721e-16
. O 0 1.6145832026502778e-14

Detection O 0 6.773783465564842e-14
of O 0 2.4018200313776005e-18
heterozygous O 0 2.7484571659319636e-15
carriers O 0 7.395594481429842e-16
of O 0 9.749061364043828e-17
the O 0 1.3451673908093653e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 0.9999997615814209
( O 0 9.713285948134698e-15
ATM O 0 6.284379483814662e-13
) O 0 5.709609008268445e-20
gene O 0 1.2240732603452643e-20
by O 0 1.79948820565328e-21
G2 O 0 2.426118117168641e-13
phase O 0 2.7657041861061597e-16
chromosomal O 0 6.937372898363492e-09
radiosensitivity O 0 1.512245120238731e-07
of O 0 5.103118338531799e-16
peripheral O 0 1.4251238553697476e-06
blood O 0 7.561470556538552e-05
lymphocytes O 0 8.643019100418314e-07
. O 0 3.6033836504911765e-12

In O 0 1.1373916253276661e-09
ataxia B-Disease 1 0.9999960660934448
- I-Disease 1 0.9999843835830688
telangiectasia I-Disease 1 0.9999992847442627
( O 0 1.7228218212039792e-06
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999986886978149
T I-Disease 1 0.9999998807907104
) O 0 6.574047675591416e-14
patients O 0 5.4788552717911104e-17
, O 0 2.9902492305983504e-21
mutations O 0 3.969018598700741e-19
in O 0 3.927535943345604e-21
a O 0 1.9117137542187814e-20
single O 0 3.7704562191028593e-19
gene O 0 2.815394315165649e-16
, O 0 4.83949668794815e-19
ATM O 0 3.1873558425845466e-14
, O 0 4.37587725745351e-18
result O 0 1.2489751442990262e-17
in O 0 2.388857586746386e-15
an O 0 1.1143765732413158e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 6.846510580693632e-10
embraces O 0 5.334724632530263e-13
a O 0 5.246972384663792e-20
variety O 0 6.15275292686783e-20
of O 0 9.345099223608756e-22
clinical O 0 3.3893691995147924e-19
features O 0 2.7138537524542573e-14
and O 0 6.574953255455984e-13
manifests O 0 2.7870455509421133e-12
extreme O 0 1.967491274068589e-12
radiosensitivity O 0 4.3660239312792726e-10
and O 0 1.7613256044765125e-15
a O 0 2.7101187242773925e-18
strong O 0 1.508409772058055e-16
pre O 0 1.8788200162322966e-11
- O 0 1.775031144291006e-08
disposition O 0 2.304382656914683e-10
to O 0 7.175316655942676e-13
malignancy B-Disease 0 4.059325419802917e-06
. O 0 2.292538175355935e-13

Heterozygotes O 0 1.868548284850169e-12
for O 0 6.43864360716629e-19
the O 0 4.0122036951540883e-20
ATM O 0 3.756066977085061e-14
gene O 0 5.494327916759486e-15
have O 0 6.102113761083849e-16
no O 0 1.8148640424433946e-18
clinical O 0 3.839750172992192e-19
expression O 0 5.322116801220267e-15
of O 0 6.809500879834118e-13
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
but O 0 3.8937351606871395e-12
may O 0 1.4333514032749932e-16
be O 0 7.245377348952773e-19
cancer B-Disease 0 2.5214167776246854e-13
prone O 0 2.5969823513882773e-10
with O 0 2.342773242615363e-19
a O 0 4.272667864473737e-18
moderate O 0 6.278017927567603e-13
increase O 0 3.673756013760843e-18
in O 0 2.575341844375912e-18
in O 0 5.0567649898889e-16
vitro O 0 1.2638619040217236e-09
radiosensitivity O 0 1.2420059647411108e-06
. O 0 1.0498686745267702e-13

We O 0 1.5810875178545736e-11
performed O 0 1.2450763449487878e-14
a O 0 1.4738145807556374e-18
blind O 0 4.038674098925596e-14
chromosomal O 0 5.382434949130488e-13
analysis O 0 5.260729067749857e-17
on O 0 7.287657072961226e-17
G2 O 0 3.143273130928187e-13
- O 0 1.589521022400328e-14
phase O 0 1.813917747822634e-16
lymphocytes O 0 5.0338669999950084e-14
from O 0 1.768128958219608e-18
7 O 0 5.2835559439338704e-17
unrelated O 0 3.4058821735127864e-11
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999982118606567
T I-Disease 1 0.9999997615814209
patients O 0 3.6803422316005266e-14
, O 0 4.576995104925123e-21
13 O 0 2.1826294604379628e-20
obligate O 0 1.076780537564298e-13
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999988079071045
T I-Disease 1 0.9999998807907104
heterozygotes O 0 8.540665397127611e-10
( O 0 1.261255963981356e-17
parents O 0 7.729140174190824e-16
of O 0 3.881478381435809e-23
the O 0 1.5304907991292687e-19
patients O 0 1.9334959077514888e-20
) O 0 5.554218929673811e-22
, O 0 3.5992768782017215e-19
and O 0 1.7401358471031726e-14
14 O 0 6.462716465506992e-17
normal O 0 2.3640240812385212e-18
controls O 0 6.030144680278102e-17
following O 0 8.527246219529129e-19
X O 0 2.663754972349365e-14
- O 0 2.070530845968632e-17
irradiation O 0 6.713781001540107e-17
with O 0 1.652679360125582e-18
1 O 0 6.034276752460655e-20
Gy O 0 1.169443465481339e-16
in O 0 2.648382763669706e-23
order O 0 3.3174615144290215e-22
to O 0 1.6425695847303013e-22
evaluate O 0 4.133643260261606e-22
this O 0 7.393388799967918e-25
cytogenetic O 0 1.6893942627522367e-19
method O 0 7.869813210520215e-22
as O 0 3.941608593961466e-24
a O 0 1.5100782204144863e-25
tool O 0 1.0088141593036433e-19
for O 0 3.6920086648145594e-24
detection O 0 1.6608964482535918e-17
of O 0 2.7414972392032234e-20
ATM O 0 1.0591206800469877e-09
carriers O 0 3.101939820455979e-13
. O 0 1.336883891350088e-13

Both O 0 4.0979872273361195e-11
A B-Disease 1 0.9999783039093018
- I-Disease 1 0.9999853372573853
T I-Disease 1 0.9999984502792358
homozygotes O 0 1.2416887074095939e-08
and O 0 6.65374079160966e-16
heterozygotes O 0 1.5043651367953564e-15
showed O 0 1.1186738988096923e-16
significantly O 0 1.6882605083251562e-19
increased O 0 1.1986038522968737e-20
levels O 0 3.45497961473885e-19
of O 0 3.4372440223004035e-20
radiation O 0 4.382938900704403e-09
- O 0 9.481978935355073e-08
induced O 0 5.534004685614491e-06
chromatid O 0 2.9306872875167755e-06
damage O 0 7.045837802088784e-10
relative O 0 1.2608243179766687e-15
to O 0 1.3370895871140177e-18
that O 0 5.809957803894856e-18
of O 0 1.9761419797134844e-19
normal O 0 9.26632614362639e-15
controls O 0 4.985544616031845e-11
. O 0 4.195571841336676e-13

These O 0 5.055304726263657e-14
results O 0 6.171022968454865e-18
show O 0 5.109604493325399e-16
that O 0 3.2714799356016177e-21
the O 0 4.07459233882748e-21
G2 O 0 7.073538261202772e-13
- O 0 5.153404612767698e-12
phase O 0 9.662987437660843e-15
chromosomal O 0 3.6777689782496736e-09
radiosensitivity O 0 1.7427293982907877e-11
assay O 0 2.743879164610291e-15
can O 0 1.0160053315070554e-19
be O 0 1.158926895735701e-24
used O 0 2.2465302343463378e-23
for O 0 2.023430933601257e-25
the O 0 2.1460033226113086e-22
detection O 0 1.096933247089326e-14
of O 0 2.636850834252316e-15
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999971389770508
T I-Disease 1 0.9999986886978149
heterozygotes O 0 3.746660315329109e-09
. O 0 3.2608450987146875e-14

In O 0 1.2383581984188468e-16
combination O 0 1.1684172652134057e-17
with O 0 3.671414523940647e-19
molecular O 0 2.7334292529655657e-17
genetic O 0 1.7351842619001134e-14
analyses O 0 8.291889744271863e-12
, O 0 4.561980752266549e-16
this O 0 1.869106576547682e-17
test O 0 2.5635740139853466e-15
may O 0 3.410238397682834e-18
be O 0 1.089523447984278e-20
of O 0 5.2911235941452716e-23
value O 0 1.653485835373427e-19
in O 0 1.5868566632144793e-20
studies O 0 2.434596194610371e-17
of O 0 4.1239747790588256e-21
familial B-Disease 0 2.263300311056149e-11
and I-Disease 0 1.3073761908136139e-12
sporadic I-Disease 0 3.480776777919914e-11
cancers I-Disease 0 7.589274209074404e-10
aimed O 0 2.487418604424363e-11
at O 0 2.489200523220908e-13
determination O 0 3.004288983386727e-14
of O 0 2.5825281504308767e-22
the O 0 5.468487394517015e-21
potential O 0 7.433597644448269e-19
involvement O 0 2.4392628167541502e-17
of O 0 1.3590045936079194e-20
ATM O 0 2.6821279572319945e-11
mutations O 0 5.419809566420408e-13
in O 0 1.2293072543307406e-16
tumor B-Disease 0 2.6260941865530185e-08
risk O 0 1.0053689825095802e-10
or O 0 3.372403445977873e-15
development O 0 1.9923270401882762e-17
. O 0 1.4523074447691728e-15
. O 0 1.7565064528747565e-13

Ataxia B-Disease 1 0.9999938011169434
- I-Disease 1 0.9999535083770752
telangiectasia I-Disease 1 0.9999960660934448
: O 0 3.611115041973062e-13
identification O 0 1.1449753306131224e-16
and O 0 4.346861829516681e-18
detection O 0 4.974359470556244e-17
of O 0 8.286756364970536e-22
founder O 0 1.6368146199663273e-15
- O 0 3.1525192070551433e-13
effect O 0 7.235914477191421e-16
mutations O 0 1.6330967276630322e-16
in O 0 1.9474780066017626e-21
the O 0 1.292084591531064e-21
ATM O 0 6.355662168295228e-15
gene O 0 2.4812438938198863e-15
in O 0 1.4805829861178525e-17
ethnic O 0 3.6006904922947225e-12
populations O 0 2.2816913289314122e-11
. O 0 2.3754032595080243e-12

To O 0 1.1940101506477351e-17
facilitate O 0 1.4343994245674856e-19
the O 0 1.714800016667552e-20
evaluation O 0 5.246531975611093e-20
of O 0 9.455463514821817e-24
ATM O 0 2.8950519405034037e-16
heterozygotes O 0 1.3973610684719284e-18
for O 0 3.1904308642080474e-23
susceptibility O 0 2.6241271288351357e-15
to O 0 3.521987770397088e-15
other O 0 7.474238784312137e-13
diseases O 0 2.674871213415031e-09
, O 0 6.603789182486737e-19
such O 0 1.83028993981644e-20
as O 0 8.834332352504882e-16
breast B-Disease 0 1.5219460136606244e-09
cancer I-Disease 0 1.873430013552002e-12
, O 0 2.4971356397717796e-18
we O 0 1.2134278432961418e-18
have O 0 2.4436353167365602e-21
attempted O 0 1.513954760750692e-17
to O 0 2.050330102793352e-18
define O 0 2.9154326120055263e-16
the O 0 2.184821295190772e-19
most O 0 2.3846190173347134e-19
common O 0 9.489199886273304e-19
mutations O 0 3.269462131894871e-19
and O 0 4.578206462464593e-18
their O 0 3.2980005351121984e-17
frequencies O 0 8.953942188388853e-13
in O 0 6.745190343770968e-13
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999977350234985
telangiectasia I-Disease 1 0.9999998807907104
( O 0 3.941625337233745e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999990463256836
T I-Disease 1 0.9999997615814209
) O 0 2.87469565296225e-14
homozygotes O 0 1.5113849841791316e-12
from O 0 6.359578065303292e-19
10 O 0 3.510205863046858e-18
ethnic O 0 2.9051758371076647e-15
populations O 0 7.396673876690352e-14
. O 0 5.147348069696814e-14

Both O 0 2.74153264511838e-17
genomic O 0 4.2736081058529496e-13
mutations O 0 7.331537286991985e-12
and O 0 2.8310160205685664e-12
their O 0 8.722359043800837e-15
effects O 0 3.3019279886606e-17
on O 0 1.419285924877468e-17
cDNA O 0 2.229671254485449e-13
were O 0 1.317050047378054e-15
characterized O 0 3.2913823305290996e-14
. O 0 3.127685039604265e-15

Protein O 0 7.7803876622623e-13
- O 0 1.789215260325494e-12
truncation O 0 1.236944466125045e-12
testing O 0 3.387064188690482e-14
of O 0 2.4571046686202148e-21
the O 0 1.7717790687714958e-21
entire O 0 4.743790340112116e-20
ATM O 0 1.4615722911462403e-15
cDNA O 0 1.3271229547164726e-13
detected O 0 7.236153343193052e-11
92 O 0 3.234166949007966e-14
( O 0 3.012430697493832e-18
66 O 0 1.872442224057705e-14
% O 0 6.636699183542618e-18
) O 0 2.189986521128283e-19
truncating O 0 6.999688423146985e-15
mutations O 0 2.8472466185702327e-15
in O 0 6.772034617152725e-19
140 O 0 2.409631056542908e-17
mutant O 0 4.099280593791721e-13
alleles O 0 1.735727989289615e-13
screened O 0 2.8742331181774716e-08
. O 0 2.600357706938894e-10

The O 0 3.972571393611986e-15
haplotyping O 0 1.867698357083114e-10
of O 0 4.477581181718436e-18
patients O 0 1.0854850303539007e-16
with O 0 7.980115771764477e-17
identical O 0 2.6654045724022746e-12
mutations O 0 8.7685440505747e-12
indicates O 0 2.592502081066872e-11
that O 0 1.0508363249657135e-13
almost O 0 4.740997989295193e-15
all O 0 4.163008117077276e-17
of O 0 7.993687647192062e-21
these O 0 2.980586518657225e-17
represent O 0 1.2970482002722008e-20
common O 0 1.4268112236612263e-15
ancestry O 0 1.6382305234596828e-10
and O 0 2.2202271271476448e-11
that O 0 1.0841577879590683e-14
very O 0 5.074216939096772e-15
few O 0 6.637472147429102e-14
spontaneously O 0 1.193917577649306e-12
recurring O 0 7.421101060056667e-12
ATM O 0 3.308000984247883e-08
mutations O 0 4.7397104019353264e-09
exist O 0 4.2439496361623696e-10
. O 0 5.3264333915725715e-11

Assays O 0 4.238030011562838e-13
requiring O 0 7.728550956896891e-16
minimal O 0 1.3312526491600832e-17
amounts O 0 3.98398657728773e-21
of O 0 6.178356716424792e-23
genomic O 0 2.7369977101281194e-17
DNA O 0 4.2692246764695907e-13
were O 0 9.154584028594831e-18
designed O 0 5.3515619414203064e-20
to O 0 2.9870653627413294e-23
allow O 0 9.577948369853673e-24
rapid O 0 1.2904134622785567e-23
screening O 0 1.1891945920497263e-20
for O 0 1.6423816465082415e-22
common O 0 1.1879132505067905e-17
ethnic O 0 5.833237445658957e-16
mutations O 0 1.534473028784629e-14
. O 0 3.984226566966205e-15

These O 0 1.1076503605712186e-16
rapid O 0 1.3976276274243236e-18
assays O 0 2.857636642338609e-16
detected O 0 6.469826539475584e-15
mutations O 0 2.4027033990604418e-15
in O 0 1.8215243683867736e-16
76 O 0 7.628810235436878e-13
% O 0 9.420178984704175e-17
of O 0 9.230352712879529e-20
Costa O 0 2.0747730519309754e-13
Rican O 0 1.8374119500202957e-12
patients O 0 4.847633614002997e-16
( O 0 2.4861429793293113e-22
3 O 0 5.2631499048703124e-20
) O 0 1.902540741278223e-19
, O 0 2.7038197439128012e-18
50 O 0 2.2711376955082572e-17
% O 0 8.54528702868891e-19
of O 0 3.138053789941648e-18
Norwegian O 0 1.1514249536048737e-06
patients O 0 1.432548495450335e-15
( O 0 3.7337233454927206e-22
1 O 0 4.138031598814042e-21
) O 0 1.277997536062637e-19
, O 0 2.713016420681227e-17
25 O 0 3.1086752379877144e-16
% O 0 5.166672469607014e-19
of O 0 1.6514246046845214e-19
Polish O 0 9.564366187930773e-09
patients O 0 5.66354286500603e-17
( O 0 7.450189822258316e-23
4 O 0 4.547220561061692e-20
) O 0 4.50272115216318e-20
, O 0 6.00049120657578e-19
and O 0 2.890817061640752e-14
14 O 0 1.0983652409899541e-14
% O 0 1.7986740499042005e-18
of O 0 2.894152968885487e-19
Italian O 0 4.430298072843897e-10
patients O 0 6.414334340606521e-16
( O 0 2.5828926672779613e-22
1 O 0 7.129372118131658e-20
) O 0 1.590973857778234e-18
, O 0 7.466104420804925e-20
as O 0 3.3375458171504624e-20
well O 0 3.1944562373819183e-19
as O 0 2.2115537046369547e-19
in O 0 7.068846407982358e-20
patients O 0 2.825083129243368e-19
of O 0 6.4022911033519875e-21
Amish O 0 1.1267595745323433e-09
/ O 0 1.767811418085241e-11
Mennonite O 0 4.531470754187694e-09
and O 0 5.411966985668926e-10
Irish O 0 7.823659498029656e-10
English O 0 9.334062385860098e-13
backgrounds O 0 4.507691095390065e-11
. O 0 1.0997446341445578e-14

Additional O 0 1.5556270943071538e-16
mutations O 0 2.324244854738644e-15
were O 0 1.2428927363624135e-15
observed O 0 3.2513582026504973e-16
in O 0 7.216331935718739e-19
Japanese O 0 3.135666842824479e-14
, O 0 1.6944276244678792e-20
Utah O 0 1.0068040199422599e-18
Mormon O 0 1.3180854392769539e-15
, O 0 2.0644264184841132e-17
and O 0 6.177415519490349e-15
African O 0 9.459326200548309e-16
American O 0 3.2937041325408183e-15
patients O 0 7.868392126021635e-17
. O 0 5.821030774446736e-17

These O 0 4.297430239893548e-19
assays O 0 4.63095153082646e-19
should O 0 8.811952440198311e-23
facilitate O 0 3.104504663423392e-23
screening O 0 1.0234048110531632e-17
for O 0 2.966669370287143e-16
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999977350234985
T I-Disease 1 0.9999997615814209
heterozygotes O 0 2.0898744974157113e-12
in O 0 6.123927621224918e-20
the O 0 2.1543637941782308e-20
populations O 0 1.6417272820202267e-18
studied O 0 7.314557979098186e-18
. O 0 1.6255937031988087e-17
. O 0 1.2447764317579887e-15

The O 0 7.487087338997611e-11
von B-Disease 1 0.7023396492004395
Hippel I-Disease 1 0.9669410586357117
- I-Disease 1 0.9136406183242798
Lindau I-Disease 0 0.10108335316181183
tumor I-Disease 0 8.368647286260966e-08
suppressor O 0 7.327011219970814e-11
gene O 0 1.8867401402073575e-13
is O 0 1.3828269467624582e-17
required O 0 1.5777785175504232e-20
for O 0 1.0159853143824665e-20
cell O 0 8.728546531389103e-12
cycle O 0 3.4860203612652185e-10
exit O 0 2.8816142180754234e-13
upon O 0 1.458621058951417e-14
serum O 0 8.395018569196111e-10
withdrawal O 0 1.6805695723931535e-11
. O 0 8.16178992880251e-13

The O 0 8.64547216911267e-15
inactivation O 0 3.879172816301235e-10
of O 0 3.976678338735867e-16
the O 0 1.6365924457653613e-12
von B-Disease 1 0.999220609664917
Hippel I-Disease 1 0.9998202919960022
- I-Disease 1 0.9999728202819824
Lindau I-Disease 1 0.9999301433563232
( I-Disease 0 1.0741257189250675e-10
VHL I-Disease 0 4.453382189240074e-06
) I-Disease 0 1.4971631332822083e-15
tumor I-Disease 0 1.4019831844937214e-13
suppressor O 0 2.194857576937048e-12
gene O 0 5.724413320749508e-14
predisposes O 0 3.573586426774966e-10
affected O 0 1.729123264706476e-16
individuals O 0 3.786641235633681e-20
to O 0 3.0747999088851772e-18
the O 0 1.1589676531572734e-15
human O 0 4.531257147277756e-08
VHL B-Disease 1 0.9998387098312378
cancer I-Disease 1 0.8325931429862976
syndrome I-Disease 1 0.9928955435752869
and O 0 3.872561366496724e-15
is O 0 4.54902932071801e-18
associated O 0 1.059252817024129e-15
with O 0 4.812143589963576e-14
sporadic B-Disease 0 0.000870903255417943
renal I-Disease 1 0.9679523706436157
cell I-Disease 1 0.9839895367622375
carcinomas I-Disease 1 0.9999997615814209
( O 0 4.644041661644449e-12
RCC B-Disease 0 2.625108436404844e-06
) O 0 2.9134151688370302e-12
and O 0 1.3002476872969737e-10
brain B-Disease 0 1.6652171552777872e-06
hemangioblastomas I-Disease 0 8.0324507507612e-06
. O 0 1.1500576966444465e-12

VHL O 0 0.0003891059313900769
- O 0 4.0859472960619314e-07
negative O 0 1.1055768106560393e-10
786 O 0 9.022353697485386e-11
- O 0 1.1601581501041736e-10
0 O 0 5.762790641878102e-17
RCC B-Disease 0 8.253568997956123e-14
cells O 0 1.5704445063512693e-15
are O 0 1.8306217669380808e-16
tumorigenic O 0 2.421136535701862e-08
in O 0 2.4454928099909568e-12
nude O 1 0.9998815059661865
mice O 0 0.18141533434391022
which O 0 6.544986991610657e-13
is O 0 1.5825412684211387e-19
suppressed O 0 1.2145897477134432e-19
by O 0 1.97595053364786e-22
the O 0 1.5242789958464223e-20
reintroduction O 0 1.3350179455299226e-14
of O 0 4.482180388642292e-17
VHL B-Disease 0 9.215241014715048e-09
. O 0 8.442946591424166e-15

Remarkably O 0 1.7396531264146642e-12
, O 0 2.56108865388198e-17
this O 0 3.833381787004329e-20
occurs O 0 2.5912780992622053e-17
without O 0 1.6800516351346048e-17
affecting O 0 1.756091734955869e-16
the O 0 7.486283122718808e-16
growth O 0 2.7320186044010875e-12
rate O 0 1.0653008856997825e-11
and O 0 2.0682921656823075e-14
cell O 0 1.274657896593867e-11
cycle O 0 3.8501212634711734e-11
profile O 0 1.6361140686618064e-13
of O 0 1.1676980743222911e-20
these O 0 1.1570573457070312e-18
cells O 0 9.343901475775302e-19
in O 0 2.999985041394936e-20
culture O 0 3.402620850009863e-12
. O 0 4.5241530655234716e-14

The O 0 2.0686223814767946e-15
786 O 0 1.343930609160049e-12
- O 0 1.573549734956714e-09
0 O 0 1.510996451860292e-15
cell O 0 1.3807175021363083e-11
line O 0 1.3264069842477966e-09
, O 0 4.500598392161398e-17
like O 0 9.545770147980346e-18
many O 0 7.629001486575905e-20
cancer B-Disease 0 1.3431596262189309e-15
cells O 0 1.4069260929030271e-16
, O 0 1.4964542990542545e-16
fails O 0 3.5460839993561866e-12
to O 0 7.965577907062736e-17
exit O 0 1.3775235292723398e-12
the O 0 8.765482867574093e-16
cell O 0 8.68401392462026e-11
cycle O 0 1.1724570099513887e-11
upon O 0 7.437264267270017e-17
serum O 0 2.8420326855793654e-11
withdrawal O 0 4.783001252006702e-13
. O 0 3.2563407807890965e-13

Here O 0 4.235367612182017e-11
, O 0 1.5349953569455092e-16
it O 0 6.555348968827748e-19
is O 0 1.2011527843128553e-21
shown O 0 4.2684583520299776e-21
that O 0 2.730679888745983e-23
reintroduction O 0 1.9338804174893552e-19
of O 0 7.10156631360346e-23
the O 0 5.13440861293181e-20
wild O 0 2.7960835415671154e-14
- O 0 2.169832091780677e-09
type O 0 1.452016133197953e-12
VHL B-Disease 0 9.286427182786383e-11
gene O 0 1.616073535945148e-15
restores O 0 3.4782376631681267e-13
the O 0 2.1490624065570756e-19
ability O 0 2.9210656458025634e-16
of O 0 1.7705722429539365e-18
VHL O 0 1.453019820019108e-07
- O 0 2.1165058594618813e-09
negative O 0 8.905524755131733e-12
RCC B-Disease 0 3.0902034403590406e-11
cancer I-Disease 0 2.9139681661551065e-14
cells O 0 2.889532337983766e-18
to O 0 2.304315909877759e-18
exit O 0 3.753930590585496e-15
the O 0 9.692248118031849e-18
cell O 0 1.1224041661372919e-11
cycle O 0 3.438190704363464e-11
and O 0 3.706770495999896e-16
enter O 0 2.384449891986671e-16
G0 O 0 9.609820716960371e-10
/ O 0 1.5114152984718743e-10
quiescence O 0 2.517553499004066e-09
in O 0 7.11499120660845e-15
low O 0 6.189505158404884e-11
serum O 0 9.381227045190954e-11
. O 0 7.466768224767897e-14

Both O 0 5.826482823772725e-14
VHL O 0 3.518065838647999e-08
- O 0 3.057421871233146e-09
positive O 0 5.130058433177459e-14
and O 0 3.5747468353497514e-13
VHL O 0 1.8329339468436956e-07
- O 0 2.764309892100414e-10
negative O 0 6.182371780315277e-13
RCC B-Disease 0 7.951693123398051e-12
cells O 0 3.0068212730858385e-15
exit O 0 6.177524447927366e-14
the O 0 3.089215516292384e-17
cell O 0 3.402174722499929e-11
cycle O 0 2.6043856741347904e-12
by O 0 1.29682202130463e-18
contact O 0 1.715637939873893e-12
inhibition O 0 8.246717544957427e-12
. O 0 1.0967126729335974e-12

The O 0 1.851149001609858e-15
cyclin O 0 4.156988555464869e-12
- O 0 1.480393363234231e-14
dependent O 0 2.0107430584739118e-17
kinase O 0 7.679154112995388e-15
inhibitor O 0 1.7286617640991205e-16
, O 0 1.1649180689175167e-19
p27 O 0 1.2397000508085304e-17
, O 0 3.359987301889931e-22
accumulates O 0 5.971400298408056e-19
upon O 0 4.366751077152789e-20
serum O 0 2.2698345752882737e-13
withdrawal O 0 1.5298583932879875e-14
, O 0 1.6826299571039326e-17
only O 0 1.231083987621692e-19
in O 0 1.1105166295401489e-20
the O 0 1.059720004498196e-18
presence O 0 3.0294662754142086e-16
of O 0 5.311519032695409e-19
VHL B-Disease 0 2.2343596157298196e-12
, O 0 2.844872520669904e-20
as O 0 4.8008438303932537e-20
a O 0 1.055918799390785e-18
result O 0 1.7423252658061694e-17
of O 0 4.107692891923456e-21
the O 0 5.671041919003313e-18
stabilization O 0 1.3485812723560689e-15
of O 0 1.5753238752385435e-21
the O 0 1.0994739945447647e-18
protein O 0 1.2755411554462096e-14
. O 0 6.241128278991633e-16

We O 0 1.8342225304666384e-15
propose O 0 1.0634548945358984e-16
that O 0 2.0509177319005097e-17
the O 0 1.0803172691078124e-16
loss O 0 4.1171027429843556e-15
of O 0 9.68990469596944e-21
wild O 0 2.080698677589532e-12
- O 0 1.4435987623073743e-06
type O 0 6.906172855813963e-10
VHL B-Disease 0 2.8543454266838353e-09
gene O 0 6.008038999709116e-15
results O 0 3.7854731661358767e-19
in O 0 8.811472773324892e-25
a O 0 3.1669540875673533e-24
specific O 0 4.784113779386942e-21
cellular O 0 6.1012088122588265e-15
defect O 0 3.852954847533008e-12
in O 0 6.55902899197542e-18
serum O 0 1.0017173757148612e-09
- O 0 1.94390858965221e-09
dependent O 0 3.8396633095238997e-11
growth O 0 1.4019357506486751e-12
control O 0 1.2120623515271545e-12
, O 0 7.334147932109157e-17
which O 0 7.22663860615115e-18
may O 0 1.6332624326192418e-19
initiate O 0 3.9555987823341984e-18
tumor B-Disease 0 5.96338245711231e-13
formation O 0 1.3965166879620263e-14
. O 0 3.2959949331466676e-13

This O 0 1.2274476199648234e-15
is O 0 1.1005025936364744e-17
corrected O 0 2.627753488640568e-15
by O 0 3.111999977982695e-22
the O 0 2.571342834857763e-21
reintroduction O 0 4.020853753913139e-16
of O 0 1.5766481235445812e-19
wild O 0 4.5185499764587023e-13
- O 0 6.344819780679245e-07
type O 0 8.9331786412572e-10
VHL B-Disease 0 3.0155192121128493e-07
, O 0 1.3096894898850916e-16
implicating O 0 7.75020759374856e-12
VHL B-Disease 0 1.794034538982192e-11
as O 0 1.795101999675861e-19
the O 0 3.057018215667865e-21
first O 0 1.9487795235968265e-20
tumor B-Disease 0 6.179061939781574e-16
suppressor O 0 2.4854216720739813e-15
involved O 0 5.955365402233715e-18
in O 0 7.371469142615176e-20
the O 0 2.9838499529689e-18
regulation O 0 4.420242705795987e-15
of O 0 2.331017300050971e-17
cell O 0 5.766728428113765e-09
cycle O 0 3.7682670495087223e-07
exit O 0 2.860797432280293e-10
, O 0 2.8299346373217293e-13
which O 0 2.383847513918319e-14
is O 0 6.820727431091272e-18
consistent O 0 1.270135698226276e-16
with O 0 1.7191696628768487e-19
its O 0 1.0206211001377385e-17
gatekeeper O 0 2.496552660782858e-12
function O 0 2.775809977381173e-15
in O 0 1.0620515164522532e-17
the O 0 6.617448966182368e-14
kidney O 0 2.249809085697052e-07
. O 0 2.7265407813448217e-13
. O 0 3.2973422169763067e-12

Piebaldism B-Disease 1 0.9999805688858032
with O 0 7.7888420491945e-05
deafness B-Disease 1 0.9999998807907104
: O 0 1.2445018025006652e-14
molecular O 0 4.503943117647771e-19
evidence O 0 2.2202434954657657e-19
for O 0 6.145501606355423e-21
an O 0 2.1011722628355564e-17
expanded O 0 1.0683180562409689e-08
syndrome O 1 0.9996236562728882
. O 0 1.7877017574607912e-11

In O 0 9.080436716538435e-17
a O 0 2.51808707416837e-16
South O 0 2.1454404008566796e-13
African O 0 1.9491667394705425e-12
girl O 0 7.531757972856212e-08
of O 0 7.145965666242323e-17
Xhosa O 0 1.9916968074795705e-09
stock O 0 3.971283480015686e-15
with O 0 7.25829977127723e-18
severe O 0 3.2575268979657956e-13
piebaldism B-Disease 0 5.908019073963544e-10
and O 0 9.247333123850107e-14
profound O 0 2.5424556557296363e-11
congenital O 1 0.968448281288147
sensorineural B-Disease 1 0.9153777956962585
deafness I-Disease 1 0.9999998807907104
we O 0 2.7688477053679217e-14
identified O 0 2.623421407287827e-19
a O 0 6.742744991767532e-21
novel O 0 3.808969851820905e-18
missense O 0 7.504897201130313e-16
substitution O 0 1.39018488374724e-16
at O 0 3.1609803165740555e-16
a O 0 3.564227151540447e-21
highly O 0 8.871868791270385e-20
conserved O 0 8.403515513663584e-16
residue O 0 3.934531034310851e-10
in O 0 7.360981013474855e-22
the O 0 4.176086059555286e-23
intracellular O 0 1.2260424717146673e-17
kinase O 0 1.0079633118833045e-13
domain O 0 9.898626074356359e-16
of O 0 5.234457723607233e-20
the O 0 1.9905342089286287e-17
KIT O 0 2.2490231899041646e-10
proto O 0 5.740863947417685e-12
- O 0 2.399245082121415e-12
oncogene O 0 1.9689113187060236e-11
, O 0 3.403472614483161e-15
R796G O 0 7.91130095462167e-12
. O 0 3.6698766313174314e-14

Though O 0 3.922476221867449e-13
auditory B-Disease 0 3.1340152695236156e-11
anomalies I-Disease 0 9.577171694585829e-11
have O 0 4.543380438140436e-16
been O 0 3.063715523240844e-16
observed O 0 2.7186655348693722e-15
in O 0 5.2142372159851916e-17
mice O 0 5.1036930757975e-12
with O 0 5.582934445184983e-16
dominant O 0 6.366667609780663e-11
white O 0 2.1827497587167954e-09
spotting O 0 3.0821175300843606e-07
( O 0 3.078055685158741e-15
W O 0 1.323188030255551e-06
) O 0 1.0012624268260375e-17
due O 0 1.642110018489655e-17
to O 0 4.957218501554022e-16
KIT O 0 3.209718357766178e-08
mutations O 0 4.217510021775617e-12
, O 0 1.0237626718589965e-12
deafness B-Disease 1 1.0
is O 0 6.497679862693326e-14
not O 0 4.000705592955038e-15
typical O 0 1.3509711334650995e-14
in O 0 8.194202687438512e-17
human O 0 1.9611531149044126e-11
piebaldism B-Disease 0 8.369273018615786e-06
. O 0 3.3348486732504012e-12

Thus O 0 6.702938053372966e-15
, O 0 2.54813504684843e-19
the O 0 2.3998667994574213e-20
occurrence O 0 1.6164690368040448e-14
of O 0 9.397105277825376e-16
sensorineural B-Disease 0 0.12867622077465057
deafness I-Disease 1 1.0
in O 0 4.872141982936208e-16
this O 0 3.3378405002436844e-19
patient O 0 3.636932166277636e-17
extends O 0 7.366473488703239e-18
considerably O 0 2.515330511320649e-17
the O 0 1.0637980824662648e-19
phenotypic O 0 2.8001728022312443e-17
range O 0 7.208403253640416e-13
of O 0 1.4496879556751195e-17
piebaldism B-Disease 0 2.0061943425964124e-11
due O 0 6.482712895070972e-18
to O 0 5.654427789605033e-19
KIT O 0 2.4689804237545965e-14
gene O 0 1.0651346253903915e-18
mutation O 0 2.3504818938401094e-18
in O 0 2.2560750208970022e-20
humans O 0 3.8893162208238955e-17
and O 0 4.7428432505707864e-15
tightens O 0 2.2366281271501975e-08
the O 0 1.2899294354529554e-18
clinical O 0 3.91485507068471e-19
similarity O 0 7.888914973327443e-18
between O 0 9.185226934386858e-18
piebaldism B-Disease 0 3.898641479094245e-11
and O 0 4.175570922630425e-18
the O 0 6.728634655688506e-22
various O 0 2.9148278313083673e-19
forms O 0 3.1522787852233947e-13
of O 0 3.322526975768625e-11
Waardenburg B-Disease 1 0.9986086487770081
syndrome I-Disease 0 0.10690291970968246
. O 0 2.0512171249601396e-15
. O 0 6.709106740217935e-14

Cycloheximide O 0 2.429305237874879e-12
facilitates O 0 2.349104001191137e-16
the O 0 1.2857824688494974e-19
identification O 0 4.8288610477861265e-17
of O 0 7.31360204265341e-20
aberrant O 0 2.1861212926715945e-12
transcripts O 0 4.4729192572035004e-11
resulting O 0 5.180780392362305e-13
from O 0 1.1887927089340569e-17
a O 0 4.889021025197465e-19
novel O 0 7.075548111567929e-17
splice O 0 1.429104212746779e-08
- O 0 2.738473510455197e-11
site O 0 4.392727772240673e-14
mutation O 0 6.332288209412451e-14
in O 0 3.644846878532727e-18
COL17A1 O 0 5.373085656956711e-11
in O 0 4.1405894771437774e-21
a O 0 3.562951241601455e-20
patient O 0 6.081315396459612e-16
with O 0 3.556114833721082e-16
generalized O 0 8.458183042847622e-10
atrophic B-Disease 1 0.9718984365463257
benign I-Disease 1 0.9989874958992004
epidermolysis I-Disease 1 0.9879055023193359
bullosa I-Disease 1 0.9431397914886475
. O 0 6.800468188572495e-09

Patients O 0 3.2573593887301466e-13
with O 0 5.0475171900498956e-15
generalized O 0 4.014382992689747e-10
atrophic B-Disease 0 0.2660427391529083
benign I-Disease 1 0.9928544163703918
epidermolysis I-Disease 1 0.6494606137275696
bullosa I-Disease 0 0.002575566526502371
often O 0 3.0039757348276908e-09
show O 0 6.418049980361218e-10
decreased O 0 4.233626524439288e-13
expression O 0 1.1439013193057835e-16
of O 0 1.6226934425350752e-18
type O 0 1.0273032424734652e-12
XVII O 0 5.136293126928315e-11
collagen O 0 1.1596531894475515e-11
, O 0 8.65902922260105e-17
a O 0 2.5106689349786065e-19
transmembrane O 0 1.856445710387276e-15
hemidesmosomal O 0 8.103508641020551e-14
protein O 0 9.531579037391386e-18
encoded O 0 2.769417648030094e-18
by O 0 1.4074244857657026e-17
COL17A1 O 0 2.465496073966733e-08
. O 0 2.6601654161254908e-14

This O 0 2.4000193634088297e-15
report O 0 8.838840089796602e-18
documents O 0 6.4055493516289625e-18
a O 0 4.757765039573316e-19
novel O 0 8.710579118375355e-17
splice O 0 1.1907905772545746e-08
- O 0 9.641633325063736e-11
site O 0 1.917892656754655e-13
mutation O 0 1.0523687092112502e-13
in O 0 5.270951200323665e-18
COL17A1 O 0 3.7320781881566845e-11
in O 0 8.754600914480648e-21
a O 0 1.037119762877325e-19
patient O 0 2.022175541572342e-15
with O 0 5.873204695275151e-16
generalized O 0 2.6021737542514245e-10
atrophic B-Disease 0 0.08008009940385818
benign I-Disease 1 0.98776775598526
epidermolysis I-Disease 0 0.05065171793103218
bullosa I-Disease 0 0.00013451270933728665
, O 0 8.648215200609058e-14
and O 0 1.114528764411291e-17
applies O 0 4.8732105017642796e-20
a O 0 5.0779140552144816e-23
new O 0 1.4072974364377797e-22
methodology O 0 4.4904244014992405e-19
to O 0 6.801389835375554e-20
define O 0 1.4113824126478708e-16
and O 0 1.8513175611663615e-16
characterize O 0 3.170052314724857e-14
the O 0 6.810350140114064e-19
resulting O 0 6.217836593477814e-17
mRNA O 0 1.6070129303874872e-14
splice O 0 1.8116278397428687e-06
variants O 0 2.9850688587629293e-10
. O 0 1.1063271826428078e-11

Mutational O 0 1.7778974736870623e-08
analysis O 0 4.5062230720959925e-14
of O 0 9.472567972491853e-18
COL17A1 O 0 1.955915811258091e-11
identified O 0 9.540428546456724e-16
a O 0 1.0644410923494086e-16
maternally O 0 1.7010169939268849e-09
inherited O 0 2.1671860750416272e-08
G O 0 1.1182474501936213e-08
- O 0 7.154500880623971e-10
to O 0 7.347612102082124e-11
- O 0 7.019808981567621e-05
T O 0 1.705179784039501e-07
transversion O 0 1.1255297908963069e-11
at O 0 1.830585933473945e-17
the O 0 9.227672292265687e-21
- O 0 2.694040401120893e-17
1 O 0 6.776779152278506e-22
position O 0 1.0837420532697718e-18
of O 0 1.1811425865537622e-20
exon O 0 4.8061357546752906e-14
32 O 0 1.5791079381599626e-14
. O 0 1.8580053945047026e-14

This O 0 3.679466124247358e-17
acceptor O 0 1.0057652275038617e-15
splice O 0 1.0849687814840081e-10
- O 0 6.138266544358784e-12
site O 0 1.340765335127586e-13
mutation O 0 4.387871224134296e-14
led O 0 5.463997255105086e-16
to O 0 3.2946289469354322e-18
the O 0 1.0153737015611888e-19
formation O 0 3.1409400298939985e-18
of O 0 9.077232049531873e-21
aberrant O 0 7.125176777799183e-15
transcripts O 0 5.207166806981333e-15
present O 0 8.103001061820865e-17
at O 0 3.222836358679135e-14
extremely O 0 2.4137816311692317e-12
low O 0 6.4594769533243834e-09
levels O 0 2.810165121436281e-11
. O 0 5.870727623653871e-13

Based O 0 1.3296806850501548e-15
on O 0 1.4667227596853148e-14
our O 0 1.0203029598567057e-15
recent O 0 1.0431115619666265e-18
finding O 0 1.2117764806007562e-18
that O 0 1.1277733942638523e-18
cycloheximide O 0 7.502017670274475e-13
stabilized O 0 1.0239898338981757e-11
mutant O 0 1.2778990918834582e-13
COL17A1 O 0 1.5834798750002932e-12
transcripts O 0 2.0376705270347016e-15
in O 0 8.289609895745774e-20
keratinocytes O 0 2.836185469421923e-14
homozygous O 0 8.308268908676104e-17
for O 0 9.298271834429661e-21
a O 0 2.213454917236362e-17
frameshift O 0 5.87597678847196e-11
mutation O 0 5.302385050129366e-13
, O 0 7.986705508099615e-14
the O 0 4.222719281177494e-15
effects O 0 1.2686861977639907e-11
of O 0 4.506415353703539e-20
the O 0 3.1736513008077143e-18
splice O 0 9.240057607939889e-09
- O 0 7.595427786071321e-14
site O 0 2.6922746352108884e-16
mutation O 0 1.8645488113725147e-17
on O 0 2.7721778670161222e-17
splicing O 0 6.380078485922897e-14
of O 0 2.268356197300971e-19
COL17A1 O 0 6.57379627621267e-14
transcripts O 0 1.0768481232496017e-17
were O 0 1.6461709051565908e-21
determined O 0 2.6839910614071688e-22
using O 0 1.8449255840520517e-21
reverse O 0 1.3519758627713089e-15
transcriptase O 0 7.003027003508588e-15
polymerase O 0 1.478047393678461e-12
chain O 0 7.473729100870852e-12
reaction O 0 2.177951200379953e-16
of O 0 2.625481159714505e-21
total O 0 2.8926930112602025e-21
RNA O 0 8.658736069791961e-16
from O 0 2.1999683163751136e-18
keratinocytes O 0 6.058233748646932e-15
incubated O 0 9.385001388767349e-15
for O 0 2.675610001201709e-21
2 O 0 1.4548955539395083e-17
. O 0 3.493431483948508e-16

5 O 0 1.9913034762786275e-11
h O 0 5.162736349539898e-10
in O 0 3.317822677721113e-18
the O 0 7.252543421394473e-18
presence O 0 7.985818156384071e-15
or O 0 6.73182733515465e-12
absence O 0 2.764219856157303e-14
of O 0 1.6712488410943614e-18
10 O 0 3.8887396428497216e-16
microg O 0 3.437430201591596e-11
cycloheximide O 0 1.1493285489994065e-10
per O 0 1.5165168832149034e-15
ml O 0 1.14408871265681e-09
. O 0 1.4980014841417533e-13

Using O 0 5.3273114822322104e-17
this O 0 9.488879146990787e-18
approach O 0 6.522642126936817e-13
, O 0 1.3468339704408253e-14
an O 0 1.0738791701990795e-15
abnormally O 0 1.5025472066554357e-07
spliced O 0 0.05113585665822029
transcript O 0 2.2070875274948776e-05
was O 0 1.6947426101365792e-11
identified O 0 3.039409648121586e-16
that O 0 1.2739180008349733e-20
contains O 0 9.854285082775145e-23
an O 0 6.780910290621404e-24
extra O 0 5.268834832877054e-20
264 O 0 2.714970655557899e-19
bases O 0 2.4707479578458786e-17
upstream O 0 2.1736447260574344e-15
from O 0 1.2906148373085168e-16
exon O 0 4.2709678025124043e-13
32 O 0 2.1529326105630513e-14
, O 0 1.1686758418728897e-17
resulting O 0 4.55726224935475e-18
in O 0 3.4318983675917795e-20
a O 0 1.1797265778099042e-16
premature O 0 9.900351372049698e-11
termination O 0 2.8865760693178033e-13
codon O 0 3.7353930712469285e-13
27 O 0 1.9656749372740784e-13
bp O 0 9.450863485901961e-13
downstream O 0 1.6409487971994624e-13
from O 0 3.595765289706281e-18
the O 0 2.0380716997056224e-18
cryptic O 0 1.1360586950337481e-12
splice O 0 9.775127374211934e-10
site O 0 4.133587569454811e-11
. O 0 1.375669760397824e-12

Three O 0 5.672216482385914e-16
other O 0 1.1635240369408176e-18
splice O 0 2.0552247403937685e-10
variants O 0 3.625234877915884e-13
, O 0 1.4256625940451903e-16
including O 0 5.662756981385559e-20
one O 0 1.5111546768290175e-19
derived O 0 2.104416746633268e-21
from O 0 1.205537144481974e-20
the O 0 9.687322179935913e-20
skipping O 0 1.7443162935110515e-14
of O 0 6.181029579120072e-20
exon O 0 1.7955038497663445e-14
32 O 0 3.966726019242984e-15
, O 0 2.2103414094107123e-17
were O 0 1.155453128170658e-16
also O 0 2.729502262638307e-16
identified O 0 3.7627374631886423e-13
. O 0 1.5980436375226392e-12

These O 0 7.565386576750821e-13
results O 0 7.458316344731737e-17
indicate O 0 7.10781824706097e-18
the O 0 3.3112047998433367e-21
usefulness O 0 5.988057730711404e-17
of O 0 5.847370042396113e-21
cycloheximide O 0 7.50373138733336e-14
treatment O 0 8.120631113767968e-19
in O 0 9.432767197717703e-24
evaluating O 0 2.6458710810345804e-21
the O 0 7.921834409412187e-21
abnormal O 0 2.759423436802269e-16
processing O 0 4.791517730878236e-18
of O 0 3.833582786238624e-22
mRNA O 0 8.264808574594772e-16
due O 0 2.1334492010619552e-15
to O 0 2.1887526571675683e-17
splice O 0 1.5086287774579432e-08
- O 0 1.0515090534402027e-11
site O 0 2.1894000555664622e-13
mutations O 0 3.60797573458263e-13
, O 0 1.1043426307377416e-16
because O 0 6.253278966619996e-17
( O 0 1.087235776602686e-20
i O 0 1.45948384671149e-14
) O 0 2.3474497211331284e-21
aberrant O 0 4.3699074949727146e-17
splicing O 0 2.161745395456169e-15
often O 0 3.715987537955003e-16
generates O 0 4.767342136705455e-18
a O 0 2.482461662500242e-18
premature O 0 1.5844588011418304e-12
termination O 0 6.561645080364539e-14
codon O 0 2.5521070174706895e-13
, O 0 1.7943842416166637e-14
( O 0 3.501700378398282e-18
ii O 0 5.457051043683547e-12
) O 0 2.4116620331009095e-18
transcripts O 0 5.266936628113149e-16
with O 0 2.0518401210015676e-18
premature O 0 2.6833967770115976e-15
termination O 0 1.7355051616556697e-18
codons O 0 2.2757948877930533e-17
can O 0 7.936948061096642e-16
occur O 0 5.182553723600018e-15
at O 0 5.1185891462857125e-12
low O 0 8.688479269380878e-09
or O 0 6.5975278573660034e-09
undetectable O 0 3.8441544347733725e-07
levels O 0 1.715053099538011e-11
due O 0 7.220942111057518e-16
to O 0 4.59388636580725e-16
nonsense O 0 9.190898042632512e-12
- O 0 3.873359271533037e-15
mediated O 0 3.939929708440121e-14
mRNA O 0 2.800434580410571e-13
decay O 0 1.4110670409905879e-09
, O 0 1.4325409565262321e-18
and O 0 7.0761115870012e-18
( O 0 6.436027087062562e-23
iii O 0 8.253876026223679e-16
) O 0 1.6725188321683294e-17
the O 0 2.247506899030516e-16
levels O 0 4.219255075241902e-16
of O 0 7.568288926201505e-24
these O 0 1.3995629392520136e-20
transcripts O 0 1.3278747744106617e-17
can O 0 1.8310799619249135e-19
be O 0 5.585689759248472e-21
increased O 0 2.2568570862388413e-21
by O 0 2.0584892469194526e-17
cycloheximide O 0 1.313099602384682e-07
. O 0 3.411320434031778e-13

A O 0 8.347383487281989e-15
deletion O 0 4.1692547309533923e-13
mutation O 0 1.3218928311990383e-14
in O 0 1.8000282603722356e-16
COL17A1 O 0 2.541150401214054e-08
in O 0 2.216285363856396e-17
five O 0 1.4477432871422318e-16
Austrian O 0 3.389642039275387e-11
families O 0 1.0288709310522434e-14
with O 0 2.339060638891314e-17
generalized O 0 1.073478025220842e-11
atrophic B-Disease 0 0.09931878745555878
benign I-Disease 1 0.9968478083610535
epidermolysis I-Disease 1 0.7584466934204102
bullosa I-Disease 0 0.00040561187779530883
represents O 0 3.767818119272204e-15
propagation O 0 1.2637026841622045e-13
of O 0 3.829961589041878e-20
an O 0 1.4426085459122209e-19
ancestral O 0 3.8701069016156e-09
allele O 0 1.5892781846105208e-07
. O 0 3.5418157295907804e-10

Patients O 0 2.6504896367962605e-12
with O 0 3.9026365418384085e-15
generalized O 0 9.28506771469273e-10
atrophic B-Disease 0 0.2576548457145691
benign I-Disease 1 0.9909035563468933
epidermolysis I-Disease 0 0.09102999418973923
bullosa I-Disease 0 0.0001523187238490209
, O 0 1.0532330597471111e-15
a O 0 2.97924193657152e-19
usually O 0 2.5431159216866116e-18
nonlethal O 0 5.104815157283386e-15
form O 0 9.199542254416599e-16
of O 0 1.428018673362702e-13
junctional B-Disease 0 0.0051904963329434395
epidermolysis I-Disease 0 0.00011187922791577876
bullosa I-Disease 0 7.997801731107756e-06
, O 0 1.0968908319144923e-15
have O 0 7.038905003048565e-18
generalized O 0 5.143946914776233e-16
blistering B-Disease 0 6.166721355782556e-09
, O 0 1.2143508854728369e-12
nail B-Disease 1 0.9999380111694336
dystrophy I-Disease 0 0.0049489932134747505
, O 0 1.2271640951674878e-12
patchy B-Disease 0 1.1277302292000968e-07
alopecia I-Disease 0 0.00018076349806506187
, O 0 2.1986987154987842e-13
and O 0 1.6757907561615326e-11
dental B-Disease 0 6.97733128163236e-07
abnormalities I-Disease 0 3.05988360196352e-05
. O 0 1.682428827330662e-12

Skin B-Disease 1 0.9998395442962646
fragility I-Disease 0 6.893985300848726e-06
in O 0 1.0536459552216731e-17
most O 0 3.184343889769972e-20
cases O 0 3.613145595146939e-18
is O 0 9.183514670518873e-17
due O 0 6.139869725312118e-16
to O 0 1.4492470088516246e-15
mutations O 0 2.0147444950563003e-16
in O 0 1.4985011924090108e-21
the O 0 3.304780165169923e-22
gene O 0 2.1127450159135407e-18
encoding O 0 1.2197128856674116e-16
type O 0 3.357220846266461e-14
XVII O 0 8.46266026005571e-12
collagen O 0 3.377715121488656e-11
( O 0 1.799438698971167e-15
COL17A1 O 0 4.961675585946068e-07
) O 0 9.071449104045004e-14
. O 0 3.6476659366624364e-13

Recently O 0 8.398308957990874e-12
, O 0 3.6668450156959135e-15
we O 0 8.658939145941066e-15
reported O 0 2.441592587493018e-15
five O 0 4.7854350582438276e-18
Austrian O 0 2.1815821718562667e-11
families O 0 3.359808701326912e-14
with O 0 7.406912694489731e-17
generalized O 0 9.219089250681045e-13
atrophic B-Disease 0 8.563068695366383e-05
benign I-Disease 0 0.011152749881148338
epidermolysis I-Disease 0 0.0009929644875228405
bullosa I-Disease 0 0.00013120996300131083
who O 0 3.742112522631125e-12
share O 0 2.985424267926129e-16
the O 0 1.0344566290458164e-19
same O 0 3.0998633160094115e-17
COL17A1 O 0 3.620433064455142e-09
mutation O 0 1.0893361408227664e-13
. O 0 2.243009380661909e-13

Affected O 0 9.566906294944388e-12
individuals O 0 3.5718294124750176e-17
in O 0 5.113455417157503e-20
three O 0 8.10772740640487e-18
families O 0 3.771409234566097e-17
are O 0 7.664464512737772e-22
homozygous O 0 1.675358687967831e-19
for O 0 2.3910486017632086e-20
4003delTC O 0 2.6848970963166963e-11
, O 0 3.45995727126861e-16
whereas O 0 7.142971140075983e-16
those O 0 6.14898406452237e-17
in O 0 8.140508005393676e-20
two O 0 1.8989110189836006e-16
others O 0 7.55845191801165e-16
are O 0 6.45972352959538e-20
compound O 0 1.5212970077736147e-15
heterozygotes O 0 3.090906233759773e-14
. O 0 1.254865420016911e-14

To O 0 1.5229169582852385e-15
determine O 0 7.987424739656996e-17
if O 0 7.444781850113022e-18
the O 0 1.3365942351740692e-19
occurrence O 0 1.8951127644294347e-15
of O 0 1.952122050592228e-18
4003delTC O 0 1.638467139741806e-11
in O 0 3.2490329679633135e-20
these O 0 5.509782205556094e-20
unrelated O 0 1.933432276882868e-17
families O 0 2.1097881295669992e-19
signifies O 0 1.0462502899152297e-21
propagation O 0 1.218292673424325e-19
of O 0 1.2439922323360115e-24
an O 0 1.4523251877674627e-21
ancestral O 0 2.403901244729667e-10
allele O 0 1.8841617155374024e-09
or O 0 1.1195119137275e-10
a O 0 3.212807827396823e-14
mutational O 0 2.3217016575927119e-07
hot O 0 5.958161750641011e-07
spot O 0 2.7335147478879662e-08
, O 0 8.2234269917149e-15
haplotypes O 0 7.006935179645901e-13
were O 0 6.90737686673108e-16
determined O 0 8.787972618027654e-18
for O 0 7.231808258797407e-22
polymorphisms O 0 1.2559388479303074e-13
both O 0 4.921590495847493e-15
within O 0 6.228400682516851e-17
and O 0 1.4983460652762126e-11
flanking O 0 9.733569186209934e-07
COL17A1 O 0 8.662031905259937e-05
. O 0 1.9203096144476683e-12

Five O 0 1.9421664526186183e-13
intragenic O 0 5.8233110174221725e-12
polymorphisms O 0 4.359768026197114e-13
were O 0 3.4227796717246385e-16
chosen O 0 1.4446909989537172e-18
based O 0 1.6617884022779866e-19
on O 0 3.30713456836787e-13
their O 0 7.776419785887612e-11
informativeness O 0 2.8274493857338712e-08
. O 0 2.641317238983188e-14

One O 0 1.5197100305605615e-12
of O 0 3.3196712195950157e-18
these O 0 2.2031198579653284e-16
, O 0 2.7711203993210344e-17
not O 0 9.291518650483187e-17
previously O 0 7.375735052827636e-15
reported O 0 2.6094076985977432e-12
, O 0 2.3842110104975716e-18
was O 0 1.4763376636036589e-15
2988 O 0 1.2292476708568572e-14
A O 0 6.29262152943759e-16
or O 0 1.6911855759121214e-13
C O 0 2.1699210137060554e-11
that O 0 7.500217220019641e-20
introduces O 0 3.2204579361544867e-18
a O 0 8.52342877292426e-22
new O 0 8.266233864531285e-22
restriction O 0 7.023288143276293e-20
site O 0 1.2212813028268734e-17
for O 0 4.120281627650104e-20
Eco0109 O 0 8.267876400874785e-14
I O 0 6.027311288958614e-11
. O 0 3.307023937394629e-15

All O 0 9.613421610686363e-16
the O 0 9.515702132714044e-18
4003delTC O 0 2.231110478659315e-12
alleles O 0 1.0894098369243423e-15
showed O 0 1.2879383296622235e-14
the O 0 3.8801503688117495e-21
same O 0 5.663707592855141e-20
haplotype O 0 5.056189113363885e-15
for O 0 1.4032035032995273e-20
these O 0 1.2801553866169676e-17
five O 0 2.187358692399294e-17
polymorphic O 0 8.422635418975366e-14
markers O 0 1.149973782865743e-09
. O 0 1.645683415929522e-11

Fourteen O 0 2.4380597367368306e-12
microsatellite O 0 7.810828372978307e-12
polymorphisms O 0 1.144728734546463e-12
were O 0 1.3493989238479653e-16
selected O 0 1.3747147244566047e-20
based O 0 1.416519818691924e-20
on O 0 7.32063064681765e-14
their O 0 3.389706224043998e-11
high O 0 1.1780830217605898e-12
heterozygosity O 0 1.8659676736154825e-14
and O 0 3.429901432100924e-17
their O 0 3.114464666823167e-18
location O 0 1.818045544515396e-17
within O 0 4.745713431638725e-18
10q23 O 0 1.2557623127115725e-12
- O 0 1.1749784478709557e-10
q25 O 0 2.7347936415456076e-11
near O 0 4.2133371444541545e-12
COL17A1 O 0 4.6075592763372697e-07
. O 0 9.688719282158892e-14

Three O 0 2.7118513665669482e-14
families O 0 7.409463057754355e-15
shared O 0 2.7793477693040583e-16
microsatellite O 0 4.966276088286259e-12
polymorphisms O 0 6.02517272185743e-11
covering O 0 1.7733566351485486e-11
at O 0 2.2826247727918136e-13
most O 0 6.829087993696529e-17
19 O 0 1.7452337784236937e-15
cM O 0 7.72340958549167e-12
, O 0 1.3315333578640368e-15
whereas O 0 5.9390854356049325e-15
the O 0 6.49556998832501e-15
others O 0 8.806797652249898e-11
shared O 0 1.153025049570322e-12
smaller O 0 3.52595523037038e-14
regions O 0 2.5777552089948676e-14
consistent O 0 4.7087175636753315e-15
with O 0 3.332880260001722e-18
cross O 0 1.9537251319794863e-13
- O 0 2.9356829467364065e-12
over O 0 6.319082309314222e-16
events O 0 1.0769842606348157e-16
during O 0 3.597452738155889e-18
passage O 0 9.825242430175626e-21
of O 0 2.0792707387394044e-23
this O 0 9.190180320904302e-23
mutation O 0 2.365581051640022e-21
through O 0 3.1576490265687814e-19
several O 0 2.3299695269126623e-16
generations O 0 1.015455341341065e-11
. O 0 5.002257890337493e-16

These O 0 7.784955812590796e-14
results O 0 9.055496228453226e-17
indicate O 0 7.263819448243122e-16
that O 0 7.809006513740738e-17
4003delTC O 0 6.171657629394645e-11
occurs O 0 1.7058334056074495e-15
on O 0 2.180353597576603e-16
a O 0 2.1234742205426012e-19
single O 0 4.724200945448058e-18
ancestral O 0 1.2561277018541261e-10
allele O 0 2.1674804312477036e-11
. O 0 2.2404385679043563e-14
. O 0 2.344890503557656e-13

The O 0 1.889115728811227e-14
haptoglobin O 0 1.0234441072398681e-09
- O 0 5.6992956361245906e-12
gene O 0 8.745619246158798e-14
deletion O 0 3.906440709106063e-12
responsible O 0 1.5923433361805794e-14
for O 0 3.476241413505125e-17
anhaptoglobinemia B-Disease 0 1.876595234762135e-08
. O 0 3.1544382449004427e-13

We O 0 2.1288580707296e-13
have O 0 4.60878153944639e-19
found O 0 5.196199974041802e-20
an O 0 5.559966784799417e-21
allelic O 0 5.6958617510038945e-12
deletion O 0 3.103459433884126e-10
of O 0 4.859390431310887e-16
the O 0 2.8286705931138828e-14
haptoglobin O 0 9.827096913994637e-10
( O 0 5.686397803292324e-19
Hp O 0 1.2488988782465488e-17
) O 0 1.7614085745693607e-20
gene O 0 1.0380073612788068e-17
from O 0 2.9479397678312884e-18
an O 0 9.263899410362529e-20
individual O 0 7.047371692926413e-17
with O 0 1.332767040175889e-13
anhaptoglobinemia B-Disease 0 8.353734415322833e-07
. O 0 2.0343251280578734e-13

The O 0 6.427021835365206e-16
Hp O 0 5.704029134060654e-15
gene O 0 2.3755265587060244e-15
cluster O 0 7.989749236292278e-15
consists O 0 3.762727974037353e-18
of O 0 1.3740277768072736e-20
coding O 0 5.116446710751177e-10
regions O 0 1.932138937775843e-13
of O 0 9.622615847271982e-19
the O 0 2.806075232210178e-17
alpha O 0 3.9468453089379785e-16
chain O 0 4.452109864040883e-14
and O 0 2.7310557210635713e-15
beta O 0 6.6365978539175805e-18
chain O 0 1.9409867983033067e-15
of O 0 1.2319008607883308e-20
the O 0 3.011201300308425e-18
haptoglobin O 0 1.622993901003334e-14
gene O 0 6.935095490534385e-17
( O 0 1.1840885289130587e-20
Hp O 0 1.0227720178845601e-18
) O 0 1.8521129677036349e-19
and O 0 1.4625475701756648e-16
of O 0 8.832086089009273e-21
the O 0 9.879189282107608e-18
alpha O 0 1.4403782033169576e-16
chain O 0 2.2363655252741893e-14
and O 0 3.2868634944587926e-15
beta O 0 3.982093377354272e-18
chain O 0 1.0338433109141577e-15
of O 0 3.316210696577703e-21
the O 0 4.661883639640151e-18
haptoglobin O 0 3.6284534404851243e-12
- O 0 7.690429646182648e-14
related O 0 1.5548625941326976e-15
gene O 0 5.362798014907702e-14
( O 0 1.6556894703746624e-18
Hpr O 0 1.6064859064877056e-14
) O 0 7.988726825338731e-19
, O 0 1.046359486641816e-18
in O 0 3.4093001163742576e-19
tandem O 0 8.524029398992994e-11
from O 0 7.871487766746054e-16
the O 0 7.317695508248824e-15
5 O 0 4.873302282548675e-13
side O 0 4.822141019822368e-10
. O 0 3.134605422450143e-12

Southern O 0 1.4773208698026785e-11
blot O 0 2.352754435719362e-08
and O 0 6.254833272078208e-16
PCR O 0 9.49603676941857e-13
analyses O 0 7.886874747037309e-13
have O 0 7.125603788283718e-17
indicated O 0 8.539588478051456e-18
that O 0 4.600365622948517e-20
the O 0 2.417821950187364e-20
individual O 0 7.306634209215387e-19
with O 0 3.0053059840827597e-16
anhaptoglobinemia B-Disease 0 1.0510634246632677e-12
was O 0 2.6189755803290534e-16
homozygous O 0 2.2174681494142854e-18
for O 0 4.3711471907183065e-22
the O 0 2.170987377992419e-20
gene O 0 3.1667148355060855e-15
deletion O 0 1.2140149996398009e-12
and O 0 5.6528458129700976e-14
that O 0 1.5321855112586309e-18
the O 0 1.6335044798836416e-20
gene O 0 2.0078084863583696e-16
deletion O 0 5.382100709929501e-15
was O 0 1.8534791214851187e-13
included O 0 8.661964886595001e-18
at O 0 7.839065992503119e-16
least O 0 1.275114019990194e-20
from O 0 9.281899474414794e-21
the O 0 4.1313008366320465e-19
promoter O 0 1.425326263265747e-11
region O 0 6.10903742957053e-14
of O 0 4.180716864919906e-19
Hp O 0 5.409181848795769e-17
to O 0 1.27748646769105e-18
Hpr O 0 1.08527441031761e-15
alpha O 0 5.383280569749564e-19
but O 0 1.1340596567265256e-17
not O 0 1.6572203583497326e-16
to O 0 2.587952977460041e-14
Hpr O 0 3.617104393782711e-10
beta O 0 5.7515739404229854e-15
( O 0 5.152268153215169e-18
Hpdel O 0 9.248798393812763e-10
) O 0 2.775079623222403e-15
. O 0 1.909562087718409e-14

In O 0 3.058437449188266e-16
addition O 0 1.1734378379412963e-17
, O 0 4.515783773846646e-17
we O 0 1.913900166957772e-15
found O 0 4.044094948322368e-17
seven O 0 6.774179082890769e-19
individuals O 0 1.5894002839877582e-21
with O 0 8.501614994273407e-20
hypohaptoglobinemia B-Disease 0 7.908671547512958e-13
in O 0 5.274425087477749e-20
three O 0 1.4740964011903342e-17
families O 0 2.1779169220153687e-17
, O 0 2.405978303052028e-22
and O 0 3.269274982281281e-19
the O 0 1.1030826733646039e-18
genotypes O 0 2.0881612411427497e-12
of O 0 1.7370947959978435e-18
six O 0 1.6428520802319428e-14
of O 0 6.982575347502199e-20
the O 0 1.0304212713374707e-16
seven O 0 1.6555837318769597e-16
individuals O 0 1.2529291813643639e-20
were O 0 3.3565225294745594e-18
found O 0 4.267845815092859e-18
to O 0 5.371593438272379e-17
be O 0 7.309942446276016e-14
Hp2 O 0 4.0456760075358034e-07
/ O 0 1.7151432496476104e-09
Hpdel O 0 1.3197961834521266e-07
. O 0 1.920755492591103e-13

The O 0 1.93842761530812e-14
phenotypes O 0 4.5909001426813756e-12
and O 0 1.3934044348039298e-13
genotypes O 0 1.1039763938083813e-12
in O 0 4.326464382791736e-18
one O 0 2.212830230437762e-17
of O 0 1.1863672337860575e-20
these O 0 2.086293765157565e-16
three O 0 3.4807827938867185e-15
families O 0 2.3180578550413555e-13
showed O 0 1.105102812102958e-13
the O 0 1.9829457987456745e-19
father O 0 8.268873866873472e-13
to O 0 7.4800566364631e-17
be O 0 1.5919051448611411e-15
hypohaptoglobinemic B-Disease 0 1.6650766876402656e-10
( O 0 1.1061965947805597e-18
Hp2 O 0 1.9350911498183798e-11
) O 0 3.991342331937411e-17
and O 0 1.1712482756397451e-14
Hp2 O 0 3.3335420535074434e-10
/ O 0 5.041518418014146e-13
Hpdel O 0 4.1220316049361827e-10
, O 0 1.2188384564982695e-16
the O 0 1.7151222939890208e-18
mother O 0 9.473821466904342e-13
to O 0 7.861543153267757e-19
be O 0 7.540761270948775e-18
Hp2 O 0 3.1582611417606266e-13
- O 0 2.066624018995985e-14
1 O 0 5.479121334435138e-19
and O 0 9.953530749997382e-16
Hp1 O 0 2.169042506369734e-12
/ O 0 2.846117100135069e-15
Hp2 O 0 3.406346385514958e-13
, O 0 1.105845999447808e-19
one O 0 2.258157633881625e-21
of O 0 1.2939970995987947e-23
the O 0 3.9328298992659433e-20
two O 0 1.1124182957964233e-16
children O 0 6.901734229698003e-14
to O 0 9.10401682338824e-18
be O 0 1.2378346791178845e-15
hypohaptoglobinemic B-Disease 0 1.4039307216773267e-10
( O 0 2.6452276976923146e-19
Hp2 O 0 1.463086271059899e-12
) O 0 2.3952414639659662e-18
and O 0 3.0268455554754038e-15
Hp2 O 0 2.492300463230457e-11
/ O 0 2.0081782374156698e-14
Hpdel O 0 7.353945577492915e-12
, O 0 1.8283377806461178e-18
and O 0 3.153700790107489e-19
the O 0 2.7773677063428385e-22
other O 0 1.0524036695283468e-19
child O 0 1.4085970506799435e-15
to O 0 1.4119886460809806e-19
be O 0 4.7441930736728525e-18
Hp1 O 0 2.319527599506377e-12
and O 0 5.393610193616793e-15
Hp1 O 0 3.079635851888085e-11
/ O 0 3.566606374388187e-14
Hpdel O 0 5.97390192869085e-13
, O 0 1.8221669292659412e-20
showing O 0 5.308316228137695e-20
an O 0 7.82552936764593e-24
anomalous O 0 1.1282688961302869e-17
inheritance O 0 1.1277103383056097e-12
of O 0 1.1045580682739198e-15
Hp O 0 6.217267911438895e-13
phenotypes O 0 2.447310102238632e-14
in O 0 2.141559025371213e-18
the O 0 2.486977036323377e-15
child O 0 2.9394204403843105e-08
with O 0 4.9467394969745365e-14
Hp1 O 0 1.969395135859031e-08
. O 0 2.3585703567063562e-14

The O 0 1.2309750929088287e-13
Hp2 O 0 1.3283823818710516e-08
/ O 0 1.6850326689521467e-09
Hpdel O 0 3.884547961074958e-10
individuals O 0 2.0200929787226191e-16
had O 0 1.3164975701382073e-15
an O 0 3.035673748923536e-19
extremely O 0 4.581452838631206e-12
low O 0 3.320997254974145e-09
level O 0 8.736720114727037e-13
of O 0 5.352343291057045e-18
Hp O 0 1.2447622439561222e-15
( O 0 3.718957828246383e-20
mean O 0 3.5588833079696236e-16
+ O 0 1.0286084186012304e-13
/ O 0 1.886205948375963e-11
- O 0 5.05616382096008e-10
SD O 0 1.600863299699995e-07
= O 0 5.676608271984462e-13
0 O 0 3.410158833247664e-19
. O 0 1.2291828777736265e-20
049 O 0 1.3029535980149057e-14
+ O 0 2.5389128614842745e-15
/ O 0 2.9840623787073806e-13
- O 0 2.7629141379284516e-13
0 O 0 2.448864687945635e-18
. O 0 3.7785170941721885e-20
043 O 0 9.65930199730734e-15
mg O 0 1.6389836807618324e-14
/ O 0 1.7592884478867185e-14
ml O 0 1.182603602718768e-12
; O 0 2.8212183863251554e-18
n O 0 3.511831845359509e-15
= O 0 3.098920859506693e-15
6 O 0 8.012204423831125e-17
) O 0 4.53842155654263e-18
, O 0 2.3433475851339314e-17
compared O 0 8.725811153047151e-17
with O 0 2.743445831157154e-18
the O 0 2.331231870701867e-16
level O 0 4.4886524747480335e-15
( O 0 1.0520854877202623e-21
1 O 0 5.352682108759591e-21
. O 0 1.2778568378103205e-18
64 O 0 9.59893635467158e-18
+ O 0 2.242283088026121e-16
/ O 0 1.3475322220508944e-15
- O 0 2.770668910907813e-15
1 O 0 1.063335572181574e-19
. O 0 4.1620673025280735e-19
07 O 0 1.4824827552870908e-16
mg O 0 2.136208887343669e-16
/ O 0 4.97437833027421e-17
ml O 0 4.663239835341656e-16
) O 0 7.103114626679355e-22
obtained O 0 1.775622146666243e-21
from O 0 1.3347904644508207e-19
52 O 0 3.041981724877289e-18
healthy O 0 1.6461483555991695e-18
volunteers O 0 3.187589281204536e-20
having O 0 4.00802998735239e-19
phenotype O 0 1.308710637435421e-16
Hp2 O 0 3.9305494622943193e-13
, O 0 3.615034048485397e-18
whereas O 0 1.8007887371401923e-18
the O 0 1.3666586056757977e-18
serum O 0 1.7749191873195347e-12
Hp O 0 3.0696346953553756e-16
level O 0 4.766450849595429e-18
of O 0 5.616111567902258e-22
an O 0 2.4116331851770467e-19
individual O 0 3.6251739593063173e-16
with O 0 5.125718642931543e-13
Hp1 O 0 9.035761650011409e-07
/ O 0 4.328025438038452e-10
Hpdel O 0 8.79583961221897e-10
was O 0 4.474680988155594e-13
0 O 0 7.659544241475267e-17
. O 0 4.838765179045244e-16

50 O 0 3.255247633948688e-13
mg O 0 1.2118294215324177e-11
/ O 0 1.7633132454175637e-10
ml O 0 1.8515864397272708e-08
, O 0 8.406465305902397e-16
which O 0 1.830517078959756e-16
was O 0 1.2467011023723873e-15
approximately O 0 4.871484279223458e-19
half O 0 2.011379822109455e-17
the O 0 1.1629700327255602e-17
level O 0 5.381112434238292e-16
of O 0 5.572731296406233e-20
Hp O 0 9.694102160656825e-17
in O 0 1.4471619942385663e-18
control O 0 1.6015268278213313e-10
sera O 0 3.8569183402614726e-08
from O 0 1.0616146492835394e-16
the O 0 6.666799922073953e-16
Hp1 O 0 6.865563673130737e-10
phenotype O 0 6.957360916223267e-15
( O 0 4.4571754890367594e-21
1 O 0 1.4308355362853465e-20
. O 0 2.845819771718248e-18
26 O 0 2.348933535810502e-16
+ O 0 1.4168314814766761e-15
/ O 0 2.463566189155747e-14
- O 0 4.335163074332092e-14
0 O 0 9.680451410972895e-20
. O 0 2.744688670027515e-20
33 O 0 1.724609125036815e-18
mg O 0 4.679759624791075e-16
/ O 0 7.123840900962245e-16
ml O 0 3.189619521195425e-13
; O 0 3.5324235207097264e-18
n O 0 4.380679236785749e-14
= O 0 1.4702974081293174e-13
9 O 0 9.226503736644177e-15
) O 0 1.9811634106412605e-17
, O 0 1.3673729795323138e-18
showing O 0 1.6017786108805905e-16
a O 0 4.669903885924237e-21
gene O 0 2.3692640206104997e-15
- O 0 2.7771292210321263e-11
dosage O 0 7.911424987350202e-11
effect O 0 1.1969364301783747e-12
. O 0 6.334800847947186e-14

The O 0 2.53452771897678e-16
other O 0 3.017838101235183e-17
allele O 0 8.23517577915045e-13
( O 0 3.4760686981932237e-17
Hp2 O 0 2.809502075429293e-10
) O 0 1.0693943160318252e-16
of O 0 1.1530466377224456e-20
individuals O 0 1.942553276965003e-19
with O 0 2.4171526098528528e-17
Hp2 O 0 1.4602051512380143e-10
/ O 0 3.527463965456029e-13
Hpdel O 0 3.5742238162217443e-12
was O 0 1.1246604894528693e-15
found O 0 3.3087729082294764e-18
to O 0 5.77220124823245e-19
have O 0 7.934184913891246e-18
, O 0 2.647942304129909e-20
in O 0 1.1425122018158987e-20
all O 0 3.1790933220577006e-17
exons O 0 1.4040719975572102e-11
, O 0 2.5383594842719214e-16
no O 0 8.596159153348804e-19
mutation O 0 9.021373932171102e-22
, O 0 1.112427793388897e-22
by O 0 7.61200996415157e-24
DNA O 0 6.735563644918834e-16
sequencing O 0 3.456255464120983e-13
. O 0 3.4178514646309235e-14

On O 0 3.31372028341409e-13
the O 0 1.6166886075963078e-17
basis O 0 7.784286552006836e-18
of O 0 2.603918039407475e-20
the O 0 2.2653393662094137e-18
present O 0 2.8533636589047317e-18
study O 0 1.028883435045255e-20
, O 0 3.110043400989355e-21
the O 0 4.0895098626282775e-21
mechanism O 0 8.116281559051967e-15
of O 0 1.1878673419827938e-18
anhaptoglobinemia B-Disease 0 9.453320071184379e-12
and O 0 1.0463840539060088e-17
the O 0 6.125673808383746e-22
mechanism O 0 2.6381534939973963e-19
of O 0 5.254836308049467e-23
anomalous O 0 1.0965258401235645e-17
inheritance O 0 1.9679859142047312e-13
of O 0 9.563311141526799e-16
Hp O 0 2.725719227148621e-13
phenotypes O 0 2.6670443400967324e-14
were O 0 2.220036085303842e-15
well O 0 1.0154305510583911e-14
explained O 0 8.333736478682852e-11
. O 0 4.580332424106159e-13

However O 0 1.5526889127724652e-13
, O 0 5.361661894247761e-18
the O 0 1.582275536649356e-19
mechanism O 0 1.810008170904584e-13
of O 0 4.012060916645929e-15
hypohaptoglobinemia B-Disease 0 3.94055405195104e-06
remains O 0 3.4334102227973062e-09
unknown O 0 3.5920395546895634e-09

ATM O 0 7.957071668229787e-10
mutations O 0 4.597176112008938e-11
and O 0 7.110307568419794e-12
phenotypes O 0 1.5480818849056277e-09
in O 0 8.617732916160747e-11
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999984502792358
telangiectasia I-Disease 1 1.0
families O 0 0.00010395349090686068
in O 0 7.759712504932988e-17
the O 0 1.0756047880708733e-16
British O 0 1.9834106145671937e-12
Isles O 0 4.2204911787635524e-10
: O 0 2.0297852111242194e-18
expression O 0 9.973268985731405e-21
of O 0 7.645534186040747e-24
mutant O 0 4.816219825510907e-18
ATM O 0 1.8292265183854958e-15
and O 0 8.52449564133314e-16
the O 0 1.7917105953535453e-17
risk O 0 6.543042583434522e-12
of O 0 3.964576090804175e-16
leukemia B-Disease 0 0.11454840749502182
, O 0 7.8793233049268e-10
lymphoma B-Disease 1 1.0
, O 0 5.338562166119776e-13
and O 0 9.242057119607239e-11
breast B-Disease 0 1.0727226253948174e-05
cancer I-Disease 0 5.349819076627682e-08
. O 0 2.344060058903641e-12

We O 0 4.830952803590305e-13
report O 0 3.0854453097784284e-18
the O 0 9.967526381263983e-21
spectrum O 0 3.3953400393983355e-16
of O 0 1.5655067761753162e-19
59 O 0 8.064758682305191e-18
ATM O 0 2.1646760447503743e-14
mutations O 0 2.430423187534049e-15
observed O 0 5.446691275085014e-13
in O 0 1.3883784746870909e-11
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
telangiectasia I-Disease 1 0.9999998807907104
( O 0 9.980219147109892e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.6785743395296773e-14
patients O 0 2.2655122469574372e-18
in O 0 3.382789294800908e-22
the O 0 2.9552359144243124e-18
British O 0 1.2834354239099621e-11
Isles O 0 9.692887914525272e-08
. O 0 6.64378328827514e-13

Of O 0 1.0742035414662305e-14
51 O 0 2.4369029895805446e-15
ATM O 0 6.76991123750581e-13
mutations O 0 2.9458647587949196e-15
identified O 0 3.713821039434163e-15
in O 0 2.5182876820105262e-17
families O 0 1.6165430674836348e-14
native O 0 1.1277733942638523e-18
to O 0 1.796996702984233e-15
the O 0 8.1844057084942e-14
British O 0 7.657003919803174e-09
Isles O 0 5.284597932586621e-07
, O 0 4.9273505739987067e-14
11 O 0 1.1877637789701022e-17
were O 0 6.396362140908672e-20
founder O 0 1.8255510505214572e-17
mutations O 0 1.9319873577888605e-17
, O 0 3.941500315973845e-18
and O 0 6.215586529862772e-16
2 O 0 4.374441685500424e-18
of O 0 2.8989550269911703e-22
these O 0 2.1363115466615414e-19
11 O 0 2.115225630404185e-21
conferred O 0 4.016658191999657e-21
a O 0 7.844220795706418e-21
milder O 0 1.5973121002706001e-16
clinical O 0 9.239379967548867e-18
phenotype O 0 4.613027192832829e-16
with O 0 1.7805889865816474e-19
respect O 0 5.478619856188778e-19
to O 0 1.8482039706226507e-18
both O 0 9.41950082895078e-16
cerebellar B-Disease 0 2.8342849844875673e-08
degeneration I-Disease 0 2.8158996911997747e-08
and O 0 1.2216799566335673e-13
cellular O 0 1.4279078136905654e-12
features O 0 1.354270254966261e-11
. O 0 5.7101441630624805e-12

We O 0 2.276287014782441e-12
report O 0 1.5016352290156946e-16
, O 0 1.0558014431413791e-19
in O 0 5.078212030066489e-20
two O 0 5.752087174626386e-12
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 3.788997761378088e-12
, O 0 2.2628127967466426e-22
an O 0 2.171629153573051e-24
ATM O 0 1.2917416770019848e-14
mutation O 0 2.1389487742302406e-16
( O 0 7.68713548153219e-20
7271T O 0 4.0980800770549185e-15
- O 0 4.698139013242786e-12
- O 0 2.723608283350387e-10
> O 0 1.171736048032751e-13
G O 0 1.5020056379211333e-11
) O 0 1.0552101124009802e-18
that O 0 9.830693337154849e-18
may O 0 3.8296275502460744e-19
be O 0 2.216846313561521e-22
associated O 0 9.704103889340831e-22
with O 0 4.189315130718098e-22
an O 0 1.2498413419870976e-19
increased O 0 1.1488572984922566e-14
risk O 0 1.637430122047867e-11
of O 0 2.4676031164186255e-16
breast B-Disease 0 2.0403765574883437e-06
cancer I-Disease 0 4.503096229235837e-10
in O 0 4.07926187032057e-19
both O 0 1.6481977369258002e-17
homozygotes O 0 1.4827797193209258e-12
and O 0 1.430212420933455e-14
heterozygotes O 0 1.1623152967714118e-14
( O 0 1.616453502186705e-18
relative O 0 4.1327163045890014e-13
risk O 0 3.673774392337625e-12
12 O 0 9.053009392659647e-17
. O 0 2.62872187725549e-18
7 O 0 7.166251311235675e-16
; O 0 5.093821622540091e-16
P O 0 1.5658193630585515e-09
= O 0 6.582073651579829e-15
. O 0 4.927236976292568e-18
0025 O 0 9.307668974748926e-15
) O 0 1.6992572283341952e-19
, O 0 1.415364027656337e-20
although O 0 3.542687739974607e-21
there O 0 5.1898332228261695e-23
is O 0 3.996387962967009e-23
a O 0 1.1599996400705794e-20
less O 0 3.240475735102411e-15
severe O 0 1.0984716425355145e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
phenotype O 0 8.872565615547501e-08
in O 0 9.567524455253214e-20
terms O 0 1.246749600966903e-21
of O 0 2.9787117596285368e-24
the O 0 2.089593936628195e-21
degree O 0 1.0011969761600692e-18
of O 0 1.369330399054344e-18
cerebellar B-Disease 0 4.8426905152609834e-08
degeneration I-Disease 0 1.47354876389727e-06
. O 0 3.3279625583082506e-11

This O 0 2.0923669913893784e-16
mutation O 0 5.862505610360145e-16
( O 0 9.946152034235613e-19
7271T O 0 1.5306230946327687e-14
- O 0 3.460837172397646e-11
- O 0 8.656880212676299e-10
> O 0 1.8639126700414899e-13
G O 0 1.7793730898441051e-12
) O 0 3.402308566117109e-20
also O 0 4.0502466524100684e-21
allows O 0 4.854465732822647e-22
expression O 0 2.6795962766620687e-19
of O 0 2.545742443082492e-21
full O 0 1.0944738531780042e-17
- O 0 4.197312104408128e-15
length O 0 5.180549458358357e-18
ATM O 0 2.925305871560695e-14
protein O 0 2.039606844352125e-15
at O 0 1.902737506866434e-18
a O 0 1.6904626303290408e-21
level O 0 1.1170134547051567e-19
comparable O 0 4.480807909890429e-19
with O 0 8.499284929885422e-19
that O 0 6.837980516153719e-16
in O 0 2.4928634587030963e-17
unaffected O 0 6.96835852909139e-11
individuals O 0 3.187243102499267e-16
. O 0 1.3913004049629502e-14

In O 0 1.9374572384818777e-16
addition O 0 4.1886508194639964e-19
, O 0 3.5501320100584148e-19
we O 0 1.89491485981352e-18
have O 0 2.218007264378517e-20
studied O 0 7.043744009632e-17
18 O 0 6.761471807795183e-13
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 1.6852454761545621e-12
, O 0 1.7657410945863205e-20
in O 0 2.1718299975595204e-22
15 O 0 1.4808356639455933e-19
families O 0 1.9939988962833377e-18
, O 0 2.1137576675446518e-21
who O 0 2.7456984921193197e-17
developed O 0 2.38264404950686e-13
leukemia B-Disease 0 0.00019314943347126245
, O 0 2.829399492476625e-10
lymphoma B-Disease 1 0.9999998807907104
, O 0 1.3785793253479062e-13
preleukemic O 0 4.02470703875224e-07
T O 0 2.3626896563655464e-06
- O 0 1.0875026573708979e-10
cell O 0 8.294155640076184e-11
proliferation O 0 2.1730643595674337e-07
, O 0 2.527715179095197e-13
or O 0 3.565233726021688e-07
Hodgkin B-Disease 1 0.9999983310699463
lymphoma I-Disease 1 1.0
, O 0 5.387678497781323e-11
mostly O 0 1.0329292353091282e-14
in O 0 2.3709726978233484e-15
childhood O 0 7.599371201649774e-06
. O 0 1.2059375850345666e-12

A O 0 6.322078413079427e-14
wide O 0 6.406607282545193e-16
variety O 0 1.0784103365544694e-17
of O 0 5.448043512586667e-20
ATM O 0 1.871866550651191e-11
mutation O 0 9.687500232341203e-14
types O 0 6.564474170408369e-14
, O 0 6.52133445417944e-17
including O 0 6.175992255984778e-18
missense O 0 2.1639175098054492e-13
mutations O 0 1.1687902165199993e-12
and O 0 5.410248204301693e-12
in O 0 7.460596848593321e-16
- O 0 1.941518501524797e-09
frame O 0 1.6197578389665068e-08
deletions O 0 1.524263493202227e-10
, O 0 1.436155204091391e-14
were O 0 4.3896413112358207e-16
seen O 0 4.910563397423663e-15
in O 0 7.97793809601731e-21
these O 0 8.877502180755086e-17
patients O 0 8.225704041270246e-18
. O 0 1.8248905302587214e-16

We O 0 1.1863345253534073e-14
also O 0 8.498539433358359e-19
show O 0 5.724606528964777e-15
that O 0 1.2785547094136162e-17
25 O 0 5.7438036208156215e-18
% O 0 2.945102859832071e-21
of O 0 2.2663127138367314e-21
all O 0 1.3555773257373227e-12
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 1.0945893713990018e-12
carried O 0 1.4481307253062618e-15
in O 0 4.5187235427243867e-20
- O 0 1.67939409801603e-14
frame O 0 9.23602600649831e-12
deletions O 0 1.1574809687109333e-11
or O 0 5.954358100329626e-13
missense O 0 4.9416095266327856e-14
mutations O 0 3.954422103354463e-14
, O 0 1.0133636424363248e-15
many O 0 4.820667989254911e-18
of O 0 1.5413131391254239e-18
which O 0 2.1372594178389187e-13
were O 0 7.148917417244827e-15
also O 0 4.504963258817718e-16
associated O 0 2.031831366446461e-17
with O 0 4.337420390005001e-18
expression O 0 1.1247206287921243e-15
of O 0 1.8181407891930527e-19
mutant O 0 2.2025770421950364e-13
ATM O 0 9.64186196161787e-13
protein O 0 1.5738955277955213e-12
. O 0 6.505141884145457e-15

The O 0 5.911889748767439e-16
DMPK O 0 9.312998289212615e-11
gene O 0 2.5019190278557923e-13
of O 0 2.6396689128678312e-15
severely O 0 0.00029440983780659735
affected O 0 5.814041692531191e-09
myotonic B-Disease 1 0.999984860420227
dystrophy I-Disease 1 0.9999978542327881
patients O 0 1.958655026362832e-12
is O 0 1.8252236524350087e-17
hypermethylated O 0 2.1571451222501814e-11
proximal O 0 2.9284033531418174e-11
to O 0 2.4898355607621235e-14
the O 0 3.513920681546997e-16
largely O 0 2.0172381018195018e-14
expanded O 0 1.781191364649999e-14
CTG O 0 3.0851900589823344e-08
repeat O 0 9.104441645035877e-09
. O 0 1.555831960660392e-12

Using O 0 5.150462914246333e-17
methylation O 0 7.577860322745267e-14
- O 0 3.378183366722909e-12
sensitive O 0 3.711695013841609e-12
restriction O 0 5.678414010702737e-14
enzymes O 0 1.3261379062207927e-14
, O 0 1.9846873241278283e-18
we O 0 5.167895145949944e-19
characterized O 0 1.5634888109098563e-20
the O 0 3.360115286683194e-22
methylation O 0 3.331677466599176e-15
pattern O 0 4.215975832333463e-11
on O 0 2.188314498141261e-13
the O 0 9.24446199979627e-17
5 O 0 5.036990608688554e-17
side O 0 2.5480235478649417e-15
of O 0 1.3341534707556695e-20
the O 0 1.68165454572561e-17
CTG O 0 2.931799551394998e-12
repeat O 0 1.675018766267647e-13
in O 0 1.533558992966987e-19
the O 0 2.169764229898046e-18
DMPK O 0 2.9891127767411874e-11
gene O 0 7.09996674794829e-16
of O 0 6.133068613228482e-20
normal O 0 6.630651252493937e-18
individuals O 0 2.4253691654833433e-20
and O 0 2.4715856850112416e-18
of O 0 2.6981179572543177e-21
patients O 0 4.417621133861151e-19
affected O 0 2.7552763750730406e-18
with O 0 1.173023402587306e-14
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999994039535522
, O 0 1.1359226395195625e-15
showing O 0 1.0036836175662047e-16
expansions O 0 2.5517656666340173e-17
of O 0 6.83214916037645e-21
the O 0 4.997256160783957e-18
repetitive O 0 5.533591362905099e-10
sequence O 0 2.0719149052689234e-12
. O 0 1.1255849767868864e-12

The O 0 1.4356825967645146e-16
gene O 0 1.3377906020036411e-15
segment O 0 3.0103678000359922e-15
analyzed O 0 2.3860044621426785e-17
corresponds O 0 5.891756453899306e-18
to O 0 1.7633321895462013e-19
the O 0 1.6279697174698213e-18
genomic O 0 1.260919008094774e-10
SacI O 0 4.832720605918439e-07
- O 0 1.8751775687775307e-09
HindIII O 0 1.2140631833190696e-09
fragment O 0 7.850184044477793e-12
carrying O 0 1.5703263071386447e-13
exons O 0 8.251126865088665e-11
11 O 0 1.7186961218367686e-13
- O 0 2.665732634632434e-10
15 O 0 9.70369414703999e-15
. O 0 7.372866999268233e-15

There O 0 2.6673228445297896e-15
is O 0 1.125293816980148e-18
constitutive O 0 4.594917826943879e-17
methylation O 0 2.814858831524307e-15
in O 0 1.6887257819100808e-17
intron O 0 1.3444319268973715e-10
12 O 0 1.8536574896831515e-15
at O 0 1.9215860578943737e-18
restriction O 0 1.960075676525261e-19
sites O 0 9.45045353042582e-16
of O 0 2.035407599106773e-17
SacII O 0 1.589634313070576e-09
and O 0 1.198480063021451e-13
HhaI O 0 2.683390619082071e-12
, O 0 1.0237395348579116e-19
localized O 0 1.4170353318668337e-17
1 O 0 3.0788008781105197e-19
, O 0 1.9673042011032088e-19
159 O 0 1.6411771241948177e-17
- O 0 4.709615418599421e-15
1 O 0 2.3622197418286017e-19
, O 0 2.932458992194479e-20
232 O 0 4.2763345493340316e-19
bp O 0 5.837995504347647e-18
upstream O 0 9.225042859581792e-19
of O 0 1.7900127871129998e-21
the O 0 5.353445922813578e-18
CTG O 0 2.407018811698136e-12
repeat O 0 8.500417383872083e-12
, O 0 1.190595069314361e-16
whereas O 0 3.214041041193576e-17
most O 0 2.4980585665402356e-19
, O 0 8.0911633214336495e-19
if O 0 1.4742715649568484e-16
not O 0 5.612148505656665e-15
all O 0 1.1138201617939087e-15
, O 0 1.7271380643235733e-17
of O 0 1.408027858527142e-22
the O 0 4.528056143362031e-21
other O 0 4.9081537127658166e-20
sites O 0 1.1712834063312325e-15
of O 0 4.828726796372709e-19
SacII O 0 2.6314692612439128e-12
, O 0 8.379238792525015e-19
HhaI O 0 3.47385531798694e-13
, O 0 6.634724703420454e-18
and O 0 1.524137532762232e-15
HpaII O 0 2.784679496541098e-13
in O 0 5.37773340285773e-21
this O 0 5.275650510318807e-21
region O 0 7.766223408970516e-18
are O 0 5.344526124075689e-19
unmethylated O 0 5.962290665524617e-13
, O 0 4.4097458367622485e-17
in O 0 1.663253545937971e-19
normal O 0 7.38068180464894e-17
individuals O 0 1.3040050509488874e-18
and O 0 1.2976249613893322e-16
most O 0 2.7484080747271626e-20
of O 0 1.3245431506897092e-21
the O 0 1.0002665013685236e-16
patients O 0 2.305943966759386e-17
. O 0 1.0393352343161382e-16

In O 0 1.767050852368237e-17
a O 0 4.920116295386982e-19
number O 0 1.2434077638272074e-18
of O 0 1.3010747677648214e-16
young O 0 9.836178094246861e-09
and O 0 5.533000169144486e-10
severely O 0 1.9714675545401406e-06
affected O 0 1.8804654471890397e-15
patients O 0 5.62643444671259e-19
, O 0 2.205721128122047e-21
however O 0 3.5009636189664385e-19
, O 0 5.930849045191479e-21
complete O 0 1.1948148157917553e-20
methylation O 0 4.511225479275887e-15
of O 0 2.772564979787979e-20
these O 0 2.3595179631528503e-19
restriction O 0 9.571279402869807e-21
sites O 0 1.3484006161102873e-16
was O 0 3.3178548206362277e-14
found O 0 4.018888769824407e-17
in O 0 2.825132792391864e-22
the O 0 1.520956540905572e-20
mutated O 0 3.867853642079179e-14
allele O 0 8.24272334415399e-12
. O 0 1.1541690997027287e-12

In O 0 1.4611645241914762e-16
most O 0 2.2955151217505012e-19
of O 0 6.855406748859185e-22
these O 0 1.7044582815319872e-18
patients O 0 3.165064119148951e-20
, O 0 3.9540840789232946e-21
the O 0 1.52445499144644e-18
onset O 0 4.31816778515004e-12
of O 0 1.1924261824927573e-17
the O 0 1.1563511433110296e-11
disease O 0 1.5267257822415559e-06
was O 0 1.4317834029498044e-08
congenital O 1 0.9914244413375854
. O 0 4.447366364068728e-10

Preliminary O 0 1.066514064562707e-12
in O 0 1.7114584455310469e-15
vivo O 0 2.528682124802728e-11
footprinting O 0 2.4085564653830716e-09
data O 0 7.889224107265967e-16
gave O 0 5.71632468086661e-19
evidence O 0 1.9850856439045152e-21
for O 0 5.31308627060753e-24
protein O 0 5.300222136596893e-20
- O 0 1.6017786108805905e-16
DNA O 0 1.0952405025662151e-13
contact O 0 2.6860546772922156e-11
in O 0 2.6635666537641333e-18
normal O 0 1.2170027111084428e-17
genes O 0 8.756116238277012e-18
at O 0 6.730831096480234e-18
an O 0 1.3319660667505748e-21
Sp1 O 0 4.70772563727212e-13
consensus O 0 1.0153388048790967e-19
binding O 0 1.5093694918201573e-18
site O 0 7.311524343832484e-16
upstream O 0 3.448034594321736e-15
of O 0 4.513520705918399e-20
the O 0 4.25680584904742e-18
CTG O 0 7.445791623235734e-14
repeat O 0 2.905781423313304e-14
and O 0 1.0095499493832062e-18
for O 0 7.412256183453315e-24
a O 0 8.067383865994925e-23
significant O 0 1.0144972122195674e-22
reduction O 0 4.0810206630980107e-19
of O 0 3.1869383008793172e-24
this O 0 3.719391762328772e-23
interaction O 0 4.031010260303592e-21
in O 0 2.086360137031317e-21
cells O 0 5.188124364817811e-18
with O 0 3.0205893866705957e-18
a O 0 4.669200631184611e-17
hypermethylated O 0 1.2494519863182063e-09
DMPK O 0 1.9682890040062517e-10
gene O 0 9.11859428026282e-15
. O 0 2.2181896328881664e-16
. O 0 1.3887278811988441e-15

The O 0 2.5559456352623744e-13
hemochromatosis B-Disease 1 0.9999202489852905
gene O 0 2.9019989129840454e-14
product O 0 4.907655956832213e-17
complexes O 0 2.1942857923620274e-18
with O 0 9.338511263173525e-21
the O 0 3.027737314453195e-21
transferrin O 0 2.611644404291449e-15
receptor O 0 1.7036464657993124e-17
and O 0 3.021592511246417e-14
lowers O 0 4.0641613880711136e-13
its O 0 1.7531079302134904e-22
affinity O 0 1.7393058935979987e-22
for O 0 3.47569649650049e-25
ligand O 0 2.1512513655647867e-20
binding O 0 1.0965770062075345e-15
. O 0 6.880398655602794e-15

We O 0 5.607256412659689e-12
recently O 0 6.60617131541274e-15
reported O 0 1.9722065004451893e-16
the O 0 7.965921964760591e-22
positional O 0 1.8509856301301563e-16
cloning O 0 9.592101791403972e-16
of O 0 9.001917214369242e-22
a O 0 1.4355428725173695e-20
candidate O 0 7.083187289960979e-18
gene O 0 3.324091219295e-12
for O 0 1.1356303050713557e-11
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
called O 0 6.057682639948325e-07
HFE O 0 0.00010648612078512087
. O 0 1.2516356007186147e-11

The O 0 5.104831992063213e-16
gene O 0 5.177850996676862e-15
product O 0 1.4608546848333265e-13
, O 0 2.4523246603708525e-17
a O 0 8.565030795934785e-19
member O 0 1.546602131962088e-18
of O 0 1.9035125492510022e-20
the O 0 1.5138961343247772e-18
major O 0 5.842518114346781e-18
histocompatibility O 0 9.889794697090048e-16
complex O 0 1.2731529884030734e-16
class O 0 1.7166819388980865e-16
I O 0 1.471522209639531e-11
- O 0 4.900503614013729e-12
like O 0 2.761837660696445e-14
family O 0 9.618975537958874e-13
, O 0 2.36551140367868e-19
was O 0 9.017331603915132e-18
found O 0 1.1062388843893765e-18
to O 0 1.2787833834939565e-18
have O 0 5.6741579083708005e-18
a O 0 3.712154590825561e-20
mutation O 0 1.3036625361367445e-17
, O 0 2.724509268112039e-16
Cys O 0 3.957667527032527e-10
- O 0 1.5248077052300996e-13
282 O 0 8.953220245267249e-14
- O 0 1.808120181356898e-10
- O 0 4.775461137640491e-10
> O 0 4.493621170016627e-15
Tyr O 0 6.982543205745137e-14
( O 0 5.955359198379121e-20
C282Y O 0 2.3423556301433578e-17
) O 0 3.10639310302936e-20
, O 0 8.787423182692811e-21
in O 0 2.965407599320512e-20
85 O 0 3.1236040613341734e-17
% O 0 1.8486745136065712e-20
of O 0 1.009938010181593e-20
patient O 0 2.7800169782719484e-15
chromosomes O 0 1.7697555920737074e-10
. O 0 9.205454324159867e-13

This O 0 6.788391501652308e-16
mutation O 0 5.825546174739651e-15
eliminates O 0 4.458692096087624e-12
the O 0 2.8329779250572604e-15
ability O 0 1.5062586323621313e-13
of O 0 4.731737801599335e-19
HFE O 0 3.5050252630841605e-12
to O 0 1.580527745374062e-17
associate O 0 4.1995364129276177e-16
with O 0 9.99126818537993e-16
beta2 O 0 5.534863021239289e-07
- O 0 4.944033094034239e-07
microglobulin O 0 2.6340913450439984e-07
( O 0 5.120646361886247e-17
beta2m O 0 3.2848519043726654e-11
) O 0 9.702420785205026e-18
and O 0 9.139230729245234e-18
prevents O 0 1.71954596905099e-16
cell O 0 5.130592131696865e-12
- O 0 5.4564970319859185e-09
surface O 0 1.7824057785276182e-09
expression O 0 4.36398417402728e-10
. O 0 1.3999878730255877e-12

A O 0 1.2353453763408462e-13
second O 0 1.0959163205086762e-15
mutation O 0 2.8913338364418718e-15
that O 0 1.7706173441496553e-13
has O 0 8.458658252996631e-12
no O 0 2.6695024297096644e-14
effect O 0 1.1983743363689747e-14
on O 0 2.558607770097865e-10
beta2m O 0 4.940465601066535e-07
association O 0 2.9417963801399183e-17
, O 0 7.59201488096742e-20
H63D O 0 4.4939707337376955e-12
, O 0 6.38524858163811e-19
was O 0 9.523919874314737e-16
found O 0 2.3019724410279475e-16
in O 0 5.393476087787163e-19
eight O 0 1.8485089852017235e-16
out O 0 1.1286909856180957e-13
of O 0 4.262735183075777e-19
nine O 0 1.3243755059432643e-15
patients O 0 4.0176718113674613e-20
heterozygous O 0 2.2067406443828898e-20
for O 0 2.4743460125647252e-21
the O 0 2.3415437027413e-16
C282Y O 0 2.953409392048023e-11
mutant O 0 1.3204698445790086e-09
. O 0 1.1696694827978416e-11

In O 0 1.0543586606548937e-15
this O 0 6.5531270583048545e-18
report O 0 6.85654840479982e-17
, O 0 3.5627764996970535e-19
we O 0 1.692434032596156e-17
demonstrate O 0 2.7472865341388143e-20
in O 0 3.586194807292739e-23
cultured O 0 6.3494277940452e-17
293 O 0 8.506916663652959e-17
cells O 0 4.8411973712875586e-18
overexpressing O 0 3.0719589198813235e-13
wild O 0 5.261640596962089e-14
- O 0 4.224423477694472e-09
type O 0 3.0606642220654123e-10
or O 0 1.393554716067058e-11
mutant O 0 4.839421398339372e-12
HFE O 0 1.5350591078214931e-13
proteins O 0 5.63967704997265e-17
that O 0 3.6421466766700186e-20
both O 0 9.497623775693683e-22
the O 0 6.990997726348608e-20
wild O 0 5.761766118470707e-14
- O 0 4.865438540946343e-08
type O 0 1.1550555650829963e-10
and O 0 2.9587769734273905e-11
H63D O 0 3.9279046681883756e-09
HFE O 0 4.107353693272309e-11
proteins O 0 7.187695263196486e-14
form O 0 7.805789773774642e-17
stable O 0 1.5111528564940024e-14
complexes O 0 4.0646027409410276e-17
with O 0 1.1129684122628017e-19
the O 0 9.81685543268745e-20
transferrin O 0 9.976501097680793e-14
receptor O 0 1.4077851696000002e-16
( O 0 2.3338989905099525e-18
TfR O 0 1.8579197208490328e-11
) O 0 2.9343113882130485e-16
. O 0 5.36062673065071e-15

The O 0 1.814843475424644e-14
C282Y O 0 5.254247384400834e-11
mutation O 0 4.2334694777546034e-11
nearly O 0 1.2399095639104019e-11
completely O 0 8.48982939505305e-10
prevents O 0 3.675234075406486e-11
the O 0 2.734766995921966e-15
association O 0 1.4199511642055984e-18
of O 0 2.7170487509569984e-22
the O 0 5.216739127145435e-19
mutant O 0 1.9115637620980425e-13
HFE O 0 1.5481089717453433e-12
protein O 0 7.640933445316432e-15
with O 0 3.754540953924609e-18
the O 0 6.159880878691001e-16
TfR O 0 6.220981507709666e-09
. O 0 8.441049915248675e-14

Studies O 0 2.0288847370816127e-13
on O 0 1.1351565405704183e-14
cell O 0 2.3690053824881874e-12
- O 0 3.0570235232119103e-10
associated O 0 4.285000089129798e-14
transferrin O 0 1.5824208263182094e-11
at O 0 3.980687239796103e-15
37 O 0 2.2343155851043367e-17
degrees O 0 1.0047994405374024e-14
C O 0 1.5953543824540062e-12
suggest O 0 3.843298674422468e-18
that O 0 4.283385165456795e-20
the O 0 6.457309196182491e-20
overexpressed O 0 4.0722313758914663e-13
wild O 0 2.043689924322717e-13
- O 0 7.540212898504706e-11
type O 0 5.580066031636577e-14
HFE O 0 4.154880432760688e-12
protein O 0 5.750410964186405e-15
decreases O 0 1.705363196442605e-17
the O 0 1.7551288025260494e-22
affinity O 0 4.977127961348398e-18
of O 0 5.92020272987591e-21
the O 0 9.872896919187917e-18
TfR O 0 6.186524274635896e-13
for O 0 9.213467242390936e-20
transferrin O 0 1.9767645853541183e-11
. O 0 1.0759341991840605e-14

The O 0 2.5834550631035312e-14
overexpressed O 0 6.16895368121817e-10
H63D O 0 1.0548371065510764e-08
protein O 0 2.838699327684102e-12
does O 0 4.000797072513341e-15
not O 0 1.3096989693749115e-17
have O 0 3.1679904902857076e-18
this O 0 6.7594590484612185e-21
effect O 0 8.58996874043961e-18
, O 0 3.704955405309965e-19
providing O 0 2.256779740004806e-21
the O 0 1.952342741410305e-21
first O 0 6.485816453303257e-22
direct O 0 6.530827720595465e-22
evidence O 0 3.6820495747364834e-17
for O 0 4.002053930544121e-20
a O 0 4.20023703490645e-18
functional O 0 1.0687952784496592e-15
consequence O 0 1.3820585555304006e-15
of O 0 3.897910275836561e-20
the O 0 5.050017843068427e-16
H63D O 0 1.3796592668313679e-07
mutation O 0 1.6552326187208727e-13
. O 0 3.795338880414195e-13

Addition O 0 9.417560064710383e-16
of O 0 4.0077699424473187e-19
soluble O 0 1.320289524884828e-15
wild O 0 3.049087946103285e-13
- O 0 5.18035903951386e-07
type O 0 2.2781494468659957e-09
HFE O 0 7.106624707375886e-06
/ O 0 4.016912580340204e-09
beta2m O 0 9.570155432014893e-12
heterodimers O 0 2.532525174270793e-14
to O 0 1.141398196325943e-18
cultured O 0 7.050440731522331e-16
cells O 0 1.3511501644664135e-16
also O 0 4.798949336568372e-16
decreased O 0 2.8552829495364263e-16
the O 0 2.1073581249589113e-20
apparent O 0 7.240083996874281e-16
affinity O 0 9.877126260572676e-16
of O 0 3.3964084419041333e-20
the O 0 1.6716569513290797e-18
TfR O 0 2.487698284877964e-15
for O 0 1.242635786009484e-24
its O 0 6.543090421372162e-24
ligand O 0 1.1770264138488697e-21
under O 0 2.981356417012359e-19
steady O 0 5.10306484840118e-14
- O 0 5.564042065628327e-13
state O 0 7.489339852867212e-16
conditions O 0 7.055883384076561e-14
, O 0 4.1939066798397186e-21
both O 0 3.9007919683150267e-22
in O 0 7.747773273038904e-22
293 O 0 2.5728673335734595e-18
cells O 0 7.908949391161054e-19
and O 0 2.9152213831643047e-16
in O 0 1.3875979590995416e-18
HeLa O 0 4.900321259881935e-10
cells O 0 3.479126980000108e-13
. O 0 7.86901942803446e-14

Furthermore O 0 4.4141640754939704e-13
, O 0 8.751446472846905e-17
at O 0 2.2896155538164873e-16
4 O 0 9.021469459124143e-16
degrees O 0 1.9803950146446425e-11
C O 0 4.7984379136778443e-08
, O 0 9.17267055768143e-15
the O 0 9.274950421337097e-16
added O 0 2.630122953196229e-13
soluble O 0 8.305987213674438e-17
complex O 0 2.493032151849269e-19
of O 0 1.9395765899825485e-19
HFE O 0 2.646058705479959e-09
/ O 0 2.1208102548436747e-12
beta2m O 0 1.6802920545840733e-13
inhibited O 0 2.886636337300187e-17
binding O 0 4.760887646385704e-19
of O 0 7.1991092800784e-22
transferrin O 0 1.2230495072653239e-15
to O 0 1.2121325818544603e-18
HeLa O 0 2.560992650585403e-12
cell O 0 3.4617330703368143e-12
TfR O 0 1.206661298658318e-10
in O 0 5.136526906158285e-19
a O 0 2.6765749787952034e-17
concentration O 0 1.30857741309498e-10
- O 0 3.8316927408743595e-09
dependent O 0 3.0184214502848583e-12
manner O 0 6.494443871574163e-11
. O 0 7.086421835618417e-13

Scatchard O 0 1.1728122473186886e-08
plots O 0 3.320007602169994e-10
of O 0 2.6153603047438292e-17
these O 0 8.093574346124088e-18
data O 0 1.1333423918737686e-16
indicate O 0 5.184706669593702e-16
that O 0 4.7749341658035894e-17
the O 0 2.741607422245755e-16
added O 0 3.8952931049988926e-13
heterodimer O 0 4.637767119397996e-15
substantially O 0 1.7488259392738808e-15
reduced O 0 9.91384029155776e-19
the O 0 1.9370616701147032e-20
affinity O 0 1.9650056880721233e-15
of O 0 1.9242853550282874e-18
TfR O 0 1.001933670578825e-12
for O 0 1.297251845030428e-19
transferrin O 0 2.1410848788372405e-11
. O 0 1.3116707528882787e-14

These O 0 4.050479298755433e-13
results O 0 2.0465411192794916e-17
establish O 0 8.265080113174455e-19
a O 0 8.957326242069916e-20
molecular O 0 6.4801908213832975e-18
link O 0 7.064244615705498e-14
between O 0 5.799982889798105e-14
HFE O 0 2.2585687986520497e-08
and O 0 3.6236499776276174e-14
a O 0 5.488636754912854e-20
key O 0 6.262780294008025e-17
protein O 0 8.011619772574172e-18
involved O 0 4.714313306619391e-20
in O 0 4.428045160542968e-20
iron O 0 3.4659614588095078e-12
transport O 0 5.670850509409569e-17
, O 0 1.5827101942118585e-19
the O 0 1.2175267300264952e-18
TfR O 0 2.8003202187654175e-11
, O 0 2.9693046022826143e-18
and O 0 5.048436141388328e-17
raise O 0 6.09791550514651e-19
the O 0 1.8196099395091293e-21
possibility O 0 1.522146420829684e-20
that O 0 5.518809460225432e-19
alterations O 0 2.9048736845735114e-17
in O 0 7.998598224285528e-21
this O 0 2.9147914159743694e-21
regulatory O 0 1.0037295426338136e-16
mechanism O 0 1.4411369233385818e-12
may O 0 4.4826680345097514e-13
play O 0 9.715976621083545e-18
a O 0 4.89619937771697e-22
role O 0 3.2900809011324625e-19
in O 0 5.513561164836465e-22
the O 0 4.940426035117602e-20
pathogenesis O 0 1.4518278072805924e-12
of O 0 1.3718218659013008e-14
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
. O 0 1.9782715465765932e-09
. O 0 1.0271616185646842e-13

Genomic O 0 2.518908909579509e-12
organization O 0 7.057521291686667e-15
of O 0 1.8334853255980352e-18
the O 0 5.5818035238515e-17
UBE3A O 0 1.3248500962959042e-08
/ O 0 8.88316503688813e-12
E6 O 0 2.526303166661137e-09
- O 0 1.0780943249244501e-08
AP O 0 1.7071453625727706e-11
gene O 0 2.644939257744766e-16
and O 0 3.743002528842046e-17
related O 0 4.7466214277971244e-17
pseudogenes O 0 1.321762388125161e-13
. O 0 2.9324439452621488e-15

The O 0 7.519315607716712e-15
UBE3A O 0 6.812196640115786e-11
gene O 0 5.633702423669853e-16
encodes O 0 8.438433388122959e-16
the O 0 3.036937991092247e-18
E6 O 0 8.384480609802125e-12
- O 0 1.3608965516997973e-11
AP O 0 1.1129039177845343e-13
ubiquitin O 0 2.7838256619192774e-16
- O 0 1.695802841446064e-15
protein O 0 2.1978389053242183e-17
ligase O 0 2.156479088874985e-18
and O 0 9.168139037292738e-19
has O 0 2.5517217310650285e-21
recently O 0 7.559525060197734e-22
been O 0 2.391566256075747e-22
shown O 0 2.9203769550801176e-22
to O 0 9.290994851325375e-23
be O 0 5.519585588284554e-20
mutated O 0 3.295696354710387e-11
in O 0 1.3471630755379493e-10
Angelman B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
patients O 0 1.2593451401057137e-13
who O 0 3.8531232309066583e-16
lack O 0 2.9986739808035546e-17
15q11 O 0 1.868874182470691e-14
- O 0 5.4082671500921276e-12
q13 O 0 2.8491466998181725e-12
deletions O 0 2.33539576566244e-10
or O 0 2.0900520203426254e-10
chromosome O 0 3.415992523514433e-06
15 O 0 4.379815086996697e-12
paternal O 0 1.3694554468202114e-07
uniparental B-Disease 0 0.00016299744311254472
disomy I-Disease 0 1.5676894690841436e-05
. O 0 8.643244106543158e-12

Previous O 0 1.1451168518191585e-13
UBE3A O 0 5.94571683554257e-11
cDNA O 0 1.3270241567935048e-13
analysis O 0 6.0425128171458925e-16
has O 0 1.39235941750055e-18
shown O 0 5.336703063432469e-19
a O 0 1.0031838866096414e-20
coding O 0 5.6858569935647196e-11
region O 0 5.85748409411696e-13
of O 0 7.792011591747469e-18
approximately O 0 6.881602712937316e-16
2 O 0 8.14000102267393e-15
. O 0 2.6126221344224647e-14

6 O 0 2.763290984919564e-11
kb O 0 1.43847245226425e-09
and O 0 1.289334409365888e-14
a O 0 6.772923621244261e-16
3 O 0 1.1558609971928924e-12
- O 0 0.003565477440133691
untranslated O 1 0.9979575872421265
region O 0 6.960650011933467e-08
( O 0 1.3975864958683644e-16
UTR O 0 3.9221638090114475e-12
) O 0 5.450436261755448e-19
of O 0 4.929617191736364e-21
< O 0 3.5117747765146877e-17
50 O 0 3.1175299913781353e-19
bp O 0 2.459710198718314e-15
, O 0 2.0802588156746218e-19
whereas O 0 1.592406741394329e-18
Northern O 0 9.892194008903014e-19
analysis O 0 5.2303937077095774e-17
has O 0 5.771615798746206e-16
indicated O 0 1.6343609905112582e-17
mRNA O 0 5.191175420507213e-17
sizes O 0 1.372910811458291e-14
of O 0 1.531712260550674e-18
5 O 0 3.3137565364242325e-14
- O 0 1.6696132476567982e-08
8 O 0 3.1751871097662754e-12
kb O 0 3.8856544648524505e-09
. O 0 1.7287952617855637e-14

We O 0 6.181304671267667e-15
have O 0 2.501385125072406e-20
analyzed O 0 3.2109358077589914e-20
additional O 0 2.6766600823516413e-22
cDNA O 0 1.174912624872862e-15
clones O 0 2.9077596233606506e-11
and O 0 1.7189950005885808e-16
provide O 0 4.924857053572966e-23
evidence O 0 5.114617859868243e-23
for O 0 2.883311753524152e-25
an O 0 2.2966315792978295e-23
additional O 0 3.044731376630992e-19
0 O 0 5.613341604502432e-17
. O 0 2.7557549476956225e-14

5 O 0 1.0373812052433262e-11
kb O 0 6.022625731461062e-10
of O 0 1.8510483965950368e-17
5 O 0 2.528455180959236e-15
- O 0 4.0234184039977805e-11
UTR O 0 9.661335065302978e-10
and O 0 9.144445725813022e-14
> O 0 8.857278475046001e-16
2 O 0 6.690617297410662e-17
kb O 0 2.282909104811548e-12
of O 0 4.890065857708696e-19
3 O 0 3.3006091451268354e-15
- O 0 1.2103315016886995e-09
UTR O 0 9.79357324126795e-08
. O 0 3.326867318957649e-13

We O 0 4.1638822381381835e-13
have O 0 6.510462659122412e-20
established O 0 1.247258611888275e-21
the O 0 4.329080330977618e-22
genomic O 0 1.6106077382156345e-16
organization O 0 3.673335806009666e-18
of O 0 2.5669238405394614e-20
UBE3A O 0 2.600816480582968e-12
and O 0 7.377272331600119e-18
the O 0 9.223163794420168e-22
sequence O 0 1.0979148624876788e-18
of O 0 7.506371314530065e-20
intron O 0 2.8087304704271787e-10
- O 0 8.551668817524671e-10
exon O 0 1.2079047484458982e-10
borders O 0 8.718394006734798e-09
. O 0 1.0804565575561753e-10

We O 0 9.39106323087635e-13
have O 0 2.8852806296352434e-18
also O 0 5.956358923697574e-20
mapped O 0 2.098002778043494e-15
two O 0 6.168501928742957e-19
highly O 0 1.1710392700738945e-20
homologous O 0 3.438073645680703e-18
processed O 0 1.3727778603727965e-17
pseudogenes O 0 6.494380754067065e-15
, O 0 2.4773436892552233e-18
UBE3AP1 O 0 5.295373514679902e-12
and O 0 2.1224652483788759e-16
UBE3AP2 O 0 1.675358311283015e-12
, O 0 4.3743207491099293e-20
to O 0 2.3642843329387457e-19
chromosomes O 0 6.996354586169887e-14
2 O 0 1.3693056539463194e-16
and O 0 5.4364546447482204e-14
21 O 0 4.231408145150429e-16
, O 0 2.8254833295634788e-18
respectively O 0 5.2057136160812e-16
, O 0 3.046523732261787e-17
and O 0 2.6542798076914943e-15
determined O 0 8.580577692770847e-16
their O 0 3.56843797196355e-17
genomic O 0 3.421451693469933e-14
organization O 0 3.652033797580225e-15
. O 0 2.6949680941040386e-15

These O 0 2.738342885777456e-11
results O 0 1.2513567554394995e-14
will O 0 2.553091240109246e-16
form O 0 3.5976399168500475e-21
the O 0 1.885754661710108e-20
basis O 0 1.9526572881473382e-19
for O 0 1.1382273416193887e-20
studies O 0 1.6564792210644974e-18
of O 0 6.623555732540425e-23
mutation O 0 5.571629078240006e-19
and O 0 8.355053582377613e-17
imprinting O 0 2.328714721056002e-10
of O 0 1.9409488671091375e-16
UBE3A O 0 3.092472056209772e-08
. O 0 3.8175330409860597e-13

Mutation O 0 1.1375781230633236e-13
spectrum O 0 3.477063743265868e-13
and O 0 7.466725534307356e-14
genotype O 0 1.9621202440589514e-09
- O 0 1.7734667068225463e-09
phenotype O 0 5.566040250232218e-12
analyses O 0 9.700115060143344e-13
in O 0 1.9772987566449638e-16
Cowden B-Disease 0 2.314947596460115e-05
disease I-Disease 0 3.028132596227806e-06
and O 0 8.803438533711017e-11
Bannayan B-Disease 1 0.9297478199005127
- I-Disease 1 0.9998165965080261
Zonana I-Disease 1 0.9995489716529846
syndrome I-Disease 1 0.9999772310256958
, O 0 4.540331119530321e-16
two O 0 5.170229288338349e-16
hamartoma B-Disease 0 3.721567964021233e-06
syndromes I-Disease 0 1.8049972538847214e-07
with O 0 1.8680320623145306e-15
germline O 0 8.3133985806505e-11
PTEN O 0 1.0324400001593403e-08
mutation O 0 9.733335665229603e-11
. O 0 1.761574393299714e-11

The O 0 5.699643881862393e-12
tumour B-Disease 1 0.9999372959136963
suppressor O 0 7.749775043919271e-09
gene O 0 2.7541445686563026e-12
PTEN O 0 3.6761101107618543e-11
, O 0 3.364536296608004e-17
which O 0 8.299581299536159e-19
maps O 0 2.0031134886108574e-14
to O 0 2.4006263556891616e-13
10q23 O 0 1.5381571571992936e-09
. O 0 1.2694746512678656e-12

3 O 0 7.623493883965413e-15
and O 0 5.525908737832669e-19
encodes O 0 7.662140926854193e-18
a O 0 7.847576854859653e-20
403 O 0 2.046143079968731e-17
amino O 0 4.387680297614029e-17
acid O 0 4.0132814778880325e-17
dual O 0 3.466468440003933e-17
specificity O 0 3.106663418270955e-14
phosphatase O 0 5.5632680684425395e-09
( O 0 4.8528833653914015e-18
protein O 0 8.360418477307285e-15
tyrosine O 0 3.6351778249892053e-13
phosphatase O 0 5.874914443815271e-10
; O 0 8.157621849075661e-16
PTPase O 0 1.043470865269569e-12
) O 0 1.786897686318436e-18
, O 0 6.682266779879969e-20
was O 0 8.387498252979903e-17
shown O 0 6.112061104258167e-16
recently O 0 1.367260360546276e-15
to O 0 4.91213199656286e-17
play O 0 6.799457987108186e-16
a O 0 1.1628983782049978e-18
broad O 0 1.8812957446181408e-17
role O 0 2.9078383581224165e-14
in O 0 7.535071426387267e-17
human O 0 1.90397784344265e-12
malignancy B-Disease 0 1.6906162727536866e-06
. O 0 2.4329580776243087e-13

Somatic O 0 6.839194575253282e-12
PTEN O 0 3.060022235601423e-10
deletions O 0 3.697966932669772e-11
and O 0 1.1122360627988104e-12
mutations O 0 7.60188776754685e-15
were O 0 2.1668878912976277e-16
observed O 0 8.873777882765127e-17
in O 0 3.965598723855717e-19
sporadic B-Disease 0 4.0839981396700864e-10
breast I-Disease 0 0.01621658354997635
, I-Disease 0 3.3260050269490193e-09
brain I-Disease 0 8.754732334637083e-06
, I-Disease 0 3.8690530813900725e-12
prostate I-Disease 0 0.0004911424475722015
and I-Disease 0 2.753786975517869e-05
kidney I-Disease 0 0.00021680766076315194
cancer I-Disease 0 2.4622583083555583e-08
cell O 0 2.6452626755713027e-08
lines O 0 8.58522497537706e-09
and O 0 2.496160830117722e-13
in O 0 1.9575582815779266e-18
several O 0 1.1782069477629708e-15
primary O 0 2.9067921403225228e-09
tumours B-Disease 1 0.9999983310699463
such O 0 6.229015360430039e-18
as O 0 1.5140783388872293e-14
endometrial B-Disease 0 0.0022519524209201336
carcinomas I-Disease 1 0.9999998807907104
, O 0 0.0064156013540923595
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9995730519294739
thyroid B-Disease 1 0.9999549388885498
tumours I-Disease 1 0.9999969005584717
. O 0 4.575052514610434e-08

In O 0 4.560208124066182e-15
addition O 0 1.7101261685841342e-16
, O 0 1.5935196095109425e-17
PTEN O 0 1.3232911131883657e-13
was O 0 4.442604693240856e-16
identified O 0 6.207734071220581e-19
as O 0 1.0141267429436364e-20
the O 0 4.6069311267225865e-21
susceptibility O 0 2.7347342792743783e-16
gene O 0 2.0557280518603016e-16
for O 0 1.4120062391786338e-17
two O 0 7.429783351053931e-12
hamartoma B-Disease 1 0.8394702672958374
syndromes I-Disease 1 0.9760646224021912
Cowden B-Disease 1 0.9624422192573547
disease I-Disease 1 0.8895153999328613
( O 0 2.5703809401560716e-14
CD B-Disease 0 6.066255764380912e-08
; O 0 4.9739499221853126e-14
MIM O 0 1.427969964495901e-09
158350 O 0 5.148492309564601e-12
) O 0 2.3948509271833616e-16
and O 0 2.567041089245048e-13
Bannayan B-Disease 0 1.5702847804277553e-06
- I-Disease 0 5.738090294471476e-06
Zonana I-Disease 0 1.0105994761033799e-06
( I-Disease 0 2.5757178724105723e-16
BZS I-Disease 0 1.3028612043386456e-11
) I-Disease 0 8.900216064067424e-18
or I-Disease 0 2.070114430013383e-15
Ruvalcaba I-Disease 0 1.88052595717636e-08
- I-Disease 0 2.622256261020084e-06
Riley I-Disease 0 3.7986352253938094e-05
- I-Disease 1 0.9978805780410767
Smith I-Disease 0 0.011079837568104267
syndrome I-Disease 1 0.9990094900131226
( O 0 2.67177140862921e-16
MIM O 0 1.87791915351454e-09
153480 O 0 7.759144021735054e-11
) O 0 2.5757977582054102e-15
. O 0 1.7626171179628385e-14

Constitutive O 0 4.971343974501108e-13
DNA O 0 1.6739966346695362e-13
from O 0 8.617349510593524e-16
37 O 0 1.3518255408929508e-16
CD B-Disease 0 4.105550101274336e-12
families O 0 6.140742889225795e-14
and O 0 5.467124924262822e-16
seven O 0 5.892658659793418e-17
BZS B-Disease 0 1.3362573851247173e-12
families O 0 1.5512286565256736e-18
was O 0 6.153295764144818e-19
screened O 0 9.027184813935741e-16
for O 0 8.038340084503896e-19
germline O 0 7.7924770585866e-13
PTEN O 0 1.25473159640066e-10
mutations O 0 4.948943164995168e-12
. O 0 5.657184790064385e-13

PTEN O 0 1.1572084401834104e-09
mutations O 0 3.819295682667978e-13
were O 0 3.2870500534654254e-16
identified O 0 3.6236651818690206e-17
in O 0 6.178275067680271e-19
30 O 0 9.101556291938139e-17
of O 0 2.015664824477633e-18
37 O 0 7.618953893247249e-16
( O 0 1.741520212275002e-18
81 O 0 9.849100904963347e-15
% O 0 5.077248661920897e-18
) O 0 3.9657801866025957e-19
CD B-Disease 0 1.654174852649959e-10
families O 0 1.67128504503615e-13
, O 0 1.9317203128678554e-19
including O 0 9.292745395520755e-20
missense O 0 8.622821423900917e-13
and O 0 4.7547726172991744e-11
nonsense O 0 2.1071848710363383e-09
point O 0 7.377536691906446e-15
mutations O 0 2.7809266254828505e-17
, O 0 2.2553449047594534e-19
deletions O 0 8.719260279642425e-16
, O 0 1.0855341814258986e-17
insertions O 0 1.17113556265952e-12
, O 0 8.4732338691098e-17
a O 0 1.3732072498287728e-17
deletion O 0 3.753265406802875e-11
/ O 0 5.047176454553437e-09
insertion O 0 4.850948115420195e-11
and O 0 1.1150042694696438e-11
splice O 0 1.2057702747370058e-07
site O 0 2.499717967341386e-11
mutations O 0 3.1033751957121325e-11
. O 0 8.911381832107934e-13

These O 0 6.1246445198434585e-15
mutations O 0 5.3295122458827445e-15
were O 0 3.705372732818249e-15
scattered O 0 7.144010555381382e-15
over O 0 3.5055544841874073e-15
the O 0 2.1326028033894114e-15
entire O 0 2.2634318193586606e-13
length O 0 1.3931015358219917e-13
of O 0 2.3009341887384893e-18
PTEN O 0 1.3784401408940133e-13
, O 0 9.960960635151844e-19
with O 0 5.1850918431440095e-20
the O 0 9.329192136532578e-19
exception O 0 1.2143176001220344e-17
of O 0 4.416051687895803e-20
the O 0 6.225054770026299e-16
first O 0 7.379665455109485e-14
, O 0 1.5636970884802537e-13
fourth O 0 4.39216046345392e-13
and O 0 5.974608286406224e-13
last O 0 1.1022573912639055e-12
exons O 0 4.444112189361249e-09
. O 0 1.062764026088514e-11

A O 0 1.4065846740390214e-13
hot O 0 2.524792874769588e-11
spot O 0 2.0392754325471163e-12
for O 0 3.672915184668183e-18
PTEN O 0 1.1063862499771648e-11
mutation O 0 1.919275014524574e-14
in O 0 2.455601122777175e-17
CD B-Disease 0 3.4754164823791456e-11
was O 0 7.51020339667674e-14
identified O 0 1.5875683097014195e-16
in O 0 3.8534849900757523e-19
exon O 0 4.8601371543813623e-14
5 O 0 1.3394968016451191e-14
that O 0 1.4897966994981745e-15
contains O 0 5.891470431387098e-16
the O 0 9.822311793940535e-15
PTPase O 0 2.778882013387829e-08
core O 0 3.9895125397704234e-11
motif O 0 1.4411568292904686e-11
, O 0 9.354565901822642e-19
with O 0 7.003867493457197e-19
13 O 0 2.5708268857974443e-18
of O 0 1.5586058603563792e-20
30 O 0 3.377796398873923e-16
( O 0 2.226062142388405e-18
43 O 0 3.790482603358361e-14
% O 0 1.0711778001505507e-17
) O 0 6.152454004473969e-18
CD B-Disease 0 6.409847045502071e-12
mutations O 0 2.9207869190233575e-16
identified O 0 1.1938696457488868e-16
in O 0 1.6474093536689154e-20
this O 0 2.2697931651213406e-19
exon O 0 3.5996741611782346e-12
. O 0 3.2377888564694146e-11

Seven O 0 1.374083247358826e-12
of O 0 4.485515580872106e-17
30 O 0 7.261519753791327e-16
( O 0 2.8591603338423502e-18
23 O 0 9.589587289396753e-14
% O 0 5.290614772409153e-17
) O 0 3.958378191910438e-17
were O 0 1.1885853248283225e-15
within O 0 5.667551559322812e-21
the O 0 2.6217018021919057e-18
core O 0 9.926586462538634e-13
motif O 0 2.378985246645482e-12
, O 0 1.2378233641142854e-18
the O 0 1.639117733982775e-18
majority O 0 4.742600750993688e-18
( O 0 9.093387113077233e-20
five O 0 2.498282808586854e-15
of O 0 1.9316409345483233e-17
seven O 0 1.7814096280998476e-13
) O 0 1.678142667716955e-17
of O 0 8.545151836357546e-20
which O 0 3.3568044448695905e-14
were O 0 4.175433666897023e-15
missense O 0 5.1463443356543175e-15
mutations O 0 5.8265460971338844e-15
, O 0 6.648564890906344e-16
possibly O 0 8.986748519825005e-15
pointing O 0 3.99258751060394e-11
to O 0 1.6774533549514573e-15
the O 0 6.461557750904928e-17
functional O 0 8.6415772998629575e-16
significance O 0 6.620269755303314e-16
of O 0 5.5331015902467e-19
this O 0 1.3910655333145884e-16
region O 0 7.15480355083925e-13
. O 0 1.8503681659814974e-12

Germline O 0 8.872963475070605e-10
PTEN O 0 1.201759802782476e-10
mutations O 0 1.0322444261119321e-13
were O 0 1.659422564603255e-15
identified O 0 1.4933641905137728e-15
in O 0 8.371478907801079e-18
four O 0 4.141373836813217e-16
of O 0 1.253150297081857e-18
seven O 0 1.2171259009333135e-13
( O 0 7.148824071567061e-18
57 O 0 5.190856764065478e-14
% O 0 7.416355788362637e-17
) O 0 1.1623546202759881e-15
BZS B-Disease 0 6.288154441591587e-10
families O 0 1.4234731726952155e-15
studied O 0 9.375974452769341e-17
. O 0 3.912086464914451e-15

Interestingly O 0 4.77207384719236e-10
, O 0 7.381456557098431e-13
none O 0 6.093117953546653e-14
of O 0 3.3965512598067694e-20
these O 0 2.5535880778723697e-16
mutations O 0 1.3736584768529205e-16
was O 0 1.5178437391509536e-13
observed O 0 1.7742877073166977e-14
in O 0 8.717988175121992e-18
the O 0 7.870501396878976e-15
PTPase O 0 3.3646293218225765e-07
core O 0 1.4856299523913208e-09
motif O 0 1.174034292006354e-08
. O 0 7.820007662251438e-13

It O 0 1.988442539151234e-14
is O 0 6.134150979060008e-18
also O 0 2.881947505356961e-18
worthy O 0 1.2305941991331074e-14
of O 0 2.7307912085560115e-18
note O 0 1.2794209051578131e-13
that O 0 4.856272324361031e-18
a O 0 3.9459079478678334e-18
single O 0 5.978666455137838e-13
nonsense O 0 1.01154808973547e-08
point O 0 7.139194834263063e-13
mutation O 0 4.9303466989397346e-15
, O 0 1.9657027961877136e-15
R233X O 0 2.6200973695885733e-14
, O 0 2.3139009479437786e-17
was O 0 9.297089744995956e-16
observed O 0 2.1874170913505402e-17
in O 0 9.721412684048182e-21
the O 0 9.380754181522129e-20
germline O 0 4.402316762244787e-17
DNA O 0 2.3474410891684283e-13
from O 0 2.7513377545863693e-18
two O 0 2.311701753868457e-19
unrelated O 0 2.550190681660492e-16
CD B-Disease 0 5.901123339979719e-11
families O 0 1.008740278265162e-13
and O 0 2.82357903571629e-16
one O 0 1.723723032621036e-16
BZS B-Disease 0 7.286039827025803e-11
family O 0 7.305402485204004e-13
. O 0 1.6724895936497813e-14

Genotype O 0 1.6815266690173303e-07
- O 0 2.872148456845025e-07
phenotype O 0 2.3708577323588997e-09
studies O 0 8.017143264364701e-13
were O 0 1.8465374154318266e-14
not O 0 1.9660906909554417e-17
performed O 0 2.5243964108342303e-16
on O 0 9.342459158991501e-15
this O 0 3.087174272355029e-19
small O 0 3.2339859063861204e-19
group O 0 8.192956357865966e-16
of O 0 3.9029858043763983e-19
BZS B-Disease 0 7.211163888243277e-10
families O 0 3.70985650172454e-15
. O 0 2.0275585153614817e-16

However O 0 5.578272587601532e-16
, O 0 1.1510487884555072e-17
genotype O 0 2.162258816006818e-13
- O 0 6.484970980352722e-12
phenotype O 0 3.8181738044699987e-13
analysis O 0 4.695764312329445e-16
inthe O 0 2.499859477408939e-12
group O 0 2.4553755499623874e-14
of O 0 3.818803116448994e-19
CD B-Disease 0 5.143359871340181e-08
families O 0 2.5912156535051745e-12
revealed O 0 4.9948050591928396e-15
two O 0 4.010442220502005e-21
possible O 0 5.586392943548499e-21
associations O 0 6.402022108094194e-21
worthy O 0 2.0874878169153976e-16
of O 0 4.56159088550024e-19
follow O 0 2.887390847250426e-13
- O 0 2.672229548750238e-09
up O 0 2.5781231316468478e-11
in O 0 3.2701249620594676e-18
independent O 0 2.5966721440366636e-16
analyses O 0 7.891166886597745e-12
. O 0 5.166880225944024e-15

The O 0 2.915524673898981e-14
first O 0 2.4790869244197032e-15
was O 0 1.41786552659319e-13
an O 0 2.5538791130990903e-17
association O 0 2.4641214139587163e-17
noted O 0 3.0929667472830874e-16
in O 0 6.536997863540683e-18
the O 0 1.1018983848195413e-15
group O 0 2.814826644272311e-15
of O 0 2.3412085464761878e-20
CD B-Disease 0 3.3056657411378865e-09
families O 0 1.7647977534635678e-13
with O 0 1.2161036253396018e-15
breast B-Disease 0 1.4761338889002218e-06
disease I-Disease 0 2.456353342950024e-07
. O 0 3.165014908143582e-13

A O 0 3.1260509012907747e-15
correlation O 0 2.3584789618513475e-15
was O 0 7.616081498643991e-15
observed O 0 1.2921814512142433e-16
between O 0 1.73917751270316e-17
the O 0 1.4616989490416344e-17
presence O 0 1.1172469606369681e-13
/ O 0 3.216786212401068e-11
absence O 0 2.2213227283507213e-16
of O 0 2.4800711484962614e-22
a O 0 1.1528707002835647e-20
PTEN O 0 3.9896717182676296e-15
mutation O 0 2.917233417286279e-17
and O 0 3.1295810699171346e-16
the O 0 2.0738737309781426e-18
type O 0 8.265006653249488e-14
of O 0 2.836047360699873e-16
breast O 0 3.139592536172131e-06
involvement O 0 1.3534537934845048e-08
( O 0 4.351846065854623e-15
unaffected O 0 1.4355288069367589e-09
versus O 0 1.1017833867477123e-10
benign O 0 6.0917402151972055e-05
versus O 0 2.402682923730026e-07
malignant O 0 0.02811483107507229
) O 0 4.1442765885690847e-11
. O 0 2.1233695357558702e-11

Specifically O 0 4.73800425976334e-12
and O 0 1.5890483780157602e-14
more O 0 6.587256039240304e-20
directly O 0 5.198271902243979e-16
, O 0 1.5169499817487464e-16
an O 0 3.7676131372989686e-17
association O 0 3.83892140005696e-16
was O 0 3.7609021799611675e-12
also O 0 6.683817046918353e-14
observed O 0 4.547804597103064e-15
between O 0 3.007621428053418e-17
the O 0 6.2691558506178235e-19
presence O 0 1.1707635216618817e-18
of O 0 3.386546797064657e-22
a O 0 4.0020866946511966e-19
PTEN O 0 1.9398139344817267e-11
mutation O 0 8.827911817353706e-13
and O 0 6.030856369854121e-10
malignant B-Disease 1 0.748104453086853
breast I-Disease 1 0.9994851350784302
disease I-Disease 0 0.43938809633255005
. O 0 7.401826374042741e-10

Secondly O 0 1.243006320095219e-08
, O 0 1.840840610641773e-14
there O 0 2.6891118935951796e-17
appeared O 0 4.4334588761687013e-14
to O 0 4.631749036334538e-18
be O 0 6.801321856638839e-17
an O 0 3.115559564440973e-17
interdependent O 0 2.0703901100205258e-05
association O 0 6.062276213387703e-16
between O 0 9.430789660555311e-16
mutations O 0 9.53937016184847e-13
upstream O 0 3.3921752125992688e-12
and O 0 1.3365862236436321e-12
within O 0 5.885239097853001e-19
the O 0 1.4224954849158472e-16
PTPase O 0 5.824225129957838e-11
core O 0 5.336169874026186e-13
motif O 0 1.2233459037447325e-11
, O 0 1.4539300687285364e-17
the O 0 1.6145176152099953e-19
core O 0 3.70770959507577e-13
motif O 0 1.9872465218534474e-12
containing O 0 1.504634916789057e-15
the O 0 2.544360448005422e-16
majority O 0 1.4814312432924134e-16
of O 0 1.266138583662588e-18
missense O 0 1.3544550138584743e-13
mutations O 0 1.6623894372614495e-13
, O 0 4.877890795549223e-15
and O 0 1.773515467378686e-15
the O 0 1.855062538671634e-18
involvement O 0 2.6862672784962183e-13
of O 0 4.218301005123383e-18
all O 0 4.3200369081907906e-16
major O 0 4.0332793963771145e-17
organ O 0 2.126191167572955e-10
systems O 0 2.842793223045703e-10
( O 0 1.1978428920159995e-16
central O 0 1.6968342963358252e-12
nervous O 0 2.511564289875423e-08
system O 0 9.364417227764044e-12
, O 0 3.2185839568223866e-15
thyroid O 0 3.5151535016098023e-09
, O 0 5.765281474608402e-15
breast O 0 3.4887959827756276e-06
, O 0 7.75005226660852e-10
skin O 1 0.9998992681503296
and O 0 9.245937690138817e-05
gastrointestinal O 0 0.025468964129686356
tract O 0 0.00270345201715827
) O 0 1.6354831378073698e-10
. O 0 2.4084897271015038e-11

However O 0 4.392076979886639e-13
, O 0 8.405911127979211e-18
these O 0 2.7399199737961467e-19
observations O 0 5.661475469340019e-15
would O 0 6.092553406087308e-16
need O 0 9.906203346552365e-19
to O 0 9.457290360168305e-19
be O 0 6.770436504209273e-18
confirmed O 0 4.678487636075928e-18
by O 0 1.2040612450506455e-21
studying O 0 5.3838730378633055e-20
a O 0 2.6953506584423513e-21
larger O 0 2.2474925373656243e-21
number O 0 2.737003968266441e-20
of O 0 2.424602601700054e-19
CD B-Disease 0 8.535397455489147e-08
families O 0 9.086697540239275e-12
. O 0 3.3936067982300163e-15

Molecular O 0 1.1397989396755293e-07
defects O 0 1.4229309272195678e-05
leading O 0 7.521118940861417e-16
to O 0 1.5685442350833992e-18
human O 0 1.0439599184028609e-17
complement B-Disease 0 6.890537216464954e-15
component I-Disease 0 1.938549876179252e-10
C6 I-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999997615814209
in O 0 3.81658963282859e-19
an O 0 3.3435130463906316e-18
African O 0 3.6183287269175857e-12
- O 0 3.1031059943842365e-09
American O 0 1.0413381094920293e-11
family O 0 3.0438731396520424e-11
. O 0 4.788546607305787e-15

Complement B-Disease 0 3.4134278736885904e-10
component I-Disease 0 7.187840083133779e-07
C6 I-Disease 1 0.9999843835830688
deficiency I-Disease 1 0.9999995231628418
( O 0 1.4074858493322642e-14
C6D B-Disease 0 2.3309656427272785e-08
) O 0 5.753285794009386e-15
was O 0 5.1520974986285495e-12
diagnosed O 0 8.17097223215768e-11
in O 0 6.500783999720688e-20
a O 0 3.503261371611746e-19
16 O 0 3.982974738296947e-18
- O 0 2.602586657469985e-13
year O 0 1.0395181140234063e-15
- O 0 5.976837080812203e-11
old O 0 1.6543713066141663e-09
African O 0 2.841431991497216e-14
- O 0 1.8404253527393817e-15
American O 0 1.3196134734789108e-17
male O 0 5.403925149090219e-16
with O 0 5.007257436134213e-17
meningococcal B-Disease 1 0.9999691247940063
meningitis I-Disease 1 0.9999892711639404
. O 0 1.754659666939858e-15

The O 0 1.306415777424172e-13
patients O 0 2.1999740083041702e-13
father O 0 1.8261018253085126e-09
and O 0 6.966746624037512e-12
two O 0 9.261453501894015e-14
brothers O 0 7.77679032282208e-11
also O 0 4.159151139317064e-17
had O 0 3.0629808280382195e-15
C6D B-Disease 0 1.2803742441280797e-11
, O 0 2.0653539257652113e-19
but O 0 3.699221492701324e-19
gave O 0 1.3477160248917261e-17
no O 0 3.280772017313944e-17
history O 0 4.043913590627427e-15
of O 0 4.1252617878487826e-15
meningitis B-Disease 1 0.9999998807907104
or O 0 1.5569763225009234e-14
other O 0 2.6429941524605148e-15
neisserial B-Disease 0 3.549970188032603e-06
infection I-Disease 0 8.98616144695552e-06
. O 0 9.63395812778045e-13

By O 0 1.1575960470809563e-18
using O 0 1.7104637161766988e-18
exon O 0 4.7580652796658934e-15
- O 0 3.175080641112937e-14
specific O 0 2.2290459482940064e-17
polymerase O 0 2.575998225493037e-12
chain O 0 1.9769059165283126e-13
reaction O 0 9.88476282507499e-19
( O 0 9.142341744573346e-24
PCR O 0 2.109331737833902e-17
) O 0 5.594560544303893e-21
/ O 0 8.071032847251406e-19
single O 0 2.108074702476278e-19
- O 0 1.5216917251270352e-15
strand O 0 1.5379325230994523e-15
conformation O 0 1.0559278818339109e-16
polymorphism O 0 4.0966652334208027e-19
as O 0 6.025248202166166e-24
a O 0 1.7318350327406813e-25
screening O 0 6.965884131171618e-23
step O 0 2.6453260223252833e-21
and O 0 5.758705118496922e-24
nucleotide O 0 2.1698342425781836e-22
sequencing O 0 1.4739937170570434e-19
of O 0 1.193538724099211e-21
target O 0 4.354050111757828e-17
exons O 0 1.1984931750914744e-14
, O 0 1.2669992444104342e-17
we O 0 1.8900426832875216e-17
determined O 0 5.011325262232565e-18
that O 0 2.600358391718445e-17
the O 0 3.257888561976032e-16
proband O 0 4.938274789090258e-10
was O 0 7.885467622024012e-15
a O 0 3.595501121822844e-20
compound O 0 3.3200508954961776e-18
heterozygote O 0 1.487937945252429e-17
for O 0 1.9284049907442013e-21
two O 0 2.736194021444963e-17
C6 O 0 5.353411935971053e-08
gene O 0 1.8470898421885096e-11
mutations O 0 1.2753564870848777e-10
. O 0 4.851472956007852e-12

The O 0 1.872734153962976e-15
first O 0 1.7731212000115186e-17
, O 0 3.738049040461833e-18
1195delC O 0 1.8196024453354977e-14
located O 0 8.085146099465209e-19
in O 0 3.2550513531544903e-19
exon O 0 2.0335985431957186e-14
7 O 0 1.0867461851206059e-13
, O 0 5.956663248614811e-17
is O 0 6.416600277817518e-19
a O 0 4.233743019593676e-19
novel O 0 2.484284106825819e-15
mutation O 0 1.4967356781053764e-14
, O 0 2.4212812879892756e-14
while O 0 5.642652703186134e-15
the O 0 4.954415649679223e-18
second O 0 2.3090622126755844e-15
, O 0 2.537982025214801e-16
1936delG O 0 4.262051215425666e-12
in O 0 2.5471837891439942e-18
exon O 0 2.3121939475914677e-13
12 O 0 6.587364388774969e-14
, O 0 3.462847043282176e-17
has O 0 9.350721621284832e-17
been O 0 1.5116298207466013e-16
described O 0 6.257867132337036e-15
before O 0 7.935347698221924e-15
to O 0 1.4206685407277381e-15
cause O 0 2.774403563875552e-14
C6D B-Disease 0 9.243462766039823e-12
in O 0 6.213888198042748e-21
an O 0 4.513297108659068e-20
unrelated O 0 2.3022200465461218e-11
African O 0 9.385307114806452e-11
- O 0 2.0993862204221614e-09
American O 0 1.771935679781289e-12
individual O 0 3.0323813393021842e-15
. O 0 1.3233256721326137e-14

Both O 0 7.170166085759648e-15
mutations O 0 6.851908363608716e-13
result O 0 4.1517543526367606e-14
in O 0 3.4212783058256303e-16
premature O 0 8.548908109196063e-11
termination O 0 6.225631175946905e-14
codons O 0 2.891535481105295e-13
and O 0 1.1041083954228814e-13
C6 O 0 6.750444754288765e-07
null O 0 2.6942480246816558e-08
alleles O 0 1.4116094577965033e-11
. O 0 1.5965241281779008e-11

Allele O 0 3.71425709199541e-13
- O 0 5.051754895885009e-15
specific O 0 2.2621098463028535e-18
PCR O 0 5.034602075515426e-12
indicated O 0 2.93439250220566e-14
that O 0 1.0064737680826981e-18
the O 0 5.998157006284732e-19
probands O 0 9.735415251732604e-11
two O 0 4.7299429387841034e-15
brothers O 0 2.1219120210913545e-11
also O 0 8.88684965254918e-18
inherited O 0 4.942926408755882e-15
the O 0 4.253168063809777e-19
1195delC O 0 2.5338418429415865e-12
mutation O 0 8.176408510450169e-16
from O 0 2.7991156654084016e-17
their O 0 6.018227366108575e-14
heterozygous O 0 9.317758831216619e-15
mother O 0 1.082365967686183e-11
and O 0 2.6333400679744043e-17
the O 0 1.3302519053755013e-18
1936delG O 0 5.1633224605607264e-12
mutation O 0 1.6954406289819944e-15
from O 0 1.0676741774044089e-16
their O 0 5.6244319233478626e-14
homozygous O 0 7.051470003608187e-14
father O 0 6.934323254492725e-11
. O 0 1.6147601848906507e-16
. O 0 1.3095958609806845e-14

PAX6 O 0 2.8611884772544727e-07
mutations O 0 4.022758515187519e-11
reviewed O 0 8.187572148043998e-11
. O 0 3.150503122273385e-11

Mutations O 0 1.1342529563154735e-12
in O 0 9.033410340661938e-18
PAX6 O 0 1.94219613265309e-13
are O 0 1.9816829265948533e-19
responsible O 0 3.4201395428199408e-18
for O 0 1.2416120787944467e-17
human O 0 1.0608978140425052e-09
aniridia B-Disease 1 0.9999998807907104
and O 0 2.6416097087533785e-10
have O 0 1.4166847065487847e-16
also O 0 2.1492591204464983e-19
been O 0 4.999792296542044e-18
found O 0 5.903227174248732e-19
in O 0 7.734104800040997e-21
patients O 0 1.6585901859877327e-19
with O 0 5.153529107340945e-17
Peters B-Disease 1 0.9999992847442627
anomaly I-Disease 1 0.9999997615814209
, O 0 2.4985140909331016e-13
with O 0 1.3665454401748378e-12
congenital B-Disease 1 0.9998220801353455
cataracts I-Disease 1 0.9227502346038818
, O 0 7.090278017485296e-12
with O 0 1.118048457092978e-13
autosomal B-Disease 0 8.785894465290767e-07
dominant I-Disease 0 2.0976945336315111e-07
keratitis I-Disease 0 0.18449032306671143
, O 0 1.3901612066352653e-12
and O 0 5.791902195481299e-14
with O 0 5.046886845071208e-13
isolated B-Disease 0 0.0008718785247765481
foveal I-Disease 1 0.9999978542327881
hypoplasia I-Disease 1 0.9999963045120239
. O 0 8.362675885109638e-09

No O 0 6.15073042411346e-14
locus O 0 1.628636244963011e-12
other O 0 2.3847238542055484e-15
than O 0 4.3610335675356947e-16
chromosome O 0 8.46106726348772e-11
11p13 O 0 8.48554299742732e-13
has O 0 1.7953659528025315e-15
been O 0 9.87840329508956e-17
implicated O 0 1.0497891618499455e-12
in O 0 2.805153739772904e-14
aniridia B-Disease 1 0.9999992847442627
, O 0 5.983383141163964e-15
and O 0 1.835622464170213e-15
PAX6 O 0 1.224032160351829e-11
is O 0 8.461485601540721e-15
clearly O 0 3.5963644714163967e-13
the O 0 4.9261471658355294e-18
major O 0 6.608231431889361e-17
, O 0 1.198931620520797e-15
if O 0 4.166110375246595e-15
not O 0 4.319542452707831e-16
only O 0 2.9438942342504447e-18
, O 0 2.202218454436411e-18
gene O 0 8.354615454585646e-15
responsible O 0 9.563367459053396e-12
. O 0 1.4358443904335938e-12

Twenty O 0 3.528707326339031e-10
- O 0 5.535760578823101e-07
eight O 0 3.012190219475741e-10
percent O 0 2.6212387295443396e-13
of O 0 1.2962710826659592e-21
identified O 0 9.443595971537184e-18
PAX6 O 0 2.158303239905776e-13
mutations O 0 2.0851343993989226e-14
are O 0 1.8597061519594945e-15
C O 0 5.779259293348105e-09
- O 0 1.291896438715412e-07
T O 0 3.460061792637248e-09
changes O 0 3.488726877671e-18
at O 0 4.2949905740743994e-18
CpG O 0 2.7343095981304487e-14
dinucleotides O 0 3.4848518385213745e-13
, O 0 4.674061082425427e-19
20 O 0 5.217432989507699e-20
% O 0 1.9668725747860663e-23
are O 0 3.41421129704098e-24
splicing O 0 1.35970731481605e-16
errors O 0 4.846420573884069e-13
, O 0 2.1271386306562111e-19
and O 0 4.2521296936470814e-19
more O 0 2.8779990443290572e-21
than O 0 5.023110169043093e-20
30 O 0 2.1666046067532466e-18
% O 0 2.391275551365842e-21
are O 0 1.1464283850284545e-20
deletion O 0 3.1708092736591046e-17
or O 0 2.2245364242921633e-16
insertion O 0 1.0183675869810185e-13
events O 0 1.599114590744577e-11
. O 0 1.740801621775978e-12

There O 0 4.158506899292272e-14
is O 0 5.932781303559486e-18
a O 0 3.9710050212429986e-18
noticeably O 0 3.2450469394929016e-11
elevated O 0 2.9070554991017516e-11
level O 0 8.279842740252508e-13
of O 0 3.76315660869102e-19
mutation O 0 2.9199611280742336e-17
in O 0 7.109004088017247e-20
the O 0 1.2309338026417253e-19
paired O 0 6.004579293636056e-15
domain O 0 1.2363305095398208e-13
compared O 0 8.101283316061525e-14
with O 0 1.1845516215845995e-16
the O 0 7.326545414360855e-16
rest O 0 4.905220652405562e-14
of O 0 3.7444939600434034e-21
the O 0 3.180861265520668e-19
gene O 0 4.7888230788597705e-14
. O 0 3.703693235890433e-14

Increased O 0 2.0507029505501678e-13
mutation O 0 3.4457418878917553e-14
in O 0 1.126407309618124e-16
the O 0 5.152624502623057e-17
homeodomain O 0 1.2784098432638835e-11
is O 0 1.8164995439505345e-17
accounted O 0 3.701383432629808e-18
for O 0 6.264146917589387e-23
by O 0 7.315276437158976e-20
the O 0 2.232365655702753e-16
hypermutable O 0 6.42507114179125e-09
CpG O 0 2.682862376701678e-09
dinucleotide O 0 4.0934481498888786e-11
in O 0 8.262372957824722e-18
codon O 0 2.4775330848296126e-14
240 O 0 3.079030196564557e-15
. O 0 1.4411650439853977e-15

Very O 0 6.15962571001564e-15
nearly O 0 4.803983756299717e-17
all O 0 4.1574655933828644e-19
mutations O 0 9.268225906178184e-17
appear O 0 1.2874065962592551e-12
to O 0 9.752476604063531e-11
cause O 0 6.246731913961412e-07
loss O 0 6.528419731893775e-12
of O 0 5.334644482306463e-20
function O 0 2.96904536387864e-17
of O 0 3.812178498341695e-20
the O 0 8.018008915625532e-18
mutant O 0 1.807103728809767e-13
allele O 0 5.977015994499454e-16
, O 0 2.198498985113278e-19
and O 0 3.741899100924173e-19
more O 0 1.2162298473431248e-21
than O 0 2.427119557207688e-19
80 O 0 1.1225628801878042e-18
% O 0 2.6094069966948752e-20
of O 0 1.0833317102936344e-20
exonic O 0 2.315170451183679e-11
substitutions O 0 1.018002481899434e-13
result O 0 1.813898864281866e-14
in O 0 1.6051978446606397e-16
nonsense O 0 1.1684181622229062e-08
codons O 0 1.6171437453027515e-11
. O 0 1.310636928847364e-12

In O 0 7.219482038014688e-16
a O 0 2.8147992062778025e-19
gene O 0 3.308444931116599e-18
with O 0 9.39206910757306e-20
such O 0 1.4854565379931782e-21
extraordinarily O 0 6.11423003799873e-16
high O 0 8.402256644032952e-18
sequence O 0 1.1160215359037349e-18
conservation O 0 1.7887380080850018e-19
throughout O 0 7.161153948229594e-20
evolution O 0 4.060725993564175e-18
, O 0 4.058385899611263e-19
there O 0 3.4868888823499073e-19
are O 0 2.600416583874538e-18
presumed O 0 1.6147135850630434e-09
undiscovered O 0 4.5566423523268895e-07
missense O 0 2.8781345362549615e-11
mutations O 0 1.4764701614100595e-11
, O 0 3.4644361167958946e-15
these O 0 1.2013619168651471e-16
are O 0 5.52257881887926e-19
hypothesized O 0 6.0499795614684494e-18
to O 0 4.632763272262091e-15
exist O 0 3.030128570475667e-14
in O 0 4.6036555011903994e-17
as O 0 9.928327691227645e-13
- O 0 7.785363322909689e-07
yet O 0 1.390576265247745e-10
unidentified O 0 2.2831878609963496e-08
phenotypes O 0 1.8740770654085415e-12
. O 0 1.4623913984760148e-16
. O 0 6.7602783722538196e-15

Genetic O 0 3.4443607688228184e-11
heterogeneity O 0 4.380151796823384e-11
and O 0 8.701281340416089e-13
penetrance O 0 3.3716243772602406e-12
analysis O 0 2.008657901585788e-17
of O 0 5.131743298057671e-21
the O 0 4.2401916679503513e-19
BRCA1 O 0 1.7399983363863836e-12
and O 0 3.035392033209905e-14
BRCA2 O 0 7.767932347704787e-13
genes O 0 8.761943434524872e-15
in O 0 4.014477978100478e-16
breast B-Disease 0 8.441379009127559e-07
cancer I-Disease 0 4.4459545733843697e-07
families O 0 2.538075478952795e-11
. O 0 2.7269866594882564e-14

The O 0 1.1443206382466542e-08
Breast B-Disease 1 0.9999817609786987
Cancer I-Disease 1 0.9999556541442871
Linkage O 0 1.338319407295785e-06
Consortium O 0 1.169759289432193e-10
. O 0 2.5613235490884456e-13

The O 0 2.3242602270631477e-17
contribution O 0 6.525487231726701e-18
of O 0 2.127762505783835e-20
BRCA1 O 0 5.284272368635823e-13
and O 0 8.488849380372532e-12
BRCA2 O 0 9.079719166038558e-05
to O 0 7.848248787922785e-05
inherited B-Disease 1 1.0
breast I-Disease 1 0.9999991655349731
cancer I-Disease 1 1.0
was O 0 1.9352009144463223e-12
assessed O 0 1.0970356728941115e-18
by O 0 3.3229729384750024e-21
linkage O 0 1.1573385208085013e-13
and O 0 9.274101270807474e-16
mutation O 0 5.130554662135652e-19
analysis O 0 7.012770024799799e-19
in O 0 3.431715483128223e-20
237 O 0 4.29597574618395e-17
families O 0 2.4994253501535815e-16
, O 0 2.0343012747642865e-21
each O 0 1.723028323109502e-21
with O 0 2.651049177708552e-17
at O 0 9.828651157924376e-14
least O 0 5.047372345761554e-19
four O 0 1.2192093187900046e-18
cases O 0 6.31074419639079e-17
of O 0 1.1804693198255278e-16
breast B-Disease 0 1.3146409116870927e-07
cancer I-Disease 0 1.1486267666172001e-11
, O 0 8.225319867574504e-20
collected O 0 5.617362860332297e-19
by O 0 1.882553092236446e-16
the O 0 6.05362870942372e-10
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.999996542930603
Linkage O 0 2.2143264999385792e-08
Consortium O 0 6.512560130934875e-13
. O 0 2.606488726499749e-15

Families O 0 9.172548831593019e-11
were O 0 7.746344604489641e-17
included O 0 6.863813537289752e-20
without O 0 1.3028303058450458e-20
regard O 0 5.501106098750307e-21
to O 0 5.367263509657182e-20
the O 0 2.080489935107648e-18
occurrence O 0 4.2294965273137475e-12
of O 0 1.6504408516943014e-13
ovarian B-Disease 0 1.6627840523142368e-05
or I-Disease 0 4.158848820878802e-10
other I-Disease 0 5.272334652195454e-12
cancers I-Disease 0 1.3278678352435236e-06
. O 0 9.86479127551565e-13

Overall O 0 1.1862206328316915e-08
, O 0 1.1552671319581265e-10
disease O 0 1.6889735443559317e-10
was O 0 4.015580709118685e-16
linked O 0 6.74567255962784e-15
to O 0 1.543654990837138e-18
BRCA1 O 0 1.524212230480268e-16
in O 0 1.57055960975489e-21
an O 0 3.2138872835042215e-21
estimated O 0 5.204321305674151e-17
52 O 0 7.171174160845999e-16
% O 0 2.251374489517987e-18
of O 0 3.93514115821969e-20
families O 0 2.176673292360342e-15
, O 0 2.8814265124336105e-21
to O 0 2.357943476555644e-19
BRCA2 O 0 4.920203648802954e-14
in O 0 2.7710148510748726e-17
32 O 0 1.0256300982927537e-14
% O 0 4.640273132546897e-18
of O 0 1.1150804370111968e-19
families O 0 1.8147787959887918e-13
, O 0 1.1108821593603664e-18
and O 0 2.36098019720503e-16
to O 0 3.3137136580282557e-17
neither O 0 1.914292640997371e-17
gene O 0 6.240455268301648e-18
in O 0 2.1480635601180236e-18
16 O 0 4.665179011395276e-16
% O 0 4.781709850355195e-19
( O 0 1.720704729147988e-19
95 O 0 6.184798766878385e-14
% O 0 1.3683208754423914e-13
confidence O 0 4.0453282390551237e-10
interval O 0 4.503406924715597e-13
[ O 0 2.0330971843942388e-15
CI O 0 9.737718270619311e-11
] O 0 1.2072079447200679e-12
6 O 0 1.192641786788547e-14
% O 0 1.1687610745632072e-16
- O 0 6.522705042755206e-09
28 O 0 1.496555934732413e-10
% O 0 1.6519310346408236e-16
) O 0 1.5870883836459193e-18
, O 0 1.0324932383137394e-19
suggesting O 0 2.4046724396428977e-17
other O 0 3.351671477073454e-19
predisposition O 0 5.942762558094894e-13
genes O 0 3.6803299665634504e-13
. O 0 2.1730748168795333e-13

The O 0 1.5129301349052493e-13
majority O 0 3.785452074684618e-15
( O 0 1.7668756555144983e-17
81 O 0 1.9623324097389414e-14
% O 0 1.7348498278153746e-18
) O 0 2.3623359025435285e-20
of O 0 4.6767673039657964e-21
the O 0 2.420433103077213e-13
breast B-Disease 1 0.9999967813491821
- I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.8320836087679666e-11
were O 0 8.601998531485546e-19
due O 0 3.1090825305414725e-21
to O 0 7.923768267211456e-21
BRCA1 O 0 9.745980149349293e-16
, O 0 2.1648439786688216e-19
with O 0 5.638632953522917e-21
most O 0 1.5730615201073396e-19
others O 0 8.159987188580868e-16
( O 0 3.73001135229905e-20
14 O 0 2.0085575387694503e-14
% O 0 3.899133779360104e-18
) O 0 1.6942742406253875e-18
due O 0 1.3743182361094928e-17
to O 0 1.0644786714955091e-14
BRCA2 O 0 3.373303414377915e-08
. O 0 2.1661734905809027e-12

Conversely O 0 1.822981002264079e-12
, O 0 6.830494862482359e-17
the O 0 1.121458594070046e-18
majority O 0 7.895083259155251e-19
of O 0 3.804899955186082e-20
families O 0 9.276551694772234e-14
with O 0 4.662602125411492e-15
male B-Disease 0 1.433824059482447e-09
and I-Disease 0 1.3757237016243096e-10
female I-Disease 0 1.6170613459376426e-10
breast I-Disease 0 6.371071670230322e-09
cancer I-Disease 0 2.6629719263038254e-11
were O 0 1.298293323324275e-16
due O 0 1.3336561671864633e-18
to O 0 2.321761314432625e-17
BRCA2 O 0 5.472563721631296e-11
( O 0 1.4961120448040045e-16
76 O 0 2.765762662296223e-12
% O 0 1.7326094670289176e-16
) O 0 1.255832223422907e-15
. O 0 2.918853310093783e-13

The O 0 8.549832514367884e-16
largest O 0 7.976523822672527e-17
proportion O 0 2.4307460659056307e-16
( O 0 5.307714001877665e-18
67 O 0 7.842573026542107e-14
% O 0 3.7599051374789545e-16
) O 0 2.2026407549545376e-16
of O 0 1.3492797271216964e-17
families O 0 4.656705251439297e-13
due O 0 1.743148724105966e-18
to O 0 5.20707662361505e-19
other O 0 1.1851419886595847e-19
genes O 0 1.914226797420612e-17
was O 0 9.818602636664508e-15
found O 0 5.704436689257182e-17
in O 0 6.659796547786936e-20
families O 0 6.836855550520647e-17
with O 0 1.5767855776979328e-20
four O 0 1.6060284156797284e-19
or O 0 4.4788643870026894e-17
five O 0 2.1475966166622375e-18
cases O 0 7.914114203508259e-18
of O 0 1.6187744262289215e-17
female O 0 2.3101089929866703e-09
breast B-Disease 0 9.58780432824824e-08
cancer I-Disease 0 2.0934672051442504e-10
only O 0 5.24186127650087e-16
. O 0 4.28895742705937e-14

These O 0 1.673095899833426e-14
estimates O 0 2.5838678646103756e-15
were O 0 2.7935485413625727e-16
not O 0 6.404062080887592e-17
substantially O 0 3.419609862677776e-15
affected O 0 1.0838583135048661e-17
either O 0 7.684555065761937e-20
by O 0 4.845832891440306e-19
changing O 0 9.490341794219682e-15
the O 0 1.9486030174712744e-18
assumed O 0 1.2631247800520725e-16
penetrance O 0 8.34970073119766e-17
model O 0 4.278406636768477e-19
for O 0 4.0070604937081803e-22
BRCA1 O 0 9.737692990751594e-16
or O 0 1.892648269129839e-16
by O 0 3.2340832939785514e-20
including O 0 4.42342173790668e-19
or O 0 7.085819815421486e-15
excluding O 0 2.304775325989971e-16
BRCA1 O 0 4.130547019329765e-14
mutation O 0 6.699841089159568e-16
data O 0 2.5666604258622883e-12
. O 0 2.1106007566662477e-12

Among O 0 3.3873082612342334e-15
those O 0 7.817564590532661e-16
families O 0 1.1181544717366564e-14
with O 0 6.760223950386958e-16
disease O 0 1.227248771357159e-11
due O 0 6.118332721488095e-17
to O 0 1.426424129604331e-16
BRCA1 O 0 3.118407496203318e-13
that O 0 6.134204663081763e-16
were O 0 8.952109239795939e-18
tested O 0 2.3075706587930022e-18
by O 0 5.851469796696757e-23
one O 0 2.145997476205368e-20
of O 0 1.186179850922075e-23
the O 0 1.2302190143871094e-21
standard O 0 6.842425102341574e-21
screening O 0 2.8497260675375444e-21
methods O 0 8.323900926533101e-19
, O 0 1.2485153367300517e-21
mutations O 0 3.2015528815821264e-21
were O 0 9.737896519575288e-20
detected O 0 1.7271512992133742e-17
in O 0 1.6639370119970287e-21
the O 0 1.1140303053741666e-19
coding O 0 2.981486585396098e-12
sequence O 0 2.987688831686437e-14
or O 0 2.590330514239689e-16
splice O 0 4.190908687792816e-13
sites O 0 9.4984495935908e-16
in O 0 1.2405023274685319e-20
an O 0 1.2344834576012149e-20
estimated O 0 3.592273082052592e-16
63 O 0 5.67953759990727e-15
% O 0 2.04452792710466e-17
( O 0 1.1941052143796327e-18
95 O 0 7.588762144996198e-15
% O 0 3.1261444984314463e-16
CI O 0 1.6020662130245e-08
51 O 0 3.888831270892901e-11
% O 0 3.511313147793599e-13
- O 0 7.4913214120897464e-06
77 O 0 1.3695796718948827e-09
% O 0 8.32731558269564e-15
) O 0 1.2449094159307076e-15
. O 0 5.080921374280879e-14

The O 0 3.4305048769013937e-16
estimated O 0 3.3610211098768984e-17
sensitivity O 0 5.184943838818933e-16
was O 0 5.234587910461915e-16
identical O 0 5.203224546899967e-19
for O 0 2.8204873640704165e-25
direct O 0 1.2056502791264684e-23
sequencing O 0 2.3184334013922017e-17
and O 0 2.603524839103298e-17
other O 0 1.244464716473117e-20
techniques O 0 3.368379192445468e-15
. O 0 8.565959492288014e-16

The O 0 3.7549136570240796e-14
penetrance O 0 1.1657240728268903e-09
of O 0 1.2586515196482838e-16
BRCA2 O 0 1.7519811990052148e-11
was O 0 1.623021683684004e-14
estimated O 0 1.1311940445907005e-19
by O 0 8.411090941052954e-22
maximizing O 0 3.02114384583519e-17
the O 0 1.1624521349440408e-15
LOD O 0 2.5662446390128935e-08
score O 0 4.299078454339522e-15
in O 0 7.89336259423417e-20
BRCA2 O 0 1.5682200546832115e-12
- O 0 3.292755998418606e-11
mutation O 0 1.1890044070844707e-12
families O 0 3.982105877681219e-12
, O 0 4.0052478170608563e-19
over O 0 4.631854915452945e-18
all O 0 5.466973153164031e-18
possible O 0 9.217593850011568e-17
penetrance O 0 8.458980911563163e-12
functions O 0 2.495711004800753e-15
. O 0 9.399915741614695e-13

The O 0 5.486617269961512e-16
estimated O 0 2.0172599976211883e-15
cumulative O 0 2.0749550623706814e-13
risk O 0 4.5226455501652663e-13
of O 0 2.062293450556584e-17
breast B-Disease 0 6.498480047412158e-07
cancer I-Disease 0 1.1417942147318172e-07
reached O 0 1.6051651327564365e-11
28 O 0 3.0844985989203835e-14
% O 0 1.6187551322411337e-18
( O 0 1.122703003291101e-20
95 O 0 2.523855931021988e-17
% O 0 8.20057295009239e-19
CI O 0 8.702164856766448e-12
9 O 0 2.0173727800581152e-14
% O 0 1.1649102675703646e-17
- O 0 2.0068984668553114e-11
44 O 0 3.28221675641345e-14
% O 0 7.696612515659604e-20
) O 0 6.531650155420812e-22
by O 0 7.786417834553867e-20
age O 0 9.850603541411776e-15
50 O 0 2.572913952955795e-20
years O 0 2.2656071659327277e-18
and O 0 1.2800870614983707e-17
84 O 0 1.0305853591555829e-18
% O 0 1.5107778118475202e-22
( O 0 6.618857908077653e-23
95 O 0 8.643014799146871e-19
% O 0 1.0917081903095696e-19
CI O 0 1.707333384913523e-12
43 O 0 2.7366143747799276e-15
% O 0 7.122067260292808e-18
- O 0 6.681073749792432e-11
95 O 0 2.0541292191506022e-12
% O 0 7.405842521300435e-16
) O 0 8.194010616100277e-18
by O 0 9.663352085344636e-16
age O 0 7.713828187316807e-11
70 O 0 1.0279792356458672e-16
years O 0 4.0511222115854754e-16
. O 0 1.181329852360379e-16

The O 0 6.740667052307359e-12
corresponding O 0 2.2310225631372305e-06
ovarian B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999994039535522
risks O 0 7.602081495861057e-06
were O 0 6.156812798301103e-13
0 O 0 6.868777575324701e-16
. O 0 5.2379263849444e-15

4 O 0 8.554155647710893e-12
% O 0 2.4947877388882458e-15
( O 0 3.0419120349106814e-18
95 O 0 5.932108425218399e-16
% O 0 1.542360804730253e-17
CI O 0 3.6842175143991795e-11
0 O 0 3.666535636911929e-16
% O 0 1.7164910917871583e-17
- O 0 5.804467692084592e-13
1 O 0 3.23625115827798e-15
% O 0 1.5116982120396472e-17
) O 0 2.8664305922671407e-20
by O 0 1.3449105022575242e-19
age O 0 5.67838658801107e-16
50 O 0 1.265933890388311e-21
years O 0 4.0372620332121312e-19
and O 0 3.9276466950748065e-18
27 O 0 7.223993282552205e-18
% O 0 3.954941652768804e-22
( O 0 1.9695905161489148e-23
95 O 0 1.741127559977981e-19
% O 0 1.9829372361338648e-20
CI O 0 4.42135152274592e-13
0 O 0 2.3397748266321923e-17
% O 0 1.8572654860789853e-17
- O 0 2.486186534422785e-10
47 O 0 9.05325727579287e-12
% O 0 7.388907950404657e-17
) O 0 6.710445850669324e-19
by O 0 9.578786565822033e-17
age O 0 2.267500423536184e-11
70 O 0 1.1464919166354016e-16
years O 0 8.185708402815429e-16
. O 0 3.3957029400766747e-16

The O 0 5.568264490989072e-14
lifetime O 0 1.2346286493158942e-10
risk O 0 6.798852453249182e-11
of O 0 2.216996904619314e-16
breast B-Disease 0 3.651294733231225e-08
cancer I-Disease 0 5.925678003837476e-11
appears O 0 1.3698093494999425e-13
similar O 0 5.032875488538679e-19
to O 0 4.3232492144688035e-17
the O 0 1.0382336282635646e-16
risk O 0 7.78498562815054e-14
in O 0 6.290689171420169e-20
BRCA1 O 0 4.5456582833773573e-13
carriers O 0 4.616266564460485e-16
, O 0 4.044694406112285e-18
but O 0 8.626653373425725e-17
there O 0 2.0624092920314932e-19
was O 0 2.6753818865668814e-16
some O 0 1.5551366091295757e-21
suggestion O 0 8.40928354333659e-17
of O 0 1.609087626852982e-20
a O 0 1.8120927359284358e-15
lower O 0 7.192609138492734e-13
risk O 0 2.4598064470721104e-13
in O 0 4.041807907665993e-19
BRCA2 O 0 2.2375666857560317e-12
carriers O 0 9.947983081239561e-17
< O 0 2.8598517393747976e-15
50 O 0 1.0293055701272592e-16
years O 0 8.390423094804464e-14
of O 0 1.344810599312248e-15
age O 0 2.0518875487596233e-10
. O 0 7.57728230746206e-14

Eye B-Disease 0 5.096009772387333e-05
movement I-Disease 0 9.219960905859637e-11
abnormalities I-Disease 0 1.081675637948365e-09
correlate O 0 2.0065787681607106e-13
with O 0 1.149882695402379e-15
genotype O 0 2.463005088770842e-08
in O 0 1.1796866084427056e-15
autosomal O 0 0.0018096226267516613
dominant O 0 0.03585510328412056
cerebellar B-Disease 1 0.8160157799720764
ataxia I-Disease 1 0.9898337125778198
type I-Disease 0 1.744889232213609e-06
I I-Disease 0 0.00023323346977122128
. O 0 6.005596627639553e-12

We O 0 3.1647420795088976e-10
compared O 0 3.958569583240035e-12
horizontal O 0 8.250711402979505e-07
eye O 0 0.00015477427223231643
movements O 0 1.4516142528009368e-06
( O 0 5.999625844960513e-14
visually O 0 5.076475351195597e-10
guided O 0 2.031815549141669e-10
saccades O 0 1.0280073325930061e-07
, O 0 7.215658531290782e-15
antisaccades O 0 1.1507456099124624e-10
, O 0 7.298201309665562e-17
and O 0 2.3105854426125436e-16
smooth O 0 2.4738463231047114e-13
pursuit O 0 6.713289646409493e-11
) O 0 8.908712697883447e-17
in O 0 2.726813296990244e-19
control O 0 7.071579243402362e-14
subjects O 0 2.3367033134824577e-12
( O 0 1.6746558429411025e-19
n O 0 3.882549663714041e-13
= O 0 8.456185513101844e-13
14 O 0 1.3224260860849381e-16
) O 0 2.0221724611517407e-18
and O 0 9.389754620029985e-17
patients O 0 1.7326778211634594e-21
with O 0 1.4912804834862587e-23
three O 0 1.0536283330434514e-20
forms O 0 1.0724617498973555e-17
of O 0 6.569324164597317e-17
autosomal O 0 6.813673962824396e-07
dominant O 0 8.643109481454303e-07
cerebellar B-Disease 0 7.288729193533072e-06
ataxias I-Disease 0 7.85805514169624e-06
type I-Disease 0 1.3065728499128682e-09
I I-Disease 0 1.0407483586050148e-07
spinocerebellar B-Disease 0 2.991016117448453e-06
ataxias I-Disease 0 1.0425682717141171e-07
1 I-Disease 0 1.1035141848697236e-14
and I-Disease 0 4.552042133531588e-14
2 I-Disease 0 1.826068356041658e-15
( O 0 6.357031899980277e-19
SCA1 B-Disease 0 4.853143997785025e-10
, O 0 1.3299842669524067e-16
n O 0 2.4141637040148156e-12
= O 0 3.2016654952227164e-12
11 O 0 1.3090115776536685e-14
; O 0 3.765745363475824e-17
SCA2 B-Disease 0 7.203520557830245e-10
, O 0 2.296832274527094e-16
n O 0 1.326162053436053e-12
= O 0 1.0136091618817566e-11
10 O 0 7.078930049428519e-15
) O 0 2.471429111301814e-15
and O 0 5.326598606636423e-10
SCA3 B-Disease 1 0.9999994039535522
/ O 0 2.6124109098191184e-08
Machado B-Disease 0 5.283993118609942e-07
- I-Disease 0 1.8091361297933872e-08
Joseph I-Disease 0 1.033655161464253e-09
disease I-Disease 0 1.1552016076166183e-05
( O 0 4.044019575624952e-16
MJD B-Disease 1 0.999992847442627
) O 0 2.5161486392685783e-15
( O 0 1.1218607072453233e-18
n O 0 1.2317138628481494e-11
= O 0 4.362344929731421e-10
16 O 0 3.28070836014098e-14
) O 0 1.3581943551535763e-15
. O 0 3.359001309521589e-14

In O 0 1.6953758309615295e-15
SCA1 B-Disease 0 9.528627019361746e-12
, O 0 5.098654441812545e-19
saccade O 0 6.263336000560983e-15
amplitude O 0 3.5822015956119425e-16
was O 0 4.797688633905502e-15
significantly O 0 3.972480337570156e-15
increased O 0 4.1764491402867726e-17
, O 0 1.0267956394509773e-16
resulting O 0 1.2507459599812344e-14
in O 0 2.793367488070097e-16
hypermetria B-Disease 0 1.723055106594984e-06
. O 0 5.141228155008948e-13

The O 0 2.128198020305452e-15
smooth O 0 1.5210961830380842e-12
pursuit O 0 4.9145304492626e-10
gain O 0 2.2008059437361727e-12
was O 0 6.13697894585874e-12
decreased O 0 4.5883200017193815e-11
. O 0 2.721677592500138e-13

In O 0 1.1276381067239997e-14
SCA2 B-Disease 0 2.978062796366032e-10
, O 0 3.89570106253607e-17
saccade O 0 7.269042139046444e-13
velocity O 0 6.379154203570853e-14
was O 0 2.8879746901203096e-13
markedly O 0 9.486487984045056e-11
decreased O 0 1.1807110844586077e-11
. O 0 1.7117702383589312e-13

The O 0 1.012266967703691e-14
percentage O 0 2.223072257962616e-13
of O 0 1.9478525578605357e-18
errors O 0 2.17470117434837e-12
in O 0 1.2695538262961817e-17
antisaccades O 0 1.7784036396295555e-11
was O 0 6.182106387952243e-15
greatly O 0 1.9165723507655673e-17
increased O 0 8.888908711888978e-20
and O 0 1.2449983907861163e-17
was O 0 5.2644629610349214e-17
significantly O 0 4.456144796144124e-18
correlated O 0 1.9788079311289545e-16
with O 0 2.1045505015444474e-16
age O 0 7.139770545616653e-12
at O 0 2.550632502516109e-13
disease O 0 2.3620189137929515e-10
onset O 0 5.414284472149422e-12
. O 0 5.80779863220901e-14

In O 0 3.3238687227979977e-16
addition O 0 1.964650321354803e-18
, O 0 9.420590359717373e-21
a O 0 3.5403759357602025e-22
correlation O 0 1.0190333683109736e-18
between O 0 1.0063211987546158e-16
smooth O 0 1.722478409904582e-11
pursuit O 0 1.3234250362259559e-09
gain O 0 1.0311541930648621e-13
and O 0 6.794065034212136e-16
the O 0 2.9162291269648204e-19
number O 0 4.986989195020949e-19
of O 0 1.0004830158938594e-18
trinucleotide O 0 1.3583220659363349e-10
repeats O 0 1.4399659242769758e-09
was O 0 9.07356492458461e-13
found O 0 5.799297131924008e-14
. O 0 4.305563338583701e-14

In O 0 3.711555368601793e-11
SCA3 B-Disease 1 0.9999459981918335
, O 0 1.1170910030333658e-10
gaze B-Disease 0 0.00017106760060414672
- I-Disease 0 2.932792267529294e-05
evoked I-Disease 0 7.456102935066156e-08
nystagmus I-Disease 0 5.1449657867408405e-09
was O 0 1.2075165086583572e-12
often O 0 6.079227989640222e-16
present O 0 2.437788304950611e-21
as O 0 1.4859333583409074e-20
was O 0 1.655072335735055e-16
saccade O 0 8.358799763463765e-13
hypometria O 0 4.0262512074340506e-11
and O 0 4.143744470274345e-16
smooth O 0 7.757194138337947e-14
pursuit O 0 2.1719829060296014e-11
gain O 0 7.26216148712799e-15
was O 0 6.919673709894492e-14
markedly O 0 1.9274659993073762e-11
decreased O 0 2.7127438750190747e-12
. O 0 1.9846232675920644e-14

Three O 0 2.947771557014131e-14
major O 0 9.157068051974328e-17
criteria O 0 2.0297872708039446e-16
, O 0 1.1882157401170435e-19
saccade O 0 7.345971162094067e-15
amplitude O 0 1.2262068490459939e-16
, O 0 1.2615440089501623e-18
saccade O 0 2.516266546254836e-13
velocity O 0 4.927550880350073e-13
, O 0 1.1083060831864017e-15
and O 0 2.16958239839405e-14
presence O 0 4.8326644877701164e-14
of O 0 1.1027272912617243e-14
gaze B-Disease 0 0.006819101981818676
- I-Disease 0 1.9513917948188464e-07
evoked I-Disease 0 1.408358707433166e-10
nystagmus I-Disease 0 2.4075687732501294e-13
, O 0 6.68787399814557e-21
permitted O 0 4.0453034606513363e-22
the O 0 1.7084778405106858e-22
correct O 0 2.9979894723030547e-16
assignment O 0 1.9420377014930533e-16
of O 0 4.6258644346827444e-20
90 O 0 2.4654273253507844e-18
% O 0 1.2309002468969544e-20
of O 0 3.000989199480587e-22
the O 0 9.202060887032925e-18
SCA1 B-Disease 0 7.171797600236118e-10
, O 0 6.191350932008356e-17
90 O 0 2.4321814889662062e-18
% O 0 3.8782579508224644e-20
of O 0 2.5768107390253245e-22
the O 0 2.4609357346246214e-18
SCA2 B-Disease 0 6.038173433475791e-11
, O 0 2.479139705160229e-18
and O 0 1.8041812364428438e-15
93 O 0 3.5071843873361614e-16
% O 0 2.534967527031065e-20
of O 0 4.9784446904089917e-23
the O 0 9.57808726733218e-18
patients O 0 4.7486493437868594e-17
with O 0 3.9177916553306824e-15
SCA3 B-Disease 1 1.0
to O 0 2.5533194265500714e-13
their O 0 4.13145105759437e-15
genetically O 0 2.962698241602398e-17
confirmed O 0 4.846397263537361e-15
patient O 0 1.0925947782148074e-13
group O 0 2.1734963682367228e-14
and O 0 8.231056895097177e-14
, O 0 5.026740186537797e-17
therefore O 0 1.9131610579193986e-17
, O 0 7.47115948179448e-17
may O 0 1.7559662152609977e-14
help O 0 9.996648115144415e-15
orient O 0 5.697600377607692e-12
diagnoses O 0 8.753342495282368e-11
of O 0 9.400425828958347e-19
SCA1 B-Disease 0 1.6194225127552642e-10
, O 0 5.536081198210693e-18
SCA2 B-Disease 0 8.030385384438787e-12
, O 0 6.102084081843471e-18
and O 0 7.872787708210205e-14
SCA3 B-Disease 1 0.9999988079071045
at O 0 8.997068557496115e-16
early O 0 9.823382714901105e-18
clinical O 0 5.21610457621803e-18
stages O 0 3.07669206799278e-16
of O 0 1.8042801178717623e-20
the O 0 2.9619331855625704e-15
diseases O 0 2.417073485805332e-10
. O 0 4.3049512514001915e-16
. O 0 1.470757516426266e-13

Genetic O 0 4.809146245295104e-13
basis O 0 1.533105149984152e-16
and O 0 6.771964224082597e-17
molecular O 0 4.3729075400881015e-14
mechanism O 0 1.14545117835263e-09
for O 0 3.243702906274848e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999946355819702
fibrillation I-Disease 1 0.9999988079071045
. O 0 0.0004324005567468703

Ventricular B-Disease 0 0.007058749906718731
fibrillation I-Disease 0 5.7630863921076525e-06
causes O 0 8.435236537041035e-11
more O 0 1.6668684027630103e-18
than O 0 6.473887188127761e-19
300 O 0 9.391638715160591e-20
, O 0 6.731774185776121e-20
000 O 0 9.756204895813836e-17
sudden O 0 2.942754750274133e-14
deaths O 0 5.542138471238689e-13
each O 0 8.332800769538712e-18
year O 0 1.3690296006148533e-15
in O 0 3.4876759447027515e-18
the O 0 7.040822460648022e-15
USA O 0 7.1967267700756565e-09
alone O 0 7.32055804864018e-11
. O 0 5.592270865846093e-16

In O 0 1.8330047088467236e-16
approximately O 0 3.6601332589707684e-17
5 O 0 3.0933561177410283e-16
- O 0 4.2013798662310364e-08
12 O 0 8.833445086509073e-11
% O 0 4.7269073976942706e-17
of O 0 7.511142895594209e-23
these O 0 3.567234809328258e-20
cases O 0 1.2154373008797546e-20
, O 0 3.1726902154867428e-21
there O 0 2.2197838043806235e-21
are O 0 4.083523708400422e-21
no O 0 3.825205339293789e-18
demonstrable O 0 1.4785168922504255e-10
cardiac O 0 2.432795440654445e-07
or O 0 2.124725995145127e-08
non O 0 9.658778665766476e-09
- O 0 0.041039109230041504
cardiac O 0 0.006548043806105852
causes O 0 1.5190211399840337e-07
to O 0 3.666551095263216e-15
account O 0 1.2958978744447705e-17
for O 0 1.7171368018980142e-20
the O 0 1.2262342948987184e-17
episode O 0 1.930325760346463e-10
, O 0 4.66839925860717e-17
which O 0 1.5846926617968126e-18
is O 0 6.777997910822636e-21
therefore O 0 2.41181723286334e-19
classified O 0 1.5467965450155496e-11
as O 0 9.76403862296138e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999980926513672
fibrillation I-Disease 1 0.9999997615814209
( O 0 4.7305459105473346e-08
IVF B-Disease 1 0.9999915361404419
) O 0 8.087276681667532e-11
. O 0 2.3884773282453753e-13

A O 0 3.4413199523906143e-15
distinct O 0 9.686967893309678e-17
group O 0 8.583720714400753e-16
of O 0 5.938804419189791e-18
IVF B-Disease 1 0.9999982118606567
patients O 0 1.4634308508391057e-14
has O 0 2.5758333964549215e-18
been O 0 1.859696197668003e-18
found O 0 4.5965107286494726e-18
to O 0 2.0323420263976208e-18
present O 0 2.0872059695973309e-19
with O 0 2.032573533571559e-19
a O 0 8.05495080178215e-18
characteristic O 0 8.238349238909315e-13
electrocardiographic O 0 1.3719025560021691e-07
pattern O 0 5.31362616129627e-08
. O 0 8.961823470821084e-12

Because O 0 5.744737910200193e-13
of O 0 1.5052058265080834e-19
the O 0 1.0422563606108232e-18
small O 0 1.7141411543849564e-18
size O 0 2.862067154048341e-15
of O 0 3.243361610888497e-20
most O 0 7.973108104410081e-19
pedigrees O 0 7.869248872319212e-13
and O 0 1.120711277745635e-16
the O 0 2.112229268801614e-18
high O 0 1.8051608385166729e-13
incidence O 0 1.803870386396511e-09
of O 0 1.9734556093445934e-16
sudden B-Disease 0 4.5687318511733466e-11
death I-Disease 0 6.385128537012008e-11
, O 0 1.7266505240705346e-17
however O 0 3.9445366375085854e-19
, O 0 9.114110653140457e-22
molecular O 0 7.273981383781827e-20
genetic O 0 3.630128043256571e-16
studies O 0 2.799245102630654e-16
of O 0 1.3602351346290171e-18
IVF B-Disease 1 0.9999986886978149
have O 0 5.764866259057658e-14
not O 0 1.1886878017528698e-18
yet O 0 6.1016848638003375e-19
been O 0 7.10161555051968e-17
done O 0 1.4755341046224224e-13
. O 0 1.2791542591860175e-14

Because O 0 4.727246719071765e-11
IVF B-Disease 1 0.999874472618103
causes O 0 8.900934335542843e-05
cardiac O 0 5.8999270549975336e-05
rhythm O 0 0.0002543653827160597
disturbance O 0 1.2453460485062351e-08
, O 0 1.1110406231774938e-15
we O 0 8.04926807097391e-18
investigated O 0 3.86755078280191e-18
whether O 0 2.6349780510233818e-17
malfunction O 0 1.1206371768046619e-11
of O 0 4.5119126666056474e-23
ion O 0 5.1153048133021836e-14
channels O 0 1.247558856221076e-07
could O 0 5.3264521682194754e-08
cause O 0 1.315853120908983e-10
the O 0 4.315017581527775e-14
disorder O 0 1.604829324985957e-10
by O 0 5.5698170195547606e-21
studying O 0 6.21242470228164e-19
mutations O 0 9.156719312628075e-17
in O 0 3.472220191279472e-20
the O 0 2.301698090034182e-18
cardiac O 0 1.0951144979449816e-14
sodium O 0 4.2638796825790145e-16
channel O 0 4.7182209528262575e-11
gene O 0 1.2701922846858338e-11
SCN5A O 0 9.01311238976632e-08
. O 0 2.718459409401658e-14

We O 0 2.139798928324499e-11
have O 0 8.988831426781863e-17
now O 0 6.974778653241004e-19
identified O 0 9.07481755456027e-19
a O 0 5.015951373205844e-19
missense O 0 1.1575807214094392e-14
mutation O 0 1.5049161317275453e-15
, O 0 1.2368563692986956e-17
a O 0 3.0976854114951053e-19
splice O 0 4.580907386753097e-07
- O 0 2.8920391414999358e-08
donor O 0 2.291530507014805e-11
mutation O 0 3.746597216497394e-12
, O 0 6.459318142852828e-16
and O 0 1.0383880794275405e-16
a O 0 2.226502667763378e-19
frameshift O 0 3.28602366129159e-15
mutation O 0 2.9353829593375803e-18
in O 0 3.934931131892284e-20
the O 0 1.872152710512439e-18
coding O 0 1.023955586987313e-09
region O 0 2.5530806310215814e-13
of O 0 4.198907342071771e-18
SCN5A O 0 7.651949074372055e-10
in O 0 2.859715113539432e-19
three O 0 1.665586132192849e-16
IVF B-Disease 1 0.9999748468399048
families O 0 1.053106278396665e-12
. O 0 3.6263635112016176e-16

We O 0 4.8067222402879695e-14
show O 0 1.1546071540145879e-16
that O 0 1.382543990973903e-22
sodium O 0 1.3201293666399146e-21
channels O 0 6.573055080032176e-18
with O 0 1.0134891514812457e-19
the O 0 1.0641065303618675e-19
missense O 0 4.775066501466708e-15
mutation O 0 4.7070782240501494e-17
recover O 0 5.3373683917652334e-14
from O 0 2.8737550180973563e-20
inactivation O 0 5.56076875762564e-15
more O 0 1.9747234699761196e-21
rapidly O 0 1.960309360218186e-17
than O 0 3.0236873202362746e-20
normal O 0 3.888112424878447e-18
and O 0 1.0573796036612761e-15
that O 0 5.159983895445717e-16
the O 0 1.3888173225841183e-16
frameshift O 0 4.9182220795973564e-11
mutation O 0 1.1195538336929915e-15
causes O 0 1.7388079747275857e-15
the O 0 1.719804944049638e-20
sodium O 0 1.583551255949066e-17
channel O 0 3.0576579462815445e-11
to O 0 1.5393528914728794e-15
be O 0 1.2424424324718295e-15
non O 0 2.6087668216113894e-15
- O 0 1.509479208294806e-10
functional O 0 1.5285132534681445e-11
. O 0 6.813063568172906e-12

Our O 0 6.142758524063652e-10
results O 0 6.227952681497092e-16
indicate O 0 2.8096114624160664e-16
that O 0 4.3753594423900516e-18
mutations O 0 1.189550836509074e-16
in O 0 2.327852713822496e-18
cardiac O 0 1.657664653600347e-14
ion O 0 3.0644798222449754e-13
- O 0 2.535103637429925e-12
channel O 0 3.905531714004651e-12
genes O 0 1.3615929266236684e-14
contribute O 0 2.2854592938388472e-18
to O 0 1.048272742473954e-19
the O 0 9.05582858962335e-20
risk O 0 8.562524376640204e-17
of O 0 3.1207256631186532e-22
developing O 0 7.797274114804531e-18
IVF B-Disease 1 0.9687809348106384
. O 0 5.585807739760747e-17
. O 0 4.033802505396493e-17

Molecular O 0 2.554415283895911e-13
heterogeneity O 0 1.1991644656428324e-12
in O 0 5.580851061772092e-15
mucopolysaccharidosis B-Disease 0 1.1773328978392783e-08
IVA I-Disease 0 2.638204250615672e-07
in O 0 6.101607934183573e-14
Australia O 0 7.974928226475719e-13
and O 0 1.0791785217192928e-12
Northern O 0 4.013980554190555e-12
Ireland O 0 4.2116135579028935e-10
: O 0 1.2076252490540599e-15
nine O 0 1.0347175399055915e-18
novel O 0 3.426027000829787e-19
mutations O 0 3.409092028751412e-19
including O 0 8.429045667691274e-22
T312S O 0 8.496307079680231e-18
, O 0 2.2076899734801847e-22
a O 0 6.922705040663441e-23
common O 0 2.253675227768318e-20
allele O 0 1.8848238022795775e-16
that O 0 5.142605132696901e-19
confers O 0 9.863995471121045e-14
a O 0 4.013545765402466e-15
mild O 0 1.66763838849171e-10
phenotype O 0 2.2047072500974707e-10
. O 0 5.3606070971046194e-11

Mucopolysaccharidosis B-Disease 0 2.010565367527306e-05
IVA I-Disease 0 0.0010273077059537172
( O 0 2.4388449038070803e-09
MPS B-Disease 1 0.9999853372573853
IVA I-Disease 1 0.9999880790710449
) O 0 9.930751967285323e-13
is O 0 3.169990100154881e-15
an O 0 7.591372192319867e-14
autosomal B-Disease 1 0.9999929666519165
recessive I-Disease 1 0.9999938011169434
lysosomal I-Disease 1 0.999991774559021
storage I-Disease 1 0.9997590184211731
disorder I-Disease 1 0.9999796152114868
caused O 0 2.6429150534745816e-10
by O 0 6.936521549910426e-18
a O 0 9.867645844310532e-14
genetic B-Disease 1 0.9999996423721313
defect I-Disease 1 0.999998927116394
in O 0 1.4123633826799097e-15
N O 0 9.061986577796333e-11
- O 0 5.30018862132664e-10
acetylgalactosamine O 0 1.3907124412071425e-06
- O 0 1.0218334622891234e-08
6 O 0 1.0742619901277228e-12
- O 0 4.0785960719880165e-10
sulfate O 0 1.7934949358977548e-10
sulfatase O 0 2.73843459019929e-09
( O 0 1.912861783973777e-17
GALNS O 0 1.0474940359550544e-10
) O 0 5.957163527449283e-17
. O 0 2.840757128584403e-16

Previous O 0 5.0603984435952654e-14
studies O 0 2.4020057086097e-16
of O 0 4.989802901573336e-20
patients O 0 1.3899818936249194e-18
from O 0 1.0164394074581897e-19
a O 0 3.341028485343737e-17
British O 0 2.4163209627614535e-11
- O 0 1.5639612911400036e-06
Irish O 0 1.6243777167801454e-07
population O 0 2.9782510550628583e-13
showed O 0 3.0531962591853756e-13
that O 0 1.3921561184779694e-20
the O 0 1.1047823049567887e-21
I113F O 0 1.7118998051176674e-18
mutation O 0 2.2902921870405678e-20
is O 0 3.686539618376407e-21
the O 0 5.86223869468611e-23
most O 0 1.3131023956445975e-22
common O 0 7.17816543451463e-20
single O 0 1.0334084852271957e-17
mutation O 0 4.666109350032893e-14
among O 0 1.5675219455779654e-10
MPS B-Disease 1 0.9999994039535522
IVA I-Disease 1 0.9999991655349731
patients O 0 5.906002353839312e-10
and O 0 1.8733217830701338e-13
produces O 0 1.8647767791729608e-13
a O 0 1.760405409058439e-15
severe O 0 1.4661549752048586e-10
clinical O 0 6.384911317106751e-14
phenotype O 0 4.950865273301019e-10
. O 0 8.783440988424651e-12

We O 0 2.414965146260717e-12
studied O 0 2.445552995917024e-16
mutations O 0 3.2917929085744574e-16
in O 0 7.882143052447625e-19
the O 0 8.168072506837299e-19
GALNS O 0 5.272174190273926e-12
gene O 0 1.561215394176664e-16
from O 0 5.54026466415868e-18
23 O 0 1.3227886889782569e-17
additional O 0 2.1765464491764908e-17
MPS B-Disease 1 0.9999945163726807
IVA I-Disease 1 0.9999980926513672
patients O 0 4.28723251344465e-10
( O 0 1.4334872925060234e-17
15 O 0 6.188167014568966e-16
from O 0 1.1684808919461232e-15
Australia O 0 2.9606791532841605e-15
, O 0 2.0581192490314576e-18
8 O 0 3.6174226152222054e-17
from O 0 2.618456243253268e-16
Northern O 0 8.924491598201814e-14
Ireland O 0 5.919936416076688e-12
) O 0 4.286658797354459e-18
, O 0 7.583696010769196e-23
with O 0 2.6631218408228555e-24
various O 0 3.472496537458724e-21
clinical O 0 2.1284498008490235e-15
phenotypes O 0 2.0301165262748277e-12
( O 0 1.4711816152350443e-16
severe O 0 1.935009964759704e-11
, O 0 2.6017377981079384e-17
16 O 0 6.5705987672031995e-18
cases O 0 2.5644404310830755e-18
; O 0 1.2508715695906382e-19
intermediate O 0 2.0837304151573245e-18
, O 0 1.8951875903087668e-20
4 O 0 7.454412093599517e-19
cases O 0 9.919222342213337e-17
; O 0 9.475835507965005e-15
mild O 0 8.022860262420217e-14
, O 0 2.2902246813477652e-18
3 O 0 1.6259409536199584e-17
cases O 0 2.2676663493496172e-17
) O 0 2.6065570185311213e-16
. O 0 3.152283596370535e-14

We O 0 5.2185113869063215e-11
found O 0 1.3180049711469647e-15
two O 0 8.73983153355768e-18
common O 0 3.384861530465473e-18
mutations O 0 2.0749101882856715e-18
that O 0 2.877476800941265e-18
together O 0 5.051889574123622e-15
accounted O 0 2.2306877363738016e-17
for O 0 1.0718998157342102e-20
32 O 0 1.6272581824971675e-15
% O 0 1.3796597135560233e-18
of O 0 5.9533804272575294e-21
the O 0 2.7990955483759043e-16
44 O 0 4.2971066675174326e-17
unrelated O 0 2.030151230273468e-16
alleles O 0 4.516111006496972e-17
in O 0 4.0834209344404864e-18
these O 0 2.4709072543030106e-14
patients O 0 4.670951329172578e-15
. O 0 3.496127812165767e-14

One O 0 2.7779180306286523e-15
is O 0 4.4402625147928e-18
the O 0 2.971036304894994e-19
T312S O 0 1.710304024327234e-14
mutation O 0 1.152710938413261e-15
, O 0 1.7323706434424613e-17
a O 0 1.2147014946443203e-18
novel O 0 3.8796438324851905e-15
mutation O 0 3.5174764729200116e-15
found O 0 4.696734165054051e-15
exclusively O 0 1.6830937473472237e-15
in O 0 4.665176562940663e-17
milder O 0 1.0443769330251151e-12
patients O 0 5.180261228928274e-15
. O 0 1.686903214500029e-14

The O 0 5.350534333084175e-15
other O 0 5.795550302857653e-17
is O 0 5.501615477217752e-19
the O 0 1.153834317229575e-20
previously O 0 1.3330312529131948e-17
described O 0 1.1166322052996746e-15
I113F O 0 1.0182039063342911e-14
that O 0 1.719748529039392e-17
produces O 0 5.543313949681571e-16
a O 0 1.6240759591236719e-16
severe O 0 1.3762774253578414e-10
phenotype O 0 7.489044107078513e-11
. O 0 1.2319064171539829e-11

The O 0 9.720366296540797e-15
I113F O 0 2.4953912634156916e-12
and O 0 1.1801277008499883e-15
T312S O 0 6.571385789851374e-15
mutations O 0 1.4232173158055855e-16
accounted O 0 2.1341725671989104e-16
for O 0 8.949504861637315e-20
8 O 0 9.849170996939732e-16
( O 0 5.676842936639148e-18
18 O 0 9.292879779489865e-14
% O 0 2.3503023956471853e-18
) O 0 5.55321138491363e-19
and O 0 2.399955412421312e-15
6 O 0 2.9679147734174027e-16
( O 0 2.52309267079127e-19
14 O 0 4.444098965238931e-15
% O 0 2.5651255434254225e-18
) O 0 3.0535713524397695e-19
of O 0 3.386238522844671e-21
44 O 0 2.3300814485854437e-19
unrelated O 0 1.5085413599498998e-17
alleles O 0 3.0582158971329996e-16
, O 0 7.661009079078425e-16
respectively O 0 3.236610808467384e-14
. O 0 7.326165498908188e-13

The O 0 2.6938388721304066e-14
relatively O 0 1.4401765777117756e-14
high O 0 5.210069843001458e-14
residual O 0 3.2119654158613287e-12
GALNS O 0 7.099203447324953e-10
activity O 0 9.541384338434405e-14
seen O 0 2.176865357081132e-14
when O 0 2.848230796408687e-18
the O 0 1.890428393729746e-21
T312S O 0 1.734400710101789e-17
mutant O 0 3.5083873064701605e-17
cDNA O 0 4.202196361079792e-16
is O 0 2.564029735908943e-18
overexpressed O 0 1.125545173014629e-14
in O 0 8.413088574154334e-20
mutant O 0 4.97309306365587e-15
cells O 0 2.0234216848224548e-19
provides O 0 3.595975735884393e-23
an O 0 3.7153486924173334e-24
explanation O 0 3.335878531228285e-20
for O 0 1.8464834866473287e-19
the O 0 2.2671950850993577e-13
mild O 0 9.394554023600676e-10
phenotype O 0 9.746088484863247e-13
in O 0 1.6535371464207994e-18
patients O 0 5.973222680695087e-19
with O 0 1.0363915531325942e-20
this O 0 4.055507311079578e-19
mutation O 0 1.363458855503175e-14
. O 0 1.4056441557594446e-12

The O 0 7.249864183390414e-17
distribution O 0 3.107748994225002e-17
and O 0 3.611769001171528e-17
relative O 0 6.9018089155046385e-19
frequencies O 0 3.021109435121708e-17
of O 0 3.527005235665911e-21
the O 0 4.842321509740018e-19
I113F O 0 1.407989939814999e-15
and O 0 1.69175624080223e-17
T312S O 0 1.2822431077649902e-16
mutations O 0 2.1496222165462573e-17
in O 0 3.824634481273551e-19
Australia O 0 3.590390631977429e-19
corresponded O 0 1.885210170071895e-18
to O 0 2.7529544790936042e-18
those O 0 5.282283574715641e-18
observed O 0 1.5743898997927962e-17
in O 0 3.535295078206204e-18
Northern O 0 2.962364240629428e-14
Ireland O 0 2.7858670231806215e-11
and O 0 1.7012892559575138e-13
are O 0 3.520741200451026e-21
unique O 0 4.2793287038426293e-23
to O 0 1.1663459636005423e-18
these O 0 1.77450838189877e-17
two O 0 1.4339530613653397e-16
populations O 0 1.613454827709593e-16
, O 0 2.4375500979368285e-18
suggesting O 0 2.5542993208502673e-16
that O 0 3.055610611143654e-19
both O 0 5.9153943386686624e-21
mutations O 0 5.17687012021963e-20
were O 0 1.1675388614414203e-18
probably O 0 4.2423253415663406e-20
introduced O 0 5.065769181858031e-21
to O 0 8.498548242831882e-17
Australia O 0 1.304405116024968e-15
by O 0 1.695594027972231e-17
Irish O 0 5.50182382291764e-12
migrants O 0 5.386907198388696e-15
during O 0 2.6017475588391665e-17
the O 0 4.738364552281651e-20
19th O 0 7.565890852522013e-17
century O 0 6.518257342300743e-15
. O 0 8.434094250092412e-15

Haplotype O 0 7.843378030392145e-11
analysis O 0 1.0376639589018666e-15
using O 0 3.065457234738636e-16
6 O 0 8.432126698435058e-16
RFLPs O 0 1.478034545882717e-14
provides O 0 5.95042551838964e-22
additional O 0 1.3760504666553582e-23
data O 0 1.9484756316569413e-19
that O 0 1.7135846427784672e-19
the O 0 6.229674261486726e-20
I113F O 0 2.136006181771479e-15
mutation O 0 1.3881544862156673e-17
originated O 0 5.596090455042618e-16
from O 0 7.54696972673508e-20
a O 0 4.9933445916882554e-20
common O 0 6.88091309246063e-18
ancestor O 0 1.945837290124111e-13
. O 0 8.903860287956533e-12

The O 0 1.4778598876889933e-14
other O 0 5.479801725230549e-15
9 O 0 1.308509795335715e-14
novel O 0 1.4317235912388276e-15
mutations O 0 1.607625335208352e-15
identified O 0 1.4795351494520728e-14
in O 0 1.9138107255724978e-17
these O 0 8.514193073716567e-16
23 O 0 6.181416161979349e-17
patients O 0 1.8126767442592571e-19
were O 0 2.348498721859165e-20
each O 0 1.7549824151855893e-21
limited O 0 1.083319868039943e-19
to O 0 2.9291333699273646e-16
a O 0 5.518754758771524e-16
single O 0 7.352024371243271e-12
family O 0 7.432120696648781e-07
. O 0 1.920215375594836e-11

These O 0 1.3219972756553907e-16
data O 0 2.187265717298443e-18
provide O 0 3.612395881937456e-21
further O 0 3.895854582572557e-22
evidence O 0 1.2340544182429705e-21
for O 0 2.5136536829835527e-23
extensive O 0 4.218894352116525e-19
allelic O 0 3.839716224010928e-14
heterogeneity O 0 2.075137208335659e-13
in O 0 5.223741971209679e-14
MPS B-Disease 1 0.999990701675415
IVA I-Disease 1 0.9999927282333374
in O 0 9.1928088405413e-12
British O 0 9.589541605237173e-08
- O 0 0.00010448238026583567
Irish O 0 2.7531573465466863e-08
patients O 0 2.0887394139740842e-15
and O 0 2.837295336232591e-21
provide O 0 1.4358895500639433e-25
evidence O 0 9.269323895625867e-24
for O 0 3.7082690602234275e-24
their O 0 1.831562957854462e-18
transmission O 0 7.195095430067645e-16
to O 0 1.791046824271002e-18
Australia O 0 2.1587507336322088e-18
by O 0 2.8954340648591787e-19
British O 0 1.2933776228837846e-12
- O 0 2.696537992896708e-10
Irish O 0 3.760814359585196e-13
migrants O 0 1.1128136748943338e-15
. O 0 3.481944668732313e-19
. O 0 2.3120645242658497e-18

Identification O 0 1.3674983556286307e-14
of O 0 5.395804187621194e-18
constitutional O 0 3.4079938645973674e-15
WT1 O 0 4.692519706139819e-10
mutations O 0 3.7782139070997867e-13
, O 0 1.639475812198143e-16
in O 0 1.9753883406272661e-19
patients O 0 3.2667087061296236e-18
with O 0 7.649349405861673e-18
isolated O 0 5.373070433023486e-09
diffuse B-Disease 0 0.028209887444972992
mesangial I-Disease 1 0.9999958276748657
sclerosis I-Disease 1 0.9999988079071045
, O 0 1.586934929168407e-13
and O 0 1.5865443262775278e-17
analysis O 0 2.0899716996741902e-18
of O 0 8.900818174005181e-20
genotype O 0 2.2796684678860757e-11
/ O 0 1.5497545738027418e-12
phenotype O 0 2.8050922769446687e-16
correlations O 0 3.58791451851254e-18
by O 0 1.524679459507236e-21
use O 0 4.995440331318341e-20
of O 0 6.342951395717678e-21
a O 0 6.716310561212325e-19
computerized O 0 3.6159860235208605e-14
mutation O 0 2.4707597435152462e-15
database O 0 1.6976556879017002e-13
. O 0 2.0713617453205213e-12

Constitutional O 0 1.5759261300443694e-12
mutations O 0 3.613761037375013e-13
of O 0 1.232607163171526e-18
the O 0 7.536731557197146e-19
WT1 O 0 1.0267026961138619e-14
gene O 0 8.33861915796741e-18
, O 0 4.207848389011645e-21
encoding O 0 2.5141671334878816e-19
a O 0 1.4765171287093584e-16
zinc O 0 9.048143567724765e-09
- O 0 4.592279334580951e-10
finger O 0 7.610769330312905e-07
transcription O 0 1.0900771604815951e-11
factor O 0 8.29358503667008e-15
involved O 0 4.045637805600902e-17
in O 0 7.277517162140306e-17
renal O 0 2.280144739685852e-09
and O 0 5.8225559790292536e-12
gonadal O 0 5.197688679459134e-08
development O 0 9.669324726413963e-16
, O 0 1.837182864295178e-17
are O 0 1.8079660799177384e-20
found O 0 1.3911800130434142e-19
in O 0 1.4596336243337625e-22
most O 0 1.3369657232796364e-20
patients O 0 2.516806098135867e-19
with O 0 2.62522869518304e-15
Denys B-Disease 1 0.9999703168869019
- I-Disease 1 0.9999961853027344
Drash I-Disease 1 0.9999842643737793
syndrome I-Disease 1 0.9999966621398926
( O 0 3.481109918010948e-14
DDS B-Disease 1 0.9999940395355225
) O 0 7.627503632058597e-16
, O 0 2.5983937136865396e-18
or O 0 3.044949546410908e-13
diffuse B-Disease 0 0.005857646930962801
mesangial I-Disease 1 0.9999980926513672
sclerosis I-Disease 1 0.9999986886978149
( O 0 3.931226438130819e-12
DMS B-Disease 0 3.7501553151741973e-07
) O 0 2.0065911411944876e-16
associated O 0 5.684476754901828e-16
with O 0 1.6258567029584642e-14
pseudohermaphroditism B-Disease 1 0.999996542930603
and O 0 2.700973819602659e-11
/ O 0 5.679789971679838e-10
or O 0 6.319384251995963e-12
Wilms B-Disease 0 2.109635630631601e-07
tumor I-Disease 0 0.00020601564028766006
( O 0 3.678698665132707e-11
WT B-Disease 1 0.9999955892562866
) O 0 1.122659839983102e-13
. O 0 3.178959035571825e-14

Most O 0 1.753020446428684e-15
mutations O 0 1.3696167680890547e-12
in O 0 7.191703829678708e-13
DDS B-Disease 1 0.9999979734420776
patients O 0 5.779896006252727e-10
lie O 0 3.4279495908506874e-11
in O 0 3.1580002164375984e-18
exon O 0 8.380794701886435e-14
8 O 0 4.888548672311345e-14
or O 0 1.0035812377526612e-14
exon O 0 6.396039974780957e-14
9 O 0 1.417394440749245e-14
, O 0 1.5303806031620402e-18
encoding O 0 2.392456417981033e-14
zinc O 0 3.231546361348592e-05
finger O 0 0.0388728566467762
2 O 0 2.717902292115326e-12
or O 0 2.5078567000846874e-10
zinc O 0 2.689930340693536e-07
finger O 0 1.1071479093516245e-05
3 O 0 5.84603031131628e-14
, O 0 4.055204116297853e-16
respectively O 0 2.6777813720877753e-16
, O 0 2.161197947474447e-18
with O 0 5.062494903079279e-17
a O 0 6.505588694025134e-15
hot O 0 5.103526291350136e-06
spot O 0 7.410505986626958e-07
( O 0 3.828404625748961e-17
R394W O 0 9.524688133197897e-15
) O 0 6.300130145642754e-19
in O 0 3.331696099256064e-19
exon O 0 2.0697504040517734e-12
9 O 0 2.7968826907254218e-11
. O 0 5.426574445875632e-13

We O 0 2.420930446942523e-14
analyzed O 0 1.2418257395466691e-16
a O 0 2.8920684737418536e-18
series O 0 4.8533561474188233e-14
of O 0 9.550468533859647e-18
24 O 0 6.577584207552792e-14
patients O 0 3.7388639788013206e-17
, O 0 3.6559152272129344e-19
10 O 0 1.2894971508648352e-17
with O 0 4.398778890912563e-15
isolated B-Disease 0 5.972093930495248e-08
DMS I-Disease 0 0.00012665946269407868
( O 0 6.453674388795053e-17
IDMS B-Disease 0 9.165903452901247e-11
) O 0 3.86629876222675e-17
, O 0 8.946164085938367e-19
10 O 0 8.818964387243025e-19
with O 0 3.231265787048237e-16
DDS B-Disease 1 0.9999995231628418
, O 0 3.685088411313877e-15
and O 0 3.540401843153923e-15
4 O 0 5.910559907040249e-16
with O 0 3.6418937120587594e-14
urogenital B-Disease 0 1.1959998118982185e-05
abnormalities I-Disease 0 0.008617217652499676
and O 0 8.144401264509327e-10
/ O 0 4.211539817333687e-06
or O 0 8.595938197686337e-06
WT B-Disease 1 0.9999935626983643
. O 0 1.3460657068142812e-11

We O 0 4.1583628901387115e-11
report O 0 5.23667074330339e-14
WT1 O 0 6.280554964988028e-10
heterozygous O 0 3.2606662053562274e-13
mutations O 0 3.2466284977279714e-13
in O 0 1.9480559235228543e-15
16 O 0 1.1894205204901389e-14
patients O 0 4.3152932589883705e-16
, O 0 3.919638759564681e-18
4 O 0 2.0638685678790074e-16
of O 0 6.301572541835894e-19
whom O 0 3.763034924219059e-15
presented O 0 9.542321665093837e-16
with O 0 8.314575021322809e-14
IDMS B-Disease 0 8.146424988808576e-06
. O 0 9.758606683146764e-13

One O 0 1.0797308359900004e-11
male O 0 4.2051118143149324e-10
and O 0 2.1755538112656035e-14
two O 0 1.5716911270913909e-15
female O 0 1.197269822346414e-12
IDMS B-Disease 0 5.058980456773554e-10
patients O 0 5.541511638932103e-18
with O 0 4.428016105823952e-18
WT1 O 0 5.138268033277882e-09
mutations O 0 2.2219140416446237e-10
underwent O 0 1.9659479599809515e-10
normal O 0 5.934381430705571e-09
puberty O 0 7.256908429553732e-05
. O 0 1.733380800006401e-11

Two O 0 1.188986192487973e-12
mutations O 0 6.472820326605677e-13
associated O 0 1.529681193995422e-13
with O 0 7.863265194410583e-16
IDMS B-Disease 0 3.1308815540143087e-09
are O 0 5.2215796846925186e-18
different O 0 2.415905573040883e-19
from O 0 7.482649351375087e-18
those O 0 1.0158444960597143e-15
described O 0 4.046979087566835e-14
in O 0 1.2085514795818824e-15
DDS B-Disease 1 0.9999963045120239
patients O 0 7.589490423924247e-14
. O 0 6.224012919501176e-15

No O 0 3.7633402795965443e-13
WT1 O 0 5.145117665250609e-11
mutations O 0 5.460512752142495e-14
were O 0 2.2222730993175406e-15
detected O 0 1.5574760719398034e-13
in O 0 1.754657081173263e-18
the O 0 9.490513159572824e-17
six O 0 1.9694481641222353e-15
other O 0 2.6402819000238473e-16
IDMS B-Disease 0 6.2795515454183715e-09
patients O 0 2.7166411261254344e-17
, O 0 4.439173970956074e-20
suggesting O 0 8.834496068091719e-17
genetic O 0 6.0440836397465756e-15
heterogeneity O 0 4.1372412901185054e-14
of O 0 4.2014066682926e-18
this O 0 3.2615708788955424e-15
disease O 0 5.700106497918966e-10
. O 0 3.15958657891649e-13

We O 0 1.4184714600823378e-13
analyzed O 0 3.5428555705471765e-14
genotype O 0 5.478268949588028e-10
/ O 0 1.6418945092411263e-09
phenotype O 0 1.4057916072549026e-12
correlations O 0 3.704500356645213e-13
, O 0 7.704350299151549e-17
on O 0 3.85584517128266e-15
the O 0 2.4957643811113198e-18
basis O 0 6.413447272117619e-18
of O 0 2.3520042228222852e-20
the O 0 2.5457681108846403e-16
constitution O 0 1.8537768683891552e-16
of O 0 9.238975343751184e-22
a O 0 2.882693673968272e-19
WT1 O 0 1.2970082906987868e-13
mutation O 0 6.813627739893729e-18
database O 0 7.128431422489669e-17
of O 0 4.903108448696641e-17
84 O 0 3.121321831642959e-14
germ O 0 7.947960511955898e-07
- O 0 7.443203230650397e-06
line O 0 5.364522337458766e-08
mutations O 0 3.0604669189540634e-13
, O 0 1.3721592533516987e-18
to O 0 3.0748086976791856e-20
compare O 0 2.06630750991512e-19
the O 0 3.8375206789032916e-21
distribution O 0 7.511145127907497e-15
and O 0 4.17494684656905e-12
type O 0 1.616247114171864e-14
of O 0 1.2214011923169053e-19
mutations O 0 9.685711240523087e-17
, O 0 3.37585927216027e-19
according O 0 4.934377115329595e-21
to O 0 3.216294322541201e-19
the O 0 3.1267139709241584e-18
different O 0 2.039134377844476e-13
symptoms O 0 6.432421956192869e-11
. O 0 2.4085752432090454e-16

This O 0 6.379296505105991e-15
demonstrated O 0 3.97484525355889e-15
( O 0 5.383506493454368e-19
1 O 0 2.4647232705724098e-17
) O 0 1.7425195672233357e-15
the O 0 2.9082586135191968e-15
association O 0 5.1198819642821866e-18
between O 0 1.4859235743452246e-18
mutations O 0 5.949237813692045e-17
in O 0 6.289396443219113e-19
exons O 0 4.3376487297852595e-12
8 O 0 1.9208130569501984e-14
and O 0 6.810155907352889e-15
9 O 0 2.499903606131425e-15
and O 0 1.2289335063367206e-14
DMS B-Disease 0 4.335901859775504e-09
; O 0 2.415871307084008e-17
( O 0 3.308201584920144e-20
2 O 0 7.187986441360017e-17
) O 0 1.3699110178058102e-17
among O 0 2.690874108832405e-19
patients O 0 5.313905190268683e-21
with O 0 3.4080612680041174e-21
DMS B-Disease 0 6.502208168591983e-13
, O 0 2.4372941877231295e-22
a O 0 1.6543153134013715e-23
higher O 0 5.993093174595744e-22
frequency O 0 4.582979294599024e-17
of O 0 3.4661194111444665e-20
exon O 0 4.2180522990447125e-14
8 O 0 1.2232641242383344e-15
mutations O 0 7.210262613779417e-16
among O 0 8.50136446194538e-18
46 O 0 9.356068682200498e-18
, O 0 3.554929399117281e-19
XY O 0 1.3436730894600402e-10
patients O 0 2.039806090654993e-18
with O 0 4.5713135664201885e-18
female O 0 3.445595891937714e-11
phenotype O 0 5.302789457539703e-13
than O 0 9.609017039360641e-17
among O 0 2.4123545983405757e-16
46 O 0 1.1141096353036329e-14
, O 0 5.16711379527923e-16
XY O 0 3.817731908384303e-08
patients O 0 2.724767513899278e-17
with O 0 1.424670875835067e-19
sexual O 0 3.3916559881788655e-13
ambiguity O 0 8.375785308378791e-12
or O 0 8.469931006560572e-11
male O 0 5.918632250967448e-10
phenotype O 0 3.4198872574976724e-13
; O 0 5.128448858819439e-16
and O 0 4.74567162910694e-13
( O 0 5.555054446715975e-19
3 O 0 4.896321100898399e-18
) O 0 2.4053200522691625e-20
statistically O 0 3.656718909110625e-22
significant O 0 6.646819808615245e-22
evidence O 0 3.360047021987556e-17
that O 0 1.2797515868204212e-15
mutations O 0 3.214839700618608e-16
in O 0 1.1271455641789246e-18
exons O 0 1.3180177435567764e-11
8 O 0 1.0240746916917107e-13
and O 0 8.101402578300498e-15
9 O 0 4.106307202192481e-17
preferentially O 0 1.32507164420613e-13
affect O 0 7.553609536531316e-16
amino O 0 6.631764637598433e-18
acids O 0 1.7941768821712514e-20
with O 0 4.859579570972397e-22
different O 0 1.1540890145412332e-21
functions O 0 2.755327505174654e-19
. O 0 4.189935559168286e-16
. O 0 2.737973185033913e-14

The O 0 1.468928031139315e-15
185delAG O 0 7.242197726936572e-12
BRCA1 O 0 3.7421658111679024e-14
mutation O 0 1.8740909683955795e-16
originated O 0 1.6448578330752173e-15
before O 0 4.132219131189072e-17
the O 0 5.933454421782951e-20
dispersion O 0 2.0982610722704298e-13
of O 0 6.771853671393729e-19
Jews O 0 2.4655169060332736e-14
in O 0 5.370422977705617e-18
the O 0 4.157596701509954e-17
diaspora O 0 1.2450497230420687e-11
and O 0 3.1716868172625146e-13
is O 0 4.061626875969307e-17
not O 0 1.1072062307567266e-17
limited O 0 7.459930939248894e-19
to O 0 7.31370801594633e-14
Ashkenazim O 0 9.836065828494611e-07
. O 0 3.1599015938577057e-12

The O 0 2.0444520845686563e-15
185delAG O 0 1.9598433119438763e-12
mutation O 0 3.6919106264292996e-16
in O 0 1.8514851893174954e-18
BRCA1 O 0 1.4027856296266322e-13
is O 0 2.994000741214875e-16
detected O 0 1.1862086562574453e-13
in O 0 1.0647208282889618e-17
Ashkenazi O 0 6.831323701161907e-11
Jews O 0 2.0483955311578934e-14
both O 0 8.1440571789082e-18
in O 0 2.473454492810152e-17
familial B-Disease 0 0.3075001835823059
breast I-Disease 1 0.9999983310699463
and I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.296855827898518e-12
in O 0 9.422710817830608e-21
the O 0 3.953390184249288e-21
general O 0 1.092854093951897e-19
population O 0 2.5860443620904598e-17
. O 0 2.1466344123804472e-14

All O 0 7.36412816035141e-14
tested O 0 2.4410456837299643e-13
Ashkenazi O 0 4.746452363091347e-12
mutation O 0 7.571124377935522e-15
carriers O 0 6.584279854770071e-16
share O 0 1.4993163108864635e-17
the O 0 4.9743708132703935e-20
same O 0 1.116895245425744e-17
allelic O 0 9.474815680296511e-13
pattern O 0 2.5870736108934977e-11
at O 0 1.8490590272218467e-16
the O 0 7.495330133563101e-19
BRCA1 O 0 1.357533443296921e-12
locus O 0 8.4231510655286e-10
. O 0 3.559401384745087e-11

Our O 0 2.0432166375483618e-11
previous O 0 4.3026550509593035e-15
study O 0 5.308179704562533e-18
showed O 0 2.490155898034863e-16
that O 0 1.485644329802654e-20
this O 0 1.6466805623128164e-20
Ashkenazi O 0 1.7209449143518185e-11
mutation O 0 5.545963468740582e-14
also O 0 1.7873188823055997e-12
occurs O 0 8.811051524894656e-14
in O 0 2.9559687964470344e-18
Iraqi O 0 2.835110347442632e-13
Jews O 0 2.312402063586608e-16
with O 0 5.434489382768162e-20
a O 0 3.307924027050541e-20
similar O 0 1.8650467741012717e-17
allelic O 0 3.5925838692829615e-11
pattern O 0 2.933870746346656e-07
. O 0 5.416528336965598e-11

We O 0 2.745914823645834e-12
extended O 0 4.547125911954076e-16
our O 0 1.4297036029480833e-16
analysis O 0 8.108337788148752e-20
to O 0 1.0864112617089039e-19
other O 0 1.1225285521923833e-18
non O 0 1.4841340724875427e-17
- O 0 4.1321961585967515e-13
Ashkenazi O 0 2.199539855807231e-11
subsets O 0 1.7671942722515639e-15
354 O 0 4.477534214403255e-16
of O 0 3.4181762066139295e-22
Moroccan O 0 3.883656651072808e-15
origin O 0 8.849612297477758e-16
, O 0 6.86478927437044e-18
200 O 0 6.007316480605108e-19
Yemenites O 0 2.3470100510422295e-14
and O 0 2.3227536002954437e-17
150 O 0 1.4481450983965856e-18
Iranian O 0 1.0344552498669016e-14
Jews O 0 2.309627437761287e-14
. O 0 1.831339611479011e-14

Heteroduplex O 0 1.302757346444139e-10
analysis O 0 1.0589244428645577e-17
complemented O 0 7.639343829172232e-19
by O 0 8.36915471667817e-24
direct O 0 6.036616082240853e-23
DNA O 0 3.730114724026225e-18
sequencing O 0 2.3843860998178307e-16
of O 0 7.119642406176503e-20
abnormally O 0 1.0253361355084091e-15
migrating O 0 3.88984826339389e-18
bands O 0 3.268242406849649e-14
were O 0 5.096795237580546e-16
employed O 0 6.597026641835064e-16
. O 0 6.793132239178972e-16

Four O 0 2.727445819108304e-13
of O 0 3.643816159790698e-19
Moroccan O 0 3.269546905351056e-13
origin O 0 1.380768143186906e-14
( O 0 6.48132134463611e-20
1 O 0 7.244651368718287e-21
. O 0 7.663712053030161e-20
1 O 0 5.48307318981161e-19
% O 0 3.2040346657578556e-20
) O 0 5.459093223853698e-19
and O 0 5.5097152019826026e-14
none O 0 1.566596568020791e-16
of O 0 1.3621737722437964e-23
the O 0 2.5771197140062297e-19
Yemenites O 0 7.779612728759516e-14
or O 0 2.2850507079752767e-17
Iranians O 0 9.696543336080592e-17
was O 0 1.7810867838742818e-17
a O 0 7.865229406119418e-20
carrier O 0 1.5468809497311612e-16
of O 0 6.863966533391331e-21
the O 0 1.0561373901394583e-16
185delAG O 0 6.3266178962351205e-09
mutation O 0 2.4314456155936914e-13
. O 0 1.6426522143377087e-13

BRCA1 O 0 2.368493845494868e-09
allelic O 0 6.551966191814529e-10
patterns O 0 4.857183988349334e-09
were O 0 1.3011480625845385e-14
determined O 0 2.8848322232969846e-16
for O 0 9.225213207089189e-20
four O 0 1.8007415878452768e-17
of O 0 1.3057452895158891e-21
these O 0 5.328345540715963e-18
individuals O 0 6.44588651046973e-21
and O 0 1.0874774975184847e-18
for O 0 5.452653529888712e-22
12 O 0 1.1971188046033996e-20
additional O 0 2.6204080141656903e-21
non O 0 2.323728349929276e-17
- O 0 6.15383716207063e-11
Ashkenazi O 0 1.3021555389514106e-07
185delAG O 0 1.4815289273162335e-10
mutation O 0 1.160689162919273e-14
carriers O 0 1.4677166879979577e-17
who O 0 3.0628507555412567e-16
had O 0 1.702170696060712e-11
breast B-Disease 1 0.9905126690864563
/ I-Disease 1 0.9998908042907715
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999955892562866
. O 0 1.4511308821241187e-11

Six O 0 1.2213041689079773e-10
non O 0 1.1555590468878552e-12
- O 0 5.197203023499242e-08
Ashkenazi O 0 2.1485209344973555e-06
individuals O 0 1.0857967120087107e-14
shared O 0 1.6759045816771824e-16
the O 0 1.9336813771544596e-19
common O 0 6.95809772900826e-17
Ashkenazi O 0 5.40874463272889e-11
haplotype O 0 2.2858011039517123e-09
, O 0 8.730214427353673e-15
four O 0 4.202659516048373e-17
had O 0 1.048318283419566e-16
a O 0 2.9482165001358658e-21
closely O 0 3.325946997543425e-17
related O 0 1.915492377140373e-15
pattern O 0 2.6064059244212956e-10
, O 0 3.475886731693352e-15
and O 0 4.8148889931522165e-14
the O 0 2.8543913414803227e-15
rest O 0 2.4021299272619645e-12
( O 0 7.538226686154335e-19
n O 0 6.9245924098904066e-12
= O 0 2.5958075966503458e-11
6 O 0 2.145492442560959e-14
) O 0 1.0375560515365979e-17
displayed O 0 2.631323203117653e-16
a O 0 5.49018577985683e-20
distinct O 0 5.508928911885578e-17
BRCA1 O 0 3.312093307950015e-11
allelic O 0 9.943351697572211e-10
pattern O 0 5.114305849929224e-07
. O 0 1.1046197984088124e-10

We O 0 4.440116639837415e-15
conclude O 0 7.949090708529451e-18
that O 0 5.409955076552868e-21
the O 0 3.436221678762076e-20
185delAG O 0 5.371822344585331e-12
BRCA1 O 0 1.4035250826133217e-12
mutation O 0 2.0228403777326417e-14
occurs O 0 2.41931481629893e-14
in O 0 1.2019422853944781e-19
some O 0 5.425481256650488e-19
non O 0 2.374736806361828e-16
- O 0 2.177452218532494e-09
Ashkenazi O 0 8.474517926515546e-06
populations O 0 1.7582421629747103e-10
at O 0 2.0370470176118982e-13
rates O 0 2.2949080380170808e-14
comparable O 0 1.5796281709482742e-19
with O 0 4.8837993829572387e-20
that O 0 2.999522072541993e-16
of O 0 7.555478964715686e-17
Ashkenazim O 0 3.239374990471333e-08
. O 0 2.322102742296356e-13

The O 0 6.986193578934624e-14
majority O 0 7.936373137483693e-16
of O 0 2.1385374379911333e-19
Jewish O 0 1.1631326327435354e-12
185delAG O 0 1.1447538750264385e-10
mutation O 0 4.115987624109295e-15
carriers O 0 2.5445337919745887e-17
have O 0 5.960066890040314e-19
a O 0 1.6683687532978166e-19
common O 0 6.210704443713035e-16
allelic O 0 2.885413297182282e-10
pattern O 0 3.941904083148984e-07
, O 0 2.5482859163203538e-15
supporting O 0 2.1062211416840085e-16
the O 0 1.206384245283888e-19
founder O 0 6.26813698330602e-16
effect O 0 1.0859897097892315e-17
notion O 0 7.365971224635297e-17
, O 0 1.6515081137372374e-17
but O 0 1.9708978345416814e-16
dating O 0 1.3738506859928279e-11
the O 0 1.1934311655779786e-18
mutations O 0 4.703683557534293e-18
origin O 0 3.0012229688804097e-19
to O 0 1.921351552190715e-18
an O 0 1.306633494893457e-19
earlier O 0 7.712506712919884e-14
date O 0 2.9787451802029685e-13
than O 0 3.880557701625939e-17
currently O 0 4.891280675835807e-18
estimated O 0 5.768113052811514e-17
. O 0 9.131543719960444e-15

However O 0 8.176101566885908e-15
, O 0 4.478125259766343e-19
the O 0 4.024879511027253e-21
different O 0 2.1086697555294334e-19
allelic O 0 5.187224347974473e-14
pattern O 0 7.684289944805134e-13
at O 0 2.739901941258793e-17
the O 0 3.438489639980635e-20
BRCA1 O 0 5.817839868985531e-15
locus O 0 2.1446722436174737e-12
even O 0 1.7023126614931772e-12
in O 0 6.758025072708221e-18
some O 0 4.62569014514274e-19
Jewish O 0 1.2151912776817847e-13
mutation O 0 5.986446012301236e-14
carriers O 0 2.353544994933591e-15
, O 0 2.5166177367026796e-16
might O 0 6.027325177588444e-14
suggest O 0 6.6915945881433365e-15
that O 0 3.1415901442246284e-16
the O 0 2.3362339973020978e-17
mutation O 0 2.873408726688729e-17
arose O 0 1.7272962212566935e-17
independently O 0 1.286858907931934e-16
. O 0 1.4276714914982815e-15
. O 0 2.065383861117251e-13

Crystal O 0 9.140069812119123e-10
structure O 0 4.219804640805992e-15
of O 0 3.91619949767405e-19
the O 0 1.0797074715602383e-16
hemochromatosis B-Disease 1 0.999982476234436
protein O 0 7.582573891690148e-14
HFE O 0 1.091033513533901e-12
and O 0 2.0612327072262705e-16
characterization O 0 1.492407466799849e-15
of O 0 1.1823862251397544e-21
its O 0 3.316756441911532e-20
interaction O 0 5.485557284276941e-21
with O 0 5.760427220785681e-21
transferrin O 0 3.281689181942253e-15
receptor O 0 2.279496190161983e-17
. O 0 1.1085258882362141e-15

HFE O 0 4.2871364236418685e-09
is O 0 5.632971857752846e-16
an O 0 2.706614838901406e-19
MHC O 0 8.827149216650634e-14
- O 0 6.894768176529675e-12
related O 0 2.4853423897901183e-14
protein O 0 1.667549189281626e-14
that O 0 1.904210870633756e-19
is O 0 5.822859768039436e-22
mutated O 0 1.0947530679937714e-18
in O 0 2.8061675765858116e-20
the O 0 1.717088885289683e-15
iron B-Disease 0 0.06865877658128738
- I-Disease 0 0.20259250700473785
overload I-Disease 1 0.995128870010376
disease I-Disease 1 0.999830961227417
hereditary B-Disease 1 0.9999997615814209
hemochromatosis I-Disease 1 1.0
. O 0 3.129812284896616e-07

HFE O 0 4.3149772643857887e-10
binds O 0 1.2285012417068142e-12
to O 0 6.217460590258572e-16
transferrin O 0 1.8712292728772367e-13
receptor O 0 9.24760608021736e-16
( O 0 5.888319104863842e-18
TfR O 0 8.893290964762102e-11
) O 0 1.4615038998531944e-17
and O 0 1.5929908756633986e-17
reduces O 0 8.354567096779856e-19
its O 0 1.3081982556561175e-21
affinity O 0 2.358709239007715e-18
for O 0 2.837817574773622e-19
iron O 0 5.903250804850657e-11
- O 0 6.646800080820081e-13
loaded O 0 2.2612332267594494e-15
transferrin O 0 2.1081765754762602e-14
, O 0 2.3954216730172292e-20
implicating O 0 4.913623219242325e-13
HFE O 0 9.533122902194435e-11
in O 0 1.162877371953342e-16
iron O 0 1.358675172369317e-09
metabolism O 0 5.328984128971648e-11
. O 0 8.309517895814522e-14

The O 0 2.0632418842002342e-13
2 O 0 1.4668836891690296e-12
. O 0 3.9739015572116954e-13

6 O 0 3.6090963551060895e-10
A O 0 4.9492549815399745e-12
crystal O 0 4.828530464351388e-09
structure O 0 2.820628659024743e-13
of O 0 1.5806656363821747e-18
HFE O 0 3.7789220537487456e-12
reveals O 0 1.2669716595913668e-15
the O 0 6.438535286087931e-22
locations O 0 1.3438803263527718e-18
of O 0 9.40728108828488e-18
hemochromatosis B-Disease 1 0.9999988079071045
mutations O 0 1.5615639207058885e-12
and O 0 4.021341094319342e-14
a O 0 2.598505440971877e-16
patch O 0 0.0007069520652294159
of O 0 3.221494997303863e-15
histidines O 0 4.700261069245926e-09
that O 0 6.025985086762593e-16
could O 0 1.594219768268632e-16
be O 0 3.35082775284865e-19
involved O 0 4.486899371318846e-18
in O 0 2.6356729819996e-16
pH O 0 4.689831712312298e-06
- O 0 9.609789408671077e-09
dependent O 0 5.146162901197016e-13
interactions O 0 2.5247084154203514e-13
. O 0 5.300460794561111e-14

We O 0 1.8478534674626346e-12
also O 0 3.3533627408936374e-17
demonstrate O 0 7.661706822468725e-17
that O 0 2.6191243074031905e-17
soluble O 0 7.924748097326573e-14
TfR O 0 6.923467132935457e-09
and O 0 7.253803135411074e-14
HFE O 0 1.8529942857892223e-10
bind O 0 1.4660033603730582e-11
tightly O 0 1.7703793292467296e-11
at O 0 4.369845515983777e-15
the O 0 1.0780641821476313e-18
basic O 0 1.8168272265871137e-15
pH O 0 1.1354397456975196e-11
of O 0 9.769001095546696e-20
the O 0 8.433280383778998e-17
cell O 0 5.262017384322082e-12
surface O 0 1.9271279017019083e-11
, O 0 1.7931619730737758e-15
but O 0 2.312023863375659e-15
not O 0 1.549403572666762e-15
at O 0 7.571384417050329e-15
the O 0 1.853134446838222e-15
acidic O 0 1.076770939079097e-08
pH O 0 5.243740552884901e-09
of O 0 1.9590674726055296e-18
intracellular O 0 6.399075713758862e-11
vesicles O 0 2.804319554350343e-10
. O 0 2.6667787769718565e-11

TfR O 0 9.787682938622311e-05
HFE O 0 3.0005361395524233e-07
stoichiometry O 0 6.629817805858806e-10
( O 0 4.762586741538337e-15
2 O 0 9.362219167101523e-16
1 O 0 2.6972794749635282e-17
) O 0 2.9717198042351466e-17
differs O 0 2.1190329967612186e-14
from O 0 1.5781007312823826e-16
TfR O 0 5.279844617067653e-11
transferrin O 0 1.9266002909777008e-13
stoichiometry O 0 1.5216859017755228e-15
( O 0 3.5542089765025355e-20
2 O 0 9.619862369807946e-19
2 O 0 6.821976060225921e-18
) O 0 1.4434901394994434e-18
, O 0 4.81752024390672e-20
implying O 0 1.0801512622306791e-18
a O 0 2.2761353952583772e-23
different O 0 6.613355445491556e-23
mode O 0 2.57087734381481e-17
of O 0 2.861695485606899e-23
binding O 0 6.528920031268796e-19
for O 0 1.9379856243965764e-20
HFE O 0 2.307313845192893e-12
and O 0 9.144999685360526e-15
transferrin O 0 3.430570931495236e-12
to O 0 1.2970176758238423e-14
TfR O 0 1.86041695937611e-10
, O 0 4.761089892045473e-18
consistent O 0 5.745578336819854e-18
with O 0 1.9040727056220654e-19
our O 0 1.093602186792108e-16
demonstration O 0 1.769376165637579e-19
that O 0 8.463295105187839e-22
HFE O 0 3.74260618359718e-15
, O 0 6.146726916105381e-19
transferrin O 0 5.532632728691422e-13
, O 0 2.033754561370647e-17
and O 0 2.4144284526328094e-14
TfR O 0 9.528650091183977e-11
form O 0 2.4679665113373807e-19
a O 0 2.747719252996756e-18
ternary O 0 2.0163302519066346e-14
complex O 0 1.1959271734810623e-13
. O 0 1.1097546492866428e-12

Identification O 0 1.2940869418263425e-14
of O 0 2.8123216452468413e-18
three O 0 1.2106268029468841e-17
novel O 0 2.502506961894811e-16
mutations O 0 2.341562866861732e-15
and O 0 5.151509542566674e-15
a O 0 6.474183422184631e-19
high O 0 1.0347857409470965e-16
frequency O 0 1.4619753433038618e-13
of O 0 1.9787067566002816e-19
the O 0 1.5827013907353943e-15
Arg778Leu O 0 2.192848125304181e-09
mutation O 0 3.987239209049705e-14
in O 0 2.936002013036209e-16
Korean O 0 2.0199220074346158e-10
patients O 0 6.783935843651955e-17
with O 0 3.98274891798972e-17
Wilson B-Disease 0 2.246640429248714e-09
disease I-Disease 0 5.2310962672663663e-08
. O 0 1.7252254583700194e-13

Four O 0 4.661892820021461e-14
mutations O 0 2.1114452417383966e-13
- O 0 4.891165517051377e-08
- O 0 1.7512087779891772e-08
R778L O 0 5.786707051036455e-12
, O 0 6.985353330191882e-18
A874V O 0 3.8953017659107783e-16
, O 0 1.0909083292754507e-20
L1083F O 0 9.921790738015314e-18
, O 0 2.347664594221936e-21
and O 0 4.81274670091395e-19
2304delC O 0 8.935955003296775e-14
- O 0 2.6242902165588e-13
- O 0 2.4106657967558343e-13
in O 0 2.89640626057287e-19
the O 0 2.2409786516004826e-20
copper O 0 5.84771322218392e-18
- O 0 8.003817378521569e-21
transporting O 0 1.416648681960691e-21
enzyme O 0 3.217791519449922e-19
, O 0 4.0505884298682434e-20
P O 0 2.8162485364580103e-12
- O 0 8.633485094368398e-13
type O 0 7.49149006717964e-14
ATPase O 0 1.8479918983960175e-11
( O 0 2.310036690994176e-18
ATP7B O 0 3.339592491435894e-11
) O 0 1.5581674610940746e-18
, O 0 4.678714813476347e-20
were O 0 1.0406269440510645e-19
identified O 0 1.969603892453077e-17
in O 0 5.113984683502566e-19
Korean O 0 4.0947111153155635e-12
Patients O 0 3.7112516973375655e-18
with O 0 7.674192121198478e-18
Wilson B-Disease 0 6.213993763992676e-10
disease I-Disease 0 7.340587249160535e-09
. O 0 1.0318069166540163e-14

Arg778Leu O 0 1.4891486266321863e-08
, O 0 9.223085535185532e-16
the O 0 1.27452622092327e-19
most O 0 1.8970909135112058e-19
frequently O 0 9.329678278850381e-14
reported O 0 2.0740505921192738e-15
mutation O 0 4.504168420967115e-18
of O 0 9.966613574533334e-21
this O 0 3.589813608876688e-20
enzyme O 0 3.2111840007168485e-18
, O 0 1.8972429079487624e-19
was O 0 2.4088797515535833e-15
found O 0 1.1424765145972952e-14
in O 0 3.630348139473959e-17
six O 0 1.6307131240098994e-15
of O 0 3.1813831647884005e-19
eight O 0 3.940767318145837e-16
unrelated O 0 9.176304964299861e-16
patients O 0 3.342055890193437e-20
studied O 0 1.700015132570447e-20
, O 0 1.5357285356465745e-22
an O 0 3.3283629410504517e-22
allele O 0 4.284250363327524e-13
frequency O 0 5.021851823272527e-10
of O 0 1.4376138625891988e-13
37 O 0 4.367770728430642e-11
. O 0 2.7128110955537688e-12

5 O 0 6.556300641280544e-11
% O 0 1.289868124825953e-14
, O 0 9.557721253470512e-18
which O 0 1.920179230467574e-18
is O 0 7.759849181019576e-20
considerably O 0 4.2414926017830834e-16
higher O 0 9.481859692312662e-18
than O 0 3.0649848939293527e-19
those O 0 9.004201766052078e-18
in O 0 1.317987195035601e-19
other O 0 4.30071873364188e-15
Asian O 0 1.8514934052062115e-13
populations O 0 3.1632375534993698e-15
. O 0 5.643190992624114e-15

The O 0 1.913978643236846e-17
novel O 0 9.731927144835405e-18
single O 0 4.1589726130613595e-19
nucleotide O 0 7.072879693086282e-16
deletion O 0 1.64091125669924e-13
, O 0 4.629901147933319e-15
2304delC O 0 3.268940673706311e-10
, O 0 1.2579034307371806e-15
was O 0 1.4650346907840728e-13
found O 0 1.0850100725105956e-14
in O 0 3.2011548493799493e-18
one O 0 1.6451590591670846e-15
patient O 0 2.75826995792261e-13
. O 0 4.8749917405839505e-14

Since O 0 2.3799074131092236e-15
a O 0 7.693651855301518e-19
mutation O 0 1.0055686463769273e-17
at O 0 9.026938644985446e-17
cDNA O 0 1.2580054727963363e-13
nucleotide O 0 1.1684364413511172e-11
2302 O 0 2.2915098984999105e-10
( O 0 2.61010787329024e-17
2302insC O 0 7.431738384411357e-12
) O 0 2.5192014518896013e-16
had O 0 6.6963951473719e-15
been O 0 2.0380037550901073e-16
previously O 0 2.606575646638516e-17
described O 0 2.3447718511824048e-15
, O 0 1.2939650945652368e-19
this O 0 9.911755667167156e-20
region O 0 1.1634053117074979e-16
of O 0 1.0796770421704419e-19
the O 0 1.0584605765206502e-16
ATP7B O 0 3.9991114586523935e-11
gene O 0 7.469709334919001e-16
may O 0 1.9800839068546543e-16
be O 0 2.564175112901599e-19
susceptible O 0 8.204094311726768e-15
to O 0 1.8561827066571534e-16
gene O 0 9.131252975969062e-10
rearrangements O 0 0.0002343216328881681
causing O 0 0.0006190298590809107
Wilson B-Disease 0 8.420992344326805e-06
disease I-Disease 0 3.846857725875452e-05
. O 0 1.3540146434620759e-11

Disruption O 0 2.5383079318985757e-11
of O 0 5.924520224932525e-20
splicing O 0 4.0446985254717356e-16
regulated O 0 5.3806758813982114e-18
by O 0 4.514330115072479e-20
a O 0 2.555377013111332e-19
CUG O 0 2.8414349866057176e-12
- O 0 2.0796679028672275e-15
binding O 0 1.401163807172195e-15
protein O 0 1.7701545253472756e-13
in O 0 1.6450398392797586e-15
myotonic B-Disease 1 0.9999706745147705
dystrophy I-Disease 1 0.9999691247940063
. O 0 3.271594583784121e-12

Myotonic B-Disease 1 0.999632716178894
dystrophy I-Disease 1 0.9999548196792603
( O 0 9.970595016284278e-08
DM B-Disease 1 0.9999991655349731
) O 0 3.6159057970053254e-09
is O 0 1.6979544940204372e-12
caused O 0 1.4560283588625073e-13
by O 0 6.886000072282072e-20
a O 0 3.31479757482343e-19
CTG O 0 1.0936789126246571e-13
expansion O 0 7.15933091970771e-18
in O 0 5.729597827770789e-19
the O 0 1.1993420741581907e-17
3 O 0 4.1156401817822434e-16
untranslated O 0 1.2411323524474938e-08
region O 0 2.067345521660456e-14
of O 0 9.546857476895547e-19
the O 0 5.492277165290889e-14
DM B-Disease 1 0.9999966621398926
gene O 0 1.0352385615419735e-11
. O 0 5.942918683207732e-14

One O 0 1.4088118794111908e-15
model O 0 4.724064106613685e-15
of O 0 1.9066922077442134e-16
DM B-Disease 1 0.9999918937683105
pathogenesis O 0 2.0343272205680663e-11
suggests O 0 9.925818373062063e-15
that O 0 3.515215940920727e-19
RNAs O 0 5.109666114972312e-15
from O 0 9.274184238056889e-21
the O 0 1.251580837585966e-22
expanded O 0 3.0702008008352537e-21
allele O 0 4.201486904812018e-18
create O 0 1.1860866870802571e-20
a O 0 2.4663382580003584e-19
gain O 0 8.784893686351609e-17
- O 0 5.08187866787857e-11
of O 0 4.1978567465932124e-15
- O 0 6.6614276594823e-11
function O 0 3.4735383857866485e-16
mutation O 0 1.0267867389875862e-18
by O 0 4.01437577127625e-21
the O 0 2.200107770625337e-21
inappropriate O 0 4.340870212924102e-15
binding O 0 1.2300478456767716e-17
of O 0 6.262928285263002e-23
proteins O 0 4.3332980837235544e-20
to O 0 3.30477266278717e-19
the O 0 2.4157791591637697e-17
CUG O 0 1.286044692960786e-08
repeats O 0 1.5883099280245006e-09
. O 0 1.3176336107270648e-14

Data O 0 3.4581793808760586e-14
presented O 0 1.0240741834719423e-14
here O 0 1.9498542274094344e-16
indicate O 0 1.8281085275393487e-17
that O 0 5.00440231626747e-21
the O 0 1.1497211737505586e-21
conserved O 0 1.2839120273688771e-16
heterogeneous O 0 1.401705791367891e-12
nuclear O 0 7.764952014710502e-10
ribonucleoprotein O 0 1.5647951142304384e-13
, O 0 1.7124092449774235e-18
CUG O 0 8.588094645156641e-12
- O 0 4.569910124147328e-14
binding O 0 2.8578887405195357e-15
protein O 0 1.1796692230914632e-14
( O 0 8.626174662033255e-21
CUG O 0 2.784001111241774e-12
- O 0 1.7751381961583768e-13
BP O 0 5.218653336075754e-14
) O 0 9.045298192684638e-20
, O 0 7.966628824521348e-20
may O 0 2.444263702583462e-18
mediate O 0 2.1863943083311535e-14
the O 0 2.4028476792116057e-17
trans O 0 5.356360428983298e-13
- O 0 3.631079117938363e-11
dominant O 0 8.046740357370297e-13
effect O 0 1.5231543657384861e-16
of O 0 5.401206293569605e-23
the O 0 7.826884737966183e-21
RNA O 0 1.239631634104496e-13
. O 0 3.2961550223736986e-15

CUG O 0 4.978538981958991e-06
- O 0 9.116051558066829e-08
BP O 0 2.7390012133365893e-11
was O 0 3.839565674492465e-16
found O 0 9.42659872826832e-20
to O 0 1.3233158093389302e-21
bind O 0 3.4195037718011325e-16
to O 0 1.5982666181006253e-19
the O 0 3.022870027016981e-19
human O 0 1.8849119042940038e-14
cardiac O 0 2.2080204331587083e-09
troponin O 0 5.661946023138853e-09
T O 0 6.621814901963674e-11
( O 0 4.546457357699641e-20
cTNT O 0 3.3696516476904807e-15
) O 0 2.568894178296214e-19
pre O 0 4.927693579990697e-16
- O 0 1.4892633228512885e-14
messenger O 0 1.3082236845467915e-13
RNA O 0 6.154344883105983e-14
and O 0 6.249719691162242e-19
regulate O 0 3.584612226099121e-21
its O 0 4.980460829556119e-22
alternative O 0 6.109901336066532e-21
splicing O 0 7.818403788425153e-15
. O 0 3.6150376219056435e-16

Splicing O 0 3.1730802881047016e-12
of O 0 2.258197778313845e-16
cTNT O 0 2.074465599299913e-12
was O 0 7.86281880804738e-15
disrupted O 0 3.4395138646947654e-12
in O 0 8.414582528515054e-16
DM B-Disease 1 0.9999986886978149
striated O 1 0.9237119555473328
muscle O 0 0.00023041838721837848
and O 0 3.107128486792843e-12
in O 0 1.7208829865699933e-18
normal O 0 4.798711637947549e-16
cells O 0 4.703185909134169e-16
expressing O 0 9.68434473815115e-17
transcripts O 0 3.219566091524728e-15
that O 0 1.9249859224131994e-15
contain O 0 1.623787367587004e-13
CUG O 0 3.0052266453139964e-08
repeats O 0 2.2366373286786256e-07
. O 0 3.376539228338443e-13

Altered O 0 1.1054909210272967e-09
expression O 0 1.5180414434171063e-12
of O 0 1.3036668374759298e-18
genes O 0 4.095093280064222e-16
regulated O 0 4.150293623143397e-16
posttranscriptionally O 0 1.7135915950095004e-11
by O 0 1.0099053392615835e-16
CUG O 0 8.072802160086212e-08
- O 0 9.928072947085198e-11
BP O 0 1.918763542149704e-13
therefore O 0 7.62254740984646e-19
may O 0 1.0456811985395225e-18
contribute O 0 6.775132020805824e-20
to O 0 7.40632268310241e-16
DM B-Disease 1 0.9999938011169434
pathogenesis O 0 1.1001547979908044e-12
. O 0 1.8136271096426073e-16
. O 0 1.23684809749257e-15

Identification O 0 6.07971789232109e-15
of O 0 1.1727251029363688e-19
a O 0 4.590780848546318e-18
novel O 0 8.401729290584414e-14
nonsense O 0 1.0152549911879305e-09
mutation O 0 5.4474755598315355e-15
and O 0 5.345492581223881e-16
a O 0 2.4754329795884082e-20
missense O 0 3.563160559655462e-17
substitution O 0 1.9476889828944033e-18
in O 0 1.9327732556264986e-20
the O 0 1.1094205829167734e-19
vasopressin O 0 1.665266943708544e-14
- O 0 1.3266029767755594e-11
neurophysin O 0 3.6027136829375195e-10
II O 0 7.558727081746763e-12
gene O 0 6.266224806427594e-16
in O 0 2.120835126647645e-19
two O 0 1.412911505641012e-17
Spanish O 0 1.2745489410517959e-14
kindreds O 0 1.1787174258870436e-07
with O 0 1.2400242508162074e-13
familial B-Disease 0 0.38039419054985046
neurohypophyseal I-Disease 1 0.9971743822097778
diabetes I-Disease 1 0.6925067901611328
insipidus I-Disease 1 0.7714125514030457
. O 0 7.242799138218459e-10

Familial B-Disease 1 0.9983627200126648
neurohypophyseal I-Disease 1 0.9990426898002625
diabetes I-Disease 1 0.9996658563613892
insipidus I-Disease 1 0.9990598559379578
( O 0 4.519711827022377e-10
FNDI B-Disease 1 0.9999946355819702
) O 0 6.047196909344209e-15
is O 0 6.2399792258591234e-18
an O 0 2.5082017033655446e-17
autosomal B-Disease 1 0.9991518259048462
dominant I-Disease 1 0.9999939203262329
disease I-Disease 1 0.9999991655349731
caused O 0 0.0019426987273618579
by O 0 2.3049133782149234e-11
deficiency O 0 0.302183598279953
in O 0 2.4913412395808456e-18
the O 0 2.027657909383886e-17
antidiuretic O 0 1.7575840088879247e-11
hormone O 0 3.5110282228508014e-15
arginine O 0 3.363512776405255e-15
vasopressin O 0 1.9609096484974383e-15
( O 0 1.0005359554530628e-19
AVP O 0 1.5641787918821925e-15
) O 0 1.2692267598897718e-21
encoded O 0 2.032470814541586e-21
by O 0 2.639922893104371e-21
the O 0 4.049696367276393e-18
AVP O 0 2.24542384685833e-09
- O 0 5.219551901802788e-09
neurophysin O 0 2.1224819235499126e-08
II O 0 1.4008740834015043e-09
( O 0 9.63911582574573e-18
AVP O 0 2.1842052472242912e-11
- O 0 1.1420256407213003e-10
NPII O 0 1.5885848192453977e-10
) O 0 2.429676320782301e-19
gene O 0 6.416187721487007e-18
on O 0 9.197648076988301e-16
chromosome O 0 5.092651855775898e-10
20p13 O 0 2.0483205409593808e-11
. O 0 8.309260228391967e-15

In O 0 1.181190621319674e-15
this O 0 1.2298595793693545e-18
study O 0 8.027886718759728e-20
, O 0 1.6420207243425299e-19
we O 0 8.271829906972888e-19
analyzed O 0 9.774672323374542e-19
two O 0 1.7579463648790802e-18
families O 0 6.28640457230254e-17
with O 0 3.34972863660972e-19
FNDI B-Disease 1 0.9835354089736938
using O 0 1.908120890381396e-21
direct O 0 4.160648051640111e-22
automated O 0 2.0431948428294696e-17
fluorescent O 0 1.3496157113429032e-15
, O 0 1.7960822862499187e-18
solid O 0 2.7750132767198315e-17
phase O 0 3.294677440398843e-19
, O 0 1.323670006623197e-20
single O 0 6.523865957726097e-19
- O 0 7.777560706741498e-15
stranded O 0 1.6917497887934522e-17
DNA O 0 6.511061718831659e-19
sequencing O 0 3.730454540161619e-19
of O 0 7.840472759773532e-23
PCR O 0 2.832880516268326e-15
- O 0 8.819416102303734e-16
amplified O 0 5.1065895219012947e-14
AVP O 0 1.8526141992020184e-12
- O 0 1.9877079582980572e-13
NPII O 0 3.005277884188251e-12
DNA O 0 1.9873744306047464e-13
. O 0 5.17986608805838e-15

In O 0 1.569462371648928e-15
one O 0 3.986899048559021e-17
of O 0 1.7923914968295866e-20
the O 0 2.607829950232167e-16
families O 0 9.159283032543486e-14
, O 0 2.196369770517778e-19
affected O 0 1.0537529755908313e-20
individuals O 0 1.1216103867611592e-22
presented O 0 2.1002566824649155e-19
a O 0 3.3463824325380015e-19
novel O 0 1.9451313728658694e-14
nonsense O 0 1.861665682723057e-11
mutation O 0 5.936768562266176e-17
in O 0 2.3812385369663623e-18
exon O 0 1.3181665638574772e-14
3 O 0 2.965813019977469e-14
of O 0 1.4712754464678293e-18
the O 0 2.51951753414527e-17
gene O 0 1.3780574895249265e-15
, O 0 4.036478434678102e-18
consisting O 0 7.619313295210091e-21
in O 0 6.119487826222267e-21
a O 0 7.119762569670113e-17
G O 0 2.6061075519834276e-10
to O 0 5.414885543669453e-15
T O 0 8.42918929100378e-11
transition O 0 2.2123997656469893e-17
at O 0 2.434175924820648e-19
nucleotide O 0 5.655962002846165e-18
2101 O 0 1.853328037912383e-12
, O 0 6.715775582151156e-18
which O 0 3.7109245474053007e-19
produces O 0 8.829362047542817e-20
a O 0 5.795649039788458e-21
stop O 0 1.367741640431741e-13
signal O 0 9.893522667780985e-10
in O 0 7.255903607713676e-15
codon O 0 1.672792113160959e-11
82 O 0 9.66185004181927e-14
( O 0 8.26659736921303e-18
Glu O 0 1.515471081958708e-10
) O 0 4.240054657476001e-15
of O 0 7.512685272033622e-17
NPII O 0 2.012760887737386e-06
. O 0 3.8807062489702726e-13

The O 0 1.347969926326388e-14
premature O 0 1.1585212823794766e-11
termination O 0 1.0422465130256308e-14
eliminates O 0 8.738611064959805e-15
part O 0 5.552559711347545e-17
of O 0 6.2601491979156164e-18
the O 0 7.19987661341754e-15
C O 0 7.495850606886734e-10
- O 0 1.4817040620168122e-14
terminal O 0 1.1350503089076344e-18
domain O 0 6.779718546016914e-17
of O 0 2.3760460980791682e-20
NPII O 0 1.541716786786912e-13
, O 0 6.531845919143051e-23
including O 0 2.5657525913800063e-25
a O 0 3.574148901270014e-23
cysteine O 0 3.0274545721644796e-17
residue O 0 1.471577525634371e-12
in O 0 1.435214843705704e-19
position O 0 1.9402328119253083e-14
85 O 0 8.478601940413024e-17
, O 0 3.364523392590448e-17
which O 0 8.575310206630109e-16
could O 0 1.0421306812700938e-15
be O 0 1.9796212564662473e-18
involved O 0 2.3817189738058908e-19
in O 0 2.656898182159672e-19
the O 0 3.3198262580572265e-16
correct O 0 1.902594881642017e-08
folding O 0 2.878717819676524e-10
of O 0 2.902677582085729e-19
the O 0 2.3650366909289903e-16
prohormone O 0 1.1826054580055256e-09
. O 0 9.355678124572941e-14

In O 0 2.2760838319071854e-15
the O 0 1.3248042634332526e-16
second O 0 7.929568392422807e-15
family O 0 1.7367886642749575e-12
, O 0 6.961484180586657e-20
a O 0 2.436531832544324e-22
G279A O 0 3.732846126107663e-19
substitution O 0 3.4406548498574776e-20
at O 0 2.8304457928533375e-18
position O 0 2.1597249042396125e-16
- O 0 5.63274416259113e-13
1 O 0 8.643480708626891e-18
of O 0 2.4542477047223174e-21
the O 0 3.430013946758807e-20
signal O 0 4.723791573762906e-16
peptide O 0 7.265082859095317e-19
was O 0 1.114991799438683e-18
observed O 0 1.990851189709238e-19
in O 0 1.2152981988275265e-20
all O 0 1.1681320533381974e-17
affected O 0 6.846773776937403e-17
individuals O 0 4.482244102228974e-19
. O 0 5.1163949447053e-15

This O 0 2.731389028528316e-15
missense O 0 6.278679832993905e-12
mutation O 0 3.806781279092064e-12
, O 0 1.0148932475667616e-12
which O 0 2.313212826583061e-13
replaces O 0 1.7825034503982096e-10
Ala O 0 1.4538451822629361e-12
with O 0 1.4581363019957033e-15
Thr O 0 5.018218374175376e-08
, O 0 5.204145016942004e-16
is O 0 6.334011463532926e-19
frequent O 0 2.896667687614027e-14
among O 0 1.227580049330962e-13
FNDI B-Disease 1 0.9999997615814209
patients O 0 2.411493585114527e-13
and O 0 9.956145699524234e-17
is O 0 3.87959158568975e-19
thought O 0 2.1261430257311846e-17
to O 0 9.510580437156268e-19
reduce O 0 9.728146929436038e-17
the O 0 6.634465433997207e-20
efficiency O 0 1.2227863579514136e-18
of O 0 6.734537733396711e-23
cleavage O 0 7.820313000688264e-15
by O 0 9.180212772308715e-19
signal O 0 5.052704673928765e-13
peptidases O 0 1.9311119543730104e-12
. O 0 8.894412564889752e-18
. O 0 3.7488913268844844e-16

Genetic O 0 2.3299933163412057e-11
heterogeneity O 0 1.0728481991684191e-10
of O 0 1.9114980323413355e-13
Saethre B-Disease 1 0.58384108543396
- I-Disease 1 0.9998607635498047
Chotzen I-Disease 1 0.9998480081558228
syndrome I-Disease 1 0.9999833106994629
, O 0 7.345743416110374e-16
due O 0 5.739773183280957e-18
to O 0 1.661929431402548e-17
TWIST O 0 6.438010125009441e-10
and O 0 1.7982190985820629e-13
FGFR O 0 1.7128743978744865e-09
mutations O 0 2.1239263060975067e-13
. O 0 1.4586405407092037e-14

Thirty O 0 4.743180848088002e-10
- O 0 5.536652802895503e-10
two O 0 1.6285498018626119e-15
unrelated O 0 3.9572366244315996e-14
patients O 0 3.3160006056268117e-18
with O 0 6.375090169598008e-22
features O 0 1.9846136802378927e-16
of O 0 2.305364543283905e-16
Saethre B-Disease 0 0.00039405422285199165
- I-Disease 0 0.0022263359278440475
Chotzen I-Disease 0 0.05694439262151718
syndrome I-Disease 1 0.9321005940437317
, O 0 7.938264930563875e-20
a O 0 2.395148768038572e-19
common O 0 4.6618575834508555e-14
autosomal B-Disease 0 0.0037358051631599665
dominant I-Disease 0 0.09490714222192764
condition I-Disease 0 7.034712325548753e-05
of O 0 3.6546579564727955e-13
craniosynostosis B-Disease 1 0.5148330330848694
and O 0 3.8898511078855336e-09
limb B-Disease 0 2.0382742604851956e-06
anomalies I-Disease 0 3.2162510876787564e-08
, O 0 7.527802824908641e-17
were O 0 6.838961283526508e-19
screened O 0 2.671924403955308e-16
for O 0 1.5539743961351317e-21
mutations O 0 2.6803234718180793e-18
in O 0 3.349204669390456e-19
TWIST O 0 1.2657187797859848e-10
, O 0 6.806253838323125e-17
FGFR2 O 0 2.4235966011865173e-10
, O 0 2.4753139948271713e-17
and O 0 7.547939392103277e-15
FGFR3 O 0 1.4482276355920476e-07
. O 0 6.868811075477765e-14

Nine O 0 2.3317081772333825e-12
novel O 0 3.1645306763482955e-14
and O 0 1.8513961234722194e-15
three O 0 2.2839616419807893e-17
recurrent O 0 2.8446278665938962e-09
TWIST O 0 4.126102837176404e-08
mutations O 0 4.770904157846978e-12
were O 0 9.204255738658185e-14
found O 0 2.0293635478660366e-14
in O 0 3.948304455538522e-17
12 O 0 1.99492987979096e-15
families O 0 2.1184298245994788e-15
. O 0 8.831501674274277e-16

Seven O 0 1.7818080995032903e-12
families O 0 1.9125365286159872e-14
were O 0 3.3063757388142978e-18
found O 0 2.0553016133711606e-19
to O 0 3.1128122184532274e-19
have O 0 1.1861240588418383e-18
the O 0 1.2916520907773854e-19
FGFR3 O 0 2.7474144487227292e-11
P250R O 0 3.3581650868323243e-16
mutation O 0 2.20164972640625e-16
, O 0 1.4056976304317124e-16
and O 0 1.3376891486323837e-14
one O 0 8.83170019762129e-17
individual O 0 2.9196925838883682e-18
was O 0 2.6701760919532747e-13
found O 0 1.826255444443883e-16
to O 0 1.0791463411840038e-18
have O 0 5.150752861730548e-19
an O 0 3.001713719628201e-20
FGFR2 O 0 6.1448708343903036e-09
VV269 O 0 1.5860400015901832e-12
- O 0 4.300766340281648e-12
270 O 0 2.452627944488084e-14
deletion O 0 1.535081263492888e-11
. O 0 1.0928246155228472e-12

To O 0 2.84357642480978e-16
date O 0 3.75503152165869e-16
, O 0 8.522397260928949e-20
our O 0 7.537762172541599e-20
detection O 0 3.161735040300852e-19
rate O 0 3.199187968979663e-19
for O 0 3.6763963186393303e-23
TWIST O 0 2.0300342624349904e-13
or O 0 1.277171630342203e-15
FGFR O 0 6.658883514032432e-12
mutations O 0 5.340498792604225e-16
is O 0 3.746716569792409e-17
68 O 0 2.0593240772983105e-15
% O 0 2.6991515501258582e-18
in O 0 1.1154135167944778e-17
our O 0 7.808713320400784e-08
Saethre B-Disease 0 0.25335100293159485
- I-Disease 1 0.8620570302009583
Chotzen I-Disease 1 0.9972558617591858
syndrome I-Disease 1 0.9999884366989136
patients O 0 8.673919601239616e-14
, O 0 2.450227623101181e-19
including O 0 2.5801281957434792e-20
our O 0 1.0718218711657998e-13
five O 0 3.1576145434769956e-18
patients O 0 4.825152600644656e-20
elsewhere O 0 5.220698091105296e-20
reported O 0 6.090200805163534e-18
with O 0 2.1420654667012485e-18
TWIST O 0 9.054267335883992e-10
mutations O 0 9.364309674908533e-12
. O 0 6.940628085282119e-13

More O 0 2.0956490124494173e-17
than O 0 1.0425982963965374e-18
35 O 0 4.733940686968141e-19
different O 0 4.503461801928842e-19
TWIST O 0 1.5046559831422002e-10
mutations O 0 6.083177852504035e-14
are O 0 1.1460109607400388e-16
now O 0 5.707503213224038e-18
known O 0 3.5833166867764523e-19
in O 0 1.0218087660612421e-18
the O 0 9.263459360616408e-16
literature O 0 1.5516771895152104e-12
. O 0 1.904464650218096e-12

The O 0 1.3500418086200415e-17
most O 0 5.501969226176589e-20
common O 0 4.885105875960675e-19
phenotypic O 0 3.699234094280968e-20
features O 0 4.816526409483213e-13
, O 0 1.0862560156243593e-15
present O 0 3.9488423710908653e-19
in O 0 4.914106141612252e-22
more O 0 7.540228386496325e-22
than O 0 6.6579133386443145e-21
a O 0 2.2364037612016962e-18
third O 0 7.310277193696771e-14
of O 0 1.0100094316698672e-16
our O 0 1.2162128075476897e-11
patients O 0 2.562669385692811e-19
with O 0 9.391956501149827e-21
TWIST O 0 1.6284902029303772e-12
mutations O 0 3.592603424902021e-15
, O 0 9.157378244704035e-18
are O 0 9.67289291887872e-18
coronal B-Disease 0 7.919834926761737e-11
synostosis I-Disease 0 2.4925979058565417e-09
, O 0 5.69926584428177e-15
brachycephaly B-Disease 0 1.277592076576184e-07
, O 0 1.4468463319788905e-12
low B-Disease 0 0.00030165910720825195
frontal I-Disease 1 0.9999876022338867
hairline I-Disease 1 0.999996542930603
, O 0 1.1865378013453665e-07
facial B-Disease 0 0.003121490590274334
asymmetry I-Disease 0 5.775696081400383e-07
, O 0 2.3380465966060804e-11
ptosis B-Disease 0 0.00017531108460389078
, O 0 5.443720561132404e-13
hypertelorism B-Disease 0 1.3755382042290876e-06
, O 0 9.115126188563583e-13
broad B-Disease 0 5.783355044863825e-11
great I-Disease 0 5.450986861887941e-08
toes I-Disease 1 0.999962329864502
, O 0 1.5371012026133696e-13
and O 0 6.188601605998378e-13
clinodactyly B-Disease 0 2.2149261980075607e-08
. O 0 1.5268740590455854e-13

Significant O 0 1.012331956306569e-15
intra O 0 2.699759582558414e-10
- O 0 3.170985291944817e-05
and O 0 1.182943742961129e-09
interfamilial O 0 3.5500434591995145e-08
phenotypic O 0 1.022438647554089e-14
variability O 0 9.963194548892607e-13
is O 0 2.350957109102021e-18
present O 0 8.9989342346749e-21
for O 0 1.4076734390996443e-22
either O 0 3.781232004340164e-18
TWIST O 0 8.92398266394423e-10
mutations O 0 4.5694355417513766e-12
or O 0 3.005082944637638e-12
FGFR O 0 7.76479680553166e-08
mutations O 0 2.3784680822092064e-12
. O 0 2.618430374867059e-13

The O 0 2.813912801601342e-16
overlap O 0 2.3026851133739435e-15
in O 0 1.0866859477108174e-17
clinical O 0 2.842208466599964e-17
features O 0 7.516914066023339e-13
and O 0 1.0176885376078637e-12
the O 0 2.759148448879432e-17
presence O 0 1.9001863329648103e-16
, O 0 2.1581743955404124e-18
in O 0 7.541982813149536e-22
the O 0 3.333472437309779e-21
same O 0 1.173553059030746e-19
genes O 0 4.480724881636444e-18
, O 0 3.0126792345717487e-21
of O 0 6.083677551694076e-25
mutations O 0 1.2710922581584384e-21
for O 0 1.870542560838994e-22
more O 0 4.9596298731433304e-20
than O 0 1.7313730636237223e-17
one O 0 4.727798420768245e-14
craniosynostotic B-Disease 0 9.020575930662744e-08
condition I-Disease 0 1.1435023934691646e-12
- O 0 9.619038286159606e-15
such O 0 2.1639604463770384e-19
as O 0 2.72576854140681e-15
Saethre B-Disease 0 1.2243649427645664e-09
- I-Disease 0 7.179321720451881e-11
Chotzen I-Disease 0 5.482910236942473e-10
, I-Disease 0 3.586137651838715e-17
Crouzon I-Disease 0 2.168397406077105e-12
, I-Disease 0 4.2683996125129635e-18
and I-Disease 0 4.327362154997764e-15
Pfeiffer I-Disease 0 1.8375820309834978e-10
syndromes I-Disease 0 3.198468573328839e-11
- O 0 4.981656566752611e-15
support O 0 2.8011863466358056e-18
the O 0 8.699536858196186e-21
hypothesis O 0 4.395113549393584e-19
that O 0 6.840419189356133e-20
TWIST O 0 4.3834900986805536e-13
and O 0 7.76232681918513e-15
FGFRs O 0 2.7286751417415767e-12
are O 0 1.098417581504958e-18
components O 0 3.464987455835218e-17
of O 0 6.8448463625843e-23
the O 0 2.6056071357559598e-20
same O 0 8.418867852449695e-20
molecular O 0 3.2786276161993855e-20
pathway O 0 2.6511851510147367e-21
involved O 0 1.652575244016635e-22
in O 0 2.4761562842591392e-23
the O 0 2.5834657968137097e-21
modulation O 0 2.362171771391492e-14
of O 0 1.979094863539837e-16
craniofacial O 0 5.364417575037805e-06
and O 0 4.583325385887349e-11
limb O 0 4.014477195113386e-09
development O 0 1.0785666736902419e-17
in O 0 4.424062802881408e-19
humans O 0 3.534366402532491e-17
. O 0 8.203988068648892e-18
. O 0 4.989567854479966e-15

Mutation O 0 6.965547388014526e-13
analysis O 0 2.9571024719610844e-14
of O 0 4.538930656431154e-15
UBE3A O 0 0.0019556409679353237
in O 0 6.894281057157059e-08
Angelman B-Disease 1 0.999996542930603
syndrome I-Disease 1 0.9999990463256836
patients O 0 2.7722630857596187e-09
. O 0 3.2950851248936264e-12

Angelman B-Disease 1 0.9999973773956299
syndrome I-Disease 1 1.0
( O 0 1.1576240410704486e-08
AS B-Disease 1 0.9999988079071045
) O 0 7.395690505319907e-13
is O 0 2.3451564041404582e-15
caused O 0 1.0893605184309884e-14
by O 0 4.02774015038588e-19
chromosome O 0 1.1542661937369303e-08
15q11 O 0 6.378019640207455e-11
- O 0 1.1695707336639716e-12
q13 O 0 2.622292370768088e-14
deletions O 0 4.823032706720298e-14
of O 0 6.532532225606239e-19
maternal O 0 4.6692216065791214e-12
origin O 0 6.97558432715763e-17
, O 0 1.744000099751436e-18
by O 0 7.565424488092656e-18
paternal O 0 1.5876171488571345e-08
uniparental B-Disease 0 7.058473329379922e-06
disomy I-Disease 0 2.6610571239871206e-06
( O 0 1.1463925173190413e-14
UPD B-Disease 1 0.9999334812164307
) O 0 1.516672949035435e-15
15 O 0 3.1292914657128736e-18
, O 0 1.1652862450694595e-20
by O 0 7.138356721300662e-19
imprinting O 0 0.008145730942487717
defects O 1 0.9989824891090393
, O 0 2.6146246897163633e-15
and O 0 1.0214122818500332e-16
by O 0 2.62046061768277e-19
mutations O 0 1.884083442544118e-16
in O 0 5.482843130203744e-19
the O 0 5.403366107345031e-17
UBE3A O 0 1.8362514841996358e-09
gene O 0 4.5205952696469875e-12
. O 0 1.9531698849419021e-13

UBE3A O 0 3.0814484297536637e-09
encodes O 0 2.5384879474062844e-14
a O 0 4.7329856035533715e-18
ubiquitin O 0 5.003711187116745e-15
- O 0 3.001803111093125e-14
protein O 0 7.706146935442014e-16
ligase O 0 6.005332305926165e-16
and O 0 1.8464943438064587e-15
shows O 0 6.460362843643819e-13
brain O 0 2.7310911778627434e-12
- O 0 2.0220522982785163e-15
specific O 0 3.87238019409024e-17
imprinting O 0 1.0840208375384464e-07
. O 0 4.097959222394004e-13

Here O 0 2.14830560838538e-14
we O 0 1.79443301218558e-17
describe O 0 2.4079873494040917e-16
UBE3A O 0 7.871316931584715e-10
coding O 0 9.647293097714282e-08
- O 0 1.7098874423027155e-06
region O 0 4.5458102559958746e-11
mutations O 0 1.3693339268473076e-13
detected O 0 1.3652187019763673e-13
by O 0 3.068484384908335e-18
SSCP O 0 3.0449165324547556e-12
analysis O 0 1.5584119136445994e-17
in O 0 8.94312329245844e-20
13 O 0 2.1676803964989025e-17
AS B-Disease 0 0.2804173529148102
individuals O 0 1.9883714624990476e-17
or O 0 9.522113322444833e-14
families O 0 1.6823317099210616e-13
. O 0 2.3246704887946393e-15

Two O 0 1.0979983415537742e-11
identical O 0 9.460685013173986e-11
de O 0 3.2002137051456714e-11
novo O 0 4.43258041382677e-10
5 O 0 3.0855119891384786e-13
- O 0 7.250812450454447e-11
bp O 0 1.5574523550172803e-13
duplications O 0 3.37057279602062e-14
in O 0 5.990450784903035e-19
exon O 0 1.4766652324201858e-14
16 O 0 4.5141350374497055e-15
were O 0 2.883952103125228e-16
found O 0 5.567709345595442e-15
. O 0 5.427441197749898e-14

Among O 0 3.808295028612761e-14
the O 0 2.318787269258252e-17
other O 0 1.584620800481097e-17
11 O 0 8.333244965527653e-18
unique O 0 1.6477738301263215e-20
mutations O 0 2.5919108924308084e-17
, O 0 4.073976599796662e-18
8 O 0 1.5490406604078942e-18
were O 0 4.0911816721944296e-20
small O 0 3.2366097087488544e-22
deletions O 0 2.183002280190579e-14
or O 0 2.2262771053743746e-12
insertions O 0 6.215054071390114e-08
predicted O 0 2.6580369016926397e-09
to O 0 4.131267810486561e-12
cause O 0 3.214978283594405e-10
frameshifts O 0 7.05979141812918e-09
, O 0 5.153433683785481e-16
1 O 0 1.138258296268874e-19
was O 0 1.4614600592807291e-16
a O 0 3.940519124670992e-20
mutation O 0 2.614211888540391e-18
to O 0 7.720649065941294e-17
a O 0 2.2734695176550442e-17
stop O 0 7.743967684985253e-13
codon O 0 2.2360572899846835e-15
, O 0 3.0082966555874452e-18
1 O 0 8.860064665435312e-20
was O 0 6.126580837160882e-16
a O 0 2.8104983323816213e-18
missense O 0 1.3562017313209843e-14
mutation O 0 2.0062791895479257e-14
, O 0 3.528402139148408e-15
and O 0 3.755164378776467e-14
1 O 0 8.018896480422801e-18
was O 0 4.605842617022571e-13
predicted O 0 1.0300450034204326e-14
to O 0 4.843838972573747e-18
cause O 0 7.666681023451476e-16
insertion O 0 3.7725515934913453e-14
of O 0 1.4478593571257852e-16
an O 0 2.2252217904135223e-14
isoleucine O 0 6.493043201771798e-06
in O 0 2.7801958610424967e-16
the O 0 9.468851615435775e-17
hect O 0 8.344420640571393e-12
domain O 0 2.7709766379775506e-14
of O 0 1.6370869021813808e-18
the O 0 3.864647047979604e-17
UBE3A O 0 3.601173179101913e-11
protein O 0 3.8078010389979225e-14
, O 0 2.3251623088801675e-19
which O 0 5.22051617599402e-21
functions O 0 2.706414905954619e-22
in O 0 1.3000842721987293e-21
E2 O 0 6.364958609001228e-14
binding O 0 2.398131591667196e-17
and O 0 8.118029113753606e-19
ubiquitin O 0 8.365003572529891e-17
transfer O 0 1.0782910571101392e-17
. O 0 1.7019724176756275e-15

Eight O 0 2.070479882378476e-13
of O 0 1.731779999003477e-20
the O 0 3.622913111841027e-20
cases O 0 1.7136900307583853e-18
were O 0 5.45381122069321e-17
familial O 0 3.664459794633368e-12
, O 0 6.485839697343426e-15
and O 0 8.734250031127572e-14
five O 0 2.86644737317683e-16
were O 0 1.7688728003854463e-16
sporadic O 0 4.23328993387484e-12
. O 0 1.261674819523842e-13

In O 0 5.102806524528091e-16
two O 0 2.364142409425147e-17
familial O 0 3.113988580882854e-11
cases O 0 5.839321810374026e-14
and O 0 2.2108591609466995e-14
one O 0 6.4152819587162614e-18
sporadic O 0 2.5251297296083157e-15
case O 0 1.280985958670032e-17
, O 0 4.43866822755968e-19
mosaicism O 0 2.0250252145167895e-14
for O 0 2.9594182946977454e-20
UBE3A O 0 4.541042021577457e-12
mutations O 0 3.020131442939874e-16
was O 0 1.084716236781193e-14
detected O 0 7.676068033155362e-14
in O 0 3.6466406196910485e-18
the O 0 3.1468674241838187e-16
mother O 0 1.0801609384714084e-08
of O 0 6.2471244119903564e-18
three O 0 5.091478454122278e-13
AS B-Disease 1 1.0
sons O 0 1.6544603909096622e-08
, O 0 1.919013913930246e-19
in O 0 1.4883664123697106e-21
the O 0 8.422763278598754e-18
maternal O 0 5.355194065970181e-10
grandfather O 0 5.872819452967803e-10
of O 0 2.7112224287837826e-20
two O 0 2.5264578772696104e-16
AS B-Disease 1 0.9999973773956299
first O 0 5.686906151273672e-16
cousins O 0 1.4491333466537526e-08
, O 0 1.511657349317387e-14
and O 0 6.049937027047259e-13
in O 0 5.985751551163606e-17
the O 0 1.2304017532474912e-14
mother O 0 7.463683004971244e-09
of O 0 8.718977379737029e-20
an O 0 6.016246325451537e-16
AS B-Disease 1 0.9999998807907104
daughter O 0 0.0009422204457223415
. O 0 3.955069605154904e-11

The O 0 1.4082523612099702e-16
frequencies O 0 3.1791970857113216e-13
with O 0 9.427194005694217e-16
which O 0 3.930723360275973e-16
we O 0 1.4815377179808612e-17
detected O 0 1.1188519411647382e-18
mutations O 0 9.623460605472552e-19
were O 0 3.1511064932125815e-17
5 O 0 7.693563967361434e-19
( O 0 2.9070422522866533e-20
14 O 0 2.718541021026126e-15
% O 0 1.4642828958391276e-17
) O 0 6.324236256644081e-18
of O 0 5.920795973471476e-19
35 O 0 5.1317309129667024e-18
in O 0 3.6337070918206335e-21
sporadic O 0 3.2376957729695222e-15
cases O 0 2.6229036956219452e-17
and O 0 2.2964318502891913e-14
8 O 0 1.2533393207558429e-14
( O 0 1.8922709837806475e-18
80 O 0 6.723600363330051e-16
% O 0 5.83590546709391e-17
) O 0 1.2756469710371453e-16
of O 0 1.6595086666603963e-18
10 O 0 4.598600435030965e-17
in O 0 1.141593514348082e-19
familial O 0 2.9946593815832756e-11
cases O 0 1.3591383945491149e-14
. O 0 5.451692513359441e-16
. O 0 3.0913897201660656e-14

The O 0 2.603758408967899e-13
hemochromatosis B-Disease 1 0.9989751577377319
845 O 0 2.185380348906918e-11
G O 0 3.0147290913662417e-11
- O 0 1.8986975620222113e-12
- O 0 9.774328698849977e-13
> O 0 1.535991017705227e-16
A O 0 7.220242432064583e-19
and O 0 2.2847871061935713e-19
187 O 0 8.593437729133505e-19
C O 0 2.0071280012643692e-15
- O 0 3.109237585278979e-13
- O 0 2.1160555946364568e-11
> O 0 1.7553224702210844e-15
G O 0 5.311879950654907e-13
mutations O 0 1.1453865386392348e-15
: O 0 1.4074185507448075e-18
prevalence O 0 5.3937469047344797e-14
in O 0 1.6443525981881051e-19
non O 0 5.332115178129657e-15
- O 0 3.0429834652068166e-08
Caucasian O 0 4.3857202399522066e-05
populations O 0 8.064668377549822e-10
. O 0 4.5333721043587516e-13

Hemochromatosis B-Disease 0 1.6664307622704655e-06
, O 0 6.011896709623432e-13
the O 0 4.184227964110221e-11
inherited B-Disease 1 0.9999998807907104
disorder I-Disease 1 1.0
of I-Disease 0 1.0698473357217964e-12
iron I-Disease 0 1.4053358427190688e-05
metabolism I-Disease 0 1.5338885717142148e-09
, O 0 2.4895492636259516e-15
leads O 0 1.196004084072673e-14
, O 0 1.4697463708454811e-15
if O 0 1.3312959133530977e-13
untreated O 0 3.735482062561246e-11
, O 0 4.929772595062773e-19
to O 0 5.760683250375113e-16
progressive O 0 3.2605626643089636e-08
iron B-Disease 1 0.9821377992630005
overload I-Disease 0 0.014154935255646706
and O 0 4.463987512970391e-11
premature B-Disease 0 1.7461972146026739e-10
death I-Disease 0 2.486008577815002e-12
. O 0 1.4127411805502088e-14

The O 0 2.3354690577293002e-12
hemochromatosis B-Disease 1 0.999954104423523
gene O 0 1.1652388776095535e-10
, O 0 4.647510200577083e-14
HFE O 0 5.823527771120496e-10
, O 0 1.5225104883496749e-15
recently O 0 5.238765794595129e-15
has O 0 4.551531542070983e-17
been O 0 1.8496507922320672e-17
identified O 0 1.0049747472407264e-16
, O 0 4.9271240661389546e-18
and O 0 1.900912187261048e-15
characterization O 0 2.6496795209329793e-13
of O 0 3.1298030252229494e-19
this O 0 3.906963250653071e-19
gene O 0 1.6215626535504907e-16
has O 0 3.381235585573836e-14
shown O 0 1.026890822131447e-14
that O 0 3.519511231347774e-18
it O 0 5.8341218175390615e-18
contains O 0 2.6001773735811454e-19
two O 0 3.93754763341676e-18
mutations O 0 4.503674709946707e-16
that O 0 1.4663358985624801e-15
result O 0 4.70700642477298e-17
in O 0 2.0987430711909142e-19
amino O 0 1.4200177811962304e-16
acid O 0 1.790343307160026e-18
substitutions O 0 1.8678786424379834e-19
- O 0 7.118431139756148e-17
cDNA O 0 7.466461492961873e-16
nucleotides O 0 1.650066900412374e-16
845 O 0 5.292759909817854e-15
G O 0 1.4957688408180625e-13
- O 0 2.0373888123467743e-13
- O 0 2.368960279677812e-12
> O 0 2.238804694288662e-16
A O 0 3.321585439609555e-17
( O 0 5.611317817953411e-21
C282Y O 0 4.227612163688586e-18
) O 0 3.8555376056462664e-22
and O 0 1.4603481126950168e-20
187 O 0 4.920979665151334e-19
C O 0 6.812988809044981e-15
- O 0 5.819291663128334e-12
- O 0 1.058056642300187e-09
> O 0 6.575577078280978e-14
G O 0 3.9240066057599776e-11
( O 0 1.4146635155374298e-18
H63D O 0 2.649242457353207e-11
) O 0 4.4069373931465084e-17
. O 0 1.291757537693922e-16

Although O 0 4.143591303407135e-10
hemochromatosis B-Disease 1 0.9999854564666748
is O 0 4.916320172146382e-14
common O 0 6.413404721946909e-16
in O 0 9.751399803635516e-18
Caucasians O 0 2.0970207449851064e-13
, O 0 2.785289837777945e-17
affecting O 0 2.3715773734685696e-16
> O 0 1.195924660175489e-17
= O 0 7.498830857041196e-16
1 O 0 8.72174274792237e-19
/ O 0 1.955293565947258e-14
300 O 0 1.1566288144509404e-19
individuals O 0 5.337657552311173e-20
of O 0 1.5292477017649664e-19
northern O 0 7.083687748789952e-14
European O 0 5.351045301305035e-11
origin O 0 7.174923849495585e-12
, O 0 3.347257367114498e-15
it O 0 1.6763266423129315e-16
has O 0 6.758669859995706e-18
not O 0 5.7626248231845586e-21
been O 0 6.740639235497217e-20
recognized O 0 1.2700410763897712e-20
in O 0 1.2663396047073098e-21
other O 0 1.076618167039312e-17
populations O 0 1.5614960267800013e-15
. O 0 1.6445513977307244e-14

The O 0 2.9615345639166587e-17
present O 0 3.5604238170891937e-20
study O 0 1.0372600302979912e-23
used O 0 2.075270014881358e-22
PCR O 0 1.572254933396907e-15
and O 0 4.261176257813844e-18
restriction O 0 1.928739102241426e-18
- O 0 6.645192640985088e-16
enzyme O 0 5.5612481683476185e-18
digestion O 0 4.13720749350391e-15
to O 0 1.1103550708267596e-21
analyze O 0 6.96137512845512e-21
the O 0 6.39998939655717e-23
frequency O 0 5.107982143989999e-18
of O 0 4.083301186516277e-23
the O 0 4.7396092006096016e-21
845 O 0 1.6914917084423357e-17
G O 0 1.8292465295388746e-16
- O 0 9.39810451200534e-17
- O 0 3.493844412510294e-16
> O 0 6.472846620766563e-20
A O 0 4.6415078417828e-20
and O 0 1.4007121063803514e-19
187 O 0 1.130434718637771e-19
C O 0 1.246410437722581e-16
- O 0 4.579820748443382e-15
- O 0 1.6904889760162994e-13
> O 0 2.09085798234151e-17
G O 0 1.2913930488288067e-16
mutations O 0 2.5973802429527517e-20
in O 0 1.7612664432912565e-21
HLA O 0 9.846922336223009e-15
- O 0 3.8617921896053325e-15
typed O 0 9.460075274135213e-14
samples O 0 2.814749030643354e-13
from O 0 1.2465903825930358e-17
non O 0 3.844666136323916e-16
- O 0 3.3396053283896165e-11
Caucasian O 0 2.90635018274088e-08
populations O 0 3.982361857814143e-13
, O 0 7.756449856442895e-19
comprising O 0 7.056046111120527e-21
Australian O 0 5.530508896014229e-18
Aboriginal O 0 6.02182911960689e-15
, O 0 9.006189481064043e-19
Chinese O 0 5.726816949948962e-21
, O 0 2.0578884430223355e-21
and O 0 3.6437765068200836e-18
Pacific O 0 2.2626544620181584e-17
Islanders O 0 2.878062947740765e-15
. O 0 1.3130455766971785e-17

Results O 0 1.930018211221407e-12
showed O 0 2.016699388865048e-14
that O 0 2.872045403792271e-20
the O 0 4.455834228598202e-20
845 O 0 2.591328689628469e-16
G O 0 5.997989377306417e-14
- O 0 1.4540023915779465e-13
- O 0 2.3241155094194665e-12
> O 0 9.251517519549103e-17
A O 0 4.7214803484133714e-18
mutation O 0 1.0933138150869598e-17
was O 0 1.5671898457789157e-14
present O 0 8.525783143820676e-19
in O 0 1.1477799448349907e-21
these O 0 8.640147584348609e-19
populations O 0 8.413281152140694e-20
( O 0 7.997609907789031e-24
allele O 0 1.4465541974340988e-19
frequency O 0 6.096386627220328e-17
0 O 0 3.0591546277040463e-20
. O 0 3.012109131030702e-18
32 O 0 1.9342671006442811e-16
% O 0 1.5537507302133477e-19
) O 0 1.774114850722348e-18
, O 0 1.3714437503936465e-16
and O 0 5.761153815293796e-13
, O 0 2.5535701313617997e-15
furthermore O 0 3.3699345566948636e-15
, O 0 5.408047287867591e-17
it O 0 1.9372449879071635e-14
was O 0 3.9820695352243973e-11
always O 0 1.5586537052345029e-12
seen O 0 2.801102222367509e-17
in O 0 3.570427449949634e-24
conjunction O 0 1.143279524925141e-20
with O 0 6.826765849562909e-18
HLA O 0 1.3713218061095489e-11
haplotypes O 0 6.090431631244897e-11
common O 0 3.5067905610614014e-12
in O 0 7.373143873162867e-16
Caucasians O 0 2.168395027608589e-14
, O 0 4.588447759779218e-20
suggesting O 0 3.5049056515731365e-19
that O 0 5.673543368105636e-21
845 O 0 2.2307982477036387e-17
G O 0 3.0539406995020585e-14
- O 0 1.941573936131355e-13
- O 0 3.3464727516863135e-11
> O 0 9.744678894984074e-16
A O 0 1.0260209616462642e-15
may O 0 7.389841539531209e-16
have O 0 3.3579003167226272e-21
been O 0 5.0692487526476526e-21
introduced O 0 6.028059024011995e-22
into O 0 2.2171435311070595e-21
these O 0 1.16175384458056e-19
populations O 0 1.6395412827681448e-20
by O 0 1.2059746616337034e-19
Caucasian O 0 1.67567973385907e-10
admixture O 0 2.6961885501997074e-10
. O 0 2.7870812754036967e-13

187 O 0 3.571170702904025e-12
C O 0 3.969960471472689e-10
- O 0 1.2118468450950104e-09
- O 0 6.949241537768103e-08
> O 0 1.895279246044712e-11
G O 0 2.671555754396593e-10
was O 0 8.179969966356018e-15
present O 0 8.52925478207747e-21
at O 0 1.5825999748186165e-21
an O 0 5.45289766656166e-24
allele O 0 6.016659783408915e-16
frequency O 0 1.2582221506005076e-12
of O 0 8.4128487579511425e-16
2 O 0 7.125074727269698e-13
. O 0 3.458115141897339e-13

68 O 0 4.020317945219176e-08
% O 0 2.713756953529045e-13
in O 0 1.538546219976434e-18
the O 0 5.144902937040997e-18
two O 0 4.983364291053394e-16
populations O 0 1.4965114737781942e-16
analyzed O 0 9.548261907152931e-15
( O 0 2.839714144821841e-18
Australian O 0 1.774444306767986e-13
Aboriginal O 0 8.722026573204644e-11
and O 0 2.8778132763092323e-13
Chinese O 0 2.5541128743401978e-17
) O 0 1.8150223182837278e-19
. O 0 1.4304174598167166e-17

In O 0 1.6311169204977232e-16
the O 0 5.322332351253009e-18
Australian O 0 1.8390770086362508e-16
Aboriginal O 0 1.0539043333578101e-15
samples O 0 8.359293379325315e-17
, O 0 5.12823757495132e-22
187 O 0 2.479335914986466e-20
C O 0 9.844733735436202e-17
- O 0 5.76378883314875e-14
- O 0 6.86169801533687e-11
> O 0 2.7817581815499717e-14
G O 0 4.2633843504169544e-12
was O 0 9.294571939560243e-16
found O 0 1.380106391086802e-19
to O 0 8.610981478677737e-22
be O 0 3.2410823607548403e-22
associated O 0 1.1228481032105637e-21
with O 0 1.559521736702583e-20
HLA O 0 8.130695010495625e-14
haplotypes O 0 3.8233188858795286e-13
common O 0 5.753354742491293e-14
in O 0 2.5709752819993363e-17
Caucasians O 0 8.500441832631073e-14
, O 0 9.744887617468039e-19
suggesting O 0 2.86007953829805e-16
that O 0 4.111210894299818e-18
it O 0 3.19421418365517e-18
was O 0 1.9469396399774915e-17
introduced O 0 7.929971152453324e-20
by O 0 1.0901762259657273e-20
recent O 0 1.6351981634656109e-15
admixture O 0 6.595005097587148e-11
. O 0 9.677625454479477e-13

In O 0 1.0737236337741399e-15
the O 0 1.977070438252287e-18
Chinese O 0 6.929535492649533e-19
samples O 0 9.771913676031678e-19
analyzed O 0 2.0134275335652242e-19
, O 0 1.3146009789290278e-22
187 O 0 1.1219580560636631e-20
C O 0 2.4042871389135705e-17
- O 0 2.3829872249054402e-15
- O 0 1.4071382947733468e-12
> O 0 1.169613586754839e-15
G O 0 3.5726560598803303e-12
was O 0 5.154539718232182e-14
present O 0 8.71080742022442e-18
in O 0 1.4403424587747377e-20
association O 0 4.0220839394404438e-22
with O 0 5.738292238169061e-23
a O 0 3.5277839486644474e-22
wide O 0 4.935659729955192e-20
variety O 0 4.163718820319824e-19
of O 0 2.818655418895948e-20
HLA O 0 2.9744917195550363e-14
haplotypes O 0 8.092109610429582e-14
, O 0 3.8155161591886495e-17
showing O 0 9.82804070127929e-16
this O 0 9.99207623750544e-22
mutation O 0 1.6280425029013774e-20
to O 0 3.538803151184042e-18
be O 0 1.6516482844551182e-15
widespread O 0 5.51917901639898e-15
and O 0 1.975726873770789e-12
likely O 0 1.0063299443697962e-14
to O 0 3.0006750134233816e-18
predate O 0 1.0754253017893501e-14
the O 0 1.9748515052564806e-21
more O 0 4.907959021894408e-23
genetically O 0 6.319738134906929e-22
restricted O 0 4.442763240112087e-21
845 O 0 1.0207078416054932e-15
G O 0 5.179834859647681e-12
- O 0 3.5994957015006435e-12
- O 0 8.136908681566357e-12
> O 0 4.3454902482557823e-16
A O 0 3.350856383637602e-17
mutation O 0 1.6173079382350054e-14
. O 0 8.37053882696108e-14

Genotype O 0 2.5462079065619037e-05
- O 0 2.444076471874723e-06
phenotype O 0 2.4615385285642333e-09
correlations O 0 5.49939538352362e-10
in O 0 1.3736508675324388e-12
attenuated B-Disease 1 0.9979538917541504
adenomatous I-Disease 1 0.9999493360519409
polyposis I-Disease 1 0.9996770620346069
coli I-Disease 1 0.9999768733978271
. O 0 7.388207734493335e-08

Germ O 0 0.0003020559379365295
- O 0 0.001038304646499455
line O 0 4.018555159746029e-07
mutations O 0 8.109020399604816e-12
of O 0 2.458588609636502e-19
the O 0 1.1355482716363914e-18
tumor B-Disease 0 6.605217810424016e-14
suppressor O 0 7.781738578169217e-13
APC O 0 2.4414428811958544e-12
are O 0 1.7594166370588626e-17
implicated O 0 1.412457065370909e-12
in O 0 2.92239512754075e-14
attenuated B-Disease 1 0.9998571872711182
adenomatous I-Disease 1 0.9999945163726807
polyposis I-Disease 1 0.9999572038650513
coli I-Disease 1 0.9999992847442627
( O 0 4.413583720719316e-09
AAPC B-Disease 1 0.9999203681945801
) O 0 1.3277849194350813e-15
, O 0 1.3869992612818122e-19
a O 0 4.852714000160981e-19
variant O 0 1.5268539765855849e-09
of O 0 1.970044127830306e-09
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999328851699829
polyposis I-Disease 1 0.9999912977218628
( O 0 5.850475486013362e-12
FAP B-Disease 0 1.955190453983846e-09
) O 0 5.627640484152062e-14
. O 0 9.571203963935904e-14

AAPC B-Disease 1 0.9998923540115356
is O 0 1.590679763472172e-14
recognized O 0 6.980102594458548e-19
by O 0 9.182655572366903e-21
the O 0 4.6059671866591495e-20
occurrence O 0 7.496714333464244e-16
of O 0 4.9961700726396746e-18
< O 0 6.809640064288011e-14
100 O 0 6.945443519997423e-18
colonic B-Disease 0 5.5662423455171695e-12
adenomas I-Disease 0 1.697363638530902e-10
and O 0 3.38676552487328e-15
a O 0 1.3225508538726326e-18
later O 0 1.318760774410635e-13
onset O 0 3.953022353897495e-09
of O 0 8.870479220948746e-13
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
( O 0 2.772665738141406e-16
age O 0 1.1303045495012973e-13
> O 0 4.749448731130831e-16
40 O 0 7.252104188489207e-17
years O 0 1.001401483166197e-14
) O 0 2.2490590869063594e-16
. O 0 9.532030214784697e-15

The O 0 5.178088165902093e-15
aim O 0 2.795748929671632e-13
of O 0 1.187875222816833e-20
this O 0 1.9661394516369646e-21
study O 0 3.285748548732668e-22
was O 0 1.3937995389470048e-18
to O 0 2.5744284301845e-18
assess O 0 9.185907141548173e-15
genotype O 0 8.53320400451274e-11
- O 0 5.4442457486647555e-11
phenotype O 0 2.5850153181211644e-12
correlations O 0 1.0019876421629714e-11
in O 0 2.8139274764471534e-13
AAPC B-Disease 1 0.9999604225158691
families O 0 9.096064873537202e-11
. O 0 8.150876078683728e-15

By O 0 1.352310334906356e-16
protein O 0 4.9940076623762944e-14
- O 0 1.137696360731244e-11
truncation O 0 2.63651444426527e-11
test O 0 3.918679183229079e-12
( O 0 2.120784461835126e-21
PTT O 0 1.423005557568772e-16
) O 0 8.822715658389147e-23
assay O 0 2.6324321829683996e-20
, O 0 4.382915922573373e-23
the O 0 4.6943479527628605e-24
entire O 0 1.043497545119959e-18
coding O 0 9.822627086708557e-12
region O 0 5.256421772864171e-15
of O 0 1.8187919677432395e-20
the O 0 6.56473281588928e-19
APC B-Disease 0 1.3215536421492662e-16
gene O 0 6.374029427592476e-19
was O 0 2.4721998252570316e-17
screened O 0 9.975616075305854e-16
in O 0 3.4672583354503754e-19
affected O 0 8.110175695581905e-17
individuals O 0 4.772015810563956e-19
from O 0 5.319252559309127e-16
11 O 0 2.3014340433391567e-11
AAPC B-Disease 1 0.9999866485595703
kindreds O 0 2.135346335307986e-07
, O 0 4.154192198162253e-15
and O 0 4.330945951397597e-15
their O 0 1.4192176791682099e-14
phenotypic O 0 1.3996138162880584e-16
differences O 0 8.845605359297792e-10
were O 0 3.400270516540349e-13
examined O 0 1.5852786097725335e-11
. O 0 3.533576494016595e-14

Five O 0 9.950276280007442e-14
novel O 0 2.2160279253974347e-13
germ O 0 1.4075470744501217e-07
- O 0 1.1311007256153971e-05
line O 0 3.53267068931018e-08
APC B-Disease 0 3.091700853663504e-11
mutations O 0 1.05500299861787e-14
were O 0 1.7172779059858187e-16
identified O 0 1.4456691416824224e-15
in O 0 1.6239079091104256e-17
seven O 0 1.844313953945284e-13
kindreds O 0 3.5353846783436893e-07
. O 0 1.3409911202300062e-12

Mutations O 0 1.8826286016238036e-12
were O 0 1.0856428696496656e-15
located O 0 8.28528348264818e-19
in O 0 2.585507777781915e-20
three O 0 2.682337087922975e-19
different O 0 2.826367378843145e-18
regions O 0 2.021102800814424e-16
of O 0 1.0005970246467239e-19
the O 0 1.508224880647537e-17
APC B-Disease 0 8.222077668229924e-15
gene O 0 3.198179886035096e-16
( O 0 2.612962903976573e-20
1 O 0 4.687021193166543e-20
) O 0 4.534614457773355e-18
at O 0 1.0426515006535368e-15
the O 0 1.3931412272565044e-17
5 O 0 4.761004378113747e-16
end O 0 4.684908060451076e-14
spanning O 0 6.162093964023939e-15
exons O 0 2.6106723120117303e-12
4 O 0 2.067541567436098e-15
and O 0 1.4203713380423703e-14
5 O 0 2.5129627895352773e-16
, O 0 8.599841471922676e-17
( O 0 1.3255553806525783e-19
2 O 0 5.636343181231816e-17
) O 0 4.877527867573924e-19
within O 0 5.351661461587754e-21
exon O 0 2.4553975304673686e-15
9 O 0 1.3183785931448339e-13
, O 0 3.3964930629977854e-16
and O 0 9.038427016376527e-14
( O 0 1.786181115263418e-19
3 O 0 7.668285886188727e-17
) O 0 7.46742261065921e-18
at O 0 6.976542533179212e-17
the O 0 4.961467571196391e-19
3 O 0 1.2261693943078575e-16
distal O 0 1.0566322816707441e-10
end O 0 3.99898968106438e-11
of O 0 1.558499651658197e-19
the O 0 3.0470001882946176e-17
gene O 0 2.6144180136772333e-13
. O 0 1.66943715795842e-13

Variability O 0 4.037440173854101e-11
in O 0 3.344110787780778e-19
the O 0 3.380264525909998e-20
number O 0 7.960166656931536e-18
of O 0 2.6097648890034686e-13
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
was O 0 6.848731026742882e-10
most O 0 4.5817904706226627e-17
apparent O 0 1.9065161572400825e-14
in O 0 8.054389456338956e-20
individuals O 0 9.817271090945257e-19
with O 0 4.177961061010397e-18
mutations O 0 6.0118675886307055e-15
in O 0 5.515573819182339e-17
region O 0 3.5137078115794404e-15
1 O 0 3.514388005505865e-17
, O 0 2.867617602133021e-16
and O 0 1.2598461336665867e-11
upper O 0 5.789146939605416e-08
- O 0 0.0011604406172409654
gastrointestinal O 0 0.00013258146645966917
manifestations O 0 6.481113246081804e-08
were O 0 1.923072297108433e-13
more O 0 2.804193363229395e-16
severe O 0 2.587335998661261e-14
in O 0 5.196933450600589e-20
them O 0 5.883343467895548e-15
. O 0 2.9256856811342435e-14

In O 0 1.4449130059583204e-16
individuals O 0 1.3275708682536097e-17
with O 0 2.216927917756227e-17
mutations O 0 3.745005404420278e-15
in O 0 3.548862908203605e-17
either O 0 2.5457319425777926e-14
region O 0 1.684425033265588e-13
2 O 0 4.5756821454630975e-15
or O 0 5.525053504984445e-12
region O 0 4.352645156737063e-14
3 O 0 1.264908843197227e-16
, O 0 2.40163681087192e-18
the O 0 1.249479683113653e-18
average O 0 2.2422391481919822e-17
number O 0 1.6876662509486644e-21
of O 0 2.6962979579583093e-20
adenomas B-Disease 0 4.0568812415334166e-13
tended O 0 1.6724272791299177e-12
to O 0 8.92457291336475e-15
be O 0 1.1785768216400483e-13
lower O 0 1.6776246461892158e-13
than O 0 1.112898589947296e-15
those O 0 2.1369016014758453e-16
in O 0 8.592843968550057e-20
individuals O 0 8.613125403194091e-20
with O 0 8.651888896155916e-19
mutations O 0 5.508235734532259e-17
in O 0 1.0364715763945102e-18
region O 0 4.814002170832265e-16
1 O 0 6.255995510469681e-18
, O 0 6.92705794195833e-17
although O 0 1.0657423599495178e-14
age O 0 1.5311143737421762e-13
at O 0 3.2305508383011954e-16
diagnosis O 0 3.04032714362214e-15
was O 0 3.0650948634558886e-16
similar O 0 1.774827442004644e-16
. O 0 4.460915957373718e-14

In O 0 3.5118487436668067e-13
all O 0 1.2936397612850481e-11
AAPC B-Disease 1 0.999924898147583
kindreds O 0 1.483054887785329e-07
, O 0 1.915929135121246e-17
a O 0 6.878993723246777e-19
predominance O 0 1.7293685580788143e-11
of O 0 3.904778741101574e-16
right O 0 0.004058212041854858
- O 1 0.9996800422668457
sided O 1 0.999988317489624
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999992847442627
and O 0 2.8730930523579445e-08
rectal B-Disease 0 0.008463439531624317
polyp I-Disease 0 1.024938910632045e-06
sparing O 0 1.564998890028757e-12
was O 0 1.4153471959970493e-13
observed O 0 6.500977870176755e-14
. O 0 1.943885217993869e-14

No O 0 5.705953185497492e-07
desmoid B-Disease 1 0.902050793170929
tumors I-Disease 1 0.9999997615814209
were O 0 1.6774415190212721e-10
found O 0 5.2882218460996444e-14
in O 0 3.426030557706421e-17
these O 0 9.636856471238048e-14
kindreds O 0 9.392124411533587e-08
. O 0 4.444239030607089e-13

Our O 0 4.936167035014816e-13
data O 0 4.256761694146322e-16
suggest O 0 7.831892152835467e-16
that O 0 8.850181397739194e-17
, O 0 6.22728365781766e-17
in O 0 5.776108779135798e-16
AAPC B-Disease 1 0.9999994039535522
families O 0 2.412092661024934e-12
, O 0 9.103860762517867e-22
the O 0 1.8363083641351177e-23
location O 0 3.7466698651070727e-19
of O 0 1.6476724924233481e-21
the O 0 3.1220894109145276e-18
APC B-Disease 0 3.4866172449188326e-11
mutation O 0 2.289898685167019e-13
may O 0 4.639709840284501e-13
partially O 0 5.863565926203518e-13
predict O 0 3.0287744612545386e-15
specific O 0 1.8000135034701076e-17
phenotypic O 0 1.557201972078072e-14
expression O 0 1.5973390388168696e-09
. O 0 2.3202919585685322e-09

This O 0 3.648564774144745e-16
should O 0 4.008968558174181e-16
help O 0 7.483024560500941e-17
in O 0 9.714813818399797e-21
the O 0 6.26217341227211e-20
design O 0 8.53985301041135e-17
of O 0 6.848506172313546e-22
tailored O 0 9.35254605084388e-16
clinical O 0 2.7719120111672476e-18
- O 0 7.524653609350309e-15
management O 0 9.56077996058058e-19
protocols O 0 2.2075091016343e-18
in O 0 6.473725803089988e-23
this O 0 3.3065674794342732e-24
subset O 0 1.2319754605242383e-21
of O 0 1.3296764768592613e-21
FAP B-Disease 0 1.6464563748290993e-14
patients O 0 4.899812630263985e-19
. O 0 2.0225419006928222e-19
. O 0 1.4290990596517602e-15

Wilms B-Disease 0 1.0667725973689812e-06
' I-Disease 0 7.200663398876372e-10
tumor I-Disease 0 1.3209988658502425e-09
1 O 0 4.813897286977571e-14
and O 0 1.1337490191457023e-12
Dax O 0 1.1411466402933002e-05
- O 0 6.610167274656575e-11
1 O 0 1.654893826022963e-18
modulate O 0 3.882666215447583e-14
the O 0 5.689614936169211e-17
orphan O 0 3.081808246097051e-12
nuclear O 0 5.630694927311508e-16
receptor O 0 3.02156721755221e-19
SF O 0 2.2123136655949338e-11
- O 0 1.4310152726421804e-13
1 O 0 1.4862062633195646e-19
in O 0 2.5417054947316777e-21
sex O 0 6.221280179455097e-16
- O 0 4.631201442769028e-18
specific O 0 4.665739386969202e-20
gene O 0 3.365911467832761e-16
expression O 0 1.0337926159922645e-14
. O 0 6.750843589891709e-16

Products O 0 2.111153439565694e-11
of O 0 1.191003895060309e-16
steroidogenic O 0 3.515013800858835e-12
factor O 0 8.858258386286856e-16
1 O 0 1.2257338506281238e-17
( O 0 1.4612466053236598e-18
SF O 0 1.7189655409310944e-05
- O 0 2.5804695269471267e-07
1 O 0 2.468190582471941e-13
) O 0 2.608389849598214e-14
and O 0 1.0998821211444243e-12
Wilms B-Disease 0 1.6676566377826774e-11
tumor I-Disease 0 7.751718711368483e-11
1 O 0 1.0427777945894614e-17
( O 0 7.057742477611114e-21
WT1 O 0 1.5308683953742935e-14
) O 0 1.6846119632772012e-20
genes O 0 2.120074637471979e-19
are O 0 1.5043080164650044e-22
essential O 0 6.893930424066854e-22
for O 0 1.1179282364910772e-22
mammalian O 0 1.836259856463022e-15
gonadogenesis O 0 4.164845551768437e-12
prior O 0 7.990829415058264e-19
to O 0 2.6248039362841327e-18
sexual O 0 1.160587349559013e-14
differentiation O 0 4.409245677041785e-15
. O 0 1.6574313807266733e-13

In O 0 2.7819160261396926e-15
males O 0 1.0111631143668292e-14
, O 0 1.1767691093350066e-16
SF O 0 1.408824346071924e-06
- O 0 2.4004478405004193e-09
1 O 0 2.303404191406603e-16
participates O 0 4.45133945581162e-17
in O 0 6.715026363311336e-20
sexual O 0 4.71506025226349e-16
development O 0 2.4326048955799082e-21
by O 0 7.4083348821112065e-22
regulating O 0 3.1708092736591046e-17
expression O 0 1.155308259066898e-15
of O 0 8.478066519327215e-21
the O 0 2.1469157436205297e-19
polypeptide O 0 2.0287055726726094e-14
hormone O 0 8.173001055722043e-18
Mullerian O 0 2.420731733013097e-14
inhibiting O 0 2.013171496639734e-14
substance O 0 1.0539340667553576e-12
( O 0 1.6997517686031677e-17
MIS O 0 7.53409279408146e-10
) O 0 1.796140987949269e-14
. O 0 5.002683312635252e-14

Here O 0 2.4458193716853094e-12
, O 0 2.00060658872434e-16
we O 0 2.7158652968853087e-16
show O 0 6.562083504618038e-14
that O 0 5.33127830957777e-16
WT1 O 0 3.5965093125867043e-09
- O 0 2.5990140595233413e-10
KTS O 0 1.0845120357316773e-09
isoforms O 0 4.5278386077856265e-18
associate O 0 2.4548624174029407e-16
and O 0 2.323239734341441e-18
synergize O 0 6.096535223269056e-14
with O 0 5.4506087082336496e-17
SF O 0 3.66310860044905e-06
- O 0 3.056372266385665e-09
1 O 0 1.639926195498066e-16
to O 0 3.5448580305498685e-17
promote O 0 1.813075548257135e-14
MIS O 0 2.205861981963153e-08
expression O 0 6.159643650173463e-13
. O 0 2.84892111800366e-14

In O 0 1.956453831678407e-14
contrast O 0 4.9400448873726174e-14
, O 0 6.534361556210415e-16
WT1 O 0 4.424963062632514e-09
missense O 0 1.964529927622749e-11
mutations O 0 2.657251046804532e-13
, O 0 4.0983284165271416e-16
associated O 0 4.565395353835168e-15
with O 0 4.968083236467358e-13
male B-Disease 0 4.108616849407554e-06
pseudohermaphroditism I-Disease 1 0.9999985694885254
in O 0 1.6562765048355743e-11
Denys B-Disease 1 0.9999054670333862
- I-Disease 1 0.9999556541442871
Drash I-Disease 1 0.9999327659606934
syndrome I-Disease 1 0.999996542930603
, O 0 2.0472012485835828e-13
fail O 0 1.965498889946321e-13
to O 0 1.3953629620035183e-19
synergize O 0 2.7056440855127706e-12
with O 0 1.3546170173799662e-14
SF O 0 0.0031695414800196886
- O 0 4.2508807496233203e-07
1 O 0 9.220140655737813e-14
. O 0 8.720933317944018e-14

Additionally O 0 4.308741211045408e-11
, O 0 3.1963398128363046e-15
the O 0 1.8692999382876723e-16
X O 0 1.4928406244507642e-07
- O 0 4.539221443167207e-09
linked O 0 1.2537012539226566e-09
, O 0 1.9097120456372975e-17
candidate O 0 3.347099081141202e-18
dosage O 0 2.64668679259407e-15
- O 0 3.0888988715538986e-16
sensitive O 0 4.974234186442411e-14
sex O 0 1.7136363942432675e-12
- O 0 2.0165379443853014e-14
reversal O 0 8.265593006513268e-17
gene O 0 3.352480304616166e-17
, O 0 4.477835229564066e-19
Dax O 0 4.0384051658293174e-10
- O 0 9.14908611111126e-14
1 O 0 3.377830288463619e-19
, O 0 1.2644051491408008e-19
antagonizes O 0 1.9812495353631505e-14
synergy O 0 3.663779140238657e-17
between O 0 1.2273246843821858e-17
SF O 0 4.124489549894861e-08
- O 0 4.294282811290184e-12
1 O 0 6.0687255421004324e-18
and O 0 8.216864127500015e-17
WT1 O 0 2.0664714514215254e-13
, O 0 7.79253897108676e-20
most O 0 1.581156826367718e-22
likely O 0 1.9567127026590928e-20
through O 0 7.7241947885617e-22
a O 0 4.2163943905660557e-22
direct O 0 1.7796908009145598e-21
interaction O 0 1.7100013635733122e-17
with O 0 6.778742843471016e-15
SF O 0 0.004614129196852446
- O 0 7.749437145321281e-07
1 O 0 4.033054543540332e-14
. O 0 6.63932071213319e-14

We O 0 4.764204150951119e-15
propose O 0 1.1346011622427273e-16
that O 0 2.423595974593365e-18
WT1 O 0 1.0870872778345753e-11
and O 0 1.2761185608656939e-13
Dax O 0 8.047295523283537e-07
- O 0 7.781999350475743e-11
1 O 0 6.56784177422156e-18
functionally O 0 1.6720867659558909e-15
oppose O 0 1.4862523786387144e-18
each O 0 3.557817228807371e-20
other O 0 6.6948268195479446e-18
in O 0 3.179842282403579e-19
testis O 0 8.7710533280827e-12
development O 0 1.8309403751965451e-19
by O 0 3.4137898976428306e-19
modulating O 0 2.1849041673127623e-12
SF O 0 1.408257503499044e-06
- O 0 4.9321630113396964e-11
1 O 0 1.620709267856132e-16
- O 0 1.3930164259514516e-13
mediated O 0 1.2518975656475306e-12
transactivation O 0 1.2681455885399373e-09
. O 0 8.117825064840102e-16
. O 0 5.351613453058977e-16

A O 0 2.2497982819715164e-15
mouse O 0 4.297626057109261e-12
model O 0 1.799028862079638e-13
for O 0 6.605245322054143e-13
Prader B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999985694885254
Willi I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999810457229614
imprinting O 0 0.0010847352677956223
- O 0 1.181289349005965e-06
centre O 0 2.0169411280024363e-11
mutations O 0 3.833969947075744e-11
. O 0 1.1032284975972736e-13

Imprinting O 0 1.2202081567380674e-09
in O 0 4.125007836783284e-16
the O 0 6.36441432151119e-17
15q11 O 0 1.8043492047703502e-12
- O 0 1.089370520873656e-11
q13 O 0 4.5410656029747087e-13
region O 0 4.7183885623506075e-16
involves O 0 1.9893110569568466e-18
an O 0 2.453715287982343e-20
imprinting O 0 2.0457904467696686e-11
centre O 0 4.857544488173771e-13
( O 0 1.5596772208083488e-19
IC O 0 1.0490829159429203e-15
) O 0 3.692072196516422e-20
, O 0 1.627389704725089e-21
mapping O 0 3.992090103211159e-16
in O 0 2.477899916518377e-19
part O 0 1.429805082499607e-19
to O 0 1.1151193920481692e-18
the O 0 4.1541006323445215e-21
promoter O 0 4.079456787160112e-15
and O 0 6.734712641504639e-17
first O 0 1.3250448551182682e-19
exon O 0 1.0575253780314986e-14
of O 0 6.534735838893983e-16
SNRPN O 0 3.5836626466334565e-06
. O 0 9.914740469602057e-13

Deletion O 0 4.370219030408462e-12
of O 0 2.6698943786550108e-18
this O 0 1.926621313078137e-18
IC O 0 1.226297573686183e-13
abolishes O 0 1.4225904525558275e-12
local O 0 4.0782082076563e-17
paternally O 0 9.452084704123995e-14
derived O 0 2.283079495216532e-19
gene O 0 3.1951419494302094e-17
expression O 0 1.1970989588602939e-15
and O 0 3.2171554781084896e-14
results O 0 2.3629918686910237e-14
in O 0 8.462079127691258e-12
Prader B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999990463256836
Willi I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999966621398926
( O 0 3.9833841086744926e-11
PWS B-Disease 1 0.9999032020568848
) O 0 7.960885639937687e-13
. O 0 5.0496861873179297e-14

We O 0 7.584932031415303e-14
have O 0 1.5155132724223184e-19
created O 0 9.574602665604224e-21
two O 0 1.3630393286043602e-19
deletion O 0 1.9914170224004596e-15
mutations O 0 1.0540490701126722e-15
in O 0 6.473547899320007e-17
mice O 0 6.816378191054628e-12
to O 0 2.901356523196848e-14
understand O 0 1.8241964883092265e-10
PWS B-Disease 1 0.9999988079071045
and O 0 8.313468235134368e-17
the O 0 3.092969118851909e-22
mechanism O 0 2.7010981129023486e-18
of O 0 3.943705143278385e-21
this O 0 1.1125785000015595e-18
IC O 0 1.4885179677390226e-12
. O 0 1.1731928303525805e-15

Mice O 0 1.8317005689993948e-09
harbouring O 0 1.9041985765966274e-09
an O 0 1.7415352090595078e-16
intragenic O 0 4.76712758157305e-09
deletion O 0 1.4236750667251385e-10
in O 0 9.439900982210689e-15
Snrpn O 0 8.79603305747878e-08
are O 0 4.019383092958469e-15
phenotypically O 0 4.627963593947793e-13
normal O 0 5.5005773258443285e-15
, O 0 6.008147631684601e-17
suggesting O 0 2.9796135583804936e-14
that O 0 1.5488413016084628e-16
mutations O 0 2.4923605659778886e-16
of O 0 1.0424586321199866e-19
SNRPN O 0 2.907820685627005e-11
are O 0 7.423958276125641e-20
not O 0 5.12589608432333e-20
sufficient O 0 6.550795468802615e-20
to O 0 3.210746149203206e-16
induce O 0 3.3309506264345146e-09
PWS B-Disease 1 0.9999716281890869
. O 0 5.896859389675768e-11

Mice O 0 1.6309226191779658e-10
with O 0 5.725820714298719e-18
a O 0 9.650733008762366e-20
larger O 0 3.636995861769742e-20
deletion O 0 7.026491404334308e-16
involving O 0 5.864850832832855e-17
both O 0 1.9794183904210186e-17
Snrpn O 0 2.3622824616570393e-12
and O 0 2.0143119705858024e-18
the O 0 5.100616669321885e-20
putative O 0 4.765161598641043e-10
PWS O 1 0.9999836683273315
- O 0 8.67958094286081e-10
IC O 0 1.1030787394616937e-10
lack O 0 2.389969741006131e-15
expression O 0 1.5605655610874424e-17
of O 0 1.261325630037274e-21
the O 0 9.851861716210694e-19
imprinted O 0 2.0972479308767333e-10
genes O 0 2.0474033167634798e-14
Zfp127 O 0 1.841046195702467e-12
( O 0 7.709807338899532e-20
mouse O 0 5.346503188091711e-12
homologue O 0 5.4028670426475855e-11
of O 0 1.0459980219490201e-15
ZNF127 O 0 2.2544891464804095e-07
) O 0 1.990801864722516e-15
, O 0 2.6069048314350876e-16
Ndn O 0 4.5087037402191665e-12
and O 0 5.312864342700053e-16
Ipw O 0 3.60345759307934e-13
, O 0 5.114906390179619e-17
and O 0 2.7993303353209713e-16
manifest O 0 4.619210321589549e-15
several O 0 5.721884885546615e-20
phenotypes O 0 4.1506935285736193e-14
common O 0 1.3152540580090022e-13
to O 0 1.7559147025281163e-08
PWS B-Disease 1 0.9999990463256836
infants O 0 7.005310180829838e-05
. O 0 2.893829110801188e-14

These O 0 1.6659999871969215e-15
data O 0 1.6233698777527966e-16
demonstrate O 0 9.456975948817474e-17
that O 0 1.662569131529266e-18
both O 0 4.400078701020433e-19
the O 0 3.3143187406463382e-18
position O 0 1.8080543369458114e-14
of O 0 3.1396548109419413e-20
the O 0 3.807548424656294e-17
IC O 0 7.0561590424789156e-12
and O 0 1.907835411055431e-15
its O 0 8.363714292638014e-20
role O 0 1.4525601749160873e-18
in O 0 3.3574760736386866e-22
the O 0 1.2089582916018658e-21
coordinate O 0 3.7417622211443594e-16
expression O 0 1.1116208936859222e-16
of O 0 7.277752325711046e-21
genes O 0 1.0135481268739813e-17
is O 0 9.920791484448304e-21
conserved O 0 1.141406364734492e-19
between O 0 9.65019541374251e-17
mouse O 0 1.0573433684157862e-07
and O 0 2.1781810730092666e-11
human O 0 3.039655997066383e-14
, O 0 1.3000428434070492e-16
and O 0 2.7723392598797986e-15
indicate O 0 3.096176075710895e-17
that O 0 3.2754148596249266e-20
the O 0 5.945346516337465e-21
mouse O 0 9.429958983814268e-13
is O 0 5.90563401133732e-20
a O 0 1.0826371491899348e-21
suitable O 0 5.896597098300354e-16
model O 0 1.6673114440739906e-13
system O 0 3.316920035075638e-13
in O 0 5.4406965202353654e-18
which O 0 9.443236147970723e-18
to O 0 5.544698920928635e-20
investigate O 0 1.409605306091668e-18
the O 0 1.210260071129839e-20
molecular O 0 4.090871608711693e-19
mechanisms O 0 1.3141774079293348e-18
of O 0 4.630184878185878e-22
imprinting O 0 3.0329009702984022e-12
in O 0 2.254218956849404e-18
this O 0 3.1441150592777067e-19
region O 0 2.131575947994433e-17
of O 0 5.647672062562851e-22
the O 0 6.07979869876795e-19
genome O 0 9.668333909623912e-15
. O 0 5.501644693236987e-16
. O 0 8.920250504234912e-15

Mutations O 0 2.339222999331314e-12
of O 0 8.192100035680433e-19
the O 0 1.1323857016606597e-19
ATM O 0 9.361514520392702e-14
gene O 0 6.8410628690487776e-15
detected O 0 4.5948683226326725e-12
in O 0 1.0653109025420102e-15
Japanese O 0 2.3181220967671834e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
telangiectasia I-Disease 1 0.9999998807907104
patients O 0 7.508735677674849e-08
: O 0 2.8507648228562126e-17
possible O 0 5.652338538172877e-18
preponderance O 0 1.0003481468743095e-13
of O 0 2.0515415604992242e-19
the O 0 1.5066371074617415e-18
two O 0 6.375199681364086e-18
founder O 0 5.743089211390339e-15
mutations O 0 2.3081187238514615e-16
4612del165 O 0 2.7490877819611945e-14
and O 0 7.687444447966639e-16
7883del5 O 0 8.479135904689017e-13
. O 0 7.996151958340574e-15

The O 0 3.6020430777035785e-16
ATM O 0 2.604314985887868e-09
( O 0 5.19165717360881e-11
A O 1 0.9999996423721313
- O 1 0.9999996423721313
T O 1 1.0
, O 0 1.1326115961990749e-13
mutated O 0 3.1911741824074743e-15
) O 0 3.810928357017489e-20
gene O 0 7.556162546773899e-19
on O 0 1.7076694553997416e-15
human O 0 5.30626703600795e-14
chromosome O 0 1.4802678194314467e-08
11q22 O 0 2.1933867222490022e-10
. O 0 4.800949880159021e-14

3 O 0 9.68328403572194e-11
has O 0 8.623540114416003e-14
recently O 0 2.024329122840736e-15
been O 0 1.2852548392880712e-16
identified O 0 2.4691260634598152e-18
as O 0 8.895959941934852e-21
the O 0 6.076794976954294e-23
gene O 0 3.2177532623465915e-20
responsible O 0 7.451706954502527e-20
for O 0 3.8744370089958065e-23
the O 0 5.338616952574764e-19
human O 0 2.2499058172087416e-11
recessive B-Disease 0 0.027800869196653366
disease I-Disease 1 0.9999927282333374
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999980926513672
telangiectasia I-Disease 1 0.9999998807907104
( O 0 1.8334582136958488e-06
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999969005584717
T I-Disease 1 0.9999991655349731
) O 0 5.186000283721737e-13
. O 0 5.275948423397224e-15

In O 0 6.100175362580005e-18
order O 0 8.83138282392989e-20
to O 0 1.5248606072146236e-20
define O 0 9.406132961594657e-18
the O 0 7.550568608634539e-20
types O 0 7.732181763625296e-15
of O 0 4.2216540313672036e-16
disease O 0 1.7367391080824746e-08
- O 0 1.8763295361878818e-09
causing O 0 1.6570791613879088e-11
ATM O 0 1.683387587311791e-13
mutations O 0 7.411545064738706e-14
in O 0 2.4807967133632953e-17
Japanese O 0 3.7878631786725236e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 2.6213272614279866e-14
as O 0 2.3226259017034414e-20
well O 0 3.7112181157434e-21
as O 0 1.4085926576917313e-21
to O 0 1.685036054899848e-20
look O 0 7.320388154850613e-19
for O 0 6.715931324820283e-25
possible O 0 5.104059404724854e-21
mutational O 0 2.5144037513972345e-14
hotspots O 0 1.2370753564323184e-14
, O 0 2.548058532641769e-18
reverse O 0 3.729740312170132e-13
- O 0 1.0078210781108016e-13
transcribed O 0 4.081969571384514e-12
RNA O 0 8.036839943548202e-11
derived O 0 7.917167988893682e-17
from O 0 6.172406221234207e-20
ten O 0 4.5135035806947796e-20
patients O 0 3.0665225885588106e-23
belonging O 0 3.1419985911598224e-23
to O 0 4.750433634406682e-21
eight O 0 5.775700739211432e-20
unrelated O 0 4.820158512172028e-16
Japanese O 0 1.1794748289162271e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 2.792968330569967e-12
was O 0 6.25549134388633e-19
analyzed O 0 3.161359900968362e-20
for O 0 2.868108924766346e-24
mutations O 0 3.4957935563649456e-22
by O 0 7.342491691578285e-24
the O 0 3.7568664418591153e-23
restriction O 0 5.011872387277806e-21
endonuclease O 0 2.3013316076637904e-16
fingerprinting O 0 3.490143143228589e-15
method O 0 1.1835811600550625e-15
. O 0 1.893609704464532e-15

As O 0 4.765933538119528e-14
has O 0 3.584444803554068e-15
been O 0 1.1449851720771783e-14
reported O 0 2.781800702603924e-14
by O 0 1.2378996094872474e-17
others O 0 3.2995643299863972e-15
, O 0 3.009544793583605e-20
mutations O 0 2.301073516972916e-19
that O 0 6.865728848148724e-19
lead O 0 6.105413483808997e-18
to O 0 1.9868149360608912e-19
exon O 0 2.0132012274961825e-15
skipping O 0 4.875910439294806e-11
or O 0 8.074233989741053e-12
premature O 0 2.2316880060515437e-13
protein O 0 2.56081518797147e-17
truncation O 0 1.2138372828101045e-15
were O 0 8.449551754346855e-15
also O 0 1.3049177827162937e-15
predominant O 0 1.2875736718140351e-12
in O 0 5.557815286087462e-17
our O 0 2.8156163164871906e-11
mutants O 0 6.87407379282301e-12
. O 0 2.702370103271857e-15

Six O 0 2.056091977448507e-13
different O 0 6.051641780909375e-18
mutations O 0 6.22806782503836e-17
were O 0 3.048314081979597e-17
identified O 0 6.431065226548263e-17
on O 0 3.695060316749599e-12
12 O 0 1.0702687346130554e-14
of O 0 6.975653525985749e-20
the O 0 1.2415225282213317e-16
16 O 0 2.061476493896402e-16
alleles O 0 3.0090112238314053e-16
examined O 0 1.9291276475569274e-12
. O 0 1.6601500989893436e-12

Four O 0 9.827736166464972e-17
were O 0 1.9078315952712654e-19
deletions O 0 1.4100915344362553e-15
involving O 0 2.5704790265713637e-14
a O 0 1.2353783089818354e-13
loss O 0 3.6809666642892425e-14
of O 0 3.8489391943817633e-22
a O 0 1.5285594616459281e-19
single O 0 2.9594229372489333e-17
exon O 0 1.272271269456629e-13
exon O 0 8.326724726392953e-12
7 O 0 3.6129961327423243e-13
, O 0 4.743546499675244e-16
exon O 0 1.0864063555021675e-13
16 O 0 8.960288057585728e-15
, O 0 3.4095375689088486e-17
exon O 0 5.534532792998703e-13
33 O 0 2.4994006972596516e-13
or O 0 1.6701769091007068e-12
exon O 0 2.6207840342351574e-09
35 O 0 5.296045268998739e-10
. O 0 8.3516700499775e-11

The O 0 3.390203843364422e-15
others O 0 3.8535351006772607e-16
were O 0 2.8513492156192237e-19
minute O 0 2.437652461537632e-18
deletions O 0 4.435239212368888e-16
, O 0 4.479289309683358e-18
4649delA O 0 4.7237579042032525e-15
in O 0 1.3905532944824346e-20
exon O 0 3.3062546197202853e-15
33 O 0 1.1499527873787643e-15
and O 0 1.3536884839813183e-16
7883del5 O 0 1.1911459266036959e-14
in O 0 1.587124676195295e-18
exon O 0 2.811580655792678e-11
55 O 0 9.677500120708338e-12
. O 0 2.6139008492409577e-12

The O 0 1.1976613887372707e-14
mutations O 0 2.8273438007053037e-14
4612del165 O 0 1.7169726469583313e-13
and O 0 3.5257653255836054e-15
7883del5 O 0 6.616865106371826e-15
were O 0 1.6482298977080163e-16
found O 0 2.7281462985473732e-18
in O 0 7.045499255387888e-22
more O 0 2.5035592610681636e-22
than O 0 1.8719131593301612e-22
two O 0 1.705432196230389e-20
unrelated O 0 2.06183150658042e-15
families O 0 2.380343211560586e-15
; O 0 1.0408850502515752e-19
44 O 0 8.586364714510717e-18
% O 0 2.178661416878409e-20
( O 0 2.712834946302121e-21
7 O 0 1.7288462584629443e-16
of O 0 6.340203324008192e-18
16 O 0 3.8237653336526203e-16
) O 0 7.217072003873033e-20
of O 0 1.6313971686107096e-23
the O 0 2.757239520235873e-20
mutant O 0 1.6080348586976906e-13
alleles O 0 2.3175417006918695e-16
had O 0 1.162001809877633e-12
one O 0 8.344924259468534e-17
of O 0 1.3717339661945728e-20
the O 0 8.328990775637293e-17
two O 0 4.265039249507982e-14
mutations O 0 6.574953255455984e-13
. O 0 4.3508816341408796e-12

The O 0 4.204298855673555e-15
4612del165 O 0 3.9233268462344e-14
mutations O 0 2.0569765254849952e-15
in O 0 3.975761930150638e-19
three O 0 8.2284303251716445e-19
different O 0 1.197581916532739e-17
families O 0 8.81713356026912e-15
were O 0 1.724096852083461e-17
all O 0 8.822956608064037e-22
ascribed O 0 1.6010368976708537e-19
to O 0 1.6531641396633263e-19
the O 0 2.239911523986804e-19
same O 0 1.3650031236209616e-16
T O 0 3.137283456026291e-13
- O 0 1.5191680169304706e-16
- O 0 9.072854448171529e-17
> O 0 5.03942097518816e-21
A O 0 1.4512167940194164e-22
substitution O 0 2.286964764169281e-21
at O 0 1.2171406951743743e-19
the O 0 2.331731724394585e-22
splice O 0 7.726439930563767e-13
donor O 0 1.332224219111641e-15
site O 0 7.241520247115469e-16
in O 0 2.0252373721164028e-18
intron O 0 1.0707084108219078e-09
33 O 0 9.705037338006428e-13
. O 0 4.0388877206348935e-15

Microsatellite O 0 1.7251640116455746e-08
genotyping O 0 6.077321978992245e-10
around O 0 7.032719404661408e-14
the O 0 6.308956679766578e-19
ATM O 0 1.1204271017917211e-12
locus O 0 1.9480970656071683e-11
also O 0 9.444300132525549e-14
indicated O 0 5.622948599250631e-15
that O 0 5.7496129102575815e-18
a O 0 4.671282479350285e-18
common O 0 1.51608953391719e-14
haplotype O 0 1.2321209330590221e-10
was O 0 9.591531128366748e-13
shared O 0 1.7100273370445464e-17
by O 0 2.9819792420083457e-21
the O 0 3.8984308180111014e-20
mutant O 0 4.690543743343656e-13
alleles O 0 1.5194170975565226e-16
in O 0 2.461705632979755e-18
both O 0 4.2041527424901536e-16
mutations O 0 2.0895557419770006e-12
. O 0 2.2470957386500068e-12

This O 0 1.2378448011616042e-14
suggests O 0 8.791477609923146e-14
that O 0 2.9972231721835856e-16
these O 0 6.263043006570572e-17
two O 0 1.0087002363707673e-16
founder O 0 2.5803046765221493e-13
mutations O 0 7.977935667776923e-14
may O 0 2.215442413872645e-15
be O 0 1.0805551331647581e-18
predominant O 0 8.52807763778796e-15
among O 0 4.338973835195375e-19
Japanese O 0 3.372826433055908e-16
ATM O 0 4.274947149746078e-12
mutant O 0 1.2974754604044847e-10
alleles O 0 1.8237217291883212e-12
. O 0 2.0675132612890668e-12

W474C O 0 1.2820897121734731e-11
amino O 0 3.0021124475254624e-14
acid O 0 1.1585957527538695e-16
substitution O 0 3.2628478406205323e-18
affects O 0 5.18215088002426e-18
early O 0 1.2526615593556346e-20
processing O 0 2.1250057971455314e-19
of O 0 3.005467278849601e-23
the O 0 3.600273828749272e-22
alpha O 0 2.4166695518847583e-20
- O 0 3.7486713836955096e-19
subunit O 0 3.15615447922296e-20
of O 0 6.421984706617355e-20
beta O 0 2.863966096036967e-16
- O 0 3.464771655345422e-12
hexosaminidase O 0 3.451278846045014e-11
A O 0 1.5611616605240726e-16
and O 0 9.269100566957897e-19
is O 0 1.1911962237292626e-21
associated O 0 4.800603269469017e-21
with O 0 3.6451942943899995e-18
subacute O 0 3.8167380367326587e-10
G B-Disease 0 2.260265530296124e-09
( I-Disease 0 1.254825213745185e-17
M2 I-Disease 0 8.154944275418075e-09
) I-Disease 0 5.561431848898069e-13
gangliosidosis I-Disease 0 4.2795858234967454e-07
. O 0 6.135969553636156e-13

Mutations O 0 1.3056821249191053e-11
in O 0 8.688614627610765e-16
the O 0 3.9189233310528836e-17
HEXA O 0 3.934587031184655e-12
gene O 0 5.911187505514606e-17
, O 0 4.5582466201330825e-21
encoding O 0 3.024124255776636e-21
the O 0 3.3109396416049866e-21
alpha O 0 6.149537908471384e-20
- O 0 1.6557652607982875e-18
subunit O 0 2.35477072191862e-19
of O 0 9.794598458096091e-20
beta O 0 4.225230627986985e-16
- O 0 2.543571256397037e-11
hexosaminidase O 0 2.041480318126787e-10
A O 0 3.1417955497143376e-15
( O 0 1.0441296500484431e-20
Hex O 0 8.60064176453311e-14
A O 0 1.026658029684273e-17
) O 0 2.5516452330142387e-20
, O 0 8.782794121657425e-22
that O 0 9.80688855254104e-22
abolish O 0 2.306710531576651e-16
Hex O 0 1.4319148089266703e-15
A O 0 4.470885684572399e-20
enzyme O 0 1.5125064998470095e-16
activity O 0 4.592145760873301e-11
cause O 0 0.03099590167403221
Tay B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
Sachs I-Disease 1 0.9999997615814209
disease I-Disease 0 0.013982243835926056
( O 0 1.3388511302669953e-17
TSD B-Disease 0 1.925098969124406e-12
) O 0 9.623203145506894e-19
, O 0 8.926830419330559e-20
the O 0 8.189354416432216e-18
fatal O 0 5.268482539122488e-09
infantile B-Disease 0 0.00010005093645304441
form I-Disease 0 1.0565747495666633e-12
of I-Disease 0 1.0849485101559891e-13
G I-Disease 0 9.982849746847933e-08
( I-Disease 0 1.3939377815068777e-18
M2 I-Disease 0 2.1189121290898782e-10
) I-Disease 0 1.0443598602290303e-14
gangliosidosis I-Disease 0 1.1049111625638375e-09
, I-Disease 0 2.5159938439974676e-16
Type I-Disease 0 2.6878288345564584e-14
1 I-Disease 0 2.3840328870788257e-15
. O 0 8.262268365137604e-13

Less O 0 2.5054935556823033e-11
severe O 0 1.3918578789517966e-10
, O 0 7.902865043485905e-17
subacute O 0 2.1013080164777875e-10
( O 0 6.16754268874561e-17
juvenile O 0 1.0004427508647495e-07
- O 0 0.3658007085323334
onset O 0 0.14582371711730957
) O 0 4.012191967550649e-11
and O 0 3.811952975496524e-09
chronic O 0 2.938898887805408e-06
( O 0 2.674664729247604e-18
adult O 0 7.1598282858076345e-09
- O 0 2.9925404305686243e-05
onset O 0 1.7183096190365177e-07
) O 0 3.562168273792643e-17
variants O 0 6.145115506233582e-17
are O 0 5.4119571929085446e-21
characterized O 0 1.4705670244343144e-20
by O 0 5.300820903480972e-23
a O 0 1.7729427357943603e-20
broad O 0 1.383592171547131e-17
spectrum O 0 2.1327869483521444e-14
of O 0 1.40684345342393e-19
clinical O 0 1.7117887561204321e-18
manifestations O 0 7.121504678214599e-16
and O 0 2.1131342540225837e-16
are O 0 2.7169388284278923e-19
associated O 0 1.131803769759971e-17
with O 0 5.670572179677057e-16
residual O 0 1.895444867727747e-08
levels O 0 7.983404519060211e-13
of O 0 6.4004105599281365e-21
Hex O 0 1.5604078901394758e-13
A O 0 2.787806234938666e-19
enzyme O 0 1.0960239896459285e-17
activity O 0 4.675158118305116e-15
. O 0 3.2665516443836345e-15

We O 0 8.914228947012881e-15
identified O 0 4.8162591165900036e-17
a O 0 1.7764175147525425e-18
1422 O 0 2.3799826042239514e-13
G O 0 1.2515400174550884e-11
- O 0 2.5066932904382888e-11
- O 0 3.0661803651632624e-10
> O 0 2.9141473305641097e-13
C O 0 7.681205671516977e-11
( O 0 9.907144135252173e-20
amino O 0 3.710827353683326e-18
acid O 0 1.74358002124723e-19
W474C O 0 1.0351468240252867e-20
) O 0 7.592028906283226e-24
substitution O 0 3.4506012928266443e-22
in O 0 8.156285965658436e-23
the O 0 1.1271432678237621e-22
first O 0 1.6615014134184897e-21
position O 0 5.478392381520326e-18
of O 0 2.2743498559310637e-21
exon O 0 9.406291561896585e-15
13 O 0 1.5875994646320107e-15
of O 0 1.0280140268624312e-17
HEXA O 0 1.9008399476660998e-07
of O 0 2.1767633690203267e-16
a O 0 8.279679974401363e-14
non O 0 8.275615435981987e-12
- O 0 6.612931997551641e-07
Jewish O 0 9.040605846166727e-07
proband O 0 3.223213980163564e-06
who O 0 4.5994825007315224e-15
manifested O 0 3.7809184367135575e-16
a O 0 7.212145109349514e-20
subacute O 0 9.490460717645477e-13
variant O 0 1.6465624003147994e-11
of O 0 2.9570589683489135e-13
G B-Disease 0 4.1283361497335136e-05
( I-Disease 0 2.828138984648274e-16
M2 I-Disease 0 3.8421454462422844e-08
) I-Disease 0 1.3361580722057176e-12
gangliosidosis I-Disease 0 2.602033077891974e-07
. O 0 5.500950172807051e-13

On O 0 8.83000443596682e-12
the O 0 3.700317979002214e-14
second O 0 1.7018785686273574e-11
maternally O 0 2.496591946510307e-07
inherited O 0 2.684654054618818e-09
allele O 0 3.319480107455419e-11
, O 0 1.3411323587387961e-15
we O 0 1.3678484429484093e-17
identified O 0 6.839614239222542e-19
the O 0 1.672269850803951e-17
common O 0 1.1525341792051336e-09
infantile O 1 0.9999853372573853
disease O 1 0.9999775886535645
- O 0 0.19617652893066406
causing O 0 2.302964639966376e-05
4 O 0 5.3559285777054697e-14
- O 0 2.0199701286638394e-12
bp O 0 4.7404918871092085e-15
insertion O 0 1.2544006318629289e-15
, O 0 2.3139980589476924e-17
+ O 0 8.954509387061322e-16
TATC O 0 2.765646652663767e-12
1278 O 0 9.448593166552777e-13
, O 0 1.8929784299995335e-18
in O 0 1.1760448113790914e-19
exon O 0 8.175500749475761e-13
11 O 0 4.372620321380083e-12
. O 0 2.2108603467928256e-13

Pulse O 0 1.163720207841834e-05
- O 0 4.344395510003096e-09
chase O 0 1.4516228930699926e-12
analysis O 0 9.747754418675995e-18
using O 0 2.5145436971219887e-17
proband O 0 1.304562013970667e-11
fibroblasts O 0 2.4962467531398913e-13
revealed O 0 8.926624088349822e-13
that O 0 1.5802255762962965e-18
the O 0 6.073745546141652e-20
W474C O 0 5.868297198136996e-17
- O 0 1.0275905931068653e-17
containing O 0 2.345142856576386e-19
alpha O 0 2.5255856509858372e-20
- O 0 7.049273505231764e-19
subunit O 0 3.157453209330218e-21
precursor O 0 2.2380154709264675e-19
was O 0 1.1518669759604406e-15
normally O 0 3.1478219270211953e-20
synthesized O 0 1.4776812623784107e-19
, O 0 1.5794585666109582e-20
but O 0 1.8200341926904895e-20
not O 0 1.905269581038467e-21
phosphorylated O 0 2.050775746348365e-18
or O 0 3.185357395400442e-17
secreted O 0 1.427922721470437e-14
, O 0 7.356761064822886e-17
and O 0 2.1578318914816175e-15
the O 0 2.1209759262295864e-16
mature O 0 2.629549749060163e-14
lysosomal O 0 2.085156888123672e-15
alpha O 0 1.1615323152727606e-19
- O 0 1.8395391709880965e-17
subunit O 0 5.91824412128175e-19
was O 0 4.1610912815176395e-15
not O 0 5.55747581116407e-17
detected O 0 2.6359285847793457e-13
. O 0 6.9571487344699794e-15

When O 0 1.4761195737955646e-13
the O 0 1.8442186971494315e-17
W474C O 0 1.8217034258578672e-14
- O 0 1.665251188895725e-14
containing O 0 1.1367846543620713e-16
alpha O 0 3.155784199576569e-18
- O 0 1.5979153465477228e-16
subunit O 0 9.925722741057085e-19
was O 0 2.5477806611673166e-15
transiently O 0 1.441399354474432e-14
co O 0 3.716868240461911e-15
- O 0 2.0816281488654107e-15
expressed O 0 3.8177544065286414e-19
with O 0 2.534539658973493e-22
the O 0 3.9089379984578285e-23
beta O 0 6.857469399245284e-23
- O 0 1.906098377238154e-21
subunit O 0 3.1532989289638048e-22
to O 0 1.9540358363369461e-19
produce O 0 2.1572925951580368e-19
Hex O 0 2.2282672126720804e-14
A O 0 1.3645598209870822e-17
( O 0 2.020335493344065e-20
alphabeta O 0 3.815407733677445e-13
) O 0 8.562413415530909e-20
in O 0 2.262228307613859e-20
COS O 0 2.564694290274616e-11
- O 0 1.8934960749946578e-13
7 O 0 6.861205762520738e-17
cells O 0 9.815484628976327e-17
, O 0 2.1640843942219507e-19
the O 0 9.155234211943343e-21
mature O 0 1.8205569062141377e-18
alpha O 0 9.717440561131115e-22
- O 0 2.5277362559549897e-19
subunit O 0 3.9000499594366886e-21
was O 0 5.427997613692949e-15
present O 0 2.1158179918891752e-18
, O 0 2.4932032748384908e-19
but O 0 1.21517888125534e-18
its O 0 1.5112469591661054e-19
level O 0 1.064001594746347e-18
was O 0 1.403040461606396e-16
much O 0 1.3235558989963998e-17
lower O 0 1.8820780920414935e-17
than O 0 2.5465122218841777e-19
that O 0 3.469734397216476e-18
from O 0 9.994754840583756e-20
normal O 0 1.726543461049876e-19
alpha O 0 9.070235345551768e-22
- O 0 1.5614384692782332e-20
subunit O 0 1.923570750142811e-21
transfections O 0 1.1520565419340361e-14
, O 0 9.698669256170808e-21
although O 0 1.5956401257853134e-20
higher O 0 1.0671182432733848e-20
than O 0 1.1313827451679392e-21
in O 0 4.630628962699307e-21
those O 0 4.376361158111853e-18
cells O 0 1.489543549350304e-19
transfected O 0 2.0515124747609353e-17
with O 0 5.072263539213692e-22
an O 0 5.781426016506842e-22
alpha O 0 2.2041683259353516e-18
- O 0 5.512171936342819e-15
subunit O 0 3.556331885913816e-16
associated O 0 1.9065823952165578e-13
with O 0 2.0758576606792756e-13
infantile O 0 0.009276611730456352
TSD B-Disease 0 2.8452106448639825e-07
. O 0 4.9841302417717726e-14

Furthermore O 0 3.829831417279106e-12
, O 0 1.3312025385585748e-16
the O 0 1.7912578070259915e-19
precursor O 0 5.435824343709367e-17
level O 0 6.533664342215707e-16
of O 0 5.8807000088651016e-21
the O 0 1.1567043463806242e-18
W474C O 0 1.686717056510557e-17
alpha O 0 1.4484308957605712e-20
- O 0 9.239975537589905e-19
subunit O 0 7.225390985142872e-20
was O 0 8.369607937752047e-15
found O 0 5.333106709603757e-17
to O 0 1.2242052828946717e-18
accumulate O 0 2.627222187224403e-15
in O 0 3.2384128554515724e-22
comparison O 0 1.32689101884791e-19
to O 0 7.185100697716034e-19
the O 0 3.2495676626811466e-19
normal O 0 3.19698110280416e-18
alpha O 0 5.181532704688044e-20
- O 0 1.1277563336637184e-18
subunit O 0 1.6564656242831785e-19
precursor O 0 6.873282599464012e-17
levels O 0 7.908362075555349e-15
. O 0 7.07009798394794e-17

We O 0 8.190246170072107e-14
conclude O 0 2.0145291633992405e-16
that O 0 2.804371043692923e-19
the O 0 2.0376118389838312e-19
1422 O 0 2.0289542615459233e-13
G O 0 3.0855843054233834e-12
- O 0 8.068475575162548e-12
- O 0 5.4345347666462374e-11
> O 0 9.754763457495846e-15
C O 0 1.207617312355344e-13
mutation O 0 1.973476131695591e-18
is O 0 5.414355289670738e-20
the O 0 5.300360511634911e-21
cause O 0 4.196299489754575e-17
of O 0 1.4354763305222923e-21
Hex B-Disease 0 2.339430593689684e-10
A I-Disease 0 7.713310025414533e-12
enzyme I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999998807907104
in O 0 1.3533831219863882e-17
the O 0 2.514938229186952e-16
proband O 0 4.212099469214081e-08
. O 0 8.0046707380977e-14

The O 0 2.679978363794716e-16
resulting O 0 1.2034397945638803e-16
W474C O 0 7.007138289676323e-16
substitution O 0 5.323611586070322e-18
clearly O 0 1.6468660423140389e-16
interferes O 0 1.589713552989239e-16
with O 0 1.0400147294235794e-21
alpha O 0 2.9624663825535822e-21
- O 0 4.9218971893964144e-20
subunit O 0 4.350222409082717e-21
processing O 0 4.874256471648853e-18
, O 0 1.7445970979715007e-20
but O 0 4.2970485897449086e-21
because O 0 1.0253632978724437e-23
the O 0 1.055492735742093e-24
base O 0 1.6208844421562744e-21
substitution O 0 2.2596690431103627e-18
falls O 0 1.6462277775772943e-13
at O 0 5.015513691264227e-18
the O 0 8.885683192176161e-21
first O 0 3.2815948035294927e-19
position O 0 1.0803508195534575e-15
of O 0 1.233481389681418e-19
exon O 0 1.7464335370660083e-14
13 O 0 5.699371299883703e-16
, O 0 6.82757048950377e-19
aberrant O 0 1.7645266478633049e-15
splicing O 0 1.519576782113563e-12
may O 0 1.2519399037423662e-13
also O 0 1.7387654940400475e-18
contribute O 0 1.005499039128381e-18
to O 0 5.392763901823367e-16
Hex B-Disease 0 1.043289898916555e-06
A I-Disease 0 6.199338264956111e-10
deficiency I-Disease 0 6.336333626677515e-06
in O 0 4.032567783235893e-19
this O 0 4.288964976902257e-18
proband O 0 2.8876820379331036e-10
. O 0 2.502115473854502e-16
. O 0 4.663758325384494e-15

Two O 0 2.3528087115441904e-15
frequent O 0 6.547898941805519e-12
missense O 0 6.9075336561752465e-09
mutations O 0 5.680309982381004e-07
in O 0 2.4130022779900173e-07
Pendred B-Disease 1 0.9999990463256836
syndrome I-Disease 1 0.9999997615814209
. O 0 1.6258741908359298e-08

Pendred B-Disease 1 0.9999672174453735
syndrome I-Disease 1 0.9999992847442627
is O 0 5.585806261976245e-10
an O 0 4.7474850362050347e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.00029248837381601334
by O 0 2.2363239190158202e-13
early O 0 1.4605066045447757e-09
childhood O 1 0.999750554561615
deafness B-Disease 1 0.9999997615814209
and O 0 8.358113518625032e-06
goiter B-Disease 1 0.9999845027923584
. O 0 1.0163737039492471e-11

A O 0 9.291670216441186e-15
century O 0 3.319549437102152e-15
after O 0 2.9462789049665677e-16
its O 0 5.875927241354156e-20
recognition O 0 2.9178204156682193e-19
as O 0 6.01062321782185e-17
a O 0 2.3243979982955076e-13
syndrome O 0 5.0455942982807755e-05
by O 0 1.948167520113655e-15
Vaughan O 0 1.5807218645136345e-08
Pendred O 0 3.147732741126674e-08
, O 0 4.063457393577662e-16
the O 0 1.232994097582563e-16
disease O 0 1.6117726727923887e-12
gene O 0 9.755135304959691e-15
( O 0 9.485043510490378e-18
PDS O 0 8.20755408081908e-11
) O 0 8.201350370621219e-20
was O 0 7.33414054952219e-19
mapped O 0 2.6124327378554586e-14
to O 0 5.495858081778701e-15
chromosome O 0 1.2496319357069297e-07
7q22 O 0 5.268401714886295e-09
- O 0 9.601178518892084e-09
q31 O 0 8.145892849142911e-10
. O 0 1.5522803040787098e-13

1 O 0 2.332560956452151e-13
and O 0 3.1919080009309986e-13
, O 0 1.900236195412135e-17
recently O 0 4.64245798785989e-15
, O 0 6.574804386081966e-20
found O 0 9.222815837341206e-21
to O 0 1.162554413443792e-22
encode O 0 2.271741950945727e-19
a O 0 2.8222058331813906e-20
putative O 0 8.851241544175978e-14
sulfate O 0 1.8916777866362366e-12
transporter O 0 5.64109592371409e-10
. O 0 3.9727268241578073e-13

We O 0 1.4930012792475217e-13
performed O 0 1.5848817594207453e-16
mutation O 0 8.347531201887056e-18
analysis O 0 4.8922137355667666e-18
of O 0 1.1211707804533172e-20
the O 0 1.9788662473621395e-18
PDS B-Disease 0 1.5637406300395007e-11
gene O 0 2.32194838959996e-16
in O 0 1.9938998414049845e-18
patients O 0 7.38681799586898e-18
from O 0 1.8258974168933273e-19
14 O 0 2.0211248369059423e-17
Pendred B-Disease 0 5.942403253494932e-12
families O 0 4.3676909818033175e-17
originating O 0 8.800759672244866e-17
from O 0 5.893111557722403e-16
seven O 0 2.283536874810076e-15
countries O 0 2.1358003593827412e-17
and O 0 5.317122271446782e-16
identified O 0 1.215537807330836e-15
all O 0 1.1965362775204108e-17
mutations O 0 7.185772667812809e-15
. O 0 5.085320270485855e-15

The O 0 7.622185218061905e-15
mutations O 0 1.2662813065635308e-14
include O 0 1.1343798583416449e-17
three O 0 4.2211824887872116e-18
single O 0 3.036486350477793e-18
base O 0 9.486314390783505e-17
deletions O 0 1.1526109927606498e-13
, O 0 2.1579130478258763e-16
one O 0 1.0395126025189849e-18
splice O 0 8.003435136849646e-10
site O 0 8.05562491712486e-11
mutation O 0 2.6133636921166215e-11
and O 0 5.4593232712285555e-11
10 O 0 2.324715974463907e-14
missense O 0 5.43127825700096e-12
mutations O 0 3.8096376747676075e-11
. O 0 9.409396872772646e-11

One O 0 8.739265821428033e-14
missense O 0 9.7195654302773e-12
mutation O 0 2.355734422636313e-13
( O 0 3.0625235890653797e-16
L236P O 0 8.493375544971898e-14
) O 0 6.229639335853313e-16
was O 0 6.515128741406764e-14
found O 0 1.1703455291003852e-15
in O 0 2.138528132209242e-20
a O 0 8.145224873589789e-21
homozygous O 0 1.8931743890866473e-17
state O 0 1.9628365210666275e-19
in O 0 5.200641869307726e-20
two O 0 1.3638416627792637e-17
consanguineous O 0 2.387477715526387e-11
families O 0 7.182135745506524e-13
and O 0 5.3541429051977155e-17
in O 0 1.2232936587738044e-20
a O 0 3.6212708352076822e-19
heterozygous O 0 1.9278730606836952e-16
state O 0 5.670952790292311e-19
in O 0 3.284237128598717e-19
five O 0 1.5724091330979767e-17
additional O 0 2.382410858689503e-18
non O 0 3.226120813635408e-14
- O 0 2.506917162747868e-08
consanguineous O 0 2.3074649107002188e-06
families O 0 5.27861865329271e-10
. O 0 8.5077048013406e-15

Another O 0 3.8291719513076916e-13
missense O 0 4.8644477335102465e-11
mutation O 0 6.62307177417415e-13
( O 0 5.476433816353147e-16
T416P O 0 2.287209863779255e-13
) O 0 7.115367395116149e-16
was O 0 6.325769443850382e-14
found O 0 5.783362557537847e-16
in O 0 2.6561974697079603e-20
a O 0 3.9196202126243836e-20
homozygous O 0 1.3042749641186665e-16
state O 0 4.336957168861971e-18
in O 0 2.980619192291421e-18
one O 0 3.325468503337565e-15
family O 0 5.627680960129666e-11
and O 0 1.7703664529906786e-14
in O 0 6.988971133847853e-20
a O 0 9.391137883149084e-20
heterozygous O 0 2.582574008548555e-17
state O 0 5.76076289132449e-19
in O 0 4.106665536833839e-18
four O 0 1.3665466294090958e-14
families O 0 2.4706682554866133e-13
. O 0 9.796268071911307e-15

Pendred B-Disease 0 1.0873440032810322e-06
patients O 0 2.2034365651513177e-11
in O 0 5.678340133547869e-17
three O 0 3.2622163709409094e-16
non O 0 1.007589905878837e-14
- O 0 3.875211262993616e-09
consanguineous O 0 8.83504185367201e-08
families O 0 4.43202870237247e-11
were O 0 6.806821284223337e-18
shown O 0 6.354000800023153e-19
to O 0 3.255073042411763e-21
be O 0 1.0669879461710364e-20
compound O 0 6.08267470236022e-19
heterozygotes O 0 2.931509737818089e-19
for O 0 2.4357433755358864e-21
L236P O 0 5.585856179457418e-15
and O 0 1.2652473122689938e-15
T416P O 0 1.1264484353970539e-12
. O 0 2.4195627428425914e-15

In O 0 1.8655299269883414e-14
total O 0 1.2688331203720765e-16
, O 0 8.275499321529204e-17
one O 0 1.3419920971802593e-15
or O 0 7.809231234758018e-13
both O 0 8.444358912984595e-16
of O 0 2.456891855405003e-19
these O 0 1.2962693116270313e-16
mutations O 0 9.286978421537006e-18
were O 0 1.8199615925990894e-16
found O 0 2.5096098625531304e-16
in O 0 1.7891552690052465e-18
nine O 0 6.669114968997918e-16
of O 0 9.013295188708072e-21
the O 0 1.088640691303566e-16
14 O 0 2.9207773369631417e-15
families O 0 1.8128385749082728e-16
analyzed O 0 6.2393217694733764e-15
. O 0 5.329667507021976e-14

The O 0 9.299102407775196e-18
identification O 0 1.1793581714174078e-15
of O 0 5.20586480401766e-19
two O 0 8.263575347563129e-17
frequent O 0 1.2551534789816132e-13
PDS B-Disease 0 3.3376472696744486e-09
mutations O 0 1.2814802487168692e-16
will O 0 2.0820441363928012e-20
facilitate O 0 2.141090372624239e-21
the O 0 2.5822872663892133e-18
molecular O 0 3.6220917758178484e-12
diagnosis O 0 4.7454296492333015e-08
of O 0 7.536004598129864e-10
Pendred B-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999997615814209
. O 0 2.1573189068480048e-10

Insertional O 0 4.581229839928369e-10
mutation O 0 7.560701319882202e-16
by O 0 2.8933487425349325e-18
transposable O 0 1.3744048759332939e-13
element O 0 1.772291398890785e-15
, O 0 1.8055986931405147e-16
L1 O 0 1.88564399650204e-08
, O 0 1.839342632874554e-17
in O 0 6.958855943437241e-20
the O 0 4.3934275485100474e-16
DMD B-Disease 1 0.9999948740005493
gene O 0 2.4302353749186545e-13
results O 0 3.1925379054525537e-15
in O 0 6.293390211837223e-16
X B-Disease 1 0.9998917579650879
- I-Disease 1 0.9998626708984375
linked I-Disease 1 0.999976634979248
dilated I-Disease 1 0.9999740123748779
cardiomyopathy I-Disease 1 0.999998927116394
. O 0 1.1494299956282816e-09

X B-Disease 1 0.9996391534805298
- I-Disease 1 0.9998660087585449
linked I-Disease 1 0.9999531507492065
dilated I-Disease 1 0.9999909400939941
cardiomyopathy I-Disease 1 0.9999996423721313
( O 0 1.4039312247471347e-13
XLDCM B-Disease 0 5.282345116874865e-10
) O 0 5.073141606781995e-19
is O 0 5.064338983347753e-21
a O 0 2.158600186760724e-20
clinical O 0 1.4209558966550941e-15
phenotype O 0 1.795677842530985e-11
of O 0 4.97640922411415e-17
dystrophinopathy B-Disease 0 1.0036057318529856e-07
which O 0 3.4460360200826894e-15
is O 0 3.390285689784107e-20
characterized O 0 7.284258456657945e-19
by O 0 1.1132359534921743e-19
preferential O 0 6.643500989134479e-14
myocardial B-Disease 0 4.80238848687975e-10
involvement I-Disease 0 5.750172609115048e-14
without O 0 8.848961471771801e-18
any O 0 3.007306882285737e-20
overt O 0 2.4418187198789465e-13
clinical O 0 8.58464639435716e-14
signs O 0 1.5703520081511435e-11
of O 0 2.5123232690721885e-14
skeletal B-Disease 1 0.999998927116394
myopathy I-Disease 1 0.9999998807907104
. O 0 6.9534418223327066e-09

To O 0 1.3879706337439988e-15
date O 0 1.409913975154687e-15
, O 0 1.6774306461553057e-19
several O 0 1.277972559085547e-20
mutations O 0 1.921566106297999e-16
in O 0 1.1431373849228663e-17
the O 0 8.321496703517228e-13
Duchenne B-Disease 0 2.3533557396149263e-05
muscular I-Disease 0 3.262466208298065e-08
dystrophy I-Disease 0 1.2331401677556642e-08
gene O 0 1.421029179743405e-11
, O 0 7.446338684546916e-12
DMD O 1 0.9999985694885254
, O 0 5.53243176006617e-17
have O 0 2.08817777757011e-19
been O 0 1.3779187051617523e-18
identified O 0 2.6775553532572013e-17
in O 0 2.1426447774733712e-19
patients O 0 1.3715260465927894e-18
with O 0 1.886490645660127e-18
XLDCM B-Disease 0 3.904822687417209e-09
, O 0 1.6784429342793116e-18
but O 0 2.1091756604845405e-20
a O 0 1.985606285791074e-23
pathogenic O 0 4.297839952790703e-19
correlation O 0 7.728424563699292e-18
of O 0 1.5788622533998384e-20
these O 0 1.3846594496042837e-16
cardiospecific O 0 2.639737115960744e-13
mutations O 0 3.8497419150858886e-17
in O 0 1.9744550999505473e-18
DMD O 1 0.9999955892562866
with O 0 4.2483724945482584e-17
the O 0 2.44873651630972e-16
XLDCM B-Disease 0 1.777460056473501e-05
phenotype O 0 4.243058959740864e-10
has O 0 3.422590552984439e-12
remained O 0 4.4762750363996906e-14
to O 0 1.2601931196122866e-17
be O 0 1.5053467421021057e-15
elucidated O 0 5.298601557512939e-10
. O 0 3.2219775350332547e-13

We O 0 1.3638329181275832e-11
report O 0 4.146922696711121e-16
here O 0 1.6749880076558308e-19
the O 0 8.135532865399371e-22
identification O 0 3.6431945852591525e-17
of O 0 1.2721794675201915e-20
a O 0 4.348285820941191e-19
unique O 0 6.05182665577628e-18
de O 0 2.0283485059336944e-15
novo O 0 1.486256864108304e-12
L1 O 0 2.1425565488453202e-10
insertion O 0 8.612945468663394e-16
in O 0 7.615891707842705e-19
the O 0 6.042803045871516e-19
muscle O 0 2.641171041096492e-14
exon O 0 4.986540135210006e-16
1 O 0 1.151927419702161e-17
in O 0 1.6837159459865412e-16
DMD O 1 0.9999984502792358
in O 0 3.7402050040103915e-17
three O 0 3.9643924567081884e-17
XLDCM B-Disease 0 3.0598252820368543e-09
patients O 0 5.237022071394087e-17
from O 0 2.835652041779352e-20
two O 0 1.7365381034455953e-18
unrelated O 0 1.4087057800642178e-13
Japanese O 0 1.3983872219902604e-11
families O 0 3.044599958972917e-14
. O 0 5.28761111416885e-16

The O 0 1.0168482301022106e-16
insertion O 0 1.1186366028902335e-14
was O 0 2.2959149907847767e-14
a O 0 6.421595931729455e-19
5 O 0 3.490883751118232e-18
- O 0 1.656787554371597e-12
truncated O 0 3.973318256442898e-13
form O 0 1.3312844360566624e-15
of O 0 3.833325306078128e-19
human O 0 7.764331481473484e-17
L1 O 0 1.1135457790231729e-12
inversely O 0 6.841607405354744e-16
integrated O 0 4.341755746992968e-19
in O 0 3.120609946690188e-20
the O 0 6.081747226098395e-19
5 O 0 1.3464524403316024e-16
- O 0 2.38154686943437e-11
untranslated O 0 8.664765687171894e-07
region O 0 4.334092546659507e-12
in O 0 1.3324516474579788e-17
the O 0 9.908552539492015e-18
muscle O 0 1.861744197933883e-14
exon O 0 2.9164320447088373e-17
1 O 0 1.1927394357907311e-18
, O 0 1.7060325096352522e-18
which O 0 9.147951694443381e-18
affected O 0 8.137617073776289e-21
the O 0 4.880104658875416e-23
transcription O 0 7.728849536010798e-15
or O 0 8.912091035854011e-14
the O 0 1.6515908979729418e-16
stability O 0 5.825244366736149e-12
of O 0 2.6012883805413807e-19
the O 0 9.721219258718682e-15
muscle O 0 6.043015532419815e-10
form O 0 2.7938868913203314e-18
of O 0 3.426391477287193e-20
dystrophin O 0 7.365662189958447e-17
transcripts O 0 9.404021831235299e-17
but O 0 5.266830600102232e-18
not O 0 3.5013376596996773e-19
that O 0 1.4897034795518622e-18
of O 0 3.209747704980727e-20
the O 0 9.320424443901628e-15
brain O 0 5.061736274569739e-08
or O 0 2.969451073919771e-11
Purkinje O 0 5.994459151281717e-09
cell O 0 1.0079254764150392e-08
form O 0 1.1677524398845396e-11
, O 0 1.5810398823479233e-10
probably O 0 7.339719054755278e-09
due O 0 3.974483231677234e-14
to O 0 4.3377226914316643e-16
its O 0 2.249950622170569e-17
unique O 0 1.5953608877050914e-19
site O 0 2.274842716881221e-15
of O 0 1.370244071739697e-19
integration O 0 8.033145275278958e-15
. O 0 2.120961860188706e-14

We O 0 7.12753819977701e-16
speculate O 0 1.6153377389379474e-18
that O 0 1.6114877077581245e-22
this O 0 1.2950383368291185e-24
insertion O 0 1.9527914465029367e-19
of O 0 1.2583555750400041e-21
an O 0 2.3044995956725342e-19
L1 O 0 1.632555921560197e-07
sequence O 0 9.363417159680143e-12
in O 0 1.865150286821382e-13
DMD O 1 0.9999995231628418
is O 0 1.4273316832211028e-18
responsible O 0 9.421309295991956e-21
for O 0 1.546363011737678e-22
some O 0 1.3497300531328995e-21
of O 0 8.611901353602097e-22
the O 0 2.531165527571772e-16
population O 0 1.8444577523464593e-17
of O 0 4.5524796202999394e-20
Japanese O 0 1.983754957177175e-12
patients O 0 2.0253058471614857e-19
with O 0 5.0360607155083766e-20
XLDCM B-Disease 0 1.8852322480888972e-10
. O 0 6.296772784972524e-17
. O 0 2.8134203578216322e-15

Severe O 0 2.7337972596797044e-07
early O 0 3.353936225969356e-11
- O 1 0.9764410257339478
onset O 1 0.9995326995849609
obesity B-Disease 1 0.9999998807907104
, O 0 1.722271605331116e-07
adrenal B-Disease 1 0.9999994039535522
insufficiency I-Disease 1 0.999998927116394
and O 0 5.533844493754714e-10
red O 0 9.537697742700857e-09
hair O 1 0.6923728585243225
pigmentation O 0 4.8131410039786715e-06
caused O 0 2.7669354654702438e-11
by O 0 5.41818314550351e-18
POMC O 0 1.4942712345256126e-10
mutations O 0 2.2200201610844336e-14
in O 0 1.5642309638177874e-17
humans O 0 1.4935245762023354e-14
. O 0 4.50717717000778e-14

Sequential O 0 4.2062101008157396e-14
cleavage O 0 7.196060414216277e-11
of O 0 1.129555968483904e-18
the O 0 2.0633999377502535e-20
precursor O 0 1.0898986551714274e-18
protein O 0 9.177110704390937e-16
pre O 0 7.19941684393377e-13
- O 0 6.773386740377418e-09
pro O 0 1.1223244555935707e-08
- O 0 5.532699560717447e-07
opiomelanocortin O 0 1.6173967765098496e-07
( O 0 3.295533675730412e-18
POMC O 0 8.333012556892283e-13
) O 0 9.096405676078198e-20
generates O 0 1.4539175266024986e-19
the O 0 1.2303650836588525e-20
melanocortin O 0 8.461650434152257e-14
peptides O 0 3.0901117168552483e-13
adrenocorticotrophin O 0 5.978196826461613e-10
( O 0 1.0367410304790494e-17
ACTH O 0 1.6277611203374676e-11
) O 0 3.4301742776259747e-18
, O 0 2.062205934847776e-18
melanocyte O 0 5.754416734782275e-11
- O 0 1.2599002952029537e-09
stimulating O 0 3.5212577298437964e-10
hormones O 0 1.0177866188731954e-10
( O 0 3.167831619909309e-19
MSH O 0 2.3361439735816725e-14
) O 0 4.9661423048800516e-20
alpha O 0 2.608421650101914e-20
, O 0 1.5778016810309554e-21
beta O 0 1.285452505372239e-21
and O 0 2.4471532577206114e-20
gamma O 0 7.97872549279669e-22
as O 0 1.4778602492380068e-21
well O 0 1.5743935393874914e-20
as O 0 3.087157801444199e-22
the O 0 7.276634743311176e-23
opioid O 0 4.323537352495429e-21
- O 0 3.24448767512082e-20
receptor O 0 1.372445793885766e-20
ligand O 0 9.34105535408266e-18
beta O 0 4.1901131713894136e-15
- O 0 3.33995747725524e-10
endorphin O 0 1.4661627290024626e-07
. O 0 1.135115899929609e-13

While O 0 1.8677256481458614e-15
a O 0 1.370568352389212e-19
few O 0 7.068257300289856e-19
cases O 0 1.2193022732113402e-18
of O 0 1.257891903148164e-18
isolated O 0 3.1138807088382237e-08
ACTH B-Disease 0 0.44817522168159485
deficiency I-Disease 0 0.0018127779476344585
have O 0 9.982963027332101e-16
been O 0 2.697027714007594e-13
reported O 0 3.3750811173627326e-11
( O 0 5.3972037772176335e-18
OMIM O 0 3.529638137322877e-09
201400 O 0 2.092204708092904e-11
) O 0 5.389227009872989e-16
, O 0 1.0309750853011872e-17
an O 0 4.595583872773107e-17
inherited O 0 5.5178525144583546e-06
POMC O 0 0.0001761033636284992
defect O 0 3.480455006865668e-06
has O 0 3.4689091876760614e-13
not O 0 2.8390132995042433e-16
been O 0 1.4410220012964301e-15
described O 0 8.864419343956181e-14
so O 0 2.2933940513271585e-14
far O 0 2.8353131948928405e-15
. O 0 3.600492266256274e-15

Recent O 0 7.789842176256917e-14
studies O 0 4.314768892654461e-15
in O 0 8.2830707745096e-19
animal O 0 2.359478037212634e-15
models O 0 1.1048566738576065e-16
elucidated O 0 4.916912769631171e-17
a O 0 5.4655260233005895e-21
central O 0 9.837580669117164e-21
role O 0 2.4714052562401285e-19
of O 0 1.4661692548919845e-21
alpha O 0 5.357058944331633e-19
- O 0 3.782507364643488e-15
MSH O 0 3.2705947867507634e-13
in O 0 2.2104477706203198e-20
the O 0 6.5941667132055294e-21
regulation O 0 4.757765039573316e-19
of O 0 2.6231869250101815e-22
food O 0 2.9543887780794815e-19
intake O 0 2.5799300843711856e-21
by O 0 2.425171257321619e-23
activation O 0 8.029304066889943e-18
of O 0 2.8924975736846155e-19
the O 0 3.766680871661397e-16
brain O 0 1.6143147582581285e-11
melanocortin O 0 5.059220728985403e-14
- O 0 1.550953748839356e-14
4 O 0 5.726782311760812e-18
- O 0 6.296124275372283e-17
receptor O 0 2.997723219407486e-18
( O 0 4.7209536928571166e-20
MC4 O 0 1.062087778835874e-10
- O 0 1.6469645092165308e-11
R O 0 1.5888317137641161e-12
; O 0 1.2047752238961074e-18
refs O 0 3.8703036001758173e-14
3 O 0 4.9560386814386285e-19
- O 0 1.2711689196032486e-15
5 O 0 3.7767631610808464e-18
) O 0 1.7576295547044724e-20
and O 0 2.9552326315512563e-20
the O 0 8.177221702994277e-23
linkage O 0 1.0289095557546382e-15
of O 0 1.5778326397194086e-20
human O 0 1.4992164682012948e-13
obesity B-Disease 1 0.9999997615814209
to O 0 3.436258168201117e-14
chromosome O 0 4.4997733317231337e-10
2 O 0 4.0302208795185875e-16
in O 0 3.3532425386259364e-20
close O 0 1.2964077485743482e-16
proximity O 0 1.4984356944063395e-17
to O 0 2.7141018057219885e-18
the O 0 3.8251597409625224e-19
POMC O 0 2.5651223224502917e-13
locus O 0 1.2119408395686732e-14
, O 0 3.699874986064756e-17
led O 0 1.791983192724412e-18
to O 0 1.212502434985848e-18
the O 0 7.450687712891497e-19
proposal O 0 3.3174574774806707e-17
of O 0 1.2876518647221245e-20
an O 0 4.648724436865351e-18
association O 0 4.311389429718263e-18
of O 0 5.668290044201714e-20
POMC O 0 2.7700630678140215e-10
with O 0 2.2958789918845184e-15
human O 0 3.787369973196064e-09
obesity B-Disease 1 0.999997615814209
. O 0 1.5122948726631336e-10

The O 0 1.3821315856523217e-16
dual O 0 1.289384654301528e-16
role O 0 6.0120221456738e-17
of O 0 1.4343282094866236e-19
alpha O 0 5.371411789409863e-16
- O 0 1.939454239568983e-12
MSH O 0 1.0170680270205068e-11
in O 0 8.416876802865885e-20
regulating O 0 5.624168538452914e-16
food O 0 4.176548785772083e-15
intake O 0 5.090538311078297e-16
and O 0 1.7758424587906956e-17
influencing O 0 2.1487329873292466e-13
hair O 0 1.0674406780708523e-07
pigmentation O 0 2.783863200725434e-12
predicts O 0 9.635928334886094e-16
that O 0 6.523340181049243e-20
the O 0 2.4873517474865024e-19
phenotype O 0 4.924219686115771e-15
associated O 0 4.723755574862648e-16
with O 0 2.8575492920659236e-16
a O 0 8.84479003302992e-15
defect O 0 2.776892327194247e-10
in O 0 1.5851702552029854e-18
POMC O 0 6.122878679765131e-12
function O 0 1.510649016150685e-17
would O 0 1.7539962548537006e-16
include O 0 1.3337854067125491e-15
obesity B-Disease 1 0.9999997615814209
, O 0 1.4692081872866194e-15
alteration O 0 4.1586498784537684e-14
in O 0 1.6789897668386582e-15
pigmentation O 0 4.070039722137153e-06
and O 0 2.9675758739244884e-08
ACTH B-Disease 0 0.3322173058986664
deficiency I-Disease 0 8.129978232318535e-05
. O 0 5.611295119962306e-14

The O 0 1.0944410802821348e-16
observation O 0 1.0914449818108865e-13
of O 0 2.071288171178455e-18
these O 0 6.360155457851846e-13
symptoms O 0 6.790282745805509e-12
in O 0 3.875047132952566e-21
two O 0 1.9736277952609024e-17
probands O 0 8.660802977566995e-12
prompted O 0 3.195166433976341e-17
us O 0 1.6195810268463282e-20
to O 0 9.448257112680442e-23
search O 0 3.181807870334158e-19
for O 0 1.6301182092510027e-20
mutations O 0 4.724242089411727e-16
within O 0 1.2337544885305312e-19
their O 0 8.583659939786787e-15
POMC O 0 2.8528948300965418e-11
genes O 0 1.3756945852394422e-14
. O 0 4.882212188239525e-14

Patient O 0 2.1155523166616064e-10
1 O 0 3.0158389976005446e-15
was O 0 4.191346366657321e-14
found O 0 4.991145876860701e-16
to O 0 1.6754306733606385e-17
be O 0 4.216303984329527e-19
a O 0 2.3242301797273968e-20
compound O 0 5.2715744809152236e-18
heterozygote O 0 1.737505491171976e-18
for O 0 1.8366176291644006e-22
two O 0 7.330752469431961e-20
mutations O 0 9.85555094174268e-18
in O 0 4.840862569934628e-19
exon O 0 1.565301809339486e-14
3 O 0 3.939448932539259e-14
( O 0 4.906492527300657e-18
G7013T O 0 1.2845663118279949e-12
, O 0 5.121120541518032e-15
C7133delta O 0 7.048284178523545e-10
) O 0 4.4750901273037325e-17
which O 0 2.5757140239527724e-19
interfere O 0 4.958137652242982e-19
with O 0 4.300143587687791e-23
appropriate O 0 2.7624389239192016e-21
synthesis O 0 5.607343635162749e-19
of O 0 1.6413068933232907e-19
ACTH O 0 5.930468789661081e-12
and O 0 3.503385510742175e-17
alpha O 0 6.248370410690657e-16
- O 0 2.5089654312471232e-11
MSH O 0 2.1092436686132032e-09
. O 0 2.2426103603811164e-14

Patient O 0 8.694073933002144e-11
2 O 0 6.268020516275773e-15
was O 0 1.677926078745364e-16
homozygous O 0 2.256577662366099e-17
for O 0 3.4031248415165085e-21
a O 0 1.2696493449774162e-19
mutation O 0 3.072491578667787e-17
in O 0 8.063563075447807e-17
exon O 0 5.060084729696657e-12
2 O 0 3.5809244024881393e-12
( O 0 1.7296114997912294e-16
C3804A O 0 2.0721165668730057e-12
) O 0 6.1029279715043975e-16
which O 0 1.0179398014613372e-14
abolishes O 0 1.987397357794407e-09
POMC O 0 2.8923865968977225e-08
translation O 0 1.0899524338636724e-11
. O 0 5.114790427133975e-13

These O 0 2.626120197360025e-15
findings O 0 3.4690858876162348e-18
represent O 0 2.5499591759890496e-22
the O 0 1.0411534532957095e-22
first O 0 1.5699366999405785e-21
examples O 0 1.0032763143495714e-19
of O 0 4.392111594628355e-20
a O 0 4.079774712506534e-12
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999995231628418
within O 0 7.477370284705773e-18
the O 0 2.4991832736793663e-19
POMC O 0 4.032577833397617e-14
gene O 0 8.902898610793934e-18
and O 0 8.441801564179698e-19
define O 0 2.500940711948554e-17
a O 0 2.958766528073842e-18
new O 0 2.051622218467164e-13
monogenic B-Disease 0 0.00020134254009462893
endocrine I-Disease 0 0.0002199445734731853
disorder I-Disease 0 8.84019973454997e-05
resulting O 0 6.960338067626276e-14
in O 0 1.7436216232621625e-17
early O 0 7.461668782848818e-11
- O 1 0.9990100860595703
onset O 1 0.9999260902404785
obesity B-Disease 1 1.0
, O 0 1.842719029809814e-06
adrenal B-Disease 1 0.9999996423721313
insufficiency I-Disease 1 0.9999986886978149
and O 0 1.0534548233742669e-10
red O 0 3.785343913320638e-11
hair O 0 1.0808432307385374e-05
pigmentation O 0 8.164247056186014e-10
. O 0 3.200939837014606e-15
. O 0 6.439246108980862e-15

A O 0 1.9212034307186654e-12
European O 0 1.0494507823519128e-12
multicenter O 0 3.146869570480604e-11
study O 0 4.0017150021182807e-14
of O 0 1.1744528960466738e-12
phenylalanine B-Disease 1 0.9999969005584717
hydroxylase I-Disease 1 0.9999849796295166
deficiency I-Disease 1 0.9999998807907104
: O 0 3.1851997710392876e-13
classification O 0 1.5259526184890795e-15
of O 0 3.2190793362660906e-20
105 O 0 3.4825741097514837e-16
mutations O 0 8.634785551463856e-17
and O 0 1.2819007211658422e-16
a O 0 8.14550517795752e-21
general O 0 1.7202361594018032e-22
system O 0 7.956003560306133e-19
for O 0 3.488987643127933e-21
genotype O 0 2.441314464224787e-14
- O 0 2.4656284179207797e-15
based O 0 5.9233286971095365e-18
prediction O 0 3.653549359751429e-13
of O 0 1.4355379611324824e-19
metabolic O 0 1.4439806295118984e-10
phenotype O 0 9.06332517716657e-13
. O 0 1.3761440717432322e-13

Phenylketonuria B-Disease 0 2.1923199255979853e-06
( O 0 3.340141612731204e-14
PKU B-Disease 0 3.882333343696587e-10
) O 0 1.7177055676269315e-14
and O 0 1.5131257358191874e-10
mild B-Disease 0 4.720424229276432e-08
hyperphenylalaninemia I-Disease 1 0.9999986886978149
( O 0 1.3227206873203667e-13
MHP B-Disease 1 0.9999995231628418
) O 0 2.0352799035960184e-13
are O 0 4.312054152058511e-15
allelic B-Disease 0 2.711374008868006e-06
disorders I-Disease 0 0.05142325907945633
caused O 0 6.250599864088269e-12
by O 0 2.5533018237495896e-19
mutations O 0 9.99950346320961e-16
in O 0 2.6138800727924838e-20
the O 0 5.64436061380935e-20
gene O 0 1.4315251525951096e-14
encoding O 0 2.196779867388865e-12
phenylalanine O 0 6.964633598727232e-07
hydroxylase O 0 1.8043722320726374e-06
( O 0 9.651520887956065e-17
PAH O 0 1.8294597607659835e-12
) O 0 1.8879549125086622e-15
. O 0 2.4626700960601877e-13

Previous O 0 1.015640696544473e-12
studies O 0 9.646850824740938e-16
have O 0 3.647849440758718e-19
suggested O 0 1.4505604657852404e-19
that O 0 1.6064127194302353e-21
the O 0 5.4032314067983904e-21
highly O 0 7.476690342242255e-17
variable O 0 7.303688903670391e-13
metabolic O 0 3.032400627489551e-06
phenotypes O 0 4.278983389838231e-09
of O 0 1.231827682392217e-13
PAH B-Disease 0 2.3430372664279275e-07
deficiency I-Disease 0 1.3056563830105006e-06
correlate O 0 8.950526951545523e-13
with O 0 3.6784052366567455e-14
PAH O 0 4.9984230088284676e-09
genotypes O 0 1.1349001738381048e-08
. O 0 2.1336721452158702e-12

We O 0 4.7358218556578166e-14
identified O 0 3.123055806024173e-17
both O 0 1.6284968383151707e-19
causative O 0 8.24205070512618e-15
mutations O 0 5.993297238295102e-15
in O 0 6.44848234152618e-17
686 O 0 2.2814138078697255e-10
patients O 0 5.092607759105139e-12
from O 0 1.8624687499169644e-14
seven O 0 2.509792070351513e-12
European O 0 2.2406405344402996e-13
centers O 0 5.93462995759908e-13
. O 0 2.181994988609704e-14

On O 0 7.076203450371308e-15
the O 0 5.468511062868526e-20
basis O 0 5.3871397550480364e-20
of O 0 1.0034398561961676e-21
the O 0 6.220674148681237e-20
phenotypic O 0 1.8961730015252133e-18
characteristics O 0 3.1116090742433836e-14
of O 0 1.0979148624876788e-18
297 O 0 4.575158679101694e-15
functionally O 0 1.4075670967325649e-13
hemizygous O 0 2.1989579601644493e-10
patients O 0 1.3888029283179709e-14
, O 0 7.06413649327327e-18
105 O 0 1.800254841685626e-16
of O 0 2.1182223021994857e-20
the O 0 6.73278200195494e-18
mutations O 0 5.69769483639263e-17
were O 0 3.651290201914209e-18
assigned O 0 7.693887084788213e-19
to O 0 8.014095524147543e-18
one O 0 2.233981983163294e-18
of O 0 5.38487712526702e-21
four O 0 2.519910196782049e-18
arbitrary O 0 1.4597906759263035e-13
phenotype O 0 2.3194047377161908e-11
categories O 0 9.680680562729194e-11
. O 0 1.9657444075282804e-11

We O 0 6.335136442400888e-15
proposed O 0 8.1695371335094e-19
and O 0 1.1471268737084871e-15
tested O 0 1.1838289966014732e-16
a O 0 3.657473994147328e-21
simple O 0 9.45977077109497e-21
model O 0 2.474573810350604e-20
for O 0 1.1052738031660649e-24
correlation O 0 1.4106804082434397e-19
between O 0 4.608853917749989e-18
genotype O 0 8.344368490446896e-13
and O 0 3.4599967112402164e-16
phenotypic O 0 2.0164975885593207e-16
outcome O 0 7.599481346943701e-15
. O 0 1.5876492828748034e-13

The O 0 1.6764353007581964e-16
observed O 0 7.433892546744353e-16
phenotype O 0 1.986296072959597e-15
matched O 0 1.046452984520814e-15
the O 0 1.4624351397868066e-17
predicted O 0 1.6951641913093285e-13
phenotype O 0 7.444257477161667e-14
in O 0 1.6150567787710877e-15
79 O 0 1.3653092545418133e-10
% O 0 3.918120304114217e-15
of O 0 7.134868345561161e-20
the O 0 6.698789841862686e-17
cases O 0 9.655650438271726e-16
, O 0 7.023730606321851e-16
and O 0 3.254345645503816e-14
in O 0 2.800481175163604e-18
only O 0 2.0808073656677152e-18
5 O 0 2.29768776332816e-19
of O 0 5.7506975492202045e-22
184 O 0 2.7924255216718916e-19
patients O 0 1.953787884101572e-21
was O 0 1.0241697463246216e-18
the O 0 4.3013663271395933e-19
observed O 0 2.6450617598847625e-15
phenotype O 0 4.730211024711909e-16
more O 0 3.2028982617678755e-20
than O 0 3.0488475307566323e-18
one O 0 1.1751329381424428e-14
category O 0 1.18021339229335e-11
away O 0 2.707966073600687e-09
from O 0 1.2618636274029497e-15
that O 0 1.3699132465612527e-14
expected O 0 1.8136072308381265e-15
. O 0 2.9054972861111477e-15

Among O 0 9.188784851283174e-14
the O 0 5.2240131673365883e-17
seven O 0 5.230231580309517e-18
contributing O 0 1.188692950952183e-17
centers O 0 2.7627278248260714e-18
, O 0 1.5496434682792923e-18
the O 0 3.737764076740809e-18
proportion O 0 9.015372013043994e-18
of O 0 1.0595087470933938e-20
patients O 0 9.552536330294665e-20
for O 0 1.6794193602059646e-22
whom O 0 2.0691796877970573e-18
the O 0 6.605600708028228e-20
observed O 0 1.5646809341891485e-14
phenotype O 0 4.250743366237403e-15
did O 0 3.4942880566043305e-14
not O 0 1.0031525543780558e-14
match O 0 1.069509623685726e-14
the O 0 6.449047471320676e-17
predicted O 0 9.663877499881818e-14
phenotype O 0 4.195437302858499e-16
was O 0 5.412368754673276e-14
4 O 0 5.002482735233342e-14
% O 0 1.028258293297318e-15
- O 0 2.484321548479329e-08
23 O 0 1.4995761576930278e-10
% O 0 2.423764926233479e-16
( O 0 4.571679593841243e-18
P O 0 2.1902022417918943e-09
< O 0 5.482937864717758e-15
. O 0 2.9953488470899894e-16
0001 O 0 3.790009105164582e-12
) O 0 7.346192343572419e-16
, O 0 2.385640502673155e-17
suggesting O 0 5.844887325057255e-16
that O 0 5.231486206503607e-19
differences O 0 3.537262630690738e-19
in O 0 2.175034191551752e-26
methods O 0 2.2004746414333626e-23
used O 0 5.046399062050902e-23
for O 0 4.970848729031096e-25
mutation O 0 6.061243486664737e-21
detection O 0 1.3478407538019318e-15
or O 0 6.487766920915128e-12
phenotype O 0 9.17184470733412e-12
classification O 0 3.5826035063926676e-13
may O 0 8.68610095146067e-15
account O 0 3.8813679560552077e-19
for O 0 2.99144698650974e-21
a O 0 4.987236832216832e-19
considerable O 0 1.0339132308369756e-17
proportion O 0 1.1297725450477858e-16
of O 0 2.1990141304513092e-16
genotype O 0 6.661461497969867e-07
- O 0 1.0198230029345723e-06
phenotype O 0 3.378356261407589e-09
inconsistencies O 0 2.2281209766106258e-08
. O 0 2.871000095647225e-12

Our O 0 1.170700689168136e-11
data O 0 2.7668348162720666e-15
indicate O 0 1.5602455943916171e-15
that O 0 1.9781783949840134e-19
the O 0 1.3880849616851822e-18
PAH O 0 1.379994751284086e-13
- O 0 9.778734245957654e-12
mutation O 0 3.271705551876475e-13
genotype O 0 3.3364030288529634e-11
is O 0 6.193045928481054e-19
the O 0 8.853502312056154e-22
main O 0 2.0703255397405964e-17
determinant O 0 5.523430380640368e-16
of O 0 8.862735554085063e-20
metabolic O 0 9.313446680536686e-10
phenotype O 0 4.371233464171148e-13
in O 0 2.8959545682596277e-18
most O 0 6.599165929422474e-16
patients O 0 7.511260324388324e-15
with O 0 9.00104752017683e-13
PAH B-Disease 0 2.618554572109133e-05
deficiency I-Disease 0 0.010286426171660423
. O 0 6.2349066881628445e-12

In O 0 2.902650408375426e-15
the O 0 4.771890389303578e-18
present O 0 5.717894773066812e-19
study O 0 7.405937047881922e-21
, O 0 3.6330021303747595e-20
the O 0 3.8692753509815067e-19
classification O 0 2.584547820308784e-15
of O 0 3.231864963596746e-19
105 O 0 3.6549725783907236e-16
PAH O 0 2.402125934348651e-15
mutations O 0 3.6871537423370786e-16
may O 0 1.2130919996956391e-15
allow O 0 2.5547448403281883e-18
the O 0 1.080482043485833e-16
prediction O 0 1.4034232760293253e-12
of O 0 1.902771075535902e-21
the O 0 6.69326582633448e-19
biochemical O 0 9.143639350447236e-15
phenotype O 0 9.996939269485144e-18
in O 0 2.962818136262309e-20
> O 0 9.746829961623405e-17
10 O 0 1.0638606762571924e-16
, O 0 1.4803070717527293e-16
000 O 0 2.0463804397763755e-14
genotypes O 0 3.444373952721236e-11
, O 0 6.44940237283162e-14
which O 0 4.321681359130414e-14
may O 0 7.937939486691624e-18
be O 0 1.754271910256362e-22
useful O 0 2.4478055510259206e-21
for O 0 6.505664950985087e-22
the O 0 1.179856511340524e-17
management O 0 2.355504266843885e-14
of O 0 1.2457829715971228e-16
hyperphenylalaninemia B-Disease 1 0.9999988079071045
in O 0 1.3932866972242615e-14
newborns O 0 2.1223410182069635e-11
. O 0 1.1311352093016811e-16

Somatic O 0 2.536286181076264e-10
instability O 0 1.2714951935777208e-07
of O 0 1.3486262544377795e-17
the O 0 5.95305210893265e-17
CTG O 0 3.154387515080792e-11
repeat O 0 5.060381367411049e-13
in O 0 8.84463257713237e-20
mice O 0 6.275359395019241e-17
transgenic O 0 1.3238632793120245e-18
for O 0 1.9826790249201904e-21
the O 0 6.356854197761899e-14
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999998807907104
region O 0 3.15027803843293e-09
is O 0 6.819310470040224e-14
age O 0 1.0012625358815294e-13
dependent O 0 4.3984220650486426e-17
but O 0 1.4685951744880043e-18
not O 0 1.1433406748981589e-20
correlated O 0 4.680218925098001e-18
to O 0 3.3473654849972325e-19
the O 0 3.1022853111827244e-19
relative O 0 2.1148608512762228e-15
intertissue O 0 1.2941030625573946e-12
transcription O 0 9.573016207867213e-13
levels O 0 6.89230519445444e-13
and O 0 3.572023912415531e-15
proliferative O 0 2.4443946866625765e-10
capacities O 0 9.145323387471649e-13
. O 0 1.055099560373857e-14

A O 0 1.845166163957912e-12
( O 0 2.2041790461960903e-16
CTG O 0 3.5831535655228564e-11
) O 0 4.125906803438117e-15
nexpansion O 0 2.2983995262571e-10
in O 0 5.205887241291775e-18
the O 0 4.82493921906589e-17
3 O 0 9.322532979957887e-13
- O 0 6.488877716037678e-06
untranslated O 0 0.031535737216472626
region O 0 2.7103999045152705e-09
( O 0 1.4406137843554127e-17
UTR O 0 1.9176962535311093e-12
) O 0 2.1068927389291222e-19
of O 0 5.293427825294986e-22
the O 0 2.461190382176196e-17
DM O 1 0.9999955892562866
protein O 0 1.0733965731773813e-14
kinase O 0 2.4780966666713977e-13
gene O 0 3.053647583750661e-15
( O 0 1.0644434772145122e-19
DMPK O 0 1.6751433139922112e-13
) O 0 8.719038610489404e-21
is O 0 4.894593383131685e-22
responsible O 0 8.978683244154817e-18
for O 0 1.1940653897690414e-16
causing O 0 0.0013926844112575054
myotonic B-Disease 1 0.9999985694885254
dystrophy I-Disease 1 0.9999994039535522
( O 0 1.6953648485085182e-09
DM B-Disease 1 0.9999972581863403
) O 0 1.9503650430796604e-11
. O 0 5.257550037690573e-13

Major O 0 4.4276939753506994e-11
instability O 0 2.86142812910839e-06
, O 0 7.170330410151415e-15
with O 0 5.9821648133095145e-18
very O 0 1.1122850835286504e-19
large O 0 4.392743551730616e-22
expansions O 0 3.922423297660718e-17
between O 0 3.268595746643596e-15
generations O 0 1.9766109582430857e-10
and O 0 2.561724161791179e-13
high O 0 1.3782789674648098e-14
levels O 0 3.1605551705546216e-18
of O 0 5.281544929489716e-23
somatic O 0 2.5193816283706276e-18
mosaicism O 0 3.102281547428219e-14
, O 0 4.353264931240877e-19
is O 0 1.948578867674797e-20
observed O 0 7.38352250830857e-18
in O 0 1.935113769632066e-18
patients O 0 1.1208914045958245e-15
. O 0 1.2155847753077612e-14

There O 0 1.2193752138654063e-13
is O 0 8.982382395854154e-18
a O 0 1.6144067213091249e-19
good O 0 4.980321126667036e-17
correlation O 0 3.6124462304826374e-16
between O 0 6.459842562126297e-14
repeat O 0 3.20579651713615e-08
size O 0 2.3842364714476982e-12
( O 0 2.4887194906293588e-18
at O 0 4.921890769027295e-15
least O 0 7.800721596802499e-19
in O 0 7.321139079750446e-20
leucocytes O 0 4.488850263717481e-11
) O 0 2.0085484604208685e-19
, O 0 1.2075209239236807e-20
clinical O 0 7.794950461066293e-19
severity O 0 5.318429073877806e-13
and O 0 5.948251331593102e-13
age O 0 1.4721173932641385e-11
of O 0 1.8258645519736148e-17
onset O 0 4.9112290623209987e-11
. O 0 1.5651354181873273e-13

The O 0 3.0128538552887107e-12
trinucleotide O 0 3.175036340508086e-07
repeat O 0 4.893113469961463e-09
instability O 0 3.1464418744076017e-12
mechanisms O 0 1.495963549340439e-16
involved O 0 1.3811505825330583e-17
in O 0 5.865432506239602e-17
DM B-Disease 1 0.9999995231628418
and O 0 4.118673565585039e-15
other O 0 1.6149379625479006e-17
human O 0 3.1427846436393736e-11
genetic B-Disease 1 0.9999998807907104
diseases I-Disease 1 0.9999998807907104
are O 0 6.98983922991543e-16
unknown O 0 3.230233666814096e-14
. O 0 3.6377265640681524e-15

We O 0 6.473758703585963e-13
studied O 0 3.0978670975807495e-16
somatic O 0 3.351015144081697e-14
instability O 0 1.1632115409776489e-10
by O 0 1.17367068928373e-17
measuring O 0 3.7500596378192697e-11
the O 0 4.60283209252144e-16
CTG O 0 1.1440057789968705e-09
repeat O 0 6.75139166794736e-10
length O 0 3.2622694693187904e-14
at O 0 3.056001488311081e-15
several O 0 6.852805495246078e-18
ages O 0 1.2372829642076904e-14
in O 0 1.492231502639157e-22
various O 0 3.508756694312454e-20
tissues O 0 4.183117949794514e-15
of O 0 2.9814348699235806e-20
transgenic O 0 2.5626170361615387e-14
mice O 0 2.7497497551501326e-13
carrying O 0 1.4154645820580445e-15
a O 0 1.4190631858180228e-18
( O 0 5.848711060496601e-20
CTG O 0 2.0540194978907467e-12
) O 0 4.1634054946435465e-17
55expansion O 0 2.609248320878388e-12
surrounded O 0 1.9111278281214086e-15
by O 0 7.499681000187553e-18
45 O 0 1.430095521122311e-17
kb O 0 5.480807661558708e-14
of O 0 6.195446977728734e-22
the O 0 7.446031720018589e-18
human O 0 3.324961486694811e-11
DM B-Disease 1 0.9999997615814209
region O 0 8.821106822418101e-14
, O 0 3.210923206179347e-20
using O 0 3.220566968898979e-19
small O 0 1.245241267557574e-16
- O 0 9.056841387966585e-10
pool O 0 1.81848015378544e-12
PCR O 0 1.1834058732951291e-10
. O 0 3.5950987839646325e-15

These O 0 8.875060788279127e-14
mice O 0 3.64459222350344e-13
have O 0 3.7030923877753424e-18
been O 0 2.1854475743120515e-18
shown O 0 3.912187103016497e-17
to O 0 1.0980866058623601e-18
reproduce O 0 1.2811393656012027e-14
the O 0 6.373029185286141e-20
intergenerational O 0 7.094288535531429e-14
and O 0 5.431412427019805e-16
somatic O 0 4.8088474459526305e-15
instability O 0 7.619452985219155e-11
of O 0 3.021104642644034e-20
the O 0 3.262674959872509e-17
55 O 0 3.4615262012800514e-17
CTG O 0 4.8256273380443276e-14
repeat O 0 2.11785714562384e-14
suggesting O 0 2.5985859091018663e-15
that O 0 1.029921670791101e-17
surrounding O 0 5.499861159487425e-16
sequences O 0 1.7637025520600424e-11
and O 0 6.061935621439613e-14
the O 0 2.191991141644017e-20
chromatin O 0 2.262189685775577e-16
environment O 0 4.1476032347446804e-16
are O 0 7.907515208209007e-23
involved O 0 3.2118405365539712e-21
in O 0 2.113928071597599e-20
instability O 0 3.023757459696963e-12
mechanisms O 0 5.926211805356088e-14
. O 0 7.211534836090369e-14

As O 0 8.03188510201168e-16
observed O 0 3.2554165492590294e-16
in O 0 8.178263630477893e-20
some O 0 3.9941081499022105e-20
of O 0 1.1546135956836081e-20
the O 0 9.959455745463426e-16
tissues O 0 5.646133560688327e-10
of O 0 2.5295851229108733e-14
DM B-Disease 1 0.9999998807907104
patients O 0 5.4061989666854757e-14
, O 0 3.6027249288863605e-19
there O 0 5.824954174810136e-20
is O 0 4.5217236880320253e-20
a O 0 1.4875788661485198e-19
tendency O 0 1.9819071717433988e-14
for O 0 4.047179256672394e-18
repeat O 0 8.106241372596301e-11
length O 0 9.013288603161324e-15
and O 0 6.507620196670005e-16
somatic O 0 7.813501744061596e-18
mosaicism O 0 1.7407790203958465e-15
to O 0 3.826400511881352e-19
increase O 0 3.0906708956668486e-21
with O 0 1.268130124384886e-18
the O 0 2.6043927011201208e-14
age O 0 3.6632454014640103e-11
of O 0 2.0618194088571663e-19
the O 0 9.361249976121407e-17
mouse O 0 2.2059881032987505e-08
. O 0 3.891535531319601e-13

Furthermore O 0 7.999203383013409e-11
, O 0 3.885563068127193e-14
we O 0 2.3717778026397136e-15
observed O 0 2.0227359779440425e-18
no O 0 2.885630229766321e-20
correlation O 0 1.0155789457506785e-19
between O 0 2.7062315570097615e-20
the O 0 1.4645272811812276e-19
somatic O 0 1.50341351645494e-14
mutation O 0 4.896635180662301e-12
rate O 0 1.3888566963160542e-09
and O 0 6.96613877693153e-11
tissue O 0 4.229194701110828e-07
proliferation O 0 2.2997780888545094e-06
capacity O 0 2.5231956145765552e-14
. O 0 2.4242203229096586e-14

The O 0 1.6707532978688962e-16
somatic O 0 2.3667357543178877e-14
mutation O 0 2.8924967889615294e-12
rates O 0 1.1932279164739157e-08
in O 0 1.548173733766908e-16
different O 0 1.942038389707323e-15
tissues O 0 1.0029130304012313e-11
were O 0 8.146022791654197e-16
also O 0 1.902019307299585e-18
not O 0 1.6593749735938924e-19
correlated O 0 7.36024117909602e-17
to O 0 1.1590731352289862e-16
the O 0 1.133758046822854e-15
relative O 0 1.5866277042198007e-11
inter O 0 3.951081128938938e-11
- O 0 2.7465789642633354e-09
tissue O 0 6.803944962996411e-09
difference O 0 1.8568776971903756e-15
in O 0 1.9066210196759683e-22
transcriptional O 0 4.058037865022892e-15
levels O 0 9.39896980910052e-16
of O 0 2.7595717616275215e-23
the O 0 1.6147137474880498e-20
three O 0 1.0300228117155615e-19
genes O 0 1.3400110029219172e-17
( O 0 3.152963694633522e-21
DMAHP O 0 2.3664358233393967e-12
, O 0 1.3181645011999017e-17
DMPK O 0 4.400453779140889e-09
and O 0 5.82874189452437e-13
59 O 0 9.168782252937059e-16
) O 0 5.213356992415859e-19
surrounding O 0 2.516232469060577e-17
the O 0 6.708076366989247e-16
repeat O 0 1.6919268763793127e-10
. O 0 4.735410748216867e-16
. O 0 1.3108553989732517e-14

A O 0 2.2065704637281615e-14
novel O 0 6.379032230826448e-14
missense O 0 9.021759034277821e-13
mutation O 0 4.321755220403414e-14
in O 0 1.8044548016150273e-17
patients O 0 4.827405871652523e-17
from O 0 8.484735339898497e-20
a O 0 8.853925382627732e-18
retinoblastoma B-Disease 0 1.3616890948142668e-10
pedigree O 0 9.633591844249167e-07
showing O 0 2.226743456290592e-09
only O 0 9.069299503831462e-15
mild O 0 3.0213275593405156e-14
expression O 0 3.1340116478013156e-17
of O 0 8.303852265683317e-20
the O 0 4.750989272303649e-16
tumor B-Disease 0 4.083278071220775e-08
phenotype O 0 1.16961218488143e-10
. O 0 1.9908040331268612e-13

We O 0 1.0903131425054474e-13
have O 0 3.90256736730872e-20
used O 0 3.213151787461517e-21
single O 0 2.8892994866413323e-19
strand O 0 3.6167378499648434e-14
conformation O 0 2.4926104406973286e-14
polymorphism O 0 3.8442995298764327e-16
analysis O 0 4.124626109474203e-18
to O 0 7.516891113217179e-19
study O 0 3.081325329942455e-20
the O 0 2.4518731955322787e-19
27 O 0 4.712252735090036e-17
exons O 0 3.979967939417295e-14
of O 0 7.452475327743407e-20
the O 0 1.246675995786435e-17
RB1 O 0 4.2694854270920735e-13
gene O 0 1.853259781244636e-17
in O 0 1.4812077659742715e-20
individuals O 0 6.177022276793165e-20
from O 0 3.6584683718723676e-19
a O 0 3.962686148540614e-16
family O 0 2.771249540955978e-08
showing O 0 2.80008998743142e-06
mild O 0 8.959174548073268e-12
expression O 0 2.2772886105432016e-17
of O 0 2.632512477648954e-20
the O 0 1.0651357255406062e-16
retinoblastoma B-Disease 0 5.99912286514126e-10
phenotype O 0 1.0522473517515785e-11
. O 0 6.028592338877536e-13

In O 0 1.5437911654454796e-17
this O 0 6.20922351331106e-20
family O 0 2.883391208495468e-16
affected O 0 5.021675463044711e-19
individuals O 0 2.2316535230533327e-21
developed O 0 1.1891107764231958e-16
unilateral B-Disease 0 5.640530957862211e-07
tumors I-Disease 1 1.0
and O 0 4.548303955687061e-09
, O 0 3.323499204674758e-17
as O 0 1.3876190522051617e-18
a O 0 5.534199155521981e-19
result O 0 6.782815365473706e-19
of O 0 9.423138140627522e-22
linkage O 0 9.650730735388802e-13
analysis O 0 2.3292476007317174e-14
, O 0 1.155109285733632e-16
unaffected O 0 1.9777770729739047e-13
mutation O 0 7.332333296368562e-16
carriers O 0 1.4820303867536978e-16
were O 0 3.7641815950714046e-16
also O 0 1.2685717312985097e-16
identified O 0 1.5974163647324512e-15
within O 0 1.4862580655054257e-18
the O 0 2.426690609797031e-14
pedigree O 0 1.1021903446817305e-05
. O 0 2.0669770148945554e-12

A O 0 1.395127638631824e-13
single O 0 3.762389061596778e-15
band O 0 7.876331694061517e-14
shift O 0 4.685600446357986e-16
using O 0 7.802779001781072e-18
SSCP O 0 6.384638043949176e-12
was O 0 8.942079178560366e-17
identified O 0 2.9349464147693055e-18
in O 0 4.88087549336232e-20
exon O 0 1.2426072269668825e-13
21 O 0 1.5361691953208467e-13
which O 0 5.549854738100268e-15
resulted O 0 1.0932017652011834e-16
in O 0 4.0024662283806906e-20
a O 0 8.66639361159461e-18
missense O 0 2.3187655680094454e-13
mutation O 0 6.971571376221115e-16
converting O 0 2.388474939612464e-15
a O 0 1.664963562976617e-16
cys O 0 7.048220229677327e-09
- O 0 1.1941761468570178e-10
- O 0 1.4939206816055872e-10
> O 0 1.1366595581836737e-15
arg O 0 1.0929062830514896e-15
at O 0 2.3359121413257535e-18
nucleotide O 0 4.229386879692819e-18
position O 0 7.870587264844004e-16
28 O 0 1.6168296625702634e-18
in O 0 9.041735378767943e-22
the O 0 4.993861514947616e-19
exon O 0 1.3113025422450963e-11
. O 0 1.577060530777441e-11

The O 0 5.284085445405023e-15
mutation O 0 2.5783661230377453e-13
destroyed O 0 7.11164044320256e-11
an O 0 1.4253789372695336e-17
NdeI O 0 1.2772478907852047e-10
restriction O 0 4.760135004672509e-15
enzyme O 0 3.134363089712065e-14
site O 0 1.5015007466534502e-12
. O 0 2.215655773001729e-13

Analysis O 0 2.3455927955148836e-13
of O 0 1.088793769347725e-17
all O 0 4.056516885017199e-17
family O 0 1.554328857496809e-15
members O 0 8.106598204702334e-22
demonstrated O 0 2.6153336569265253e-22
that O 0 4.929442859787197e-23
the O 0 1.977256104756888e-21
missense O 0 2.287984009541398e-15
mutation O 0 1.5730939724707216e-16
co O 0 1.492017013410285e-12
- O 0 2.897984315627239e-13
segregated O 0 3.145346735345701e-14
with O 0 8.038410167381295e-17
patients O 0 5.357703619949736e-15
with O 0 5.1563023599141e-13
tumors B-Disease 1 1.0
or O 0 5.166932992572981e-10
who O 0 7.9006549566496e-12
, O 0 1.9599951970215385e-17
as O 0 2.3533180893654005e-17
a O 0 3.30488929525354e-17
result O 0 2.5341594581680712e-17
of O 0 5.669603153034464e-22
linkage O 0 4.486118999202796e-15
analysis O 0 1.2314288071658166e-16
had O 0 9.37187153105196e-15
been O 0 1.6243804939379894e-15
predicted O 0 2.3996062230888064e-16
to O 0 9.999908434293903e-19
carry O 0 1.4456248842109284e-15
the O 0 7.244721766958294e-17
predisposing O 0 1.4433748640740873e-10
mutation O 0 4.139305651712499e-12
. O 0 1.2644634471425942e-11

These O 0 1.4544468911752595e-16
observations O 0 3.0115623282498576e-15
point O 0 1.9110914057046766e-15
to O 0 2.5108344538191784e-17
another O 0 4.1869933769911086e-17
region O 0 2.4911750586649115e-14
of O 0 1.1287117272712172e-18
the O 0 3.300393469362641e-16
RB1 O 0 1.8819116404111824e-11
gene O 0 1.0548248199434592e-16
where O 0 1.1153964768738592e-17
mutations O 0 2.4528754799407516e-18
only O 0 6.314202426566842e-20
modify O 0 2.250595392914442e-16
the O 0 2.9253254274338644e-16
function O 0 1.761541555526415e-14
of O 0 5.906792860356234e-17
the O 0 4.8676422051072143e-14
gene O 0 4.512093389891225e-12
and O 0 3.583546491232187e-13
raise O 0 2.447836037155137e-19
important O 0 4.689877793557335e-22
questions O 0 8.862769158297448e-20
for O 0 3.450347831817797e-24
genetic O 0 7.859482398207704e-17
counseling O 0 3.79334430417066e-15
in O 0 8.039651101151307e-21
families O 0 1.327094991247208e-17
with O 0 3.9132093205390275e-21
these O 0 1.742942549338287e-18
distinctive O 0 2.0494807074182683e-15
phenotypes O 0 3.3872822149711053e-15
. O 0 2.44331401652219e-17
. O 0 3.740695700784648e-14

Maternal B-Disease 0 1.5825122318346985e-05
disomy I-Disease 0 0.00027594497078098357
and O 0 4.816111868422013e-06
Prader B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999984502792358
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999929666519165
consistent O 0 1.7731790428326955e-13
with O 0 7.16744721587808e-18
gamete O 0 3.2046208135044774e-13
complementation O 0 3.205291865260307e-10
in O 0 9.97726901791621e-20
a O 0 3.2689101423167698e-21
case O 0 4.329827802559953e-20
of O 0 9.957373425869427e-22
familial O 0 1.9350497766634778e-12
translocation O 0 1.3509893204144419e-10
( O 0 2.183583175385806e-16
3 O 0 1.3686797760076373e-15
; O 0 4.1219720177607653e-16
15 O 0 1.1228166840151539e-16
) O 0 4.3037953947071436e-19
( O 0 4.1457556199269867e-22
p25 O 0 6.518769697972158e-18
; O 0 1.909833049236217e-20
q11 O 0 4.374611174807936e-17
. O 0 1.3577253394035605e-19
2 O 0 1.5335488496647255e-17
) O 0 1.5488463970410362e-17
. O 0 3.132102528182433e-15

Maternal B-Disease 0 0.0007969140424393117
uniparental I-Disease 0 0.0012075485428795218
disomy I-Disease 0 0.00017951495829038322
( I-Disease 0 7.899449323833796e-12
UPD I-Disease 1 0.9999603033065796
) I-Disease 0 2.7379000013872702e-14
for I-Disease 0 1.064817711818207e-18
chromosome I-Disease 0 3.988586128045313e-10
15 I-Disease 0 1.0647456933381751e-16
is O 0 1.1048792401848223e-21
responsible O 0 5.809812892191295e-22
for O 0 7.375279906242891e-24
an O 0 1.1934117591453263e-20
estimated O 0 9.920594720876346e-15
30 O 0 6.604533577209224e-15
% O 0 4.568521625057669e-19
of O 0 1.3500035922295067e-20
cases O 0 3.066558271690948e-15
of O 0 1.0402507327755828e-10
Prader B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999996423721313
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999979734420776
( O 0 6.379163169922819e-11
PWS B-Disease 1 0.9999592304229736
) O 0 5.724784659993584e-14
. O 0 1.080957273967868e-14

We O 0 2.320648187503771e-11
report O 0 6.394148321246144e-18
on O 0 4.422643283402085e-20
an O 0 1.1950049956409635e-22
unusual O 0 6.739945179264496e-20
case O 0 3.0466269644022337e-18
of O 0 8.84490683920422e-19
maternal B-Disease 0 5.1686601665323906e-09
disomy I-Disease 0 1.276445527054193e-08
15 I-Disease 0 4.798970194754698e-15
in O 0 2.6965723745061383e-15
PWS B-Disease 1 0.9999997615814209
that O 0 9.842477446128997e-14
is O 0 6.350005827857252e-18
most O 0 3.392446052899548e-20
consistent O 0 3.454996106652313e-17
with O 0 8.052980664358202e-19
adjacent O 0 7.27621969295357e-15
- O 0 2.291738132598198e-09
1 O 0 4.923430674925403e-15
segregation O 0 3.9485702034436354e-12
of O 0 5.282761517088635e-20
a O 0 4.492348092731794e-17
paternal O 0 6.047930600772133e-09
t O 0 8.33884405970764e-10
( O 0 1.2610718697661535e-19
3 O 0 1.3319790791740273e-17
; O 0 4.56700809133185e-18
15 O 0 8.86558532054228e-18
) O 0 1.3001599018714347e-19
( O 0 3.8439505642348905e-22
p25 O 0 6.800514859233232e-18
; O 0 5.813407977460989e-21
q11 O 0 8.015042645948917e-18
. O 0 2.818773679874149e-20
2 O 0 8.868180728961135e-20
) O 0 5.591955511024687e-22
with O 0 6.268477069761454e-22
simultaneous O 0 4.547105794921579e-17
maternal O 0 4.4355043943289374e-11
meiotic O 0 1.6880483122427847e-11
nondisjunction O 0 3.6916459472680074e-11
for O 0 5.995160544515759e-19
chromosome O 0 9.052558147537582e-10
15 O 0 2.4315011809550313e-13
. O 0 5.057407400851921e-14

The O 0 3.2497371086443946e-14
patient O 0 1.3491030124643255e-12
( O 0 7.663723819674375e-17
J O 0 1.570518270987975e-09
. O 0 9.990244546063173e-15
B O 0 2.2013667277942517e-10
. O 0 2.540324766145674e-17
) O 0 2.780775199731965e-19
, O 0 3.695989995316112e-20
a O 0 6.751293063292958e-20
17 O 0 7.89424005191833e-19
- O 0 2.1382411629061043e-14
year O 0 1.4991462491699675e-15
- O 0 3.420765060102582e-11
old O 0 6.240817196356829e-09
white O 0 7.649682970400917e-11
male O 0 1.0071369465399632e-13
with O 0 1.69631880362495e-17
PWS B-Disease 1 0.9999822378158569
, O 0 2.7289971184308694e-20
was O 0 2.2290860562139576e-19
found O 0 2.4067256776991345e-19
to O 0 2.921285320157839e-18
have O 0 4.170449301518905e-16
47 O 0 2.110497566189234e-18
chromosomes O 0 1.9483429829886788e-14
with O 0 1.2126743231171366e-17
a O 0 1.855538432221648e-16
supernumerary O 0 9.315583859859089e-09
, O 0 4.097760325505462e-11
paternal O 0 7.443965296261013e-05
der O 1 0.5729940533638
( O 0 4.8289788780100235e-14
15 O 0 3.658866812365725e-15
) O 0 4.0163121849343656e-18
consisting O 0 1.969512695790543e-18
of O 0 2.139395120888774e-18
the O 0 8.030029007184691e-13
short O 0 1.7679361974387575e-07
arm O 0 0.00044547056313604116
and O 0 4.0306728224179245e-13
the O 0 1.1499040035749584e-16
proximal O 0 3.195546582901443e-08
long O 0 3.4077854138558905e-07
arm O 0 4.730239379568957e-05
of O 0 1.8035257123510078e-17
chromosome O 0 7.464690532366092e-10
15 O 0 6.15981046907726e-16
, O 0 1.3698319806982808e-18
and O 0 2.1596517417687934e-15
distal O 0 1.890709540930402e-06
chromosome O 1 0.698708176612854
arm O 1 0.9983338713645935
3p O 0 0.00024448000476695597
. O 0 3.1551095069914936e-11

The O 0 4.179743356980126e-12
t O 0 1.391391446503576e-09
( O 0 5.9305185509938474e-18
3 O 0 4.718602504344238e-17
; O 0 1.944824042842826e-17
15 O 0 1.7830513378290952e-17
) O 0 1.8903726559736266e-19
was O 0 4.580222665576854e-15
present O 0 5.180705071711094e-19
in O 0 1.6305092015322439e-21
the O 0 1.9195263781691167e-19
balanced O 0 2.98261112592451e-17
state O 0 5.929449704395458e-20
in O 0 1.6519538710295846e-19
the O 0 1.4343415053809947e-16
patients O 0 3.6894330550585807e-16
father O 0 5.839505528432154e-12
and O 0 7.072667934849468e-15
a O 0 3.0850599594182645e-16
sister O 0 3.323108899166982e-08
. O 0 4.272029344859485e-12

Fluorescent O 0 1.3302343269603039e-14
in O 0 4.12457488889971e-20
situ O 0 1.6374429000375083e-18
hybridization O 0 6.502626441137573e-18
analysis O 0 1.120547661420472e-18
demonstrated O 0 2.586269934243503e-18
that O 0 8.465111772335384e-20
the O 0 3.729748646974333e-16
PWS B-Disease 1 0.9999980926513672
critical O 0 1.148200729373522e-13
region O 0 1.3387649545907796e-16
resided O 0 1.2154822207936723e-15
on O 0 1.6054259294575116e-14
the O 0 8.379275085074391e-18
derivative O 0 1.1221882967413655e-14
chromosome O 0 1.6706365457697103e-11
3 O 0 2.021342696426954e-15
and O 0 2.3910821070241128e-15
that O 0 3.9868207145550125e-18
there O 0 1.8133950989224712e-20
was O 0 9.426792459137659e-17
no O 0 5.85635535706969e-17
deletion O 0 1.9628265687603695e-14
of O 0 1.8484303699563064e-17
the O 0 2.7480120609602032e-11
PWS B-Disease 1 0.9999996423721313
region O 0 7.435605408299961e-13
on O 0 1.2228787860807389e-12
the O 0 8.910455415232863e-15
normal O 0 5.899753206589295e-14
pair O 0 4.684356743646367e-13
of O 0 8.622235505171656e-19
15s O 0 1.2870547346701499e-17
present O 0 1.3429782858947827e-18
in O 0 2.029701045496892e-17
J O 0 1.6924313683830405e-07
. O 0 1.0114221201014406e-13

B O 0 0.001637779176235199
. O 0 6.377898209564137e-11

Methylation O 0 1.5583935780282693e-14
analysis O 0 1.8686441494980403e-16
at O 0 4.853938434262713e-18
exon O 0 1.0657534640220608e-16
alpha O 0 2.7169534695247344e-16
of O 0 4.2813291692702033e-19
the O 0 9.20561230427486e-17
small O 0 3.790345045207727e-14
nuclear O 0 1.4235163270370776e-08
ribonucleoprotein O 0 2.221242504166221e-12
- O 0 2.480325190026833e-12
associated O 0 1.9167362873750635e-14
polypeptide O 0 6.742265079573428e-11
N O 0 4.496577155760351e-12
( O 0 4.147563078227868e-20
SNRPN O 0 9.006457146916447e-13
) O 0 2.8892219384589055e-19
gene O 0 2.0146676003465573e-16
showed O 0 2.2077251051605407e-13
a O 0 4.3073429655592304e-19
pattern O 0 3.4446742333549274e-12
characteristic O 0 7.825416374195471e-15
of O 0 6.63403132573433e-21
only O 0 1.531122170581194e-18
the O 0 7.785983761187672e-17
maternal O 0 1.0027695651615431e-07
chromosome O 0 9.604808326457714e-08
15 O 0 3.0510541467430874e-13
in O 0 1.4176857142039821e-15
J O 0 4.134811206313316e-06
. O 0 6.744160893808193e-13

B O 0 0.0012727408902719617
. O 0 9.99993005068589e-11

Maternal B-Disease 0 4.324457768234424e-05
disomy I-Disease 0 1.2019552286801627e-07
was O 0 2.2277837940284234e-13
confirmed O 0 7.744242738553144e-18
by O 0 1.3812688383413804e-21
polymerase O 0 1.227551317973391e-14
chain O 0 3.7227873914006185e-14
reaction O 0 5.114335718275019e-19
analysis O 0 3.2664419290729653e-21
of O 0 3.4576619134727344e-23
microsatellite O 0 1.03457086647607e-12
repeats O 0 5.354843304883339e-11
at O 0 3.883813567235009e-18
the O 0 2.8125639283869626e-21
gamma O 0 1.7536684266333336e-16
- O 0 7.406620455840951e-12
aminobutyric O 0 5.841628292202472e-10
acid O 0 5.3530661145635185e-15
receptor O 0 7.593818289799151e-18
beta3 O 0 1.4125370794912384e-13
subunit O 0 8.94290291810157e-16
( O 0 1.0088537114616204e-17
GABRB3 O 0 2.2976194558044227e-10
) O 0 1.9387363905811297e-16
locus O 0 4.974393466583571e-11
. O 0 6.538863200900025e-12

A O 0 2.3312100947553427e-12
niece O 0 1.3975975043933886e-08
( O 0 3.7503239242960874e-15
B O 0 6.055742018951094e-10
. O 0 5.817349225150834e-16
B O 0 9.783006869878985e-12
. O 0 3.5458549693036328e-19
) O 0 8.000673445959014e-21
with O 0 1.8785625330791125e-18
45 O 0 1.228475654505765e-19
chromosomes O 0 7.21890774967645e-15
and O 0 4.2850610649140884e-16
the O 0 4.190456399644835e-19
derivative O 0 6.107000347096119e-17
3 O 0 7.322709844034896e-18
but O 0 1.2955094489579613e-14
without O 0 1.0441408175088703e-14
the O 0 1.4294651684673872e-14
der O 0 1.4788937733101193e-05
( O 0 9.546102343714347e-17
15 O 0 1.5791124062587594e-16
) O 0 8.176427548011967e-19
demonstrated O 0 2.038678023094624e-18
a O 0 1.1589917075694864e-19
phenotype O 0 6.695804447770309e-16
consistent O 0 6.847743629662009e-16
with O 0 3.2043451609254744e-17
that O 0 1.632991536758895e-15
reported O 0 2.0038775123292808e-14
for O 0 4.3152186943430155e-20
haploinsufficiency O 0 1.4812831516941571e-10
of O 0 1.223056949409295e-18
distal O 0 3.971204698416386e-09
3 O 0 6.616424769179119e-11
p O 0 1.8825038239356218e-07
. O 0 1.8971038932488749e-13

Uniparental B-Disease 1 0.9994760155677795
disomy I-Disease 1 0.999876856803894
associated O 0 3.0949399293378477e-11
with O 0 7.8389502666267e-15
unbalanced O 0 4.5864109665672004e-07
segregation O 0 6.321986045776384e-09
of O 0 3.0855896197080944e-16
non O 0 2.5355084243110226e-13
- O 0 2.712273428073786e-08
Robertsonian O 0 1.8567965298643685e-07
translocations O 0 3.3032282686917824e-08
has O 0 1.1541564579053976e-11
been O 0 1.278401348539862e-13
reported O 0 5.44310588626324e-14
previously O 0 2.65043358989669e-16
but O 0 3.177035931968379e-15
has O 0 2.6872893169207048e-15
not O 0 6.882783794503143e-16
, O 0 4.8389821816071416e-18
to O 0 1.2633223769567992e-16
our O 0 4.567381222580005e-15
knowledge O 0 7.681832995311784e-19
, O 0 1.6334608590310265e-20
been O 0 1.0171575294768564e-18
observed O 0 3.928438668812538e-19
in O 0 1.3637394402596067e-22
a O 0 2.497761847807225e-20
case O 0 7.73931489277192e-17
of O 0 1.743769787853483e-15
PWS B-Disease 1 0.9999943971633911
. O 0 1.1630306093191045e-12

Furthermore O 0 5.526969548697025e-09
, O 0 3.942954090400269e-13
our O 0 4.428348150415512e-13
findings O 0 5.501890928361732e-18
are O 0 2.0182855556092254e-21
best O 0 6.238402309418868e-20
interpreted O 0 7.73954383568596e-19
as O 0 1.714794394424326e-19
true O 0 3.879259279527137e-15
gamete O 0 7.89004874889726e-13
complementation O 0 9.499063757800741e-09
resulting O 0 4.539175364249616e-14
in O 0 2.853236041479827e-16
maternal B-Disease 0 9.492159733781591e-05
UPD I-Disease 1 0.9999866485595703
15 I-Disease 0 7.1217975960991e-10
and O 0 1.5803773845135538e-09
PWS B-Disease 1 0.9998540878295898

Schwartz B-Disease 0 0.2821870744228363
- I-Disease 1 0.9996358156204224
Jampel I-Disease 1 0.9994068145751953
syndrome I-Disease 1 0.999969482421875
type I-Disease 0 1.4951406779317722e-10
2 I-Disease 0 4.4556293875806785e-13
and O 0 2.8566518942008123e-11
Stuve B-Disease 0 0.31250521540641785
- I-Disease 1 0.9999618530273438
Wiedemann I-Disease 1 0.9999793767929077
syndrome I-Disease 1 0.9999974966049194
: O 0 1.77263432150297e-17
a O 0 3.388601369515087e-22
case O 0 4.544252808276088e-21
for O 0 7.877055180822085e-21
" O 0 4.637840133638049e-14
lumping O 0 9.840300796426504e-10
" O 0 3.878991745864813e-12
. O 0 9.435221125177109e-15

Recent O 0 4.3651158534128986e-14
studies O 0 3.4766028980502553e-15
demonstrated O 0 2.806236036121258e-17
the O 0 4.894691671413943e-20
existence O 0 1.4664406791850334e-17
of O 0 2.1767164923072724e-21
a O 0 3.971502725477814e-19
genetically O 0 1.2993778232817811e-17
distinct O 0 2.3122421199433648e-17
, O 0 7.107496473802687e-17
usually O 0 2.4801344725648853e-17
lethal O 0 2.7203523960207455e-18
form O 0 2.850413984539156e-19
of O 0 1.5953261719687583e-17
the O 0 1.023939474875668e-10
Schwartz B-Disease 1 0.9998481273651123
- I-Disease 1 0.9999392032623291
Jampel I-Disease 1 0.9998770952224731
syndrome I-Disease 1 0.9999854564666748
( O 0 5.048036844763036e-15
SJS B-Disease 0 8.270928083220497e-05
) O 0 7.07649705316665e-16
of O 0 9.797336451773036e-18
myotonia B-Disease 0 1.8515071360525326e-06
and O 0 1.0332737269969083e-11
skeletal B-Disease 0 3.604634912335314e-05
dysplasia I-Disease 0 7.848274435673375e-06
, O 0 2.359351829303493e-15
which O 0 2.3461483856008114e-16
we O 0 1.205903548709647e-15
called O 0 2.9552066851701872e-15
SJS B-Disease 0 0.001041502458974719
type I-Disease 0 2.6225801044721386e-12
2 I-Disease 0 2.864832462511242e-14
. O 0 2.6853693896908108e-14

This O 0 5.073585648829315e-12
disorder O 0 8.390864536522713e-08
is O 0 6.530925990576352e-15
reminiscent O 0 3.8025377985251296e-11
of O 0 9.461364224685129e-20
another O 0 4.962457334158341e-17
rare O 0 7.320678652409935e-16
condition O 0 5.75243574562484e-13
, O 0 2.241212947924049e-17
the O 0 3.9036339231338004e-15
Stuve B-Disease 1 0.9964693784713745
- I-Disease 1 0.999984622001648
Wiedemann I-Disease 1 0.9999802112579346
syndrome I-Disease 1 0.9999946355819702
( O 0 1.2755168456006234e-14
SWS B-Disease 0 1.4849083527224138e-05
) O 0 8.282614265937242e-15
, O 0 1.7784321958524766e-17
which O 0 2.5162134439064882e-17
comprises O 0 3.257052820044139e-18
campomelia B-Disease 0 1.927502775445067e-11
at O 0 9.945483936998466e-16
birth O 0 1.6456126283696804e-13
with O 0 4.551102096366725e-15
skeletal B-Disease 0 1.074336250894703e-05
dysplasia I-Disease 0 1.8883760048993281e-06
, O 0 1.181983973553896e-15
contractures B-Disease 0 2.235372303927008e-10
, O 0 5.568681130613959e-17
and O 0 1.1599450232992864e-15
early B-Disease 0 2.296424498043209e-13
death I-Disease 0 1.0424558993804567e-09
. O 0 1.9067097889718249e-13

To O 0 1.6170858461962354e-14
test O 0 4.816057615392786e-17
for O 0 4.462634356013791e-22
possible O 0 1.2022232269497741e-17
nosologic O 0 4.552487276043848e-09
identity O 0 5.0072994639549506e-08
between O 0 1.3707418533570603e-10
these O 0 8.719980987281772e-11
disorders O 0 2.0417011831197485e-11
, O 0 2.7124405410930593e-22
we O 0 6.54931508611699e-22
reviewed O 0 6.863780034051562e-22
the O 0 8.205043602809298e-20
literature O 0 1.2143413732928392e-16
and O 0 5.0317287473759816e-17
obtained O 0 3.575161849159416e-21
a O 0 1.2763355654221303e-20
follow O 0 1.4859931774578679e-16
- O 0 9.871458685195567e-12
up O 0 1.5527230542988768e-11
of O 0 2.9407934831008043e-20
the O 0 1.3940328814279272e-19
only O 0 4.834735746535024e-19
two O 0 1.8848937734875934e-18
surviving O 0 4.601467522443413e-14
patients O 0 4.824213944519864e-20
, O 0 2.5717632914093584e-22
one O 0 6.658449794352124e-20
with O 0 4.567849102404245e-16
SJS B-Disease 0 3.977612323069479e-06
type I-Disease 0 1.7086485492538023e-13
2 I-Disease 0 1.2896756365886894e-15
at O 0 4.219792917870002e-13
age O 0 2.3042077143889395e-13
10 O 0 9.571654283708355e-19
years O 0 1.0178062045132205e-17
and O 0 1.77042355723883e-18
another O 0 5.546539397791565e-20
with O 0 4.560344919887164e-16
SWS B-Disease 0 2.4825658329064026e-05
at O 0 2.83019274682772e-10
age O 0 1.2075015987100812e-10
7 O 0 4.944192638308732e-14
years O 0 9.094283079423907e-14
. O 0 4.9648289867059835e-15

Patients O 0 9.902838965514249e-12
reported O 0 1.0342980405518912e-13
as O 0 2.9872569031168527e-17
having O 0 6.851300532765767e-15
either O 0 2.3189512376314836e-13
neonatal O 0 0.00904808659106493
SJS B-Disease 1 0.6712619662284851
or O 0 2.6859316853977688e-11
SWS B-Disease 0 4.8943295638537165e-08
presented O 0 8.867682223395101e-18
a O 0 6.142079388909055e-21
combination O 0 1.4370823654972558e-20
of O 0 9.134541771932447e-22
a O 0 6.133239012434668e-18
severe O 0 6.4689634129023316e-15
, O 0 1.3929438206033187e-18
prenatal O 0 3.07175923808245e-07
- O 0 0.14568334817886353
onset O 0 0.001092036603949964
neuromuscular B-Disease 1 0.9995809197425842
disorder I-Disease 1 0.9994375109672546
( O 0 4.615051601576767e-16
with O 0 3.6544309008209545e-15
congenital B-Disease 1 0.9406276941299438
joint I-Disease 0 2.7511928291090726e-09
contractures I-Disease 0 0.26543453335762024
, O 0 6.699253998765364e-12
respiratory O 0 2.3359485567198135e-05
and O 0 2.0240387057363085e-12
feeding O 0 1.4283838822848338e-07
difficulties O 0 2.4844409515778487e-11
, O 0 2.277859727057381e-19
tendency O 0 1.0281797309914602e-15
to O 0 3.977844729574016e-17
hyperthermia B-Disease 0 2.3589464603901433e-08
, O 0 2.4669995061820333e-17
and O 0 2.950496599648302e-16
frequent O 0 3.04428942991819e-12
death O 0 2.9854347882718457e-09
in O 0 3.0413247366757688e-15
infancy O 0 1.1615608919157694e-08
) O 0 6.4483951133918815e-21
with O 0 3.0326945921122507e-22
a O 0 1.1084772092775509e-19
distinct O 0 3.4501659409752646e-15
campomelic B-Disease 0 0.00011673308472381905
- I-Disease 0 0.00010063662193715572
metaphyseal I-Disease 0 0.0008497328963130713
skeletal I-Disease 1 0.8002776503562927
dysplasia I-Disease 1 0.6346184611320496
. O 0 7.258903981371967e-12

The O 0 9.415045435648222e-16
similarity O 0 2.8684393829105353e-15
of O 0 2.8513587798950563e-20
the O 0 1.532880446370752e-19
clinical O 0 1.5637885669466787e-18
and O 0 4.215297313795856e-16
radiographic O 0 7.353914027209696e-13
findings O 0 8.387177968646723e-17
is O 0 9.46667110530254e-20
so O 0 8.780897535453335e-19
extensive O 0 5.746170598138442e-18
that O 0 2.0151491586517523e-11
these O 0 2.4660767872219935e-10
disorders O 0 2.04052374996877e-09
appear O 0 6.361893472050823e-16
to O 0 9.440288076267584e-17
be O 0 9.664346290266476e-16
a O 0 4.0796706629792935e-17
single O 0 3.692212280272805e-13
entity O 0 5.62371704759812e-09
. O 0 8.921638539050036e-09

The O 0 1.5709478556801752e-15
follow O 0 2.5585927826291335e-14
- O 0 5.929227941958715e-11
up O 0 1.2863707495036625e-12
observation O 0 3.148637492227102e-13
of O 0 1.026315257347541e-21
an O 0 1.8518629656920846e-22
identical O 0 2.305468999651658e-17
and O 0 4.362560063181712e-18
unique O 0 6.766327587913992e-19
pattern O 0 2.7419806009065795e-11
of O 0 4.7763367332502344e-17
progressive O 0 8.347843305500646e-08
bone B-Disease 1 0.9999781847000122
dysplasia I-Disease 0 0.00567537872120738
in O 0 7.963788417612763e-16
the O 0 3.8569761720254813e-16
two O 0 5.1372649894926986e-14
patients O 0 2.5730076316771546e-16
( O 0 6.099700922799917e-21
one O 0 2.485344486196663e-16
with O 0 2.7766124902767197e-13
SJS B-Disease 0 0.02773534320294857
type I-Disease 0 1.576220816194851e-12
2 I-Disease 0 1.3016506178200563e-16
, O 0 4.58311412503887e-19
one O 0 1.542742610621492e-18
with O 0 5.38778811265384e-16
SWS B-Disease 0 2.9462873499142006e-05
) O 0 3.365273080276239e-14
surviving O 0 4.5501588608054533e-10
beyond O 0 6.907503458108977e-10
infancy O 0 3.7690501812903676e-06
adds O 0 1.8164851946830124e-14
to O 0 6.152262822354892e-19
the O 0 1.292751336263286e-19
evidence O 0 8.04675476540073e-17
in O 0 6.065250659744674e-19
favor O 0 4.677668644551439e-17
of O 0 1.7456431906406962e-19
identity O 0 6.032490063034857e-10
. O 0 1.1325602998837891e-12

The O 0 1.0801899891725976e-15
hypothesis O 0 7.36005630356737e-14
that O 0 4.2009666280590566e-14
SWS B-Disease 0 5.8880785218207166e-05
and O 0 4.3197040389131303e-10
SJS B-Disease 0 0.0012504570186138153
type I-Disease 0 6.86847714120864e-12
2 I-Disease 0 3.004218552597163e-15
are O 0 8.681850804829143e-17
the O 0 1.2180442837008798e-15
same O 0 2.22243855263482e-11
disorder O 0 2.495194939555745e-09
should O 0 6.219755073472508e-18
be O 0 6.931246851788723e-21
testable O 0 9.058626786539252e-20
by O 0 2.2223148866831305e-23
molecular O 0 5.93898257321422e-19
methods O 0 4.389793988924563e-15
. O 0 3.0409535244866346e-15
. O 0 4.9310643052526484e-14

A O 0 2.1227170818620064e-15
mouse O 0 4.4536457854960076e-11
model O 0 4.573682144820568e-12
of O 0 4.195133823658992e-12
severe O 1 0.7014796733856201
von B-Disease 1 0.9999998807907104
Willebrand I-Disease 1 0.9999992847442627
disease I-Disease 1 1.0
: O 1 0.9996752738952637
defects O 1 0.9999327659606934
in O 0 1.0958385891421396e-12
hemostasis O 0 0.00040198638453148305
and O 0 3.648067681272238e-10
thrombosis B-Disease 0 6.232088480828679e-07
. O 0 2.0886244123108355e-11

von B-Disease 0 0.0014634589897468686
Willebrand I-Disease 0 0.000878326129168272
factor I-Disease 0 9.336893924682954e-09
( I-Disease 0 1.507646953243999e-13
vWf I-Disease 0 5.045686890525758e-08
) I-Disease 0 5.4522111270216556e-09
deficiency I-Disease 1 0.9997686743736267
causes O 0 0.029570920392870903
severe O 1 0.9999420642852783
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999988079071045
disease I-Disease 1 1.0
in O 0 5.530488844662784e-10
humans O 0 2.239503166245882e-10
. O 0 6.63547558912847e-13

We O 0 4.746897997289293e-15
generated O 0 3.6126611775007123e-19
a O 0 8.846383227350656e-21
mouse O 0 3.386755936460317e-13
model O 0 2.0681737504762814e-14
for O 0 1.4032316726767938e-18
this O 0 2.871918147224909e-17
disease O 0 2.0856731811748033e-16
by O 0 7.199322114750628e-24
using O 0 4.384962944678307e-20
gene O 0 2.317118554795157e-15
targeting O 0 7.599304865935075e-12
. O 0 9.582415122619172e-15

vWf B-Disease 0 8.733192771614995e-06
- I-Disease 0 0.18790096044540405
deficient I-Disease 1 0.8537830710411072
mice O 0 0.00010132241004612297
appeared O 0 5.8082147091909064e-08
normal O 0 3.2229733747286826e-13
at O 0 1.659632311136819e-14
birth O 0 1.533718762885758e-13
; O 0 1.601263674405664e-18
they O 0 3.1525460976711535e-19
were O 0 5.147158244981123e-19
viable O 0 6.266648769578752e-18
and O 0 1.1508612302146945e-15
fertile O 0 4.5179060145783545e-12
. O 0 2.124090486832486e-11

Neither O 0 1.0528988791946858e-09
vWf O 0 2.8872770840848716e-08
nor O 0 1.564678830945354e-09
vWf O 0 3.0300910225378175e-08
propolypeptide O 0 4.431140951055568e-06
( O 0 1.479885821092236e-13
von B-Disease 0 8.623555345366185e-07
Willebrand I-Disease 0 9.941139751390438e-07
antigen O 0 6.107516981046501e-08
II O 0 0.000127349907415919
) O 0 2.6243002454288955e-13
were O 0 3.292983561612589e-14
detectable O 0 4.30246014867814e-14
in O 0 5.888762758015506e-20
plasma O 0 1.9001240739256048e-13
, O 0 4.564295799190513e-16
platelets O 0 5.506421707490716e-12
, O 0 3.319432123038957e-17
or O 0 6.098087707606431e-16
endothelial O 0 1.8871763039416783e-16
cells O 0 2.702593944963059e-17
of O 0 6.84315615551966e-21
the O 0 4.0678294070744744e-17
homozygous O 0 5.0259865713719876e-12
mutant O 0 1.51504195855523e-08
mice O 0 2.0735122063797462e-08
. O 0 1.0960602000661956e-12

The O 0 1.2363818058551065e-14
mutant O 0 6.244317951598077e-09
mice O 0 5.967243055238214e-08
exhibited O 0 3.3501468266194934e-10
defects O 0 8.787378646957222e-06
in O 0 5.6581416237602425e-18
hemostasis O 0 2.8050364808684947e-10
with O 0 7.70893205256448e-18
a O 0 3.0821881206803784e-17
highly O 0 7.48493823345131e-13
prolonged O 0 5.876892714695714e-07
bleeding O 1 0.9083627462387085
time O 0 1.2574953522914711e-08
and O 0 6.462052226652304e-09
spontaneous O 0 6.234933402904375e-11
bleeding O 0 1.2646924915316049e-05
events O 0 3.104057267298843e-14
in O 0 2.070837978130073e-18
approximately O 0 1.3146198833826017e-16
10 O 0 4.270213689079464e-15
% O 0 7.158320932179783e-18
of O 0 5.76692207816556e-18
neonates O 0 2.232654727762906e-09
. O 0 6.438856473825125e-14

As O 0 9.43230563777266e-15
in O 0 5.202313821045546e-18
the O 0 5.537372675301072e-17
human O 0 5.907593208023809e-13
disease O 0 2.8070379354261377e-10
, O 0 1.6243894988329328e-19
the O 0 1.4341907876450147e-20
factor O 0 2.2333272697084584e-17
VIII O 0 1.1262206445206147e-12
level O 0 3.467873800012326e-15
in O 0 6.880463519797708e-19
these O 0 1.7353820440932973e-15
mice O 0 4.854670742552962e-14
was O 0 1.2209651709403678e-16
reduced O 0 1.0602248560904917e-19
strongly O 0 1.170053593901158e-18
as O 0 2.2308653734103474e-18
a O 0 6.813865223447593e-17
result O 0 1.5841699764593438e-14
of O 0 3.1959707844039876e-17
the O 0 1.5415815325658944e-13
lack O 0 6.829199325589534e-15
of O 0 8.095534966932024e-22
protection O 0 4.794346908293018e-20
provided O 0 3.943193809950508e-21
by O 0 3.403517606904629e-19
vWf O 0 3.3894976669140986e-12
. O 0 3.6711315953320833e-13

Defective O 0 1.1561228774326082e-07
thrombosis B-Disease 0 2.763311179876382e-08
in O 0 2.912388322653535e-15
mutant O 0 6.1386273841890215e-09
mice O 0 1.623104139980569e-08
was O 0 3.021159017402297e-11
also O 0 1.0533708508318057e-13
evident O 0 5.740267067016677e-14
in O 0 1.3449244892031359e-21
an O 0 4.603907353453115e-22
in O 0 3.401907965131389e-19
vivo O 0 1.9552432589664548e-12
model O 0 4.33139635269697e-13
of O 0 6.109939816120887e-16
vascular B-Disease 0 1.9230644738854608e-06
injury I-Disease 0 0.007206651847809553
. O 0 1.894632541132868e-11

In O 0 1.0705447588277639e-17
this O 0 3.54605607759006e-20
model O 0 2.1795873305443583e-17
, O 0 8.963718797241303e-20
the O 0 4.433270357074889e-19
exteriorized O 0 1.2219752987263632e-10
mesentery O 0 5.753187509727198e-11
was O 0 2.1865152646360214e-14
superfused O 0 8.577416663220483e-13
with O 0 2.3885610499414114e-19
ferric O 0 5.481223046516041e-15
chloride O 0 3.53022156591911e-14
and O 0 9.686026937114067e-13
the O 0 1.2246227650857303e-15
accumulation O 0 5.450334281120739e-11
of O 0 1.048329748142856e-17
fluorescently O 0 7.919592759364491e-11
labeled O 0 1.8971926460387145e-11
platelets O 0 1.4484816991677807e-11
was O 0 1.6769094539202016e-15
observed O 0 2.218813765475756e-18
by O 0 1.5322782847342076e-19
intravital O 0 3.349382620213004e-12
microscopy O 0 3.271705551876475e-13
. O 0 3.330205238633553e-14

We O 0 8.118453012715549e-14
conclude O 0 7.316933972689683e-17
that O 0 9.619459119259326e-19
these O 0 3.1489779507013294e-18
mice O 0 1.7574521492784982e-16
very O 0 1.8191051008415306e-19
closely O 0 1.163237969760856e-14
mimic O 0 6.6222769490309474e-09
severe O 0 3.244108768285514e-07
human O 0 0.04438818618655205
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
and O 0 0.18220840394496918
will O 0 2.34080289873706e-12
be O 0 1.4285789681872562e-18
very O 0 9.160923300086955e-22
useful O 0 1.4457797122251436e-22
for O 0 2.3426230378192102e-25
investigating O 0 3.397832178065876e-21
the O 0 2.2028611349982734e-22
role O 0 1.632589702136689e-19
of O 0 1.3070852170950613e-22
vWf O 0 5.979267199623741e-18
in O 0 2.806627695801544e-20
normal O 0 3.5494738307168124e-16
physiology O 0 6.190818121814753e-14
and O 0 2.1309653192957793e-14
in O 0 7.104790071187311e-16
disease O 0 1.159098719782925e-10
models O 0 3.2341178210970253e-14
. O 0 2.9744657791710267e-16
. O 0 1.8885609222307753e-14

Oral O 0 5.274874426142162e-10
contraceptives O 0 5.622861820597791e-08
and O 0 1.09774851968919e-12
the O 0 6.361023039818401e-15
risk O 0 2.6785063056422587e-09
of O 0 5.849267467952779e-13
hereditary B-Disease 1 0.9999929666519165
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999996542930603
. O 0 2.5308546924840414e-10

Hereditary B-Disease 1 0.9997454285621643
Ovarian I-Disease 1 0.9832619428634644
Cancer I-Disease 0 7.614676178491209e-07
Clinical O 0 5.798595111017324e-12
Study O 0 2.2550320985526007e-14
Group O 0 7.242415217892373e-13
. O 0 9.232846827572985e-14

BACKGROUND O 0 2.5920202460838482e-05
Women O 0 9.976149246970767e-12
with O 0 6.060816537391568e-17
mutations O 0 6.201776054704484e-17
in O 0 9.916521002977286e-20
either O 0 8.406837673662847e-19
the O 0 1.939762524674614e-18
BRCA1 O 0 1.0650119024527283e-12
or O 0 1.80750257968397e-14
the O 0 2.825806757182987e-18
BRCA2 O 0 6.581826148552641e-14
gene O 0 1.2838931544160211e-15
have O 0 7.219615842750574e-17
a O 0 6.914220243608114e-19
high O 0 1.4278689179376275e-13
lifetime O 0 1.0204943834413172e-10
risk O 0 6.010925801547273e-08
of O 0 1.856776260522608e-10
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999978542327881
. O 0 2.9385990862884626e-10

Oral O 0 1.1765988183753961e-08
contraceptives O 0 1.321035779255908e-05
protect O 0 1.7098554963013157e-05
against O 0 0.00040629622526466846
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999997615814209
in O 0 3.58500553936515e-15
general O 0 9.484102178953293e-18
, O 0 1.52082495631211e-14
but O 0 3.4000566576618263e-13
it O 0 4.219353595761579e-15
is O 0 6.939670626502416e-18
not O 0 4.66773573567881e-19
known O 0 4.6172785584183854e-20
whether O 0 1.9658582532033143e-17
they O 0 4.906984153825922e-16
also O 0 5.194146653267504e-17
protect O 0 8.921241024563431e-14
against O 0 4.617215897811944e-13
hereditary B-Disease 0 0.005741757340729237
forms I-Disease 0 6.58936869513127e-07
of I-Disease 0 1.4131885109236464e-05
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999939203262329
. O 0 1.0684095752208633e-12

METHODS O 0 6.439027913293649e-14
We O 0 2.5926253382520378e-15
enrolled O 0 1.205944365109793e-16
207 O 0 4.3314378234300677e-13
women O 0 2.6099622815614967e-14
with O 0 1.0214188002344304e-11
hereditary B-Disease 1 0.999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 0 1.740044740239366e-12
161 O 0 4.3433686954207063e-16
of O 0 5.685920623476458e-19
their O 0 8.455851470412501e-12
sisters O 0 7.366893206572911e-11
as O 0 8.007865365209916e-17
controls O 0 1.3755082379910463e-14
in O 0 2.524845259714117e-19
a O 0 7.645057579253442e-19
case O 0 7.124222065788509e-16
- O 0 1.0810089628998654e-10
control O 0 1.3327995651568614e-10
study O 0 2.71749006489682e-14
. O 0 9.114838536174695e-15

All O 0 3.4872799071690734e-16
the O 0 4.7123400026446605e-18
patients O 0 8.308740567061382e-18
carried O 0 3.4890613895107166e-17
a O 0 3.76963427299262e-20
pathogenic O 0 1.4135754338878714e-16
mutation O 0 6.914253847820499e-17
in O 0 2.9997938592758595e-18
either O 0 5.040815822713244e-17
BRCA1 O 0 1.0489685292255913e-12
( O 0 5.223292775741116e-18
179 O 0 2.1096397401893473e-15
women O 0 5.398136208291328e-16
) O 0 3.338709732650628e-17
or O 0 1.4759120574997509e-12
BRCA2 O 0 2.8725889222869228e-08
( O 0 5.315806829279696e-15
28 O 0 3.789120493064013e-12
women O 0 1.1583587550528102e-13
) O 0 1.2626918138671276e-15
. O 0 4.872239899944911e-14

The O 0 2.1724768793814075e-14
control O 0 6.585875941822472e-12
women O 0 8.730851734943187e-14
were O 0 2.0121943964894728e-16
enrolled O 0 4.58142129991528e-18
regardless O 0 1.5196424546426065e-17
of O 0 1.5849864999379636e-21
whether O 0 8.432090567185902e-17
or O 0 7.502414759320147e-14
not O 0 3.117607465114307e-15
they O 0 7.998951005184555e-17
had O 0 5.357700972971776e-16
either O 0 6.067684121709228e-18
mutation O 0 8.108853927137494e-15
. O 0 2.9660815904081206e-12

Lifetime O 0 2.9485070635049127e-11
histories O 0 9.114574546498222e-12
of O 0 2.0842153497914337e-18
oral O 0 1.5581772796948584e-13
- O 0 1.7530164602916343e-12
contraceptive O 0 3.4476536209249176e-11
use O 0 2.293654312788114e-16
were O 0 1.7194935588873788e-16
obtained O 0 1.0835921429396179e-20
by O 0 8.00931974518218e-20
interview O 0 4.069624411767725e-12
or O 0 2.6455562153677222e-15
by O 0 4.167514609979162e-20
written O 0 1.0548041735153698e-17
questionnaire O 0 8.58430635827444e-17
and O 0 1.935564169475601e-18
were O 0 5.35783597711955e-19
compared O 0 9.532255703444197e-21
between O 0 5.593475435205414e-20
patients O 0 2.1363043605299698e-18
and O 0 9.360214345994491e-17
control O 0 4.0546149879423787e-13
women O 0 2.4844630425359263e-16
, O 0 1.3543984739098348e-20
after O 0 1.5800679983896052e-19
adjustment O 0 6.574731878531397e-19
for O 0 4.119000140148968e-24
year O 0 9.072217105509557e-20
of O 0 2.6522776918140316e-21
birth O 0 7.924643065241113e-14
and O 0 1.0941625176155625e-14
parity O 0 2.3289689946547065e-13
. O 0 8.852212159230237e-16

RESULTS O 0 8.148579602957132e-14
The O 0 7.581578829147449e-17
adjusted O 0 5.636680358578339e-12
odds O 0 4.404593578755112e-09
ratio O 0 1.9400008266501345e-09
for O 0 5.932585267487411e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 3.2612557099298556e-10
with O 0 3.422358248017961e-18
any O 0 5.0620432340304914e-20
past O 0 3.1733522915598886e-16
use O 0 4.381253104254492e-19
of O 0 2.6453071199558168e-20
oral O 0 4.0663615730922656e-14
contraceptives O 0 1.613415998025225e-11
was O 0 1.4825217876240915e-13
0 O 0 1.030377530026679e-17
. O 0 6.826014190540282e-17

5 O 0 3.772776904255315e-13
( O 0 9.58932140575461e-16
95 O 0 2.914215526880759e-12
percent O 0 1.1912262287694375e-09
confidence O 0 1.5909856765361496e-11
interval O 0 1.965542664609035e-14
, O 0 8.6239170599594e-18
0 O 0 9.084853581836012e-21
. O 0 1.328076084322363e-19
3 O 0 1.6777579253345412e-18
to O 0 4.8299664919567424e-17
0 O 0 1.6107042867367317e-18
. O 0 2.920172886311047e-17
8 O 0 2.0316551108015383e-15
) O 0 4.7120548734875135e-17
. O 0 2.41100326315235e-15

The O 0 4.4755600050669364e-13
risk O 0 2.5875225573290805e-11
decreased O 0 8.585886789405119e-15
with O 0 1.9706165424686009e-19
increasing O 0 1.0005096924686142e-18
duration O 0 5.965395628905411e-17
of O 0 2.5309068598416414e-22
use O 0 6.820749868365387e-19
( O 0 1.1153783512786866e-19
P O 0 1.2312287962171903e-13
for O 0 1.5213388292111294e-21
trend O 0 9.761831312165973e-16
, O 0 7.86360929534155e-20
< O 0 2.467072380793999e-19
0 O 0 1.6111865522189473e-22
. O 0 4.346206564338839e-22
001 O 0 2.710272528172539e-19
) O 0 7.357158509072516e-23
; O 0 1.809224875992708e-24
use O 0 1.3114103205573347e-22
for O 0 5.282318523096522e-20
six O 0 5.545659039805383e-17
or O 0 1.051109323155218e-16
more O 0 6.47329123034581e-20
years O 0 1.9417614066248483e-18
was O 0 1.8869656541268856e-18
associated O 0 5.1506856533057785e-22
with O 0 2.655121024195487e-22
a O 0 8.836341383961233e-19
60 O 0 8.735902756520298e-17
percent O 0 9.42942741981789e-15
reduction O 0 1.2305506722275303e-16
in O 0 3.430895703197213e-17
risk O 0 4.451479809763903e-11
. O 0 1.0332036739840386e-13

Oral O 0 7.94149208199757e-12
- O 0 7.382456733602549e-13
contraceptive O 0 2.032170959287427e-11
use O 0 1.950561870497306e-15
protected O 0 1.5743782943999918e-09
against O 0 5.246126966085285e-05
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999988079071045
both O 0 2.1650917451116754e-19
for O 0 7.97041582134771e-23
carriers O 0 1.6955776801691407e-21
of O 0 2.5408596023384528e-23
the O 0 6.991698632670776e-18
BRCA1 O 0 7.12172248257259e-12
mutation O 0 1.030174768867952e-14
( O 0 3.3413967047934147e-18
odds O 0 5.669369054078777e-13
ratio O 0 9.664268733812243e-17
, O 0 1.721814572885487e-19
0 O 0 2.0236511224292745e-21
. O 0 5.480728132775022e-20
5 O 0 5.6606244063688205e-18
; O 0 1.3814509318134763e-17
95 O 0 7.665398297931978e-15
percent O 0 1.308978619940504e-11
confidence O 0 1.557946263316956e-12
interval O 0 4.334499254611329e-15
, O 0 4.5512163862576e-18
0 O 0 7.390866043303405e-21
. O 0 7.012579385517999e-20
3 O 0 1.1526431997657185e-18
to O 0 4.818887234832207e-17
0 O 0 8.134672504666056e-20
. O 0 1.1674587283195792e-18
9 O 0 2.0397526134283915e-17
) O 0 8.318558793804429e-21
and O 0 6.767227922311968e-20
for O 0 1.161743211997735e-22
carriers O 0 8.14935916106542e-21
of O 0 1.5894358269047039e-22
the O 0 1.457790686083444e-16
BRCA2 O 0 1.264845173043483e-10
mutation O 0 1.734489356070186e-14
( O 0 2.7285627839857937e-18
odds O 0 2.412192624465237e-13
ratio O 0 2.0947060265511068e-17
, O 0 6.909760835377658e-20
0 O 0 2.006945749516433e-21
. O 0 4.63269836825911e-20
4 O 0 3.0567794483684645e-17
; O 0 6.673412602414049e-17
95 O 0 7.108700292909192e-14
percent O 0 8.0418081915834e-11
confidence O 0 1.0236143530018005e-12
interval O 0 9.167493492307811e-15
, O 0 1.1795054558885565e-17
0 O 0 2.271325032529955e-20
. O 0 2.6097067527316977e-19
2 O 0 2.6124073940341067e-18
to O 0 2.4739734659264678e-17
1 O 0 1.3552836314822747e-18
. O 0 3.096483125154275e-17
1 O 0 6.774880532050214e-18
) O 0 7.526769180015195e-17
. O 0 9.806138546845661e-15

CONCLUSIONS O 0 4.957812589287403e-13
Oral O 0 3.9245115403957476e-13
- O 0 1.3702954786490307e-13
contraceptive O 0 7.248855378796937e-13
use O 0 1.6646133016180376e-17
may O 0 2.557448430529481e-16
reduce O 0 1.751013805524304e-17
the O 0 7.813382630053389e-18
risk O 0 3.89955095991823e-10
of O 0 1.2238448102164234e-12
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
in O 0 6.073893270259296e-17
women O 0 5.138780973327492e-19
with O 0 8.012153505209867e-22
pathogenic O 0 1.2400595435027459e-17
mutations O 0 1.0444892312768336e-18
in O 0 7.809705392177936e-21
the O 0 1.0076801076085301e-18
BRCA1 O 0 1.3801487730447093e-11
or O 0 1.0160942183132238e-12
BRCA2 O 0 1.3350984318094561e-08
gene O 0 6.022332854627166e-08

A O 0 1.497443797649281e-14
Japanese O 0 4.040184189263961e-14
family O 0 2.791898732939558e-15
with O 0 1.472011740610578e-17
adrenoleukodystrophy B-Disease 1 0.9999717473983765
with O 0 4.356371511428897e-19
a O 0 2.9150726250708947e-19
codon O 0 8.989521493936079e-16
291 O 0 6.806464537768755e-16
deletion O 0 4.655106595335967e-13
: O 0 7.967948275826067e-17
a O 0 2.2371107421314876e-19
clinical O 0 2.3980219075179714e-17
, O 0 4.7726395667843673e-17
biochemical O 0 4.516568325937942e-13
, O 0 1.7824062693002019e-16
pathological O 0 7.183614597269794e-13
, O 0 7.732535823397248e-15
and O 0 4.863941823092521e-13
genetic O 0 1.671160015925821e-10
report O 0 2.2424256895803296e-11
. O 0 1.3571935730209012e-13

We O 0 5.114754106361197e-12
report O 0 2.0050760110100865e-16
a O 0 4.52365845056009e-19
Japanese O 0 4.572177123127359e-14
family O 0 5.642873863488662e-13
with O 0 1.0539456135084946e-13
adrenoleukodystrophy B-Disease 1 0.9999973773956299
( O 0 3.848363964534273e-16
ALD B-Disease 1 0.9999991655349731
) O 0 1.4893689677121458e-17
with O 0 3.2848854717934836e-21
a O 0 1.9523724278238903e-21
three O 0 1.5185100573087185e-20
base O 0 4.121828419206426e-17
pair O 0 3.4386856968653123e-13
deletion O 0 1.0987932975601786e-13
( O 0 4.0548729669473266e-19
delGAG O 0 2.437863008252633e-13
291 O 0 1.5929012556071122e-15
) O 0 9.156679277086428e-18
in O 0 8.347717524320034e-19
the O 0 1.670398099896421e-14
ALD B-Disease 1 0.9999936819076538
gene O 0 3.6930630775700024e-10
. O 0 7.205846162816609e-13

A O 0 3.377037986748775e-15
variety O 0 2.7561832710812253e-16
of O 0 2.036152227094193e-18
phenotypes O 0 3.04290040430491e-13
were O 0 6.28521232048972e-15
observed O 0 2.887663430923182e-15
within O 0 6.485232487216808e-19
this O 0 4.013511434098322e-17
family O 0 2.0986083704155334e-10
. O 0 2.50591160235597e-13

While O 0 2.0537620215588248e-11
the O 0 6.422000941691238e-15
proband O 0 1.8638605325804747e-08
( O 0 1.3889762736106264e-16
patient O 0 6.47206423111564e-14
1 O 0 5.647880034671216e-17
) O 0 5.5833338907027844e-18
was O 0 2.478518194735181e-16
classified O 0 4.7632543755543407e-17
as O 0 1.0154826955315897e-18
having O 0 3.4231791730771317e-19
a O 0 5.075728468744912e-22
rare O 0 1.708786865978689e-19
intermediate O 0 9.625709544121961e-17
type O 0 2.927926612675323e-16
of O 0 6.849042237049268e-18
adult O 0 8.808336815491202e-07
cerebral O 0 7.021560577413766e-06
and O 0 3.167870410436535e-10
cerebello O 0 0.0010317335836589336
- O 0 0.0010309210047125816
brain O 0 0.0013565411791205406
stem O 0 2.6404437747373777e-08
forms O 0 3.009051991950673e-12
, O 0 3.168119521064494e-13
his O 0 4.7556301119300315e-09
younger O 0 2.916221486515269e-09
brother O 0 2.2436063423780794e-11
( O 0 2.003788423736538e-19
patient O 0 2.8112946757009383e-16
2 O 0 3.00914913138313e-16
) O 0 1.024225992951914e-15
and O 0 1.0644067008000468e-12
nephew O 0 4.893680460860139e-10
( O 0 9.098318789738668e-19
patient O 0 3.2393265231512236e-15
3 O 0 6.545239047439937e-16
) O 0 3.9929867669951665e-17
had O 0 1.1824902493816347e-13
a O 0 8.76986912181233e-15
childhood O 0 0.00036578867002390325
ALD B-Disease 1 0.9999988079071045
type O 0 7.883111385886821e-10
. O 0 3.7832180422268935e-13

Another O 0 3.4009991004002593e-12
nephew O 0 5.1774717846342355e-09
( O 0 3.4264784528470612e-15
patient O 0 4.267436230775967e-12
4 O 0 1.5511799743989085e-12
) O 0 4.354521504121821e-14
of O 0 2.2587911976852908e-17
patient O 0 5.953742409020926e-14
1 O 0 1.9587375826374858e-19
was O 0 2.0121865879044903e-16
classified O 0 2.7134112836184354e-16
as O 0 7.238119542181141e-17
having O 0 6.302808159419507e-16
an O 0 7.769606246803612e-17
adolescent O 0 1.162164244306041e-05
form O 0 1.5122442144008263e-12
. O 0 5.243797618348367e-10

The O 0 1.7017378954283565e-16
tau O 0 1.8962408005569406e-15
level O 0 2.2515853520836335e-14
in O 0 8.571778079240059e-16
the O 0 3.317581279138615e-11
cerebrospinal O 1 0.9990766048431396
fluid O 0 3.48543721884198e-06
( O 0 3.5295098549555093e-13
CSF O 0 7.255588343468844e-07
) O 0 1.798945514037628e-14
in O 0 1.5294592687162633e-17
patient O 0 1.2675620203797793e-14
1 O 0 6.004338113412034e-19
was O 0 4.042540973736401e-15
as O 0 1.832465453261788e-17
high O 0 7.238092410657049e-17
as O 0 1.316047973487047e-19
that O 0 7.195884030976428e-18
of O 0 3.0195623385425346e-19
patients O 0 3.1361762140282444e-17
with O 0 9.071860084431012e-15
Alzheimers B-Disease 0 0.3960532248020172
disease I-Disease 0 2.997338697241503e-07
( O 0 2.2653912717928514e-18
AD B-Disease 0 1.2458960252370588e-10
) O 0 9.195723406373903e-15
. O 0 1.6683284595931e-14

His O 0 4.04607987739003e-12
brain O 0 4.279744527518892e-12
magnetic O 0 1.3934468542139283e-13
resonance O 0 4.165582267144641e-13
image O 0 3.1127789235085856e-10
( O 0 7.94781685038612e-18
MRI O 0 1.0634986641333555e-10
) O 0 7.153739406406956e-13
showed O 0 1.7513548389302969e-09
abnormalities B-Disease 0 3.9096927084703026e-11
in I-Disease 0 8.499689108386902e-23
the I-Disease 0 4.535386062188502e-21
bilateral I-Disease 0 6.513544911768143e-12
cerebellar I-Disease 0 0.001457196893170476
hemispheres I-Disease 1 0.829642653465271
and O 0 1.3994758774060756e-07
brain O 0 4.165712041981351e-08
stem O 0 2.456484841928397e-11
, O 0 2.2256749953919507e-15
but O 0 2.5224052481334722e-15
not O 0 4.677385814956395e-16
in O 0 1.2233049174774231e-17
the O 0 1.461563400688426e-12
cerebral O 0 4.368064401205629e-05
white O 0 2.778439145423306e-10
matter O 0 1.4074904021343557e-15
, O 0 8.261604500573312e-21
where O 0 2.61731113557841e-21
marked O 0 1.8655572375970358e-19
reductions O 0 3.475284779126707e-18
of O 0 4.891086650283375e-21
the O 0 4.365317786067524e-13
cerebral O 0 0.01268825400620699
blood O 0 0.00013507285621017218
flow O 0 5.26811341217126e-08
and O 0 1.710732666637682e-09
oxygen O 0 4.0835659506632815e-12
metabolism O 0 1.0817203659500493e-14
were O 0 3.478627415982034e-18
clearly O 0 3.451437782452263e-18
demonstrated O 0 1.1559036218151822e-22
by O 0 8.499393285547444e-24
positron O 0 5.09368810897178e-15
emission O 0 1.4408907958929004e-14
tomography O 0 1.3152552831574571e-11
( O 0 1.7409639912157032e-16
PET O 0 9.884959517592051e-10
) O 0 3.156716246838459e-15
. O 0 1.7251060944870923e-14

In O 0 1.8775633852568044e-14
patients O 0 3.913519221144732e-15
2 O 0 5.003155215865991e-16
and O 0 1.0750971612255838e-14
3 O 0 7.235110589984918e-17
, O 0 3.863992962665046e-20
the O 0 3.122824916650755e-20
autopsy O 0 3.530871775514477e-12
findings O 0 5.531173934668343e-14
showed O 0 1.1621635728417679e-12
massive O 0 1.4891901730859636e-13
demyelination B-Disease 1 0.9999924898147583
of I-Disease 0 4.798711637947549e-16
the I-Disease 0 8.001987744296613e-13
cerebral I-Disease 0 1.2338458645899664e-06
white I-Disease 0 1.7141668293141343e-11
matter I-Disease 0 6.663004767792723e-18
with O 0 5.95280951915409e-22
sparing O 0 4.988035578495828e-19
of O 0 2.699476867982313e-21
the O 0 6.53209044912059e-17
U O 0 1.6976194061602e-10
- O 0 2.045916214221677e-10
fibers O 0 9.145541268740232e-11
, O 0 9.151751555382296e-19
compatible O 0 5.582231937234353e-16
with O 0 7.985892697764971e-19
the O 0 3.4798082163064534e-18
findings O 0 6.017925568269468e-15
of O 0 2.6411281388777135e-16
childhood O 0 1.1100797564722598e-05
ALD B-Disease 1 0.99997878074646
. O 0 4.1222770639712247e-13

Oleic O 0 0.0002542128786444664
and O 0 4.95243290821179e-10
erucic O 0 8.407992027059663e-06
acids O 0 7.992230141584677e-12
( O 0 2.885856074371978e-16
Lorenzos O 0 1.203009775130326e-10
Oil O 0 9.135677240743045e-14
) O 0 5.713291254464013e-20
were O 0 1.6148801529628408e-20
administered O 0 6.1442822419661176e-21
to O 0 7.8295540110288e-18
patients O 0 2.1183285108976678e-19
1 O 0 5.336493925677987e-21
and O 0 6.810283068174096e-16
4 O 0 2.891496519707304e-17
, O 0 7.6798410409991795e-19
but O 0 3.6518473080567635e-18
sufficient O 0 5.379966750121945e-22
effectiveness O 0 7.599197619805994e-21
was O 0 5.5700592962325334e-18
not O 0 9.663262468597072e-19
obtained O 0 7.202254976054312e-18
. O 0 9.958972259057133e-14

The O 0 6.137905667665672e-15
findings O 0 2.245981180934274e-16
in O 0 9.075540045126547e-20
this O 0 4.3714346642539435e-20
family O 0 1.670171942099504e-14
suggest O 0 1.2870946213192872e-16
that O 0 2.8970816018442312e-18
delGAG291 O 0 1.788648032853904e-13
is O 0 1.7691466230175955e-19
part O 0 2.101257344823906e-20
of O 0 1.0890871586787702e-20
the O 0 1.833744936233285e-17
cause O 0 3.0875770554638846e-14
of O 0 2.3403258219779716e-19
Japanese O 0 2.000651866396197e-09
ALD B-Disease 1 0.9999964237213135
with O 0 2.058058583605333e-16
phenotypic O 0 7.024212885706194e-16
variations O 0 1.7219496661891043e-11
. O 0 6.27655150076123e-11

Moreover O 0 4.4569553668376283e-13
, O 0 6.455225517879712e-17
although O 0 1.1039456295386498e-18
the O 0 3.1613749065416616e-18
scale O 0 2.4138059606659823e-11
of O 0 7.33621522189605e-18
the O 0 1.2264461093838136e-15
study O 0 3.8349234707203686e-17
is O 0 2.0205687647391535e-18
limited O 0 6.428332671583846e-20
, O 0 2.4513600850585544e-18
there O 0 2.2659247709762054e-20
is O 0 5.559688196993017e-22
a O 0 2.165525105660632e-23
possibility O 0 5.20143286076848e-21
that O 0 9.198446107756068e-18
PET O 0 9.401114331453186e-10
can O 0 2.8858024995380644e-15
detect O 0 2.803792788219628e-12
an O 0 8.848531271678825e-16
insidious B-Disease 0 0.00028012762777507305
lesion I-Disease 1 0.9998461008071899
which O 0 4.4631940454564756e-07
is O 0 1.1835711989476028e-13
undetectable O 0 9.97779468639784e-14
by O 0 2.1587250393344313e-19
computed O 0 5.0222027633882536e-15
tomogram O 0 1.0874139366734425e-09
( O 0 3.7661599463988354e-18
CT O 0 1.6785375173133943e-12
) O 0 6.722645317138409e-18
or O 0 8.86558532054228e-18
MRI O 0 1.8724840674852992e-15
analysis O 0 9.608017143436187e-19
, O 0 9.920564494455992e-21
and O 0 2.4490046882643097e-18
that O 0 4.602983520340277e-19
the O 0 4.435875459016548e-19
higher O 0 2.6504425234473057e-17
level O 0 8.272559687068313e-18
of O 0 6.227478769448542e-23
tau O 0 1.6154215362114082e-21
reflects O 0 1.6914045176281002e-21
the O 0 1.0444666690976378e-23
process O 0 9.517394725193086e-21
of O 0 1.333613460756166e-21
neuronal B-Disease 0 6.242113488423573e-13
degeneration I-Disease 0 1.8987956096339076e-08
in O 0 5.4310241471167836e-14
ALD B-Disease 1 0.9999915361404419
. O 0 1.74978129208192e-10

Lorenzos O 0 2.3129585358105942e-08
Oil O 0 7.772052858061318e-13
should O 0 1.743129616233816e-17
be O 0 1.7861530686707736e-20
given O 0 4.376937051109394e-22
in O 0 1.4230018773905279e-21
the O 0 2.761168589371409e-18
early O 0 3.744580871507114e-13
stage O 0 6.907127647615141e-12
. O 0 8.489086620113256e-17
. O 0 5.074698265569049e-16

Nonsense O 0 1.7431167620429733e-09
mutation O 0 2.274253647818053e-14
in O 0 5.209028625104068e-17
exon O 0 1.0408014511006924e-12
4 O 0 5.883865443478964e-13
of O 0 2.998569631969281e-18
human O 0 2.9587256835495552e-15
complement O 0 8.111699957840269e-15
C9 O 0 3.9730604873763897e-13
gene O 0 1.3146155688085266e-15
is O 0 8.176056660904814e-18
the O 0 1.5329500135527374e-20
major O 0 1.4887667802262072e-17
cause O 0 4.217601677516773e-14
of O 0 6.07446648574428e-19
Japanese O 0 3.6817028592484036e-11
complement B-Disease 0 4.692362384067783e-12
C9 I-Disease 0 2.466035198267491e-07
deficiency I-Disease 0 4.416472165758023e-06
. O 0 1.8359140976139526e-14

Deficiency B-Disease 1 0.9995367527008057
of I-Disease 0 4.2499937685488623e-17
the I-Disease 0 3.357305083693065e-17
ninth I-Disease 0 1.1395565209775665e-13
component I-Disease 0 2.4579466761221304e-15
of I-Disease 0 3.0602283469132314e-20
human I-Disease 0 3.2969076640868933e-16
complement I-Disease 0 2.9432362038013526e-15
( O 0 4.8791629710003936e-20
C9 O 0 6.059712668172838e-15
) O 0 1.6848433153547746e-20
is O 0 3.523424829519941e-23
the O 0 7.724098421313518e-24
most O 0 3.827476573691881e-21
common O 0 3.9769247194443996e-14
complement B-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
in O 0 5.4092206435664976e-18
Japan O 0 1.963680377971202e-14
but O 0 2.818670215089155e-17
is O 0 8.688691421766365e-21
rare O 0 8.064315462130879e-21
in O 0 1.295683433040845e-20
other O 0 1.0484622790205993e-16
countries O 0 4.4314866446543144e-15
. O 0 1.1572319132417599e-14

We O 0 9.885580581122516e-14
studied O 0 8.632705026787163e-18
the O 0 2.6548589961572086e-21
molecular O 0 6.494764192812833e-19
basis O 0 1.6781291226344243e-18
of O 0 3.4653047623181936e-17
C9 B-Disease 0 7.370121011263109e-07
deficiency I-Disease 0 9.167197276838124e-06
in O 0 1.2882569021037673e-19
four O 0 1.9436224802850314e-17
Japanese O 0 2.0723920084349257e-13
C9 B-Disease 0 1.734334204028798e-10
- I-Disease 0 4.546517384795834e-09
deficient I-Disease 0 8.81586856849026e-08
patients O 0 8.77803536645681e-15
who O 0 3.689476889013601e-15
had O 0 3.0798336971005202e-12
suffered O 0 2.4411157539816486e-09
from O 0 8.733550720726319e-14
meningococcal B-Disease 1 0.9999985694885254
meningitis I-Disease 1 0.999998927116394
. O 0 2.2360223481815433e-12

Direct O 0 2.2958063720441812e-17
sequencing O 0 2.5975950923118156e-15
of O 0 1.883944997324995e-18
amplified O 0 4.220339897866021e-13
C9 O 0 2.6898765875284225e-13
cDNA O 0 3.3349343929846634e-14
and O 0 3.456592962281234e-16
DNA O 0 2.4385489863552965e-15
revealed O 0 2.4211138719272508e-15
a O 0 2.049076788456015e-20
nonsense O 0 1.0049938716564887e-16
substitution O 0 2.3338789507671437e-20
( O 0 2.6017311705656184e-22
CGA O 0 5.292638784106397e-15
- O 0 2.875049590761458e-12
- O 0 3.4332350330734673e-12
> O 0 9.396491178938616e-17
TGA O 0 2.67417191905997e-13
) O 0 4.64957343436656e-19
at O 0 2.238117834527271e-19
codon O 0 2.655682226659219e-19
95 O 0 3.20666197394467e-21
in O 0 1.5863404629303615e-22
exon O 0 2.2173774077010884e-16
4 O 0 1.191881659421681e-15
in O 0 1.4303349692301297e-18
the O 0 1.998188706706623e-16
four O 0 3.9089557464381045e-14
C9 B-Disease 0 3.349478916447879e-08
- I-Disease 0 7.638758461325779e-07
deficient I-Disease 0 2.025480085876552e-07
individuals O 0 3.1801521661813277e-15
. O 0 2.6215771361474266e-14

An O 0 8.361744646352555e-18
allele O 0 9.758298973017686e-15
- O 0 2.6264505402094542e-15
specific O 0 6.958571703499252e-18
polymerase O 0 3.046823557339984e-11
chain O 0 1.7824719131254163e-11
reaction O 0 1.2772051146133992e-16
system O 0 6.519714751822e-18
designed O 0 8.686156776225849e-17
to O 0 3.355059751034139e-20
detect O 0 1.4003716129908305e-17
exclusively O 0 6.104269803214566e-19
only O 0 1.2171639596291024e-19
one O 0 7.615277396990914e-20
of O 0 4.061972785776253e-22
the O 0 3.543003987924892e-18
normal O 0 1.0961248891370478e-16
and O 0 7.506300099449203e-16
mutant O 0 9.723449665875392e-14
alleles O 0 6.192674420988441e-17
indicated O 0 5.128999641993391e-15
that O 0 1.0310779865693888e-16
all O 0 1.2641267770152825e-17
the O 0 1.9161483379835726e-17
four O 0 5.317444541013433e-17
patients O 0 1.178563705591286e-20
were O 0 2.4260435923323868e-21
homozygous O 0 1.8041078962832894e-20
for O 0 1.7695693747126631e-22
the O 0 1.6108816394299419e-19
mutation O 0 7.353950801409799e-18
in O 0 2.8328870096361347e-18
exon O 0 9.02897988850921e-15
4 O 0 9.68354628254342e-14
and O 0 5.102055930517047e-13
that O 0 1.494299611349073e-14
the O 0 2.5342490980766923e-15
parents O 0 2.8721885980687034e-12
of O 0 5.903832308565603e-20
patient O 0 4.294128393795768e-15
2 O 0 2.667543986303472e-17
were O 0 6.395082340506615e-16
heterozygous O 0 1.6081359605502749e-13
. O 0 1.1069466334225411e-13

The O 0 1.1020322821996565e-16
common O 0 1.8344036366986732e-16
mutation O 0 3.8371643360869993e-16
at O 0 8.133296756896412e-15
codon O 0 3.78899140185472e-15
95 O 0 7.551703712399993e-17
in O 0 1.2134001327456212e-18
exon O 0 6.431516425117398e-14
4 O 0 1.894336670491513e-14
might O 0 5.547883692432008e-16
be O 0 1.4254202497712518e-20
responsible O 0 1.5090290811486976e-19
for O 0 8.218352809618305e-21
most O 0 8.799617501255053e-17
Japanese O 0 4.1220316049361827e-10
C9 B-Disease 0 2.8452919309529534e-07
deficiency I-Disease 0 7.719359018665273e-08
. O 0 1.2084166590682036e-17
. O 0 4.416500937751491e-15

BRCA1 O 0 1.472931043626502e-12
required O 0 1.4655178764936693e-17
for O 0 1.9301282163708896e-20
transcription O 0 2.5417899122276433e-12
- O 0 5.455855145442001e-08
coupled O 0 6.538492663965556e-11
repair O 0 8.71070143099173e-12
of O 0 1.579211543338186e-20
oxidative O 0 6.251585562469977e-17
DNA O 0 3.5750982035898105e-11
damage O 0 2.9665853773508388e-08
. O 0 1.4112499959872266e-13

The O 0 5.661927090366836e-12
breast B-Disease 1 0.9979958534240723
and I-Disease 0 0.3240894377231598
ovarian I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999556541442871
susceptibility O 0 6.393798793365157e-13
gene O 0 1.2092254213463653e-14
BRCA1 O 0 3.6441333349339355e-13
encodes O 0 5.670915668477827e-13
a O 0 1.1174770825480781e-13
zinc O 0 5.1798879212583415e-06
finger O 0 0.02487306483089924
protein O 0 4.731253722134454e-10
of O 0 3.418026716740327e-18
unknown O 0 1.3981163774455518e-13
function O 0 4.808187183770246e-15
. O 0 3.935320493954342e-13

Association O 0 5.848681609144481e-15
of O 0 5.073465838963896e-21
the O 0 8.519045079184835e-21
BRCA1 O 0 2.7050384291092756e-17
protein O 0 8.61299796568097e-19
with O 0 1.5505931742122861e-21
the O 0 2.874148292395424e-21
DNA O 0 5.435770580940018e-14
repair O 0 1.538657395938614e-11
protein O 0 4.09087743826706e-16
Rad51 O 0 2.3516883834165045e-14
and O 0 8.289424555589773e-19
changes O 0 5.637745920455763e-23
in O 0 1.9615055990604404e-25
the O 0 7.140019496200639e-26
phosphorylation O 0 1.1097157022185216e-21
and O 0 2.4039649107059505e-18
cellular O 0 2.012438944165768e-17
localization O 0 1.4957524528481155e-16
of O 0 8.000482781433665e-23
the O 0 1.460944264347423e-20
protein O 0 2.316612280555605e-17
after O 0 1.9270778754172358e-17
exposure O 0 2.530247059306818e-17
to O 0 7.456910437543369e-20
DNA O 0 2.1877230929612246e-12
- O 0 1.7471491267628814e-11
damaging O 0 1.8827533932938567e-13
agents O 0 1.3705233961568955e-16
are O 0 9.960494538263716e-21
consistent O 0 9.207243192957615e-21
with O 0 4.167092650805314e-24
a O 0 8.114041340057061e-25
role O 0 8.459615605490399e-22
for O 0 5.103119423313741e-23
BRCA1 O 0 4.9185072429799284e-17
in O 0 1.6150157007233744e-20
DNA O 0 2.653343864067459e-11
repair O 0 9.249194476979028e-08
. O 0 2.4731232618996173e-14

Here O 0 4.910327786739055e-12
, O 0 7.557232918486543e-18
it O 0 2.051133753994887e-20
is O 0 4.233623617607062e-22
shown O 0 1.6671155746697988e-19
that O 0 4.482224844430338e-20
mouse O 0 1.9852527824784638e-13
embryonic O 0 4.778895513904771e-14
stem O 0 3.671639381419567e-11
cells O 0 2.7332888556663715e-13
deficient B-Disease 0 7.834717249965983e-12
in I-Disease 0 3.9002603088815214e-20
BRCA1 I-Disease 0 2.7407541297250204e-13
are O 0 7.408099202360377e-17
defective O 0 2.5566915663570444e-13
in O 0 1.1683581062899716e-19
the O 0 4.80183515465861e-19
ability O 0 4.620406967385782e-16
to O 0 4.54576816115302e-18
carry O 0 3.27005354328538e-16
out O 0 2.8695993945318e-15
transcription O 0 1.3913389754552363e-12
- O 0 5.932262459040771e-10
coupled O 0 4.222081451815685e-12
repair O 0 2.734896510647733e-12
of O 0 1.4919874480077433e-21
oxidative O 0 1.0327464098649083e-17
DNA O 0 2.111237920598974e-11
damage O 0 1.622310064064436e-10
, O 0 3.8291746688607016e-19
and O 0 4.948031883301845e-18
are O 0 3.237613351866107e-20
hypersensitive O 0 6.251243880178725e-12
to O 0 8.445418101215356e-17
ionizing O 0 1.987154608614275e-13
radiation O 0 8.113534258509525e-13
and O 0 2.9568514643350775e-16
hydrogen O 0 5.817130055375732e-15
peroxide O 0 3.915840308260643e-12
. O 0 3.0739839977812896e-15

These O 0 8.019222764131528e-13
results O 0 2.4643293340774876e-16
suggest O 0 3.1787677437686e-16
that O 0 2.0737945284344906e-18
BRCA1 O 0 6.808727386287345e-15
participates O 0 7.383975968720371e-17
, O 0 1.4619325448466194e-18
directly O 0 8.640881541706127e-17
or O 0 1.0125913813224894e-14
indirectly O 0 6.499737813941975e-14
, O 0 1.7370217973087857e-18
in O 0 5.4318959615214805e-21
transcription O 0 2.3395051521046817e-11
- O 0 9.24707421745552e-09
coupled O 0 3.779428506267557e-11
repair O 0 7.442873574403652e-12
of O 0 1.7602322655771734e-21
oxidative O 0 5.284440034572567e-18
DNA O 0 7.155704522844586e-13
damage O 0 1.077667746707256e-10
. O 0 4.2767957438845605e-17
. O 0 2.6856803778373952e-15

Truncation O 0 1.4044094880094615e-11
mutations O 0 1.231512992711653e-13
in O 0 1.8066234623859882e-18
the O 0 1.4343398675633818e-18
transactivation O 0 1.7155553644343513e-09
region O 0 1.047600916605218e-12
of O 0 8.457761290315873e-18
PAX6 O 0 1.1932539678571885e-10
result O 0 2.4878024699304764e-15
in O 0 1.5052066019899076e-18
dominant O 0 2.721347973355659e-11
- O 0 2.3368579604721162e-07
negative O 0 1.999461707313799e-09
mutants O 0 2.266283383178802e-09
. O 0 1.5444415901342753e-14

PAX6 O 0 1.0652477122619075e-08
is O 0 2.7392566940588874e-15
a O 0 2.421081138736051e-19
transcription O 0 2.742358105195259e-14
factor O 0 4.63900357574275e-16
with O 0 1.686664049742929e-19
two O 0 9.60446233475374e-19
DNA O 0 2.5538366994065642e-12
- O 0 8.601147571951628e-11
binding O 0 1.2655890604170578e-13
domains O 0 2.140162005948021e-11
( O 0 1.1884519518807157e-18
paired O 0 1.5179125182262707e-14
box O 0 3.022321542339723e-12
and O 0 3.2125349769086885e-16
homeobox O 0 1.210174765285736e-16
) O 0 6.741899393461653e-20
and O 0 1.2838709061526756e-19
a O 0 3.710566630231658e-21
proline O 0 3.079795533184049e-14
- O 0 1.2235821215825574e-14
serine O 0 3.7178788693525977e-13
- O 0 1.8498157717508797e-14
threonine O 0 1.9215910058902747e-13
( O 0 4.8752926704624404e-20
PST O 0 2.144460824193839e-11
) O 0 7.09405809757115e-18
- O 0 3.1004342956251997e-15
rich O 0 1.8838163293807124e-17
transactivation O 0 2.55226894306515e-12
domain O 0 1.3516110160347733e-13
. O 0 1.680938747298643e-14

PAX6 O 0 1.9404829743052687e-08
regulates O 0 1.4343361567914492e-12
eye O 0 1.5135472042349107e-10
development O 0 2.2110160579183106e-17
in O 0 3.17587827781186e-19
animals O 0 1.7729048095632748e-17
ranging O 0 3.732904804232366e-18
from O 0 8.397502035721391e-21
jellyfish O 0 2.176065030059985e-17
to O 0 2.1964359449667824e-20
Drosophila O 0 1.4683879657445598e-18
to O 0 6.23854810000183e-19
humans O 0 2.068636106057518e-17
. O 0 6.063525057589312e-16

Heterozygous O 0 2.3003161875312372e-10
mutations O 0 1.519185493549513e-12
in O 0 2.7945718630419743e-16
the O 0 1.3703396627992352e-17
human O 0 4.042309733741801e-15
PAX6 O 0 1.0158471286381143e-10
gene O 0 6.425613079813486e-12
result O 0 1.2771089287282825e-14
in O 0 1.6218190997029096e-20
various O 0 1.72501627884395e-19
phenotypes O 0 1.8359456072395905e-14
, O 0 1.1107937130733691e-17
including O 0 2.8186732326440297e-15
aniridia B-Disease 1 0.9999995231628418
, O 0 1.9702584008740587e-09
Peters B-Disease 1 0.9999988079071045
anomaly I-Disease 1 0.999998927116394
, O 0 3.271401378956984e-12
autosomal B-Disease 0 2.4692215561117337e-07
dominant I-Disease 0 3.429028083701269e-07
keratitis I-Disease 1 0.6990715265274048
, O 0 2.1766363017539092e-11
and O 0 5.6900338607501766e-11
familial B-Disease 0 0.0461239218711853
foveal I-Disease 1 0.6983901858329773
dysplasia I-Disease 1 0.9484487175941467
. O 0 2.467535620276351e-10

It O 0 5.963262720534886e-15
is O 0 2.5294919468051335e-19
believed O 0 1.963541485743676e-18
that O 0 6.1184841427153366e-21
the O 0 1.5930734425056982e-20
mutated O 0 5.3547230804149373e-14
allele O 0 1.798383761787009e-13
of O 0 2.5339065063367524e-18
PAX6 O 0 2.264361441406404e-12
produces O 0 1.0831929294201285e-17
an O 0 1.2694978756056781e-21
inactive O 0 1.609588863459206e-15
protein O 0 3.713529483917455e-12
and O 0 1.955895445604483e-09
aniridia B-Disease 1 0.9999998807907104
is O 0 3.6086130611456824e-11
caused O 0 6.73863254693069e-13
due O 0 4.6411426648068125e-17
to O 0 2.5092571792097174e-15
genetic O 0 4.7356079058147316e-09
haploinsufficiency O 0 5.5618552323721815e-06
. O 0 7.47433798881092e-13

However O 0 2.162745622782264e-13
, O 0 3.1076881964499793e-18
several O 0 3.135083022470452e-20
truncation O 0 1.4313577788847322e-15
mutations O 0 1.398057102079903e-14
have O 0 5.766179964807202e-16
been O 0 1.4293272026821472e-16
found O 0 5.3313368739651385e-17
to O 0 2.464254424601215e-16
occur O 0 1.1914491167532097e-16
in O 0 9.209315991250399e-21
the O 0 2.411002257300725e-16
C O 0 4.0721075400540485e-09
- O 0 6.194825468569531e-13
terminal O 0 2.129407080428319e-16
half O 0 2.293554445204809e-19
of O 0 1.6840118244062354e-23
PAX6 O 0 2.5670662249477577e-16
in O 0 5.148367790639622e-22
patients O 0 2.8394405936083304e-20
with O 0 5.862946580344697e-18
Aniridia B-Disease 1 0.9999994039535522
resulting O 0 3.1019739050617764e-14
in O 0 1.0294296327434814e-19
mutant O 0 1.1280468848243446e-14
proteins O 0 1.8785429206267889e-16
that O 0 7.586315865040871e-19
retain O 0 1.3676689874069856e-20
the O 0 1.288275239017737e-21
DNA O 0 5.95271716034157e-15
- O 0 6.096997787961552e-15
binding O 0 2.536606258420003e-17
domains O 0 1.9570108066632036e-13
but O 0 7.513273315128133e-13
have O 0 8.376379966165345e-15
lost O 0 1.965635457068407e-15
most O 0 6.728865886597044e-22
of O 0 9.906825743417761e-23
the O 0 6.578068518327283e-19
transactivation O 0 2.7963917639817204e-11
domain O 0 6.894255132061655e-12
. O 0 7.664265272780413e-13

It O 0 2.706261863910653e-13
is O 0 5.48282739309259e-17
not O 0 1.2248684749507861e-18
clear O 0 1.9511619006962072e-18
whether O 0 2.620329496630983e-20
such O 0 3.900961538321116e-19
mutants O 0 7.868682268263871e-12
really O 0 3.1121936625022606e-12
behave O 0 9.094585343131134e-16
as O 0 1.3080960587839062e-17
loss O 0 1.0891106225357247e-15
- O 0 9.98766282352126e-13
of O 0 7.530363246689513e-16
- O 0 2.6467134039975804e-10
function O 0 2.2580192449443877e-14
mutants O 0 7.348168948317912e-12
as O 0 2.163492215621424e-17
predicted O 0 1.8988032869806217e-15
by O 0 2.2370616593018902e-17
haploinsufficiency O 0 1.0443076803312579e-07
. O 0 3.922086993287527e-13

Contrary O 0 7.413740303087446e-13
to O 0 2.92095420803044e-16
this O 0 5.246995326001093e-19
theory O 0 7.187602629555792e-17
, O 0 1.9113383158088013e-16
our O 0 2.004440450426026e-13
data O 0 1.49485272386363e-14
showed O 0 6.890764136591523e-14
that O 0 8.956984383832385e-20
these O 0 6.560902452665276e-19
mutants O 0 3.2368438695828212e-15
are O 0 4.1916534204640785e-20
dominant O 0 7.929326140999893e-15
- O 0 1.1453784448667292e-10
negative O 0 3.407204260483937e-13
in O 0 9.78465968916581e-21
transient O 0 5.224426219975467e-19
transfection O 0 6.441257812230591e-16
assays O 0 8.233278831924415e-16
when O 0 1.1649774842669407e-16
they O 0 5.0859086871723534e-20
are O 0 9.025230136711312e-22
coexpressed O 0 1.3489260147656014e-15
with O 0 4.25284339541935e-19
wild O 0 2.337112166121702e-13
- O 0 4.03771593937563e-08
type O 0 4.475906104084437e-11
PAX6 O 0 3.074135435099379e-08
. O 0 1.3310014169379963e-13

We O 0 1.329674353478874e-13
found O 0 1.0796534235790141e-17
that O 0 5.156159004021465e-19
the O 0 1.1445244220535105e-18
dominant O 0 2.378006472292249e-11
- O 0 4.80218295706436e-06
negative O 0 1.4966194328280835e-07
effects O 0 1.5429379995879344e-09
result O 0 5.406376052157989e-17
from O 0 7.643000680357539e-23
the O 0 1.5631277850878217e-24
enhanced O 0 1.0471565333231476e-21
DNA O 0 3.2757431727799278e-18
binding O 0 8.207175919332094e-19
ability O 0 6.241687121179498e-20
of O 0 1.1972082841492458e-23
these O 0 3.1597216309911096e-19
mutants O 0 1.0256849013244411e-14
. O 0 4.128547772758317e-17

Kinetic O 0 1.2457480359773232e-11
studies O 0 2.94097211861466e-13
of O 0 1.047801469244649e-18
binding O 0 9.621250194116748e-13
and O 0 4.436872744206788e-12
dissociation O 0 1.956570485055903e-13
revealed O 0 2.786001874849231e-17
that O 0 3.3917050638605884e-22
various O 0 6.069404927994183e-23
truncation O 0 8.897238313123907e-16
mutants O 0 1.2004659148256297e-13
have O 0 1.772924331025731e-18
3 O 0 8.764461973669789e-20
- O 0 3.939155859139509e-14
5 O 0 1.2509982063929267e-15
- O 0 1.026179662078075e-11
fold O 0 5.275150975758702e-12
higher O 0 6.018320163794694e-21
affinity O 0 2.221536060088624e-22
to O 0 6.155815726032916e-24
various O 0 3.3451212812399134e-25
DNA O 0 7.644941256979802e-19
- O 0 9.840738980405211e-20
binding O 0 6.211609412390392e-22
sites O 0 1.5538870857674483e-19
when O 0 4.653852129482567e-18
compared O 0 2.1068736760106842e-22
with O 0 5.011307432707619e-25
the O 0 4.378540016468803e-22
wild O 0 1.838593855749181e-15
- O 0 4.0197156714327775e-10
type O 0 6.594143091807891e-13
PAX6 O 0 1.415709216523453e-09
. O 0 3.51469511318276e-14

These O 0 9.490268949386219e-15
results O 0 3.3368236367769153e-18
provide O 0 6.210736187544523e-21
a O 0 8.623016189186495e-21
new O 0 8.545771575582107e-20
insight O 0 5.61397865765119e-19
into O 0 6.5417776653180096e-21
the O 0 2.385407082563271e-22
role O 0 1.5076423903999349e-19
of O 0 1.6907593934906977e-21
mutant O 0 4.321442157026109e-14
PAX6 O 0 2.4833701067761282e-11
in O 0 4.816870542029023e-15
causing O 0 9.636332976015183e-08
aniridia B-Disease 1 0.9999916553497314
. O 0 7.319419592990983e-13
. O 0 4.109488628296215e-13

Reversal O 0 8.612955904041542e-10
of O 0 5.673740015137152e-13
severe O 0 7.1768513407732826e-06
hypertrophic B-Disease 1 0.8605798482894897
cardiomyopathy I-Disease 1 0.9999986886978149
and O 0 3.499891210179129e-10
excellent O 0 2.4976562159641225e-13
neuropsychologic O 0 1.2073933519651803e-10
outcome O 0 2.703265681794901e-16
in O 0 1.3401227550226731e-18
very B-Disease 0 2.0515468325348583e-14
- I-Disease 0 5.90483679729914e-08
long I-Disease 0 2.4384214647454883e-09
- I-Disease 0 4.237347278612802e-11
chain I-Disease 0 2.9904667609402524e-13
acyl I-Disease 0 1.1248069838010969e-14
- I-Disease 0 3.474030670747681e-15
coenzyme I-Disease 0 5.051000930682834e-16
A I-Disease 0 1.2368522003084083e-16
dehydrogenase I-Disease 0 1.419931372481642e-08
deficiency I-Disease 0 2.5560371796018444e-05
. O 0 1.0409829939782116e-14

Very B-Disease 0 2.832799966823174e-11
- I-Disease 0 2.0223339447511535e-07
long I-Disease 0 2.4730208991741165e-09
- I-Disease 0 3.5462094372107344e-10
chain I-Disease 0 5.603468535529676e-13
acyl I-Disease 0 1.4415670669979883e-14
- I-Disease 0 1.154532906282805e-15
coenzyme I-Disease 0 2.973749374586107e-17
A I-Disease 0 6.300274385262068e-19
dehydrogenase I-Disease 0 1.423734651766033e-14
( I-Disease 0 1.6505050124879097e-19
VLCAD I-Disease 0 2.0275955914250687e-10
) I-Disease 0 4.4481819419773825e-17
deficiency I-Disease 0 4.514580983355776e-12
is O 0 1.5059165354051862e-21
a O 0 7.587415498267684e-19
disorder O 0 7.059572371126421e-10
of O 0 3.323671801079446e-20
fatty O 0 3.665967540384535e-13
acid O 0 2.6023954397821425e-15
beta O 0 7.638786774728466e-20
oxidation O 0 2.0326209930592043e-18
that O 0 9.827805649636426e-18
reportedly O 0 1.120623166202088e-13
has O 0 6.301966420428173e-16
high O 0 1.886702150779673e-15
rates O 0 2.2924506260305066e-13
of O 0 8.185356652531747e-18
morbidity O 0 7.431206654473499e-07
and O 0 6.143915931566823e-11
mortality O 0 7.053912298715659e-08
. O 0 1.325331988252798e-13

We O 0 4.253973611085052e-14
describe O 0 8.435693765934183e-17
the O 0 8.568555877813968e-20
outcome O 0 7.447192357815578e-19
of O 0 2.2895999887330515e-22
a O 0 6.987798217588647e-20
5 O 0 1.1104753932941434e-18
- O 0 6.56172327844623e-13
year O 0 2.099629166005517e-14
- O 0 1.1713316983019695e-09
old O 0 2.735277604415387e-08
girl O 0 1.0405642569821794e-06
with O 0 2.945935054059212e-13
VLCAD B-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9999997615814209
who O 0 4.177469219418173e-17
was O 0 1.047126179672076e-18
first O 0 1.8919730565884607e-20
seen O 0 6.26159238323906e-15
at O 0 1.9398005749827914e-17
5 O 0 3.817989429220183e-18
months O 0 4.888599303705767e-16
of O 0 7.132208494602709e-18
age O 0 5.114114687287952e-10
with O 0 3.7747961006973085e-11
severe O 0 5.763976787420688e-06
hypertrophic B-Disease 1 0.9988429546356201
cardiomyopathy I-Disease 1 1.0
, O 0 2.8957763333892217e-06
hepatomegaly B-Disease 1 0.9999995231628418
, O 0 1.2069420463056701e-10
encephalopathy B-Disease 0 2.9087657821946777e-05
, O 0 2.442265953275097e-13
and O 0 4.9008984370768616e-11
hypotonia B-Disease 0 1.4318907233246136e-05
. O 0 2.1843487576448523e-13

Biochemical O 0 4.927614427607807e-10
studies O 0 2.9422037722826033e-11
indicated O 0 5.2008399507030845e-06
VLCAD B-Disease 1 0.9999991655349731
deficiency I-Disease 1 1.0
caused O 0 7.277264444383036e-07
by O 0 1.3682561271851121e-16
a O 0 6.469502655252377e-16
stable O 0 1.6215513307105134e-11
yet O 0 7.604353480456308e-15
inactive O 0 7.400568872995006e-14
enzyme O 0 5.554919995124849e-14
. O 0 5.230638936982697e-15

Molecular O 0 2.8142711685358313e-13
genetic O 0 3.4082979494254317e-12
analysis O 0 1.1632251965040113e-13
of O 0 3.932298047464478e-16
her O 0 3.0128468608836556e-09
VLCAD O 0 2.3074239408060748e-08
gene O 0 1.837817414527751e-13
revealed O 0 3.340667586310131e-12
a O 0 1.4234608708651456e-17
T1372C O 0 8.269989239858416e-14
( O 0 9.29204138727129e-19
F458L O 0 9.230698752018748e-14
) O 0 1.583612665837742e-16
missense O 0 1.692457697426153e-12
mutation O 0 2.665079311750529e-12
and O 0 5.528925581255173e-11
a O 0 6.065095799721865e-13
1668 O 0 6.255191351556277e-07
ACAG O 0 4.308330244384706e-05
1669 O 0 5.782542222831921e-10
splice O 0 1.9944158324847194e-08
site O 0 7.178417582576202e-11
mutation O 0 1.2590492537434272e-10
. O 0 4.27685803439104e-11

After O 0 7.088330103439792e-16
initial O 0 1.446687399362114e-18
treatment O 0 8.526270663394199e-19
with O 0 1.3564932280317687e-19
intravenous O 0 1.2816061654584345e-14
glucose O 0 3.9756038738847366e-11
and O 0 6.702151854331984e-13
carnitine O 0 3.338057955049045e-11
, O 0 2.3550231154030255e-18
the O 0 3.61875402510289e-21
patient O 0 5.091718118785981e-18
has O 0 6.045985106290431e-19
thrived O 0 1.711992949790544e-16
on O 0 5.279670180288341e-16
a O 0 1.3879063651191259e-16
low O 0 1.3072714568837518e-12
- O 0 4.3110594954987036e-11
fat O 0 3.8258465839824396e-11
diet O 0 7.97260867757164e-15
supplemented O 0 2.3179106232450682e-18
with O 0 2.4920242839716613e-19
medium O 0 6.929575694454484e-15
- O 0 1.2661611125883154e-13
chain O 0 3.677268857254709e-14
triglyceride O 0 1.54348810208621e-13
oil O 0 4.9027716207512097e-17
and O 0 3.44338583834861e-20
carnitine O 0 6.398519309038997e-17
and O 0 5.693294324714257e-21
avoidance O 0 5.326480926722758e-16
of O 0 2.9141925178238354e-20
fasting O 0 4.089526297896412e-13
. O 0 3.860963447275783e-17

Her O 0 2.9067468858556822e-05
ventricular O 0 6.177193426992744e-06
hypertrophy O 0 7.337983554123184e-09
resolved O 0 5.045772827338979e-12
significantly O 0 1.4335325359768076e-15
over O 0 1.3398219094338876e-17
1 O 0 2.0932270689748926e-18
year O 0 1.216645832304963e-16
, O 0 2.1468125487032107e-16
and O 0 1.1998942421251324e-12
cognitively O 0 1.1371616981392663e-09
, O 0 4.09123497881503e-17
she O 0 2.2673174102094684e-12
is O 0 3.4015964799319747e-19
in O 0 3.0486899144797465e-22
the O 0 1.7586030428878707e-19
superior O 0 3.7327789073431355e-17
range O 0 1.1703511152826723e-13
for O 0 1.8425187946685207e-15
age O 0 1.20334020525803e-10
. O 0 8.445688267667839e-14

Clinical O 0 9.202470599781187e-13
recognition O 0 2.7670554649666945e-12
of O 0 1.2358096768139148e-09
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
is O 0 2.456409311322864e-15
important O 0 1.4284591303960126e-18
because O 0 1.2737116331015672e-16
it O 0 2.0136292570672318e-17
is O 0 1.5962557937302972e-19
one O 0 9.516128751114968e-20
of O 0 2.443709835693111e-21
the O 0 8.581522399204832e-17
few O 0 7.857460342097777e-13
directly O 0 9.762340241747935e-11
treatable O 0 9.603499347576872e-05
causes O 0 8.836963161229505e-08
of O 0 1.1752743223070183e-10
cardiomyopathy B-Disease 1 1.0
in O 0 9.850806802214063e-12
children O 0 6.704822252956433e-10
. O 0 1.3175821164178276e-16
. O 0 9.548917510654106e-15

Cloning O 0 2.0977340958044932e-12
of O 0 3.589791804912729e-17
a O 0 1.8069974886435663e-16
novel O 0 3.19821988716603e-14
member O 0 1.9935377811421476e-15
of O 0 3.550311797764553e-17
the O 0 9.236756731657511e-14
low O 0 3.166603645965438e-09
- O 0 2.782826857838927e-09
density O 0 3.0379274992825686e-15
lipoprotein O 0 4.080568348496794e-12
receptor O 0 3.985460101047292e-14
family O 0 1.5695862665143778e-10
. O 0 5.720985886631738e-14

A O 0 4.270456364018852e-16
gene O 0 8.414097072757159e-17
encoding O 0 7.661301305445227e-16
a O 0 6.25005957967594e-17
novel O 0 4.719633277266598e-15
transmembrane O 0 2.5357007007900494e-14
protein O 0 7.308266337479989e-15
was O 0 3.4409208013491105e-18
identified O 0 2.4048693034588065e-21
by O 0 4.303885312733435e-23
DNA O 0 1.6211048587122794e-16
sequence O 0 1.8174570220531769e-16
analysis O 0 9.320441599627532e-19
within O 0 4.341301742774537e-22
the O 0 2.114196304298265e-18
insulin B-Disease 0 3.820781273589091e-07
- I-Disease 1 0.6572297811508179
dependent I-Disease 0 0.029632629826664925
diabetes I-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999996423721313
( O 0 3.0287949340408737e-13
IDDM B-Disease 0 2.594697612323671e-08
) O 0 1.1705457994528516e-16
locus O 0 5.404294633332141e-13
IDDM4 O 0 3.3791360820600858e-09
on O 0 9.9489145220788e-13
chromosome O 0 3.4924369174405e-07
11q13 O 0 2.6540754038961722e-09
. O 0 5.337269255029087e-13

Based O 0 5.377503438608279e-15
on O 0 1.8425638619035123e-12
its O 0 1.244843664998177e-14
chromosomal O 0 1.1353938234037741e-08
position O 0 8.22017714313672e-12
, O 0 3.1867186038164595e-17
this O 0 1.080376235970248e-21
gene O 0 2.394253603519425e-19
is O 0 8.053249498057281e-21
a O 0 1.5376094955889835e-23
candidate O 0 3.2141815223109816e-21
for O 0 2.563594226528124e-22
conferring O 0 1.9549803331633635e-14
susceptibility O 0 2.6038331490951805e-09
to O 0 1.7440544564095717e-09
diabetes B-Disease 0 0.031120430678129196
. O 0 3.5936156272953212e-09

The O 0 2.437626885113092e-16
gene O 0 1.0367742566698944e-14
, O 0 2.416131835889738e-15
termed O 0 9.944855269145014e-13
low O 0 4.447553159092621e-10
- O 0 6.031848354126623e-09
density O 0 2.211205089202358e-14
lipoprotein O 0 4.592298763483882e-13
receptor O 0 6.906455189005349e-16
related O 0 7.946100781487317e-15
protein O 0 2.6193495072587836e-13
5 O 0 6.117049598921903e-17
( O 0 6.114773946862352e-21
LRP5 O 0 3.826631123516472e-13
) O 0 2.274532942343012e-20
, O 0 2.778267133992535e-23
encodes O 0 3.8169806695384775e-20
a O 0 1.4831925147682586e-20
protein O 0 1.3445643244828337e-15
of O 0 1.6549875559261228e-19
1615 O 0 5.693437258105782e-13
amino O 0 2.0108132033898562e-16
acids O 0 1.936131899719148e-19
that O 0 5.319827124907967e-21
contains O 0 7.222128241292749e-23
conserved O 0 9.651096677426206e-21
modules O 0 1.193269861718936e-14
which O 0 2.1919204942158504e-16
are O 0 9.040611568279672e-19
characteristic O 0 1.0283444788997012e-15
of O 0 1.984649480614804e-18
the O 0 3.065972172325293e-12
low O 0 3.666421662273933e-06
- O 0 7.646605808986351e-05
density O 0 1.1308410458044094e-10
lipoprotein O 0 2.226530710913721e-07
( O 0 9.759968898473198e-16
LDL O 0 5.627128540908188e-09
) O 0 7.092113561387161e-17
receptor O 0 4.283541170169359e-16
family O 0 1.9457130351341334e-11
. O 0 3.5470883635911957e-14

These O 0 2.802556075012132e-17
modules O 0 1.9254623255064707e-16
include O 0 1.9986563738808216e-21
a O 0 3.784110226537466e-22
putative O 0 1.3751835497482845e-17
signal O 0 1.2672409465854222e-17
peptide O 0 2.990537346329873e-19
for O 0 3.0426472399457535e-23
protein O 0 1.2214198038806877e-19
export O 0 5.013425887398143e-19
, O 0 2.834193489714874e-19
four O 0 3.249928727018526e-18
epidermal O 0 6.193587743369422e-12
growth O 0 2.4752151283474744e-13
factor O 0 5.783630325828298e-15
( O 0 1.4144908415845593e-18
EGF O 0 1.1806435169792184e-11
) O 0 5.47096357170066e-16
repeats O 0 1.3815514288140207e-09
with O 0 3.7190344742849544e-17
associated O 0 5.159590025125243e-16
spacer O 0 4.281016430240925e-09
domains O 0 1.8611951979607966e-09
, O 0 5.618274671447682e-15
three O 0 2.596641207481754e-17
LDL O 0 4.044616030984827e-11
- O 0 1.8382627505700994e-13
receptor O 0 6.949161002019135e-16
( O 0 6.858712805590626e-19
LDLR O 0 3.6451241330892614e-11
) O 0 5.370729861712874e-18
repeats O 0 2.6184143742113974e-10
, O 0 8.51008894266113e-19
a O 0 1.340929323974572e-20
single O 0 9.372894363040439e-18
transmembrane O 0 2.8215685606643344e-14
spanning O 0 3.6820691623733887e-14
domain O 0 4.2837153962915764e-11
, O 0 1.2197326956504655e-14
and O 0 5.162838396477964e-16
a O 0 1.0773448452074398e-18
cytoplasmic O 0 4.9786744171775865e-11
domain O 0 8.60643611932943e-10
. O 0 2.7114883255352495e-11

The O 0 1.4925077252259935e-18
encoded O 0 9.704017740095621e-17
protein O 0 1.2098021660801508e-14
has O 0 1.11692924254892e-17
a O 0 5.389498714211911e-22
unique O 0 1.4219058024943776e-21
organization O 0 2.094687818237873e-19
of O 0 2.4628597050306315e-19
EGF O 0 6.88070087018211e-11
and O 0 4.939237495567295e-13
LDLR O 0 5.078037546013547e-09
repeats O 0 2.82280288033121e-09
; O 0 5.910914370476341e-18
therefore O 0 2.286932088919498e-19
, O 0 3.4149099518910157e-19
LRP5 O 0 4.642166165358397e-11
likely O 0 9.56174201299201e-16
represents O 0 5.0536645972057325e-22
a O 0 2.862691760132208e-21
new O 0 2.151994405106937e-16
category O 0 8.060934190111391e-13
of O 0 7.081215291380652e-18
the O 0 4.699623936538222e-13
LDLR O 0 1.822309241106268e-05
family O 0 2.5634924738504594e-10
. O 0 3.292939515899332e-14

Both O 0 2.8893272153898263e-15
human O 0 5.2267095511403846e-15
and O 0 1.1862808912271872e-13
mouse O 0 5.085277532401733e-09
LRP5 O 0 9.236251763411474e-09
cDNAs O 0 2.0399884906319166e-11
have O 0 4.412389439825519e-16
been O 0 7.097580894363891e-17
isolated O 0 5.697193069956544e-14
and O 0 4.108579301899042e-17
the O 0 2.4845879767129396e-22
encoded O 0 2.816517932494323e-19
mature O 0 2.9931168573713314e-19
proteins O 0 4.2786007657184854e-20
are O 0 4.327018942768967e-21
95 O 0 5.72623327062923e-19
% O 0 9.852270395132083e-20
identical O 0 1.9780466073280505e-15
, O 0 2.683260914250347e-17
indicating O 0 4.284147804578271e-15
a O 0 8.535782620053099e-17
high O 0 8.554473725523246e-14
degree O 0 7.932032900130112e-19
of O 0 2.599062675004309e-22
evolutionary O 0 3.163643242576435e-18
conservation O 0 6.415823927453606e-17
. O 0 2.308391891976951e-16
. O 0 4.0097831603474673e-14

The O 0 1.477053194685852e-15
APC B-Disease 0 3.840216176737715e-13
variants O 0 1.1905917129463074e-14
I1307K O 0 1.2521501034385568e-13
and O 0 1.4843783885532663e-16
E1317Q O 0 7.272109253818782e-16
are O 0 1.0978052869059097e-19
associated O 0 1.67452603026157e-14
with O 0 1.4578128002540325e-06
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.815955164019556e-10
but O 0 4.196415943549933e-15
not O 0 3.9918161409922815e-16
always O 0 8.50939209097153e-15
with O 0 1.9854360001303712e-19
a O 0 4.4332069950399675e-17
family O 0 2.7228239107834895e-10
history O 0 1.7577517566480516e-11
. O 0 2.933274825291099e-13

Classical O 0 0.05548559129238129
familial B-Disease 1 0.9999872446060181
adenomatous I-Disease 1 0.9989542961120605
polyposis I-Disease 1 0.9999715089797974
( O 0 1.6644770685445703e-13
FAP B-Disease 0 4.1522341120980855e-12
) O 0 2.2180192998564295e-17
is O 0 9.845545029011115e-20
a O 0 1.0184664600781603e-17
high O 0 2.822243327926799e-09
- O 1 0.9999854564666748
penetrance O 1 0.9999555349349976
autosomal B-Disease 1 0.9999946355819702
dominant I-Disease 0 0.0891912505030632
disease I-Disease 0 1.2864569725934416e-05
that O 0 1.977085534298466e-18
predisposes O 0 4.647490210599528e-15
to O 0 1.1994271555003054e-20
hundreds O 0 1.4016580649589882e-19
or O 0 4.4491468481619256e-18
thousands O 0 3.4270238361859746e-17
of O 0 4.4332789663707045e-15
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and I-Disease 0 2.0904863049509004e-06
carcinoma I-Disease 1 0.9999998807907104
and O 0 5.159723759362578e-10
that O 0 1.6568681038167492e-14
results O 0 2.661201661674783e-17
from O 0 3.0680263336441336e-19
truncating O 0 4.6307691025943704e-14
mutations O 0 1.2716587164049984e-15
in O 0 4.258409803953949e-20
the O 0 7.218531202172364e-20
APC B-Disease 0 3.6103695174542066e-14
gene O 0 2.0081475748229792e-14
. O 0 1.1087469511299533e-13

A O 0 2.797132973037116e-15
variant O 0 3.5790292984057975e-14
of O 0 2.2987158971307752e-17
FAP B-Disease 0 2.2429658130818098e-10
is O 0 3.280927572267729e-14
attenuated B-Disease 0 0.03307904303073883
adenomatous I-Disease 1 0.99997878074646
polyposis I-Disease 1 0.999893307685852
coli I-Disease 1 0.9999995231628418
, O 0 1.177553454051461e-11
which O 0 3.97435948016364e-15
results O 0 2.982428815317503e-17
from O 0 3.4799031766407745e-17
germ O 0 4.993013362764032e-07
- O 0 3.05569756164914e-08
line O 0 3.33501753990717e-10
mutations O 0 9.781629648516858e-15
in O 0 2.1607764472535628e-19
the O 0 1.228658409722351e-19
5 O 0 3.390429541662509e-19
and O 0 4.1756365180530005e-17
3 O 0 1.0449713741763754e-18
regions O 0 2.1728785649043082e-18
of O 0 3.59943806533007e-21
the O 0 1.996114410699942e-18
APC B-Disease 0 9.300753120141184e-14
gene O 0 2.1786431098308294e-14
. O 0 2.0970077684403544e-14

Attenuated B-Disease 1 0.9935241937637329
adenomatous I-Disease 1 0.9999263286590576
polyposis I-Disease 1 0.999728262424469
coli I-Disease 1 0.9999963045120239
patients O 0 6.190573831332813e-09
have O 0 1.1871042241925773e-14
" O 0 1.0705387178946632e-13
multiple O 0 8.849398297483546e-11
" O 0 0.0019716827664524317
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999991655349731
( O 0 1.2804205310905153e-15
typically O 0 2.7965861470952144e-17
fewer O 0 2.4567509762069274e-19
than O 0 1.3181530188990237e-19
100 O 0 8.185606461076738e-18
) O 0 1.4698346012383385e-17
without O 0 3.995533556839544e-16
the O 0 1.4635361370344494e-15
florid O 0 7.666359351787833e-07
phenotype O 0 5.0812652696574645e-12
of O 0 1.1824241833594652e-18
classical O 0 1.088329404895505e-12
FAP B-Disease 0 4.3216819012315e-10
. O 0 2.4338290646633114e-14

Another O 0 7.760405409647578e-14
group O 0 1.3902128146586756e-14
of O 0 1.7800321906318226e-19
patients O 0 2.9606179650798887e-18
with O 0 5.712269944901452e-19
multiple O 0 1.2983895642665333e-13
adenomas B-Disease 0 6.913148276055381e-09
has O 0 2.0399661126990765e-10
no O 0 2.5431163048366713e-14
mutations O 0 1.5119008712897227e-16
in O 0 1.169075814718332e-19
the O 0 1.168121972074482e-19
APC B-Disease 0 1.4199852233673203e-16
gene O 0 9.41841328496862e-18
, O 0 3.2819220051605457e-18
and O 0 7.078602988831761e-16
their O 0 2.0601353739255202e-13
phenotype O 0 6.215640930553809e-14
probably O 0 6.212772538181227e-14
results O 0 8.600854437300808e-18
from O 0 1.8714814534453523e-18
variation O 0 8.665080346566896e-16
at O 0 1.654531953066904e-13
a O 0 4.8964704069989645e-18
locus O 0 8.272012632162817e-13
, O 0 6.173033818054202e-15
or O 0 2.127873394928417e-15
loci O 0 8.45383456468641e-16
, O 0 2.321435881727312e-15
elsewhere O 0 8.331847030292438e-18
in O 0 1.4295472267151022e-21
the O 0 1.0707564550260315e-18
genome O 0 3.1041016111676978e-12
. O 0 3.276252966838422e-12

Recently O 0 2.2491078444097923e-11
, O 0 2.2572329548473634e-16
however O 0 7.108302664707196e-19
, O 0 9.655257622089546e-21
a O 0 4.356652041978826e-20
missense O 0 6.8275844572755935e-15
variant O 0 8.06161474381506e-12
of O 0 1.534919944543424e-15
APC B-Disease 0 1.50714984936684e-09
( O 0 5.447074661784578e-17
I1307K O 0 2.303078517826296e-13
) O 0 2.1487776651408407e-17
was O 0 3.261542715050046e-17
described O 0 5.934702430532141e-19
that O 0 6.314914850005791e-23
confers O 0 1.31016219568782e-19
an O 0 7.457188217556202e-22
increased O 0 4.582354647505093e-15
risk O 0 1.7353276859921607e-07
of O 0 1.3054099099463201e-06
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.2009768602170594e-13
including O 0 1.724082081739648e-19
multiple O 0 2.3049977250781846e-14
adenomas B-Disease 0 4.985587942485381e-09
, O 0 3.5336862017239234e-13
in O 0 4.452007881274034e-14
Ashkenazim O 0 0.000412682828027755
. O 0 2.005143412420196e-10

We O 0 7.272938761654357e-13
have O 0 3.05421386498057e-18
studied O 0 4.355740269223942e-19
a O 0 1.2118724270894638e-20
set O 0 1.246195817440848e-17
of O 0 2.128825037052118e-21
164 O 0 9.369645528466575e-17
patients O 0 5.84625447948016e-21
with O 0 3.219535061084819e-19
multiple O 0 4.4997906911703467e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and I-Disease 0 1.7685248110410612e-07
/ I-Disease 0 2.302904817952367e-07
or I-Disease 0 6.372627314732426e-09
carcinoma I-Disease 1 0.9999996423721313
and O 0 1.559237287895865e-11
analyzed O 0 2.5864923538457957e-14
codons O 0 2.6542912426362822e-14
1263 O 0 1.9151458197086413e-11
- O 0 1.060880636810646e-11
1377 O 0 1.1669732020991308e-11
( O 0 3.5288835185602445e-17
exon O 0 1.800058583092956e-13
15G O 0 2.1865351543248757e-11
) O 0 3.246720961962076e-17
of O 0 1.068449668825265e-21
the O 0 9.422710817830608e-21
APC B-Disease 0 1.1431685034575106e-16
gene O 0 4.353051622040415e-18
for O 0 3.5149341825245763e-19
germ O 0 2.1970190999809347e-08
- O 0 7.322282780108935e-09
line O 0 8.570773535332421e-10
variants O 0 4.962923735168934e-12
. O 0 1.856993942297991e-12

Three O 0 3.45168196054426e-14
patients O 0 9.739694370787278e-17
with O 0 5.621307477878409e-19
the O 0 1.5276683813310554e-18
I1307K O 0 1.468951303369541e-14
allele O 0 4.1178117095612074e-14
were O 0 1.892381189053658e-16
detected O 0 8.48977152566045e-16
, O 0 5.83487258734253e-20
each O 0 1.1266629689149852e-20
of O 0 2.320954234308957e-18
Ashkenazi O 0 8.501324373355601e-07
descent O 0 1.1694680779328337e-06
. O 0 7.908050325688976e-10

Four O 0 1.0104426112012357e-13
patients O 0 5.548857250925758e-16
had O 0 9.35100749490453e-17
a O 0 1.628740794557328e-17
germ O 0 1.0211928014314253e-07
- O 0 1.128618350776378e-06
line O 0 1.7630931381518167e-08
E1317Q O 0 4.941425740812022e-12
missense O 0 8.984508287086107e-14
variant O 0 2.986965126736303e-14
of O 0 3.1767625855854676e-19
APC O 0 3.527637098990448e-14
that O 0 2.0824682202606298e-17
was O 0 1.830797340986179e-15
not O 0 5.483960233485094e-16
present O 0 6.632678258584998e-17
in O 0 9.289174586063334e-18
controls O 0 5.654339843563783e-12
; O 0 2.6074519617794547e-16
one O 0 3.488236525003879e-17
of O 0 8.634960830712539e-22
these O 0 7.877728182723276e-18
individuals O 0 2.3411460232541062e-20
had O 0 2.2251803678554236e-17
an O 0 9.722261069241867e-22
unusually O 0 7.54778403434935e-18
large O 0 5.765442407146067e-20
number O 0 7.257169180815992e-17
of O 0 1.0586508942359864e-15
metaplastic B-Disease 0 3.0806736504018772e-06
polyps I-Disease 0 1.031782872473741e-07
of I-Disease 0 1.1269918947006275e-16
the I-Disease 0 1.0305874433198543e-14
colorectum I-Disease 0 7.160131332284436e-08
. O 0 5.781085245931683e-14

There O 0 4.456972443021845e-13
is O 0 3.08915662103277e-17
increasing O 0 5.566636526255366e-19
evidence O 0 2.2045144183036438e-17
that O 0 5.975553406827562e-17
there O 0 8.850476866653998e-19
exist O 0 3.1862550518011847e-18
germ O 0 9.458803532091942e-12
- O 0 2.960685169250965e-11
line O 0 1.7757496861836586e-11
variants O 0 6.624366006636236e-15
of O 0 2.0762304460914886e-20
the O 0 3.578889008677306e-20
APC B-Disease 0 3.231755568960736e-18
gene O 0 5.348334967679069e-21
that O 0 1.2304162169916402e-21
predispose O 0 1.7757805856808766e-18
to O 0 2.2239368730566863e-21
the O 0 1.90013100421073e-21
development O 0 4.3677508024712416e-20
of O 0 4.374773695118787e-19
multiple O 0 1.0558605936239474e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999996423721313
and I-Disease 0 3.120640030829236e-06
carcinoma I-Disease 1 0.9999996423721313
, O 0 1.298439030990653e-13
but O 0 3.835379214150661e-16
without O 0 9.761076162441161e-18
the O 0 5.405159765785291e-17
florid O 0 1.197285655507585e-06
phenotype O 0 4.91122680718048e-12
of O 0 1.117720952622831e-19
classical O 0 2.86024594850845e-14
FAP B-Disease 0 2.6708702523942085e-12
, O 0 1.6960719108916183e-18
and O 0 5.43467614464084e-20
possibly O 0 1.493496406390799e-21
with O 0 9.65480614121627e-23
importance O 0 1.2405894354031474e-17
for O 0 8.72530086376555e-12
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.7709247401853645e-09
in O 0 4.753784866993355e-22
the O 0 1.0932031900197885e-21
general O 0 6.168001080575579e-21
population O 0 2.86494522145624e-19
. O 0 1.8454009036808922e-17
. O 0 1.1648570562988736e-13

Genomic O 0 8.423897863985008e-12
structure O 0 9.939275016088503e-14
of O 0 1.7194786406850314e-18
the O 0 4.743582498575503e-16
human O 0 2.6009230880141843e-10
congenital B-Disease 1 0.9997826218605042
chloride I-Disease 1 0.999742329120636
diarrhea I-Disease 1 1.0
( O 0 1.6840203548047078e-13
CLD B-Disease 0 2.288568765607124e-07
) O 0 3.744675220389526e-16
gene O 0 1.511389890193962e-13
. O 0 7.698075304377744e-14

Congenital B-Disease 1 0.9994521737098694
chloride I-Disease 1 0.999316930770874
diarrhea I-Disease 1 0.9999998807907104
( O 0 6.113196060475445e-11
CLD B-Disease 0 0.00044933019671589136
) O 0 5.679437389133346e-12
is O 0 1.3054568006026085e-13
caused O 0 3.1191569509550487e-13
by O 0 2.4012428661051916e-18
mutations O 0 1.1129399675067694e-13
in O 0 1.1205177795208434e-18
a O 0 2.335955464910336e-19
gene O 0 6.166110806018056e-16
which O 0 4.614271950762211e-18
encodes O 0 5.3993483256737385e-17
an O 0 5.108369161119097e-19
intestinal O 0 3.251371936130454e-07
anion O 0 1.0527256150139053e-10
transporter O 0 5.076460183772724e-06
. O 0 1.1433834434804169e-10

We O 0 6.708067434857412e-11
report O 0 2.038098066914828e-15
here O 0 1.6445541717636267e-18
the O 0 5.845050463168627e-21
complete O 0 1.6811012601235098e-19
genomic O 0 7.8552300281146915e-16
organization O 0 3.0425516109603074e-17
of O 0 2.29240731371626e-20
the O 0 5.1953129779312035e-18
human O 0 6.799098315742958e-15
CLD B-Disease 0 5.713189921152662e-10
gene O 0 1.1271871294422225e-13
which O 0 2.5484136488887997e-14
spans O 0 2.1164782166432916e-12
approximately O 0 8.761968210238579e-17
39kb O 0 2.7785820866377264e-10
, O 0 4.1676342404582645e-16
and O 0 9.489798846100492e-15
comprises O 0 7.443937828103197e-16
21 O 0 8.213640902437916e-16
exons O 0 1.0657261878543878e-10
. O 0 1.0851269969386346e-12

All O 0 5.971412448036893e-15
exon O 0 3.791657959828498e-12
/ O 0 8.571443554927782e-10
intron O 0 3.8709191407804155e-09
boundaries O 0 7.0643196153907795e-12
conform O 0 7.535255243124733e-14
to O 0 1.0082765875482421e-17
the O 0 3.4460063077550865e-17
GT O 0 6.759412474188764e-12
/ O 0 5.775814895803144e-11
AG O 0 2.775040641722626e-09
rule O 0 9.287249788658691e-13
. O 0 2.3287012644807384e-14

An O 0 3.3155847405738506e-17
analysis O 0 1.2930240008425775e-17
of O 0 2.7902718551651204e-21
the O 0 6.437973768584707e-21
putative O 0 2.1475413940845434e-16
promoter O 0 9.426802464714348e-15
region O 0 1.602084072137194e-16
sequence O 0 3.4040163037561797e-16
shows O 0 3.5890852735556006e-14
a O 0 6.989748037388799e-19
putative O 0 1.9571202297674617e-12
TATA O 0 6.426134624426538e-10
box O 0 2.4884284854920224e-08
and O 0 7.176364363870036e-11
predicts O 0 3.3316426874263616e-13
multiple O 0 2.1865245634695955e-17
transcription O 0 1.0903463461969798e-13
factor O 0 9.255512073988795e-16
binding O 0 1.927822423995317e-15
sites O 0 2.3124476292157858e-11
. O 0 7.596826813449642e-12

The O 0 4.595305675389493e-16
genomic O 0 9.203642486804373e-14
structure O 0 2.748488506151012e-15
was O 0 3.650818543528931e-17
determined O 0 1.4890087900089855e-20
using O 0 4.004724657635159e-21
DNA O 0 1.3039635831605528e-13
from O 0 6.593117001621154e-19
several O 0 8.48255946714657e-22
sources O 0 1.1252112023164693e-20
including O 0 1.4148488547846622e-23
multiple O 0 2.77683187465556e-19
large O 0 3.1900478817048935e-19
- O 0 7.046637145319279e-12
insert O 0 9.895965991102429e-12
libaries O 0 1.688884709166727e-12
and O 0 1.3419527984238929e-20
genomic O 0 2.854791207205876e-17
DNA O 0 1.3587813871025062e-13
from O 0 1.1724713601135893e-17
Finnish O 0 1.7754134750899708e-12
CLD B-Disease 0 2.5471613707139795e-09
patients O 0 4.0184309749861956e-16
and O 0 9.459969680890426e-17
controls O 0 3.5074727410683293e-12
. O 0 3.34609916814374e-13

Exon O 0 6.087684067783428e-13
- O 0 1.5668049540076834e-13
specific O 0 1.5299560403049382e-16
primers O 0 1.3907619500486135e-10
developed O 0 8.360254894069347e-16
in O 0 2.000739875438368e-20
this O 0 1.8418728311883657e-22
study O 0 1.376706798928502e-23
will O 0 8.438785891060219e-24
facilitate O 0 9.043214272084179e-23
mutation O 0 6.569889770020665e-20
screening O 0 7.428134178540902e-17
studies O 0 4.973486629573878e-17
of O 0 2.444146801525731e-22
patients O 0 3.516888832930259e-21
with O 0 1.6908239160018575e-21
the O 0 1.9376419975434975e-16
disease O 0 1.3491970041190626e-10
. O 0 1.564549644082324e-14

Genomic O 0 7.780943756332832e-15
sequencing O 0 2.34505793656034e-15
of O 0 2.5324378471591645e-18
a O 0 6.443121549412346e-17
BAC O 0 2.2236766247796247e-11
clone O 0 4.224039074074426e-08
H O 1 0.9999970197677612
_ O 0 9.651682935946787e-14
RG364P16 O 0 1.34615846166539e-14
revealed O 0 4.9662144784978074e-14
the O 0 1.257033289672334e-18
presence O 0 5.4335203148311616e-18
of O 0 4.850303576468956e-21
another O 0 3.995847426387074e-19
, O 0 3.18403870536038e-21
highly O 0 5.934399398892404e-22
homologous O 0 5.926221761301941e-18
gene O 0 2.1295146906703116e-14
3 O 0 1.882883435085875e-16
of O 0 3.4141774769962514e-21
the O 0 2.4707750480109397e-18
CLD B-Disease 0 4.1412403020690824e-12
gene O 0 2.8350520969868493e-16
, O 0 9.57738871330488e-19
with O 0 4.040077339195781e-21
a O 0 1.4064671508687038e-20
similar O 0 3.3879342996459543e-19
genomic O 0 1.5240584402137491e-12
structure O 0 1.4439020725592888e-12
, O 0 3.4472795455129587e-18
recently O 0 2.642576532130294e-18
identified O 0 4.745568675031528e-18
as O 0 3.182043643692106e-16
the O 0 2.2573014568649796e-09
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
gene O 0 8.331649606341252e-12
( O 0 2.0248828838648932e-17
PDS B-Disease 0 1.1800181665133636e-10
) O 0 1.7580749501053016e-17
. O 0 2.0753228686932742e-17
. O 0 5.995564830198197e-14

The O 0 3.535947720400786e-15
APCI1307K O 0 2.582073932444473e-08
allele O 0 1.5901385097549792e-08
and O 0 5.54197043811655e-09
cancer B-Disease 0 1.9212439639204604e-08
risk O 0 4.423684682453022e-11
in O 0 5.465093385222004e-19
a O 0 1.0855046717575457e-18
community O 0 1.4474112237571285e-17
- O 0 5.727471448502275e-14
based O 0 7.66775500167159e-18
study O 0 8.298572035791268e-18
of O 0 5.646040178193745e-20
Ashkenazi O 0 2.731184852930446e-12
Jews O 0 1.7915424460786256e-14
. O 0 1.4391707049110874e-15

Mutations O 0 6.375486943932529e-12
in O 0 5.538513522801905e-17
APC O 0 2.567738903447303e-11
are O 0 1.777084440701942e-15
classically O 0 3.339882814756834e-09
associated O 0 1.0828956620301255e-09
with O 0 3.7159463772695744e-07
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999215602874756
polyposis I-Disease 1 0.9999969005584717
( O 0 1.6723874414763425e-14
FAP B-Disease 0 1.901256279149277e-12
) O 0 2.956126581148879e-18
, O 0 1.0544927529394407e-20
a O 0 7.60410541808959e-19
highly O 0 5.5909412516319534e-11
penetrant O 1 0.9999004602432251
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999997615814209
disorder I-Disease 1 1.0
characterized O 0 2.5348668941660435e-08
by O 0 1.0472511542549236e-16
multiple O 0 1.963442863156528e-12
intestinal O 0 1.7667511201580055e-05
polyps B-Disease 0 3.0841042644169647e-06
and O 0 9.908823978346804e-13
, O 0 2.5294919468051335e-19
without O 0 2.6669702047167563e-20
surgical O 0 3.712556657471929e-17
intervention O 0 6.911326951941041e-17
, O 0 8.253099242106934e-21
the O 0 8.49570731719058e-22
development O 0 9.017331603915132e-18
of O 0 1.1610225584754441e-12
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
( O 0 2.3371801595739605e-16
CRC B-Disease 0 7.420421915815822e-12
) O 0 7.100261621293053e-17
. O 0 1.234227589312002e-15

APC B-Disease 0 7.48870132571966e-11
is O 0 4.813249899695985e-16
a O 0 4.825935276872302e-16
tumour O 1 0.9999954700469971
- O 0 3.6745137488303214e-10
suppressor O 0 7.276786812004943e-12
gene O 0 1.4408228299692127e-13
, O 0 1.310228530403068e-17
and O 0 1.4746195102097127e-17
somatic O 0 7.284374926169734e-14
loss O 0 6.154112592790528e-13
occurs O 0 2.0196377122777553e-13
in O 0 7.531581153012723e-13
tumours B-Disease 1 0.9999994039535522
. O 0 8.969740861175524e-08

The O 0 1.5060886159089584e-14
germline O 0 5.7362448124820276e-12
T O 0 1.2962492190737862e-09
- O 0 1.8395718975883213e-12
to O 0 7.364345318423263e-16
- O 0 1.4104346759535175e-13
A O 0 6.364095608821174e-18
transversion O 0 1.926484535455129e-15
responsible O 0 2.8893404660089835e-21
for O 0 7.447994244865382e-25
the O 0 3.150856552492368e-23
APC O 0 3.1399095696459106e-18
I1307K O 0 2.8655464783639893e-19
allele O 0 7.456028973203117e-20
converts O 0 8.524737923568532e-20
the O 0 8.24425713372314e-21
wild O 0 7.064571093967105e-17
- O 0 5.907423530383815e-13
type O 0 1.5016302791669091e-15
sequence O 0 2.8278059418813256e-15
to O 0 5.6725192966645575e-16
a O 0 3.1537313027323348e-15
homopolymer O 0 8.172346497303806e-07
tract O 0 9.720248499434092e-07
( O 0 1.2992652142219106e-15
A8 O 0 3.932539698325854e-07
) O 0 1.4707390934596632e-15
that O 0 2.0889216848764215e-16
is O 0 2.1326099237601242e-16
genetically O 0 1.9351630486854482e-13
unstable O 0 1.5993808119674213e-05
and O 0 2.5746843546059495e-10
prone O 0 7.299274784600129e-06
to O 0 2.5312621422673184e-16
somatic O 0 1.0593104491458602e-13
mutation O 0 6.150286985424913e-13
. O 0 1.1644245680522691e-12

The O 0 5.057327102128521e-15
I1307K O 0 4.254270113274172e-12
allele O 0 9.176498970420166e-12
was O 0 6.609849386579603e-12
found O 0 4.215384280786133e-13
in O 0 3.0600245771731835e-16
6 O 0 9.038689935403355e-13
. O 0 3.8505873836691684e-13

1 O 0 1.076926850647475e-12
% O 0 8.31398042536966e-16
of O 0 5.441129962876343e-19
unselected O 0 6.75812669714837e-11
Ashkenazi O 0 5.766024546716153e-09
Jews O 0 8.922480809747668e-11
and O 0 1.358736040346642e-11
higher O 0 7.368150143835517e-13
proportions O 0 3.3627262086000087e-10
of O 0 7.186591748672803e-16
Ashkenazim O 0 3.1702376190878567e-07
with O 0 7.863202276803261e-13
family O 0 2.8542790353469627e-10
or O 0 9.1221484305095e-14
personal O 0 9.460246822023954e-12
histories O 0 1.035489818890234e-10
of O 0 4.353867139406331e-17
CRC B-Disease 0 6.237577121481763e-10
( O 0 6.205579782712763e-19
ref O 0 3.047356854704586e-12
. O 0 4.458699907425464e-16
2 O 0 3.971707420005787e-15
) O 0 8.695412067012481e-16
. O 0 3.173537008269861e-14

To O 0 7.367292066637421e-17
evaluate O 0 1.2452263617629359e-17
the O 0 9.44595992448089e-21
role O 0 1.1520987288070208e-17
of O 0 4.269553736262628e-19
I1307K O 0 7.602902513017661e-15
in O 0 6.828039397513511e-19
cancer B-Disease 0 5.832509632599028e-14
, O 0 2.7848120582561346e-17
we O 0 1.089850399936033e-15
genotyped O 0 2.736086097271384e-12
5 O 0 5.635268508179987e-17
, O 0 3.00132923056985e-17
081 O 0 1.9627509686981348e-11
Ashkenazi O 0 7.951302810615957e-11
volunteers O 0 9.72592452674068e-16
in O 0 8.421758460949655e-20
a O 0 9.332969663594954e-18
community O 0 2.476893744361025e-15
survey O 0 1.7380081748785692e-12
. O 0 3.206918237907974e-14

Risk O 0 2.4476802806816522e-09
of O 0 1.3172855225373906e-16
developing O 0 1.1210256898111504e-12
colorectal B-Disease 1 0.9999959468841553
, I-Disease 0 1.0553064498652898e-11
breast I-Disease 0 2.651253616647864e-08
and I-Disease 0 2.320031970357017e-12
other I-Disease 0 1.1881721580385196e-16
cancers I-Disease 0 4.427488757563491e-12
were O 0 6.766179915495136e-17
compared O 0 5.939911600439693e-19
between O 0 8.1871638353750225e-19
genotyped O 0 9.668532467699276e-12
I1307K O 0 2.9116996848674173e-15
carriers O 0 5.290753490597878e-18
and O 0 1.1844290830486559e-17
non O 0 9.121155178499726e-18
- O 0 1.601898648451172e-11
carriers O 0 3.733138472829245e-15
and O 0 6.784145749004196e-16
their O 0 3.0697737940471825e-17
first O 0 2.325614931771599e-19
- O 0 8.438393619926085e-14
degree O 0 8.280515510199848e-18
relatives O 0 1.82717606337843e-15
. O 0 5.617068549470351e-17

Sperm O 0 8.936772898310644e-14
DNA O 0 1.2582880260468814e-14
analysis O 0 2.753398385569331e-16
in O 0 2.843235607785844e-19
a O 0 5.686859432112675e-17
Friedreich B-Disease 0 1.0494558182472247e-06
ataxia I-Disease 0 0.00026424063253216445
premutation O 0 2.1014631101934356e-07
carrier O 0 2.8325161226944173e-13
suggests O 0 3.5382922017196676e-17
both O 0 1.4852759759361265e-20
meiotic O 0 1.736025026803558e-14
and O 0 8.616326188914123e-17
mitotic O 0 2.2414302740790017e-14
expansion O 0 4.8489999178515875e-17
in O 0 5.035448537231602e-19
the O 0 3.283939788187777e-17
FRDA B-Disease 0 2.824192435468831e-09
gene O 0 1.57315122300411e-12
. O 0 1.554686148699455e-13

Friedreich B-Disease 0 0.010773874819278717
ataxia I-Disease 1 0.9992080330848694
is O 0 6.090649407042292e-08
usually O 0 2.4803430420661243e-09
caused O 0 1.0674314622309555e-13
by O 0 1.1210339402230765e-20
an O 0 6.7508007131139044e-21
expansion O 0 2.401126117833536e-16
of O 0 6.211790895816786e-17
a O 0 6.175454028353733e-13
GAA O 0 5.050848272958319e-08
trinucleotide O 0 1.9677119933447784e-09
repeat O 0 2.466922326138654e-11
in O 0 4.43272907076155e-19
intron O 0 1.7260038884248097e-11
1 O 0 2.367979601025107e-16
of O 0 3.838620812962116e-20
the O 0 6.454585610957841e-17
FRDA B-Disease 0 3.762312406063728e-10
gene O 0 2.822808176441982e-13
. O 0 5.6562109054629495e-14

Occasionally O 0 4.359279870413957e-08
, O 0 4.170816913818013e-15
a O 0 1.0763799390228967e-17
fully O 0 6.752231003389532e-17
expanded O 0 1.884800302078375e-18
allele O 0 1.064284362137409e-13
has O 0 8.066459398731825e-16
been O 0 1.2660674254503932e-16
found O 0 7.666789681896741e-18
to O 0 5.867242542855991e-18
arise O 0 1.5738073992054363e-17
from O 0 6.638182980771651e-21
a O 0 2.816678974219829e-19
premutation O 0 7.43172450662355e-12
of O 0 5.0179961895294695e-20
100 O 0 1.629970667371587e-18
or O 0 1.0086348560151511e-16
less O 0 2.2694490890057915e-17
triplet O 0 1.4665424430404528e-08
repeats O 0 5.72891485717264e-06
. O 0 1.3136507506783524e-11

We O 0 2.3483695456988363e-12
have O 0 1.974199087550962e-18
examined O 0 1.782526657166553e-18
the O 0 2.519070311192275e-21
sperm O 0 1.5852445277501865e-16
DNA O 0 1.2250485897241387e-14
of O 0 2.9697431889530264e-20
a O 0 9.359460122711965e-18
premutation O 0 4.804825981530314e-10
carrier O 0 7.21530799517589e-13
. O 0 1.1828460201601405e-14

This O 0 1.7735280405239967e-16
mans O 0 1.320504984655621e-13
leucocyte O 0 9.292039360175863e-12
DNA O 0 3.1088021046343783e-11
showed O 0 1.2285134715073198e-11
one O 0 2.287805798441507e-18
normal O 0 3.00929526938195e-18
allele O 0 2.646081164036783e-15
and O 0 9.762091774797254e-16
one O 0 1.4408227301781436e-17
allele O 0 3.886934245062208e-14
of O 0 1.5080170515186331e-18
approximately O 0 5.367274033462525e-16
100 O 0 7.1142276064065e-16
repeats O 0 2.4622815786301544e-08
. O 0 3.9941088630923716e-12

His O 0 1.1417696215570983e-12
sperm O 0 1.1034185717906375e-12
showed O 0 1.4038816182625788e-15
an O 0 8.814680762970672e-22
expanded O 0 3.90370271147354e-18
allele O 0 1.0294893409978911e-10
in O 0 4.639282461340634e-14
a O 0 4.3114660062612553e-13
tight O 0 1.418744149939144e-10
range O 0 7.770470088060914e-16
centering O 0 3.6164916005464176e-13
on O 0 2.704404354538642e-13
a O 0 1.0069735299292873e-17
size O 0 1.5941960513461088e-15
of O 0 1.2651054350775093e-18
approximately O 0 3.507425262330537e-16
320 O 0 7.32719244165344e-15
trinucleotide O 0 1.100540658605098e-09
repeats O 0 1.2109190095088707e-07
. O 0 7.496787045313535e-12

His O 0 6.540616381833786e-10
affected O 0 4.597895328362078e-11
son O 0 2.8298650089908506e-09
has O 0 2.4667786801928215e-13
repeat O 0 2.538148337338786e-11
sizes O 0 1.9651565869916766e-14
of O 0 4.0240390341325883e-19
1040 O 0 6.811513701167338e-13
and O 0 1.145658681854858e-13
540 O 0 1.259595509492395e-12
. O 0 3.340345578264903e-14

These O 0 1.238844845316824e-16
data O 0 1.2239863488660443e-17
suggest O 0 5.2837749813600745e-18
that O 0 1.5073713918140957e-20
expansion O 0 2.5950542821560865e-19
occurs O 0 1.8670764768011298e-16
in O 0 9.254327379711642e-20
two O 0 2.80972951763309e-16
stages O 0 5.013378797660232e-15
, O 0 1.5712923875722418e-19
the O 0 1.1314042526716591e-21
first O 0 4.132478825834853e-21
during O 0 1.1599615768377049e-17
meiosis O 0 8.285986648207396e-17
followed O 0 1.2725689823469987e-18
by O 0 4.666517413343206e-22
a O 0 1.8590701705783167e-20
second O 0 1.7887935842824077e-18
mitotic O 0 2.2202682400940255e-12
expansion O 0 9.370160355091917e-14
. O 0 1.206519693180974e-12

We O 0 7.70525223486862e-12
also O 0 3.4867348944070745e-16
show O 0 9.439622477777632e-13
that O 0 2.193716692100591e-18
in O 0 3.387270277178053e-22
all O 0 1.3711159839210197e-21
informative O 0 8.744075698019016e-16
carrier O 0 3.3104175748978034e-16
father O 0 3.675221070401427e-14
to O 0 6.593098658891071e-17
affected O 0 3.1453931103995634e-15
child O 0 6.304604061035946e-11
transmissions O 0 2.428010570376671e-10
, O 0 1.8319821316298733e-18
with O 0 1.560021437803096e-20
the O 0 7.147177342375576e-21
notable O 0 1.2110689309842937e-19
exception O 0 5.1010057027037265e-20
of O 0 1.3362003186801156e-21
the O 0 1.9445729769833038e-16
premutation O 0 4.184501356530035e-10
carrier O 0 2.5061767321387903e-15
, O 0 3.1691719109955865e-20
the O 0 9.640499233621437e-21
expansion O 0 7.314948408347311e-18
size O 0 1.0298059199007406e-13
decreases O 0 1.1764275263583673e-13
. O 0 7.424710180200524e-16
. O 0 2.2598385023085005e-13

The O 0 1.5337025464399827e-15
R496H O 0 4.502479118706493e-13
mutation O 0 6.467976196002307e-15
of O 0 3.2203965179940047e-18
arylsulfatase O 0 2.0256396560114354e-10
A O 0 1.6602465794301677e-14
does O 0 3.0303664850898915e-13
not O 0 8.245674650887713e-13
cause O 0 5.201740691518353e-07
metachromatic B-Disease 1 0.9999924898147583
leukodystrophy I-Disease 1 0.9999737739562988
. O 0 3.5528460173850362e-09

Deficiency B-Disease 1 0.9992247819900513
of I-Disease 0 4.574579837961364e-16
arylsulfatase I-Disease 0 1.2749442390713739e-08
A I-Disease 0 1.1302915390752274e-13
( O 0 5.028696634122607e-17
ARSA O 0 2.9028055337221303e-07
) O 0 9.270771637231377e-17
enzyme O 0 4.59757218732558e-14
activity O 0 5.634813102228797e-11
causes O 0 5.764696311416628e-07
metachromatic B-Disease 1 0.999987006187439
leukodystrophy I-Disease 1 0.9999890327453613
( O 0 2.086053552119438e-10
MLD B-Disease 1 0.9999737739562988
) O 0 4.3541751692903474e-13
. O 0 9.569488213997945e-14

A O 0 1.3983450932819694e-14
number O 0 9.809084236268636e-17
of O 0 8.600662696834819e-17
ARSA O 0 2.5381991690665018e-06
gene O 0 3.30640950816502e-13
mutations O 0 2.4565793531870252e-14
responsible O 0 5.6158318284278e-15
for O 0 2.302403898435455e-15
MLD B-Disease 1 0.9999970197677612
have O 0 6.370323461579253e-15
been O 0 2.5224326178855804e-16
identified O 0 1.2657547908835175e-14
. O 0 1.0050567691467782e-13

Recently O 0 4.608024465474481e-12
, O 0 8.145459911790967e-17
the O 0 3.3252096073863645e-18
R496H O 0 3.2073586950405464e-14
mutation O 0 3.525427094739855e-16
of O 0 1.0175223161269923e-18
ARSA O 0 2.9690505609636375e-10
was O 0 4.692162503244593e-17
proposed O 0 7.196803029444768e-22
to O 0 5.150966119232222e-20
be O 0 1.1179176406628596e-18
a O 0 3.753783670073817e-17
cause O 0 4.967168690250823e-11
of O 0 7.846527247390434e-13
MLD B-Disease 1 0.9999997615814209
( O 0 2.4127871145392674e-16
Draghia O 0 2.0860445315573628e-11
et O 0 2.798341799167131e-13
al O 0 2.3252962055853033e-11
. O 0 6.129438726324918e-14
, O 0 4.227199661951996e-15
1997 O 0 2.8251536699652356e-15
) O 0 2.1661866009568603e-15
. O 0 1.8810700338958014e-13

We O 0 1.2314395380144671e-14
have O 0 4.325469594707564e-20
investigated O 0 3.632574516772161e-19
the O 0 4.6325216230266624e-20
R496H O 0 6.919244327717705e-16
mutation O 0 2.0319167314856766e-17
and O 0 3.09041929569422e-16
found O 0 6.005074407554783e-18
this O 0 3.092829320077729e-21
mutation O 0 2.893093402219595e-19
at O 0 9.92932552621506e-18
a O 0 3.572341680258493e-20
relatively O 0 8.255626989736622e-19
high O 0 2.5640997567477955e-17
frequency O 0 5.97332589546474e-15
in O 0 7.537162725091439e-19
an O 0 9.517632110519252e-17
African O 0 1.0142900408460775e-11
American O 0 4.23590719791922e-12
population O 0 7.558888987012433e-15
( O 0 1.7763904245874813e-18
f O 0 2.977458904429575e-11
= O 0 2.8015126839458365e-14
0 O 0 1.4289768420618942e-18
. O 0 1.3498827914190843e-16
09 O 0 1.0694413020082005e-12
, O 0 7.472990528798427e-15
n O 0 6.975289790212003e-10
= O 0 1.4157551797566725e-09
61 O 0 4.943912033233966e-13
subjects O 0 2.314959751670287e-10
) O 0 4.080970858553329e-13
. O 0 1.2913759688329418e-12

The O 0 2.0080864190441874e-14
ARSA O 0 1.905339441776732e-09
enzyme O 0 4.5206853126374125e-14
activity O 0 1.0893106281903951e-14
in O 0 2.1478259524870678e-18
subjects O 0 4.355645618486781e-13
with O 0 6.028951290264759e-16
and O 0 2.8355740810405948e-14
without O 0 9.034272262860218e-18
the O 0 3.9379345083741905e-20
R496H O 0 6.395834611642895e-17
mutation O 0 2.70190213245775e-18
was O 0 6.859380803566099e-15
determined O 0 4.936820995272073e-15
and O 0 2.674618127546254e-15
found O 0 4.610634854152428e-16
to O 0 3.272584914483139e-17
be O 0 8.270454049188222e-16
normal O 0 2.6388296726236916e-14
. O 0 3.1744219882931524e-13

It O 0 1.2152098446439885e-13
is O 0 1.281943999255491e-17
therefore O 0 2.398201129122378e-20
concluded O 0 2.591443380288351e-19
that O 0 6.551320211503703e-20
the O 0 1.4342797935713951e-18
R496H O 0 1.6884523022352854e-13
mutation O 0 2.136234457150764e-15
of O 0 1.0811082688403723e-17
ARSA O 0 1.4068679377032822e-07
does O 0 7.817032442083548e-15
not O 0 3.0409938127319593e-19
negatively O 0 5.172036735879421e-19
influence O 0 1.736572224645863e-17
the O 0 4.618921532985372e-18
activity O 0 2.70945375510645e-13
of O 0 5.015112095076833e-18
ARSA O 0 2.055827366120866e-07
and O 0 4.417714312448433e-15
is O 0 9.815132570567866e-20
not O 0 3.9870467416573926e-19
a O 0 9.767184891264865e-18
cause O 0 1.6238694416914612e-11
of O 0 3.9238570725963484e-11
MLD B-Disease 1 0.9999942779541016

Down O 0 3.677490951758955e-07
- O 0 1.2022688400392667e-10
regulation O 0 4.650693689206044e-14
of O 0 3.256195654134381e-18
transmembrane O 0 1.0440701038103017e-12
carbonic O 0 2.238553960254297e-11
anhydrases O 0 1.1833957813678353e-08
in O 0 1.3770229023073264e-14
renal B-Disease 0 2.523134298826335e-06
cell I-Disease 0 1.0587742508505471e-05
carcinoma I-Disease 1 0.9999995231628418
cell O 0 4.170942247583298e-06
lines O 0 2.837836077240752e-10
by O 0 1.998409861715195e-16
wild O 0 1.2784964198431226e-09
- O 0 0.43054816126823425
type O 0 9.952898835763335e-05
von B-Disease 1 0.9998393058776855
Hippel I-Disease 1 0.9994508624076843
- I-Disease 1 0.997892439365387
Lindau I-Disease 1 0.9978036284446716
transgenes O 0 0.0007629854371771216
. O 0 2.363113871250988e-10

To O 0 2.2645826067911297e-15
discover O 0 6.965486926802751e-15
genes O 0 9.402627932641474e-16
involved O 0 1.5628496489571847e-14
in O 0 8.119417139497431e-13
von B-Disease 1 0.9997219443321228
Hippel I-Disease 1 0.999843955039978
- I-Disease 1 0.9999700784683228
Lindau I-Disease 1 0.9999362230300903
( O 0 4.3799342624994964e-11
VHL B-Disease 0 6.130591714281763e-07
) O 0 6.70633571428264e-16
- O 0 4.016672587527255e-14
mediated O 0 2.402476817747051e-13
carcinogenesis O 0 3.3339191407577573e-09
, O 0 2.0575953624623033e-16
we O 0 1.8475924690830147e-16
used O 0 3.871231948286008e-15
renal B-Disease 0 6.2842508441463e-07
cell I-Disease 0 0.0017579100094735622
carcinoma I-Disease 1 1.0
cell O 0 0.14114344120025635
lines O 0 4.6279311050057004e-07
stably O 0 1.1062765992164714e-07
transfected O 0 2.3793780834502343e-10
with O 0 1.113187216424073e-15
wild O 0 2.0717065216113717e-11
- O 0 1.5147265912673902e-05
type O 0 2.4346451255041757e-07
VHL O 0 0.031494781374931335
- O 0 8.85934170469227e-08
expressing O 0 2.3348501951292455e-12
transgenes O 0 2.321026926210834e-09
. O 0 1.1606079324596313e-13

Large O 0 3.6113440288600227e-16
- O 0 1.0871075090471138e-12
scale O 0 4.95912447391611e-14
RNA O 0 3.202702046709721e-13
differential O 0 8.24887112029659e-16
display O 0 8.858050863214779e-17
technology O 0 2.6577218782738948e-17
applied O 0 7.293017265369116e-19
to O 0 6.949820628926809e-17
these O 0 8.807178064402686e-16
cell O 0 3.2273426552736906e-12
lines O 0 7.240336836209036e-15
identified O 0 9.36416533283132e-20
several O 0 2.0908686348768362e-22
differentially O 0 6.612467920114612e-17
expressed O 0 7.065550711203413e-22
genes O 0 5.313360414287135e-20
, O 0 7.82499985265191e-22
including O 0 1.1752351158369481e-23
an O 0 4.483539447681186e-21
alpha O 0 5.966787012870174e-16
carbonic O 0 2.064051749341763e-14
anhydrase O 0 2.7284537205529008e-14
gene O 0 1.8798341958850984e-15
, O 0 1.6356715754737872e-16
termed O 0 8.944860368891028e-13
CA12 O 0 6.250718911360309e-07
. O 0 1.5807790189684146e-12

The O 0 1.8750052014957976e-17
deduced O 0 7.05267372212953e-16
protein O 0 7.596202058888406e-16
sequence O 0 6.002993303851661e-17
was O 0 1.849686030126162e-17
classified O 0 3.1189825205337784e-18
as O 0 4.632294665346093e-19
a O 0 9.547408792773814e-18
one O 0 7.910417655111746e-14
- O 0 1.2626847819774412e-05
pass O 0 2.136768273430789e-07
transmembrane O 0 1.385890527672018e-06
CA O 0 1.0529677574311336e-08
possessing O 0 2.1320487644325682e-16
an O 0 1.4066885638542295e-18
apparently O 0 1.770909460740988e-11
intact O 0 8.64326310718623e-15
catalytic O 0 1.2356261201172577e-16
domain O 0 1.60244013831844e-14
in O 0 3.806747631105281e-18
the O 0 1.3759548956694902e-17
extracellular O 0 2.021541822827544e-09
CA O 0 2.213749439761159e-06
module O 0 4.370258377406344e-09
. O 0 6.711413109289355e-13

Reintroduced O 0 1.8490849476582305e-11
wild O 0 2.809597346442594e-11
- O 0 4.342343231655832e-07
type O 0 4.5258022329797143e-10
VHL B-Disease 0 6.618112280420974e-08
strongly O 0 5.196252787455962e-15
inhibited O 0 1.3555338246662506e-15
the O 0 4.844926611681677e-19
overexpression O 0 1.6409659284408206e-15
of O 0 1.543912580049766e-20
the O 0 3.077685218259339e-19
CA12 O 0 1.8502755751159672e-13
gene O 0 1.5937801714038967e-18
in O 0 6.539607124003625e-21
the O 0 6.700831323614467e-18
parental O 0 2.1814164483657805e-06
renal B-Disease 0 8.54722259191476e-07
cell I-Disease 0 1.1051667570427526e-05
carcinoma I-Disease 1 0.9999996423721313
cell O 0 0.09321427345275879
lines O 0 5.5538315791636705e-05
. O 0 1.1867246074714899e-09

Similar O 0 5.6008376511955046e-14
results O 0 4.7640176978236046e-17
were O 0 5.023055303704026e-19
obtained O 0 9.503245413074454e-21
with O 0 5.769911508899326e-19
CA9 O 0 1.3699772653114062e-12
, O 0 3.838928097634982e-20
encoding O 0 9.228249425226354e-18
another O 0 2.5005615389732047e-15
transmembrane O 0 2.387875175369203e-10
CA O 0 1.8671331147857018e-09
with O 0 2.1841130217912737e-19
an O 0 7.140098970465852e-19
intact O 0 3.876935231184042e-12
catalytic O 0 9.878794830775472e-14
domain O 0 2.980447832978683e-11
. O 0 4.650458837462956e-12

Although O 0 5.471425416415151e-15
both O 0 4.0843379158482897e-19
domains O 0 1.3891571151448652e-15
of O 0 6.0175854755455565e-21
the O 0 5.649422571417263e-20
VHL B-Disease 0 7.272976573205123e-14
protein O 0 8.582267171948859e-19
contribute O 0 5.211800891200236e-21
to O 0 7.397667503578379e-20
regulation O 0 8.074859715637321e-17
of O 0 2.112334113944255e-18
CA12 O 0 1.7530593643400039e-09
expression O 0 3.596346887012412e-15
, O 0 3.943453547894024e-19
the O 0 3.878522260877569e-21
elongin O 0 8.013041456495645e-14
binding O 0 2.7688498547140253e-16
domain O 0 4.244495813848781e-12
alone O 0 2.5976609752120794e-10
could O 0 3.341745935484951e-15
effectively O 0 5.532039263527258e-14
regulate O 0 4.2654014001386464e-12
CA9 O 0 2.7435444280854426e-06
expression O 0 4.057676972202273e-10
. O 0 1.1954859845120236e-11

We O 0 2.2424362442884788e-13
mapped O 0 2.7206991867756436e-11
CA12 O 0 1.12688304909625e-07
and O 0 3.1220719640210476e-14
CA9 O 0 3.0223865077338985e-11
loci O 0 1.1889034068758401e-14
to O 0 1.5545897436445633e-15
chromosome O 0 7.420258851809081e-10
bands O 0 1.0976764636128067e-10
15q22 O 0 2.329602136197373e-11
and O 0 1.2025736716115773e-14
17q21 O 0 9.073137206827564e-12
. O 0 1.7711904466417676e-14

2 O 0 1.2739006897966032e-13
respectively O 0 1.0250512359766002e-14
, O 0 8.296741319659565e-17
regions O 0 1.1197167393045722e-14
prone O 0 6.474144953472205e-08
to O 0 4.664378565260121e-16
amplification O 0 5.712224963871915e-12
in O 0 4.338212312043944e-19
some O 0 1.1391711159242205e-18
human O 0 9.354803986571375e-14
cancers B-Disease 0 4.570360090383474e-08
. O 0 2.5664924829457703e-13

Additional O 0 1.3029615832856671e-17
experiments O 0 4.286299776484065e-14
are O 0 1.3293598117643781e-17
needed O 0 7.208353261722782e-19
to O 0 1.1563023366029234e-19
define O 0 5.844036321643061e-17
the O 0 2.388606544875102e-19
role O 0 1.1089451907209287e-14
of O 0 3.190781384113075e-17
CA O 0 3.281295374302218e-11
IX O 0 2.75610860089176e-13
and O 0 1.7871007408284956e-12
CA O 0 3.4220570821474894e-11
XII O 0 4.987246560688016e-15
enzymes O 0 6.086673541595485e-17
in O 0 2.603065267894721e-19
the O 0 2.9552149040367536e-17
regulation O 0 8.968090078062887e-14
of O 0 2.963150543961342e-17
pH O 0 1.5101474237777524e-10
in O 0 1.2644046159970466e-20
the O 0 1.8790336576744012e-20
extracellular O 0 5.276574804261719e-14
microenvironment O 0 1.7173749922161363e-10
and O 0 9.622268022787487e-15
its O 0 5.636079889642841e-19
potential O 0 5.4400533873091054e-18
impact O 0 4.8294480978668554e-18
on O 0 3.1876427495844406e-13
cancer B-Disease 0 1.5700592215228681e-10
cell O 0 1.9548342111708195e-11
growth O 0 4.1873673446842993e-14
. O 0 1.6861912409562143e-15

A O 0 2.270020505372943e-17
gene O 0 5.02963449150112e-18
encoding O 0 2.981335530701892e-18
a O 0 9.585132416308083e-20
transmembrane O 0 1.024280150120979e-16
protein O 0 7.490935715879398e-17
is O 0 2.039625119046603e-20
mutated O 0 5.684086060954907e-16
in O 0 4.627389298198016e-17
patients O 0 7.195051303886257e-13
with O 0 1.5035435119159501e-09
diabetes B-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999998807907104
and O 0 7.742982433001089e-08
optic B-Disease 1 0.9999024868011475
atrophy I-Disease 1 0.8964501023292542
( O 0 1.046176811847488e-09
Wolfram B-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999996423721313
) O 0 4.994298377636319e-12
. O 0 2.662329178729911e-13

Wolfram B-Disease 1 0.9999682903289795
syndrome I-Disease 1 0.9999991655349731
( O 0 4.162246991512575e-09
WFS B-Disease 0 6.917894643265754e-05
; O 0 2.958864436016645e-13
OMIM O 0 9.517271415404593e-09
222300 O 0 1.9056273486278696e-12
) O 0 8.511103521041457e-17
is O 0 6.520215444246778e-17
an O 0 1.0159153927173994e-13
autosomal B-Disease 1 0.9999972581863403
recessive I-Disease 1 0.9999961853027344
neurodegenerative I-Disease 1 0.9999910593032837
disorder I-Disease 1 0.9997097849845886
defined O 0 1.72920176983761e-13
by O 0 9.19575284076882e-16
young O 0 3.6678896031538955e-10
- O 0 2.3480304207623703e-06
onset O 0 0.0002913153439294547
non O 0 1.5242350714927966e-09
- O 0 2.482574700479745e-06
immune O 0 8.015135790628847e-06
insulin B-Disease 0 0.00042327240225858986
- I-Disease 0 0.008477391675114632
dependent I-Disease 0 6.766440492356196e-05
diabetes I-Disease 1 0.9999995231628418
mellitus I-Disease 1 0.9999990463256836
and O 0 1.5846770076710648e-11
progressive O 0 1.265337418177026e-10
optic B-Disease 0 0.0022580481600016356
atrophy I-Disease 0 4.5409356062009465e-06
. O 0 1.34187127555363e-12

Linkage O 0 3.963873500267834e-12
to O 0 4.327623941118025e-16
markers O 0 3.998286077222524e-12
on O 0 1.5464542840737394e-11
chromosome O 0 1.8416718603475601e-06
4p O 0 6.305806437012507e-06
was O 0 6.3698473579121284e-12
confirmed O 0 7.861503196473704e-14
in O 0 8.45163353633808e-18
five O 0 9.318185735822035e-15
families O 0 1.545043254577369e-13
. O 0 1.0103996835714689e-14

On O 0 6.626030638135828e-16
the O 0 5.574857409074436e-20
basis O 0 4.7010958651595887e-20
of O 0 3.714760855989957e-20
meiotic O 0 3.331838693831912e-10
recombinants O 0 5.33564116267371e-06
and O 0 5.195581742611921e-10
disease O 0 5.735731534173283e-08
- O 0 1.4844835583005533e-08
associated O 0 5.5758404837735753e-11
haplotypes O 0 5.4677076199993735e-09
, O 0 3.5344223199418995e-16
the O 0 1.1251951756921011e-18
WFS B-Disease 0 9.294936375485799e-14
gene O 0 4.725857064431966e-19
was O 0 2.7730754406988035e-18
localized O 0 1.0641523070539541e-17
to O 0 6.719363064467799e-18
a O 0 8.563700296599009e-17
BAC O 0 4.439245498977229e-11
/ O 0 4.365828011609896e-12
P1 O 0 2.2600585847243337e-09
contig O 0 8.069152984679917e-12
of O 0 3.1117759162420633e-21
less O 0 1.9858440005051644e-20
than O 0 1.5268279076675647e-20
250 O 0 1.0960150354157977e-18
kb O 0 1.3921918305681569e-11
. O 0 3.0405548684300093e-14

Mutations O 0 2.735847312584916e-11
in O 0 7.929171239849664e-16
a O 0 8.339386781575859e-17
novel O 0 6.572815157949866e-15
gene O 0 6.777753813920484e-13
( O 0 1.2151893326823796e-16
WFS1 O 0 6.5994562245541566e-12
) O 0 4.073428631414937e-20
encoding O 0 4.2401737026214224e-20
a O 0 1.6306343893402814e-20
putative O 0 1.5710318178210718e-15
transmembrane O 0 1.1887259322975667e-15
protein O 0 7.26659485757392e-15
were O 0 1.1801496972368373e-16
found O 0 1.2467426665438068e-17
in O 0 1.2777921787820479e-20
all O 0 1.817872167459005e-17
affected O 0 2.8710953093105716e-18
individuals O 0 5.188396041950247e-20
in O 0 4.392384060167312e-18
six O 0 6.158054887414957e-14
WFS B-Disease 0 1.5357620730682697e-09
families O 0 1.8964986373860848e-14
, O 0 4.452183841780914e-19
and O 0 3.604061663096004e-17
these O 0 1.5709514340635051e-18
mutations O 0 1.8633178011849133e-18
were O 0 2.4865274620060933e-18
associated O 0 1.2186925635517062e-19
with O 0 2.617723166843102e-19
the O 0 4.177536426188582e-15
disease O 0 5.012323445185984e-09
phenotype O 0 8.728242737940373e-13
. O 0 7.326580883865522e-14

WFS1 O 0 1.1418765488713234e-08
appears O 0 1.1172474620804729e-12
to O 0 4.884698799701722e-18
function O 0 7.929283041581256e-18
in O 0 7.625459602590529e-18
survival O 0 2.7021912485380994e-10
of O 0 5.712967878543293e-19
islet O 0 5.79163716984965e-10
beta O 0 6.194955030729143e-13
- O 0 9.532054034977477e-10
cells O 0 1.1243549223171473e-13
and O 0 5.437841830605939e-15
neurons O 0 3.0211224714881617e-16
. O 0 4.946937109761131e-18
. O 0 5.678754517947533e-16

Stable O 0 7.734564399543287e-13
interaction O 0 1.5297460026037987e-16
between O 0 1.29121007647731e-17
the O 0 2.1771256720606734e-19
products O 0 2.8357104665799925e-17
of O 0 5.905985765046047e-23
the O 0 1.214732743330664e-20
BRCA1 O 0 1.5381886235110546e-14
and O 0 4.187091381350084e-16
BRCA2 O 0 3.756165487016827e-15
tumor B-Disease 0 3.297498998963195e-16
suppressor O 0 2.1908680822486665e-15
genes O 0 5.349202651707304e-17
in O 0 1.383421123521152e-20
mitotic O 0 1.253335271938355e-13
and O 0 9.91128921691781e-15
meiotic O 0 6.578521755118416e-11
cells O 0 1.293106854233228e-11
. O 0 2.353701218302251e-12

BRCA1 O 0 1.317715536686137e-08
and O 0 5.801161200719163e-12
BRCA2 O 0 7.862632528561619e-13
account O 0 7.867457081057205e-18
for O 0 1.2029174598469475e-22
most O 0 1.2160907049012183e-21
cases O 0 1.243672771815954e-19
of O 0 1.6782162779057429e-21
familial O 0 9.518849467329837e-13
, O 0 2.436975000615951e-17
early O 0 1.6333778896619614e-15
onset O 0 9.491515212678436e-12
breast B-Disease 0 4.2306996306251676e-07
and I-Disease 0 1.7334157575987774e-07
/ I-Disease 0 0.0003899302682839334
or I-Disease 0 0.197096586227417
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 0 2.9202077602456724e-16
encode O 0 6.809571039374616e-19
products O 0 6.070855945768063e-18
that O 0 1.907807870374204e-21
each O 0 9.997179978235603e-23
interact O 0 2.5594454492553857e-19
with O 0 4.735570625685661e-17
hRAD51 O 0 1.0309464393287726e-08
. O 0 1.1635182021411256e-13

Results O 0 3.571260735730055e-15
presented O 0 8.440650893909091e-17
here O 0 9.494378036907886e-19
show O 0 6.367478066151189e-16
that O 0 8.36227835879341e-20
BRCA1 O 0 1.1388649355167924e-14
and O 0 3.086558583048106e-14
BRCA2 O 0 4.763429668069863e-12
coexist O 0 1.3101394968906277e-12
in O 0 1.1820621787503738e-20
a O 0 2.252919973094966e-19
biochemical O 0 1.424902879606886e-14
complex O 0 1.117906010503447e-16
and O 0 2.1442949412614487e-13
colocalize O 0 2.7560773663282134e-09
in O 0 7.53354809057119e-17
subnuclear O 0 3.0797253636194455e-10
foci O 0 1.0389772375773987e-11
in O 0 1.117187550374705e-20
somatic O 0 8.133373314116465e-19
cells O 0 6.232224407616439e-18
and O 0 2.734815235440929e-18
on O 0 4.247886443220322e-17
the O 0 1.4222219042340272e-19
axial O 0 3.594550330131285e-15
elements O 0 9.06428422175077e-15
of O 0 3.2818469385199566e-18
developing O 0 8.260207068108813e-16
synaptonemal O 0 2.3377866482932053e-12
complexes O 0 1.0078051369507342e-14
. O 0 8.576393244132292e-15

Like O 0 7.0909471599611e-14
BRCA1 O 0 4.574467107193447e-12
and O 0 2.811631407296372e-13
RAD51 O 0 1.3790187880502458e-09
, O 0 2.9483347465737825e-17
BRCA2 O 0 2.924781388759755e-14
relocates O 0 2.4064104387541002e-14
to O 0 2.0930855135566664e-16
PCNA O 0 1.1098732599634786e-08
+ O 0 6.7283507358564896e-15
replication O 0 1.7268895858850073e-15
sites O 0 8.16229577687861e-15
following O 0 1.361270249422412e-15
exposure O 0 2.1693808045526036e-13
of O 0 1.5389498194918745e-20
S O 0 5.809836932293283e-14
phase O 0 1.2048384030465654e-20
cells O 0 5.491126213127469e-21
to O 0 2.2586412195004772e-20
hydroxyurea O 0 9.077739975392614e-16
or O 0 5.574650562222509e-18
UV O 0 8.188188625399273e-13
irradiation O 0 3.9720881613155776e-14
. O 0 8.331891254676708e-15

Thus O 0 2.4674693169766948e-14
, O 0 1.014116648108989e-17
BRCA1 O 0 6.9665766346893934e-15
and O 0 1.8705348329154303e-15
BRCA2 O 0 7.270091917799953e-14
participate O 0 2.2539366401063395e-17
, O 0 3.189578531153525e-16
together O 0 1.024942825923747e-12
, O 0 3.0655361064100427e-18
in O 0 1.1324756898640175e-20
a O 0 1.631650257605376e-18
pathway O 0 3.491811332266559e-13
( O 0 1.0000952948340598e-15
s O 0 1.378477776370346e-08
) O 0 7.8929185274922e-18
associated O 0 1.0545456149504617e-19
with O 0 8.614853965307031e-23
the O 0 4.9799643520568094e-23
activation O 0 6.8213221739516975e-19
of O 0 6.75059432185755e-21
double O 0 5.925036123625299e-14
- O 0 1.3222392070133537e-09
strand O 0 1.928907664705548e-07
break O 0 1.417675008497099e-07
repair O 0 8.327531553220524e-09
and O 0 3.4422503122040547e-16
/ O 0 1.67399412533443e-16
or O 0 2.879252537996566e-20
homologous O 0 1.0184864447617596e-16
recombination O 0 2.460482176076112e-13
. O 0 4.2463455711752585e-14

Dysfunction O 0 2.895751322284923e-06
of O 0 4.767908424552809e-17
this O 0 2.1730526864232506e-18
pathway O 0 1.4507134981690296e-14
may O 0 5.4921514656015163e-14
be O 0 1.4153808620742723e-19
a O 0 3.498610483994181e-21
general O 0 3.627419630592307e-21
phenomenon O 0 3.4510778566462785e-13
in O 0 5.674183054661422e-17
the O 0 1.5921298203504003e-15
majority O 0 6.311466159629426e-17
of O 0 2.159728674373748e-20
cases O 0 6.139140615232989e-17
of O 0 2.8560317299705215e-18
hereditary B-Disease 0 3.5391505662119016e-05
breast I-Disease 1 0.9880430698394775
and I-Disease 0 0.0011588301276788116
/ I-Disease 0 0.015897691249847412
or I-Disease 0 0.009484851732850075
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999996542930603
. O 0 2.8099679362319184e-14
. O 0 5.52509765911792e-15

A O 0 1.0864125219020235e-13
novel O 0 1.588164278906734e-13
Arg362Ser O 0 1.3181691849162291e-10
mutation O 0 7.840086984841916e-15
in O 0 1.12724509468613e-17
the O 0 2.8889163779406284e-17
sterol O 0 8.066679269003174e-11
27 O 0 7.369818866504244e-14
- O 0 9.194265140899383e-12
hydroxylase O 0 7.40968009171894e-10
gene O 0 9.848617418557054e-14
( O 0 3.2076089261093943e-18
CYP27 O 0 7.136670421292735e-11
) O 0 3.356024938977078e-17
: O 0 3.9944453552487966e-19
its O 0 6.9024105601533e-20
effects O 0 2.3779449105623293e-17
on O 0 1.8704616638271663e-17
pre O 0 5.841788772657081e-16
- O 0 7.329697038669131e-18
mRNA O 0 1.3558782709451238e-18
splicing O 0 1.4784793864107914e-15
and O 0 5.012625176565192e-18
enzyme O 0 2.9749621040821707e-18
activity O 0 2.1583247852475807e-16
. O 0 1.2220227709843536e-16

A O 0 5.721182398275501e-14
novel O 0 1.0489918937824083e-13
C O 0 3.4631500445136965e-10
to O 0 5.855972620600262e-18
A O 0 1.7611021002750006e-17
mutation O 0 7.685471556031251e-18
in O 0 1.0723875517964095e-18
the O 0 7.575912311079215e-17
sterol O 0 2.829658451997119e-10
27 O 0 2.7219890295741844e-13
- O 0 3.97785658579064e-11
hydroxylase O 0 2.3551161021373446e-08
gene O 0 3.434538244084795e-12
( O 0 3.3255790676069613e-17
CYP27 O 0 6.936131790452604e-12
) O 0 1.0549318695224327e-19
was O 0 1.0441614771149808e-20
identified O 0 1.3785205479217862e-22
by O 0 5.6664407358831776e-24
sequencing O 0 3.344573450576894e-17
amplified O 0 6.174503183048463e-12
CYP27 O 0 6.612557181505385e-13
gene O 0 1.235568945393318e-17
products O 0 3.168947124664125e-17
from O 0 2.5749746747347535e-21
a O 0 9.73065061127978e-21
patient O 0 4.177696091899139e-15
with O 0 9.504196041287827e-12
cerebrotendinous B-Disease 1 0.9999983310699463
xanthomatosis I-Disease 1 0.9999949932098389
( O 0 1.9281910527339623e-14
CTX B-Disease 0 6.02821437212242e-09
) O 0 2.211574861435482e-15
. O 0 8.922734851869209e-15

The O 0 2.748843730593267e-16
mutation O 0 1.4611431630793376e-15
changed O 0 8.99161811223877e-15
the O 0 1.5147907818560416e-19
adrenodoxin O 0 2.876676015992931e-14
cofactor O 0 2.292683136574528e-16
binding O 0 3.4605774582046776e-16
residue O 0 2.0070622681195305e-12
362Arg O 0 8.918455709182316e-13
to O 0 2.487326807991034e-16
362Ser O 0 3.3967738344298226e-11
( O 0 1.0008838882982179e-18
CGT O 0 8.732784325315643e-14
362Arg O 0 2.1360543542292554e-12
to O 0 5.377990522257619e-17
AGT O 0 3.08922505631859e-11
362Ser O 0 1.6199847019393587e-10
) O 0 1.6449134990217197e-16
, O 0 1.0154981017704985e-18
and O 0 2.2046813847102876e-18
was O 0 1.2476988873319181e-17
responsible O 0 6.311607690232234e-18
for O 0 4.65081720381511e-18
deficiency O 0 3.6490352406381987e-10
in O 0 8.165536337959675e-22
the O 0 8.742931806493529e-18
sterol O 0 7.437850682578961e-12
27 O 0 3.9041384371330087e-16
- O 0 1.585354806145963e-14
hydroxylase O 0 9.860808350414807e-12
activity O 0 2.5979120943923255e-15
, O 0 6.282867710208211e-21
as O 0 7.848706574357867e-22
confirmed O 0 7.74199112707638e-20
by O 0 1.4505866140630024e-21
expression O 0 1.2671200954979282e-17
of O 0 1.0373447495415909e-20
mutant O 0 2.544953900464092e-15
cDNA O 0 5.751464249656316e-15
into O 0 1.237240527857033e-14
COS O 0 9.956485635953527e-10
- O 0 1.0842492675173718e-13
1 O 0 1.238503513372957e-18
cells O 0 1.7321601425201788e-16
. O 0 1.6010279014613067e-15

Quantitative O 0 9.680665692896398e-14
analysis O 0 1.531131992027479e-13
showed O 0 5.138446525915219e-12
that O 0 4.947616225044037e-18
the O 0 1.1212190218851353e-18
expression O 0 2.3329589179417595e-15
of O 0 1.4352321886491734e-18
CYP27 O 0 1.6833541505167915e-11
gene O 0 4.857349478954698e-17
mRNA O 0 9.856199252819575e-16
in O 0 2.2402118939467372e-18
the O 0 3.3799714454792126e-18
patient O 0 1.3737431272080867e-15
represented O 0 9.01086718742803e-18
52 O 0 8.891241828077115e-14
. O 0 1.3906219654535174e-13

5 O 0 8.266926726507862e-11
% O 0 1.3090315676312237e-14
of O 0 3.371895267568551e-19
the O 0 3.546484598506393e-15
normal O 0 1.1170136864080416e-11
level O 0 2.577405129600141e-11
. O 0 1.292470037245197e-12

As O 0 1.5400099243421527e-16
the O 0 3.5986179771450347e-19
mutation O 0 2.966611467644264e-17
occurred O 0 5.982718643816843e-16
at O 0 1.9309327852259166e-18
the O 0 2.7909532290388396e-21
penultimate O 0 2.0158898424196657e-16
nucleotide O 0 4.2171451029354015e-17
of O 0 1.3992967228040908e-19
exon O 0 5.614568055270497e-15
6 O 0 1.650408630560988e-14
( O 0 3.590789798321774e-18
- O 0 3.039126025491945e-12
2 O 0 4.3950027650941444e-16
position O 0 2.3115122554755174e-15
of O 0 6.711773863293384e-20
exon O 0 1.0180291634372726e-14
6 O 0 4.076563322612291e-15
- O 0 3.1423876088038094e-12
intron O 0 8.157398645458613e-10
6 O 0 8.563186306418703e-15
splice O 0 1.2587617614912006e-09
site O 0 2.362085527174429e-11
) O 0 5.714065733331789e-16
of O 0 2.2662434455383657e-21
the O 0 2.247228065751806e-20
gene O 0 2.762887470684294e-17
, O 0 1.0782328235950155e-18
we O 0 9.261355183744075e-20
hypothesized O 0 3.243460484821091e-20
that O 0 1.2604568868301144e-18
the O 0 4.069383183137094e-16
mutation O 0 7.272929220675239e-12
may O 0 1.058560739064518e-10
partially O 0 7.499761228713098e-12
affect O 0 3.6925022260033975e-16
the O 0 8.025253957966336e-20
normal O 0 2.5211299262940467e-19
splicing O 0 3.653634531031858e-16
efficiency O 0 3.614055080230441e-18
in O 0 7.518313451896051e-22
exon O 0 8.330866159522073e-17
6 O 0 9.77785611673684e-16
and O 0 8.525795836907175e-16
cause O 0 1.807629934396312e-18
alternative O 0 8.791518534518516e-20
splicing O 0 6.573899953045415e-13
elsewhere O 0 4.2145483609111467e-13
, O 0 1.5173137757821472e-17
which O 0 1.9983107323905868e-16
resulted O 0 8.855960809417429e-16
in O 0 1.5826876793895606e-17
decreased O 0 4.305645670186174e-14
transcript O 0 3.331820496582649e-13
in O 0 9.015199959476583e-18
the O 0 3.870196768145345e-16
patient O 0 6.766984542161403e-12
. O 0 1.0624002220495365e-13

Transfection O 0 9.10381103835789e-10
of O 0 1.3406813666339424e-16
constructed O 0 3.214726526428943e-14
minigenes O 0 3.8868628315924525e-09
, O 0 9.880178755556344e-16
with O 0 3.5313629428155354e-16
or O 0 1.4312562636800696e-12
without O 0 2.113038459890205e-15
the O 0 1.0013196677244261e-17
mutation O 0 8.06703988099849e-17
, O 0 4.656871338718386e-18
into O 0 1.284362807715494e-16
COS O 0 1.451337161562094e-09
- O 0 3.5983114952302733e-14
1 O 0 3.4945440511781735e-20
cells O 0 5.611452137867723e-19
confirmed O 0 2.4196881665845116e-18
that O 0 9.268070210107386e-20
the O 0 1.4099164293995645e-19
mutant O 0 6.120306626951344e-13
minigene O 0 6.880300365899594e-13
was O 0 2.2080828754661975e-17
responsible O 0 5.606762670029401e-20
for O 0 7.740262181261496e-24
a O 0 8.933908064226073e-22
mRNA O 0 5.310128955676014e-16
species O 0 8.72174274792237e-19
alternatively O 0 1.743418099773783e-14
spliced O 0 2.6048834911307495e-07
at O 0 3.284829819174412e-13
an O 0 2.4652942009709516e-19
activated O 0 6.920178406005784e-13
cryptic O 0 8.03426075668412e-12
5 O 0 1.1797574151031401e-17
splice O 0 2.2249591058454143e-10
site O 0 2.321307902841685e-11
88 O 0 5.949697911401082e-15
bp O 0 7.08992919576509e-15
upstream O 0 2.145061599252338e-15
from O 0 3.6391245257731466e-17
the O 0 2.330092677562259e-17
3 O 0 6.490637715473148e-16
end O 0 9.78271215662345e-15
of O 0 1.4389591284472135e-19
exon O 0 1.8196043630180903e-12
6 O 0 1.468975115159754e-12
. O 0 5.187306205238496e-13

Our O 0 1.1090007899635865e-13
data O 0 6.755399436007855e-17
suggest O 0 9.03589668014715e-17
that O 0 2.518698015293141e-19
the O 0 1.0024351621394845e-18
C O 0 1.1634877089550244e-12
to O 0 3.4732685780823975e-19
A O 0 6.583817423584527e-19
mutation O 0 7.775405346414401e-20
at O 0 5.706302870757647e-19
the O 0 4.194832360780341e-22
penultimate O 0 2.2691979569718204e-17
nucleotide O 0 1.269369137544914e-18
of O 0 6.212702760983254e-21
exon O 0 5.43904260568779e-16
6 O 0 4.910692040552527e-16
of O 0 2.5075377655544092e-20
the O 0 3.173640878331996e-17
CYP27 O 0 3.8743130231777556e-11
gene O 0 2.4422527437962843e-16
not O 0 1.487008161156695e-16
only O 0 5.476049909423152e-19
causes O 0 5.388084184550224e-13
the O 0 6.162804641607345e-13
deficiency B-Disease 0 1.2903527704111184e-06
in I-Disease 0 1.4757152867069194e-19
the I-Disease 0 8.419233533488868e-17
sterol I-Disease 0 3.1579631271094755e-11
27 I-Disease 0 1.2495387686248076e-15
- I-Disease 0 4.1356868152537044e-14
hydroxylase I-Disease 0 9.471681078343508e-11
activity I-Disease 0 5.406727583007198e-13
, O 0 1.7420601047890094e-16
but O 0 2.6690327922920592e-15
also O 0 1.8357414722993022e-15
partially O 0 1.833902631533449e-13
leads O 0 2.7559399807194612e-17
to O 0 3.8924144361479706e-19
alternative O 0 1.4519286225184031e-18
pre O 0 1.1634465939757647e-14
- O 0 4.205435732707448e-16
mRNA O 0 3.53872398999942e-17
splicing O 0 3.403097844755648e-14
of O 0 4.3522498901563953e-20
the O 0 1.3018323576724403e-19
gene O 0 7.132270466974201e-16
. O 0 4.626985766407988e-16

To O 0 3.211037528537061e-14
our O 0 1.9350872138256805e-15
knowledge O 0 1.789947087646613e-18
, O 0 2.251201505372387e-19
this O 0 4.978525861040695e-21
is O 0 4.6477091114375334e-20
the O 0 2.5340502289681835e-19
first O 0 1.1858448026670404e-16
report O 0 4.838211431255977e-16
regarding O 0 6.422845491442293e-19
effects O 0 3.359036471976812e-16
on O 0 1.0991521716556448e-16
pre O 0 3.165277420594595e-15
- O 0 2.0381272035247248e-17
mRNA O 0 1.5050401318916313e-18
splicing O 0 3.421293340660444e-15
of O 0 4.545397451760451e-21
a O 0 2.319649505526671e-21
mutation O 0 4.2753372797080223e-20
at O 0 2.9307954156603612e-18
the O 0 2.8172822473803218e-18
- O 0 6.807737967101657e-12
2 O 0 5.000388594502022e-16
position O 0 1.3202348489080827e-14
of O 0 2.087435835334741e-20
a O 0 2.2662728395306798e-18
5 O 0 6.3134378273375076e-18
splice O 0 3.7471177272152545e-09
site O 0 2.9214256014320483e-10
. O 0 9.49813903743102e-13

ATM O 0 2.7389308598912976e-09
germline O 0 3.730514230859683e-10
mutations O 0 3.653169780570842e-11
in O 0 1.072112098534847e-13
classical O 0 0.0012381849810481071
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.999998927116394
telangiectasia I-Disease 1 0.9999997615814209
patients O 0 8.804576282273047e-06
in O 0 4.213290110408659e-15
the O 0 8.497390481141884e-15
Dutch O 0 1.0079193035750222e-09
population O 0 1.9478850346257457e-15
. O 0 1.0282392138801812e-14

Germline O 0 1.822781925397976e-09
mutations O 0 1.2331854287728206e-11
in O 0 1.5338297602007485e-17
the O 0 4.5977341546248327e-20
ATM O 0 1.36715149563673e-14
gene O 0 1.583823067498351e-17
are O 0 1.6362914888586415e-21
responsible O 0 4.9818335333592704e-20
for O 0 6.205390565147642e-19
the O 0 4.6587690150090566e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999974966049194
telangiectasia I-Disease 1 0.9999997615814209
( O 0 4.222716597723775e-06
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999983310699463
T I-Disease 1 0.9999995231628418
) O 0 3.521818687374223e-12
. O 0 2.2872999880848427e-14

In O 0 1.9463348033960104e-13
our O 0 2.0953175988974032e-13
study O 0 1.4819214677465399e-18
, O 0 1.252180324416062e-18
we O 0 1.0153321073010744e-17
have O 0 3.673148016623571e-21
determined O 0 6.744468419342612e-21
the O 0 2.1237465903580203e-22
ATM O 0 1.6806343236573998e-14
mutation O 0 2.600904000050485e-17
spectrum O 0 2.8630391243553155e-15
in O 0 2.033715683881857e-17
19 O 0 2.835268355086195e-16
classical O 0 2.7532595647805636e-10
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999990463256836
T I-Disease 1 0.9999998807907104
patients O 0 1.2173289643769235e-15
, O 0 6.119202245952803e-23
including O 0 1.0302009676521889e-24
some O 0 3.04376174263265e-23
immigrant O 0 2.0316852863502843e-16
populations O 0 4.6349153182832683e-17
, O 0 1.356395000334028e-19
as O 0 9.587916654551148e-19
well O 0 4.143852930196263e-17
as O 0 4.1976464706640565e-16
12 O 0 2.6606752770201786e-16
of O 0 6.102080876518597e-19
Dutch O 0 2.0827367608333702e-11
ethnic O 0 1.872201178809707e-12
origin O 0 3.759250940052472e-13
. O 0 1.5249299490250473e-13

Both O 0 4.857293892417534e-17
the O 0 2.6478036932161696e-18
protein O 0 1.785830479398816e-15
truncation O 0 8.368722381746352e-13
test O 0 1.1484837603506493e-12
( O 0 1.0486726972248205e-19
PTT O 0 5.819178147160875e-13
) O 0 9.417837567262282e-18
and O 0 8.25465091661381e-19
the O 0 4.933283160891558e-22
restriction O 0 6.885001639433327e-20
endonuclease O 0 3.4841304798525043e-15
fingerprinting O 0 5.4570870120906195e-14
( O 0 9.03780445332279e-22
REF O 0 1.7439951780267915e-16
) O 0 3.3994102154206803e-23
method O 0 4.3731673814550434e-21
were O 0 6.314828628139939e-20
used O 0 9.014610179699833e-19
and O 0 5.052328191606512e-17
compared O 0 2.041501138826479e-20
for O 0 1.126638572365972e-25
their O 0 5.566628153475044e-22
detection O 0 1.2022718813256636e-20
efficiency O 0 6.431928796887758e-23
, O 0 1.7048748484881382e-25
identifying O 0 9.75265458492597e-20
76 O 0 6.7956390431125386e-18
% O 0 6.86939248278051e-20
and O 0 1.2042079369800097e-14
60 O 0 2.2140314687407563e-15
% O 0 6.701083200110989e-19
of O 0 3.173961278664333e-21
the O 0 1.1965322408790215e-16
mutations O 0 3.9340499445334604e-14
, O 0 6.6453228723007286e-15
respectively O 0 4.7801901190613547e-14
. O 0 4.831054176493432e-13

Most O 0 6.116912485463566e-16
patients O 0 1.2506547345328151e-15
were O 0 1.0755760683600054e-16
found O 0 2.9362466599741776e-17
to O 0 3.002955136781884e-17
be O 0 1.2445954049352927e-16
compound O 0 4.473202339680231e-14
heterozygote O 0 4.4244837828222305e-12
. O 0 4.5492469248056486e-14

Seventeen O 0 7.602729557021348e-11
mutations O 0 2.6236546030351804e-13
were O 0 8.043176178253522e-14
distinct O 0 1.971109195731801e-15
, O 0 9.661808367798265e-15
of O 0 1.992638721843086e-17
which O 0 9.059557574617183e-13
10 O 0 5.182946429250189e-16
were O 0 4.878560798610501e-15
not O 0 5.161426434906538e-14
reported O 0 1.314775653800393e-12
previously O 0 1.6122145935978938e-13
. O 0 6.858498144413083e-13

Mutations O 0 1.0711315731951054e-12
are O 0 1.5833217960471438e-17
small O 0 9.218464705760464e-19
deletions O 0 5.6664777037251923e-11
or O 0 5.007793735245514e-09
point O 0 3.890294753006174e-10
mutations O 0 1.6266408359166817e-11
frequently O 0 2.1878003575448446e-10
affecting O 0 6.238447800878399e-13
splice O 0 2.805318501941656e-07
sites O 0 3.648315072268815e-08
. O 0 1.5498093086652176e-10

Moreover O 0 1.4471064971322e-11
, O 0 9.866468468513849e-16
a O 0 2.230790703816452e-16
16 O 0 1.3399874878314635e-14
. O 0 8.183032159866932e-14

7 O 0 1.1137963381452343e-12
- O 0 1.0908092137884573e-11
kb O 0 5.551769547557095e-12
genomic O 0 9.975763704678231e-13
deletion O 0 7.403969104480268e-11
of O 0 1.9838633281606336e-17
the O 0 7.370328150357736e-17
3 O 0 1.0619595108070801e-15
end O 0 2.8903553270405447e-13
of O 0 2.3452580156272897e-20
the O 0 8.465531824990196e-20
gene O 0 2.2056752835753007e-17
, O 0 5.336967761228486e-19
most O 0 1.5252095740355444e-20
likely O 0 1.2457733101275682e-16
a O 0 1.0538584992800686e-18
result O 0 1.8385429146583376e-17
of O 0 3.496635832619781e-21
recombination O 0 3.9890494878645766e-14
between O 0 1.0697937354768941e-13
two O 0 4.471325653482294e-14
LINE O 0 1.9412593754708496e-09
elements O 0 1.537628938020827e-13
, O 0 4.0361554206489e-18
was O 0 5.258163484361963e-16
identified O 0 4.094392519119047e-15
. O 0 8.838786263499782e-15

The O 0 9.119707281555513e-15
most O 0 3.344700836391227e-17
frequently O 0 4.645016142557079e-12
found O 0 2.3188604780511853e-15
mutation O 0 6.013054467078266e-17
, O 0 3.4508058164642723e-18
identified O 0 3.4429953703253935e-18
in O 0 3.782293852215089e-21
three O 0 4.869533166953599e-19
unrelated O 0 6.695473168949473e-12
Turkish O 0 1.6494779629283585e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 9.496943162434768e-13
, O 0 3.2588920561361506e-18
was O 0 4.289063411395151e-18
previously O 0 1.735543186114453e-20
described O 0 8.158761038079366e-19
to O 0 1.0393331334066293e-20
be O 0 1.0576038696961321e-18
a O 0 2.9573702720152707e-16
Turkish O 0 1.0440402320455178e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 0.9999992847442627
founder O 0 1.9777941437371105e-11
mutation O 0 4.324872640462489e-14
. O 0 7.767980340591578e-16

The O 0 3.1368137254350614e-15
presence O 0 2.262733375048596e-16
of O 0 1.370614687428212e-20
a O 0 3.201566694852121e-20
founder O 0 9.729560415666768e-16
mutation O 0 4.0435568838775144e-16
among O 0 6.003605024594159e-19
relatively O 0 3.740669703738766e-20
small O 0 1.620521266246511e-19
ethnic O 0 3.3117602491741435e-14
population O 0 4.984769042256856e-17
groups O 0 1.9606609119785212e-17
in O 0 4.2782313985557075e-17
Western O 0 2.6066431998983397e-11
Europe O 0 5.723576279592635e-09
could O 0 1.4800305078721543e-12
indicate O 0 1.872368844534693e-16
a O 0 1.4092543617920953e-20
high O 0 6.662878209159003e-18
carrier O 0 6.2642582176084736e-18
frequency O 0 3.0063509580418755e-15
in O 0 7.149580528237241e-20
such O 0 1.9209338259813756e-18
communities O 0 9.064876806000668e-14
. O 0 2.385590911011676e-13

In O 0 2.285611046739665e-15
patients O 0 1.7638210905940657e-14
of O 0 7.314111301567407e-18
Dutch O 0 1.2844696140046352e-10
ethnic O 0 6.763026944023309e-11
origin O 0 5.424116711338911e-11
, O 0 3.86924270835004e-13
however O 0 5.014394728977169e-14
, O 0 2.781403743260171e-17
no O 0 5.082791185615309e-18
significant O 0 1.8386797241924228e-21
founder O 0 9.528072368635357e-14
effect O 0 7.288721052222096e-15
could O 0 7.179878483170221e-16
be O 0 3.701524466924248e-18
identified O 0 1.1151896870146769e-14
. O 0 2.6876612914394915e-13

The O 0 1.954560686571514e-16
observed O 0 9.771624865920805e-17
genetic O 0 3.9387984959390627e-16
heterogeneity O 0 7.145833052646519e-16
including O 0 5.3289146409773995e-18
the O 0 1.8330946068356958e-17
relative O 0 4.5256140957135316e-13
high O 0 4.841819761965127e-13
percentage O 0 3.076443315591995e-14
of O 0 1.1460879485076006e-19
splice O 0 1.3381378494159435e-07
- O 0 8.275912399824392e-09
site O 0 6.554125298041669e-11
mutations O 0 1.0416326134965459e-10
had O 0 2.989647158307962e-12
no O 0 2.4647618502761793e-16
reflection O 0 2.848505097771616e-16
on O 0 9.554929750513717e-15
the O 0 1.9185347077286738e-15
phenotype O 0 2.3375502922196034e-12
. O 0 4.2857359913543724e-14

All O 0 3.87235426694112e-15
patients O 0 3.13390570250846e-16
manifested O 0 1.0089822586375335e-14
classical O 0 3.770701459404613e-11
A B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999959468841553
T I-Disease 1 0.9999997615814209
and O 0 2.6775390783132132e-14
increased O 0 1.9176810868565272e-20
cellular O 0 1.5604158413965703e-18
radioresistant O 0 1.4009232498151747e-15
DNA O 0 1.249843171090227e-16
synthesis O 0 1.1176038579692937e-15
. O 0 1.1325477426203461e-15

Determination O 0 2.516392693177605e-12
of O 0 8.026386161429768e-20
the O 0 2.2137555237182516e-20
genomic O 0 7.949193298777742e-15
structure O 0 5.947224575195099e-15
of O 0 1.4834469697418467e-20
the O 0 3.745426509248829e-19
COL4A4 O 0 5.241569981870309e-13
gene O 0 1.2612800349371813e-17
and O 0 3.0959502967626987e-18
of O 0 2.1971816999877873e-20
novel O 0 3.2827145949460013e-12
mutations O 0 2.0634065549529623e-06
causing O 0 0.1454717367887497
autosomal B-Disease 1 0.9999853372573853
recessive I-Disease 1 0.9999836683273315
Alport I-Disease 1 0.999984622001648
syndrome I-Disease 1 0.9999876022338867
. O 0 4.914544433631818e-07

Autosomal B-Disease 1 0.9998705387115479
recessive I-Disease 1 0.9999048709869385
Alport I-Disease 1 0.9999479055404663
syndrome I-Disease 1 0.9999788999557495
is O 0 1.9656524400789993e-13
a O 0 1.1197551946003775e-14
progressive O 0 6.363496254380152e-07
hematuric B-Disease 1 0.9996246099472046
glomerulonephritis I-Disease 1 0.9999979734420776
characterized O 0 2.4579890123277437e-07
by O 0 5.477466353751015e-13
glomerular B-Disease 1 0.97226881980896
basement I-Disease 1 0.9997591376304626
membrane I-Disease 0 0.2961265444755554
abnormalities I-Disease 1 0.9885313510894775
and O 0 3.896248254586787e-11
associated O 0 6.687438959800812e-14
with O 0 3.1756408687042513e-16
mutations O 0 6.522137176715641e-15
in O 0 3.218836662153883e-18
either O 0 5.813019695650282e-17
the O 0 2.0228922902643966e-16
COL4A3 O 0 5.935174129945153e-09
or O 0 1.2034823685573917e-14
the O 0 4.513250036912335e-18
COL4A4 O 0 9.180490569138389e-12
gene O 0 8.711309684292362e-17
, O 0 2.6920431476824896e-20
which O 0 5.209290950369989e-23
encode O 0 8.802659623393839e-20
the O 0 9.082060141208632e-18
alpha3 O 0 2.4363620010348086e-09
and O 0 2.3375502922196034e-12
alpha4 O 0 4.7817003689942794e-08
type O 0 8.883457858210875e-11
IV O 0 2.692745795229712e-07
collagen O 0 7.625570930258618e-08
chains O 0 1.8673036095151474e-07
, O 0 1.3465873991498796e-14
respectively O 0 2.2036348169395675e-14
. O 0 4.8246241122215996e-14

To O 0 7.048985025993136e-17
date O 0 5.99409151697161e-17
, O 0 5.767289992592387e-20
mutation O 0 3.075676591087513e-20
screening O 0 9.740362732722221e-17
in O 0 3.0166149906224316e-19
the O 0 1.5489274917603393e-19
two O 0 1.0733124431188204e-18
genes O 0 3.457555932863144e-16
has O 0 9.372479700708088e-15
been O 0 2.2961439607310785e-13
hampered O 0 2.1563151264558655e-10
by O 0 4.0005339629041003e-17
the O 0 7.008555481676198e-16
lack O 0 2.2135320104694518e-16
of O 0 1.189579021008236e-22
genomic O 0 1.3165018847122824e-16
structure O 0 1.668886020354119e-17
information O 0 3.1393601976420835e-17
. O 0 7.098910603742182e-16

We O 0 6.027491873672464e-12
report O 0 1.9198222772178391e-16
here O 0 7.355097170341221e-19
the O 0 5.7709620605890115e-21
complete O 0 1.4046509078127817e-18
characterization O 0 7.746618593178298e-15
of O 0 4.859120966369602e-20
the O 0 4.5948278296932334e-18
48 O 0 7.519099168464812e-19
exons O 0 2.3518665991486068e-15
of O 0 2.0835138360085034e-20
the O 0 3.473934572212837e-17
COL4A4 O 0 3.506016657550681e-11
gene O 0 6.273782987295062e-16
, O 0 7.710987492989098e-19
a O 0 2.2541039238142965e-21
comprehensive O 0 8.194846016820167e-20
gene O 0 4.6721476785072796e-14
screen O 0 8.542512546227954e-07
, O 0 6.465364539316037e-14
and O 0 1.2416457450453776e-16
the O 0 2.2763111787116094e-21
subsequent O 0 6.026826569327937e-19
detection O 0 4.553756591744302e-16
of O 0 2.32389332980998e-20
10 O 0 6.947215961254971e-19
novel O 0 3.7629448607939643e-17
mutations O 0 1.2786584908019896e-15
in O 0 4.47946012247985e-18
eight O 0 5.606652024158637e-14
patients O 0 5.326707296277912e-15
diagnosed O 0 5.153173998628802e-10
with O 0 2.47416965387659e-11
autosomal B-Disease 1 0.9999957084655762
recessive I-Disease 1 0.9999974966049194
Alport I-Disease 1 0.9999971389770508
syndrome I-Disease 1 0.9999940395355225
. O 0 1.4674468218345282e-07

Furthermore O 0 1.3988594137204213e-11
, O 0 1.6719583345852634e-16
we O 0 7.08512868285864e-19
identified O 0 1.2520924485928817e-21
a O 0 2.0371414643238953e-23
glycine O 0 1.0194687755059062e-18
to O 0 6.035589255448229e-20
alanine O 0 3.059614361763806e-17
substitution O 0 6.718385750574067e-19
in O 0 1.6135377616132894e-20
the O 0 8.967993640797583e-20
collagenous O 0 2.6302132130270883e-13
domain O 0 6.617597366354727e-15
that O 0 6.878036704229375e-15
is O 0 5.7034386462173e-16
apparently O 0 5.7490383981173565e-12
silent O 0 1.3430446858808676e-11
in O 0 1.6223273634152322e-19
the O 0 1.1333418293909521e-17
heterozygous O 0 5.649504776212948e-14
carriers O 0 2.042176107039384e-15
, O 0 7.807368034383393e-17
in O 0 7.613662187258175e-17
11 O 0 1.3787957321015343e-12
. O 0 2.027724098655967e-13

5 O 0 1.6786154063974656e-11
% O 0 3.1979008945580943e-15
of O 0 6.929558240116378e-20
all O 0 1.4893747579764336e-17
control O 0 3.360808539017851e-14
individuals O 0 1.7701552612071485e-16
, O 0 7.923547470475487e-16
and O 0 1.3425720225227616e-13
in O 0 4.687669754465573e-18
one O 0 1.2339540241398185e-16
control O 0 7.184261878672262e-16
individual O 0 2.6009583645575404e-21
homozygous O 0 7.717546001270878e-20
for O 0 3.3962075190315735e-24
this O 0 7.252881037049704e-24
glycine O 0 2.2855738169946552e-17
substitution O 0 6.454683549142367e-17
. O 0 6.489378600997055e-15

There O 0 3.408710623877334e-14
has O 0 3.15602835020617e-16
been O 0 2.7686296790872984e-15
no O 0 3.2389417584349333e-16
previous O 0 2.2277379441349885e-16
finding O 0 6.5782733489264665e-18
of O 0 3.566384143379924e-24
a O 0 6.541617618062115e-24
glycine O 0 5.286534559281128e-19
substitution O 0 1.33416498666076e-18
that O 0 5.732839424514292e-17
is O 0 3.2702744749551866e-18
not O 0 1.701373538912139e-17
associated O 0 1.0140160629465025e-17
with O 0 4.992071185909321e-19
any O 0 9.428914673717225e-17
obvious O 0 1.6338921535186124e-11
phenotype O 0 4.1327770876732964e-14
in O 0 2.424177120672472e-19
homozygous O 0 7.766076464636035e-14
individuals O 0 4.304756116184968e-15
. O 0 1.2841792516524175e-12

Founder O 0 4.2513201292671e-11
BRCA1 O 0 4.914024187563371e-10
and O 0 4.559986828238383e-13
BRCA2 O 0 3.298847306432151e-11
mutations O 0 4.4809391386204517e-14
in O 0 8.790664098304779e-16
French O 0 1.188617815284232e-10
Canadian O 0 3.878429666315242e-08
breast B-Disease 1 0.9999874830245972
and I-Disease 1 0.9992952346801758
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999969005584717
families O 0 2.0619537327570825e-11
. O 0 6.570855970742867e-16

We O 0 8.901563297233905e-13
have O 0 2.176520434346226e-18
identified O 0 4.441027160551044e-17
four O 0 1.240021658630691e-17
mutations O 0 1.1150311277409068e-16
in O 0 5.684033617704071e-19
each O 0 3.4300959022629353e-18
of O 0 6.596592090772066e-18
the O 0 7.360311904229533e-13
breast B-Disease 0 1.9287801933387527e-06
cancer I-Disease 0 6.627640103396004e-11
- O 0 1.584744976305258e-13
susceptibility O 0 3.502067884818272e-14
genes O 0 2.4988819255783586e-16
, O 0 1.1847131989095525e-18
BRCA1 O 0 2.268716762848441e-14
and O 0 7.298546126190478e-14
BRCA2 O 0 1.2972075670580896e-11
, O 0 4.1615340150512575e-16
in O 0 4.5339742199792386e-18
French O 0 3.089956068791366e-11
Canadian O 0 2.3778183866340896e-09
breast B-Disease 0 0.40644270181655884
cancer I-Disease 0 2.9112075935699977e-05
and O 0 3.52536062564468e-08
breast B-Disease 1 0.9997773766517639
/ I-Disease 1 0.9999113082885742
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999991655349731
families O 0 2.0105354880950443e-10
from O 0 3.656395064346519e-16
Quebec O 0 6.391214055385952e-13
. O 0 3.666345384841646e-13

To O 0 2.857826280310005e-13
identify O 0 1.7010404586639827e-12
founder O 0 1.914051278584239e-10
effects O 0 9.669244294130408e-10
, O 0 5.5024662093167056e-15
we O 0 4.39939780729921e-16
examined O 0 5.538808991716709e-17
independently O 0 5.269971123646688e-16
ascertained O 0 2.32730046172136e-12
French O 0 1.1973703278878034e-12
Canadian O 0 4.274113344065328e-13
cancer B-Disease 0 1.3882607285964355e-09
families O 0 1.7447736542448774e-16
for O 0 1.6950384432533242e-24
the O 0 2.8567218753716616e-23
distribution O 0 1.5022000589572188e-19
of O 0 1.5619797313577655e-21
these O 0 2.8555972119947474e-17
eight O 0 9.824807119915922e-18
mutations O 0 8.789687363437476e-17
. O 0 2.517579277916491e-15

Mutations O 0 1.1856351837813417e-11
were O 0 3.072385350148289e-14
found O 0 6.82005782838541e-16
in O 0 2.2888970564646176e-18
41 O 0 1.727125855137732e-16
of O 0 3.3405916512622475e-19
97 O 0 5.9840939712133e-14
families O 0 6.088122492036926e-14
. O 0 5.226632047625711e-14

Six O 0 3.333881998593413e-12
of O 0 7.626855883464519e-18
eight O 0 4.523699627610983e-16
mutations O 0 1.5815177151311656e-16
were O 0 2.1070658188208783e-15
observed O 0 1.5560137119080162e-15
at O 0 4.096519334146308e-14
least O 0 8.742937100449449e-17
twice O 0 3.392498955367973e-12
. O 0 1.1592529020054698e-11

The O 0 1.6737077752586988e-15
BRCA1 O 0 1.2494834810902744e-12
C4446T O 0 1.771333459684582e-13
mutation O 0 7.476351661412251e-16
was O 0 2.1881256436753413e-14
the O 0 2.3473636297259376e-18
most O 0 7.976881081979089e-19
common O 0 3.3017659274349887e-16
mutation O 0 9.042348821273962e-16
found O 0 1.2996687059896317e-12
, O 0 1.3820472794042902e-16
followed O 0 2.218001267319076e-18
by O 0 1.5098228837310644e-20
the O 0 5.4142604068845994e-17
BRCA2 O 0 4.221008431670725e-09
8765delAG O 0 2.5624085076003666e-09
mutation O 0 6.140804553224355e-13
. O 0 4.662784373020423e-13

Together O 0 4.701352640523737e-10
, O 0 9.565240656110864e-17
these O 0 1.361403113653942e-18
mutations O 0 7.70846221397655e-18
were O 0 1.126261911118772e-15
found O 0 1.533187762166289e-15
in O 0 9.453683852697574e-19
28 O 0 1.384976425215014e-16
of O 0 8.859215835955165e-21
41 O 0 6.235886336188211e-18
families O 0 9.14581860243876e-19
identified O 0 1.0585477473985405e-19
to O 0 2.496268961284977e-18
have O 0 1.5759168421163446e-16
a O 0 2.4104398737458624e-17
mutation O 0 6.754343720612177e-13
. O 0 2.6425557922427068e-11

The O 0 8.148882586642365e-16
odds O 0 3.671073658278491e-14
of O 0 1.774890689591373e-21
detection O 0 1.0775642929152277e-15
of O 0 1.0064694253844822e-19
any O 0 7.43933155705691e-18
of O 0 2.1872229624005317e-19
the O 0 3.29240680893787e-17
four O 0 1.3932852890319867e-16
BRCA1 O 0 6.042207885284881e-14
mutations O 0 5.182613439422799e-15
was O 0 3.852471466836427e-11
18 O 0 6.25704661152103e-14
. O 0 1.94930199369156e-14

7x O 0 2.7446320771673527e-08
greater O 0 1.5425911249000122e-16
if O 0 3.863586271562066e-17
one O 0 2.2807540837194925e-20
or O 0 1.3515141177320823e-19
more O 0 2.1207763838994566e-21
cases O 0 3.8042547238060056e-16
of O 0 2.756262449180036e-12
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
were O 0 1.485004502178866e-12
also O 0 4.083237995176214e-16
present O 0 1.9065594948867354e-18
in O 0 5.387204507780363e-19
the O 0 9.064106980106556e-16
family O 0 2.2307435898483163e-09
. O 0 2.437956249639467e-13

The O 0 1.8231518098460247e-15
odds O 0 1.5226832110731142e-13
of O 0 7.287392534138983e-21
detection O 0 6.218385444357855e-16
of O 0 3.4722466869084677e-20
any O 0 1.9716776342487474e-18
of O 0 2.183080080001348e-19
the O 0 5.965103005491914e-16
four O 0 3.51295755214641e-15
BRCA2 O 0 1.026541156766425e-12
mutations O 0 1.2937654292953884e-15
was O 0 6.311623858105964e-13
5 O 0 2.8301585758923244e-15
. O 0 1.165148164582186e-13

3x O 0 1.515925718287292e-09
greater O 0 2.9628371814755276e-15
if O 0 1.4708295142267826e-14
there O 0 7.451491112061439e-17
were O 0 6.539470223673543e-17
at O 0 1.0380983511461876e-17
least O 0 1.2641580572055754e-21
five O 0 6.311911120114199e-21
cases O 0 3.455732504192638e-18
of O 0 1.3264066115414413e-17
breast B-Disease 0 1.708032755232125e-06
cancer I-Disease 0 1.8723291805855524e-09
in O 0 1.0762074718651794e-17
the O 0 7.809516718742561e-16
family O 0 2.1475397848913502e-10
. O 0 1.4047695840770091e-13

Interestingly O 0 2.379458262369294e-11
, O 0 3.812855549291985e-16
the O 0 2.924350231122501e-19
presence O 0 4.0280516149057794e-17
of O 0 1.8773365480137323e-19
a O 0 3.418732839470233e-17
breast B-Disease 0 1.989659652312792e-11
cancer I-Disease 0 7.818642651716279e-15
case O 0 2.9543115400897844e-18
< O 0 2.647483003564489e-16
36 O 0 3.7831216984495415e-18
years O 0 2.1398218799104025e-16
of O 0 1.513727854768911e-19
age O 0 2.1759842310577508e-15
was O 0 1.7086769026560077e-18
strongly O 0 8.566693428966017e-20
predictive O 0 3.337385581926053e-17
of O 0 1.4465645695034984e-20
the O 0 1.2446137518012791e-17
presence O 0 9.719248848325131e-16
of O 0 1.260725487884647e-19
any O 0 8.724213701848189e-17
of O 0 6.493376597335276e-19
the O 0 5.810651312120421e-16
eight O 0 4.08394140309935e-15
mutations O 0 7.219867967401281e-16
screened O 0 4.2795100796411134e-11
. O 0 2.3873353380970963e-12

Carriers O 0 1.0056128293359917e-13
of O 0 1.9216729118586918e-19
the O 0 1.7253057920583436e-19
same O 0 2.490001620578816e-18
mutation O 0 6.082469561568307e-18
, O 0 1.2113797854584911e-17
from O 0 1.1407017102501733e-18
different O 0 3.090808401454365e-16
families O 0 2.2478606094013774e-14
, O 0 4.410224507441922e-21
shared O 0 4.377659198363405e-20
similar O 0 2.210953772510655e-20
haplotypes O 0 5.656596136047361e-15
, O 0 2.198307337705107e-18
indicating O 0 2.8418925249649995e-18
that O 0 4.3784275716042844e-20
the O 0 3.6700525516750326e-21
mutant O 0 2.15334325213588e-14
alleles O 0 5.75448641027256e-17
were O 0 8.000118613632565e-15
likely O 0 2.483723741591651e-16
to O 0 1.2834799082168794e-18
be O 0 2.9485372403877355e-17
identical O 0 4.854369114120445e-16
by O 0 5.7802471306531766e-18
descent O 0 9.413808274572055e-12
for O 0 1.9740946559986273e-17
a O 0 1.7012120732565688e-16
mutation O 0 2.0615405507630382e-15
in O 0 4.207278823461114e-17
the O 0 5.107714551061838e-16
founder O 0 1.48916975972746e-10
population O 0 1.6057376164062775e-15
. O 0 3.173778920879597e-14

The O 0 6.003925557081524e-19
identification O 0 2.3386135064111985e-18
of O 0 1.6723049455570256e-21
common O 0 2.818057439691376e-17
BRCA1 O 0 4.042300782297614e-12
and O 0 8.726228290303895e-13
BRCA2 O 0 4.365934155002582e-13
mutations O 0 5.7976485291994546e-18
will O 0 7.593401700963154e-21
facilitate O 0 1.1496911440247073e-20
carrier O 0 3.3819868296826674e-16
detection O 0 1.3551985054982563e-14
in O 0 6.320067514510998e-17
French O 0 2.885487638756845e-12
Canadian O 0 2.219193925845353e-11
breast B-Disease 0 3.2448562706122175e-05
cancer I-Disease 0 6.386684248127494e-08
and O 0 9.682638024699486e-11
breast B-Disease 1 0.9739975929260254
/ I-Disease 1 0.9991833567619324
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999974966049194
families O 0 2.12133033361539e-10
. O 0 2.1024895115651e-15

Are O 0 5.352377612302672e-13
Dp71 O 0 1.7007000252533544e-08
and O 0 6.516300086328863e-13
Dp140 O 0 2.0226967670233797e-11
brain O 0 1.8787545304210784e-12
dystrophin O 0 3.921469895904134e-15
isoforms O 0 1.5394453239432485e-17
related O 0 9.293184923109114e-17
to O 0 1.7808227147355304e-16
cognitive B-Disease 0 1.5228561467406365e-11
impairment I-Disease 0 4.57078888627116e-11
in O 0 6.17784523624515e-13
Duchenne B-Disease 0 0.35118573904037476
muscular I-Disease 0 0.17517612874507904
dystrophy I-Disease 1 0.9812965989112854
? O 0 2.5373023163410835e-05

Molecular O 0 4.391427846361928e-11
study O 0 1.9168834000573426e-13
and O 0 1.9242850368694775e-11
neuropsychological O 0 7.296086478036923e-13
analysis O 0 5.33157816254982e-18
were O 0 1.0217615392181442e-19
performed O 0 3.5144364524403667e-20
concurrently O 0 7.068958335858994e-19
on O 0 5.4348893278616944e-14
49 O 0 1.4434276256886092e-13
patients O 0 2.9209094741029134e-16
with O 0 1.1614908796038492e-14
Duchenne B-Disease 0 8.612537385488395e-06
muscular I-Disease 0 3.6504320632957388e-06
dystrophy I-Disease 0 0.00036840501707047224
( O 0 1.614239991676314e-12
DMD B-Disease 1 0.9999985694885254
) O 0 2.2607082357387412e-14
in O 0 4.2954775120365547e-20
order O 0 1.8273816891049772e-19
to O 0 1.3375735394711495e-19
find O 0 1.758456321726719e-18
a O 0 1.1005207899943634e-22
molecular O 0 1.788505201979008e-20
explanation O 0 1.4736557039168904e-20
for O 0 5.5583735129628115e-22
the O 0 1.5337837027842415e-16
cognitive B-Disease 0 1.3395212673447676e-12
impairment I-Disease 0 2.419256858069514e-16
observed O 0 2.6717296856391128e-17
in O 0 6.285873687785403e-18
most O 0 1.2330994515405425e-13
DMD B-Disease 1 0.9999949932098389
patients O 0 1.4313325915130126e-12
. O 0 9.365224863514855e-15

Complete O 0 2.536824374697877e-13
analysis O 0 5.503512930281275e-16
of O 0 6.123907587944457e-19
the O 0 6.566013291477512e-18
dystrophin O 0 1.9635968605226026e-15
gene O 0 7.22843491156937e-17
was O 0 3.726366020899473e-15
performed O 0 7.63323394229567e-17
to O 0 3.6186314828187845e-20
define O 0 1.8168044427243215e-17
the O 0 5.557319241383751e-20
localization O 0 1.530680756400653e-15
of O 0 3.7753456158490006e-21
deletions O 0 5.535989418617437e-13
and O 0 1.9831391737112902e-11
duplications O 0 3.868477586876917e-12
in O 0 1.1827804914083224e-18
relation O 0 4.4049875630065984e-17
to O 0 2.7265130304278873e-18
the O 0 6.119170324576366e-18
different O 0 7.169963814291844e-14
DMD B-Disease 1 0.9999641180038452
promoters O 0 8.709206099355438e-12
. O 0 3.7950762324379106e-14

Qualitative O 0 1.1899158145357164e-13
analysis O 0 9.689860404945433e-15
of O 0 1.4878292950789702e-18
the O 0 1.0800369541418304e-16
Dp71 O 0 2.0616704524134555e-11
transcript O 0 2.0188808957932736e-11
and O 0 1.2727075761277597e-14
testing O 0 4.0860209699008937e-19
for O 0 1.176543762123e-25
the O 0 5.05583567257895e-25
specific O 0 6.708589889413457e-23
first O 0 1.2840024957247312e-20
exon O 0 1.4879500882638213e-16
of O 0 2.9176215304296886e-18
Dp140 O 0 9.850383990471848e-14
were O 0 5.209210273966584e-16
also O 0 2.867431519582421e-16
carried O 0 2.0491557669449767e-12
out O 0 1.340877409106156e-10
. O 0 6.302312729848658e-13

Neuropsychological O 0 3.8457706463823627e-10
analysis O 0 5.960806748504322e-15
assessed O 0 4.554794990610164e-14
verbal O 0 5.07197972857143e-12
and O 0 1.6283013035717111e-15
visuospatial O 0 7.557573490635239e-12
intelligence O 0 2.820865015098345e-13
, O 0 2.7413264190655033e-15
verbal O 0 7.711456473380451e-12
memory O 0 2.378878760644909e-10
, O 0 5.285534295261301e-16
and O 0 2.522965831478624e-13
reading O 0 3.156672839788044e-12
skills O 0 1.6726434148330027e-13
. O 0 3.721292875880571e-16

Comparison O 0 1.109529677335852e-13
of O 0 7.062061924296987e-18
molecular O 0 8.438406494826883e-15
and O 0 2.997597761916597e-14
psychometric O 0 1.2040707515238724e-13
findings O 0 2.550442343090055e-17
demonstrated O 0 4.262425765827894e-19
that O 0 9.941964763579926e-22
deletions O 0 7.803795275881654e-17
and O 0 1.1270827919237798e-15
duplications O 0 5.562786898325768e-14
that O 0 1.5170599636829914e-16
were O 0 9.392472073778344e-18
localized O 0 1.6214759650222952e-16
in O 0 6.867954997972257e-19
the O 0 4.086337076971981e-17
distal O 0 3.649160418284225e-10
part O 0 4.12869825133777e-13
of O 0 6.115859782328807e-17
the O 0 1.6292564589511935e-17
gene O 0 2.1663352552391034e-15
seemed O 0 1.9347475536138315e-15
to O 0 5.244226128874245e-22
be O 0 1.2408520011088237e-21
preferentially O 0 6.045464197571482e-16
associated O 0 1.8968919571351424e-15
with O 0 5.2988433004450344e-14
cognitive B-Disease 0 8.153964614621145e-09
impairment I-Disease 0 1.287692730223e-10
. O 0 9.424582425240913e-13

Two O 0 8.093560408461639e-14
altered O 0 4.576727451882645e-12
Dp71 O 0 4.1939537953616934e-10
transcripts O 0 1.5153798355038717e-12
and O 0 8.272536691447284e-16
two O 0 6.804993564036415e-21
deleted O 0 1.6249860563208272e-17
Dp140 O 0 2.488235383175862e-18
DNA O 0 4.203910213134553e-17
sequences O 0 3.663543493025753e-16
were O 0 2.890004658113534e-19
found O 0 4.803536691028026e-20
in O 0 2.4751092765112936e-22
four O 0 2.222124297383558e-19
patients O 0 5.476112464956976e-19
with O 0 7.372834176741527e-16
severe O 0 2.2164165613958176e-07
cerebral B-Disease 0 0.007725783158093691
dysfunction I-Disease 0 8.010518649825826e-05
. O 0 1.0650637316533818e-10

These O 0 5.45958575928502e-14
findings O 0 2.8905271963782897e-16
suggest O 0 6.648434394892908e-17
that O 0 1.0510836702164712e-19
some O 0 2.0159463873877406e-21
sequences O 0 2.9354962417224695e-17
located O 0 1.1561749507885902e-18
in O 0 1.2201252662220422e-19
the O 0 1.557204829656216e-18
distal O 0 2.675724225520426e-12
part O 0 9.309125024385256e-15
of O 0 1.035665861118853e-17
the O 0 2.6846533900935188e-17
gene O 0 6.038967137228686e-15
and O 0 5.203339386965211e-13
, O 0 1.6205583601271052e-19
in O 0 3.4047441773174227e-23
particular O 0 3.5298068253147944e-20
, O 0 2.4829041007303813e-20
some O 0 8.158788050696244e-20
DMD B-Disease 1 0.9999949932098389
isoforms O 0 4.087178815963315e-17
expressed O 0 3.84273066603944e-16
in O 0 1.7896545552229835e-17
the O 0 3.684260944827704e-14
brain O 0 3.575635432184754e-08
may O 0 6.173171884424605e-16
be O 0 1.3118212098038717e-21
related O 0 3.333107217682291e-19
to O 0 3.5066975315750795e-19
the O 0 6.794583312496737e-16
cognitive B-Disease 0 6.152969106443251e-11
impairment I-Disease 0 4.818965678024057e-15
associated O 0 1.7726903514089418e-15
with O 0 1.6306658714299038e-12
DMD B-Disease 1 0.9999954700469971
. O 0 1.997296371260976e-13
. O 0 2.1087798323412947e-14

I1307K O 0 1.0633789682135131e-10
APC O 0 2.6764096147657845e-11
and O 0 1.3667246587939497e-13
hMLH1 O 0 5.297012481420005e-11
mutations O 0 8.32982974588968e-14
in O 0 1.2914416870488248e-17
a O 0 2.7873215257112735e-16
non O 0 1.3152440291389067e-13
- O 0 4.8397819085721494e-08
Jewish O 0 1.2999642251543264e-07
family O 0 2.6598641511554888e-08
with O 0 2.5887922177041806e-14
hereditary B-Disease 0 0.07238608598709106
non I-Disease 0 2.978310931212036e-07
- I-Disease 1 0.9859617352485657
polyposis I-Disease 1 0.999854564666748
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999961853027344
. O 0 1.1678934208614322e-10

We O 0 2.1207929618190235e-13
describe O 0 2.894843305700583e-15
a O 0 8.936797928134235e-16
French O 0 2.151918920834106e-10
Canadian O 0 2.4219907857059297e-08
hereditary B-Disease 1 0.9999799728393555
non I-Disease 0 0.42575281858444214
- I-Disease 1 0.9999209642410278
polyposis I-Disease 1 0.9999369382858276
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
( O 0 1.5420823255493654e-12
HNPCC B-Disease 0 3.193225666109356e-07
) O 0 1.6715837766159876e-14
kindred O 0 5.016643767064011e-10
which O 0 1.4938022918359605e-16
carries O 0 2.45734528272958e-16
a O 0 5.648970207019773e-20
novel O 0 1.1016413235549394e-16
truncating O 0 1.0602131152170902e-11
mutation O 0 1.5829875387937675e-12
in O 0 3.86403420111342e-14
hMLH1 O 0 4.568329643461766e-07
. O 0 1.178500981698083e-12

Interestingly O 0 1.7011961500959516e-12
, O 0 2.323976504113042e-17
the O 0 7.501161369140688e-20
I1307K O 0 2.1097593571233673e-16
APC O 0 6.359199907278554e-16
polymorphism O 0 3.1828827886450388e-15
, O 0 1.868186172680094e-18
associated O 0 5.488197315212435e-20
with O 0 1.2351470600164613e-21
an O 0 4.7303098810669156e-20
increased O 0 8.011146813199227e-14
risk O 0 3.655287628134829e-08
of O 0 5.291945770480311e-10
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.363959703046531e-15
is O 0 5.219443749254542e-20
also O 0 4.1126360230976702e-19
present O 0 1.5060328778736657e-19
in O 0 1.2333450341273174e-19
this O 0 5.0740178598843877e-17
family O 0 8.561733960688045e-11
. O 0 1.0661617259617034e-13

The O 0 1.076697884089305e-14
I1307K O 0 1.217916067476621e-12
polymorphism O 0 5.4231623532186024e-12
has O 0 1.2185822555015047e-13
previously O 0 1.1510756883690275e-16
only O 0 6.181123929408692e-20
been O 0 4.597352384922745e-18
identified O 0 2.198544291863379e-16
in O 0 2.0786018953594957e-18
individuals O 0 9.821556664068058e-16
of O 0 1.0340483987665116e-15
self O 0 3.523879513522843e-06
- O 0 0.0003263959370087832
reported O 0 8.480004680677666e-07
Ashkenazi O 0 2.774693541596207e-07
Jewish O 0 2.1054724630431565e-10
origins O 0 1.3421650457701162e-09
. O 0 3.191274826862267e-13

In O 0 2.528212823657203e-16
addition O 0 1.6783989282707238e-17
, O 0 1.7664509809880135e-17
in O 0 3.207179050684808e-19
this O 0 8.337732420350753e-17
family O 0 1.2844450503202154e-10
, O 0 2.484254460672665e-16
there O 0 4.5230223486690365e-18
appears O 0 1.125042967180202e-14
to O 0 3.3622522855006223e-17
be O 0 1.0575691272832243e-15
no O 0 2.0786822145969746e-17
relationship O 0 3.233976755700594e-17
between O 0 5.763156028234182e-20
the O 0 4.983009923130814e-21
I1307K O 0 1.4645728019643121e-18
polymorphism O 0 4.2270342125945955e-17
and O 0 3.5746664434527274e-16
the O 0 9.436930343366078e-19
presence O 0 2.817899256288476e-15
or O 0 2.7243587160524774e-12
absence O 0 8.788723228185264e-15
of O 0 3.5482636158498106e-19
cancer B-Disease 0 3.7356975287694896e-14
. O 0 5.232489452509542e-17
. O 0 3.5067047549297787e-15

Identification O 0 1.2903528817816666e-14
of O 0 2.5246237304063175e-19
a O 0 7.887948309384099e-19
novel O 0 1.9884179169622486e-16
mutation O 0 2.2148340324582797e-15
of O 0 1.665730512432867e-18
the O 0 3.019692309296282e-17
CPO O 0 2.6652649531833106e-10
gene O 0 9.513851729683762e-18
in O 0 6.26310528293094e-20
a O 0 1.3539097051643394e-17
Japanese O 0 9.294241765100963e-11
hereditary B-Disease 0 0.005472035147249699
coproporphyria I-Disease 0 0.0007046725368127227
family O 0 2.1533006488994033e-08
. O 0 1.327330443907232e-13

Hereditary B-Disease 1 0.9955294728279114
coproporphyria I-Disease 0 0.00026705930940806866
( O 0 3.0212526816279783e-14
HCP B-Disease 0 1.144898620353274e-09
) O 0 4.759841825393641e-16
is O 0 3.020706101855027e-17
an O 0 1.7904963603887665e-15
autosomal B-Disease 1 0.9948717951774597
dominant I-Disease 1 0.9998648166656494
disease I-Disease 1 0.9939823746681213
characterized O 0 4.347408197324931e-11
by O 0 2.0504102731383207e-16
a O 0 4.998352941395709e-14
deficiency B-Disease 0 5.440056611405453e-06
of I-Disease 0 7.295298732896114e-19
coproporphyrinogen I-Disease 0 1.94392346664074e-09
oxidase I-Disease 0 2.1883628589791648e-11
( O 0 8.328796388193343e-18
CPO O 0 1.0025780206035506e-08
) O 0 3.807056549976845e-16
caused O 0 2.667250105575444e-16
by O 0 1.644551581977451e-21
a O 0 3.172645294086485e-19
mutation O 0 6.925156088293948e-17
in O 0 2.6888118441677337e-19
the O 0 8.891088126007902e-18
CPO O 0 3.426957606578185e-10
gene O 0 1.2288210203613252e-14
. O 0 1.3520589778792582e-14

Only O 0 4.4409682637032433e-13
11 O 0 1.6953379685887872e-14
mutations O 0 8.806813310839774e-15
of O 0 2.0112397700919922e-19
the O 0 1.2307230525312833e-18
gene O 0 2.726341728602217e-14
have O 0 1.5587769451401966e-14
been O 0 9.660518336619597e-15
reported O 0 1.4820722502983247e-13
in O 0 5.529644078683805e-18
HCP B-Disease 0 7.91318797155327e-08
patients O 0 4.1250751864905025e-14
. O 0 2.1966686485747587e-14

We O 0 2.94707747788836e-12
report O 0 5.868297198136996e-17
another O 0 4.57041942295211e-20
mutation O 0 1.373432491109571e-17
in O 0 1.1513474833747001e-17
a O 0 3.358794591130812e-15
Japanese O 0 1.5641865580562353e-09
family O 0 5.655273471738553e-10
. O 0 5.331833200861516e-14

Polymerase O 0 6.846598288312578e-11
chain O 0 4.584112256456052e-11
reaction O 0 4.448458220301975e-15
- O 0 3.110340760989483e-13
single O 0 5.935613818131052e-17
strand O 0 2.60339963969276e-14
conformational O 0 3.730698299948381e-18
polymorphism O 0 1.6461374616305022e-16
and O 0 6.225422036150321e-20
direct O 0 1.160897704568632e-21
sequence O 0 2.63721044606054e-17
analyses O 0 1.0300754436669746e-16
demonstrated O 0 2.971182353971898e-20
a O 0 9.950083088927736e-22
C O 0 3.06112201423547e-16
to O 0 4.6847690647018965e-20
T O 0 6.674790619140114e-16
substitution O 0 9.160329571815249e-22
in O 0 6.543022374230478e-22
exon O 0 2.236310910177937e-17
1 O 0 1.289063687544342e-18
of O 0 3.7199507680988735e-20
the O 0 1.2106728769070033e-17
CPO O 0 2.0573443122728907e-12
gene O 0 2.78472395318114e-19
at O 0 2.880087473427362e-20
nucleotide O 0 4.646115819406089e-19
position O 0 6.142426282505168e-15
85 O 0 6.499284863073431e-16
, O 0 6.2456325884468946e-15
which O 0 1.5166675207400893e-11
lies O 0 6.497172799768691e-10
in O 0 1.787504423297744e-18
the O 0 1.874789762305258e-18
putative O 0 8.766025963924048e-14
presequence O 0 1.2186119016546586e-14
for O 0 3.3397715105706304e-22
targeting O 0 7.338489637708325e-16
to O 0 8.269728247831544e-16
mitochondria O 0 4.3033350320687e-12
. O 0 6.05327257503091e-13

This O 0 6.947776169324823e-18
mutation O 0 3.1751772422427215e-18
changes O 0 2.986477440485886e-20
the O 0 6.837177372408103e-22
codon O 0 7.619868895625436e-20
for O 0 8.471394245438435e-24
glutamine O 0 4.555904018788938e-19
to O 0 1.782938938847251e-21
a O 0 1.2692274667091429e-20
termination O 0 2.184116276746984e-16
codon O 0 2.689913266172621e-16
at O 0 1.2176911768409932e-15
amino O 0 1.983532416210943e-15
acid O 0 4.726696261497278e-15
position O 0 1.730226916873013e-14
29 O 0 4.3681665272757297e-13
. O 0 4.319983227477758e-14

MaeI O 0 1.7216787995266714e-09
restriction O 0 2.3166437843578913e-13
analysis O 0 3.102299165713522e-14
showed O 0 2.509680831208616e-13
two O 0 2.183396735079591e-19
other O 0 1.1317766899346676e-19
carriers O 0 1.2635475437913423e-18
in O 0 8.169626701660103e-20
the O 0 5.834439173652874e-16
family O 0 7.158076908986288e-10
. O 0 2.066510753750278e-13

The O 0 8.255247180288805e-12
C O 0 0.0016087543917819858
- O 1 0.7024421095848083
T O 0 0.0019694543443620205
mutation O 0 1.945593425950465e-12
is O 0 1.3627866766260135e-16
located O 0 4.592354766456853e-19
within O 0 2.810772646152259e-21
a O 0 1.3249878410483132e-21
recently O 0 1.5073088039685287e-19
proposed O 0 6.137155457978185e-23
putative O 0 4.004518988223136e-17
alternative O 0 1.9073595853342273e-18
translation O 0 2.9525698716053846e-15
initiation O 0 1.809965920901175e-14
codon O 0 2.6915085828485563e-13
( O 0 2.772102469503288e-18
TIC O 0 4.868735969942861e-11
- O 0 2.3854282264756943e-12
1 O 0 4.508448667046771e-18
) O 0 9.718191526420626e-20
, O 0 4.100460312221802e-21
supporting O 0 5.642921190296537e-19
that O 0 2.815507996665184e-19
TIC O 0 6.244569965285773e-12
- O 0 4.5265007020400816e-14
1 O 0 3.4017265023845104e-19
is O 0 1.9785794224847367e-18
the O 0 1.442085871162664e-19
real O 0 3.866922244650378e-15
TIC O 0 3.6579094787880795e-12
rather O 0 5.674721218367949e-18
than O 0 4.70181286272961e-20
TIC O 0 2.502846237553702e-12
- O 0 1.1598847967156378e-12
2 O 0 1.0535219112170146e-16
. O 0 7.15924985600768e-18
. O 0 1.7156616347735595e-15

Human B-Disease 0 9.187628820716762e-14
complement I-Disease 0 4.232127235465066e-12
factor I-Disease 0 8.659993255832887e-08
H I-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9917389154434204
associated O 0 8.047367217045576e-10
with O 0 1.481050730944844e-07
hemolytic B-Disease 1 0.9999536275863647
uremic I-Disease 1 0.9999822378158569
syndrome I-Disease 1 0.9999678134918213
. O 0 8.70091332316747e-10

This O 0 3.884452729694329e-17
study O 0 7.788259603886505e-20
reports O 0 4.2787822284653643e-19
on O 0 7.351794672425118e-17
six O 0 2.042672726426826e-17
cases O 0 1.008134775704026e-16
of O 0 1.876329914703189e-16
deficiency B-Disease 0 1.0645829773281434e-09
in I-Disease 0 8.836188140472873e-23
the I-Disease 0 6.3174243112086075e-22
human I-Disease 0 4.650706348688331e-20
complement I-Disease 0 4.0623954637601575e-20
regulatory I-Disease 0 2.6831059006035546e-18
protein I-Disease 0 1.4729007215410561e-15
Factor I-Disease 0 3.146653071908604e-15
H I-Disease 1 0.9998887777328491
( O 0 3.0450434434417745e-20
FH O 0 1.7055886867775594e-12
) O 0 3.867310732403208e-20
in O 0 7.343387837566616e-24
the O 0 4.144978434163163e-23
context O 0 1.1741894969639232e-18
of O 0 1.2654704188292755e-21
an O 0 1.4685246316981852e-15
acute B-Disease 0 6.703354301862419e-05
renal I-Disease 1 0.9999984502792358
disease I-Disease 1 0.9999992847442627
. O 0 2.060211379273369e-08

Five O 0 7.682146341584858e-14
of O 0 4.799104166167478e-20
the O 0 4.9793067550818623e-20
cases O 0 2.442118668158747e-19
were O 0 2.3985971289159407e-18
observed O 0 2.4415424851633157e-18
in O 0 6.738248166539056e-20
children O 0 2.236553227775301e-14
presenting O 0 1.9895970450583417e-13
with O 0 3.3827760037574706e-11
idiopathic O 1 0.9999781847000122
hemolytic B-Disease 1 0.9999947547912598
uremic I-Disease 1 0.999996542930603
syndrome I-Disease 1 0.9999963045120239
( O 0 3.951047489181292e-09
HUS B-Disease 1 0.99834144115448
) O 0 6.231010152291105e-11
. O 0 1.3761743480888988e-11

Two O 0 1.363541462391356e-15
of O 0 1.687191635877373e-19
the O 0 3.795381590462374e-17
children O 0 3.479784006516634e-13
exhibited O 0 6.336728123187898e-16
a O 0 1.0913351163436717e-16
homozygous O 0 6.156235521359577e-10
deficiency O 0 0.0010303484741598368
characterized O 0 1.487870021415691e-13
by O 0 1.030480801871795e-15
the O 0 6.575373197450574e-15
absence O 0 2.122174769017527e-15
of O 0 1.2395218680266508e-22
the O 0 1.8879347349885826e-21
150 O 0 7.164179781372662e-22
- O 0 8.555434777046134e-18
kD O 0 1.3312742716612954e-15
form O 0 4.3011696132501705e-19
of O 0 9.500102126746753e-19
Factor O 0 5.732108039092909e-13
H O 1 0.9999997615814209
and O 0 1.5315665199294205e-14
the O 0 1.02326325977084e-19
presence O 0 1.0553388423838088e-18
, O 0 3.3111054412346023e-20
upon O 0 1.0036055710074588e-19
immunoblotting O 0 7.027828297610783e-13
, O 0 2.998337788753219e-20
of O 0 3.6533148796412877e-23
the O 0 4.2197617285369693e-20
42 O 0 6.721385314270338e-19
- O 0 1.5805828025156337e-16
kD O 0 5.284168624040443e-14
Factor O 0 3.7723380734260015e-13
H O 1 0.9999929666519165
- O 0 3.126150813909101e-12
like O 0 2.2019350706303564e-16
protein O 0 6.743353171660021e-16
1 O 0 2.5766462823525138e-20
( O 0 5.76097369313372e-22
FHL O 0 1.2297683420095344e-14
- O 0 7.7132943053300645e-16
1 O 0 1.5294286475239624e-19
) O 0 1.5395661659834545e-20
and O 0 5.654470699599309e-19
other O 0 4.362455877198622e-20
FH O 0 3.7732444664421994e-13
- O 0 1.2107837191090854e-17
related O 0 7.684914863479003e-18
protein O 0 5.724691232259502e-16
( O 0 6.8503353198717e-22
FHR O 0 1.527343112010457e-13
) O 0 3.711035958294054e-20
bands O 0 4.9270754576974385e-15
. O 0 8.040529602634002e-16

Southern O 0 3.4631464362888664e-12
blot O 0 1.061108312327974e-09
and O 0 5.5005901868484925e-18
PCR O 0 1.1677545611938527e-15
analysis O 0 2.6248515250187486e-20
of O 0 1.6052953587002794e-24
DNA O 0 2.3811479606892877e-18
of O 0 1.6639353143683607e-23
one O 0 2.5994023118095317e-20
patient O 0 1.1537216571688498e-17
with O 0 1.9163822646608026e-17
homozygous O 0 2.387939013193119e-10
deficiency O 0 4.041714419145137e-06
ruled O 0 1.0861323064624128e-14
out O 0 1.682338946970563e-12
the O 0 8.98803390059427e-19
presence O 0 1.1787311321171456e-18
of O 0 4.4356291859820514e-23
a O 0 1.2524459592526166e-21
large O 0 3.587210898003987e-21
deletion O 0 6.603025689156522e-14
of O 0 3.1866076375372855e-18
the O 0 4.032329568040777e-15
FH O 0 1.7056034362639139e-10
gene O 0 2.20262298711498e-17
as O 0 6.748724667490981e-18
the O 0 1.884203698061571e-18
underlying O 0 1.1273375624936549e-13
defect O 0 1.9004637680187716e-14
for O 0 6.805727234465659e-19
the O 0 5.4907745017374054e-12
deficiency O 0 0.00021798729721922427
. O 0 6.499616925399743e-13

The O 0 7.115848516447635e-18
other O 0 2.342586868483597e-18
four O 0 2.5752829077572674e-18
children O 0 1.4113984268645298e-16
presented O 0 1.8344088727519507e-18
with O 0 1.6341187258534537e-16
heterozygous O 0 7.486845171600365e-11
deficiency O 0 9.282703672397474e-08
and O 0 2.8743200150259667e-16
exhibited O 0 5.368526159916804e-15
a O 0 1.655898788428669e-17
normal O 0 9.532539281585997e-15
immunoblotting O 0 9.094544006771343e-10
pattern O 0 8.043399279955565e-12
of O 0 9.45695641830773e-21
proteins O 0 2.862861512134188e-17
of O 0 1.8616259324889068e-19
the O 0 9.093861765235942e-15
FH O 0 4.114291982659779e-07
family O 0 2.4229481268567277e-11
. O 0 4.481058739672604e-14

Factor B-Disease 0 6.512490926979808e-06
H I-Disease 1 0.999997615814209
deficiency I-Disease 0 0.012408384121954441
is O 0 8.925375589578837e-18
the O 0 1.0583384060800792e-18
only O 0 2.2173131115476447e-13
complement B-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999998807907104
associated O 0 4.1685130689047764e-14
with O 0 4.4345922062521276e-14
HUS B-Disease 1 0.6890138983726501
. O 0 7.340661065113885e-12

These O 0 4.909230908718514e-16
observations O 0 5.899930067068682e-15
suggest O 0 1.466278551784973e-17
a O 0 1.9688187009501338e-21
role O 0 1.886231738128398e-18
for O 0 2.75689537432696e-18
FH O 0 3.276709747979112e-08
and O 0 1.0180573831869433e-12
/ O 0 5.94088736538545e-11
or O 0 4.9123671710255e-13
FH O 0 6.298690041761645e-11
receptors O 0 3.853016392258741e-18
in O 0 5.105110748052234e-21
the O 0 6.572497327654768e-20
pathogenesis O 0 2.7638612224074356e-14
of O 0 9.687142138905712e-19
idiopathic O 0 1.2084837575088159e-09
HUS B-Disease 0 0.006306882947683334
. O 0 6.700238454337981e-12
. O 0 2.8993474288085963e-11

Further O 0 7.622086360052538e-18
evidence O 0 8.036465486440698e-20
for O 0 4.892332002906342e-23
a O 0 2.8586529437587702e-22
major O 0 9.540441075658064e-21
ancient O 0 6.029736595685982e-15
mutation O 0 4.006162068748154e-09
underlying O 0 3.3035737487807637e-06
myotonic B-Disease 1 0.9999926090240479
dystrophy I-Disease 1 0.9999927282333374
from O 0 3.2054488051510774e-15
linkage O 0 1.431655575340196e-11
disequilibrium O 0 7.766784437812646e-11
studies O 0 7.886847121057734e-16
in O 0 9.015534554034361e-20
the O 0 4.001111913998091e-18
Japanese O 0 4.377543466604905e-12
population O 0 1.2073200657301421e-17
. O 0 8.517474267595994e-16

The O 0 6.176629763210428e-10
myotonic B-Disease 1 0.9998785257339478
dystrophy I-Disease 1 0.9999785423278809
( O 0 5.90381743492685e-10
DM B-Disease 1 0.999997615814209
) O 0 2.469245511185769e-13
mutation O 0 4.8823988743011e-14
is O 0 2.544458809706422e-15
an O 0 5.235785932686688e-16
unstable O 0 0.0006579818436875939
( O 0 8.194018325423586e-16
CTG O 0 2.165506385320981e-10
) O 0 3.68234326223512e-14
n O 0 1.1436436242462378e-09
repeat O 0 2.8468329915654067e-08
, O 0 8.475376941875692e-15
present O 0 6.300785603560141e-17
at O 0 3.2321764798154336e-17
a O 0 2.3630015648323707e-21
copy O 0 4.467485227275267e-16
number O 0 2.5556125527907564e-18
of O 0 2.7602719772861897e-19
5 O 0 3.6395430791630985e-16
- O 0 5.605783545692411e-11
37 O 0 6.170063802903773e-16
repeats O 0 1.8873765050830826e-10
on O 0 2.5173705351169695e-13
normal O 0 2.339634172840834e-15
chromosomes O 0 1.1950766168767474e-13
but O 0 1.4839302551846096e-17
amplified O 0 4.499296079004994e-16
to O 0 8.99125680305593e-19
50 O 0 1.9589244737571345e-19
- O 0 1.3833138583582314e-15
3000 O 0 5.63434722750095e-16
copies O 0 2.4416778413591592e-14
on O 0 3.545063265164572e-08
DM B-Disease 1 0.9999973773956299
chromosomes O 0 1.0891896806697332e-07
. O 0 1.3783276820236723e-12

Previous O 0 5.215379384328027e-14
findings O 0 1.662203903164683e-15
in O 0 4.425111461102972e-18
Caucasian O 0 2.366707008150115e-08
populations O 0 9.074326576610781e-13
of O 0 1.4435734365871275e-17
a O 0 1.3493656062305015e-12
DM B-Disease 1 0.9999994039535522
founder O 0 6.339645475250677e-11
chromosome O 0 3.5975518120068273e-09
raise O 0 2.3368793675864787e-14
a O 0 9.843822554632444e-19
question O 0 4.1820769463023384e-17
about O 0 1.5723544357799716e-18
the O 0 4.353345581350601e-20
molecular O 0 2.4350327805376765e-17
events O 0 9.879872367857454e-17
involved O 0 1.3075715435574864e-18
in O 0 3.1076834320835215e-21
the O 0 2.4563002273965713e-20
expansion O 0 4.0740253207347416e-17
mutation O 0 1.111626219405578e-14
. O 0 1.2792403854960943e-13

To O 0 3.3929836996181924e-16
investigate O 0 2.5314926278732002e-17
whether O 0 1.6167732333428508e-19
a O 0 7.394588356059893e-21
founder O 0 1.2211275299509997e-17
chromosome O 0 3.078844145777693e-14
for O 0 5.281656261618596e-19
the O 0 2.283850488758797e-15
DM B-Disease 1 0.9999985694885254
mutation O 0 3.2533572004060174e-15
exists O 0 4.412199998921632e-18
in O 0 8.197593322741352e-21
the O 0 2.7174998636783563e-18
Japanese O 0 1.963428725160199e-11
population O 0 1.0165251498985596e-18
, O 0 1.1538304882880677e-19
we O 0 2.2065588779056298e-17
genotyped O 0 1.47837302024844e-14
families O 0 8.897690235755251e-21
using O 0 1.3175542015278464e-20
polymorphic O 0 8.674779509087668e-14
markers O 0 2.53024778906763e-09
near O 0 1.9828895470030972e-11
the O 0 1.9473353102429777e-15
( O 0 1.5261365462341837e-18
CTG O 0 3.573364694420267e-12
) O 0 1.4908086921119066e-15
n O 0 5.150344040139032e-10
repeat O 0 9.357578534263666e-08
region O 0 2.11626549617705e-11
and O 0 5.382085836030948e-13
constructed O 0 2.211443484931297e-12
haplotypes O 0 1.3595106373998078e-08
. O 0 4.638002221862836e-13

Six O 0 2.046824200337442e-15
different O 0 3.6392043693817733e-19
haplotypes O 0 2.071312176952448e-14
were O 0 7.681728034363857e-16
found O 0 1.880623207075466e-15
and O 0 8.591989424620861e-13
DM B-Disease 1 0.9999980926513672
alleles O 0 1.2116028098952476e-15
were O 0 5.36364919566942e-17
always O 0 3.902189731958732e-15
haplotype O 0 7.132117704582164e-13
A O 0 9.513793595430312e-15
. O 0 3.457402821070016e-13

To O 0 6.511646250147423e-15
find O 0 3.534071595362177e-16
an O 0 1.3398249893891996e-20
origin O 0 8.781112213637711e-16
of O 0 1.3157079402167417e-17
the O 0 1.55296576972644e-15
( O 0 3.302428639726348e-19
CTG O 0 9.668191946901952e-14
) O 0 7.167064231254468e-18
n O 0 3.745095054387415e-13
repeat O 0 4.984173230387912e-12
mutation O 0 9.31591060532571e-15
and O 0 1.320783895664493e-14
to O 0 4.651737545644152e-19
investigate O 0 4.1079658647567724e-18
the O 0 1.1254087078435877e-20
mechanism O 0 5.481695727296556e-18
of O 0 7.671450791132154e-23
the O 0 4.0550525192624196e-22
expansion O 0 6.793370727272604e-22
mutation O 0 2.1008085347181106e-20
in O 0 8.648447954054666e-21
the O 0 2.3359297189137702e-18
Japanese O 0 9.750341267884821e-14
population O 0 3.785180502526572e-21
we O 0 1.3335231979029954e-19
have O 0 6.0214891379578246e-21
studied O 0 1.4911241105551338e-19
90 O 0 2.683881201482064e-20
Japanese O 0 1.2689874921267136e-13
DM B-Disease 1 0.999998927116394
families O 0 8.840670805928305e-16
comprising O 0 3.5197724035287677e-22
190 O 0 2.531248671631043e-19
affected O 0 1.4608063384426285e-18
and O 0 2.63307884433696e-17
130 O 0 1.4746765525847544e-16
unaffected O 0 4.198805745366657e-13
members O 0 6.580209199714024e-17
. O 0 2.722547063350165e-15

The O 0 6.209786916448745e-14
results O 0 4.502746679473871e-16
suggest O 0 1.6741857665387462e-16
that O 0 3.932997209469529e-19
a O 0 4.8425599057774954e-20
few O 0 3.963861075882684e-18
common O 0 2.0676952346396485e-19
ancestral O 0 7.704039093952772e-14
mutations O 0 8.91045096830989e-16
in O 0 2.3106361901431237e-18
both O 0 7.194848202326165e-16
Caucasian O 0 3.1036111636240094e-07
and O 0 1.3088887612644484e-11
Japanese O 0 3.4150525289600164e-12
populations O 0 6.0795698799310026e-18
have O 0 7.8003348898661305e-19
originated O 0 3.81011642754748e-19
by O 0 9.029459693340745e-23
expansion O 0 1.1221414857878774e-21
of O 0 6.33769352418841e-24
an O 0 1.2133381483218487e-21
ancestral O 0 4.605566275572848e-11
n O 0 2.2854936693184058e-11
= O 0 7.951658537348749e-13
5 O 0 5.349797096782709e-16
repeat O 0 2.279233746182996e-11
to O 0 1.5091371891300803e-13
n O 0 9.769013376015323e-10
= O 0 6.665523688553776e-10
19 O 0 3.0840762344115646e-13
- O 0 3.1087915575156444e-10
37 O 0 5.903667599948441e-15
copies O 0 7.923841433259832e-14
. O 0 3.0614768532777337e-13

These O 0 1.4320048659411153e-19
data O 0 3.614809973012275e-20
support O 0 9.490348988778156e-21
multistep O 0 2.1576260624754347e-15
models O 0 6.138529761541209e-14
of O 0 3.911543142909624e-18
triplet O 0 3.9971197907107126e-08
repeat O 0 1.5307268256756212e-12
expansion O 0 8.171905455000716e-19
that O 0 1.1841665359222316e-18
have O 0 2.1403877941693875e-21
been O 0 1.0673980983059436e-22
proposed O 0 1.1191388224362294e-24
for O 0 1.030681987422061e-21
both O 0 1.258298342908179e-13
DM B-Disease 1 0.9999998807907104
and O 0 3.032434026106756e-11
Friedreichs B-Disease 0 1.872721977491665e-09
ataxia I-Disease 0 5.795618651660561e-09
. O 0 2.692943685360101e-15
. O 0 1.532141994113785e-14

The O 0 6.121971985311083e-18
molecular O 0 2.87755488679109e-17
basis O 0 7.73680621941017e-17
of O 0 2.056597012372978e-14
C6 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
in O 0 7.820837181733717e-18
the O 0 6.245218174268728e-18
western O 0 2.3270862775821854e-13
Cape O 0 7.630982651329887e-12
, O 0 8.818406544909725e-16
South O 0 1.5465145169254318e-13
Africa O 0 2.6810820816063063e-13
. O 0 7.338601869573836e-16

Deficiency B-Disease 1 0.9997286200523376
of I-Disease 0 1.5800938064247168e-17
the I-Disease 0 1.7715391343719497e-17
sixth I-Disease 0 9.52080618120063e-14
component I-Disease 0 1.061473991521714e-14
of I-Disease 0 1.7799099229975296e-19
human I-Disease 0 2.5418963762223e-16
complement I-Disease 0 8.725049749836909e-16
( O 0 8.174083783445086e-20
C6 O 0 1.9476904533632933e-09
) O 0 2.318284442707493e-16
has O 0 1.6192577445521138e-15
been O 0 3.922157686657305e-15
reported O 0 3.869059891111452e-16
in O 0 3.608824702308633e-23
a O 0 8.46174565615224e-22
number O 0 3.933983347700186e-21
of O 0 1.8126895720211002e-20
families O 0 8.712344785023686e-16
from O 0 1.5082341153435944e-20
the O 0 6.503738585471151e-19
western O 0 1.9620040997685856e-13
Cape O 0 2.0355292972007444e-12
, O 0 2.0550146913000359e-16
South O 0 2.81707826960435e-14
Africa O 0 1.1068748727912497e-13
. O 0 8.174568331372259e-16

Meningococcal B-Disease 0 0.00011742144852178171
disease I-Disease 0 1.6381404748244677e-06
is O 0 1.0374428197751622e-14
endemic O 0 9.031306952289597e-11
in O 0 4.175875738686151e-17
the O 0 1.0550713541767134e-14
Cape O 0 8.350295281622788e-12
and O 0 2.924980949722128e-15
almost O 0 5.351993497055512e-19
all O 0 8.874068574711894e-20
pedigrees O 0 3.38083131368877e-13
of O 0 1.28805173546246e-17
total O 0 1.893909855332776e-11
C6 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
( O 0 3.9130394299196714e-16
C6Q0 O 0 8.161693543229376e-10
) O 0 4.420387846214988e-18
have O 0 5.609266183852081e-20
been O 0 3.3838674661643374e-18
ascertained O 0 1.0199999549956491e-14
because O 0 4.623350936273083e-16
of O 0 5.911796972189935e-17
recurrent O 1 0.8305023908615112
disease O 0 0.0036637887824326754
. O 0 4.8074266789654985e-11

We O 0 5.64967689330783e-14
have O 0 7.97627258724098e-19
sequenced O 0 8.138653207966391e-18
the O 0 2.3864481204642213e-19
expressed O 0 1.0021828720526558e-18
exons O 0 9.170173843366103e-14
of O 0 1.444999640719776e-18
the O 0 7.812880365985447e-17
C6 O 0 1.1837829327898675e-10
gene O 0 3.0425049579737594e-17
from O 0 2.64984191148194e-20
selected O 0 9.02412749849243e-22
cases O 0 1.0238835967626408e-20
and O 0 2.616266811977126e-18
have O 0 8.966292905759385e-18
found O 0 2.1792217167136098e-17
three O 0 3.81342074526093e-17
molecular O 0 1.0736187329787872e-12
defects O 0 2.6088356364084575e-08
leading O 0 8.070988166263438e-15
to O 0 1.6874091642200828e-13
total O 0 2.3562345650984806e-12
deficiency O 0 1.8622154129843693e-06
879delG O 0 5.914919110061589e-10
, O 0 2.322277408960409e-15
which O 0 1.5183278661259127e-16
is O 0 1.2250407870121386e-19
the O 0 3.044893969320147e-19
common O 0 4.3642166432360935e-14
defect O 0 2.5445708040638948e-11
in O 0 4.835565512086991e-19
the O 0 2.577753980797094e-15
Cape O 0 3.882862781301455e-12
and O 0 2.356176938058947e-15
hitherto O 0 1.5180100964217944e-15
unreported O 0 4.800965804378429e-15
, O 0 4.890966099048853e-17
and O 0 4.965409458384737e-14
1195delC O 0 1.3940824050706624e-09
and O 0 3.926190969560928e-12
1936delG O 0 7.457063300186917e-10
, O 0 4.020913046219447e-17
which O 0 2.5616735119340856e-18
have O 0 2.32889082549125e-19
been O 0 1.456550411472982e-17
previously O 0 2.973422075761332e-16
reported O 0 2.6844218986360122e-14
in O 0 2.212947193776377e-18
African O 0 4.864516992345025e-13
- O 0 4.439568990211029e-10
Americans O 0 1.1514025139141432e-13
. O 0 6.304996680796975e-16

We O 0 9.627565671771476e-13
also O 0 4.287413434227291e-17
show O 0 5.4789370739979915e-14
that O 0 1.2659212419566397e-18
the O 0 2.1872084764000543e-17
879delG O 0 1.1198680027746377e-07
and O 0 8.05037592144231e-10
1195delC O 0 1.4601336033592816e-06
defects O 0 2.0568862169056956e-07
are O 0 1.6716871046473467e-20
associated O 0 2.9459358969479846e-20
with O 0 1.6148878560822952e-18
characteristic O 0 8.853289195503988e-13
C6 O 0 1.830764063015522e-06
/ O 0 1.4346411558729955e-10
C7 O 0 2.229752382731931e-09
region O 0 1.5810660877516015e-15
DNA O 0 8.025343085395209e-13
marker O 0 2.550023525671463e-10
haplotypes O 0 5.68737557049559e-11
, O 0 1.2564927767728674e-16
although O 0 2.1134462582778326e-18
small O 0 2.17862933131793e-19
variations O 0 3.37120743545635e-15
were O 0 3.3854735878704805e-15
observed O 0 3.760583017946642e-14
. O 0 1.159596778408517e-13

The O 0 5.2445671232508734e-14
1936delG O 0 4.416615517754963e-09
defect O 0 4.970223121958384e-10
was O 0 1.7213657663986068e-14
observed O 0 6.878741329762372e-16
only O 0 9.82068527892357e-18
once O 0 1.4701452810119905e-14
in O 0 1.0957145413787725e-17
the O 0 1.5437706722774142e-13
Cape O 0 7.766818299614897e-10
, O 0 1.9181395668587797e-15
but O 0 4.2000808962940246e-16
its O 0 1.012793944950486e-18
associated O 0 6.49717077140748e-18
haplotype O 0 1.868183748974725e-13
could O 0 6.823857300549438e-16
be O 0 1.1018088772598181e-17
deduced O 0 1.1738789736266686e-13
. O 0 2.942917719413185e-14

The O 0 4.2607255436416763e-16
data O 0 2.1660625106300875e-15
from O 0 7.960803586003202e-18
the O 0 1.0220037738906515e-18
haplotypes O 0 3.160731767461178e-13
indicate O 0 4.06542865100416e-15
that O 0 3.360442538397448e-18
these O 0 1.5312456479671328e-17
three O 0 1.4810413434388804e-16
molecular O 0 3.06254132297068e-12
defects O 0 6.134577290595189e-09
account O 0 3.8854478610584546e-16
for O 0 5.038703071079886e-16
the O 0 3.902033904323865e-11
defects O 0 0.010868232697248459
in O 0 2.3590256355920164e-17
all O 0 3.366025221710599e-17
the O 0 6.483059070157325e-18
38 O 0 6.588268172267945e-18
unrelated O 0 3.4964845083277675e-16
C6Q0 O 0 1.6659017915143792e-11
individuals O 0 9.161500912877e-18
we O 0 4.593062626266045e-16
have O 0 3.1710237615919396e-19
studied O 0 5.909829109512671e-19
from O 0 2.9446130542027533e-18
the O 0 2.6227062310661166e-15
Cape O 0 4.951058226593252e-12
. O 0 1.2169627285063545e-14

We O 0 1.466237396254011e-12
have O 0 6.993405933455085e-18
also O 0 8.607410102149233e-20
observed O 0 1.784635967728563e-18
the O 0 1.9587984321112968e-18
879delG O 0 5.523163038034795e-10
defect O 0 1.2465110540982316e-11
in O 0 2.7622099063650366e-19
two O 0 1.4865899174631644e-14
Dutch O 0 2.1097244825796224e-05
C6 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999979734420776
deficient I-Disease 1 0.9999997615814209
kindreds O 0 2.269559473688787e-07
, O 0 2.299837347246244e-18
but O 0 4.808688475280583e-20
the O 0 7.187286716355161e-21
879delG O 0 6.872745645161715e-13
defect O 0 2.5348606135129625e-13
in O 0 2.746521392072203e-20
the O 0 7.81323770801007e-17
Cape O 0 1.8672086446458458e-12
probably O 0 2.429211345966742e-13
did O 0 8.843981116565293e-15
not O 0 3.1937072344362383e-15
come O 0 1.3951375489173069e-14
from O 0 2.2058602411602675e-17
The O 0 3.0111601993581486e-15
Netherlands O 0 5.6007393167689656e-11
. O 0 9.180232020801569e-15
. O 0 3.322553481801237e-14

Complement B-Disease 0 1.6168944057426415e-05
C7 I-Disease 1 0.999977707862854
deficiency I-Disease 1 0.9999995231628418
: O 0 5.381557005579296e-11
seven O 0 2.9194407189723744e-15
further O 0 2.713205348733134e-15
molecular O 0 9.710013904040693e-10
defects O 0 0.001810927875339985
and O 0 6.621215077953768e-13
their O 0 6.482850009852797e-14
associated O 0 4.503814788020359e-15
marker O 0 1.2253135173168062e-09
haplotypes O 0 8.734642875651843e-08
. O 0 2.1594410287706367e-12

Seven O 0 2.318903570852377e-16
further O 0 4.393939986899524e-19
molecular O 0 9.76655590312708e-17
bases O 0 2.6340904284161137e-12
of O 0 3.3989384223831465e-11
C7 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999998807907104
are O 0 1.6249947622313382e-14
described O 0 2.5677817077490728e-12
. O 0 1.5342542232336942e-13

All O 0 6.323399000971667e-16
these O 0 7.626041110561154e-18
new O 0 1.2473373266861712e-17
molecular O 0 5.783324801044223e-14
defects O 0 2.993505790471751e-11
involve O 0 1.1230761716072875e-19
single O 0 6.253582624622864e-19
- O 0 3.679273106614502e-15
nucleotide O 0 1.207131799422725e-16
events O 0 1.168516467329908e-15
, O 0 2.9505357966356037e-20
deletions O 0 5.1014220227060244e-17
and O 0 2.955374185935507e-16
substitutions O 0 7.297286778780324e-16
, O 0 1.817691676649346e-17
some O 0 4.2070321943916025e-20
of O 0 3.3672147823946934e-20
which O 0 1.5358864091362411e-15
alter O 0 2.2241793639059954e-13
splice O 0 1.0377779746661986e-09
sites O 0 4.400365488654856e-11
, O 0 2.528300809204599e-15
and O 0 6.0634586713820705e-15
others O 0 1.5993797871041867e-15
codons O 0 1.329480975857016e-14
. O 0 1.2515143035676888e-14

They O 0 8.127032101218519e-15
are O 0 2.535315686058419e-20
distributed O 0 7.218310836087301e-20
along O 0 1.3194330157564763e-16
the O 0 6.77219993746995e-16
C7 O 0 1.7050579836919155e-09
gene O 0 1.0361975627580858e-13
, O 0 2.220993444292476e-15
but O 0 3.3859483630723064e-17
predominantly O 0 1.4005464117638994e-19
towards O 0 1.4481963174201148e-16
the O 0 3.304109561720923e-16
3 O 0 7.555544900936673e-15
end O 0 1.0562886286133444e-12
. O 0 3.7855691346379283e-14

All O 0 6.555278103106618e-14
were O 0 2.521366150465428e-15
found O 0 2.945829183411135e-16
in O 0 7.494100736377694e-19
compound O 0 2.5858804572446992e-14
heterozygous O 0 4.9896254527203796e-15
individuals O 0 2.9575846772300445e-16
. O 0 1.4995424064793983e-13

The O 0 9.169846956411098e-13
C6 O 0 0.00030233629513531923
/ O 0 9.72351244854508e-07
C7 O 0 1.2380726275296183e-06
marker O 0 2.77970757522894e-09
haplotypes O 0 2.4559954070468848e-09
associated O 0 1.9725941800136093e-12
with O 0 1.7290978007784993e-15
most O 0 3.517880973503973e-14
C7 B-Disease 0 0.09720879793167114
defects I-Disease 1 0.9441956281661987
are O 0 2.2118220341198203e-13
tabulated O 0 1.902333579550941e-08
. O 0 5.7002441673358484e-15
. O 0 1.9014328414730663e-13

A O 0 2.9150115836911817e-15
genome O 0 9.938055458051046e-15
- O 0 3.6476676713859124e-12
wide O 0 9.933729237272945e-16
search O 0 3.544102583040036e-16
for O 0 1.0963113211714565e-19
chromosomal O 0 1.0876783848590144e-11
loci O 0 4.0062208785844947e-14
linked O 0 6.738690855323526e-11
to O 0 1.448993513066335e-14
mental O 0 5.677477151605492e-12
health O 0 8.378767857922774e-17
wellness O 0 3.2090946467142967e-15
in O 0 2.1418838682450504e-20
relatives O 0 1.9062050314506442e-16
at O 0 8.131577505006612e-18
high O 0 4.780857440733959e-17
risk O 0 1.9341719947261722e-15
for O 0 5.154607419987469e-18
bipolar B-Disease 0 0.00021735781047027558
affective I-Disease 0 0.00032400310738012195
disorder I-Disease 0 1.7946615116670728e-05
among O 0 1.7716820380945744e-16
the O 0 1.658536568140427e-15
Old O 0 1.8031269632956537e-07
Order O 0 7.875344799034012e-13
Amish O 0 2.2926387455157737e-09
. O 0 4.2215275058207075e-15

Bipolar B-Disease 1 0.9747205972671509
affective I-Disease 0 0.15068453550338745
disorder I-Disease 1 0.9403659701347351
( O 0 1.4369478940068348e-09
BPAD B-Disease 1 0.999982476234436
; O 0 6.876249472043128e-07
manic B-Disease 1 0.9998084902763367
- I-Disease 1 0.9999752044677734
depressive I-Disease 1 0.9999853372573853
illness I-Disease 1 0.9999582767486572
) O 0 1.3702640367860286e-13
is O 0 4.3420389529551905e-18
characterized O 0 2.0259415096128386e-17
by O 0 1.8409132007036083e-19
episodes O 0 3.4711482820026784e-12
of O 0 4.4411265049426114e-18
mania B-Disease 0 1.9552753656171262e-06
and O 0 4.8851276756439743e-14
/ O 0 1.1779195674410659e-11
or O 0 1.1118240524207387e-13
hypomania B-Disease 0 6.47012043941686e-08
interspersed O 0 1.5043624332355954e-11
with O 0 1.90947894614068e-17
periods O 0 3.730649212403854e-14
of O 0 1.2504106831648875e-16
depression B-Disease 0 4.156120725351542e-10
. O 0 2.985586834724531e-14

Compelling O 0 1.7915348227821003e-15
evidence O 0 6.95631236305364e-19
supports O 0 2.706172452370055e-18
a O 0 4.0368598166392773e-20
significant O 0 3.597351534546648e-21
genetic O 0 1.416382977531105e-15
component O 0 8.216206353476912e-17
in O 0 4.061724894125396e-22
the O 0 3.2574826906219637e-21
susceptibility O 0 4.281354289918226e-15
to O 0 9.318464621419918e-16
develop O 0 1.634341828538055e-10
BPAD B-Disease 1 0.9999912977218628
. O 0 2.5214001025952726e-11

To O 0 1.4057733604711528e-15
date O 0 1.751443906355607e-14
, O 0 1.4525228028960122e-16
however O 0 2.9415144356281296e-18
, O 0 1.7689365643784468e-20
linkage O 0 1.193501398175068e-15
studies O 0 6.951146764884854e-17
have O 0 3.0944374351211275e-19
attempted O 0 5.04870580226802e-17
only O 0 5.427007598751105e-21
to O 0 2.7587140343012344e-19
identify O 0 1.6771654696285093e-15
chromosomal O 0 1.6619408974016814e-11
loci O 0 8.144011723679179e-14
that O 0 2.1296297516258667e-13
cause O 0 2.1904735512424944e-13
or O 0 4.2021503566028445e-15
increase O 0 5.514558268864793e-19
the O 0 2.491011136613794e-16
risk O 0 3.7517908918482945e-11
of O 0 1.3507893813704424e-16
developing O 0 4.996685287750324e-10
BPAD B-Disease 1 0.9999841451644897
. O 0 4.186589009497199e-12

To O 0 5.481055757508959e-15
determine O 0 2.0869533589780148e-17
whether O 0 1.2208195292499156e-18
there O 0 1.6648276447942654e-19
could O 0 2.1520813572989527e-19
be O 0 1.1245969762830025e-21
protective O 0 2.551026167166395e-17
alleles O 0 1.1887557339606757e-18
that O 0 9.085005731369933e-18
prevent O 0 7.312651460929243e-13
or O 0 1.2150621220979874e-12
reduce O 0 3.0398199148823357e-13
the O 0 2.922637156617516e-16
risk O 0 3.44212424405535e-13
of O 0 1.0994522810536852e-19
developing O 0 1.2013815574416116e-14
BPAD B-Disease 1 0.9999982118606567
, O 0 8.356188241533489e-20
similar O 0 2.5040259511796923e-23
to O 0 2.2064786365394508e-21
what O 0 2.9560771393358204e-21
is O 0 2.2815859507969112e-23
observed O 0 2.0324173386074543e-20
in O 0 4.777459175982438e-20
other O 0 2.8545985020222986e-11
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 9.137279410180222e-18
we O 0 8.472061381950536e-19
used O 0 5.947691647691061e-18
mental O 0 5.982057297432286e-12
health O 0 1.842926429274387e-15
wellness O 0 8.147468810726366e-12
( O 0 7.185213401074494e-18
absence O 0 7.963754800992669e-17
of O 0 4.980237656388411e-20
any O 0 1.310271335874802e-13
psychiatric B-Disease 0 1.5129258201795892e-07
disorder I-Disease 0 1.273010052926793e-08
) O 0 1.2725004039043393e-19
as O 0 6.004174486747114e-20
the O 0 5.324137155952023e-19
phenotype O 0 1.5763024803353617e-15
in O 0 1.1370215320061366e-19
our O 0 1.2635164216171033e-14
genome O 0 1.885694816847151e-15
- O 0 2.8491889837028994e-13
wide O 0 1.3687214923802896e-15
linkage O 0 8.053781253014591e-11
scan O 0 6.652590284206283e-11
of O 0 9.796653484930402e-20
several O 0 6.96648254868498e-19
large O 0 2.4332857750839645e-18
multigeneration O 0 4.685561383332981e-10
Old O 0 3.255573588489824e-11
Order O 0 1.4294153205784412e-15
Amish O 0 5.553770984767503e-12
pedigrees O 0 8.85768865075071e-15
exhibiting O 0 1.6447862993230243e-18
an O 0 5.896941506322124e-21
extremely O 0 1.2626010331110056e-14
high O 0 7.783193035383607e-13
incidence O 0 2.454711705013324e-07
of O 0 5.645783320018527e-12
BPAD B-Disease 1 0.9999966621398926
. O 0 1.0328624067135195e-10

We O 0 1.2115879410856678e-09
have O 0 4.341880299713703e-15
found O 0 4.0124701791432405e-17
strong O 0 2.7169997683745827e-20
evidence O 0 5.882312869695706e-22
for O 0 1.6281270246142064e-23
a O 0 1.7672639470187277e-20
locus O 0 5.392690417480028e-13
on O 0 8.104271032038923e-09
chromosome O 0 0.0826241746544838
4p O 0 1.0900759662035853e-05
at O 0 1.0003310706900928e-13
D4S2949 O 0 7.53499706748241e-14
( O 0 5.605846438254028e-19
maximum O 0 5.0408518877879515e-18
GENEHUNTER O 0 2.3413723737597536e-10
- O 0 6.53324408461664e-11
PLUS O 0 9.509372591665413e-14
nonparametric O 0 3.2827145949460013e-12
linkage O 0 1.542933489306897e-11
score O 0 7.952993732324165e-13
= O 0 3.5025754269602666e-14
4 O 0 9.612976918389055e-17
. O 0 8.747540856866674e-17
05 O 0 3.6596241445238653e-13
, O 0 6.396204659161726e-16
P O 0 5.467057917485363e-10
= O 0 2.440053062759736e-14
5 O 0 9.301271440777432e-17
. O 0 2.3949422479229874e-16
22 O 0 8.422996742054841e-16
x O 0 2.364501476559422e-11
10 O 0 1.3537355737192297e-15
( O 0 5.149593257909326e-19
- O 0 7.469183258002055e-12
4 O 0 9.60092872174731e-15
) O 0 1.3364834084816236e-17
; O 0 3.445687016038641e-19
SIBPAL O 0 9.624035102922049e-14
Pempirical O 0 1.58243584590643e-15
value O 0 2.732507789272818e-20
< O 0 1.7450382114201902e-18
3 O 0 5.328728525339575e-19
x O 0 2.5394397955985637e-12
10 O 0 2.506777860833545e-16
( O 0 1.6799985249694e-19
- O 0 1.7123296053647707e-12
5 O 0 4.834874650839387e-15
) O 0 3.89445301242785e-17
) O 0 1.7756654007805786e-18
and O 0 1.5859027649944317e-17
suggestive O 0 7.227308093051726e-16
evidence O 0 1.739817706553306e-21
for O 0 5.69119854374786e-25
a O 0 1.4848836104058215e-22
locus O 0 1.2735186101747557e-14
on O 0 4.5055981168218295e-09
chromosome O 0 0.2255016714334488
4q O 0 1.2477801647037268e-05
at O 0 7.13728596081313e-14
D4S397 O 0 7.300495657221878e-14
( O 0 4.712553415242699e-19
maximum O 0 1.5216313070279137e-18
GENEHUNTER O 0 2.1081526802024797e-10
- O 0 5.7869521674636104e-11
PLUS O 0 4.985404179324443e-14
nonparametric O 0 2.1702633180159525e-12
linkage O 0 3.021406735914667e-11
score O 0 6.242137340871368e-13
= O 0 3.734165754387675e-14
3 O 0 1.980271875377051e-17
. O 0 5.3806583451692253e-17
29 O 0 1.1717577659575186e-14
, O 0 1.6131779538149592e-16
P O 0 1.519033371311096e-10
= O 0 1.104604443327782e-15
2 O 0 7.039683380004977e-18
. O 0 4.9700349703138167e-17
57 O 0 2.0617831462930878e-16
x O 0 1.3938098938903742e-11
10 O 0 2.6832023829502028e-15
( O 0 8.608431928699677e-19
- O 0 3.2320428885318497e-12
3 O 0 1.5345628142770379e-15
) O 0 4.6940398723628436e-18
; O 0 8.467307678367771e-20
SIBPAL O 0 2.1121893093605827e-14
Pempirical O 0 2.6337031010016416e-16
value O 0 4.798882265274638e-21
< O 0 2.842422385846128e-19
1 O 0 8.394587516531849e-21
x O 0 1.1682113609801092e-11
10 O 0 6.980595876999399e-15
( O 0 1.5287993440235685e-18
- O 0 9.51653079256376e-12
3 O 0 4.650469648991495e-15
) O 0 2.2319802060809157e-18
) O 0 3.57529836627223e-21
that O 0 1.8695449105402663e-21
are O 0 4.8544818255851135e-23
linked O 0 6.9423249167392e-16
to O 0 4.2289554553725356e-16
mental O 0 2.8618000330604687e-11
health O 0 5.521913662269191e-16
wellness O 0 2.612304632592516e-13
. O 0 6.633972630807521e-16

These O 0 5.145622968515118e-13
findings O 0 1.124253532473361e-14
are O 0 2.434689169711222e-17
consistent O 0 1.2455588883691822e-17
with O 0 1.5664618143536455e-20
the O 0 1.0592339357219187e-20
hypothesis O 0 8.119302971896938e-18
that O 0 1.5445849227914066e-19
certain O 0 6.755985245317665e-19
alleles O 0 1.2473004840616881e-15
could O 0 1.2589422776834724e-12
prevent O 0 1.820903670901597e-11
or O 0 3.15547311587408e-13
modify O 0 1.347203954432186e-14
the O 0 5.770179101827487e-18
clinical O 0 1.795947282102144e-16
manifestations O 0 9.305437551152679e-14
of O 0 9.69136650893499e-17
BPAD B-Disease 1 0.9999997615814209
and O 0 3.426583061416047e-15
perhaps O 0 1.6660919386617644e-19
other O 0 4.2533138543927394e-19
related O 0 3.298430322276613e-12
affective B-Disease 0 6.177396016937564e-07
disorders I-Disease 0 1.1969211755058495e-07
. O 0 1.0203585209828808e-13

Segregation O 0 2.567229273608973e-07
distortion O 0 0.00029547614394687116
in O 0 1.913394165331539e-10
myotonic B-Disease 1 0.9999440908432007
dystrophy I-Disease 1 0.9999672174453735
. O 0 9.49113054815598e-09

Myotonic B-Disease 1 0.9999039173126221
dystrophy I-Disease 1 0.9999809265136719
( O 0 8.466770062831586e-10
DM B-Disease 1 0.9999979734420776
) O 0 7.972900226312085e-14
is O 0 1.4238525905160262e-16
an O 0 1.3236222554251388e-16
autosomal B-Disease 1 0.755672037601471
dominant I-Disease 1 0.9999904632568359
disease I-Disease 1 0.9999983310699463
which O 0 6.674988894950218e-10
, O 0 2.0848696910149938e-16
in O 0 1.4625501579585124e-20
the O 0 1.4519230390492684e-18
typical O 0 1.8912564351788227e-15
pedigree O 0 5.955568677107337e-11
, O 0 5.468763999190208e-19
shows O 0 3.566358109031347e-16
a O 0 2.394763805936308e-20
three O 0 3.3624798842461663e-19
generation O 0 1.2965353752636757e-14
anticipation O 0 1.3404622497983996e-15
cascade O 0 2.0612212024012644e-12
. O 0 5.255472164227004e-14

This O 0 7.214912295264251e-16
results O 0 1.2061933398567265e-15
in O 0 1.4379908938946806e-15
infertility B-Disease 0 0.0939326286315918
and O 0 4.032072320114821e-05
congenital B-Disease 1 0.999991774559021
myotonic I-Disease 1 0.9999983310699463
dystrophy I-Disease 1 0.9999978542327881
( O 0 1.93323259283602e-14
CDM B-Disease 0 3.2401594428355107e-12
) O 0 7.374964497691096e-18
with O 0 9.999936674757004e-21
the O 0 3.866455440574525e-20
disappearance O 0 8.210802914312976e-13
of O 0 2.049432876526528e-16
DM B-Disease 1 0.9999991655349731
in O 0 1.3110535603460283e-17
that O 0 1.3567962213950147e-15
pedigree O 0 2.093022111182563e-08
. O 0 1.0723903319173611e-13

The O 0 9.974773806918928e-17
concept O 0 2.5945646201847765e-15
of O 0 4.042662470024773e-16
segregation O 0 3.0336388956442306e-10
distortion O 0 3.921190039335443e-09
, O 0 4.892475124640333e-18
where O 0 1.5773699678760045e-19
there O 0 1.9777066326861907e-23
is O 0 1.688746409787191e-23
preferential O 0 2.188400815894019e-18
transmission O 0 3.302780575073494e-12
of O 0 2.4175625676730174e-21
the O 0 2.602528892966269e-19
larger O 0 6.076738130501504e-19
allele O 0 1.2545010052671785e-15
at O 0 3.4527728966286765e-15
the O 0 2.302277902284551e-14
DM B-Disease 1 0.9999995231628418
locus O 0 6.827015619492727e-10
, O 0 1.0146987145919634e-14
has O 0 2.8238392865893337e-15
been O 0 3.184315968391793e-15
put O 0 9.398477005331807e-14
forward O 0 7.065302983373092e-16
to O 0 4.673461934828239e-16
explain O 0 1.2372216390223092e-14
partially O 0 1.3085322417088173e-14
the O 0 2.0047375617906543e-18
maintenance O 0 2.0958669844669923e-15
of O 0 7.931704199234199e-18
DM B-Disease 1 0.9999994039535522
in O 0 9.30470903796708e-18
the O 0 1.0927264341339859e-16
population O 0 3.686394324360306e-16
. O 0 6.339418193949259e-14

In O 0 5.558281815952942e-17
a O 0 1.6468651489589773e-17
survey O 0 1.1557320720020567e-14
of O 0 3.608821922085124e-17
DM B-Disease 1 0.9999996423721313
in O 0 3.682309990780952e-13
Northern O 0 4.15241070694794e-11
Ireland O 0 3.503401302396014e-08
, O 0 1.0966702264185446e-13
59 O 0 4.334317566044143e-15
pedigrees O 0 5.055020638189411e-12
were O 0 8.22543001287692e-16
ascertained O 0 1.7972050713951915e-12
. O 0 9.361050346337607e-14

Sibships O 0 2.1919838388839707e-08
where O 0 1.7415379576814216e-13
the O 0 1.747123905975712e-17
status O 0 1.6028979384506074e-15
of O 0 1.0340799507437969e-15
all O 0 5.736633634486135e-14
the O 0 9.634085244132428e-17
members O 0 7.769687331183158e-19
had O 0 1.401013405884498e-16
been O 0 1.0636323620004186e-18
identified O 0 2.306541025725527e-18
were O 0 1.0830678364470557e-19
examined O 0 1.6231754820370405e-19
to O 0 6.97761985708641e-21
determine O 0 1.912553504099236e-19
the O 0 2.1950035654138732e-20
transmission O 0 9.785796034177813e-14
of O 0 5.605175052747764e-22
the O 0 1.230029746964969e-16
DM B-Disease 1 0.999998927116394
expansion O 0 6.233840718533367e-18
from O 0 6.4757918748857405e-18
affected O 0 3.1344319217269415e-16
parents O 0 7.425499111981553e-17
to O 0 1.3514787040621074e-18
their O 0 2.8026549925785037e-15
offspring O 0 1.8207282198850344e-13
. O 0 5.290274503392373e-16

Where O 0 1.9897562872524255e-13
the O 0 1.8394268398609118e-17
transmitting O 0 4.290778932158901e-08
parent O 0 6.346687064784362e-11
was O 0 4.5566005829611456e-11
male O 0 2.125518233642154e-10
, O 0 3.383162670232134e-15
58 O 0 3.207952295729982e-14
. O 0 3.659217568709183e-14

3 O 0 2.413091211225793e-12
% O 0 4.698523522155126e-16
of O 0 3.591017221291438e-21
the O 0 4.6205605913691456e-18
offspring O 0 1.081164671679069e-12
were O 0 2.954398065167091e-13
affected O 0 1.370278338937343e-15
, O 0 1.0661391948853065e-17
and O 0 2.6129397294260377e-15
in O 0 3.6572527394893415e-20
the O 0 2.3643825283247437e-20
case O 0 1.328091335464907e-19
of O 0 1.146917170818394e-22
a O 0 2.9007751700744336e-18
female O 0 4.1755973136624325e-13
transmitting O 0 2.0932777289317528e-08
parent O 0 8.938755226457762e-13
, O 0 3.9797416201547224e-17
68 O 0 9.740446906621354e-15
. O 0 1.8480666487147995e-14

7 O 0 2.712234603574615e-10
% O 0 9.758149895218969e-15
were O 0 3.4443273428698407e-15
affected O 0 3.173809075252519e-14
. O 0 2.0420526096356743e-14

Studies O 0 3.008140526901187e-15
on O 0 5.786978726478133e-17
meiotic O 0 2.1400711064378797e-12
drive O 0 1.4790767352210188e-12
in O 0 2.1449693256006465e-17
DM B-Disease 1 0.999997615814209
have O 0 5.276344914225878e-17
shown O 0 9.555934543347398e-18
increased O 0 3.3752890829931053e-21
transmission O 0 4.198400965261823e-15
of O 0 1.286128653831322e-22
the O 0 4.2246719017336525e-21
larger O 0 2.3585437560331774e-21
allele O 0 9.12745961825636e-17
at O 0 7.366589293988996e-17
the O 0 4.786772179160407e-16
DM B-Disease 1 0.9999984502792358
locus O 0 1.937869725798791e-10
in O 0 1.2262080931256351e-14
non O 0 2.099024842827646e-10
- O 0 0.05822864919900894
DM O 1 0.9999966621398926
heterozygotes O 0 7.010528824125117e-10
for O 0 2.2078228760560599e-16
CTGn O 0 2.0094642394496987e-08
. O 0 1.9802380763801752e-13

This O 0 9.343091707314643e-17
study O 0 5.625294100690003e-20
provides O 0 1.2147553211608602e-21
further O 0 2.3601098658110946e-21
evidence O 0 1.0540428442343943e-19
that O 0 3.4499519592769644e-17
the O 0 1.2003554617293077e-14
DM B-Disease 1 0.9999991655349731
expansion O 0 2.7377301289296984e-16
tends O 0 1.2716988107095567e-13
to O 0 2.45747269129138e-19
be O 0 9.77590172055995e-19
transmitted O 0 1.8215429165024943e-11
preferentially O 0 2.4546158508553795e-11
. O 0 1.6980702597074043e-13

Diagnosis O 0 1.5738768297524075e-06
of O 0 3.7150456322354586e-12
hemochromatosis B-Disease 1 0.9999014139175415
. O 0 2.039220126093255e-09

If O 0 4.855402746528625e-10
untreated O 0 1.2138725651311688e-06
, O 0 1.4701572749985237e-13
hemochromatosis B-Disease 1 0.9999992847442627
can O 0 1.4349635080179723e-07
cause O 0 1.8602329987515986e-07
serious O 0 4.149981123191537e-06
illness O 0 0.045562319457530975
and O 0 8.382365439783823e-13
early B-Disease 0 8.70348443923058e-14
death I-Disease 0 1.8131554591072074e-10
, O 0 3.528948534956391e-18
but O 0 9.88401885883206e-17
the O 0 1.0392559573262311e-16
disease O 0 4.7905662076130895e-11
is O 0 6.019457506763917e-17
still O 0 1.4723509548066407e-14
substantially O 0 6.793238965330326e-15
under O 0 5.738482876816581e-14
- O 0 0.0028940329793840647
diagnosed O 0 0.0004986746935173869
. O 0 3.154259405752091e-12

The O 0 9.05805254741826e-17
cornerstone O 0 1.5283410396420998e-15
of O 0 8.77676495242213e-22
screening O 0 3.613846372222136e-19
and O 0 2.3541495609773812e-20
case O 0 6.573135766669315e-24
detection O 0 1.2254842333686494e-20
is O 0 2.2705085450847443e-22
the O 0 2.0511238029878842e-22
measurement O 0 1.6297608736887283e-16
of O 0 5.407915236237615e-20
serum O 0 1.876861703163299e-14
transferrin O 0 1.5939293206710184e-14
saturation O 0 1.4562228376271968e-13
and O 0 9.181662447691244e-16
the O 0 1.613004841456364e-17
serum O 0 5.2209781636891606e-12
ferritin O 0 4.721580904032407e-10
level O 0 3.8508418323665236e-14
. O 0 4.558990514204504e-15

Once O 0 9.212208773590191e-11
the O 0 7.124276064138897e-16
diagnosis O 0 1.076212361415807e-12
is O 0 1.3871744426259144e-18
suspected O 0 2.573472847582775e-13
, O 0 7.451828601751361e-18
physicians O 0 2.5700509386840813e-19
must O 0 9.420703127699319e-20
use O 0 1.4225318643191873e-18
serum O 0 9.988364579882614e-10
ferritin O 0 7.991641723492648e-06
levels O 0 6.916639483378617e-10
and O 0 6.212802407951079e-12
hepatic O 0 4.460964078134566e-07
iron O 0 5.162461320651346e-07
stores O 0 4.787142565492418e-14
on O 0 1.8614885633904017e-14
liver O 0 6.383705819816218e-14
biopsy O 0 1.1712802765444924e-13
specimens O 0 2.334994384436126e-18
to O 0 3.6358602332615863e-19
assess O 0 1.0070541800390112e-17
patients O 0 1.3617964897339993e-20
for O 0 6.962270517136982e-23
the O 0 2.0806884584546607e-18
presence O 0 1.6348686252974816e-14
of O 0 1.0701496841323188e-15
iron B-Disease 0 5.693761522707064e-06
overload I-Disease 0 1.3469028203871858e-07
. O 0 2.459720828981802e-14

Liver O 0 1.247925752068113e-06
biopsy O 0 2.306825486186881e-08
is O 0 7.057359508393741e-15
also O 0 1.097324462325469e-18
used O 0 1.2924661915965024e-18
to O 0 3.1574083687093167e-19
establish O 0 5.9184272383898536e-18
the O 0 5.2568972362802664e-17
presence O 0 9.003253803835203e-15
or O 0 1.1531486703020288e-11
absence O 0 5.861507568379054e-13
of O 0 4.101250812544067e-17
cirrhosis B-Disease 0 4.196794856081709e-10
, O 0 3.0470453109970324e-18
which O 0 6.20904333269413e-17
can O 0 3.6566060814295035e-15
affect O 0 1.0927656755822454e-13
prognosis O 0 1.466705402963786e-11
and O 0 9.893610792275666e-15
management O 0 1.0877866465116952e-14
. O 0 6.038780048826461e-16

A O 0 6.870271529685421e-16
DNA O 0 1.6554464437180776e-14
- O 0 4.552202798741023e-12
based O 0 6.867228960869104e-17
test O 0 8.712506118330358e-17
for O 0 4.872775194432827e-23
the O 0 1.5489732451879712e-21
HFE O 0 2.3478675977859416e-16
gene O 0 7.445512793431183e-20
is O 0 7.591135284649792e-23
commercially O 0 5.0884122009950334e-20
available O 0 3.386813593993037e-17
, O 0 3.040000982997888e-16
but O 0 2.3448421019774677e-16
its O 0 2.581005653427639e-19
place O 0 1.883881014904614e-17
in O 0 4.675821781595686e-21
the O 0 1.2156518217705672e-18
diagnosis O 0 2.0159488661741776e-11
of O 0 1.164702066210185e-16
hemochromatosis B-Disease 1 0.9999998807907104
is O 0 1.7041319527386078e-12
still O 0 3.394370610190203e-15
being O 0 9.212250924998965e-17
evaluated O 0 1.5876720977072377e-15
. O 0 5.567794472406641e-15

Currently O 0 3.6117216530885676e-13
, O 0 2.7397138403874985e-17
the O 0 1.5282896909063107e-21
most O 0 1.826903879967435e-23
useful O 0 5.57091678000906e-23
role O 0 5.331735132995749e-20
for O 0 3.0979080394021557e-20
this O 0 3.581050160199269e-18
test O 0 6.20279315598568e-17
is O 0 8.54099623196699e-24
in O 0 4.195383852946143e-26
the O 0 6.298408251108403e-24
detection O 0 2.608495367404129e-17
of O 0 1.8536689461346354e-18
hemochromatosis B-Disease 1 0.9999998807907104
in O 0 1.631813869794636e-16
the O 0 2.3478752409348016e-17
family O 0 1.53110358593056e-12
members O 0 4.711529262246782e-19
of O 0 4.960686547908253e-21
patients O 0 1.2246897683955577e-20
with O 0 2.7086868253616557e-22
a O 0 4.815423050248214e-21
proven O 0 3.028866999604026e-15
case O 0 1.0224059077454441e-17
of O 0 3.581157745377689e-19
the O 0 3.5975034257985927e-13
disease O 0 4.6284256427497894e-08
. O 0 3.631726538423641e-13

It O 0 1.32962917485905e-16
is O 0 8.603672021262317e-19
crucial O 0 6.514873445676462e-16
to O 0 5.6148065797484437e-14
diagnose O 0 0.00962904840707779
hemochromatosis B-Disease 1 0.9999990463256836
before O 0 8.641546628496144e-06
hepatic B-Disease 1 0.9996259212493896
cirrhosis I-Disease 1 0.9942461848258972
develops O 0 4.5223766398372334e-10
because O 0 9.658486939853844e-16
phlebotomy O 0 1.8797610135123932e-09
therapy O 0 4.919007909331974e-12
can O 0 2.489267201654516e-13
avert O 0 1.9920858562727517e-07
serious O 0 0.00012966309441253543
chronic O 1 0.9998998641967773
disease O 0 0.0031801837030798197
and O 0 5.35397524925596e-11
can O 0 1.2992077032258909e-12
even O 0 1.2700552957413402e-13
lead O 0 8.654518480989346e-14
to O 0 5.164929509066498e-15
normal O 0 5.748662179963504e-13
life O 0 2.6867412808440072e-11
expectancy O 0 2.751167566331092e-12
. O 0 5.132022390735051e-19
. O 0 3.593095498104817e-16

Prevalence O 0 6.167383048705233e-07
of O 0 3.000927096715057e-18
the O 0 2.745225510245062e-18
I1307K O 0 2.114909343912453e-15
APC B-Disease 0 8.925214752580533e-16
gene O 0 3.864192363340496e-16
variant O 0 3.3069643486267897e-13
in O 0 6.859243028363272e-17
Israeli O 0 1.2654195746808483e-10
Jews O 0 2.941359178790237e-13
of O 0 5.0253713447956894e-20
differing O 0 1.8939627583848594e-16
ethnic O 0 1.4065846740390214e-13
origin O 0 8.229675892579974e-14
and O 0 1.5070153241633633e-12
risk O 0 6.809877097987971e-13
for O 0 2.2508284857936144e-15
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999973773956299
. O 0 6.638184468256425e-13

BACKGROUND O 0 4.559111630442203e-07
& O 0 1.4760726863016771e-08
AIMS O 0 5.6390277863860305e-11
Israeli O 0 3.006645488135007e-10
Jews O 0 2.683331890018792e-10
of O 0 1.0990693794790066e-14
European O 0 3.827067551753771e-10
birth O 0 8.174690258044848e-09
, O 0 6.751726049991982e-14
i O 0 4.494707991214986e-12
. O 0 7.89128960207093e-19
e O 0 1.0372637093645094e-16
. O 0 7.733434589874373e-19
, O 0 7.503025498199259e-19
Ashkenazim O 0 5.898402697258193e-14
, O 0 2.0033976778323347e-20
have O 0 2.711605322934515e-20
the O 0 5.4697057443176e-18
highest O 0 3.673872939202738e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.0731013389886357e-05
of O 0 1.6155472224280765e-18
any O 0 6.63579428103971e-16
Israeli O 0 2.3392320969151115e-08
ethnic O 0 4.559476352028469e-08
group O 0 9.459841798786783e-10
. O 0 5.492028273129668e-13

The O 0 2.600718314546579e-15
I1307K O 0 2.3046294690340363e-13
APC B-Disease 0 1.1381879867853467e-13
gene O 0 7.550934500604768e-15
variant O 0 5.219992407073937e-12
was O 0 7.434364929226334e-11
found O 0 1.7846482755143334e-12
in O 0 8.479543602822354e-16
6 O 0 1.0942721338433326e-12
. O 0 7.718309498472298e-13

1 O 0 1.2674181365870951e-12
% O 0 1.3837993141161266e-15
of O 0 2.2138230552604483e-20
American O 0 5.575358264867385e-16
Jews O 0 1.5269353164683308e-13
, O 0 2.6057316908031404e-16
28 O 0 1.61888716763769e-15
% O 0 8.201601109744399e-20
of O 0 8.968503035420899e-21
their O 0 7.128412443657695e-11
familial O 1 0.9965877532958984
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
cases O 0 5.013929267431994e-13
, O 0 6.018513197376626e-18
but O 0 3.1210805648958456e-16
not O 0 1.1979898257625686e-15
in O 0 2.3409989546770973e-16
non O 0 3.69442584163826e-12
- O 0 4.479641120269662e-07
Jews O 0 8.62831761594407e-09
. O 0 4.506625281286425e-11

We O 0 1.7629455549881363e-15
assessed O 0 4.6231544643339894e-17
the O 0 4.315568759763187e-18
I1307K O 0 4.48249944107193e-12
prevalence O 0 2.1701147545627464e-08
in O 0 5.2899465759103326e-18
Israeli O 0 1.2653071949572658e-12
Jews O 0 1.7196789849874446e-14
of O 0 1.9484599604617425e-20
differing O 0 4.787299854216767e-17
ethnic O 0 8.663796032860622e-15
origin O 0 1.693237496286186e-14
and O 0 1.5627192736459433e-13
risk O 0 4.3347023561714215e-13
for O 0 1.6445692065984404e-15
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999959468841553
. O 0 1.5664861985689726e-12

METHODS O 0 3.500314685436133e-16
DNA O 0 2.23131983471069e-15
samples O 0 4.4976170479452994e-15
from O 0 2.664205547389754e-19
500 O 0 1.142735152840376e-19
unrelated O 0 4.8499065078029457e-17
Jews O 0 1.9836706604582643e-13
of O 0 2.6258079598398434e-16
European O 0 8.731465550582129e-11
or O 0 1.157499762705072e-09
non O 0 2.0091407378942938e-13
- O 0 1.8390028388992619e-09
European O 0 3.339000256841196e-11
origin O 0 7.977134035795641e-13
, O 0 3.154642524895123e-17
with O 0 3.4808023840051656e-19
or O 0 4.0677801898280275e-18
without O 0 1.6245932243705167e-20
a O 0 1.6844752644108347e-22
personal O 0 7.689032211226268e-15
and O 0 3.2304077490254157e-13
/ O 0 1.6218698259407027e-11
or O 0 1.5071475968284065e-12
family O 0 6.845707160862968e-12
history O 0 1.4095167802298959e-14
of O 0 3.094142493533964e-19
neoplasia B-Disease 0 1.6360766636868557e-13
, O 0 2.719821811356581e-19
were O 0 3.821818060534779e-20
examined O 0 8.062232679509607e-19
for O 0 5.8573459900253125e-22
the O 0 9.82941306836177e-19
I1307K O 0 4.554208166184306e-16
variant O 0 2.674501774666931e-18
by O 0 1.9448720645547937e-21
the O 0 6.452332299237178e-21
allele O 0 9.931793502290673e-17
- O 0 2.275275286019472e-16
specific O 0 9.725284057335992e-18
oligonucleotide O 0 6.826299525641844e-10
( O 0 8.653283956938502e-17
ASO O 0 1.7634395277354997e-08
) O 0 3.1142729677162077e-19
method O 0 7.933493887207519e-17
. O 0 8.557210488975824e-15

RESULTS O 0 1.2494429319290234e-12
In O 0 1.4352047882913826e-18
persons O 0 3.1159976392933808e-18
at O 0 3.0927189901460155e-16
average O 0 8.14000102267393e-15
risk O 0 2.3721874616543237e-13
for O 0 2.3009632393877766e-12
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.762832264331441e-14
I1307K O 0 1.9563966569544674e-15
was O 0 1.1601529698878374e-15
found O 0 2.238258093339887e-16
in O 0 2.855933502272781e-18
5 O 0 4.0146329321902666e-15
. O 0 3.9144468916285646e-14

0 O 0 1.054553926821411e-11
% O 0 1.374708384778954e-14
of O 0 5.508022818242588e-18
120 O 0 7.577477336798166e-16
European O 0 2.4496230781670403e-13
and O 0 7.14963721906714e-12
1 O 0 5.990805690880754e-15
. O 0 5.091553670647994e-14

6 O 0 1.703964608301689e-10
% O 0 1.936517047792293e-14
of O 0 7.881154364820471e-18
188 O 0 1.8738782837164798e-14
non O 0 6.114449224714491e-13
- O 0 5.856289135408588e-05
European O 0 4.502207389123214e-07
Jews O 0 1.8536075785391404e-08
( O 0 1.0212258022527392e-15
P O 0 9.720650950839627e-10
= O 0 3.615453409203627e-15
0 O 0 3.479660616265901e-19
. O 0 1.130845129468568e-18
08 O 0 4.307859221387234e-16
) O 0 1.6383622285702997e-17
. O 0 3.054113451871651e-15

It O 0 7.117902729898706e-13
occurred O 0 8.946943121264372e-13
in O 0 5.027680194585902e-17
15 O 0 7.042595300606625e-15
. O 0 2.2350180652616972e-14

4 O 0 1.2712109143109274e-10
% O 0 1.632310416390184e-14
of O 0 1.5521165315156727e-18
52 O 0 3.4142417490229046e-14
Ashkenazi O 0 2.8218300585081124e-08
Israelis O 0 1.1049159809317644e-08
with O 0 1.87659154708697e-12
familial O 0 0.0018160751787945628
cancer B-Disease 0 0.003637671237811446
( O 0 1.058421742177601e-13
P O 0 1.737543442459355e-07
= O 0 1.5372134988533848e-12
0 O 0 1.629896862181432e-17
. O 0 6.666773981689944e-16
02 O 0 2.125345689371616e-12
) O 0 5.729710117538943e-18
and O 0 3.095020272784587e-16
was O 0 4.070161447596943e-15
not O 0 3.2182735589518873e-17
detected O 0 7.557882542464506e-14
in O 0 4.2313256256125206e-17
51 O 0 3.543835757073739e-14
non O 0 6.044594485317065e-14
- O 0 3.362024258990459e-08
European O 0 3.4217717548301607e-10
Jews O 0 3.077128482575908e-11
at O 0 1.3178203645512754e-13
increased O 0 2.4282891078757767e-17
cancer B-Disease 0 2.0000373698782908e-13
risk O 0 1.2818782493817515e-13
. O 0 9.286386424916214e-16

Colorectal B-Disease 0 9.89893038649825e-08
neoplasia I-Disease 0 7.089080895639199e-07
occurred O 0 9.132672916523088e-12
personally O 0 2.2662971759651596e-12
or O 0 7.76301156061969e-14
in O 0 1.5126377858179309e-18
the O 0 9.515930236039761e-16
families O 0 1.521308036142588e-12
of O 0 1.993815081241592e-19
13 O 0 2.4781105270420906e-17
of O 0 1.5532047910090627e-20
20 O 0 3.0455809945176604e-18
Ashkenazi O 0 1.4420236177565583e-14
I1307K O 0 6.192559409796071e-16
carriers O 0 6.759569005321551e-19
, O 0 2.0626061351678867e-19
8 O 0 1.743701528909335e-17
of O 0 1.0193127614875604e-19
whom O 0 2.253458650149781e-14
also O 0 2.783244385559224e-14
had O 0 4.634376649798044e-13
a O 0 5.1172876777270365e-17
personal O 0 1.9962644870474833e-09
or O 0 4.185325863659273e-09
family O 0 3.4043337038269783e-09
history O 0 4.763427608085735e-13
of O 0 7.530961993104104e-17
noncolonic O 0 2.272062999963964e-07
neoplasia B-Disease 0 3.388586833352747e-08
. O 0 7.377291052351742e-13

CONCLUSIONS O 0 1.4901825433344396e-12
The O 0 7.792877153540444e-17
I1307K O 0 1.3721104330857714e-13
APC O 0 2.8087262875751973e-13
variant O 0 1.6579319297646555e-12
may O 0 3.80486793330817e-14
represent O 0 2.5008592110706455e-21
a O 0 1.9263546895022566e-20
susceptibility O 0 9.427691769899627e-17
gene O 0 6.166487735679584e-16
for O 0 2.2783598094364577e-15
colorectal B-Disease 1 0.9999997615814209
, I-Disease 0 9.201049210733059e-13
or I-Disease 0 7.639129942765138e-14
other I-Disease 0 3.366916663007091e-14
, I-Disease 0 8.620020523113572e-14
cancers I-Disease 0 7.615799546556445e-09
in O 0 3.810167649052551e-15
Ashkenazi O 0 1.480447963331244e-06
Jews O 0 2.5000266745678346e-08
, O 0 9.97684899105289e-13
and O 0 2.8467769049196623e-13
partially O 0 2.5149337907343083e-12
explains O 0 5.442386585884432e-15
the O 0 4.4409695344966824e-20
higher O 0 8.29136199870001e-17
incidence O 0 3.3512475017261067e-09
of O 0 1.1040637154513533e-10
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.672982157818585e-13
European O 0 1.9499510513221185e-12
Israelis O 0 2.852733049785172e-10
. O 0 6.8537088168414e-14

Systematic O 0 4.094222858419712e-14
analysis O 0 2.914911422045169e-15
of O 0 1.3891451177172608e-17
coproporphyrinogen O 0 3.751852162281466e-09
oxidase O 0 6.8758541083013824e-09
gene O 0 1.6439265948520188e-07
defects O 0 0.3285864591598511
in O 0 5.614393778241599e-16
hereditary B-Disease 0 7.2868456300057005e-06
coproporphyria I-Disease 0 9.098097280002548e-07
and O 0 1.4804165380556678e-13
mutation O 0 6.286006329174476e-14
update O 0 2.0013453394529535e-10
. O 0 1.446018652040415e-12

Hereditary B-Disease 1 0.9288750886917114
coproporphyria I-Disease 0 0.00018601102055981755
( O 0 2.2391910577796402e-14
HC B-Disease 0 1.4271591908254777e-08
) O 0 1.1898969765229694e-14
is O 0 3.31317175546536e-16
an O 0 8.171923153357102e-15
acute O 0 0.00020451568707358092
hepatic B-Disease 1 0.9988321661949158
porphyria I-Disease 1 0.9999794960021973
with O 0 1.0953836238059012e-07
autosomal O 1 0.9998645782470703
dominant O 0 0.003644033335149288
inheritance O 0 0.013092867098748684
caused O 0 2.58253265883468e-07
by O 0 2.0930534851233484e-16
deficient B-Disease 0 9.888913993227888e-11
activity I-Disease 0 1.7221661066546437e-15
of I-Disease 0 1.2602262068367887e-18
coproporphyrinogen I-Disease 0 2.0634102759764517e-10
III I-Disease 0 1.9932680506151712e-11
oxidase I-Disease 0 3.108202931145776e-11
( O 0 2.088498532362264e-17
CPO O 0 1.6029211291623824e-09
) O 0 3.137649588135324e-16
. O 0 1.7076823726521872e-15

Clinical O 0 3.6152450390986024e-12
manifestations O 0 2.347838867766683e-10
of O 0 2.3994860172021902e-17
the O 0 2.2636421884614406e-14
disease O 0 2.863592418744787e-10
are O 0 4.496423528891781e-19
characterized O 0 2.829013016770722e-16
by O 0 1.1689216137764915e-16
acute O 0 2.3303700302790276e-08
attacks O 0 8.37757283989049e-07
of O 0 1.4013262121873038e-12
neurological B-Disease 0 0.0070050121285021305
dysfunction I-Disease 0 1.7722639356065883e-08
often O 0 2.965733398880427e-14
precipitated O 0 5.145068280519279e-15
by O 0 1.0731564032510805e-19
drugs O 0 1.3394391398772348e-16
, O 0 2.392374042372551e-18
fasting O 0 4.960650488473883e-13
, O 0 1.2419476866484748e-18
cyclical O 0 2.4325683069433e-13
hormonal O 0 9.684332329118472e-12
changes O 0 2.7003076839244113e-16
, O 0 1.423722226851488e-16
or O 0 3.503195650234048e-11
infectious B-Disease 0 6.16510135387216e-07
diseases I-Disease 0 3.632688958532526e-07
. O 0 2.6084223756633884e-12

Skin O 1 0.9998422861099243
photosensitivity O 0 0.09885627776384354
may O 0 5.61968194201512e-10
also O 0 5.776659879947106e-16
be O 0 8.527125016889874e-17
present O 0 2.5897983657905766e-15
. O 0 7.275283890953443e-13

The O 0 8.933632777768583e-15
seven O 0 8.012234864077667e-17
exons O 0 1.2233114098526149e-14
, O 0 2.092268987030403e-18
the O 0 2.702642820997503e-19
exon O 0 4.1492373095307e-14
/ O 0 8.623812601527003e-12
intron O 0 2.4212032379011816e-10
boundaries O 0 4.343493880537563e-12
and O 0 8.775323166959701e-15
part O 0 1.236289021626182e-19
of O 0 1.1966798293842818e-21
3 O 0 3.953303718025882e-19
noncoding O 0 1.5970882453445086e-14
sequence O 0 1.3954968602935321e-14
of O 0 1.2797684780553247e-19
the O 0 4.80066552127246e-18
CPO O 0 2.1019484763851182e-11
gene O 0 1.8473933336223487e-18
were O 0 2.8413814307440183e-19
systematically O 0 3.6556142058482687e-16
analyzed O 0 1.8210560838644193e-19
by O 0 6.308583136836125e-23
an O 0 3.862913013347976e-22
exon O 0 3.8291514044059736e-16
- O 0 1.6119808125044516e-13
by O 0 2.641309456867985e-16
- O 0 4.511820084207585e-11
exon O 0 4.4353517386630514e-11
denaturing O 0 1.227974735229509e-07
gradient O 0 2.5605603748424244e-10
gel O 0 2.2075287375855623e-08
electrophoresis O 0 2.3396415915755142e-09
( O 0 2.9216450692780445e-16
DGGE O 0 6.566083614323315e-12
) O 0 1.2599899433743283e-19
strategy O 0 8.783712017487546e-19
followed O 0 3.648456190662723e-22
by O 0 8.323235665727128e-26
direct O 0 1.9141334367396966e-23
sequencing O 0 4.268157993056037e-17
in O 0 2.036151089720851e-19
seven O 0 6.949813825366271e-19
unrelated O 0 1.607667475097478e-16
heterozygous O 0 7.853946137924891e-15
HC B-Disease 0 2.1952429207772184e-08
patients O 0 1.93020321948012e-11
from O 0 1.0653329347160012e-12
France O 0 1.5436737443863535e-09
, O 0 2.2952332309061907e-13
Holland O 0 1.4141332549399976e-09
, O 0 4.043900292210155e-14
and O 0 4.159526889591092e-12
Czech O 0 1.4140395521167193e-08
Republic O 0 6.366230459464717e-11
. O 0 1.4510415438651059e-12

Seven O 0 3.867828366616033e-12
novel O 0 1.4797502958206754e-13
mutations O 0 9.024434709714244e-15
and O 0 4.021238942145903e-15
two O 0 1.497519896900788e-19
new O 0 4.1921332498428447e-20
polymorphisms O 0 1.3699654237908036e-14
were O 0 1.7826111189245394e-15
detected O 0 2.5103380745655768e-12
. O 0 3.740595750896872e-14

Among O 0 2.1323505993293664e-15
these O 0 1.4587968685805534e-17
mutations O 0 1.0676374505852115e-16
two O 0 7.513319355603981e-16
are O 0 7.254210918247706e-16
missense O 0 1.4929955871861161e-13
( O 0 1.1303539703003493e-17
G197W O 0 3.425617740317709e-14
, O 0 2.3404977824875637e-17
W427R O 0 4.3400917896455754e-15
) O 0 8.438746889575116e-18
, O 0 1.9028102987603388e-18
two O 0 2.226030378652883e-16
are O 0 1.176616961041856e-15
nonsense O 0 1.2061682382047412e-11
( O 0 8.570648386269786e-20
Q306X O 0 5.174257035881662e-15
, O 0 5.2642394568334096e-18
Q385X O 0 1.384792142609427e-15
) O 0 1.7702074563038006e-18
, O 0 4.844002754335032e-19
two O 0 1.5289969626417863e-19
are O 0 6.611624909333087e-20
small O 0 8.003150141035271e-20
deletions O 0 1.789214392963756e-13
( O 0 6.209087338702718e-18
662de14bp O 0 2.1755276802991807e-15
; O 0 1.3873702776359364e-18
1168del3bp O 0 2.223486558717777e-14
removing O 0 1.1308289539516895e-16
a O 0 1.800656355930441e-20
glycine O 0 1.3858852650976383e-16
at O 0 1.823497822804978e-17
position O 0 1.292037918834353e-17
390 O 0 9.202662909082741e-17
) O 0 5.0873692167154836e-18
, O 0 2.1280336297392358e-17
and O 0 1.559460288970394e-15
one O 0 2.4363972149580827e-18
is O 0 2.4507592482034598e-20
a O 0 8.916275950143552e-21
splicing O 0 4.136266849863457e-12
mutation O 0 5.375680708409082e-14
( O 0 1.208614169118966e-18
IVS1 O 0 3.993440647609425e-11
- O 0 8.671872898588506e-13
15c O 0 1.9189988140211334e-12
- O 0 8.72743110419405e-12
- O 0 2.3807941729181437e-10
> O 0 5.483236477712983e-13
g O 0 3.99322545516223e-12
) O 0 3.547981133670624e-18
which O 0 3.685711629970287e-20
creates O 0 1.1087852855881128e-20
a O 0 5.760926866350386e-23
new O 0 2.625951699467251e-21
acceptor O 0 5.976302584308351e-18
splice O 0 2.4242347018699206e-10
site O 0 1.7871060187246712e-10
. O 0 3.6125204390391463e-13

The O 0 1.895445436619469e-15
pathological O 0 8.994676748211305e-14
significance O 0 1.5562571280012334e-15
of O 0 3.4648783817316955e-19
the O 0 2.1806851646533386e-17
point O 0 2.980301010320485e-14
mutations O 0 1.2647111139436022e-16
G197W O 0 2.3188604780511853e-15
, O 0 1.6706687806898086e-18
W427R O 0 1.2888984838595836e-15
, O 0 4.689422136593266e-18
and O 0 8.595315801355276e-17
the O 0 1.1900852200002016e-18
in O 0 4.4361845143729134e-17
- O 0 7.552653502607143e-10
frame O 0 4.938740971738298e-08
deletion O 0 4.888087764415294e-12
390delGly O 0 3.238040478109605e-12
were O 0 1.320897113032986e-18
assessed O 0 4.952221242911696e-19
by O 0 1.0524879385532506e-19
their O 0 7.033658594793324e-14
respective O 0 1.5522624147428637e-13
expression O 0 4.034883795893222e-15
in O 0 7.808815688343301e-20
a O 0 7.266128984076256e-21
prokaryotic O 0 1.0124380504919351e-19
system O 0 2.884439784386712e-21
using O 0 3.098509522492104e-21
site O 0 1.8469240012689535e-15
- O 0 8.331708803779869e-13
directed O 0 4.778020359463668e-14
mutagenesis O 0 5.14354774050485e-11
. O 0 7.86611969544283e-15

These O 0 4.520752058833656e-15
mutations O 0 1.4439667113375597e-14
resulted O 0 2.3997002437459516e-14
in O 0 8.364010294050338e-18
the O 0 6.026878971219742e-17
absence O 0 6.5771536607057025e-15
or O 0 4.478783693879574e-15
a O 0 1.4084020478136178e-17
dramatic O 0 6.56717925482872e-14
decrease O 0 2.9292811665887486e-14
of O 0 3.512831334311102e-18
CPO O 0 1.0641332437444362e-07
activity O 0 1.771645113599063e-12
. O 0 2.005636460947549e-14

The O 0 1.0842304620624537e-17
two O 0 8.883383403891065e-20
polymorphisms O 0 3.896819966589613e-15
were O 0 1.7030821631854287e-16
localized O 0 6.4100573536184785e-15
in O 0 3.828404625748961e-17
noncoding O 0 1.8812952584656983e-10
part O 0 1.4790725000562825e-14
of O 0 1.5098186508927736e-18
the O 0 1.3262534435413906e-19
gene O 0 1.6610793792460579e-18
1 O 0 1.1093437940602995e-20
) O 0 6.3202202866922e-22
a O 0 7.703041906217643e-21
C O 0 8.13930696387695e-14
/ O 0 6.597130932766695e-15
G O 0 3.346978523868262e-14
polymorphism O 0 1.344153407624297e-16
in O 0 3.6955528174376805e-20
the O 0 9.66942082825753e-19
promotor O 0 6.809416919217881e-11
region O 0 1.80188408308989e-15
, O 0 2.323478789538469e-18
142 O 0 4.1512571892953477e-17
bp O 0 3.667922441604821e-15
upstream O 0 6.649804205987296e-17
from O 0 1.6414374973871946e-20
the O 0 3.658516628450315e-23
transcriptional O 0 6.750498452917024e-19
initiation O 0 5.57592111164339e-20
site O 0 1.5050990643743727e-16
( O 0 6.86632367501968e-21
- O 0 2.7821390075630573e-15
142C O 0 2.3316433487197315e-14
/ O 0 3.44455265363381e-14
G O 0 2.153187228666996e-14
) O 0 2.126877971828029e-20
, O 0 9.882943932456169e-21
and O 0 5.683362050444255e-19
2 O 0 2.7597019981453524e-20
) O 0 3.2157373327209203e-22
a O 0 2.8714178491649497e-22
6 O 0 9.913678862091342e-21
bp O 0 2.6587346782159047e-18
deletion O 0 2.9013047207628324e-19
polymorphism O 0 2.4641778276764924e-17
in O 0 1.0279815496836308e-19
the O 0 5.095660047995103e-19
3 O 0 8.703267668940999e-18
noncoding O 0 4.941911070362008e-14
part O 0 5.557452236516613e-18
of O 0 5.6382678308306575e-21
the O 0 1.8152508269279456e-19
CPO O 0 2.6913239974286907e-13
gene O 0 7.235572156766722e-19
, O 0 5.08315475734392e-20
574 O 0 3.3032776165480417e-16
bp O 0 5.476227669709609e-15
downstream O 0 2.1634612724490696e-15
of O 0 1.1929657763170152e-20
the O 0 1.2410762518731501e-18
last O 0 1.158851980220414e-16
base O 0 1.680050663197385e-18
of O 0 6.600228800028678e-22
the O 0 8.423213264851983e-18
normal O 0 1.5171801735400746e-14
termination O 0 1.0660966060687185e-13
codon O 0 2.4225655593439026e-14
( O 0 1.016238862688555e-17
+ O 0 1.3874857209342228e-12
574 O 0 1.5776735386857643e-12
delATTCTT O 0 1.258705917273062e-10
) O 0 1.5123581843779453e-14
. O 0 3.2473206930524676e-14

Five O 0 8.920842363424608e-12
intragenic O 0 2.377147367838006e-09
dimorphisms O 0 4.269046449678626e-09
are O 0 3.667990415998838e-16
now O 0 1.1717967612368278e-16
well O 0 1.1357443920237246e-16
characterized O 0 6.005338912783154e-14
and O 0 2.3797089109380345e-14
the O 0 9.280750082396727e-17
high O 0 1.0168414538386326e-14
degree O 0 6.315912363989354e-20
of O 0 6.59514474926671e-22
allelic O 0 4.708588920546467e-16
heterogeneity O 0 1.0085468837026448e-15
in O 0 1.0841063849705708e-17
HC B-Disease 0 1.9406808104971418e-10
is O 0 1.1161334617124194e-16
demonstrated O 0 2.1946958671507006e-18
with O 0 6.198002533651965e-21
seven O 0 3.891356485069212e-21
new O 0 5.591653724396786e-23
different O 0 1.9353534795457798e-22
mutations O 0 5.482442593841509e-20
making O 0 1.3056264832770305e-20
a O 0 2.58927807347628e-20
total O 0 8.844834848641533e-20
of O 0 4.397849656064756e-18
nineteen O 0 3.922122904231884e-10
CPO O 0 0.0024941200390458107
gene B-Disease 0 3.213391153167322e-07
defects I-Disease 0 0.17677903175354004
reported O 0 1.303709501465633e-10
so O 0 1.2618594557656845e-14
far O 0 4.412389439825519e-16
. O 0 1.3097494439358895e-16
. O 0 1.1748914829304985e-13

Coincidence O 0 3.7518873099474936e-13
of O 0 3.3809239439545674e-19
two O 0 1.378681158891373e-18
novel O 0 1.5875319137544672e-16
arylsulfatase O 0 3.645080331321493e-12
A O 0 1.0036447897082514e-17
alleles O 0 1.31852232298928e-16
and O 0 5.417548085860028e-16
mutation O 0 1.499362798436889e-16
459 O 0 1.790277614130138e-15
+ O 0 9.65819153711349e-16
1G O 0 2.0748663204228635e-11
> O 0 2.6517106720591772e-14
A O 0 7.335714943061577e-17
within O 0 2.264707555317788e-19
a O 0 1.025386520733881e-16
family O 0 9.685561241923324e-10
with O 0 4.98547381155845e-09
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999969005584717
: O 0 1.3297001138683825e-16
molecular O 0 7.535495439169262e-19
basis O 0 9.740571285634161e-20
of O 0 5.937484342329733e-20
phenotypic O 0 6.019093414945495e-16
heterogeneity O 0 6.637055349756338e-10
. O 0 1.298397056537226e-09

In O 0 9.707133100805843e-16
a O 0 6.807318585207604e-17
family O 0 3.678687671322678e-13
with O 0 9.267412622199922e-17
three O 0 8.095127228831646e-16
siblings O 0 2.913504073415174e-12
, O 0 1.1423858629020283e-20
one O 0 7.713186177831355e-21
developed O 0 7.815856727265535e-18
classical O 0 9.975103208714753e-12
late O 0 5.2571999731299e-06
infantile O 1 0.9999363422393799
metachromatic B-Disease 1 0.9999951124191284
leukodystrophy I-Disease 1 0.9999818801879883
( O 0 1.2082306726293734e-12
MLD B-Disease 1 0.9999791383743286
) O 0 1.2701176034849403e-14
, O 0 6.903053160582041e-17
fatal O 0 1.3915565748312542e-12
at O 0 4.0140473952544886e-13
age O 0 2.998670105627821e-12
5 O 0 6.235960451571096e-17
years O 0 1.6956401846504116e-16
, O 0 1.1248211349588623e-19
with O 0 2.5900823269686987e-17
deficient O 0 6.335489910469505e-10
arylsulfatase O 0 3.0789443217216217e-10
A O 0 1.2878818325646416e-14
( O 0 1.4992926742004598e-18
ARSA O 0 2.1805288241694143e-08
) O 0 1.1954640032923583e-17
activity O 0 1.5356813212838872e-15
and O 0 5.24587985226555e-17
increased O 0 2.815166112578258e-18
galactosylsulfatide O 0 1.9108413462642915e-10
( O 0 1.142911217199782e-16
GS O 1 0.9999892711639404
) O 0 1.5651696086722432e-15
excretion O 0 4.5410918948773915e-13
. O 0 1.1292653417189699e-14

The O 0 2.7596354597368786e-15
two O 0 1.3689146158922636e-15
other O 0 5.52792336102996e-15
siblings O 0 4.167776346264418e-09
, O 0 3.657554758330428e-15
apparently O 0 8.142687912826574e-11
healthy O 0 1.695819930335775e-14
at O 0 3.229110882290863e-15
12 O 0 3.1179595049112034e-18
( O 0 6.81733139908117e-22
1 O 0 2.0382027561339238e-19
/ O 0 3.492728838355025e-14
2 O 0 2.1499922309778645e-16
) O 0 1.4839239686119542e-18
and O 0 2.5328074480004655e-16
15 O 0 1.0894159952840027e-19
years O 0 2.0011300720429457e-19
, O 0 3.6736926714360845e-22
respectively O 0 3.0282235657908183e-20
, O 0 1.99396733417309e-19
and O 0 6.050592833836341e-14
their O 0 7.424134224054413e-11
father O 0 2.7246690592619416e-07
, O 0 2.3392415730697814e-15
apparently O 0 3.573028917007448e-13
healthy O 0 2.111092360748448e-19
as O 0 1.176941090653361e-21
well O 0 4.553384736835831e-19
, O 0 7.946596190295933e-20
presented O 0 3.460128795440429e-16
ARSA O 0 1.9009826246474404e-06
and O 0 2.6915231154944763e-10
GS O 1 0.9999991655349731
values O 0 3.7779902904017115e-13
within O 0 5.9005422461467874e-21
the O 0 4.40540315922586e-19
range O 0 1.2831992142036536e-13
of O 0 2.4354717156579216e-15
MLD B-Disease 1 0.9999898672103882
patients O 0 5.165244605322876e-15
. O 0 2.0125475033493594e-16

Mutation O 0 3.1322834544199665e-14
screening O 0 1.5295500055325512e-13
and O 0 1.4098870818586118e-15
sequence O 0 8.417659905091547e-17
analysis O 0 1.6696612230049307e-19
disclosed O 0 3.2246622884129406e-18
the O 0 1.122471812772241e-20
involvement O 0 1.3538381705849659e-16
of O 0 1.0490082385166587e-20
three O 0 7.569780524595936e-19
different O 0 7.535955558384995e-19
ARSA O 0 3.7186079215878465e-10
mutations O 0 5.046838028444875e-17
being O 0 1.1077253279501343e-18
the O 0 1.5572619140042114e-21
molecular O 0 5.397409745190159e-18
basis O 0 1.132049297645292e-18
of O 0 6.543459384895641e-18
intrafamilial O 0 4.8694211329802783e-08
phenotypic O 0 4.353386412209864e-13
heterogeneity O 0 1.4447920193561004e-08
. O 0 9.260148203793506e-10

The O 0 4.943362884833602e-14
late O 0 2.8006861274576522e-09
infantile O 1 0.9891743659973145
patient O 0 8.436711027570709e-07
inherited O 0 4.5647552724403795e-06
from O 0 2.31525757767026e-12
his O 0 1.8217054531532995e-08
mother O 0 1.524881376724352e-08
the O 0 2.8300355112695112e-18
frequent O 0 1.6113959870763493e-14
0 O 0 6.796313195311769e-18
- O 0 2.157941116380166e-13
type O 0 7.744166432795997e-15
mutation O 0 2.304916145217452e-16
459 O 0 5.499169239448637e-16
+ O 0 2.6364055993245258e-17
1G O 0 1.5731953771375845e-13
> O 0 1.4801440179103829e-15
A O 0 1.071579475747284e-15
, O 0 2.170504351405489e-15
and O 0 3.892955402484688e-12
from O 0 4.687730628341212e-15
his O 0 5.768166499997562e-10
father O 0 2.1080913056858996e-11
a O 0 6.834107413541441e-20
novel O 0 8.710275543090548e-18
, O 0 4.567441120382522e-19
single O 0 1.2708335739654747e-16
basepair O 0 2.0065359096488322e-10
microdeletion O 0 1.463912433115333e-12
of O 0 1.5530793608629552e-21
guanine O 0 7.048063753585905e-19
at O 0 1.8399784542996807e-20
nucleotide O 0 1.0379791130608881e-18
7 O 0 5.830561632182633e-18
in O 0 4.521999953431921e-20
exon O 0 7.336198095948647e-15
1 O 0 3.3806598996312344e-15
( O 0 2.0102916163828048e-16
7delG O 0 6.087940374044365e-09
) O 0 3.629266483694271e-14
. O 0 7.068868060344791e-14

The O 0 2.703359861270724e-15
two O 0 3.4166369887911503e-15
clinically O 0 2.2616011841058992e-10
unaffected O 0 1.1902637986338505e-08
siblings O 0 4.840506329095717e-10
carried O 0 5.902045955370923e-15
the O 0 3.1570950740523123e-19
maternal O 0 1.245323966560588e-13
mutation O 0 1.7376257218740106e-17
459 O 0 4.845193629719313e-16
+ O 0 8.656320702403307e-17
1G O 0 1.0007036432141403e-12
> O 0 1.0339582109334527e-14
A O 0 1.5678048340502697e-15
and O 0 2.62976049085744e-14
, O 0 7.505520068131565e-18
on O 0 4.547859146024867e-14
their O 0 5.720571179300762e-14
paternal O 0 1.1304301678755069e-12
allele O 0 5.864204970210574e-16
, O 0 5.928836023622649e-21
a O 0 1.4732324503800693e-22
novel O 0 4.3104640214079695e-20
cytosine O 0 8.401303698880066e-16
to O 0 4.784373888915499e-19
thymidine O 0 8.454479368517507e-16
transition O 0 3.126311787438529e-16
at O 0 1.4649917689445702e-18
nucleotide O 0 2.156528512916585e-18
2435 O 0 2.2895205273077172e-15
in O 0 2.3027233222423046e-20
exon O 0 1.0251836695779034e-15
8 O 0 1.3848192476637392e-14
, O 0 5.43737704443719e-18
resulting O 0 3.115162509992129e-20
in O 0 1.3488800775956292e-22
substitution O 0 4.881902102050681e-19
of O 0 1.589468647557329e-19
alanine O 0 6.682316375586361e-13
464 O 0 5.5538391810841525e-14
by O 0 2.3378054287077118e-15
valine O 0 1.8351109076775174e-08
( O 0 2.9589613704671287e-16
A464V O 0 4.312455340743648e-12
) O 0 6.0856585578966584e-15
. O 0 9.707401440843533e-14

The O 0 7.72681885922305e-14
fathers O 0 4.863315999914519e-11
genotype O 0 2.3365339611031155e-12
thus O 0 1.3573448869865987e-15
was O 0 5.365420022336587e-13
7delG O 0 9.347660068215191e-08
/ O 0 4.838450085031809e-09
A464V O 0 8.844644461269979e-10
. O 0 2.890432576445334e-13

Mutation O 0 8.952751734403464e-12
A464V O 0 2.225951367673673e-11
was O 0 2.5184270901340566e-13
not O 0 3.7653306482039143e-16
found O 0 2.362223482752922e-16
in O 0 1.0240374387856437e-17
18 O 0 2.3614768232099173e-15
unrelated O 0 1.5334607195160999e-10
MLD B-Disease 1 0.9999946355819702
patients O 0 6.860879594484948e-13
and O 0 4.695480132775641e-15
50 O 0 3.9785748984443286e-16
controls O 0 5.678920528273679e-11
. O 0 8.179326140000942e-12

A464V O 0 2.814429592157275e-11
, O 0 3.1541024090423505e-16
although O 0 3.85258998065297e-18
clearly O 0 1.9169901431493556e-16
modifying O 0 4.063709682341002e-14
ARSA O 0 4.705660103354603e-06
and O 0 4.032080447302633e-09
GS O 1 0.9999994039535522
levels O 0 2.016008693317417e-09
, O 0 1.0504925905253882e-15
apparently O 0 1.2688937357438479e-12
bears O 0 1.1214083593914456e-16
little O 0 2.0226942909492266e-21
significance O 0 2.7985331599742803e-21
for O 0 3.772061733050972e-22
clinical O 0 1.051850311547943e-18
manifestation O 0 1.0274706161838426e-14
of O 0 2.755007483471318e-15
MLD B-Disease 1 0.9999984502792358
, O 0 1.2102308282789325e-15
mimicking O 0 1.5096390934207782e-12
the O 0 2.303263901574714e-16
frequent O 0 1.094110912980284e-09
ARSA O 0 0.03797046095132828
pseudodeficiency O 0 2.7794017114501912e-06
allele O 0 2.10710560111238e-08
. O 0 7.170093945657596e-12

Our O 0 1.6418404136242515e-10
results O 0 5.436529432463507e-17
demonstrate O 0 4.677003777454584e-19
that O 0 1.9490089773595176e-21
in O 0 3.167535596383637e-23
certain O 0 1.8375595003075886e-19
genetic O 0 6.712060768299111e-11
conditions O 0 5.21188980862064e-10
MLD B-Disease 1 0.9999886751174927
- O 0 3.3146607680833995e-10
like O 0 2.8330333210120108e-14
ARSA O 0 8.30423778097611e-06
and O 0 1.0001570405204774e-10
GS O 1 0.9999951124191284
values O 0 2.017399715705838e-14
need O 0 1.957682458836212e-21
not O 0 2.9322417386390037e-23
be O 0 2.5684874045054652e-23
paralleled O 0 2.303349349331991e-18
by O 0 1.89662154021237e-18
clinical O 0 1.3225983249408064e-15
disease O 0 6.4506143482301326e-12
, O 0 8.534564570751721e-20
a O 0 3.6941010508391646e-20
finding O 0 5.215212296491269e-17
with O 0 1.9980897097309126e-16
serious O 0 7.031619617082693e-14
diagnostic O 0 3.3610650205942796e-14
and O 0 1.4162701739183544e-14
prognostic O 0 2.3449792108110046e-10
implications O 0 9.438362634853203e-13
. O 0 1.0977500917823402e-13

Moreover O 0 3.239961901199684e-12
, O 0 3.7546307691955203e-16
further O 0 3.1598108817112525e-16
ARSA O 0 1.8782789368287922e-07
alleles O 0 1.4758352417758303e-13
functionally O 0 1.2154191498733868e-12
similar O 0 1.8982737590396897e-16
to O 0 3.4798400462164245e-15
A464V O 0 1.933525822089832e-12
might O 0 2.0751767817149547e-13
exist O 0 2.4750601827280155e-16
which O 0 6.82635657713943e-16
, O 0 2.9384975011389956e-18
together O 0 8.380278858821557e-15
with O 0 7.887565510876124e-17
0 O 0 2.8370954977976513e-17
- O 0 5.840240617505099e-12
type O 0 9.500602344766906e-13
mutations O 0 4.5421331626438466e-12
, O 0 2.456596717362444e-15
may O 0 1.57263965576155e-14
cause O 0 4.932171631424594e-15
pathological O 0 1.076078896128374e-12
ARSA O 0 0.00014133128570392728
and O 0 2.844784887656715e-07
GS O 1 0.9999997615814209
levels O 0 2.1497598839959053e-11
, O 0 2.918978210031852e-19
but O 0 1.1660968788385872e-18
not O 0 4.185679948595224e-19
clinical O 0 1.1294956876967643e-18
outbreak O 0 4.549363667121604e-16
of O 0 3.1295372772952954e-21
the O 0 2.5575573272027625e-15
disease O 0 7.548775493582127e-11
. O 0 1.233102226632236e-16
. O 0 1.6442188525956324e-14

Human O 0 1.744148470095297e-08
MLH1 O 1 0.8280070424079895
deficiency O 1 0.9182154536247253
predisposes O 0 1.3174312698538415e-06
to O 0 7.081510378093014e-11
hematological B-Disease 0 0.03753780946135521
malignancy I-Disease 1 0.9475114941596985
and O 0 3.6574842710024313e-08
neurofibromatosis B-Disease 0 0.0006242703530006111
type I-Disease 0 7.123601014624725e-11
1 I-Disease 0 1.6170372603863808e-13
. O 0 3.2394178485495306e-12

Heterozygous O 0 4.354812899176608e-10
germ O 0 1.7999449255512445e-06
- O 0 1.6830665572342696e-06
line O 0 3.051128516506907e-10
mutations O 0 3.3032776165480417e-16
in O 0 9.836938473231442e-22
the O 0 1.479292871128986e-21
DNA O 0 8.252467855124693e-14
mismatch O 0 2.0917500370698505e-11
repair O 0 1.169637628938014e-12
genes O 0 8.035815800755061e-14
lead O 0 1.2888759070434075e-12
to O 0 6.404075403657061e-13
hereditary B-Disease 1 0.9999363422393799
nonpolyposis I-Disease 1 0.9999662637710571
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
. O 0 2.2556314593913385e-09

The O 0 3.439878048204503e-14
disease O 0 2.9966606973630405e-10
susceptibility O 0 1.4354172147776345e-12
of O 0 7.786424813890286e-18
individuals O 0 4.2141100383016016e-15
who O 0 1.3023462516748019e-12
constitutionally O 0 5.765903754451074e-09
lack O 0 2.8635771596834114e-13
both O 0 2.903322886361097e-17
wild O 0 1.1537070127368154e-12
- O 0 2.886600611873291e-07
type O 0 1.7628684970127928e-11
alleles O 0 2.6200424818535913e-14
is O 0 3.2183751632008884e-15
unknown O 0 4.075947912518529e-12
. O 0 4.171728880311004e-13

We O 0 2.9454391670905716e-14
have O 0 2.348607450873276e-19
identified O 0 1.10337301375961e-18
three O 0 3.372578725549673e-18
offspring O 0 1.482597512369576e-14
in O 0 9.499413498886803e-19
a O 0 1.9921513576140817e-14
hereditary B-Disease 1 0.9999229907989502
nonpolyposis I-Disease 1 0.9999833106994629
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 1.4186644747837818e-08
who O 0 3.0814408099807955e-14
developed O 0 1.0793131830172473e-14
hematological B-Disease 0 1.2196508691886265e-07
malignancy I-Disease 0 1.2233179802478844e-07
at O 0 5.44322006630453e-14
a O 0 6.4935535105887854e-18
very O 0 7.32618224898472e-16
early O 0 8.581544329311352e-12
age O 0 1.2096622592494555e-09
, O 0 1.0325500371874882e-16
and O 0 1.1437056017554086e-15
at O 0 1.5676426537106501e-16
least O 0 1.18801117447415e-20
two O 0 1.0251855499662308e-19
of O 0 3.186604096170288e-20
them O 0 1.3455810393052468e-14
displayed O 0 5.667277758192313e-11
signs O 0 2.4771162551728843e-11
of O 0 2.33954139626333e-18
neurofibromatosis B-Disease 0 1.4012735505275487e-07
type I-Disease 0 1.9263174497359536e-13
1 I-Disease 0 1.4642899963575057e-15
( O 0 6.925631220837798e-17
NF1 B-Disease 0 8.52328962963611e-09
) O 0 4.804907556901772e-14
. O 0 1.9751344657037428e-13

DNA O 0 6.1961544293824555e-15
sequence O 0 2.773713147320245e-16
analysis O 0 1.0322536790535258e-18
and O 0 2.385436698294919e-20
allele O 0 1.9579019751224424e-18
- O 0 1.0458772403446976e-17
specific O 0 2.3046676684332474e-18
amplification O 0 2.1664265867360477e-11
in O 0 2.4598843880660665e-18
two O 0 4.0962807143771543e-16
siblings O 0 6.84927245128697e-12
revealed O 0 1.7085044181274975e-14
a O 0 1.0067008084813286e-17
homozygous O 0 1.1827254670429554e-12
MLH1 O 0 9.659003552542345e-08
mutation O 0 2.8637736713271744e-13
( O 0 1.1977331747795505e-16
C676T O 0 6.942948820032324e-12
- O 0 2.6943487796415866e-07
- O 0 9.71009831118863e-06
> O 0 2.0933864017247394e-11
Arg226Stop O 0 8.153999431215198e-08
) O 0 1.6327557863138505e-14
. O 0 1.4595339910619676e-14

Thus O 0 3.3844829066057014e-13
, O 0 7.035552936334255e-17
a O 0 6.716749173732131e-18
homozygous O 0 3.072064629593141e-13
germ O 0 9.499367479293142e-06
- O 0 1.127433824876789e-05
line O 0 8.332301604241366e-08
MLH1 O 0 1.834311660786625e-06
mutation O 0 9.857193186690871e-13
and O 0 4.8853586615286906e-15
consequent O 0 1.7266032353857597e-11
mismatch O 0 1.9645653992483858e-07
repair O 0 0.0009540938772261143
deficiency O 0 0.017072847113013268
results O 0 1.2624695206580325e-16
in O 0 2.363058037680636e-19
a O 0 6.596897072263914e-17
mutator O 0 9.492724828419341e-09
phenotype O 0 9.563380903160335e-13
characterized O 0 2.4232680884703553e-14
by O 0 1.9744581522470077e-15
leukemia B-Disease 0 0.05335263907909393
and O 0 1.107701308455944e-08
/ O 0 0.06026225537061691
or O 0 0.2697920501232147
lymphoma B-Disease 1 1.0
associated O 0 1.62036573048141e-09
with O 0 3.070318793044896e-13
neurofibromatosis B-Disease 0 5.629145562124904e-06
type I-Disease 0 1.2836160086238113e-12
1 I-Disease 0 8.10538585661408e-16
. O 0 4.333127061236777e-15
. O 0 3.2452418031493624e-13

Missense O 0 1.8416715263924743e-08
mutations O 0 1.8957936609442783e-10
in O 0 7.028715924612035e-16
the O 0 5.2625325696394064e-18
most O 0 2.1385781507869074e-19
ancient O 0 9.079847763942297e-17
residues O 0 6.291746637576701e-12
of O 0 1.1899069851964163e-20
the O 0 1.7928163962458004e-19
PAX6 O 0 2.860879190339817e-14
paired O 0 1.3070642171441953e-16
domain O 0 1.0029147498781142e-15
underlie O 0 2.0081514711745366e-14
a O 0 1.0119250951145757e-18
spectrum O 0 1.0205303399221655e-12
of O 0 1.7522983508411498e-15
human O 0 1.206550166443776e-07
congenital B-Disease 1 0.999957799911499
eye I-Disease 1 0.99897301197052
malformations I-Disease 1 0.8779516220092773
. O 0 3.486040345279662e-10

Mutations O 0 6.08167552776373e-12
of O 0 2.442045410975748e-18
the O 0 9.691841145170473e-18
human O 0 1.9395888974788056e-14
PAX6 O 0 1.1212439865460055e-08
gene O 0 1.5750585191653954e-07
underlie O 0 0.0012937553692609072
aniridia B-Disease 1 0.9999969005584717
( O 0 9.632975667139831e-11
congenital B-Disease 0 0.4133963882923126
absence I-Disease 0 4.345929865978704e-12
of I-Disease 0 6.395950747800897e-19
the I-Disease 0 2.693300405344903e-17
iris I-Disease 0 1.0835645575246744e-10
) O 0 2.361855235179103e-15
, O 0 8.03592233897098e-18
a O 0 1.9394010467469283e-17
rare O 0 1.3237763749757159e-12
dominant O 0 3.588747131288983e-05
malformation B-Disease 1 0.9722973108291626
of I-Disease 0 3.540255179399106e-14
the I-Disease 0 1.1278157227567753e-12
eye I-Disease 0 1.7264106645598076e-05
. O 0 2.090466688642323e-10

The O 0 2.1346122302380946e-16
spectrum O 0 3.020030921304859e-14
of O 0 5.068444151480883e-18
PAX6 O 0 2.720295655400662e-10
mutations O 0 1.6672494981828656e-11
in O 0 1.1740766778928213e-12
aniridia B-Disease 1 0.9999992847442627
patients O 0 2.4264883722105446e-13
is O 0 1.2200454400617566e-20
highly O 0 1.1510252151005192e-20
biased O 0 5.648467584369035e-15
, O 0 1.820453467278538e-17
with O 0 3.190515561351425e-16
92 O 0 6.51075872902529e-13
% O 0 1.0558957210516948e-16
of O 0 9.674585537207157e-19
all O 0 4.149585609478611e-14
reported O 0 2.3731833013497516e-13
mutations O 0 2.681491905792341e-16
leading O 0 5.365086782634478e-15
to O 0 3.953583032516913e-15
premature O 0 3.394212265851043e-13
truncation O 0 2.4039791153823015e-14
of O 0 1.7367178084336724e-17
the O 0 1.0600450045880486e-15
protein O 0 4.1927878812082764e-13
( O 0 4.782017393522003e-20
nonsense O 0 1.1513222278962377e-15
, O 0 2.988651162487441e-22
splicing O 0 1.9297112876153596e-17
, O 0 1.6679934200948707e-19
insertions O 0 9.983043918978564e-15
and O 0 2.041038965307695e-15
deletions O 0 3.4951012082336946e-14
) O 0 4.555146784568983e-16
and O 0 8.207979651855823e-14
just O 0 9.358943605991196e-14
2 O 0 2.517903373897934e-17
% O 0 2.543170226416943e-21
leading O 0 2.3046201023168513e-21
to O 0 2.366898966844495e-21
substitution O 0 1.2484688684051131e-19
of O 0 3.31191222505959e-21
one O 0 9.362999628553079e-17
amino O 0 1.2235341953996105e-16
acid O 0 1.6050798721616773e-18
by O 0 1.3147977675393555e-20
another O 0 1.0759412851440599e-16
( O 0 2.870724360164872e-17
missense O 0 2.638736668406083e-12
) O 0 5.4395768081918e-14
. O 0 4.775691018858719e-13

The O 0 4.8661190823728625e-18
extraordinary O 0 2.8013665686117656e-19
conservation O 0 8.451173132779012e-20
of O 0 4.5136516315851166e-23
the O 0 1.2089674802536898e-21
PAX6 O 0 8.089169410838897e-16
protein O 0 9.866948663403048e-18
at O 0 8.804775396304385e-20
the O 0 2.227757938576734e-21
amino O 0 1.883823608570103e-17
acid O 0 4.479308748427753e-17
level O 0 8.453176331578068e-19
amongst O 0 1.1702053815435616e-18
vertebrates O 0 2.343205740202491e-16
predicts O 0 1.649793366156893e-12
that O 0 7.295206105872865e-14
pathological O 0 3.64754615400642e-10
missense O 0 7.062679607816591e-11
mutations O 0 1.981109998272501e-10
should O 0 8.012886187902524e-11
in O 0 1.41838198190407e-17
fact O 0 2.4884941252714687e-16
be O 0 5.371944361375449e-16
common O 0 5.495459552777018e-15
even O 0 4.3685642939477604e-14
though O 0 1.310569080661256e-16
they O 0 4.713654971664436e-17
are O 0 3.479012054966871e-18
hardly O 0 4.3133224991937294e-14
ever O 0 2.0972357897097553e-14
seen O 0 3.8765027299270116e-10
in O 0 2.816280628842316e-12
aniridia B-Disease 1 0.9999973773956299
patients O 0 8.310545307477213e-11
. O 0 3.774135206289532e-14

This O 0 1.7672212714267576e-15
indicates O 0 1.3319796912876806e-16
that O 0 3.04931111379118e-19
there O 0 3.856720041752659e-19
is O 0 7.378088758864709e-18
a O 0 3.553309566478894e-15
heavy O 0 2.2482690553715656e-07
ascertainment O 0 1.6465796761622187e-06
bias O 0 8.280589014475481e-08
in O 0 9.562499048688619e-18
the O 0 3.976124403279998e-20
selection O 0 1.340386607866619e-21
of O 0 2.1966598047590224e-22
patients O 0 5.817419783237032e-22
for O 0 3.566399762825847e-23
PAX6 O 0 4.570134926691529e-15
mutation O 0 5.6405996045098305e-18
analysis O 0 2.753839636795291e-16
and O 0 4.738249790897826e-15
that O 0 1.4310186215986956e-16
the O 0 3.5348130138888206e-16
missing O 0 8.072336576958605e-09
PAX6 O 0 1.5983181000933655e-08
missense O 0 2.5845237408561594e-11
mutations O 0 2.4722437638735606e-12
frequently O 0 3.1463609495574474e-10
may O 0 2.132862463033458e-12
underlie O 0 1.9648981053332903e-10
phenotypes O 0 1.0588671432720798e-11
distinct O 0 5.396968001626298e-14
from O 0 2.933466403814977e-12
textbook O 0 0.0013008081587031484
aniridia B-Disease 1 0.9999909400939941
. O 0 3.604901488429846e-09

Here O 0 2.7329982894841454e-12
we O 0 9.005212144009254e-15
present O 0 2.732197829187658e-18
four O 0 6.474754590397599e-18
novel O 0 1.492527957236596e-14
PAX6 O 0 1.259530257868846e-09
missense O 0 1.640606227260033e-11
mutations O 0 4.530590746315566e-12
, O 0 1.1583139978318772e-14
two O 0 3.7728048536955964e-17
in O 0 4.766848516674914e-19
association O 0 8.557678452758896e-20
with O 0 3.7910263191011595e-17
atypical O 0 2.349223038322634e-10
phenotypes O 0 1.7350563208395897e-09
ectopia B-Disease 0 1.4195300082064932e-06
pupillae I-Disease 0 2.4832731924107065e-06
( O 0 3.803429501957143e-15
displaced B-Disease 0 3.381414939718219e-11
pupils I-Disease 0 3.879476184742714e-10
) O 0 2.4240115123475015e-11
and O 0 1.4081741710469942e-06
congenital B-Disease 1 0.9876682162284851
nystagmus I-Disease 0 3.9387394679124554e-08
( O 0 6.532364411339467e-17
searching B-Disease 0 1.1298265925260842e-12
gaze I-Disease 0 2.8074053304294466e-08
) O 0 4.453957052316432e-16
, O 0 6.102622245549998e-17
and O 0 9.033906232130441e-15
two O 0 9.52351568078022e-17
in O 0 3.2290675421626684e-19
association O 0 2.6730291007553155e-21
with O 0 1.5876195434591034e-20
more O 0 1.0380231604285066e-17
recognizable O 0 6.350304460056577e-08
aniridia B-Disease 1 0.999996542930603
phenotypes O 0 1.7804969942858406e-08
. O 0 2.4462474147030067e-13

Strikingly O 0 6.184410206167001e-10
, O 0 4.1564394612746136e-13
all O 0 4.2503380609721416e-15
four O 0 2.1531275763716855e-16
mutations O 0 8.492654084659075e-16
are O 0 5.4062709175021335e-18
located O 0 9.237960835810456e-20
within O 0 4.5260899738200835e-20
the O 0 3.421940521808622e-18
PAX6 O 0 1.252991037748591e-13
paired O 0 9.45240064741332e-16
domain O 0 1.4621509840558045e-13
and O 0 9.854899014893892e-13
affect O 0 1.1862480432894926e-15
amino O 0 2.0833261719919698e-17
acids O 0 1.171134201973882e-18
which O 0 1.0417917952992982e-17
are O 0 1.772779521104159e-21
highly O 0 2.732464531927308e-21
conserved O 0 7.015395702859195e-18
in O 0 4.18352674576196e-18
all O 0 9.81951895425987e-19
known O 0 5.872140305112312e-20
paired O 0 2.715171523961948e-16
domain O 0 2.4242006717452823e-15
proteins O 0 1.7313295843637486e-14
. O 0 1.3264288620381745e-14

Our O 0 2.7685945203081985e-10
results O 0 3.0554987742568854e-16
support O 0 2.6236127962020563e-18
the O 0 5.0667762580979433e-20
hypothesis O 0 8.100582323671214e-19
that O 0 3.0055982373329324e-20
the O 0 3.816789464801181e-21
under O 0 7.852072969229791e-19
- O 0 1.9819751037857686e-14
representation O 0 7.141955163760421e-18
of O 0 1.0100936551998373e-17
missense O 0 2.0696607622161522e-11
mutations O 0 6.134965365584e-12
is O 0 2.631416101456143e-14
caused O 0 7.841526093819301e-14
by O 0 1.2185914769109734e-17
ascertainment O 0 5.3622488671578594e-09
bias O 0 2.8153520403861876e-08
and O 0 1.1570604229512588e-13
suggest O 0 3.0250646819386914e-17
that O 0 9.975742449633394e-21
a O 0 2.0467869360317922e-21
substantial O 0 3.795826623971685e-19
burden O 0 3.995741584827961e-11
of O 0 4.3382144833930516e-18
PAX6 B-Disease 0 2.5249494228773983e-06
- I-Disease 0 0.001147555303759873
related I-Disease 0 3.5053644751315005e-06
disease I-Disease 0 0.027415914461016655
remains O 0 2.402908818102678e-12
to O 0 5.661444969536473e-18
be O 0 1.427859838042218e-18
uncovered O 0 5.799059583228017e-12
. O 0 1.094023585683367e-16
. O 0 7.529529978027652e-16

The O 0 6.051694124898537e-16
chromosomal O 0 7.192952899970351e-09
order O 0 5.6802120922431684e-14
of O 0 1.1197956508460846e-18
genes O 0 6.634582918046018e-15
controlling O 0 1.1797592626937563e-14
the O 0 8.934062640371869e-18
major O 0 1.4951411994626633e-17
histocompatibility O 0 7.85445128719881e-16
complex O 0 1.0197449504329223e-18
, O 0 5.57490006057477e-20
properdin O 0 5.5500485392386e-14
factor O 0 5.148857482408821e-15
B O 0 7.246875877164882e-10
, O 0 8.764680303856569e-16
and O 0 1.3755084571354104e-10
deficiency B-Disease 0 1.0135608619066261e-07
of I-Disease 0 4.308453827116624e-22
the I-Disease 0 1.5919329736984892e-18
second I-Disease 0 8.340118670981846e-17
component I-Disease 0 2.2623955544864293e-17
of I-Disease 0 2.98440322855436e-21
complement I-Disease 0 1.9715530409961622e-15
. O 0 5.429405382451286e-15

The O 0 2.440939578030244e-16
relationship O 0 2.3258579760471307e-16
of O 0 2.795352472804429e-22
the O 0 2.3490864118739576e-23
genes O 0 2.3266506523713947e-21
coding O 0 5.273039624575208e-19
for O 0 1.8877960532414448e-23
HLA O 0 2.4378676939330182e-17
to O 0 3.833689071677195e-20
those O 0 3.4864218484212416e-20
coding O 0 3.5001545432695427e-16
for O 0 1.3081490610278904e-20
properdin O 0 8.853250706326865e-14
Factor O 0 9.403232370058679e-17
B O 0 1.1020423126579387e-13
allotypes O 0 5.5727696898289283e-14
and O 0 1.0149067379428751e-16
for O 0 2.593759020714405e-18
deficiency B-Disease 0 2.946450861074368e-10
of I-Disease 0 4.2614581644401146e-23
the I-Disease 0 6.165020015351991e-19
second I-Disease 0 1.9370867608291274e-17
component I-Disease 0 5.2440789146358997e-17
of I-Disease 0 1.3068166257340517e-21
complement I-Disease 0 9.590560323788867e-17
( O 0 2.4710456911676094e-20
C2 O 0 6.01526077212422e-12
) O 0 2.7726615918985855e-19
was O 0 3.262674959872509e-17
studied O 0 4.0847432343484407e-19
in O 0 2.068568887616108e-21
families O 0 2.68326968236484e-18
of O 0 3.5605018600451803e-22
patients O 0 6.064213271858956e-18
with O 0 1.2796295081968982e-15
connective O 0 8.948934555519372e-05
tissue O 1 0.9990825653076172
disorders O 1 0.5623791217803955
. O 0 1.8723772532425187e-11

Patients O 0 6.583360701202523e-13
were O 0 2.5982561949097027e-17
selected O 0 9.15108360703766e-20
because O 0 1.0283390468046186e-18
they O 0 1.9493092229192416e-18
were O 0 2.4536054668313296e-18
heterozygous O 0 4.4690851269288425e-17
or O 0 6.43035702759502e-16
homozygous O 0 7.865231903270153e-12
for O 0 1.801915214261207e-11
C2 B-Disease 1 0.999998927116394
deficiency I-Disease 1 0.999998927116394
. O 0 1.1835745925004026e-11

12 O 0 2.314876805867283e-13
families O 0 3.156666536592367e-16
with O 0 9.776974341169883e-21
15 O 0 6.787652174858639e-20
matings O 0 1.936269714171695e-14
informative O 0 5.044820464150668e-12
for O 0 1.4650312907260599e-10
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
were O 0 5.859719718996625e-13
found O 0 1.7486334510366172e-14
. O 0 6.98997549634082e-15

Of O 0 5.376785578185481e-15
57 O 0 4.117196763641501e-15
informative O 0 2.4201376579852107e-13
meioses O 0 4.851181678589e-10
, O 0 1.3311053282929875e-17
two O 0 1.320951135035569e-20
crossovers O 0 5.886413115296397e-17
were O 0 3.456602698197044e-18
noted O 0 3.483698033136984e-19
between O 0 1.217880912221178e-16
the O 0 1.223953438600489e-10
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999994039535522
gene O 0 6.367130948078937e-18
and O 0 1.5641347420330322e-18
the O 0 1.2452624933998331e-20
HLA O 0 3.4710935840030765e-13
- O 0 2.2485600881250178e-10
B O 0 2.822960398426999e-12
gene O 0 7.725886566784827e-19
, O 0 1.2525026057764987e-22
with O 0 3.9378022784640166e-26
a O 0 6.561153980247043e-26
recombinant O 0 2.7696338402457965e-22
fraction O 0 2.7041793089853204e-19
of O 0 3.828387916700587e-18
0 O 0 4.766273981836853e-16
. O 0 2.4099839013519767e-14

035 O 0 0.00031324202427640557
. O 0 1.7157517628874075e-09

A O 0 2.385573726407242e-12
lod O 0 2.899382991472521e-07
score O 0 2.689612595141444e-11
of O 0 7.725915518106266e-19
13 O 0 1.3820827323653443e-18
was O 0 4.2963484427486935e-19
calculated O 0 1.1211285490056373e-19
for O 0 7.109186709947895e-22
linkage O 0 4.608888271029343e-11
between O 0 2.9443512072901967e-09
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999997615814209
and O 0 2.7744022086228365e-15
HLA O 0 2.4334385201330022e-11
- O 0 5.562037497242045e-09
B O 0 1.4157086614119407e-10
at O 0 5.265482295703771e-19
a O 0 3.336789805675512e-23
maximum O 0 2.4745308363639313e-24
likelihood O 0 1.3900473834688757e-23
value O 0 4.032805568884356e-23
of O 0 4.035694555012979e-25
the O 0 2.6870426278240533e-23
recombinant O 0 5.24042869131603e-21
fraction O 0 3.1025575053030426e-19
of O 0 2.6449854888692015e-19
0 O 0 4.379987517917286e-17
. O 0 1.0319244636512715e-15

04 O 0 9.053124813362956e-06
. O 0 1.1933518062612336e-10

18 O 0 1.1999229387882338e-10
families O 0 3.72887044321462e-14
with O 0 4.365171679170695e-19
21 O 0 5.498594200030402e-19
informative O 0 1.5992011822663242e-17
matings O 0 2.2619816989529612e-13
for O 0 2.661494773124841e-18
both O 0 1.2165251301099792e-16
properdin O 0 1.688983120029519e-10
Factor O 0 1.5107955779968506e-14
B O 0 4.626377406169446e-12
allotype O 0 2.531864691859842e-13
and O 0 4.599374609909866e-16
HLA O 0 2.1483181900094905e-10
- O 0 4.1462681110715494e-07
B O 0 4.407714015997044e-08
were O 0 2.658919801236994e-16
found O 0 4.3592373282919236e-16
. O 0 3.1920857486773975e-16

Of O 0 1.8382688492073196e-14
72 O 0 9.785217341268249e-14
informative O 0 2.0267507290505637e-12
meioses O 0 1.8486575825704676e-08
, O 0 4.165569968226247e-15
three O 0 9.474778199088595e-17
recombinants O 0 1.0284157553330786e-10
were O 0 1.4492581261590573e-15
found O 0 4.857717408891161e-18
, O 0 2.436792345969664e-22
giving O 0 6.546310946017727e-24
a O 0 8.963559239394714e-25
recombinant O 0 2.430907115450579e-21
fraction O 0 8.884844153154045e-19
of O 0 3.655038570859993e-18
0 O 0 1.3130668749435906e-15
. O 0 6.547843186708799e-14

042 O 0 2.1830128389410675e-06
. O 0 1.663755938574596e-10

A O 0 2.25713436656505e-12
lod O 0 2.0676198531077716e-08
score O 0 4.166925051535264e-13
of O 0 4.678232722275594e-20
16 O 0 5.263835172309024e-19
between O 0 1.5984563268042355e-18
HLA O 0 3.592151923137443e-11
- O 0 1.268603995185913e-07
B O 0 2.955910360924463e-08
and O 0 3.690379910838669e-14
Factor O 0 3.620352647770546e-15
B O 0 2.5963592712417716e-13
allotypes O 0 1.3659674706314106e-15
was O 0 6.155482312696525e-18
calculated O 0 1.854142713830475e-18
at O 0 4.6127190484091136e-20
a O 0 2.877151164006351e-23
maximum O 0 2.1121433615208692e-23
likelihood O 0 8.827298498486374e-22
value O 0 2.3315285138254e-21
of O 0 1.2818618945215988e-23
the O 0 1.5713197939884844e-22
recombinant O 0 1.129244596375589e-20
fraction O 0 2.370135860290734e-19
of O 0 6.4483526396061315e-19
0 O 0 8.394891924167147e-17
. O 0 1.835573548017509e-15

04 O 0 1.662853901507333e-05
. O 0 1.9427992548060047e-10

A O 0 9.950384022598333e-15
crossover O 0 1.563300541535667e-13
was O 0 1.4278171472838913e-13
shown O 0 4.766058306072659e-15
to O 0 7.723355600905567e-18
have O 0 1.4181763448037894e-17
occurred O 0 8.870519452896158e-19
between O 0 3.5737145860100356e-22
genes O 0 2.2478453815956665e-20
for O 0 4.6252952027509565e-22
Factor O 0 1.2040407081916756e-17
B O 0 3.2195617293050496e-14
and O 0 1.3350260816784276e-17
HLA O 0 3.378716577351337e-13
- O 0 5.189597362953435e-11
D O 0 1.7899322432221587e-12
, O 0 5.842623528176093e-20
in O 0 4.803384906616797e-22
which O 0 1.0614678371325205e-18
HLA O 0 7.67536533462232e-14
- O 0 9.776422726925915e-12
D O 0 5.6746890986138915e-14
segregared O 0 7.242791325931942e-16
with O 0 1.9493892461811575e-20
HLA O 0 5.877805566486399e-14
- O 0 3.014150886347655e-13
A O 0 6.953009707973221e-15
and O 0 5.789728505650737e-13
B O 0 3.3933370002792174e-10
. O 0 1.5342342184330624e-16

These O 0 1.635866768922526e-14
studies O 0 5.169697245768355e-16
suggest O 0 8.376781962708156e-18
that O 0 9.497478372851633e-22
the O 0 9.490298823535472e-24
genes O 0 1.8921029497940256e-20
for O 0 7.483783467693685e-20
Factor O 0 9.53174930477807e-13
B O 0 6.584523362107575e-05
and O 0 0.0012115509016439319
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.3041744102942243e-19
located O 0 1.218775002924181e-21
outside O 0 9.459486912435546e-20
those O 0 9.589076710736768e-21
for O 0 3.259492796560888e-23
HLA O 0 1.2428879718020852e-15
, O 0 1.995589151010971e-18
that O 0 8.808877953648707e-19
the O 0 9.279426495188944e-20
order O 0 3.7928468609113275e-18
of O 0 7.249849520321586e-21
genese O 0 2.2015006327256656e-14
is O 0 2.62620344833239e-20
HLA O 0 1.028740307983865e-16
- O 0 1.6459728884228066e-14
A O 0 1.3803671366138521e-15
, O 0 2.1536603468606187e-17
- O 0 8.514238034225408e-13
B O 0 7.265355309558907e-13
, O 0 1.5621661297233384e-19
- O 0 5.4541501794558994e-15
D O 0 8.24059931417106e-16
, O 0 2.0683873360119367e-21
Factor O 0 5.111139492388114e-18
B O 0 3.4875533450745566e-12
allotype O 0 2.2613121097858624e-10
, O 0 1.8127040667115235e-12
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999997615814209
, O 0 5.073598418083071e-22
that O 0 4.695276442048306e-25
the O 0 2.6432226765772358e-25
genes O 0 1.021399066088784e-19
coding O 0 4.635101438950351e-13
for O 0 2.7469714870831385e-13
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
and O 0 7.070570799856679e-13
Factor O 0 2.6594195189121386e-14
B O 0 4.70923924855704e-11
allotypes O 0 9.445458738072121e-13
are O 0 3.157876371990263e-20
approximately O 0 4.309508401618272e-21
3 O 0 8.443347357949406e-19
- O 0 2.8077421030531236e-12
- O 0 1.981116659610649e-11
5 O 0 8.725811153047151e-17
centimorgans O 0 1.7922260016670598e-14
from O 0 1.9968872807256602e-22
the O 0 2.5486062164277232e-23
HLA O 0 1.2767750923642543e-18
- O 0 1.6364687914686505e-18
A O 0 6.864756393941091e-20
and O 0 3.2094448534789557e-18
HLA O 0 1.4017551632243205e-14
- O 0 4.818334045555289e-14
B O 0 1.39196259414529e-16
loci O 0 2.0114468237390719e-19
, O 0 6.828452212337963e-20
and O 0 8.546194859411187e-20
that O 0 8.181191882158074e-21
the O 0 2.226273383637336e-19
apparent O 0 7.480214364585791e-13
lack O 0 2.0911769431857106e-17
of O 0 5.339688648261063e-22
recombinants O 0 5.56469433181969e-15
between O 0 1.3639957884993673e-20
the O 0 2.424601276918604e-20
Factor O 0 7.283766015359777e-17
B O 0 7.690605829035677e-14
gene O 0 8.244695480800687e-14
and O 0 6.227876383491093e-07
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
gene O 0 5.233213070109403e-15
suggests O 0 6.480419851151301e-16
that O 0 2.1982389402082066e-19
these O 0 1.0104090798469191e-18
two O 0 6.346062161568844e-17
genes O 0 4.803647930817778e-12
lie O 0 6.1962204256360565e-09
in O 0 8.68469126033459e-19
close O 0 6.879430835757261e-14
proximity O 0 2.4794555955099957e-15
to O 0 5.774261294398718e-15
one O 0 1.3027789186453582e-15
another O 0 1.4648096510706463e-15
. O 0 1.0596868434825657e-12

Distribution O 0 5.828016292220434e-14
of O 0 4.034081761571291e-16
emerin O 0 2.1053981669183486e-08
and O 0 6.5414206169844835e-12
lamins O 0 3.18050297209993e-08
in O 0 2.2631478917971585e-16
the O 0 2.330131903128651e-14
heart O 0 1.500958385358686e-10
and O 0 8.046267721456058e-16
implications O 0 6.766770439734438e-18
for O 0 6.17457240046333e-20
Emery B-Disease 0 6.416317432922369e-08
- I-Disease 0 3.3913267998286756e-06
Dreifuss I-Disease 0 0.0034043577034026384
muscular I-Disease 0 0.008321895264089108
dystrophy I-Disease 0 0.006449098698794842
. O 0 1.2208821627279764e-11

Emerin O 0 2.015099056507097e-07
is O 0 1.8578990071665274e-14
a O 0 2.460505145756757e-17
nuclear O 0 1.1848473049046182e-13
membrane O 0 4.375066203554179e-15
protein O 0 6.6090423064824044e-12
which O 0 3.9558027670584875e-14
is O 0 2.4341421386285284e-16
missing O 0 3.749885818526977e-12
or O 0 2.939467584812429e-14
defective O 0 4.4140677224469016e-11
in O 0 2.952758508489716e-17
Emery B-Disease 0 6.184231551742414e-06
- I-Disease 0 0.0010510385036468506
Dreifuss I-Disease 1 0.9190300703048706
muscular I-Disease 1 0.9683879017829895
dystrophy I-Disease 1 0.9891820549964905
( O 0 2.740934736122913e-11
EDMD B-Disease 1 0.9999879598617554
) O 0 1.3645841184448115e-12
. O 0 3.83845685542495e-14

It O 0 7.846448371682385e-14
is O 0 2.8071029214032136e-17
one O 0 3.891213938585215e-18
member O 0 1.6625120560669997e-18
of O 0 3.1380758653242454e-19
a O 0 4.066933405034957e-15
family O 0 1.6305440331265686e-09
of O 0 1.18446585949869e-16
lamina O 0 3.169813922454523e-08
- O 0 2.3581105818015757e-11
associated O 0 1.7446280439872884e-15
proteins O 0 9.335146802967194e-17
which O 0 7.72589008230243e-18
includes O 0 4.5184479235593446e-20
LAP1 O 0 1.9366262066222717e-12
, O 0 2.399620971719128e-19
LAP2 O 0 1.1875543083628148e-11
and O 0 7.764873000224576e-15
lamin O 0 1.3154523026415177e-09
B O 0 3.0428470854104717e-10
receptor O 0 1.2869628018168707e-15
( O 0 8.829004912313347e-17
LBR O 0 2.7529184487562475e-10
) O 0 1.8787015010763826e-15
. O 0 1.6063080295687822e-14

A O 0 6.5984457481294e-13
panel O 0 1.794802777536561e-13
of O 0 2.534854041728432e-18
16 O 0 1.3916645444269748e-17
monoclonal O 0 9.774085231934783e-17
antibodies O 0 7.288753070067502e-14
( O 0 1.794452533648036e-18
mAbs O 0 6.149827148178508e-14
) O 0 3.640636115624526e-18
has O 0 8.830579037019035e-19
been O 0 9.546671102763781e-20
mapped O 0 4.690485179485683e-15
to O 0 5.241056479395692e-18
six O 0 9.090430184725426e-22
specific O 0 8.475790567263231e-24
sites O 0 6.185706251508294e-18
throughout O 0 2.9833817170434066e-19
the O 0 7.904447460677234e-21
emerin O 0 1.8456753622081373e-17
molecule O 0 1.5075308603616305e-22
using O 0 1.2630740184335726e-20
phage O 0 1.8485452223299982e-15
- O 0 4.232782456107349e-15
displayed O 0 6.899999209760495e-17
peptide O 0 5.543520033459382e-18
libraries O 0 2.441746178389157e-19
and O 0 4.256267664661378e-19
has O 0 3.663560415751681e-22
been O 0 4.3790053812940113e-23
used O 0 1.3763195881308962e-21
to O 0 2.9162958184017075e-19
localize O 0 1.7582546529837373e-11
emerin O 0 3.48880757616854e-10
in O 0 5.249920960430117e-18
human O 0 1.366302497573038e-13
and O 0 1.5227000216277986e-10
rabbit O 1 0.9273295998573303
heart O 0 1.9918472389690578e-05
. O 0 1.4593294021120196e-12

Several O 0 2.7300231879008683e-16
mAbs O 0 2.595438241496245e-13
against O 0 1.2718416424343808e-17
different O 0 7.0720328627982775e-19
emerin O 0 2.2338526427939653e-12
epitopes O 0 1.326475713124553e-12
did O 0 2.0082702251937416e-14
not O 0 1.98099731277426e-17
recognize O 0 7.950857930277334e-16
intercalated O 0 1.2681091528417288e-13
discs O 0 5.069359758635983e-07
in O 0 7.252464687829141e-13
the O 0 2.170835733394938e-11
heart O 0 1.194419212424691e-07
, O 0 1.2039821603479191e-15
though O 0 2.9955545172774946e-16
they O 0 3.588217514770918e-17
recognized O 0 2.212443043736638e-16
cardiomyocyte O 0 6.645926031723093e-09
nuclei O 0 4.557589115133931e-12
strongly O 0 1.6016947493248564e-14
, O 0 8.17693016363167e-18
both O 0 6.94448978075115e-18
at O 0 3.8034186260541003e-13
the O 0 2.4319452633886178e-14
rim O 0 1.759258907441108e-06
and O 0 1.6012205450444128e-11
in O 0 6.898104635285504e-17
intranuclear O 0 5.3643405689696166e-11
spots O 0 1.4339503976584789e-12
or O 0 5.368239439264158e-15
channels O 0 1.8834458992422753e-10
. O 0 3.734226469709334e-12

A O 0 6.495958014118147e-14
polyclonal O 0 4.287991142715164e-11
rabbit O 0 1.385008463472559e-08
antiserum O 0 1.8367339593705623e-10
against O 0 3.978262489399975e-13
emerin O 0 8.000478501912767e-09
did O 0 6.091795904522579e-13
recognize O 0 6.908434599123964e-15
both O 0 2.4269555272922187e-17
nuclear O 0 2.788910595519223e-13
membrane O 0 9.945441320653308e-17
and O 0 6.727192841817593e-16
intercalated O 0 3.1053686331198704e-16
discs O 0 4.278764842435834e-12
but O 0 4.899425178865065e-17
, O 0 1.2517575424287356e-22
after O 0 1.7452342148551708e-22
affinity O 0 1.330138817507303e-20
purification O 0 2.172447603805168e-18
against O 0 1.1580448806127651e-21
a O 0 1.6438867678718542e-21
pure O 0 1.139024527111967e-16
- O 0 2.732709059038996e-10
emerin O 0 1.2699415963268734e-09
band O 0 8.811825374195267e-14
on O 0 1.916310266860286e-16
a O 0 4.764140017156686e-19
western O 0 9.732118058120782e-17
blot O 0 1.0696927347453311e-05
, O 0 7.283523658057744e-15
it O 0 4.921949891927013e-14
stained O 0 1.0141579878109042e-06
only O 0 1.3160198700257355e-16
the O 0 1.1547342916747373e-17
nuclear O 0 2.5099501470282615e-12
membrane O 0 1.3403529825482038e-14
. O 0 5.922946323937833e-14

These O 0 1.918342736181508e-13
results O 0 7.46554656502994e-17
would O 0 3.754397438088331e-18
not O 0 6.703333131377134e-19
be O 0 2.890458366679519e-18
expected O 0 1.316270174879094e-17
if O 0 1.6750663830188702e-17
immunostaining O 0 7.344994702512472e-14
at O 0 7.335682517581565e-18
intercalated O 0 7.84663132021108e-17
discs O 0 4.754718146982029e-11
were O 0 7.0593525769186306e-15
due O 0 4.604758960127545e-18
to O 0 5.136742490105432e-19
a O 0 6.8688457680944e-19
product O 0 5.546613672406718e-16
of O 0 1.9814476647964158e-20
the O 0 4.0174326010740686e-17
emerin O 0 1.4435772455884122e-12
gene O 0 1.9439211321908324e-15
and O 0 7.463137502742787e-14
, O 0 3.1014469119331136e-18
therefore O 0 1.660597960129552e-18
, O 0 9.377687047509571e-18
cast O 0 7.278347439717073e-14
some O 0 9.295763700027778e-19
doubt O 0 7.140239591169986e-18
upon O 0 1.198123255514219e-21
the O 0 2.3571598844839633e-20
hypothesis O 0 2.927905754488997e-15
that O 0 7.66458006410493e-15
cardiac B-Disease 0 1.9308320275968072e-08
defects I-Disease 0 0.00578072015196085
in O 0 1.6360211796406787e-12
EDMD B-Disease 1 0.9999998807907104
are O 0 4.6232306177840243e-11
caused O 0 1.3851534936409893e-12
by O 0 5.68085343912105e-17
absence O 0 3.366340138501872e-13
of O 0 1.3459287357421828e-16
emerin O 0 2.5188899854811098e-08
from O 0 3.810950519254051e-16
intercalated O 0 5.203421894750537e-12
discs O 0 6.652396677964134e-08
. O 0 9.695897513692375e-13

Although O 0 8.255490068680496e-14
emerin O 0 4.7689209352330675e-12
was O 0 1.6639422265306856e-15
abundant O 0 3.19088912438786e-18
in O 0 2.7313731301169426e-19
the O 0 2.468204377462278e-17
membranes O 0 1.5614293191745787e-09
of O 0 3.5180115859844395e-16
cardiomyocyte O 0 2.48781972800316e-09
nuclei O 0 3.750086612769321e-12
, O 0 3.9068332592198085e-17
it O 0 4.260237970301413e-16
was O 0 4.5331213826063643e-13
absent O 0 9.271534278168514e-13
from O 0 7.880072412579252e-18
many O 0 1.1958106746870793e-17
non O 0 1.5757433327110554e-15
- O 0 3.854686014825859e-10
myocyte O 0 1.1971237334762463e-08
cells O 0 1.6167051421558942e-12
in O 0 1.784202243846177e-16
the O 0 1.7028304832270198e-14
heart O 0 1.9700639342090653e-08
. O 0 2.9065313524034853e-13

This O 0 1.7917096027368103e-18
distribution O 0 1.47207907311244e-17
of O 0 1.275211876102894e-19
emerin O 0 2.8179463970601226e-12
was O 0 2.7488540538073115e-16
similar O 0 7.597632115873252e-21
to O 0 1.1588155180990126e-18
that O 0 1.0898363064327562e-18
of O 0 7.416170984581565e-21
lamin O 0 7.678722024548335e-13
A O 0 2.574931984654198e-16
, O 0 2.7940118989904035e-20
a O 0 1.269632878105554e-22
candidate O 0 2.7571238441970865e-20
gene O 0 2.6817143760180873e-18
for O 0 2.3160168578561134e-20
an O 0 1.0108028798570403e-17
autosomal O 0 7.751181669846119e-07
form O 0 6.82302259136236e-09
of O 0 5.3306699498989474e-08
EDMD B-Disease 1 0.9999984502792358
. O 0 2.4217401417558904e-09

In O 0 2.6526096704777456e-15
contrast O 0 4.217567626792294e-15
, O 0 3.6714619275936007e-16
lamin O 0 1.0998595456612748e-07
B1 O 0 0.0007881663623265922
was O 0 4.5655459968152456e-10
absent O 0 2.603682824897646e-10
from O 0 7.568814519088359e-15
cardiomyocyte O 0 1.3923524555536915e-09
nuclei O 0 3.1799506604313077e-12
, O 0 1.4359893815100983e-16
showing O 0 4.4521973456036756e-13
that O 0 2.770742814532461e-15
lamin O 0 2.806290311241355e-09
B1 O 0 1.728187370986234e-08
is O 0 2.2396465676968455e-19
not O 0 9.680335573375394e-21
essential O 0 5.30651105185364e-21
for O 0 1.3063623680703892e-22
localization O 0 1.2775858294534104e-15
of O 0 3.189352856119893e-20
emerin O 0 4.475377013424264e-11
to O 0 6.429130947403869e-16
the O 0 1.951760210359434e-15
nuclear O 0 9.440753734324403e-10
lamina O 0 9.89440973597766e-10
. O 0 4.248849061754163e-14

Lamin O 0 0.0003446668270044029
B1 O 0 0.051145944744348526
is O 0 7.747912012488756e-13
also O 0 2.0828298937999867e-13
almost O 0 1.7437283171203855e-13
completely O 0 8.035656406946146e-08
absent O 0 6.877797886772896e-08
from O 0 9.375391088473073e-12
skeletal O 0 0.1462133824825287
muscle O 0 1.2948867151862942e-06
nuclei O 0 1.7037380395379387e-09
. O 0 1.1165311161525845e-13

In O 0 2.7646235994938095e-12
EDMD B-Disease 1 0.999967098236084
, O 0 8.14191825528026e-17
the O 0 4.267546353092895e-21
additional O 0 5.259534624761444e-21
absence O 0 4.774565077814268e-19
of O 0 1.028009014664907e-19
lamin O 0 3.541346771385179e-08
B1 O 0 1.700973734841682e-05
from O 0 2.286571539750204e-14
heart O 0 2.914603101089597e-07
and O 0 5.947829451180553e-10
skeletal O 0 0.003289576852694154
muscle O 0 1.6208334230327637e-08
nuclei O 0 9.767717884523464e-12
which O 0 2.837121440828639e-14
already O 0 4.453859495296732e-14
lack O 0 3.056731182379722e-18
emerin O 0 6.787155744109735e-14
may O 0 1.5586310958274106e-18
offer O 0 3.240821090023031e-23
an O 0 5.0896854376421895e-23
alternative O 0 3.7600321924210426e-17
explanation O 0 9.75930355409313e-15
of O 0 2.358755643840079e-17
why O 0 7.035915903716439e-13
these O 0 1.2118055684069966e-16
tissues O 0 1.8606828656509734e-14
are O 0 1.1197182060612344e-19
particularly O 0 1.728811512741314e-18
affected O 0 1.0150803962406745e-17
. O 0 4.526146196252343e-18
. O 0 3.1217608911711684e-15

Genetic O 0 1.3260803588023562e-13
mapping O 0 1.6780510357986e-12
of O 0 1.9398152987976948e-17
the O 0 6.874121691477386e-17
copper B-Disease 0 4.956292754682012e-12
toxicosis I-Disease 0 8.92710644989636e-12
locus O 0 7.64501529708925e-15
in O 0 3.655471186320358e-18
Bedlington O 0 2.9063402726126064e-11
terriers O 0 3.603380371863807e-10
to O 0 1.3537052711155417e-14
dog O 0 8.57743387427945e-09
chromosome O 0 9.018990887454947e-09
10 O 0 3.596513752503021e-14
, O 0 2.3046323064620607e-18
in O 0 3.718913157262131e-21
a O 0 4.1047233167555645e-18
region O 0 9.020482115169176e-14
syntenic O 0 1.1262486943053318e-08
to O 0 5.6289578744949265e-15
human O 0 6.209434550742687e-13
chromosome O 0 5.210364406593726e-07
region O 0 5.053557919354468e-11
2p13 O 0 3.629107847569202e-10
- O 0 1.1456690457434249e-10
p16 O 0 8.412035651383931e-11
. O 0 6.708134346394487e-14

Abnormal O 0 0.4381069540977478
hepatic B-Disease 1 0.9827949404716492
copper I-Disease 0 1.3097394457872724e-06
accumulation I-Disease 0 5.5467550691412626e-11
is O 0 6.239190715940207e-19
recognized O 0 1.728408365590271e-19
as O 0 1.5523310773511506e-16
an O 0 6.357566556536298e-11
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.8483980080037654e-14
man O 0 2.1781560929912125e-11
, O 0 7.295886858311639e-18
mouse O 0 2.1785384260453178e-11
, O 0 6.786734493449242e-16
rat O 0 6.911858463354292e-08
and O 0 1.4371930728840354e-11
dog O 0 3.6115216062171385e-06
. O 0 4.239058756794201e-12

The O 0 4.007439663704387e-16
major O 0 3.477942268898101e-15
cause O 0 1.91616986167098e-10
of O 0 2.738274559356546e-15
hepatic B-Disease 0 0.0003737334336619824
copper I-Disease 0 1.1875823474838398e-05
accumulation I-Disease 0 2.3114678171509695e-08
in O 0 3.403053796395413e-17
man O 0 1.7689302713591593e-12
is O 0 2.903188469511557e-18
a O 0 5.348138732003438e-18
dysfunctional O 0 4.250840035524561e-08
ATP7B O 0 5.368831779151151e-08
gene O 0 1.4130135950196632e-10
, O 0 2.2444516406018578e-13
causing O 0 8.455605993162862e-09
Wilson B-Disease 0 2.2163825974530482e-07
disease I-Disease 0 1.0703458428906742e-05
( O 0 2.6548787446884978e-14
WD B-Disease 0 0.0022895289584994316
) O 0 2.7337700245905205e-12
. O 0 7.603200295920598e-13

Mutations O 0 9.360136277170028e-11
in O 0 5.338299153919324e-16
the O 0 4.416496292305171e-17
ATP7B O 0 2.313621169647284e-11
genes O 0 6.730375568116901e-16
have O 0 1.30897469003056e-17
also O 0 6.187446691215894e-20
been O 0 7.286041754661033e-18
demonstrated O 0 5.024264848554732e-18
in O 0 1.2929727201682432e-20
mouse O 0 5.453896001483827e-09
and O 0 1.4542349269230925e-10
rat O 0 1.3215019862400368e-05
. O 0 1.8661049268342556e-12

The O 0 1.64911842997573e-14
ATP7B O 0 4.650499152436538e-10
gene O 0 2.5970911077081993e-14
has O 0 1.2739462771098244e-14
been O 0 3.7146818499017003e-17
excluded O 0 1.9732126746704927e-18
in O 0 1.553582414306771e-22
the O 0 7.954655768856587e-22
much O 0 4.2589640149643594e-19
rarer O 0 7.5446532219052855e-16
human O 0 1.2215440756081688e-14
copper B-Disease 0 6.8613381642990134e-09
overload I-Disease 0 1.1418988833611365e-05
disease O 0 2.5817044502218778e-08
non B-Disease 0 6.564227243363585e-13
- I-Disease 0 2.5798124170250958e-06
Indian I-Disease 0 1.3930697706499018e-09
childhood I-Disease 0 0.02857005037367344
cirrhosis I-Disease 0 3.7968184187775478e-06
, O 0 5.7636894563317026e-18
indicating O 0 4.174633313406096e-17
genetic O 0 6.719347622660124e-15
heterogeneity O 0 3.881085990781186e-12
. O 0 3.3187171001765325e-13

By O 0 6.813780354716745e-19
investigating O 0 1.7162169972193827e-16
the O 0 2.501256794204223e-16
common O 0 7.218284997501101e-12
autosomal O 0 0.00015318799705710262
recessive O 0 0.00020334863802418113
copper B-Disease 0 0.00011476077634142712
toxicosis I-Disease 0 8.954011718742549e-07
( O 0 5.135082648808767e-17
CT B-Disease 0 2.245533099742847e-11
) O 0 4.667546468482852e-16
in O 0 2.450669471965134e-17
Bedlington O 0 1.0576147735363861e-09
terriers O 0 4.687121446522724e-08
, O 0 2.4757222977949724e-15
we O 0 1.9592786600877205e-16
have O 0 1.9618240164539457e-21
identified O 0 8.482624090631926e-22
a O 0 6.728349277367433e-23
new O 0 1.618882325800598e-21
locus O 0 6.610002868949645e-15
involved O 0 1.7609551599109867e-16
in O 0 1.953711774269908e-15
progressive O 0 0.01038316823542118
liver B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999996423721313
. O 0 6.781152306345462e-10

We O 0 2.3150697938539855e-14
examined O 0 5.314625178613607e-17
whether O 0 2.0253851479328354e-17
the O 0 4.361416320548735e-16
WD B-Disease 0 1.4839238247077446e-06
gene O 0 3.674271824294362e-12
ATP7B O 0 4.261082153789175e-09
was O 0 1.4423640191222361e-15
also O 0 4.5936291900556816e-21
causative O 0 9.374100547469906e-20
for O 0 8.2000912223987415e-22
CT B-Disease 0 7.823688257576483e-14
by O 0 4.97002714570221e-20
investigating O 0 8.157582409104054e-18
the O 0 2.5165288892330853e-18
chromosomal O 0 2.1560899732264716e-09
co O 0 3.983290693815311e-12
- O 0 1.566726688163357e-14
localization O 0 1.8011977746443773e-14
of O 0 2.2013524997326445e-19
ATP7B O 0 2.188533902713896e-11
and O 0 4.902470361572118e-18
C04107 O 0 4.311584334150096e-19
, O 0 9.16171321017718e-25
using O 0 5.115473852836498e-24
fluorescence O 0 5.0435202044229856e-20
in O 0 3.4194802883535685e-22
situ O 0 5.8905661409978425e-18
hybridization O 0 8.054712639940184e-16
( O 0 9.604279321043213e-19
FISH O 0 2.7675024815224103e-13
) O 0 7.259945648937973e-15
. O 0 7.906042899345767e-14

C04107 O 0 1.0039896691793615e-09
is O 0 4.4199390444843965e-15
an O 0 2.055059507945624e-18
anonymous O 0 6.993743149712184e-13
microsatellite O 0 1.065827390789309e-07
marker O 0 7.2358263825123e-10
closely O 0 3.139400902869155e-14
linked O 0 5.717214353849476e-13
to O 0 9.369686821322754e-16
CT B-Disease 0 5.423709037444269e-09
. O 0 1.519414477048342e-12

However O 0 9.41625076522623e-12
, O 0 3.5969115191750514e-14
BAC O 0 1.979433145171683e-10
clones O 0 1.247807412951829e-11
containing O 0 4.5672873713294496e-14
ATP7B O 0 2.2189411419404337e-10
and O 0 1.3135113621001071e-17
C04107 O 0 3.959131257140106e-18
mapped O 0 3.381417398548986e-17
to O 0 2.4812768813691246e-19
the O 0 7.642750133085331e-20
canine O 0 1.2714333058605476e-11
chromosome O 0 3.179166929712096e-09
regions O 0 1.6701640070948542e-12
CFA22q11 O 0 1.558003148716125e-08
and O 0 3.408088156305056e-13
CFA10q26 O 0 2.218288400190893e-11
, O 0 8.423662423924599e-18
respectively O 0 2.369423089096655e-18
, O 0 7.78074647747905e-20
demonstrating O 0 7.033214827614812e-18
that O 0 2.6155298767694025e-17
WD B-Disease 0 1.2894908252292225e-08
cannot O 0 1.2404533873534396e-15
be O 0 1.5300988253788437e-20
homologous O 0 1.6212162964844025e-16
to O 0 1.7051837101610817e-14
CT B-Disease 0 2.7667905744266363e-09
. O 0 2.3451412253100434e-13

The O 0 3.3518043987940365e-16
copper O 0 2.2562713077544337e-14
transport O 0 3.9850134076346454e-17
genes O 0 3.3060655196148108e-15
CTR1 O 0 8.445999455375386e-09
and O 0 1.5243957355096094e-12
CTR2 O 0 4.378718720943198e-09
were O 0 3.6820251166601314e-15
also O 0 6.793173217706518e-19
excluded O 0 6.488841579626954e-20
as O 0 2.0952612143454985e-21
candidate O 0 1.105614001135381e-19
genes O 0 5.531730021393511e-19
for O 0 1.62539277844308e-20
CT B-Disease 0 1.7114871802767495e-12
since O 0 1.0772760237804754e-16
they O 0 4.740223931514048e-21
both O 0 5.0027152583355645e-24
mapped O 0 6.599065873655579e-16
to O 0 2.037032181829827e-16
canine O 0 1.486225897906479e-08
chromosome O 0 9.668800885265227e-06
region O 0 3.5530292041840994e-09
CFA11q22 O 0 3.37709366249328e-06
. O 0 1.0443191450493217e-12

2 O 0 7.778233612754093e-10
- O 0 5.381845312513178e-06
22 O 0 1.1702236402122423e-10
. O 0 8.895656563798204e-13

5 O 0 3.854340457909444e-10
. O 0 7.642986070421909e-12

A O 0 5.5529680076979015e-15
transcribed O 0 7.211579966005799e-13
sequence O 0 2.4313005019091678e-14
identified O 0 1.7425471804974162e-14
from O 0 5.2313317305242125e-17
the O 0 1.739018363153305e-17
C04107 O 0 1.5480116103902541e-12
- O 0 1.6703497959791314e-11
containing O 0 2.0709616747188742e-13
BAC O 0 4.1481949169044907e-13
was O 0 5.194146653267504e-17
found O 0 1.9570337198225973e-20
to O 0 2.284269308497675e-22
be O 0 1.7862463991200147e-22
homologous O 0 4.979898706207721e-19
to O 0 9.536520821165931e-19
a O 0 8.059333799203521e-21
gene O 0 5.183418451594936e-17
expressed O 0 6.986335917362018e-19
from O 0 4.107771651796233e-21
human O 0 1.2758263368811713e-17
chromosome O 0 3.0332290498757963e-13
2p13 O 0 1.1451993020062442e-14
- O 0 1.6431645083345376e-15
p16 O 0 5.354860236224921e-16
, O 0 4.308230375260135e-19
a O 0 5.059555165220811e-19
region O 0 1.0368613316568721e-14
devoid O 0 1.08763844285098e-12
of O 0 1.8728364269875024e-20
any O 0 6.354801097265798e-19
positional O 0 2.36126304056436e-13
candidate O 0 1.8108783786732752e-13
genes O 0 1.3193557357737973e-11
. O 0 2.746710844880873e-12

Molecular O 0 8.866482716215693e-14
analysis O 0 2.127694882734783e-15
of O 0 1.4431865383652423e-19
the O 0 1.589389806905195e-19
APC B-Disease 0 2.997337521631465e-16
gene O 0 3.481601130284162e-18
in O 0 5.652117370756595e-20
205 O 0 4.016602938919678e-18
families O 0 1.0853898053217836e-16
: O 0 3.522986462670353e-20
extended O 0 1.852220676959147e-17
genotype O 0 3.5469469028548417e-10
- O 0 1.8916941624258499e-10
phenotype O 0 2.1801782384631152e-13
correlations O 0 3.006626243749733e-15
in O 0 1.0684506502944488e-19
FAP B-Disease 0 2.911277650701448e-15
and O 0 7.619785660576298e-19
evidence O 0 7.392159320804086e-22
for O 0 1.0254137652488552e-24
the O 0 4.650306242854824e-24
role O 0 2.916483420379695e-20
of O 0 7.952619119325923e-23
APC B-Disease 0 5.071717768385898e-16
amino O 0 5.652659174057818e-19
acid O 0 3.076769632718819e-19
changes O 0 5.886157139085964e-20
in O 0 4.7086117692602195e-14
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
predisposition O 0 1.5746782082715072e-05
. O 0 1.8660123359687253e-12

BACKGROUND O 0 4.960497013151155e-10
/ O 0 5.289962044796592e-12
AIMS O 0 4.5806766752365825e-15
The O 0 4.342929244863542e-20
development O 0 1.4464335583116368e-18
of O 0 8.750920994782252e-15
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 4.842439713849552e-16
a O 0 1.6737281768477891e-21
variable O 0 2.225017826865057e-18
range O 0 2.032885172047541e-14
of O 0 4.061057537479854e-15
extracolonic O 0 0.0014599680434912443
manifestations O 0 6.260846930672415e-06
in O 0 7.093315379513854e-10
familial B-Disease 1 0.9999990463256836
adenomatous I-Disease 1 0.9997790455818176
polyposis I-Disease 1 0.9999927282333374
( O 0 2.127526670461788e-13
FAP B-Disease 0 4.7046869872113817e-11
) O 0 5.827010165309861e-16
is O 0 1.222805631259686e-17
the O 0 9.12957484315975e-19
result O 0 3.591271134720219e-17
of O 0 8.723463703649136e-21
the O 0 1.3728465163636384e-16
dominant O 0 2.6350892579074525e-09
inheritance O 0 9.886985452567387e-08
of O 0 8.349889668579635e-10
adenomatous B-Disease 1 0.999995231628418
polyposis I-Disease 1 0.9999063014984131
coli I-Disease 1 0.9999967813491821
( O 0 3.635742812905683e-15
APC B-Disease 0 7.008325126831028e-13
) O 0 7.098903721599486e-18
gene O 0 3.052634320587508e-15
mutations O 0 2.443488120174031e-12
. O 0 1.480405967084486e-12

In O 0 1.9625401339813436e-16
this O 0 2.3545717138954673e-20
study O 0 9.661699775785943e-22
, O 0 1.5421098523899608e-22
direct O 0 4.4320143350135156e-21
mutation O 0 2.929310254229553e-17
analysis O 0 1.1499703633124198e-15
of O 0 2.724555546282372e-20
the O 0 5.13135909528136e-18
APC B-Disease 0 7.848041365370463e-16
gene O 0 9.476286562935586e-19
was O 0 1.0173792965990819e-17
performed O 0 8.477779267934809e-20
to O 0 8.775597892666284e-21
determine O 0 5.613984158402263e-17
genotype O 0 1.7756436512111895e-12
- O 0 2.0540782616484954e-12
phenotype O 0 3.338141598536147e-14
correlations O 0 1.0961014946164402e-13
for O 0 8.342254914544601e-16
nine O 0 8.538014045766928e-13
extracolonic O 0 2.75953837558518e-09
manifestations O 0 2.1356549341489117e-12
and O 0 8.623720190973612e-18
to O 0 4.8760903666098e-21
investigate O 0 5.614599560098487e-19
the O 0 3.0453817473876117e-19
incidence O 0 1.950409625472993e-11
of O 0 1.6064081432796785e-19
APC B-Disease 0 5.241970052471956e-13
mutations O 0 3.425511141221297e-15
in O 0 2.4846796645947417e-17
non O 0 1.5643512960711314e-12
- O 0 1.87033128895564e-05
FAP O 1 0.9077743291854858
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999972581863403
. O 0 1.7531320839481168e-10

METHODS O 0 5.1483692526180236e-14
The O 0 4.256321038490403e-17
APC B-Disease 0 2.5913118019090832e-14
gene O 0 3.9701305093557953e-16
was O 0 4.047339415382597e-15
analysed O 0 4.670057921171461e-16
in O 0 1.0402777187362023e-19
190 O 0 9.337778064495725e-18
unrelated O 0 5.26763966545937e-16
FAP B-Disease 0 1.472252181278222e-11
and O 0 6.426219419878448e-14
15 O 0 1.983501923024842e-15
non O 0 1.0810568342204882e-13
- O 0 1.756909910000104e-06
FAP O 0 0.43945926427841187
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999971389770508
patients O 0 1.1123553241907508e-15
using O 0 3.6753803379899557e-19
denaturing O 0 8.254459615830712e-12
gradient O 0 1.243045786745653e-13
gel O 0 2.3761022663326692e-11
electrophoresis O 0 6.82920950692556e-12
, O 0 3.823979871216292e-18
the O 0 3.270531384005631e-21
protein O 0 1.275178633782027e-18
truncation O 0 1.502426701895565e-15
test O 0 1.1148446481436128e-15
, O 0 6.058165995123063e-22
and O 0 6.092814280693308e-22
direct O 0 7.652227651888885e-21
sequencing O 0 1.0998416532983363e-13
. O 0 1.88563926842647e-13

RESULTS O 0 2.0231327030328927e-11
Chain O 0 1.6910855582617096e-13
terminating O 0 2.0625838412441713e-14
signals O 0 2.5691742136513263e-11
were O 0 9.130210490101466e-17
only O 0 5.810902201816322e-21
identified O 0 2.6781479454480343e-17
in O 0 4.446398126986412e-18
patients O 0 2.0916077388487282e-17
belonging O 0 1.6818141088657715e-18
to O 0 8.911834642951344e-18
the O 0 3.5334363206517363e-17
FAP B-Disease 0 4.373973405691345e-11
group O 0 1.4191689747737428e-14
( O 0 2.38175516295769e-19
105 O 0 6.288014728995711e-16
patients O 0 2.5380968378838236e-17
) O 0 4.786313854926604e-17
. O 0 3.1420128136653083e-14

Amino O 0 6.736378121985354e-11
acid O 0 3.968455880749844e-13
changes O 0 2.0250277076805148e-19
were O 0 2.282931378188097e-19
identified O 0 7.251488662715891e-19
in O 0 1.1891724261942493e-19
four O 0 1.8737182738987876e-17
patients O 0 2.8350060395703424e-18
, O 0 1.719615564925803e-19
three O 0 3.578539501604048e-17
of O 0 4.963514636417306e-18
whom O 0 4.491718734017094e-15
belonged O 0 3.4991816200505028e-15
to O 0 1.7784193910965943e-16
the O 0 6.311490644175558e-17
non O 0 1.5638566017248806e-15
- O 0 1.7149542419839237e-12
FAP O 0 4.702823686031365e-10
group O 0 1.9625730348585974e-13
of O 0 1.0779758874001222e-14
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
patients O 0 2.3548866849576466e-12
. O 0 2.63994943959205e-16

Genotype O 0 7.14410089130979e-06
- O 0 1.7204229152412154e-06
phenotype O 0 4.4261490306229945e-11
correlations O 0 1.1101308674404953e-13
identified O 0 6.043510960770937e-14
significant O 0 9.129622860994308e-16
differences O 0 2.5410024084848715e-10
in O 0 1.0710716728779602e-17
the O 0 4.513647993505034e-17
nature O 0 5.5142356474155094e-14
of O 0 2.5366424062127716e-19
certain O 0 2.693517656060984e-16
extracolonic O 0 1.8443588323258098e-10
manifestations O 0 3.593619949142021e-14
in O 0 6.132714638087446e-21
FAP B-Disease 0 2.3594116298295692e-14
patients O 0 7.434561309861893e-19
belonging O 0 1.3308551526865997e-19
to O 0 1.1422693209085379e-18
three O 0 5.2172390544281466e-18
mutation O 0 4.5957663130820336e-14
subgroups O 0 7.957943332081996e-12
. O 0 6.737581846605334e-12

CONCLUSIONS O 0 1.0552637322996938e-12
Extended O 0 3.7061946935902645e-14
genotype O 0 2.3176105479194575e-10
- O 0 5.380823786538258e-09
phenotype O 0 4.736974267699479e-12
correlations O 0 4.85738727885876e-13
made O 0 1.461941089291475e-14
in O 0 4.662523877434267e-18
this O 0 8.384262984168086e-18
study O 0 2.044886923490508e-17
may O 0 1.5952312103109482e-14
have O 0 1.6533937546616133e-16
the O 0 1.000929693424638e-18
potential O 0 1.8249660683922597e-17
to O 0 2.78477880559551e-18
determine O 0 8.322122488216112e-19
the O 0 2.998824754483278e-23
most O 0 2.9336373814917594e-25
appropriate O 0 2.0322194850349045e-24
surveillance O 0 1.0301288588550302e-19
and O 0 4.517340660722292e-22
prophylactic O 0 7.35206044814087e-21
treatment O 0 4.994882973951987e-22
regimens O 0 9.204228668924485e-20
for O 0 4.094467749287952e-24
those O 0 5.398474714379427e-20
patients O 0 4.537633444865942e-22
with O 0 5.594555470350551e-23
mutations O 0 8.244710170204877e-18
associated O 0 1.0986794902133855e-14
with O 0 2.0307420092843982e-14
life O 0 2.911664020999183e-09
threatening O 0 2.3872640667832457e-05
conditions O 0 1.43528097393264e-11
. O 0 1.4544740195229777e-13

This O 0 2.142607162468991e-16
study O 0 6.3571977238437e-20
also O 0 4.557655315242078e-21
provided O 0 1.28096306640619e-22
evidence O 0 2.815612541308618e-21
for O 0 3.7031412907900917e-22
the O 0 5.564173595981489e-19
pathological O 0 9.446173769404875e-14
nature O 0 3.388107436819968e-16
of O 0 1.5707769506530447e-19
amino O 0 3.060014306898698e-15
acid O 0 5.2276014768338434e-17
changes O 0 5.437472564410894e-21
in O 0 6.805409577723393e-21
APC O 0 3.275560898568868e-15
associated O 0 3.6607738276371295e-18
with O 0 5.3670353887538764e-21
both O 0 6.332561829509427e-19
FAP B-Disease 0 2.7214192271224347e-12
and O 0 1.7854021348373897e-14
non O 0 2.497884982622517e-13
- O 0 1.0106948593602283e-06
FAP O 0 0.007101419847458601
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
patients O 0 8.714984571674134e-13
. O 0 3.3645474221872426e-18
. O 0 1.7208584730725403e-16

Inherited B-Disease 1 0.9310992360115051
colorectal I-Disease 1 0.9999951124191284
polyposis I-Disease 1 0.9997919201850891
and O 0 5.404410217124678e-07
cancer B-Disease 0 8.811515073148257e-08
risk O 0 1.8833982984300945e-11
of O 0 4.2479120418753413e-20
the O 0 5.474318930593808e-18
APC O 0 8.29106314853556e-13
I1307K O 0 1.0997913056599515e-13
polymorphism O 0 2.735938645775926e-13
. O 0 1.0060368201480693e-13

Germ O 0 1.1519235840751207e-06
- O 0 7.189334496615629e-07
line O 0 1.1834583313330427e-09
and O 0 1.6546880739445771e-15
somatic O 0 1.794270315685258e-15
truncating O 0 1.2549959986160597e-12
mutations O 0 2.3949309400331416e-14
of O 0 2.2482140585796208e-20
the O 0 1.3719125208846107e-19
APC B-Disease 0 3.0427736924111656e-16
gene O 0 1.3349184448012192e-18
are O 0 1.1442088914239128e-20
thought O 0 9.448847948041436e-20
to O 0 5.455551469115293e-20
initiate O 0 2.9773763749602056e-13
colorectal B-Disease 1 0.9999986886978149
tumor I-Disease 0 0.0001301025040447712
formation O 0 8.205965684737748e-09
in O 0 2.0742074724466875e-09
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.999984622001648
polyposis I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999971389770508
and O 0 5.012684156646685e-10
sporadic O 0 3.3267653520852036e-07
colorectal O 1 0.9999861717224121
carcinogenesis O 0 0.00020910007879137993
, O 0 8.043061876239488e-12
respectively O 0 1.6972873844237069e-12
. O 0 4.836060480024884e-13

Recently O 0 2.9721238491153823e-12
, O 0 4.460517851888508e-17
an O 0 1.8043919358884733e-18
isoleucine O 0 8.179560495591431e-08
- O 0 3.825888938990829e-08
- O 0 1.93659310809835e-08
> O 0 6.798116350447206e-14
lysine O 0 4.083898475469583e-13
polymorphism O 0 2.8061332486731087e-14
at O 0 2.1767230555459934e-15
codon O 0 2.341455717193904e-15
1307 O 0 5.494603117764049e-14
( O 0 1.7493494767728166e-19
I1307K O 0 1.1981725731209387e-15
) O 0 5.5996508554660054e-18
of O 0 1.1668075626940895e-20
the O 0 2.9227903752823793e-18
APC B-Disease 0 1.6182769439266644e-14
gene O 0 1.5085645210070513e-17
has O 0 4.3848189144390855e-17
been O 0 3.8377292673581485e-19
identified O 0 3.1677230524539116e-19
in O 0 4.5059856075259236e-20
6 O 0 1.5557814131222317e-16
% O 0 1.421295125905844e-18
- O 0 1.0544760203901049e-10
7 O 0 7.856509193215899e-11
% O 0 9.941045484354854e-16
of O 0 1.5134852582048856e-19
the O 0 2.250141753831628e-15
Ashkenazi O 0 1.9035967468994386e-08
Jewish O 0 2.1615201295510644e-10
population O 0 1.682667880357168e-14
. O 0 1.0447627599207213e-13

To O 0 1.3535349327898488e-14
assess O 0 2.0513669227368615e-14
the O 0 1.2679518256038502e-17
risk O 0 4.376649678709512e-16
of O 0 9.32799384772987e-24
this O 0 1.602079058404862e-22
common O 0 1.613698577156597e-19
APC B-Disease 0 2.960148275384469e-15
allelic O 0 1.6614503826548055e-14
variant O 0 8.258171707228867e-13
in O 0 4.762244201414467e-14
colorectal O 1 0.9999982118606567
carcinogenesis O 0 3.1824863526708214e-06
, O 0 1.0161202899873403e-14
we O 0 2.021410214217273e-17
have O 0 6.663220037508172e-22
analyzed O 0 3.0716314840216724e-20
a O 0 3.1689285227938655e-21
large O 0 1.0754232012469026e-18
cohort O 0 9.57663722628288e-12
of O 0 2.2986019116423654e-17
unselected O 0 1.2262539428320451e-08
Ashkenazi O 0 1.5910281092601508e-07
Jewish O 0 6.678936848025785e-10
subjects O 0 1.801057081252111e-10
with O 0 9.810954987941986e-17
adenomatous B-Disease 0 6.622967729796869e-10
polyps I-Disease 0 2.2530612042714893e-08
and O 0 4.212276361048595e-12
. O 0 2.3067305850816774e-14
or O 0 9.684868018666748e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
, I-Disease 0 4.432864521586855e-19
for O 0 1.2037064469699133e-23
the O 0 9.872392532884716e-21
APC O 0 8.480781859112121e-14
I1307K O 0 1.4769637268307982e-14
polymorphism O 0 1.4839050940709114e-13
. O 0 1.2164017894073648e-13

The O 0 5.353597204221447e-15
APC O 0 1.3199139047362363e-12
I1307K O 0 8.208860566120968e-13
allele O 0 3.1842462152285866e-13
was O 0 8.097142341388988e-14
identified O 0 2.0093352844216192e-14
in O 0 5.3667597256448643e-17
48 O 0 4.282936865101052e-16
( O 0 5.3282991022793864e-20
10 O 0 8.715223530719687e-19
. O 0 1.7553399187689256e-18
1 O 0 3.277719720853623e-17
% O 0 9.47133485299369e-19
) O 0 9.006425227538621e-20
of O 0 9.735143559099135e-21
476 O 0 1.1651742870782793e-14
patients O 0 1.1927771055958268e-16
. O 0 4.359054686812672e-16

Compared O 0 1.5433050413256495e-14
with O 0 8.21096492352547e-19
the O 0 1.4492661866205363e-19
frequency O 0 5.235631942096877e-14
in O 0 9.842920927764761e-19
two O 0 1.4646460281280384e-17
separate O 0 6.463705244124014e-16
population O 0 2.354124797257793e-18
control O 0 2.599407531060703e-16
groups O 0 8.331524429853543e-19
, O 0 4.2523219485160147e-20
the O 0 5.0575263755215544e-20
APC O 0 3.069052783720612e-14
I1307K O 0 1.553487118505475e-15
allele O 0 2.5094293386562468e-15
is O 0 4.80735451729587e-18
associated O 0 4.1912737057888255e-18
with O 0 1.2901607358317405e-18
an O 0 2.811089270211229e-17
estimated O 0 6.823737538561025e-13
relative O 0 4.1231462688529064e-11
risk O 0 6.445012856737264e-10
of O 0 4.550507161600397e-17
1 O 0 1.2689940989837022e-14
. O 0 2.8428648324307915e-13

5 O 0 2.3673263002677025e-11
- O 0 1.679559602507652e-08
1 O 0 2.7692979203200463e-13
. O 0 5.57432463903218e-13

7 O 0 5.373103004191471e-12
for O 0 1.0278862552510603e-14
colorectal B-Disease 1 0.9999912977218628
neoplasia I-Disease 0 0.00020911403407808393
( O 0 9.362978870951916e-14
both O 0 8.026384461581881e-13
P O 0 0.0011109885526821017
= O 0 5.760835808388265e-09
. O 0 1.2176651830939078e-12
01 O 0 1.6877732544884338e-09
) O 0 4.351397561909052e-15
. O 0 7.906193332397199e-14

Furthermore O 0 2.1509196333757696e-12
, O 0 1.773656551303963e-16
compared O 0 1.657491276543956e-17
with O 0 1.3098030700550013e-18
noncarriers O 0 4.739115783830572e-12
, O 0 2.0592647132340846e-19
APC O 0 1.8157946934244107e-15
I1307K O 0 1.8770888032843696e-16
carriers O 0 5.8038631371415655e-19
had O 0 2.514236978550854e-17
increased O 0 5.815495235258622e-20
numbers O 0 1.3654704641234418e-18
of O 0 1.8057141840976393e-18
adenomas B-Disease 0 8.713460175613363e-08
and O 0 1.5369063532943983e-07
colorectal B-Disease 1 0.9999998807907104
cancers I-Disease 0 0.0017395438626408577
per O 0 7.192351043318541e-16
patient O 0 9.715570904213211e-14
( O 0 3.16434469173588e-17
P O 0 7.972382150001067e-07
= O 0 1.5093180871783574e-10
. O 0 3.402320742848519e-13
03 O 0 8.671744745891719e-12
) O 0 4.139887095467439e-17
, O 0 2.5249031623569956e-19
as O 0 2.588527633252587e-20
well O 0 3.923676434929705e-19
as O 0 7.746514383310368e-19
a O 0 9.995875515217401e-17
younger O 0 9.783931442797211e-10
age O 0 1.369934710376136e-13
at O 0 1.8238466945001285e-16
diagnosis O 0 6.583847507977969e-14
. O 0 8.840838624330979e-16

We O 0 2.410991023526262e-14
conclude O 0 2.5450580590468248e-17
that O 0 1.2944730351601326e-20
the O 0 1.3231045511263345e-20
APC O 0 4.838380096691599e-15
I1307K O 0 6.478195330873575e-16
variant O 0 2.1382328619832212e-14
leads O 0 1.2077140773992384e-13
to O 0 1.8167250744136748e-13
increased O 0 1.6418262149126006e-12
adenoma B-Disease 1 0.9999996423721313
formation O 0 2.103772451383934e-12
and O 0 6.134371422693253e-15
directly O 0 7.443958805403531e-18
contributes O 0 2.000162922130991e-17
to O 0 2.185271591636731e-19
3 O 0 1.124367664207303e-17
% O 0 5.804217273841315e-19
- O 0 1.0395158041645591e-12
4 O 0 3.925095654316174e-13
% O 0 5.145315700166661e-18
of O 0 7.473509787550548e-21
all O 0 1.4444955987098253e-14
Ashkenazi O 0 3.227495881219511e-06
Jewish O 0 0.00019863442867062986
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
. O 0 2.086824463232162e-11

The O 0 3.319384900952148e-15
estimated O 0 2.1750630827276117e-15
relative O 0 9.446606095021154e-14
risk O 0 6.509070084141644e-13
for O 0 1.0510767322390834e-17
carriers O 0 1.95972913867885e-14
may O 0 2.260300537605404e-16
justify O 0 1.8494371676689965e-19
specific O 0 4.405310105950787e-23
clinical O 0 3.303379337528868e-23
screening O 0 2.8435348347178803e-22
for O 0 1.2373380919928591e-24
the O 0 8.341934282282614e-24
360 O 0 1.8071178966724447e-20
, O 0 6.316481212219198e-23
000 O 0 6.746732664710763e-21
Americans O 0 9.538875571725323e-21
expected O 0 5.185900202166453e-21
to O 0 2.0615588146524694e-20
harbor O 0 3.331686638377808e-17
this O 0 3.6531774916260344e-22
allele O 0 5.080697591484937e-18
, O 0 1.6472458562509654e-20
and O 0 4.494042903088854e-18
genetic O 0 2.437330529460671e-15
testing O 0 2.366328416173553e-15
in O 0 2.245788254498081e-20
the O 0 7.513103142999569e-20
setting O 0 2.7303056733887776e-15
of O 0 3.033578397034363e-19
long O 0 1.1742687443076771e-13
- O 0 1.0706455253611802e-12
term O 0 5.5154140396517295e-14
- O 0 1.254598746940061e-12
outcome O 0 1.5279962178232285e-16
studies O 0 2.2422049029146225e-17
may O 0 3.099269203874203e-19
impact O 0 9.348420466859256e-21
significantly O 0 2.462137628054661e-18
on O 0 1.929165334424443e-11
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
prevention O 0 1.0718581577862096e-10
in O 0 6.801360916365858e-21
this O 0 1.9129829594711674e-20
population O 0 9.494522793515083e-19
. O 0 6.121094181245042e-15

Localization O 0 4.541187033618027e-13
of O 0 2.899921519682279e-19
human O 0 1.9824713486258293e-17
BRCA1 O 0 6.203849933772432e-12
and O 0 1.0928418760214331e-11
its O 0 1.726951481123562e-12
loss O 0 8.359019856504779e-14
in O 0 3.183495577277708e-19
high O 0 3.118063966744966e-12
- O 0 3.0447188237303635e-06
grade O 0 1.732573551294081e-08
, O 0 1.3515381373199915e-14
non B-Disease 0 2.8928829817753687e-12
- I-Disease 0 0.00012532388791441917
inherited I-Disease 1 0.8561170101165771
breast I-Disease 1 0.9997898936271667
carcinomas I-Disease 1 0.9999958276748657
. O 0 1.3078917948661228e-09

Although O 0 4.112613468363908e-15
the O 0 7.572259481494181e-20
link O 0 2.5236838443673526e-16
between O 0 1.6645244624202494e-17
the O 0 2.894089565491535e-17
BRCA1 O 0 5.216265197560688e-10
tumour B-Disease 1 0.9999961853027344
- O 0 8.108556361074992e-12
suppressor O 0 1.1578209745122248e-11
gene O 0 7.666758894409043e-11
and O 0 1.012898584451527e-10
hereditary B-Disease 1 0.999919056892395
breast I-Disease 1 0.9999996423721313
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
is O 0 2.22184915932744e-15
established O 0 2.1268639549940552e-18
, O 0 7.244413890334302e-18
the O 0 8.375239891251204e-20
role O 0 5.87300670132373e-15
, O 0 3.3461431085072746e-17
if O 0 2.6507431829204534e-19
any O 0 6.679587247839051e-21
, O 0 1.3909844365273337e-18
of O 0 7.735200491235203e-20
BRCA1 O 0 4.35679853305615e-10
in O 0 4.1094162578012017e-14
non B-Disease 0 5.720997009461826e-10
- I-Disease 0 0.0001194536016555503
familial I-Disease 1 0.9917423725128174
cancers I-Disease 1 0.9653039574623108
is O 0 1.0348900149380683e-13
unclear O 0 3.4539092506197244e-13
. O 0 1.2306505268240998e-14

BRCA1 O 0 3.886058141944204e-11
mutations O 0 7.787510463959715e-14
are O 0 3.8517986169609404e-17
rare O 0 2.0083667340101694e-17
in O 0 7.986846374972699e-17
sporadic B-Disease 0 6.644595096361172e-09
cancers I-Disease 0 2.2757851638743887e-06
, O 0 2.9009374112945463e-13
but O 0 1.522443087396963e-12
loss O 0 1.8051244076296115e-15
of O 0 2.894946351415199e-20
BRCA1 O 0 4.204213921443767e-10
resulting O 0 1.172114922481926e-11
from O 0 1.3071298092580484e-15
reduced O 0 1.3818950781715805e-15
expression O 0 4.703331704680215e-15
or O 0 2.835661935297884e-13
incorrect O 0 2.0553775348375325e-10
subcellular O 0 1.9483125182628847e-11
localization O 0 1.2189892378920014e-13
is O 0 4.5137446262951564e-20
postulated O 0 3.081666218827706e-20
to O 0 3.2901793873241446e-20
be O 0 4.098507713611779e-20
important O 0 7.021603796753982e-19
in O 0 1.6623605579378107e-17
non B-Disease 0 1.6685276207559219e-12
- I-Disease 0 8.461096513201483e-06
familial I-Disease 1 0.9999802112579346
breast I-Disease 1 0.9999973773956299
and I-Disease 1 0.9999605417251587
ovarian I-Disease 1 0.9999997615814209
cancers I-Disease 1 0.9999978542327881
. O 0 1.3427782323549575e-11

Epigenetic O 0 1.9672343114507385e-06
loss O 0 2.0934228359692497e-06
, O 0 3.1607905176663995e-14
however O 0 2.543263805036524e-16
, O 0 1.1801754928642398e-18
has O 0 3.59265302265155e-18
not O 0 6.372157414468692e-19
received O 0 7.233494931765191e-21
general O 0 8.79460430594425e-20
acceptance O 0 2.1452415937536296e-15
due O 0 1.1539906728476643e-16
to O 0 3.6134487568414394e-18
controversy O 0 5.2808556955422523e-17
regarding O 0 6.312516399833912e-20
the O 0 2.970704867194476e-21
subcellular O 0 1.7467923190466416e-15
localization O 0 1.5164061601268295e-16
of O 0 1.054914683714296e-21
BRCA1 O 0 4.4079819568240404e-16
proteins O 0 7.187469486564396e-16
, O 0 4.560343000828143e-17
reports O 0 3.7359431047967223e-16
of O 0 3.691565225273807e-20
which O 0 9.185697077377254e-15
have O 0 1.1024412482354366e-14
ranged O 0 3.2728146906989275e-14
from O 0 6.004060103178034e-20
exclusively O 0 1.4644744377817704e-15
nuclear O 0 4.7150699143683195e-12
, O 0 1.1974561190021172e-21
to O 0 1.905597626006004e-20
conditionally O 0 1.6706203401659569e-15
nuclear O 0 6.910401748440667e-14
, O 0 1.3096811626966392e-21
to O 0 5.7520390923865106e-21
the O 0 1.9842320645981944e-19
ER O 0 3.862645880231552e-12
/ O 0 6.39466398564001e-17
golgi O 0 4.1655721705119095e-14
, O 0 8.771791310884892e-19
to O 0 1.5347828583820474e-18
cytoplasmic O 0 6.458370296891225e-12
invaginations O 0 1.0894479762768583e-10
into O 0 4.6972844055975216e-17
the O 0 1.0548404040261997e-17
nucleus O 0 4.010745050962369e-15
. O 0 9.57871761204617e-16

In O 0 4.0506740782168186e-16
an O 0 3.480817376653768e-18
attempt O 0 2.6089000751405855e-12
to O 0 1.71749008244515e-13
resolve O 0 9.3448261281881e-12
this O 0 6.340925659478104e-19
issue O 0 3.479269357768212e-15
, O 0 5.734542920267784e-18
we O 0 3.475261568438719e-16
have O 0 3.3110962517749848e-18
comprehensively O 0 3.33367209705282e-12
characterized O 0 2.2957311846352225e-14
19 O 0 2.5316277891852914e-17
anti O 0 3.676092633422834e-13
- O 0 6.046090711420149e-11
BRCA1 O 0 5.70780315373165e-12
antibodies O 0 3.657204747375964e-12
. O 0 5.556612366953463e-15

These O 0 5.629639047803197e-17
reagents O 0 9.393981843832376e-17
detect O 0 1.2136102779802403e-15
a O 0 2.569384541303093e-19
220 O 0 1.0301535295167996e-17
- O 0 5.394148059538299e-14
kD O 0 1.2801783287955115e-12
protein O 0 6.482324087095847e-16
localized O 0 4.802648223569913e-16
in O 0 2.790603333255317e-20
discrete O 0 2.1105572886294605e-15
nuclear O 0 2.1290724738776134e-10
foci O 0 2.740235816034442e-10
in O 0 3.129185545235436e-17
all O 0 2.474833601414625e-16
epithelial O 0 9.337552432653329e-13
cell O 0 1.207843780548501e-08
lines O 0 3.0001090500775263e-10
, O 0 1.4680750226393157e-17
including O 0 2.932973718255337e-20
those O 0 9.313799752899038e-18
derived O 0 4.442685326806968e-18
from O 0 8.921033162678175e-15
breast B-Disease 0 1.159366911451798e-05
malignancies I-Disease 0 2.7336451239534654e-05
. O 0 3.6177558344896443e-12

Immunohistochemical O 0 1.4880661183269694e-06
staining O 0 4.641376705194489e-08
of O 0 7.601908943370532e-17
human O 0 8.153396001701809e-15
breast O 0 1.3042995572476457e-09
specimens O 0 7.231699641245884e-14
also O 0 1.8825898058207535e-15
revealed O 0 7.132475166038432e-12
BRCA1 O 0 1.450512598921705e-09
nuclear O 0 5.263698921176285e-10
foci O 0 5.583992643276581e-11
in O 0 4.6057631573911845e-17
benign O 0 3.429602912774499e-08
breast O 0 1.6385420167353004e-06
, O 0 1.6408368804302076e-12
invasive B-Disease 0 5.60499779922452e-09
lobular I-Disease 1 0.9407587051391602
cancers I-Disease 1 0.9998555183410645
and O 0 1.2364961321509327e-06
low B-Disease 0 0.0001214224539580755
- I-Disease 1 0.8372083306312561
grade I-Disease 0 2.058471363852732e-05
ductal I-Disease 0 0.00071516796015203
carcinomas I-Disease 1 0.9999940395355225
. O 0 8.480547819544881e-08

Conversely O 0 1.3136350731149382e-12
, O 0 1.78655858362632e-16
BRCA1 O 0 4.880166908603767e-13
expression O 0 7.172415873030191e-13
was O 0 1.8722066952303607e-10
reduced O 0 1.2999685963105412e-12
or O 0 3.794421374325729e-12
undetectable O 0 2.4238877571747253e-10
in O 0 9.18190332268562e-17
the O 0 3.6282054902245404e-15
majority O 0 3.862247099237567e-16
of O 0 1.5347485924251724e-17
high O 0 4.8072615332905855e-11
- O 0 1.810744798547148e-08
grade O 0 7.205574678592619e-12
, O 0 2.949032556138532e-17
ductal B-Disease 0 1.8609660687451957e-11
carcinomas I-Disease 1 0.9999988079071045
, O 0 3.4245477005361014e-13
suggesting O 0 1.2740203857164456e-12
that O 0 5.6771086270519e-16
absence O 0 1.651830317129439e-16
of O 0 6.004540901909081e-20
BRCA1 O 0 1.045175990026237e-12
may O 0 2.5069225446488477e-15
contribute O 0 5.0545181522782463e-20
to O 0 9.870025697733563e-20
the O 0 1.9346110506147868e-19
pathogenesis O 0 4.7731543245882815e-15
of O 0 5.73376569118603e-22
a O 0 1.7228647045225172e-20
significant O 0 1.0833323403726166e-19
percentage O 0 4.494068826929251e-14
of O 0 8.11320847057977e-17
sporadic B-Disease 0 3.37046770937377e-07
breast I-Disease 0 0.04878669232130051
cancers I-Disease 0 0.00019069512200076133
. O 0 2.9174523040464972e-12
. O 0 2.49061231707981e-12

